<SEC-DOCUMENT>0001731122-25-001596.txt : 20251125
<SEC-HEADER>0001731122-25-001596.hdr.sgml : 20251125
<ACCEPTANCE-DATETIME>20251125163144
ACCESSION NUMBER:		0001731122-25-001596
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		64
CONFORMED PERIOD OF REPORT:	20250930
FILED AS OF DATE:		20251125
DATE AS OF CHANGE:		20251125

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				980608404
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37606
		FILM NUMBER:		251521783

	BUSINESS ADDRESS:	
		STREET 1:		630 5TH AVENUE
		STREET 2:		20TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10111
		BUSINESS PHONE:		844-689-3939

	MAIL ADDRESS:	
		STREET 1:		630 5TH AVENUE
		STREET 2:		20TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>e7052_10-k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:avxl="http://anavex.com/20250930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2025%2D(with%2DECD%2Dand%2DCYD)_currency -->
<!-- Field: Set; Name: xdx; ID: xdx_034_avxl_anavex.com_20250930 -->
<!-- Field: Set; Name: xdx; ID: xdx_043_20241001_20250930 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001314052 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_Ratio_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000005" name="dei:EntityCentralIndexKey">0001314052</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-09-30" id="xdx2ixbrl0106" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-09-30" id="xdx2ixbrl0108" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:OtherFinancingExpense" contextRef="From2024-10-01to2025-09-30" id="xdx2ixbrl0178" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:OtherFinancingExpense" contextRef="From2023-10-012024-09-30" id="xdx2ixbrl0179" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:NoncashFinancingRelatedCharges" contextRef="From2024-10-01to2025-09-30" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:NoncashFinancingRelatedCharges" contextRef="From2023-10-012024-09-30" id="xdx2ixbrl0239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForDelayedTaxExemptExchange" contextRef="From2023-10-012024-09-30" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForDelayedTaxExemptExchange" contextRef="From2022-10-012023-09-30" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommonStockIssuedUponCashlessExerciseOfStockOptions" contextRef="From2023-10-012024-09-30" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommonStockIssuedUponCashlessExerciseOfStockOptions" contextRef="From2022-10-012023-09-30" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2022-10-012023-09-30" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-10-012024-09-30" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreement" contextRef="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfStockOptions" contextRef="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0434" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesWithheldRelatedToCashlessExerciseOfStockOption" contextRef="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0441" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2025-09-30" id="xdx2ixbrl0991" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-09-30" id="xdx2ixbrl0992" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2024-10-01to2025-09-30" id="xdx2ixbrl1000" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2022-10-012023-09-30" id="xdx2ixbrl1002" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount" contextRef="From2024-10-01to2025-09-30" id="xdx2ixbrl1008" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount" contextRef="From2023-10-012024-09-30" id="xdx2ixbrl1009" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2024-10-01to2025-09-30" id="xdx2ixbrl1032" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2023-10-012024-09-30" id="xdx2ixbrl1033" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="avxl-20250930.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-10-01to2025-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-11-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-11-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_custom_MichaelJFoxFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:MichaelJFoxFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-02</xbrli:startDate>
        <xbrli:endDate>2023-02-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockIncludingCommitmentSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommonStockIncludingCommitmentSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockExcludingCommitmentSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommonStockExcludingCommitmentSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommitmentSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommitmentSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockIncludingCommitmentSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommonStockIncludingCommitmentSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockExcludingCommitmentSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommonStockExcludingCommitmentSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommitmentSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommitmentSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_BoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avxl:BoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ChiefExecutiveOfficer1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avxl:ChiefExecutiveOfficer1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_custom_ChiefExecutiveOfficer1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avxl:ChiefExecutiveOfficer1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_custom_ChiefExecutiveOffice1rMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avxl:ChiefExecutiveOffice1rMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-242022-03-25_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-24</xbrli:startDate>
        <xbrli:endDate>2022-03-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_ForeignCountryMember_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_ForeignCountryMember_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_custom_PreclinicalStudiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:PreclinicalStudiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_custom_PreclinicalStudiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:PreclinicalStudiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_custom_PreclinicalStudiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:PreclinicalStudiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_custom_ClinicalTrialsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:ClinicalTrialsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_custom_ClinicalTrialsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:ClinicalTrialsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_custom_ClinicalTrialsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:ClinicalTrialsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_custom_PersonnelCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:PersonnelCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_custom_PersonnelCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:PersonnelCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_custom_PersonnelCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:PersonnelCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_custom_NonCashShareBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:NonCashShareBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_custom_NonCashShareBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:NonCashShareBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_custom_NonCashShareBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:NonCashShareBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_custom_OtherResearchAndDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:OtherResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_custom_OtherResearchAndDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:OtherResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_custom_OtherResearchAndDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:OtherResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-09-30_2023-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="ecd:RestatementDateAxis">
            <ecd:RestatementDateAxis.domain>2023-11-30</ecd:RestatementDateAxis.domain>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Ratio">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Washington, D.C. 20549</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>FORM <span id="xdx_903_edei--DocumentType_c20241001__20250930_ze2ZQi9G7Yck"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000011" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(Mark One)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 12pt Courier New, Courier, Monospace; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_edei--DocumentAnnualReport_c20241001__20250930_zSjIt0lfGe0f"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:booleantrue" id="Fact000012" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span>&#160;ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the fiscal year ended <b><span style="text-decoration: underline"><span id="xdx_90A_edei--DocumentPeriodEndDate_c20241001__20250930_zKO2IXHxy46d"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:datemonthdayyearen" id="Fact000013" name="dei:DocumentPeriodEndDate"><span id="xdx_903_edei--CurrentFiscalYearEndDate_c20241001__20250930_zYrPjP5PrCjf"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:datemonthdayen" id="Fact000014" name="dei:CurrentFiscalYearEndDate">September 30</ix:nonNumeric></span>, <span id="xdx_90C_edei--DocumentFiscalYearFocus_c20241001__20250930_zvpmJPA4XV3g"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000015" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric></span></ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_edei--DocumentTransitionReport_c20241001__20250930_zdi5o27vAk82"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:booleanfalse" id="Fact000016" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the transition period from ______________ to________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission file number<b>: <span style="text-decoration: underline"><span id="xdx_90D_edei--EntityFileNumber_c20241001__20250930_z5dmci5jT6ma"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000017" name="dei:EntityFileNumber">001-37606</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_905_edei--EntityRegistrantName_c20241001__20250930_zlyjUTGDxpWc"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000018" name="dei:EntityRegistrantName">ANAVEX LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b>(Exact name of registrant as specified
in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20241001__20250930_zdh7emFNUjpg"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt-sec:stateprovnameen" id="Fact000019" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></b></span></td>
    <td style="width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20241001__20250930_z03qgQtuM948"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000020" name="dei:EntityTaxIdentificationNumber">98-0608404</ix:nonNumeric></span></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation or organization)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90C_edei--EntityAddressAddressLine1_c20241001__20250930_zP1WQcFWVJHk"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000021" name="dei:EntityAddressAddressLine1">630 5th Avenue</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressAddressLine2_c20241001__20250930_zgR6NQb2iLX4"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000022" name="dei:EntityAddressAddressLine2">20th Floor</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressCityOrTown_c20241001__20250930_z4pJgibsGulc"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000023" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressStateOrProvince_c20241001__20250930_ztiRbpkjfuR3"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000024" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_90E_edei--EntityAddressCountry_c20241001__20250930_zdy7KvMNHDBb"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000025" name="dei:EntityAddressCountry">US</ix:nonNumeric></span>A
<span id="xdx_902_edei--EntityAddressPostalZipCode_c20241001__20250930_zo4Jm7xmmQh1"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000026" name="dei:EntityAddressPostalZipCode">10111</ix:nonNumeric></span></span></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;(Address of principal executive offices) (Zip
Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">1-<span id="xdx_904_edei--CityAreaCode_c20241001__20250930_zjgOV37gNJke"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000027" name="dei:CityAreaCode">844</ix:nonNumeric></span>-<span id="xdx_90F_edei--LocalPhoneNumber_c20241001__20250930_zfO3TFmx3Ahl"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000028" name="dei:LocalPhoneNumber">689-3939</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b>(Registrant&#8217;s telephone number,
including area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Securities Registered Pursuant to Section&#160;12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Each Class</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Each Exchange on Which Registered</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20241001__20250930_zYgnYxxsE8zj"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000029" name="dei:Security12bTitle">Common Stock Par Value $0.001</ix:nonNumeric></span></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--TradingSymbol_c20241001__20250930_z72a4zX0mOO7"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000030" name="dei:TradingSymbol">AVXL</ix:nonNumeric></span></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--SecurityExchangeName_c20241001__20250930_zAETr2jFRF73"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Securities registered pursuant to Section 12(g) of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">None</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Title of class)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
    by checkmark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; width: 75%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right; padding-right: 5.4pt; padding-left: 5.4pt; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntityWellKnownSeasonedIssuer_c20241001__20250930_zDj4v7hAq9Ye"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000032" name="dei:EntityWellKnownSeasonedIssuer">Yes</ix:nonNumeric></span>
    &#9746; No &#9744;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
    by checkmark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
    &#9744; <span id="xdx_90F_edei--EntityVoluntaryFilers_c20241001__20250930_z5ckCyoZGbi4"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000033" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td colspan="2" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by checkmark whether the registrant has (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; width: 75%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 5.4pt; padding-left: 5.4pt; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--EntityCurrentReportingStatus_c20241001__20250930_zF2H9pshTnV"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000034" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td colspan="2" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: right; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--EntityInteractiveDataCurrent_c20241001__20250930_z0z9uYr3ZMhi"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000035" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
<td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--EntityFilerCategory_c20241001__20250930_zHAkKeebx4y9"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt-sec:entityfilercategoryen" id="Fact000036" name="dei:EntityFilerCategory">Large accelerated filer</ix:nonNumeric></span>	&#9746;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
filer &#9744;</span></td></tr>
<tr>
<td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer	&#9744;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company <span id="xdx_909_edei--EntitySmallBusiness_c20241001__20250930_zyOtZkj6VbXb"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:booleanfalse" id="Fact000037" name="dei:EntitySmallBusiness">&#9744;</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr>
<td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company <span id="xdx_907_edei--EntityEmergingGrowthCompany_c20241001__20250930_zYlwmy11vCBi"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:booleanfalse" id="Fact000038" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            an emerging growth company, indicate by check mark if the registrant has elected not to use
                                            the extended transition period for complying with any new or revised financial accounting
                                            standards provided pursuant to Section 13(a) of the Exchange Act</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Symbol; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></p></td></tr>
  <tr>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
    by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
    of its internal controls over financial reporting under Section&#160;404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the
    registered public accounting firm that prepared or issued its audit report.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Wingdings; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"></span><span id="xdx_902_edei--IcfrAuditorAttestationFlag_dbT_c20241001__20250930_zQzvPOUSIPqg"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:booleantrue" id="Fact000039" name="dei:IcfrAuditorAttestationFlag">&#9746;</ix:nonNumeric></span></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr>
    <td colspan="2" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
    included in the filing reflect the correction of an error to previously issued financial statements</span></td></tr>
  <tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 75%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--DocumentFinStmtErrorCorrectionFlag_c20241001__20250930_z7m68nOU1jR4"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:booleanfalse" id="Fact000040" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></td></tr>
  <tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
                                            by check mark whether any of those error corrections are restatements that required a recovery
                                            analysis of incentive-based compensation received by any of the registrant&#8217;s executive
                                            officers during the relevant recovery period pursuant to &#167;240.10D-1(b).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p></td></tr>
  <tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr>
    <td colspan="2" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td colspan="2" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
    by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).</span></td></tr>
  <tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
    &#9744; <span id="xdx_905_edei--EntityShellCompany_c20241001__20250930_zQXlnTf1DSG8"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:booleanfalse" id="Fact000041" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">State the aggregate market value of the voting and
non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average
bid and asked price of such common equity, as of the last business day of the registrant&#8217;s most recently completed second fiscal
quarter: $<span id="xdx_900_edei--EntityPublicFloat_iI_pn3n3_dm_c20250331_zdDrf0plm04b"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2025-03-31" id="Fact000042" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">708</ix:nonFraction></span> million based on a price of $8.58 per share, being the closing price of the registrant&#8217;s common stock on March 31,
2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate the number of shares outstanding of each
of the registrant&#8217;s classes of common stock, as of the latest practicable date: <span id="xdx_90C_edei--EntityCommonStockSharesOutstanding_iI_c20251124_zQgBjipVfyW6"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-11-24" id="Fact000043" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">89,348,107</ix:nonFraction></span> issued and outstanding as of November
24, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">DOCUMENTS INCORPORATED BY REFERENCE</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">TABLE OF CONTENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; color: #365F91"></p>



<table cellpadding="0" cellspacing="0" style="width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%; text-align: left; padding-top: 0cm; padding-bottom: 0pt; padding-left: 0cm"><a href="#a_001">PART I</a></td>
    <td style="width: 10%; text-align: right; padding-top: 0cm; padding-bottom: 0pt">6</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_002">ITEM 1. BUSINESS</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">6</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_003">ITEM 1A. RISK FACTORS</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">32</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_004">ITEM 1B. UNRESOLVED STAFF COMMENTS</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">63</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_005">ITEM 1C. CYBERSECURITY</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">63</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_006">ITEM 2. PROPERTIES</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">64</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_007">ITEM 3. LEGAL PROCEEDINGS</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">64</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_008">ITEM 4. MINE SAFETY DISCLOSURES</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">65</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0cm"><a href="#a_009">PART II</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">65</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_010">ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">65</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_012">ITEM 7 MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">66</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_013">ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">72</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_014">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">F-1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_015">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL MATTERS</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">73</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_016">ITEM 9A. CONTROLS AND PROCEDURES</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">73</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_017">ITEM 9B OTHER INFORMATION</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">73</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_018">ITEM 9C DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">73</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0cm"><a href="#a_019">PART III</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">74</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_020">ITEM 10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">74</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_021">ITEM 11. EXECUTIVE COMPENSATION</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">78</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_022">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">88</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_023">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">92</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_024">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">92</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0cm"><a href="#a_025">PART IV</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">94</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_026">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">94</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_027">ITEM 16. FORM 10-K SUMMARY</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">95</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Forward Looking Statements.</i></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Annual Report on Form 10-K includes forward-looking
statements. All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements
regarding our anticipated future clinical and regulatory milestone events, future financial position, business strategy and plans and
objectives of management for future operations, are forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221;
&#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;forecast,&#8221;
&#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;could,&#8221; &#8220;would&#8221;, &#8220;will&#8221;, &#8220;suggest,&#8221; &#8220;plan&#8221;
and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such forward-looking statements include,
without limitation, statements regarding:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">volatility in our stock price and in the markets
in general;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to successfully conduct preclinical
studies and clinical trials for our product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to raise additional capital on favorable
terms and the impact of such activities on our stockholders and stock price;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to generate any revenue or to continue
as a going concern;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to execute our research and development
plan on time and on budget;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top"><td style="width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our product candidates&#8217;
    ability to demonstrate efficacy or an acceptable safety profile;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 12pt Times New Roman, Times, Serif"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our ability to secure regulatory
    approval on our product candidates and commercialize such product candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to obtain the support of qualified
scientific collaborators;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability, whether alone or with commercial
partners, to successfully commercialize any of our product candidates that may be approved for sale;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to identify and obtain additional
product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our reliance on third parties in non-clinical
studies and clinical trials;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to defend against product liability
claims;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to safeguard against security breaches;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to obtain and maintain sufficient
intellectual property protection for our product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to comply with our intellectual property
licensing agreements;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to defend against claims of intellectual
property infringement;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">competition;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the anticipated start dates, durations and completion
dates of our ongoing and future clinical trials;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the anticipated designs of our future clinical
trials;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt"></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to attract and retain qualified employees;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the impact of Fast Track designation on receipt
of actual U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our anticipated future regulatory submissions
and our ability to receive regulatory approvals to develop and market our product candidates, including any orphan drug or Fast Track
designations;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the timing and likelihood of the accomplishment
of various scientific, clinical, regulatory filings and approvals and other product development objectives, including the timing of a
decision by the European Medicines Agency, or EMA, regarding whether to approve the Marketing Authorization Application, or MAA, for blarcamesine
for the treatment of Alzheimer&#8217;s disease; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our anticipated future cash position and ability
to obtain funding for our operations. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have based these forward-looking statements largely
on our current expectations and projections about future events, including the responses we expect from the FDA, EMA and other regulatory
authorities and financial trends that we believe may affect our financial condition, results of operations, business strategy, preclinical
studies and clinical trials, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and
assumptions including, without limitation, the risks described in &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report
on Form 10-K. These risks are not exhaustive. Other sections of this Annual Report on Form 10-K include additional factors which could
adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment.
New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the
impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements. You should not rely upon forward-looking statements as predictions
of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved
or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable
laws including the securities laws of the United States, we assume no obligation to update or supplement forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As used in this Annual Report on Form 10-K, the terms
&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Company&#8221; and &#8220;Anavex&#8221; mean Anavex Life Sciences Corp.,
unless the context clearly requires otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_001"></span>PART I</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_002"></span>ITEM 1. BUSINESS</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Overview and Strategy</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. is a clinical stage biopharmaceutical
company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;)
diseases with high unmet need. We analyze genomic data from clinical trials to identify biomarkers, which we use in the analysis of our
clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s focus is on developing innovative
treatments for Alzheimer&#8217;s disease, Parkinson&#8217;s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases,
including Rett syndrome, and other central nervous system (CNS) disorders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development pipeline includes ANAVEX<sup>&#174;</sup>2-73
currently in three different clinical trial indications, and ANAVEX<sup>&#174;</sup>3-71 currently in one clinical trial and several other
compounds in different stages of clinical and pre-clinical development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes key information about our programs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><img src="image_001.jpg" alt="" style="height: 192.75pt; width: 468pt"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>* = Orphan Drug Designation by the FDA </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex has a portfolio of compounds varying in sigma-1
receptor (SIGMAR1) binding activities. Sigma receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative
nature, including Alzheimer&#8217;s disease, as well as of neurodevelopmental nature, like Rett syndrome. When bound by the appropriate
ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development)
of disease. Multiple viruses including SARS-CoV-2 (COVID-19) induce cellular stress by intrinsic mitochondrial apoptosis and other related
cellular processes, in order to ensure survival and replication. Hence, it is possible that SIGMAR1 could also play a role in modulating
the cellular response to viral infection and ameliorate pathogenesis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The SIGMAR1 gene encodes the SIGMAR1 protein, which
is an intracellular chaperone protein with important roles in cellular communication. SIGMAR1 is also involved in transcriptional regulation
at the nuclear envelope and restores homeostasis and stimulates recovery of cell function when activated. In order to validate the ability
of our compounds to activate quantitatively the SIGMAR1, we performed, in collaboration with Stanford University, a quantitative Positron
Emission Tomography (PET) imaging scan in mice, which demonstrated a dose-dependent ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) target engagement
or receptor occupancy with SIGMAR1 in the brain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><img src="image_002.jpg" alt="" style="height: 310pt; width: 468pt"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>Source: Reyes S et al., Sci Rep. 2021 Aug 25; 11(1):17150</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Cellular Homeostasis</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Many diseases are possibly directly caused by chronic
homeostatic imbalances or cellular stress of brain cells. In pediatric diseases, such as Rett syndrome or infantile spasms, chronic cellular
stress is possibly caused by the presence of a constant genetic mutation. In neurodegenerative diseases, such as Alzheimer&#8217;s and
Parkinson&#8217;s diseases, chronic cellular stress is possibly caused by age-correlated buildup of cellular insult and hence chronic
cellular stress. Specifically, defects in homeostasis of protein or ribonucleic acid (&#8220;RNA&#8221;) lead to the death of neurons
and dysfunction of the nervous system. The spreading of protein aggregates resulting in a proteinopathy, a characteristic found in Alzheimer&#8217;s
and Parkinson&#8217;s diseases that results from disorders of protein synthesis, trafficking, folding, processing or degradation in cells.
The clearance of macromolecules in the brain is particularly susceptible to imbalances that result in aggregation and degeneration in
nerve cells. For example, Alzheimer&#8217;s disease pathology is characterized by the presence of amyloid plaques, and neurofibrillary
tangles, which are aggregates of hyperphosphorylated Tau protein that are a marker of other diseases known as tauopathies as well as inflammation
of microglia. With the SIGMAR1 activation through SIGMAR1 agonists like ANAVEX<sup>&#174;</sup>2-73 (blarcamesine), our approach is to
restore cellular balance (i.e. homeostasis). Therapies that correct defects in cellular homeostasis might have the potential to halt or
delay neurodevelopmental and neurodegenerative disease progression.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Clinical Program Overview </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX&#174;2-73 (blarcamesine)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe ANAVEX<sup>&#174;</sup>2-73 may offer a
disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of SIGMAR1. ANAVEX<sup>&#174;</sup>2-73 is
being developed as well as an oral once-daily capsule formulation for diseases such as Alzheimer&#8217;s disease and Parkinson&#8217;s
disease, and in an oral liquid once-daily formulation for rare diseases such as Rett syndrome and Fragile X.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 7; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Alzheimer&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, we completed a Phase 2a clinical
trial, consisting of Part A and Part B, which lasted a total of 57 weeks, for ANAVEX<sup>&#174;</sup>2-73 in mild-to-moderate Alzheimer&#8217;s
patients. This open-label randomized trial in Australia met both primary and secondary endpoints and was designed to assess the safety
and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients. ANAVEX<sup>&#174;</sup>2-73 targets sigma-1 and muscarinic receptors,
which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis and to reverse
the pathological hallmarks observed in Alzheimer&#8217;s disease. In October 2017, we presented positive pharmacokinetic (&#8220;PK&#8221;)
and pharmacodynamic (&#8220;PD&#8221;) data from the Phase 2a clinical trial, which established a concentration-effect relationship between
ANAVEX<sup>&#174;</sup>2-73 and trial measurements. These measures obtained from all patients who participated in the entire 57 weeks include
exploratory cognitive and functional scores as well as biomarker signals of brain activity. Additionally, the clinical trial appeared
to show that ANAVEX<sup>&#174;</sup>2-73 activity was enhanced by its active metabolite (ANAVEX19-144), which also targets the SIGMAR1
receptor and has a half-life approximately twice as long as the parent molecule.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Two consecutive trial extensions for the Phase 2a
trial have allowed participants who completed the 52-week Part B of the trial to continue taking ANAVEX<sup>&#174;</sup>2-73, providing
an opportunity to gather extended safety data for a cumulative period of five years. In August 2020, patients completing these Phase 2a
trial extensions were granted continued access to treatment with ANAVEX<sup>&#174;</sup>2-73 through the Australian Government Department
of Health &#8211; Therapeutic Goods Administration&#8217;s compassionate use Special Access Scheme.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In July 2018, we presented
the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a clinical trial. More than 33,000 genes were analyzed
using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA and RNA data in patients treated
with ANAVEX<sup>&#174;</sup>2-73. The analysis identified genetic variants that impacted response to ANAVEX<sup>&#174;</sup>2-73, among
them variants related to the SIGMAR1, the target for ANAVEX<sup>&#174;</sup>2-73. Results showed that trial participants with the common
SIGMAR1 wild type gene variant, which is estimated to be about 80% of the population worldwide, demonstrated improved cognitive (MMSE)
and functional (ADCS-ADL) scores. The results from this evaluation supported the continued evaluation of genomic information in subsequent
clinical trials, since these signatures can now be applied to neurological indications tested in future clinical trials with ANAVEX<sup>&#174;</sup>2-73
including Alzheimer&#8217;s disease, Parkinson&#8217;s disease dementia and Rett syndrome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">ANAVEX<sup>&#174;</sup>2-73
data met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled trial. This larger Phase 2b/3 double-blind,
placebo-controlled trial of ANAVEX<sup>&#174;</sup>2-73 in early Alzheimer&#8217;s disease commenced in August 2018. The trial enrolled
508 patients, which were treated with a convenient once-daily oral formulation of ANAVEX<sup>&#174;</sup>2-73 for 48 weeks, randomized
1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses or placebo. The trial took place at 52 sites across North America, Europe and
Australia. Primary and secondary endpoints to assess safety and both cognitive and functional efficacy, were measured through the Alzheimer&#8217;s
Disease Assessment Scale &#8211; Cognitive Subscale test (&#8220;ADAS-Cog&#8221;), Alzheimer&#8217;s Disease Cooperative Study &#8211;
Activities of Daily Living (&#8220;ADCS-ADL&#8221;) and Clinical Dementia Rating &#8211; Sum of Boxes for cognition and function (&#8220;CDR-SB&#8221;).
In addition to these endpoints, the ANAVEX<sup>&#174;</sup>2-73 Phase 2b/3 trial design incorporated pre-specified statistical analyses
related to potential genomic precision medicine biomarkers previously identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a clinical trial.
The trial was completed in mid-2022 and, in December 2022, the Company presented topline results from the Phase 2b/3 clinical trial. All
statistical analyses were performed by outside consultancy companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Furthermore, all pre-specified clinical endpoints
were analyzed using a mixed model for repeated measures (MMRM). Under the multiplicity control rule, a trial is successful in meeting
the co-primary endpoints if the significance of each endpoint is P &lt; 0.05, or if the significance of only one co-primary endpoint is
P &lt; 0.025. If only one primary endpoint is significant at an &#945; level of 0.025, then the secondary endpoint will be evaluated
at the same level of 0.025. The trial was successful, the differences in the least-squares mean (LSM) change from baseline to 48 weeks
between the ANAVEX<sup>&#174;</sup>2-73 and placebo groups for ADAS-Cog13 was significant at a level of P &lt; 0.025 and for CDR-SB was
significant at a level of P &lt; 0.025, in the patients with early Alzheimer&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 8; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The comparison of individual dose groups vs placebo
also supports blarcamesine&#8217;s efficacy. For the primary endpoint ADAS-Cog13, blarcamesine is significantly better than placebo (&#8722;2.027;
P = 0.0079) as well as for both the 50 mg (&#8722;2.149; P = 0.021) and the 30 mg (&#8722;1.934; P = 0.026) blarcamesine dosage groups
at Week 48, representing that blarcamesine slowed clinical progression at 48 weeks by 36.3% and by 38.5% and 34.6% in 50 mg and 30 mg
groups vs. placebo, respectively. The functional co-primary endpoint, ADCS-ADL, was trending in a positive direction but did not reach
significance at Week 48. The key secondary endpoint CDR-SB was significantly improved vs. placebo (&#8722;0.483, P = 0.0104) as well as
in both 50 mg (&#8722;0.465; P = 0.045) and 30 mg (&#8722;0.502; P = 0.020) groups at Week 48. Clinical Global Impression &#8211; Improvement
(&#8220;CGI-I&#8221;) was also significantly improved vs. placebo (&#8722;0.278, P = 0.004) as well as in both the 50 mg (&#8722;0.314;
P = 0.008) and the 30 mg (&#8722;0.248; P = 0.024) groups at Week 48. The findings are supported by biomarkers, including plasma A&#946;42/40-ratio
and reduction of brain atrophy. Blarcamesine significantly slowed brain atrophy in key regions of interest, including the whole brain
by 37.6%, total grey matter by 63.5%, and lateral ventricles by 25.1%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the respective safety population, common treatment-emergent
adverse events included dizziness, which was transient and mostly mild to moderate in severity, and occurred in 120 participants (35.8%)
during titration and in 76 participants (25.2%) during maintenance with ANAVEX<sup>&#174;</sup>2-73 and 10 (6.0%) during titration and
9 (5.6%) during maintenance with placebo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2024, we announced the submission of a Marketing Authorisation
Application (&#8220;MAA&#8221;) to the European Medicines Agency (EMA), under the centralized procedure, for ANAVEX<sup>&#174;</sup>2-73
for the treatment of Alzheimer&#8217;s disease and, in December 2024, the EMA accepted the submission for scientific review. The MAA,
if approved, would allow direct market access throughout the European Union for oral ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) for the
treatment of Alzheimer&#8217;s disease. A company seeking to market a new pharmaceutical product through the centralized procedure must
file safety data and efficacy data as part of the MAA. After the EMA evaluates the MAA, it provides a recommendation to the European Commission
(&#8220;EC&#8221;) and the EC then approves or denies the MAA. On November 14, 2025, we announced that we were informed by the Committee
for Medicinal Products for Human Use (CHMP) of the EMA of a negative trend vote on the MAA following an oral explanation. The CHMP is
expected to adopt a formal opinion on the MAA at its December 2025 meeting.&#160;We plan to request a re-examination of the CHMP opinion
upon its formal adoption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A long-term open label extension study of ANAVEX<sup>&#174;</sup>2-73, referred
to as the ATTENTION-AD trial, was initiated for patients who completed the 48-week Phase 2b/3 placebo-controlled trial referenced above.
This trial extension for a duration of up to 96/144 additional weeks was completed in June 2024. The trial extension demonstrated that
blarcamesine-treated patients continued to accrue&#160;benefit through up to 192 weeks, as measured by the clinical endpoints ADAS-Cog13
(LS mean difference -3.83; P = 0.0165) and ADCS-ADL (LS mean difference +4.30, P = 0.0206). No new safety findings were observed&#160;with
continued blarcamesine&#160;treatment over three years,&#160;confirming good comparative safety profile and no associated neuroimaging
adverse events. Delayed-start analysis of treatment with oral blarcamesine&#160;was significant, reflecting the importance of early treatment&#160;initiation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additional precision medicine population 48-week data
demonstrates cognitive stabilization in early Alzheimer&#8217;s disease. Cognitive outcomes observed in the oral blarcamesine 30 mg precision
medicine cohort move toward normal aging profiles across validated clinical scales. For ADAS-Cog13, blarcamesine showed a 48-week change
from baseline of 0.853 compared to ~1 point typical annual decline in prodromal (pre-dementia) aging adults. For CDR-SB, blarcamesine
demonstrated a change from baseline of 0.465, aligning with the 0-0.5 point annual range seen in prodromal aging. These data are similar
to referenced barely detectable prodromal Alzheimer&#8217;s disease decline, in spite of the more advanced stage of Alzheimer&#8217;s
disease impairment at baseline of the blarcamesine population.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Further
posthoc analysis demonstrates continued long-term benefit from oral blarcamesine compared to decline observed in the Alzheimer&#8217;s
Disease Neuroimaging Initiative (ADNI) control group. Externally matched control participants from the ADNI database were compared with
participants over the 144-week period of ANAVEX</span><span style="font-family: Symbol"><sup>&#210;</sup></span><span style="font-family: Times New Roman, Times, Serif">2-73-AD-004
and its ATTENTION-AD (ANAVEX</span><span style="font-family: Symbol"><sup>&#210;</sup></span><span style="font-family: Times New Roman, Times, Serif">2-73-AD-EP-004)
open-label extension (OLE) Phase IIb/III trial.<span style="line-height: 115%"><sup>[1]</sup></span> For ADAS-Cog13, total score ranges
from 0 to 85 with higher scores indicating increased cognitive impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 1px; width: 25%; margin-top: 3pt; margin-bottom: 3pt"/>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt; line-height: 115%"><sup>[1]</sup></span>
<span style="font-size: 10pt">Observed raw data was used. Scheduled visits were [OLE Week 0 = Combined Week 48], [OLE Week 48 = Combined
Week 96], [OLE Week 96 = Combined Week 144]; Combined = DB (double-blind) + OLE (open-label-extension) trials. Up to 144 weeks ADNI control
group data was available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 9; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the intent-to-treat (ITT) population, significantly
less cognitive decline was observed for the blarcamesine participants compared to the ADNI control group at 48 weeks with a significant,
and clinically meaningful difference in mean change from baseline ADAS-Cog13 total score of &#8722;2.68 points (<i>p</i> &lt; 0.0001).<span style="line-height: 115%"><sup>[2]</sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Over the course of the open-label extension study
at time point 96 weeks, these two groups diverged sharply, with statistically significant differences in mean change in ADAS-Cog13 total
score at 96 weeks of &#8722;6.41 points (<i>p</i> &lt; 0.0001). The difference between groups continues to increase at 144 weeks (ADAS-Cog13
total score difference of &#8722;12.78 points; <i>p</i> &lt; 0.0001).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="image_003.jpg" alt="" style="height: 224.25pt; width: 468pt"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The results provide evidence of the significant beneficial
therapeutic effect of blarcamesine, which positively separates from the ADNI control group with duration of treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Parkinson&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2016, we presented positive preclinical
data for ANAVEX<sup>&#174;</sup>2-73 in an animal model of Parkinson&#8217;s disease, which demonstrated significant improvements on behavioral,
histopathological, and neuroinflammatory endpoints. The study was funded by the Michael J. Fox Foundation. Additional data announced in
October 2017 indicated that ANAVEX<sup>&#174;</sup>2-73 induced robust neurorestoration in experimental Parkinsonism. We believe the encouraging
results we have gathered in this preclinical model, coupled with the favorable profile of this product candidate in the Alzheimer&#8217;s
disease trial, support the notion that ANAVEX<sup>&#174;</sup>2-73 has the potential to treat Parkinson&#8217;s disease dementia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, we completed a double-blind, randomized,
placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease dementia in Spain and Australia,
to study the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s disease. The trial enrolled approximately
132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses, 30 mg and 50 mg, or placebo. The ANAVEX<sup>&#174;</sup>2-73
Phase 2 Parkinson&#8217;s disease dementia trial design incorporated genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73
Phase 2a Alzheimer&#8217;s disease trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trial demonstrated that ANAVEX<sup>&#174;</sup>2-73
was safe and well tolerated in oral doses up to 50 mg once daily. The results showed clinically meaningful, dose-dependent, and statistically
significant improvements in the Cognitive Drug Research (&#8220;CDR&#8221;) computerized assessment system analysis. Treatment with ANAVEX<sup>&#174;</sup>2-73
also resulted in clinically meaningful improvements as measured by the global composite score of Parkinson&#8217;s disease symptom severity,
MDS-Unified Parkinson&#8217;s Disease Rating Scale (&#8220;MDS-UPDRS&#8221;) total score on top of standard of care including dopaminergic
therapy, levodopa and other anti-PD medications after 14 weeks of treatment, suggesting ANAVEX<sup>&#174;</sup>2-73&#8217;s potential capability
of slowing and reversing symptoms that progress in Parkinson&#8217;s disease. In addition, the trial confirmed the precision medicine
approach of targeting SIGMAR1 as a genetic biomarker in response to ANAVEX<sup>&#174;</sup>2-73 may result in improved clinical outcomes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 1px; width: 25%; margin-top: 3pt; margin-bottom: 3pt"/>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="line-height: 115%"><sup>[2]</sup></span> ADAS-Cog13 scores
LS mean difference between the treatment groups being larger than 2 points are considered clinically meaningful improvements: Muir RT,
Hill MD, Black SE, Smith EE. Minimal clinically important difference in Alzheimer's disease: Rapid review.&#160;Alzheimers Dement. 2024;20(5):3352-3363.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 10; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A 48-week OLE ANAVEX2-73-PDD-EP-001 Phase 2 trial
was offered to participants after completion of the double-blind placebo-controlled ANAVEX2-73-PDD-001 Phase 2 trial discussed above.
The OLE trial assessed safety, tolerability and efficacy, measuring among others, MDS-Unified Parkinson&#8217;s Disease Rating Scale Parts
I, II, III, REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ), CGI-I, as well as cognitive efficacy endpoint Montreal Cognitive
Assessment (MoCA) over a 48-week period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2023, we reported the preliminary ANAVEX2-73-PDD-EP-001
OLE trial data, which demonstrated longitudinal beneficial effects of ANAVEX<sup>&#174;</sup>2-73 on the pre-specified primary and secondary
objectives. Preliminary analysis reveals that ANAVEX<sup>&#174;</sup>2-73 was found to be generally safe and well tolerated, and safety
findings in this trial were consistent with the known safety profile of ANAVEX<sup>&#174;</sup>2-73. In respect to efficacy, across all
efficacy endpoints, patients performed better while on ANAVEX<sup>&#174;</sup>2-73. While all patients were on drug holiday due to COVID-19
between the DB EOT and the OLE Baseline, the respective efficacy endpoints, including the MDS-UPDRS Part II + III and CGI-I, measured
at the end of trial of the double-blind study (DB EOT) and the OLE Baseline, were worsening, as expected in a progressive disease like
Parkinson&#8217;s. However, when patients resumed daily oral ANAVEX<sup>&#174;</sup>2-73 treatment, a consistent improvement was observed
during the extension phase from OLE Baseline through OLE Week 24, and OLE Week 48, respectively. These results are consistent with the
pattern observed for all efficacy measures in the extension phase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We anticipate conducting further clinical trials of
ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease dementia after submitting the results of the trial to regulatory authorities to
obtain regulatory guidance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Also with respect to Parkinson&#8217;s disease, in
January 2021, we were awarded a research grant of $1.0 million from&#160;The Michael J. Fox Foundation for Parkinson&#8217;s Research&#160;to
explore utilization of PET imaging biomarkers to enable measurement of target engagement and pathway activation of the SIGMAR1 with clinically
relevant doses including in people with Parkinson&#8217;s disease. This study is currently in the planning stage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Rett Syndrome </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, we presented positive preclinical
data for ANAVEX<sup>&#174;</sup>2-73 in Rett syndrome, a rare neurodevelopmental disease. The data demonstrated dose related significant
improvements in an array of behavioral and gait paradigms in a mouse model with an MECP2-null mutation that causes neurological symptoms
that mimic Rett syndrome. The study was funded by the International Rett Syndrome Foundation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Rett syndrome program includes several clinical trials that were conducted
in a range of patient age demographics and geographic regions, utilizing an oral liquid once-daily formulation of ANAVEX<sup>&#174;</sup>2-73.
The FDA has granted Orphan Drug Designation and the Rare Pediatric Disease (RPD) designation for the treatment of Rett syndrome. The RPD
designation is intended to encourage the development of treatments for rare pediatric diseases. Additionally, the FDA has granted Fast
Track designation for the ANAVEX<sup>&#174;</sup>2-73 clinical development program for the treatment of Rett syndrome. The FDA Fast Track
program is designed to facilitate and expedite the development and review of new drugs to address unmet medical needs in the treatment
of serious and life-threatening conditions. An earlier application for a proposed Rett syndrome study in the United States resulted in
the FDA requesting additional information. The resulting clinical hold and subsequent partial clinical hold have since been removed after
the Company satisfactorily provided the additional information requested. The following is a summary of clinical trials conducted by the
Company in Rett syndrome. The first Phase 2 trial, (ANAVEX<sup>&#174;</sup>2-73-RS-001), took place in the United States, and was completed
in December 2020. This trial was a randomized double-blind, placebo-controlled safety, tolerability, PK and efficacy trial of oral liquid
ANAVEX<sup>&#174;</sup>2-73 formulation in 25 adult female patients with Rett syndrome over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73-specific
genomic precision medicine biomarkers. The primary endpoint of the trial was safety. The dosing of 5 mg ANAVEX<sup>&#174;</sup>2-73 was
well-tolerated and demonstrated dose-proportional PK. All secondary efficacy endpoints of the trial showed statistically significant and
clinically meaningful response in the Rett Syndrome Behaviour Questionnaire (&#8220;RSBQ&#8221;) response, when compared to placebo, in
the intent to treat (&#8220;ITT&#8221;) cohort (all participants, p = 0.011). 66.7% of ANAVEX<sup>&#174;</sup>2-73 treated subjects showed
a statistically significant improvement in RSBQ response as compared to 10% of the subjects on placebo in the ITT cohort (all participants,
p = 0.011). ANAVEX<sup>&#174;</sup>2-73 treatment resulted in a sustained improvement in CGI-I response throughout the 7-week clinical
trial, when compared to placebo in the ITT cohort (all participants, p = 0.014). Consistent with previous ANAVEX<sup>&#174;</sup>2-73 clinical
trials, patients carrying the common form of the SIGMAR1 gene treated with ANAVEX<sup>&#174;</sup>2-73 experienced stronger improvements
in the prespecified efficacy endpoints.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 11; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This clinical trial was funded, in part, by a financial
grant from the International Rett Syndrome Foundation of $0.6 million. No other clinical trials with ANAVEX<sup>&#174;</sup>2-73 related
to Rett syndrome have been conducted in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
second, international trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome, called the AVATAR trial, commenced in June
2019.</span> This trial took place in Australia and the United Kingdom using a higher dose than the U.S. based Phase 2 trial for Rett
syndrome. The trial was a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of ANAVEX<sup>&#174;</sup>2-73
in 33 adult patients over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73 specific precision medicine biomarkers. Based
upon the input from the successful U.S. Phase 2 Rett syndrome trial (ANAVEX<sup>&#174;</sup>2-73-RS-001), we updated the endpoints for
the AVATAR trial (ANAVEX<sup>&#174;</sup>2-73-RS-002) to appropriately assess the clinically meaningful outcome following International
Conference on Harmonization (ICH) guidelines. These updates were approved by the respective regulatory authorities in the U.K. and in
Australia, respectively, where the AVATAR trial was conducted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The data from the AVATAR trial was released in February
2022. The clinical trial met all primary and secondary efficacy and safety endpoints, with consistent improvements in primary efficacy
endpoint, RSBQ response (p = 0.037), and secondary efficacy endpoints, Anxiety, Depression, and Mood Scale (ADAMS) (p = 0.010) and CGI-I
(p = 0.037) response. Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome
symptoms. Convenient once daily oral liquid doses of up to 30 mg of ANAVEX<sup>&#174;</sup>2-73 were also well tolerated with good medication
compliance. All patients who participated in the trial were eligible to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label
extension protocol and subsequent Compassionate Use Program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The very first trial of ANAVEX<sup>&#174;</sup>2-73
in pediatric Rett syndrome patients, the EXCELLENCE trial, completed enrollment in February 2023. This randomized, double-blind, placebo-controlled
Phase 2/3 trial in pediatric patients with Rett syndrome included trial sites in Canada, Australia, and the United Kingdom. 92 pediatric
patients with Rett syndrome between the ages of 5 through 17 years were treated daily with up to 30 mg ANAVEX<sup>&#174;</sup>2-73. Participants
were randomized 2:1 (ANAVEX<sup>&#174;</sup>2-73:placebo) for 12 weeks, followed by a week 16 safety visit and topline results from this
trial were announced in early January 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After 12 weeks, the study showed improvement on the
key co-primary endpoint RSBQ, which is a detailed 45-item questionnaire for assessing multiple Rett syndrome characteristics by the patients&#8217;
caregivers. The other co-primary endpoint, the CGI-I, which represents a less granular assessment by the site investigators using a seven-point
scoring (one=&#8220;very much improved&#8221; to seven=&#8220;very much worse&#8221;), was not met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In an ad-hoc analysis, using the predefined mixed-effect
model for repeated measure (MMRM) method, after 12 weeks of treatment, ANAVEX<sup>&#174;</sup>2-73-treated patients improved LS Mean (SE)
-12.93 (2.150) points on their RSBQ total score compared to LS Mean (SE) -8.32 (2.537) points in placebo-treated patients. The LS Mean
difference (SE) of -4.61 (2.439) points between treated and placebo groups did not reach statistical significance (n=77; p=0.063). ANAVEX<sup>&#174;</sup>2-73-treated
patients demonstrated a rapid onset of action with improvements at 4 weeks after treatment with a RSBQ total score LS Mean (SE) -10.32
(2.086) points in the drug-treated group compared to a LS Mean (SE) -5.67 (2.413) points in placebo-treated patients. The LS Mean difference
of -4.65 (2.233) points between treated and placebo groups was statistically significant (n=77; p=0.041).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The key secondary endpoint, the ADAMS, trended favorably.
In the same analysis, scores for all RSBQ and ADAMS subscales improved over the course of the study. Collectively, the RSBQ and ADAMS
demonstrated improvements in multiple areas, impacting positively in particular repetitive movements, nighttime disruptive behaviors,
and social avoidance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A preliminary review of the safety results indicates
there were no new safety signals in the EXCELLENCE study, reinforcing the favorable and manageable safety profile observed with ANAVEX<sup>&#174;</sup>2-73
to date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All patients who participated in the trial were eligible
to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label extension protocol, which was completed in June 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 12; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A high enrollment rate in the Open Label Extension
(&#8220;OLE&#8221;) of over 91% and the high level of requests for the Compassionate Use Program (93%) provide solid numerical evidence
for the reported positive Real World Evidence (RWE) from patients with Rett syndrome under Compassionate Use Authorization. Families whose
children were previously on drug or placebo in the placebo-controlled trial commented favorably on the improvement of their child&#8217;s
daily life due to ANAVEX<sup>&#174;</sup>2-73 treatment in the Compassionate Use Program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><i>Other indications</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe preclinical data from our studies also
supports further research into the use of ANAVEX<sup>&#174;</sup>2-73 as a potential platform drug for other neurodegenerative diseases
beyond Alzheimer&#8217;s disease, Parkinson&#8217;s disease or Rett syndrome, more specifically, epilepsy, infantile spasms, Fragile X
syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex (TSC). ANAVEX<sup>&#174;</sup>2-73 demonstrated significant
improvements in all of these indications in the respective preclinical animal models.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In a preclinical study sponsored by the Foundation
for Angelman Syndrome, ANAVEX<sup>&#174;</sup>2-73 was assessed in a mouse model for the development of audiogenic seizures. The results
indicated that ANAVEX<sup>&#174;</sup>2-73 administration significantly reduced audiogenic-induced seizures in mice. In a study sponsored
by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX<sup>&#174;</sup>2-73 restored hippocampal brain-derived
neurotrophic factor (BDNF) expression to normal levels. BDNF under-expression has been observed in many neurodevelopmental and neurodegenerative
pathologies. BDNF signaling promotes maturation of both excitatory and inhibitory synapses. ANAVEX<sup>&#174;</sup>2-73 normalization of
BDNF expression could be a contributing factor for the positive preclinical data observed in both neurodevelopmental and neurodegenerative
disorders like Angelman and Fragile X syndromes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, preclinical data to-date also indicates
that ANAVEX<sup>&#174;</sup>2-73 has the potential to demonstrate protective effects of mitochondrial enzyme complexes during pathological
conditions, which, if impaired, may play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, preclinical data on ANAVEX<sup>&#174;</sup>2-73
related to multiple sclerosis indicates that ANAVEX<sup>&#174;</sup>2-73 may promote remyelination in multiple sclerosis disease. Further,
our data also demonstrates that ANAVEX<sup>&#174;</sup>2-73 has the potential to provide protection for oligodendrocytes and oligodendrocyte
precursor cells (&#8220;OPCs&#8221;), as well as central nervous system neurons in addition to helping repair by increasing OPC proliferation
and maturation in tissue culture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2018, we presented preclinical data of ANAVEX<sup>&#174;</sup>2-73
in a genetic mouse model of tuberous sclerosis complex (&#8220;TSC&#8221;). TSC is a rare genetic disorder characterized by the growth
of numerous benign tumors in many parts of the body with a high incidence of seizures. The preclinical data demonstrated that treatment
with ANAVEX<sup>&#174;</sup>2-73 significantly increased survival and reduced seizures in those mice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><i>ANAVEX<sup>&#174;</sup>2-73
(blarcamesine)-specific Biomarkers</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of some of our clinical trials, we have incorporated
a genomic analysis to better understand potential populations for whom our clinical programs might benefit. A full genomic analysis of
Alzheimer&#8217;s disease patients treated with ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) has helped us identify actionable genetic variants.
A significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) and COMT, a gene
involved in memory function, on the drug response level was identified, leading to an early ANAVEX<sup>&#174;</sup>2-73 (blarcamesine)
specific biomarker hypothesis. We believe that <i>excluding</i> patients with SIGMAR1 identified biomarker variant (approximately 10%-20%
of the population) in prospective studies would identify approximately 80%-90% patients that would display clinically significant improved
functional and cognitive scores. The consistency between the identified DNA and RNA data related to ANAVEX<sup>&#174;</sup>2-73 (blarcamesine),
which are considered independent of Alzheimer&#8217;s disease pathology, as well as multiple endpoints and time-points, provides support
for the potential precision medicine clinical development of ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) by using genetic biomarkers identified
within the trial population itself to either confirm the mechanism of action of ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) or target patients
who are most likely to respond to ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) treatment. We may in the future utilize such an approach in
certain indications in which ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) is being studied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 13; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>3-71</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>3-71 is an orally available
clinical drug candidate with a novel mechanism of action via SIGMAR1 activation and M1 muscarinic allosteric modulation, which has been
shown to enhance neuroprotection and cognition in Alzheimer&#8217;s disease models. ANAVEX<sup>&#174;</sup>3-71 is a CNS-penetrable potential
disease modifying treatment for cognitive impairments. We believe it is effective against the major Alzheimer&#8217;s hallmarks in transgenic
(3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also has beneficial effects on inflammation and mitochondrial
dysfunctions. ANAVEX<sup>&#174;</sup>3-71 indicates extensive therapeutic advantages in Alzheimer&#8217;s and other protein-aggregation-related
diseases given its ability to enhance neuroprotection and cognition via SIGMAR1 activation and M1 muscarinic allosteric modulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A preclinical study examined the response of ANAVEX<sup>&#174;</sup>3-71
in aged transgenic animal models and showed a significant reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation
with the administration of ANAVEX<sup>&#174;</sup>3-71. The FDA has granted Orphan Drug Designation to ANAVEX<sup>&#174;</sup>3-71 for the
treatment of Frontotemporal Demetia (&#8220;FTD&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During pathological conditions ANAVEX<sup>&#174;</sup>3-71
demonstrated the formation of new synapses between neurons (synaptogenesis) without causing an abnormal increase in the number of astrocytes.
In neurodegenerative diseases such as Alzheimer&#8217;s and Parkinson&#8217;s disease, synaptogenesis is believed to be impaired. Additional
preclinical data presented also indicates that in addition to reducing oxidative stress, ANAVEX<sup>&#174;</sup>3-71 has the potential
to demonstrate protective effects of mitochondrial enzyme complexes during pathological conditions, which, if impaired, are believed to
play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the First-in-Human Phase
1 clinical trial of ANAVEX<sup>&#174;</sup>3-71. <span style="background-color: white">The Phase 1 clinical trial was a prospective double-blind,
randomized, placebo-controlled trial conducted in Australia. A total of 36 healthy male and female subjects were included. Single escalating
doses of ANAVEX<sup>&#174;</sup>3-71 were administered in order to evaluate the safety, tolerability, and PK of ANAVEX<sup>&#174;</sup>3-71
and the effects of food and gender on its PK in healthy volunteers. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The trial met
its primary and secondary endpoints of safety, with no serious adverse events (&#8220;SAEs&#8221;) or dose-limiting toxicities observed.
ANAVEX<sup>&#174;</sup>3-71 was well tolerated in all cohorts receiving ANAVEX<sup>&#174;</sup>3-71 in single doses ranging from 5 mg to
200 mg daily with no SAEs and no significant lab abnormalities in any subject. In the trial, ANAVEX<sup>&#174;</sup>3-71 exhibited linear
PK. Its pharmacokinetics was also dose proportional for doses up to 160 mg. Gender had no effect on the PK of the drug and food had no
effect on the bioavailability of ANAVEX<sup>&#174;</sup>3-71. The trial also met the secondary objective of characterizing the effect of
ANAVEX<sup>&#174;</sup>3-71 on electrocardiogram (&#8220;ECG&#8221;) parameters. There were no clinically significant ECG parameters throughout
the trial. Participant QTcF measures were normal across all dose groups with no difference between ANAVEX<sup>&#174;</sup>3-71 and placebo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In October 2023
a peer-reviewed publication in the journal <i>Neurobiology of Aging</i>, titled &#8216;<i>Early treatment with an M1 and sigma-1 receptor
agonist prevents cognitive decline in a transgenic rat model displaying Alzheimer-like amyloid pathology</i>&#8217;, featured the orally
available small molecule ANAVEX<sup>&#174;</sup>3-71 (AF710B). The preclinical study described the potential disease-modifying properties
of ANAVEX<sup>&#174;</sup>3-71 on Alzheimer&#8217;s disease pathology as a possible drug candidate for a potential once daily oral preventive
strategy for Alzheimer&#8217;s disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In January 2024,
in another peer-reviewed publication in the journal <i>Clinical Pharmacology in Drug Development</i>, entitled, &#8216;<i>Population-Based
Characterization of the Pharmacokinetics and Food Effect of ANAVEX3-71, a Novel Sigma-1 Receptor and Allosteric M1 Muscarinic Receptor
Agonist in Development for Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer Disease&#8217;</i>, reported the population-based
characterization of the PK and food effect of ANAVEX<sup>&#174;</sup>3-71 as part of the single ascending dose study in healthy participants
with the primary objective of assessing dose proportionality of ANAVEX<sup>&#174;</sup>3-71, and to characterize the effect of food on
the PK of ANAVEX<sup>&#174;</sup>3-71. The results from this PK evaluation demonstrated that ANAVEX<sup>&#174;</sup>3-71, at single ascending
doses of 5 to 200 mg, is linear, dose proportional, and time invariant. Food had no effect on the PK of ANAVEX<sup>&#174;</sup>3-71. This
data also expands the safety objectives met in this first-in-human study of ANAVEX<sup>&#174;</sup>3-71, further supporting its drug development
program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Based on these
results, and ANAVEX<sup>&#174;</sup>3-71 pre-clinical profile, the Company intends to advance ANAVEX<sup>&#174;</sup>3-71 into a biomarker-driven
clinical development dementia program for the treatment of schizophrenia, FTD and Alzheimer&#8217;s disease, evaluating longitudinal effect
of treatment with ANAVEX<sup>&#174;</sup>3-71. The first of these trials is being conducted in schizophrenia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 14; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><i>Schizophrenia</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In March 2024,
we commenced the U.S. FDA-cleared ANAVEX<sup>&#174;</sup>3-71-SZ-001 clinical trial: a double-blind, placebo-controlled Phase 2 trial in
schizophrenia. The trial consists of two parts to explore multiple ascending doses in individuals with schizophrenia followed by a 28-day
treatment period in a larger cohort. The trial will utilize standard clinical outcome measures for schizophrenia including the Positive
and Negative Symptoms Scale (PANSS), and novel fluid and electrophysiological biomarkers will also be assessed, leveraging several advances
in electroencephalography/event-related potential (EEG/ERP) biomarkers in schizophrenia developed in collaboration with the industry-led
ERP Biomarker Qualification Consortium. In addition to the electrophysiological biomarkers, we are also applying novel neuroinflammatory,
metabolomic, and transcriptomic biomarkers at the intersection of schizophrenia pathophysiology and ANAVEX<sup>&#174;</sup>3-71&#8217;s
novel, dual mechanism of action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Preliminary
results from Part A of the ANAVEX<sup>&#174;</sup>3-71-SZ-001 clinical trial, consisting of a multiple ascending dose study in 16 participants,
demonstrated a dose-dependent effect of ANAVEX<sup>&#174;</sup>3-71 on two key EEG biomarkers in patients with schizophrenia. The effects
were most pronounced in the higher dose group indicating a dose-dependent pharmacodynamic effect. The observed changes reversed known
electroencephalography (EEG) and ERP biomarker abnormalities associated with schizophrenia. These EEG biomarkers correlate with positive,
negative, and cognitive symptoms of schizophrenia. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In May 2025
we announced the completion of enrollment of Part B of the study, which included more participants and a longer treatment duration. The
top-line data of the Phase 2 ANAVEX<sup>&#174;</sup>3-71-SZ-001 clinical was announced in October 2025. The study successfully achieved
its primary endpoint, demonstrating that ANAVEX<sup>&#174;</sup>3-71 was safe and well-tolerated. The safety profile was consistent with
previous studies of ANAVEX<sup>&#174;</sup>3-71 in healthy volunteers, with no serious treatment-emergent adverse events (TEAEs) and no
severe TEAEs reported in either Part A or Part B of the study. In addition to meeting the primary safety endpoint, secondary and exploratory
analyses revealed encouraging trends in several outcome measures. The study demonstrated positive trends in objective electroencephalography
(EEG) and event-related potential (ERP) biomarkers of schizophrenia. Furthermore, neuroinflammatory biomarker assessments showed that
glial fibrillary acidic protein (GFAP), a marker of neuroinflammation, was reduced in participants receiving ANAVEX<sup>&#174;</sup>3-71
compared to placebo. This reduction in neuroinflammatory markers suggests a potential disease-modifying effect that may become more pronounced
with longer treatment durations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ANAVEX<sup>&#174;</sup>1-41</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1-41 is a sigma-1 agonist. Pre-clinical
tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration or death) through the modulation of
endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell viability. In addition, in animal models, ANAVEX<sup>&#174;</sup>1-41
prevented the expression of caspase-3, an enzyme that plays a key role in apoptosis (programmed cell death) and loss of cells in the hippocampus,
the part of the brain that regulates learning, emotion and memory. These activities involve both muscarinic and SIGMAR1 systems through
a novel mechanism of action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data presented also indicates that ANAVEX<sup>&#174;</sup>1-41
has the potential to demonstrate protective effects of mitochondrial enzyme complexes during pathological conditions, which, if impaired,
are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>1066</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1066, a mixed sigma-1/sigma-2
ligand, is designed for the potential treatment of neuropathic and visceral pain. ANAVEX<sup>&#174;</sup>1066 was tested in two preclinical
models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic constriction injury model of neuropathic
pain, a single oral administration of ANAVEX<sup>&#174;</sup>1066 dose-dependently restored the nociceptive threshold in the affected paw
to normal levels while leaving the contralateral healthy paw unchanged. Efficacy was rapid and remained significant for two hours. In
a model of visceral pain, chronic colonic hypersensitivity was induced by injection of an inflammatory agent directly into the colon and
a single oral administration of ANAVEX<sup>&#174;</sup>1066 returned the nociceptive threshold to control levels in a dose-dependent manner.
Companion studies in rats demonstrated the lack of any effects on normal gastrointestinal transit with ANAVEX<sup>&#174;</sup>1066 and
a favorable safety profile in a battery of behavioral measures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 15; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>1037 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1037 is designed for the treatment
of prostate and pancreatic cancer. It is a low molecular weight, synthetic compound exhibiting high affinity for sigma-1 receptors at
nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels. In advanced pre-clinical studies,
this compound revealed antitumor potential. It has also been shown to selectively kill human cancer cells without affecting normal/healthy
cells and also to significantly suppress tumor growth in immune-deficient mice models. Scientific publications highlight the possibility
that these ligands may stop tumor growth and induce selective cell death in various tumor cell lines. Sigma receptors are highly expressed
in different tumor cell types. Binding by appropriate sigma-1 and/or sigma-2 ligands can induce selective apoptosis. In addition, through
tumor cell membrane reorganization and interactions with ion channels, we believe our drug candidates may play an important role in inhibiting
the processes of metastasis (spreading of cancer cells from the original site to other parts of the body), angiogenesis (the formation
of new blood vessels) and tumor cell proliferation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1037 is currently in the pre-clinical
and clinical testing stages of development, and there is no guarantee that the activity demonstrated in pre-clinical models will be shown
in human testing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We continue to identify and initiate discussions with
potential strategic and commercial partners to most effectively advance our programs and increase stockholder value. Further, we may acquire
or develop new intellectual property and assign, license, or otherwise transfer our intellectual property to further our goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Target Indications </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are developing compounds with potential application
to two broad categories and several specific indications, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Central Nervous System Diseases</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Alzheimer&#8217;s disease &#8211; An estimated 7.2
    million Americans aged 65 and older are living with Alzheimer&#8217;s dementia in 2025, according to the Alzheimer&#8217;s Association<sup>&#174;</sup>.
    The Alzheimer&#8217;s Association<sup>&#174;</sup> estimates that the annual number of new cases of Alzheimer&#8217;s and other dementias
    is projected to double by 2050. Medications on the market today treat only the symptoms of Alzheimer&#8217;s disease and do not have the
    ability to stop its onset or its progression. We believe that there is an urgent and unmet need for both a disease modifying cure for
    Alzheimer&#8217;s disease as well as for better symptomatic treatments.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Parkinson&#8217;s disease &#8211; Parkinson&#8217;s
    disease is a progressive disease of the nervous system marked by tremors, muscular rigidity, and slow, imprecise movement. It is associated
    with degeneration of the basal ganglia of the brain and deficiency of the neurotransmitter dopamine. Parkinson&#8217;s disease currently
    is estimated to afflict more than 10 million people worldwide, typically middle-aged and elderly people. The Parkinson&#8217;s disease
    market is expected to reach $11.5 billion by 2029, according to GlobalData.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rett syndrome &#8211; Rett syndrome is a rare X-linked
    genetic neurological and developmental disorder that affects the way the brain develops, including protein transcription, which is altered
    and as a result leads to severe disruptions in neuronal homeostasis. It is considered a rare, progressive neurodevelopmental disorder
    and is caused by a single mutation in the MECP2 gene. Because males have a different chromosome combination from females, boys who have
    the genetic MECP2 mutation are affected in devastating ways. Most of them die before birth or in early infancy. For females who survive
    infancy, Rett syndrome leads to severe impairments, affecting nearly every aspect of the child&#8217;s life: severe mental retardation,
    their ability to speak, walk and eat, sleeping problems, seizures and even the ability to breathe easily. Rett syndrome affects approximately
    1 in every 10,000-15,000 females.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Schizophrenia - Schizophrenia is a persistent
and often disabling mental illness impacting how a person thinks, feels, and behaves, and affects nearly 24 million people worldwide,
including 2.8 million people in the U.S., according to the World Health Organization. It is characterized by three symptom domains: positive
symptoms (hallucinations and delusions), negative symptoms (difficulty enjoying life and withdrawal from others), and cognitive impairment
(deficits in memory, concentration, and decision-making). In part due to limitations with current treatments, people living with schizophrenia
often struggle to maintain employment, live independently, and manage relationships. While current treatments can be effective in managing
select symptoms, approximately 34% of people do not respond to therapy, with an additional 50-60% experiencing only a partial improvement
in symptoms or unacceptable side effects.</p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 16; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fragile X &#8211; Fragile X syndrome (FXS) is the
    most prevalent genetic form of intellectual disability and autism spectrum disorder, primarily affecting boys. As with most neurodevelopmental
    disorders, FXS is considered a condition of synaptic development and function. The disease has a range of clinical presentations depending
    on the specific genetic changes associated with an &#8220;expansion&#8221; of the FMR1 gene. The disease is characterized by deficits
    in long-term potentiation and homeostatic plasticity. FXS has been detected in all populations and ethnic groups. Researchers do not know
    the exact number for how many Americans could have full mutation FXS. Studies estimate that the disease affects approximately 1:4,000
    males and 1:6,000 females. Worldwide, more than 1,400,000 people could be affected by FXS.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Depression &#8211; Depression is a major cause of morbidity worldwide according to the World Health Organization. The global antidepressant drug market is projected to reach $21 billion by 2030 according to Allied Market Research. Pharmaceutical treatment for depression has been historically dominated by blockbuster brands. However, the dominance of the leading brands is waning, largely due to an increase in the number of approvals for antidepressant drugs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Epilepsy &#8211; Epilepsy is a common chronic neurological
    disorder characterized by recurrent unprovoked seizures. These seizures are transient signs and/or symptoms of abnormal, excessive or
    synchronous neuronal activity in the brain. According to the Centers for Disease Control and Prevention, data from 2021 and 2022 suggest
    epilepsy affects roughly 3.4 million Americans. Today, epilepsy is often controlled, but not cured, with medications that are categorized
    as older traditional anti-epileptic drugs and second-generation anti-epileptic drugs. Because epilepsy afflicts sufferers in different
    ways, there is a need for drugs used in combination with both traditional anti-epileptic drugs and second generation anti-epileptic drugs.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuropathic Pain &#8211; We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in any part of the body. Neuralgia is more difficult to treat than some other types of pain because it does not respond well to normal pain medications. Special medications have become more specific to neuralgia and typically fall under the category of membrane stabilizing drugs or antidepressants.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Cancer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Malignant Melanoma &#8211; Predominantly a skin cancer,
    malignant melanoma can also occur in melanocytes found in the bowel and the eye. Malignant melanoma accounts for a large majority of skin
    cancer deaths. The treatment includes surgical removal of the tumor, adjuvant treatment, chemo and immunotherapy, or radiation therapy.
    According to iHealthcareAnalyst, Inc. the worldwide malignant melanoma market is expected to grow to $7.5 billion by 2029.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prostate Cancer &#8211; Specific to men, prostate
    cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system. Cancer cells may metastasize from the
    prostate to other parts of the body, particularly the bones and lymph nodes. Drug therapeutics for prostate cancer are expected to increase
    to nearly $10.1 billion by the end of 2030 according to Market Research Future.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pancreatic Cancer &#8211; Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States, approximately 67,000 new cases of pancreatic cancer will be diagnosed this year and approximately 52,000 patients will die as a result of their cancer, according to the American Cancer Society. Sales predictions by Market Data Forecast predict that the market for the global pharmaceutical treatment of pancreatic cancer will increase to $3.7 billion by 2027.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Competition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The drug discovery and development industry is very
competitive, characterized by rapid advancements in technology, where protection of proprietary advancements is essential. Any product
candidates that we may successfully develop and commercialize, may compete with existing therapies, or new therapies that may become available
in the future. Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that
are more effective, have fewer side effects, are more convenient or are less expensive than any products that we may develop.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 17; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe our approach to the treatment of Alzheimer&#8217;s
disease and other CNS diseases differs from our competitors. Our platform may offer a disease-modifying approach in neurodegenerative
and neurodevelopmental diseases by activation of SIGMAR1. In our preclinical studies, when activated by SIGMAR1 agonists, such as ANAVEX<sup>&#174;</sup>2-73,
SIGMAR1 demonstrated reduced cellular stress before and after RNA gene transcription. Our studies confirm the potential existence of a
predictive biomarker of response established through SIGMAR1 mRNA expression that could be used in future clinical trials. Because of
its role in maintaining neuronal homeostasis, we believe sigma receptors show significant promise as viable targets for therapeutic molecules
in an effort to treat Alzheimer&#8217;s disease and other CNS diseases and disorders by restoring healthy gene expression.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At this time, our competitors are primarily other
biomedical development companies that are aiming to discover and develop compounds to be used in the treatment of Alzheimer&#8217;s disease
and other CNS diseases, and those companies already doing so. We also face competition from academic institutions and government agencies,
both in the United States and abroad.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our competitors may have significantly greater financial
resources, an established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing,
or may be in the process of obtaining regulatory approvals and marketing of approved products. These competitors also compete with us
in recruiting and retaining qualified scientific and technical personnel, establishing clinical trial sites and patient registration for
clinical trials, as well as in acquiring or developing technologies complementary to, or necessary for, our programs. Smaller or early-stage
companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For additional discussion of the risks related to
competition, see Item 1A &#8220;Risk Factors.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Patents, Trademarks and Intellectual Property
</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We hold ownership or exclusive rights to thirty (30)
issued U.S. patents, seventeen (17) pending U.S. patent applications, and numerous PCT and ex-U.S. patents and patent applications relating
to our drug candidates, methods associated therewith, and to our research programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We own one issued U.S. patent entitled &#8220;ANAVEX<sup>&#174;</sup>2-73
and certain anticholinesterase inhibitors composition and method for neuroprotection,&#8221; which claims a composition of matter of ANAVEX<sup>&#174;</sup>2-73,
a synergistic neuroprotective compound, combined with donepezil and other cholinesterase inhibitors. This patent is expected to expire
in June 2034, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We own another issued U.S. patent entitled &#8220;A2-73
crystalline polymorph compositions of matter and methods of use thereof&#8221;. It claims crystals of A2-73 freebase or its fumarate salt,
dosage forms and pharmaceutical formulations. This patent is expected to expire in July 2039, absent any patent term extension for regulatory
delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We own five issued U.S. patents each with claims directed
to crystalline forms of ANAVEX<sup>&#174;</sup>2-73. The first of these five patents claims crystalline forms of ANAVEX<sup>&#174;</sup>2-73,
dosage forms and compositions containing crystalline ANAVEX<sup>&#174;</sup>2-73, and methods of treatment for Alzheimer&#8217;s disease
using them. This patent is expected to expire in July 2036, absent any patent term extension for regulatory delays. The second of these
five patents claims pharmaceutical compositions containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73, and methods of treatment
for Alzheimer&#8217;s disease using the compositions. This patent is expected to expire in June 2036, absent any patent term extension
for regulatory delays. The third of these five patents claims pharmaceutical compositions containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73,
and methods of treating for Alzheimer&#8217;s disease using the compositions. This patent is expected to expire in June 2037, absent any
patent term extension for regulatory delays. The fourth patent claims method of making certain crystalline forms of ANAVEX<sup>&#174;</sup>2-73.
This patent is expected to expire in October 2036, absent any patent term extension for regulatory delays. The fifth patent claims crystalline
forms of the dihydrogen phosphate salt of ANAVEX<sup>&#174;</sup>2-73 and dosage forms (including transdermal and oral dosage forms) and
pharmaceutical compositions containing the same. This patent is expected to expire in July 2039, absent any patent term extension for
regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 18; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own three issued U.S. patents for seizure
treatment. The first of these three patents claims methods and dosage forms for treating seizures, the dosage forms containing a low-dose
anti-epilepsy drug combined with either: (i) ANAVEX<sup>&#174;</sup>2-73 and its active metabolite ANAVEX<sup>&#174;</sup>19-144; or (ii)
ANAVEX<sup>&#174;</sup>19-144. The second of these three patents further claims a combination seizure treatment involving administration
of an anti-epilepsy drug combined with (i) ANAVEX<sup>&#174;</sup>19-144, or (ii) ANAVEX<sup>&#174;</sup>19-144 and ANAVEX<sup>&#174;</sup>2-73.
The third of these three patents claims a dosage form for seizure reduction, comprising (i) ANAVEX<sup>&#174;</sup>19-144, (ii) ANAVEX<sup>&#174;</sup>2-73,
or (iii) a combination of ANAVEX<sup>&#174;</sup>19-144 and ANAVEX<sup>&#174;</sup>2-73; and optionally further comprising a low-dose anti-epilepsy
drug. All three patents are expected to expire in October 2035, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own four issued U.S. patents with claims directed
to treating neurodevelopmental disorders. These patents claim methods for treating a neurodevelopmental disorder, multiple sclerosis,
their related biochemical and functional abnormalities, or loss-of-function associated with a neurodevelopmental disorder, by administering
ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144, and/or ANAVEX<sup>&#174;</sup>1-41 (another sigma receptor ligand similar to
ANAVEX<sup>&#174;</sup>2-73), or compositions thereof. All four patents are expected to expire in January 2037, absent any patent term
extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, we own one issued U.S. patent with claims
directed to methods of treating melanoma with a compound related to ANAVEX<sup>&#174;</sup>2-73. This patent is expected to expire in February
2030, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own an issued U.S. patent that claims crystalline
forms of ANAVEX<sup>&#174;</sup>19-144, dosage forms and compositions containing the crystalline forms of ANAVEX<sup>&#174;</sup>19-144,
and methods of treatment for Alzheimer&#8217;s disease. This patent is expected to expire in July 2036, absent any patent term extension
for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, we own two issued U.S. patents with claims
directed to methods of treating cardiac dysfunction with ANAVEX<sup>&#174;</sup>2-73. These patents are expected to expire in July 2038,
absent any patent term extension for regulatory delays. Additionally, we own three issued U.S. patents for the treatment of insomnia,
anxiety, or agitation. The first of the three patents claims methods of treating insomnia or anxiety with ANAVEX<sup>&#174;</sup>2-73,
ANAVEX<sup>&#174;</sup>19-144, and/or ANAVEX<sup>&#174;</sup>1-41. This patent is expected to expire in September 2038. The second and third
of the three patents claim dosage forms comprising any of, or any combination of ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144,
and/or ANAVEX<sup>&#174;</sup>1-41. These patents are expected to expire in July 2037, absent any patent term extension for regulatory
delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, we own one issued U.S. patent with claims
directed to a method of treating Alzheimer&#8217;s disease based upon selection of particular responders to ANAVEX<sup>&#174;</sup>A2-73
treatment based upon the absence of certain genetic polymorphisms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, we own one issued U.S. patent with claims
directed to a method of treating systolic hypertension using ANAVEX<sup>&#174;</sup>2-73. This patent is expected to expire in July 2039,
absent any patent term extension for regulatory delays. Additionally, we own one issued U.S. patent with claims directed to pharmaceutical
dosage forms of the (-) enantiomer of ANAVEX<sup>&#174;</sup>2-73. This patent is expected to expire in July 2036, absent any patent term
extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own three issued U.S. patents related to ANAVEX<sup>&#174;</sup>1066.
The first of these three patents claims methods for treating or preventing pain using the (+) ANAVEX<sup>&#174;</sup>1066 isomer. The second
patent claims methods for treating or preventing pain using the (-) ANAVEX<sup>&#174;</sup>1066 isomer. The third patent claims dosage
forms and pharmaceutical compositions comprising the (+) ANAVEX<sup>&#174;</sup>1066 isomer. All three patents are expected to expire in
November 2036, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144,
ANAVEX<sup>&#174;</sup>1-41, and ANAVEX<sup>&#174;</sup>1066, we also have granted or pending applications in Australia, Canada, China,
Europe, Japan, and Hong Kong, which are expected to expire after 2035.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With regard to ANAVEX<sup>&#174;</sup>3-71, we own
exclusive rights to two issued U.S. patents with claims respectively directed to the ANAVEX<sup>&#174;</sup>3-71 compound and methods of
treating various diseases including Alzheimer&#8217;s with the same. These patents are expected to expire in April 2030, and January 2030,
respectively, absent any patent term extension for regulatory delays. We also own exclusive rights to related patents or applications
that are granted or pending in Australia, Canada, China, Europe, Japan, Korea, New Zealand, Russia, and South Africa, which are expected
to expire in January 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own other patent applications and certain
granted foreign patents directed to enantiomers, crystals, formulations, uses, and patient selection methods that may provide additional
protection for one or more of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We regard patents and other intellectual property
rights as corporate assets. Accordingly, we attempt to optimize the value of intellectual property in developing our business strategy
including the selective development, protection, and exploitation of our intellectual property rights. In addition to filings made with
intellectual property authorities, we protect our intellectual property and confidential information by means of carefully considered
processes of communication and the sharing of information, and by the use of confidentiality and non-disclosure agreements and provisions
for the same in contractor&#8217;s agreements. While no agreement offers absolute protection, such agreements provide some form of recourse
in the event of disclosure, or anticipated disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Our
intellectual property position, like that of many biomedical companies, is uncertain and involves complex legal and technical questions
for which important legal principles are unresolved. For more information regarding challenges to our existing or future patents, see
&#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Government regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Government authorities in the United States, at the
federal, state and local levels, and in other countries extensively regulate, among other things, the research, development, testing,
manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing
and export and import of products such as those we are developing. A new drug must be approved by the local regulatory authority through
an NDA, MAA or other regulatory process before it may be legally marketed in each jurisdiction. We are subject to various government regulations
in connection with the development of our pipeline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>U.S. Drug Development and Regulation </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, the FDA regulates drugs under
the Federal Food, Drug, and Cosmetic Act and its implementing regulations (&#8220;FDCA&#8221;). The process of obtaining regulatory approvals
and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial
time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process,
approval process or post approval may subject an applicant to administrative or judicial sanctions. These sanctions could include the
FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, import refusal, a clinical hold, warning letters, product
recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts,
restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect
on us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Once a drug candidate is identified for development,
it enters the preclinical testing stage and an Investigational New Drug Application (&#8220;IND&#8221;) may be opened for the regulatory
development of the product. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as
other preclinical studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and
analytical data, to the FDA as part of the IND to conduct clinical trials. The sponsor must also include a protocol detailing, among other
things, the objectives of the clinical trials, the parameters to be used in monitoring the safety of the trial, and the effectiveness
criteria to be evaluated should the trial include an efficacy evaluation. Some preclinical testing may continue even after the IND is
filed. The IND automatically becomes effective thirty (30) days after receipt by the FDA, unless the FDA, within the 30-day time period,
places the clinical trial on a clinical hold. Clinical holds also may be imposed by the FDA at any time before or during clinical trials
due to safety concerns about ongoing or proposed clinical trials or non-compliance with specific FDA requirements, and the trials may
not begin or continue until the FDA notifies the sponsor that the hold has been lifted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All clinical trials must be conducted under the supervision
of one or more qualified investigators in accordance with FDA good clinical practice (&#8220;GCP&#8221;) requirements, which include a
requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical
trials must be conducted under protocols detailing the objectives of the trial, dosing procedures, subject selection inclusion and exclusion
criteria and the safety and/or effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND,
and timely safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events. An Institutional
Review Board (&#8220;IRB&#8221;) at each institution participating in the clinical trial must review and approve each protocol before
a clinical trial may commence at the institution and must also approve the information regarding the trial as well as the informed consent
form that must be provided to each trial participant or his or her legal representative, monitor the study until completed and otherwise
comply with all applicable IRB regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 20; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Human clinical trials are typically conducted in three
sequential phases that may overlap or be combined in certain cases:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Phase 1: The compound is initially introduced into
healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to
gain an early indication of its effectiveness. In most cases, initial Phase 1 clinical trials are conducted with healthy volunteers. However,
where the compound being evaluated is for the treatment of severe or life-threatening diseases, such as cancer, and especially when the
product may be too toxic to ethically administer to healthy volunteers, the initial human testing may be conducted on patients with the
target disease or condition. Sponsors sometimes subdivide their Phase 1 clinical trials into Phase 1a and Phase 1b clinical trials. Phase
1b clinical trials are typically aimed at confirming dosage, PK and safety in a larger number of patients. Some Phase 1b clinical trials
evaluate biomarkers or surrogate markers that may be associated with efficacy in patients with specific types of diseases or conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Phase 2: This phase involves clinical trials in a
limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product
for specific targeted diseases or conditions and to confirm dosage tolerance and appropriate dosage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Phase 3: Phase 3 clinical trials are undertaken to
further evaluate dosage, clinical efficacy and safety in an expanded patient population, generally at geographically dispersed clinical
trial sites. These clinical trials, often referred to as &#8220;pivotal&#8221; or &#8220;confirmatory&#8221; clinical trials, are intended
to establish the overall risk-benefit ratio of the compound and provide, if appropriate, an adequate basis for product approval and labeling.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA or the sponsor may suspend a clinical trial
at any time on various grounds, including any finding that the research subjects or patients are being exposed to an unacceptable health
risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted
in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected, serious harm to study subjects. In
addition, clinical trials may be overseen by an independent group of qualified experts organized by the sponsor, known as a data safety
monitoring board or committee. Depending on its charter, this board or committee may determine whether a trial may move forward at designated
check points based on access to certain data from the trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Phase 4: Phase 4 or post-approval trials may also
be conducted after a drug receives initial marketing approval. These trials, often referred to as &#8220;Phase 4&#8221; trials, are used
to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may
mandate the performance of such clinical trials as a condition of approval of continued marketing of the product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the development of a new drug, sponsors are
given several opportunities to meet with the FDA. These meetings can provide an opportunity for the sponsor to share information about
the progress of the application or clinical trials, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement
on the next phase of development. These meetings may occur prior to the submission of an IND, at the end of Phase 2 clinical trials, or
before an NDA is ultimately submitted. Sponsors typically use the meetings at the end of the Phase 2 trials to discuss Phase 2 clinical
results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug. Meetings at
other times may be made upon request and are subject to approval by the FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Concurrent with clinical trials, companies typically
complete additional, animal or other non-clinical studies, develop additional information about the chemistry and physicochemical characteristics
of the drug, and finalize a process for manufacturing the product in commercial quantities in accordance with the FDA&#8217;s current
Good Manufacturing Practices (&#8220;cGMP&#8221;) requirements. The manufacturing process must consistently produce quality batches of
the drug and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the
final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate the
effectiveness of the packaging and that the compound does not undergo unacceptable deterioration over its shelf life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While the IND is active, progress reports summarizing
the results of ongoing clinical trials and nonclinical studies performed since the last progress report must be submitted on at least
an annual basis to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected adverse
events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal
or in vitro testing suggesting a significant risk to humans, and any clinically important, increased incidence of a serious adverse reaction
compared to that listed in the protocol or investigator brochure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are also requirements governing the submission
of certain clinical trials and completed trial results to public registries. Sponsors of certain clinical trials of FDA-regulated products
are required to register and disclose specified clinical trial registration and results information, which is made publicly available
at www.clinicaltrials.gov. Failure to properly report clinical trial results can result in civil monetary penalties. Disclosure of clinical
trial results can often be delayed until the new product or new indication being studied has been approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>U.S. review and approval process </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The results of product development, preclinical and
other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the
chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of a New Drug Application (&#8220;NDA&#8221;).
The submission of an NDA is subject to the payment of substantial user fees; a waiver of which may be obtained under certain limited circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA reviews NDAs to determine, among other things,
whether the product is safe and effective for its intended use and whether it is manufactured in a cGMP-compliant manner, which will assure
and preserve the product&#8217;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;),
the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard, completed NDA for a new molecular entity to review
and act on the submission. This review typically takes twelve months from the date the NDA is submitted to the FDA because the FDA has
approximately two months to make a &#8220;filing&#8221; decision after the application is submitted. The FDA conducts a preliminary review
of all NDAs within the first sixty days after submission, before accepting them for filing, to determine whether they are sufficiently
complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event,
the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts
it for filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA may refer an application for a new drug to
an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that
reviews, evaluates and provides a recommendation as to whether and under what conditions the application should be approved. The FDA is
not bound by the recommendations of such an advisory committee, but it considers advisory committee recommendations carefully when making
decisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Before approving an NDA, the FDA will also inspect
the facility where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes
and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required
specifications. Before approving an NDA, the FDA may also inspect one or more clinical trial sites to assure compliance with GCP requirements
and inspect the clinical trial records.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After the FDA evaluates an NDA, it will issue an approval
letter or a Complete Response Letter. A Complete Response Letter indicates that the review cycle of the application is complete, and the
application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA
identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial or other significant and time-consuming
requirements related to clinical trials, nonclinical studies or product manufacturing. If a Complete Response Letter is issued, the sponsor
must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and
information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. An approval letter authorizes commercial
marketing of the drug with prescribing information for specific indications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 22; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Pediatric Research Equity Act (&#8220;PREA&#8221;),
requires IND sponsors to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form,
new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless
the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the
claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for
which the product is safe and effective. The sponsor or the FDA may request a deferral of pediatric clinical trials for some or all of
the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for
use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before
the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment,
keeps a deferral current or fails to submit a request for approval of a pediatric formulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a drug receives FDA approval, the approval may
be limited to specific diseases and dosages, which could restrict the commercial value of the product. In addition, the FDA may require
testing and surveillance programs to monitor the safety of approved products which have been commercialized and may require a sponsor
to conduct post-marketing clinical trials (Phase 4 clinical trials), which are designed to further assess a drug&#8217;s safety and effectiveness
after NDA approval. The FDA may also place other conditions on approval, including a requirement for a risk evaluation and mitigation
strategy (&#8220;REMS&#8221;) to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit
a proposed REMS. The FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician
communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescribing or dispensing
of products. Marketing approval may be withdrawn for non-compliance with REMS or other regulatory requirements, or if problems occur following
initial marketing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Post-approval requirements </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Once an approval is granted, the FDA may withdraw
the approval if compliance with regulatory standards is not maintained or if problems occur after the drug reaches the market. Later discovery
of previously unknown problems with a drug may result in restrictions on the drug or even complete withdrawal of the drug from the market.
After approval, some types of changes to the approved drug, such as adding new indications, certain manufacturing changes and additional
labeling claims, are subject to further FDA review and approval. Manufacturers and other entities involved in the manufacture and distribution
of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced
inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any drug product manufactured or distributed by us
pursuant to FDA approval will be subject to continuing regulation by the FDA, including, among other things, record-keeping requirements,
reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug sampling and distribution
requirements, complying with certain electronic records and signature requirements, and complying with FDA promotion and advertising requirements.
FDA strictly regulates labeling, advertising, promotion and other types of information regarding approved drugs that are placed on the
market, and imposes requirements and restrictions on drug manufacturers, such as those related to direct-to-consumer advertising, the
prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known
as &#8220;off-label use&#8221;), industry-sponsored scientific and educational activities, and promotional activities involving the internet.
Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions
on the marketing of a product for a certain indication or withdrawal of the product from the market as well as possible civil or criminal
sanctions. Failure to comply with the applicable governmental requirements at any time during the product development process, approval
process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse
publicity. The FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-marketing
clinical trials, enforcement letters, import refusals, product recalls, product seizures, total or partial suspension of production or
distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment,
restitution, disgorgement of profits, or civil or criminal penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 23; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Expedited development and review programs </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA has a fast track designation program that
is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, new drugs
are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate
the potential to address unmet medical needs for the disease or condition. With regard to a fast track product, the FDA may consider for
review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the
submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and
the sponsor pays any required user fees upon submission of the first section of the NDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any product submitted to the FDA for approval, including
a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review,
such as priority review and accelerated approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A product is eligible for priority review if it is
intended to treat a serious condition, and if approved, would provide a significant improvement in safety or efficacy compared to currently
marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for
priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within
six months of the filing date, as compared to ten months for review of NDAs under its current PDUFA review goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, a product may be eligible for accelerated
approval. Drugs intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination
that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on a clinical endpoint
that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible
morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability
or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval
perform adequate and well-controlled post-marketing clinical trials. Drugs receiving accelerated approval may be subject to expedited
withdrawal procedures if the sponsor fails to conduct the required post-marketing trials or if such trials fail to verify the predicted
clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval, pre-approval of promotional materials,
which could adversely impact the timing of the commercial launch of the product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Food and Drug Administration Safety and Innovation
Act (&#8220;FDASIA&#8221;) established a category of drugs referred to as &#8220;breakthrough therapies&#8221; that may be eligible to
receive breakthrough therapy designation. A sponsor may seek FDA designation of a compound as a &#8220;breakthrough therapy&#8221; if
the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition
and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or
more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes
all of the fast track program features, as well as more intensive FDA interaction and guidance. The breakthrough therapy designation is
a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria
are met. If a product is designated as breakthrough therapy, the FDA will work to expedite the development and review of such drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fast track designation, priority review and breakthrough
therapy designation do not change the standards for approval but may expedite the development or approval process. However, even if a
product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification
or decide that the time period for FDA review or approval will not be shortened.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Orphan drug designation </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the Orphan Drug Act, the FDA may grant orphan
designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals
in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the
cost of developing and making a drug product available in the United States for this type of disease or condition will be recovered from
sales of the product. Orphan designation must be requested before an NDA is submitted. After the FDA grants orphan designation, the identity
of the therapeutic agent and its potential orphan use are publicly disclosed by the FDA. Orphan designation does not convey any advantage
in or shorten the duration of the regulatory review and approval process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 24; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a product that has orphan designation subsequently
receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product
exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven
years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or inability
to manufacture the product in sufficient quantities. The designation of such drug also entitles a party to financial incentives such as
opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. However, competitors may receive approval
of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for
a different indication for which the orphan product has exclusivity. Orphan exclusivity also could block the approval of one of our compounds
for seven years if our compound is determined to be contained within the competitor&#8217;s product for the same indication or disease,
or if a competitor obtains approval of the same drug as defined by the FDA. In addition, if an orphan designated product receives marketing
approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Abbreviated New Drug Applications, 505(b)(2) Applications,
and Marketing exclusivity </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In seeking approval for a drug through an NDA, applicants
are required to list with the FDA each patent with claims that cover the applicant&#8217;s drug or an approved method of use of the drug.
Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Approved Drug
Products with Therapeutic Equivalence Evaluations, commonly known as the &#8220;Orange Book.&#8221; Drugs listed in the Orange Book can,
in turn, be cited by competitors in support of approval of an Abbreviated New Drug Application, or ANDA, or a 505(b)(2)&#160;application.
In this case, the original NDA (the&#160;so-called&#160;pioneer drug) is known as the &#8220;listed&#8221; drug or &#8220;reference-listed&#8221;
drug. An ANDA provides for marketing of a drug that has the same active ingredient and the same strength, route of administration and
dosage form as the listed drug and has been shown through testing to be bioequivalent to the listed drug or receives a waiver from bioequivalence
testing. ANDA applicants are generally not required to conduct or submit results of preclinical or clinical tests to prove the safety
or effectiveness of their drug, other than the requirement for bioequivalence testing. Drugs approved in this way are considered therapeutically
equivalent and are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug. These drugs then generally can be substituted
by pharmacists under prescriptions written for the original listed drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A 505(b)(2) application is a type of NDA that relies,
in part, upon data the applicant does not own and to which it does not have a right of reference. Such applications often are submitted
for changes to previously approved drug products and rely on the FDA&#8217;s prior findings of safety and effectiveness for a third party&#8217;s
NDA to abbreviate the showings the sponsor of the 505(b)(2) application must make to establish that its product is safe and effective.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ANDA or 505(b)(2)&#160;applicant is required to
certify to the FDA concerning any patents listed for the referenced approved drug in FDA&#8217;s Orange Book. Specifically, for each listed
patent, the applicant must certify that: (1)&#160;the required patent information has not been filed; (2)&#160;the listed patent has expired;
(3)&#160;the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (4)&#160;the
listed patent is invalid, unenforceable or will not be infringed by the new drug. A certification that the new drug will not infringe
the already approved drug&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification.
If the ANDA or 505(b)(2)&#160;applicant does not include a Paragraph IV certification, the ANDA or 505(b)(2)&#160;application will not
be approved until all of the listed patents claiming the referenced drug have expired, except for any listed patents that only apply to
uses of the drug not being sought by the ANDA or 505(b)(2)&#160;applicant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the ANDA or 505(b)(2)&#160;applicant has made a
Paragraph IV certification, the applicant must also send notice of a Paragraph IV Notice Letter to the NDA and patent holders once the
ANDA or 505(b)(2)&#160;application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement
lawsuit in response to the notice of the Paragraph IV Notice Letter. The filing of a patent infringement lawsuit within 45&#160;days of
the receipt of notice of a Paragraph IV Notice Letter automatically prevents the FDA from approving the ANDA until the earlier of 30&#160;months,
expiration of the patent, settlement of the lawsuit, modification by a court or a decision in the infringement case that is favorable
to the ANDA or 505(b)(2)&#160;applicant. As discussed below, the ANDA or 505(b)(2)&#160;application also will not be approved until any
applicable&#160;non-patent&#160;exclusivity listed in the Orange Book for the reference-listed drug has expired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 25; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Market exclusivity provisions under the FDCA can delay
the submission or approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity
within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity
if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible
for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated
new drug application (&#8220;ANDA&#8221;), or an NDA submitted under Section 505(b)(2) (a &#8220;505(b)(2) NDA&#8221;), submitted by another
company for another drug containing the same active moiety, regardless of whether the drug is intended for the same indication as the
original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data
required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or
non-infringement to one of the patents listed with the FDA by the innovator NDA holder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDCA alternatively provides three years of marketing
exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were
conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, as, for example, new
indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received
approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs
containing the active ingredient for the original indication or condition of use. Five-year and three-year exclusivity will not delay
the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of
reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pediatric exclusivity is another type of marketing
exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached
to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The
issuance of a written request does not require the sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity,
as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>United States Patent Term Restoration</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depending upon the timing, duration and specifics
of FDA approval of our future product candidates, some of our United States patents may be eligible for limited patent term extension
under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman
Amendments permit restoration of the patent term of up to five years as compensation for patent term lost during the FDA regulatory review
process for a drug that has not been previously approved for commercial marketing. Patent-term restoration, however, cannot extend the
remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date and only those claims covering such approved
drug product, a method for using it or a method for manufacturing it may be extended. The patent-term restoration period is generally&#160;one-half&#160;the
time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the
approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence.
Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior
to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application
for any patent term extension or restoration. In the future, we may apply for restoration of patent-term for our currently owned or licensed
patents to add patent life beyond their current expiration dates, depending on the expected length of the clinical trials and other factors
involved in the filing of the relevant NDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Foreign Regulatory Requirements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to regulations in the U.S., our business
is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products. Irrespective
of whether it concerns an FDA approved or investigational drug, the commencement of clinical trials and the subsequent marketing of a
drug product in foreign countries are subject to preliminary approvals from the corresponding regulatory authorities of such countries.
For example, the conduct of clinical trials in the EU is governed by the Clinical Trials Regulation (EU) No 536/2014 (the &#8220;CTR&#8221;)
and the principles and guidelines on GCP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 26; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Before any clinical trial can begin, the sponsor must
obtain approval from both a national ethics committee and the relevant National Competent Authority (NCA) in each country where the trial
will take place. Since the implementation of the EU Clinical Trials Regulation (Regulation (EU) No. 536/2014), these applications are
submitted through the central Clinical Trials Information System (CTIS), which harmonizes and streamlines trial approvals across Member
States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">One NCA (the reporting EU member state selected by
the sponsor) takes the lead in validating and evaluating the application, as well as consulting and coordinating with the other concerned
member states in which the clinical trial is to be conducted. If an application is rejected, it may be amended and resubmitted through
CTIS. A concerned member state may in limited circumstances declare an &#8220;opt-out&#8221; from an approval and prevent the clinical
trial from being conducted in that member state.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Once sufficient evidence has been gathered to demonstrate
that the medicine is safe and effective, a sponsor prepares a Marketing Authorisation Application (MAA). This application includes comprehensive
information on quality, nonclinical, and clinical aspects, compiled in the Common Technical Document (CTD) format.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Most innovative medicines &#8212; particularly those
for serious or rare diseases or involving novel mechanisms of action &#8212; are evaluated through the centralised procedure, which is
administered by the European Medicines Agency (EMA). Under this route, the EMA&#8217;s Committee for Medicinal Products for Human Use
(CHMP) conducts a scientific assessment of the application. The evaluation process typically takes 210 active days, during which rapporteurs
and co-rapporteurs review the data and issue questions to the sponsor. The sponsor may also be invited to an oral explanation meeting
to clarify aspects of the data or the scientific rationale supporting the application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At the conclusion of its review, the CHMP issues an opinion &#8212; positive
or negative &#8212; on whether the medicine should be authorised. If the CHMP issues a negative opinion, the applicant has the right to
request a re-examination within fifteen days. In this process, new rapporteurs are appointed to reassess the case, often considering additional
analyses, such as updated clinical findings, that may address earlier concerns.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When the CHMP adopts a positive opinion, the file
is forwarded to the European Commission, which issues the final legally binding decision on marketing authorisation, typically within
67 days. A centrally granted marketing authorisation is valid in all EU Member States, as well as Iceland, Liechtenstein, and Norway.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After approval, the sponsor enters the post-authorisation
phase, which involves continuous monitoring of the medicine&#8217;s safety and efficacy through pharmacovigilance activities. Sponsors
must submit periodic safety update reports, comply with Good Pharmacovigilance Practice (GVP) requirements, and may be required to conduct
post-authorisation safety or efficacy studies. The MA can also be varied, renewed, or, in rare cases, withdrawn, depending on emerging
data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Failure to comply with the EU member state laws implementing
the EU Community Code on medicinal products, and EU rules governing the promotion of medicinal products, interactions with physicians,
misleading and comparative advertising and unfair commercial practices, with the EU Member State laws that apply to the promotion of medicinal
products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements can result in enforcement
action by the relevant EU Member State authorities. This may include any of the following sanctions: fines, imprisonment, orders forfeiting
products or prohibiting or suspending their supply to the market, orders to suspend, vary, or withdraw the marketing authorization or
requiring the manufacturer to issue public warnings, or to conduct a product recall.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval process in other countries outside the
U.S. and the EU varies from country to country, and the time may be longer or shorter than that required for the FDA approval. In addition,
the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement for market access vary greatly
from country to country. In all cases, clinical trials are conducted in accordance with GCP and the applicable regulatory requirements
and the ethical principles that have their origin in the Declaration of Helsinki.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 27; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Foreign Sales</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales outside the United States of potential drug
compounds we develop will also be subject to foreign regulatory requirements governing human clinical trials and marketing for drugs.
The requirements vary widely from country to country, but typically the registration and approval process takes several years and requires
significant resources. In most cases, if the FDA has not approved a potential drug compound for sale in the United States, the potential
drug compound may be exported for sale outside of the United States, only if it has been approved in any one of the following: the European
Union or a country in the European Economic Area (the countries in the European Union and the European Free Trade Association) if the
drug or device is marketed in that country or the drug or device is authorized for general marketing in the European Economic Area, Canada,
Australia, New Zealand, Japan, Israel, Switzerland and South Africa. There are specific FDA regulations that govern this process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>U.S. coverage and reimbursement </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Significant uncertainty exists as to the coverage
and reimbursement status of any compound for which we may seek regulatory approval. Sales in the United States will depend in part on
the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health programs such
as Medicare, Medicaid, CHIP, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers.
Prices at which we or our customers seek reimbursement for our therapeutic compounds can be subject to challenge, reduction or denial
by payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The process for determining whether a payor will provide
coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product.
A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be available. Additionally,
in the United States there is no uniform policy among payors for coverage or reimbursement. Third-party payors often rely upon Medicare
coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and
approval processes. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. If coverage and adequate
reimbursement are not available, or are available only at limited levels, successful commercialization of, and obtaining a satisfactory
financial return on, any product we develop may not be possible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Third-party payors are increasingly challenging the
price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy.
In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to conduct expensive studies
in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended
to obtain regulatory approvals. Third-party payors may not consider our compounds to be medically necessary or cost-effective compared
to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost
or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development. Additionally,
we or our collaborators may develop companion diagnostic tests for use with our product candidates. Companion diagnostic tests require
coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products.
Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion
diagnostics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Fraud and Abuse Laws </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Federal and state health care laws and regulations
restrict business practices in the biopharmaceutical industry. In the biopharmaceutical industry, there are a number of federal and state
health care regulatory requirements that apply to entities, including, but not limited to, the federal and state fraud and abuse laws.
These laws include, but are not limited to, anti-kickback and self-referral law, civil false claims act law, criminal false statement
law, civil monetary penalty laws, exclusion law, and other civil, criminal, and administrative laws. Health care laws, regulations, and
guidance continuously evolve and are thereby subject to constant change.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The federal Anti-Kickback Statute, 42 U.S.C. &#167;
1320a-7b(b), among other things, prohibits the knowing and willful offer, payment, solicitation or receipt of any form of remuneration,
whether directly or indirectly and overtly or covertly in cash or in kind, in return for, or to induce the referral of an individual for
the:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 28; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">furnishing or arranging for the furnishing of items or services reimbursable in whole or in part under Medicare, Medicaid or other federal healthcare programs; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchase, lease, or order of, or the arrangement or recommendation of the purchasing, leasing, or ordering of any item or service reimbursable in whole or in part under Medicare, Medicaid or other federal healthcare programs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are a number of narrow safe harbors to the Federal
Anti-Kickback Statute. Such safe harbors permit certain payments and business practices that, although they would otherwise potentially
implicate the Federal Anti-Kickback Statute, are not treated as an offense under the same if all of the requirements of the specific applicable
safe harbor are met. Actual knowledge of the statute or specific intent to violate it is not required in order for a person or entity
to have committed a violation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Federal Anti-Kickback Statute applies to certain
arrangements with healthcare providers, product end users and other parties, including marketing arrangements and discounts and other
financial incentives offered in connection with the sales of our products. Regulatory authorities may determine that certain marketing,
pricing, or other activities violate the Federal Anti-Kickback Statute or other applicable laws. Noncompliance with the Federal Anti-Kickback
Statute can result in civil, administrative and/or criminal penalties, restrictions on the ability to operate in certain jurisdictions,
and exclusion from participation in Medicare, Medicaid or other federal healthcare programs. In addition, non-compliance can result in
the need to curtail and/or restructure operations. Any penalties, damages, fines, exclusions, curtailment or restructuring of operations
could adversely affect the ability to operate a business, financial condition, and results of operations. A violation of the Federal Anti-Kickback
Statute can serve as a false or fraudulent claim for purposes of the civil False Claims Act and the civil monetary penalties statute.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The federal Health Insurance Portability and Accountability
Act of 1996 (&#8220;HIPAA&#8221;) among other things, enacted numerous provisions that prohibit knowingly and willfully executing, or
attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses,
representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program,
regardless of the payor (e.g., public or private), willfully obstructing a criminal investigation of a healthcare offense, and knowingly
and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious
or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare
matters. These provisions include 18 U.S.C. &#167;&#167; 286, 287, 669, 1035, 1347, and 1518, all as described further below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Ethics in Patient Referrals Act, commonly known
as the &#8220;Stark Law,&#8221; 42 U.S.C. &#167; 1395nn, prohibits a physician from making referrals for certain &#8220;designated health
services&#8221; payable by Medicare to an entity in which the physician or an immediate family member of such physician has an ownership
or investment interest or with which the physician has entered into a compensation arrangement, unless a statutory exception applies.
There are a number of exceptions to the Stark Law. Such exceptions permit certain payments and arrangements that, although they would
otherwise potentially implicate the Stark Law, are not treated as a violation under the same if the requirements of the specific exceptions
are met. Violation of the Stark Law could result in denial of payment, disgorgement of reimbursements received under a noncompliance arrangement,
civil penalties, damages and exclusion from Medicare or other governmental programs. These requirements are highly technical and there
can be no guarantee that regulatory authorities will not determine or assert that arrangements are in violation of the Stark Law and do
not otherwise meet applicable Stark Law exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The federal false statements statute, 42 U.S.C. &#167;
1320a-7b(a), prohibits knowingly and willfully falsifying, concealing, or omitting a material fact or making any materially false statement
in connection with the delivery of health care benefits, items, or services. Similarly, 18 U.S.C. &#167; 1035 prohibits a person or entity,
in any matter involving a health care benefit program, from knowingly or willfully falsifying, concealing, or covering up by any trick,
scheme, or device a material fact; making any materially false, fictitious, or fraudulent statements or representations; or making or
using any materially false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or
entry. In addition to criminal penalties, violation of these statutes may result in collateral administrative sanctions, including exclusion
from participation in Medicare, Medicaid and other federal health care programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">18 U.S.C. &#167; 669 prohibits knowingly and willfully
embezzling, stealing, or otherwise without authority converting to the use of any person or entity other than the rightful owner, or intentionally
misapplying any of the moneys, funds, securities, premiums, credits, property, or other assets of a health care benefit program. In addition
to criminal penalties, violation of this statute may result in collateral administrative sanctions, including exclusion from participation
in Medicare, Medicaid and other federal health care programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 29; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The criminal health care fraud statute, 18 U.S.C.
&#167; 1347, establishes criminal liability for whoever knowingly and willfully executes, or attempts to execute, a scheme or artifice
to defraud any health care benefit program, or to obtain, by means of false or fraudulent pretenses, representations, or promises, any
of the money or property owned by, or under the custody or control of, any health care benefit program, in connection with the delivery
of or payment for health care benefits, items, or services. In addition to criminal penalties, violation of this statute may result in
collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid and other federal health care programs.
A person or entity need not have actual knowledge of this law or specific intent to commit a violation of this law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">18 U.S.C. &#167; 1518 establishes criminal liability
for whoever willfully prevents, obstructs, misleads, delays or attempts to prevent, obstruct, mislead, or delay the communication of information
or records relating to a violation of a Federal health care offense to a criminal investigator. In addition to criminal penalties, violation
of this statute may result in collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid and other
federal health care programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">18 U.S.C. &#167; 286 establishes criminal liability
for whoever enters into any agreement, combination, or conspiracy to defraud the United States, or any department or agency thereof, by
obtaining or aiding to obtain the payment or allowance of any false, fictitious or fraudulent claim. In addition to criminal penalties,
violation of this statute may result in collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid
and other federal health care programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">18 U.S.C. &#167; 287 establishes criminal liability
for whoever knowingly makes or presents a false, fictitious or fraudulent claim to the United States Government, including any department
or agency thereof. In addition to criminal penalties, violation of this statute may result in collateral administrative sanctions, including
exclusion from participation in Medicare, Medicaid and other federal health care programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Federal False Claims Act, 31 U.S.C. &#167; 3729,
et seq., provides, in part, that the federal government&#8212;or a private party on behalf of the government&#8212;may bring a lawsuit
against any person whom it believes has knowingly presented, or caused to be presented, a false or fraudulent claim for payment, or who
has made a false statement or used a false record to get a claim paid or to avoid, decrease or conceal an obligation to pay money to the
federal government or who has knowingly retained an overpayment. Knowledge under the Federal False Claims Act means actual knowledge,
deliberate indifference, or reckless disregard. In addition, amendments in 1986 to the Federal False Claims Act have made it easier for
private parties to bring whistleblower lawsuits against companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The civil monetary penalties law, 42 U.S.C. &#167;
1320a-7a, provides, in part, that the federal government may seek civil monetary penalties against any person who presents or causes to
be presented claims to a Federal health care program that the person knows or should know is for an item or services that were not provided
as claimed or is false or fraudulent, or the person has made a false statement or used a false record to get a claim paid. The federal
government may also seek civil monetary penalties for a wide variety of other conduct, including offering remuneration to influence a
Medicare or Medicaid beneficiary&#8217;s selection of providers and violations of the Federal Anti-Kickback Statute.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Violations of the Federal False Claims Act and/or
the Civil Monetary Penalties Law can result in penalties ranging from $12,537 to $25,076 for each false claim violation of the Federal
False Claims Act and varying amounts based on the type of violation of the Civil Monetary Penalties Law, plus up to three times the amount
of damages that the federal government sustained. In addition, the federal government may also seek exclusion from participation in all
federal health care programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">42 U.S.C. Section 1320a-7 provides that individuals
and entities can be mandatorily or permissively excluded from participation in federal health care programs. The grounds for mandatory
exclusion include, but are not limited to, conviction for a criminal offense related to the delivery of an item or service reimbursed
under a federal or state health care program, and a conviction related to health care fraud. The grounds for permissive exclusion include,
but are not limited to, criminal offenses relating to fraud inside and outside of health care, convictions related to obstruction of an
investigation or audit, and/or failure to disclose certain required information. Exclusion from federal health care programs&#8212;whether
mandatory or permissive&#8212;may mean that our customers may not be able to get reimbursed by federal and/or state health care programs
for use or dispensing of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 30; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>State Fraud and Abuse Provisions</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Many states have also adopted some form of anti-kickback
and anti-referral laws and false claims acts and civil monetary penalties and other fraud and abuse provisions that apply regardless of
payer, in addition to items and services reimbursed under Medicaid and other state programs. A determination of liability under such laws
could result in fines, penalties, and exclusion, as well as restrictions on the ability to operate in these jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Corporate liability can be present as a result of
the illegal activities of employees, representatives, contractors, collaborators, agents, subsidiaries, or affiliates, even if they were
not explicitly authorized. There can be no assurance that all employees, representatives, contractors, collaborators, agents, subsidiaries
or affiliates will comply with the foregoing laws at all times. Violation of the aforementioned and other laws could result in whistleblower
complaints, investigations, sanctions, settlements, prosecution, government oversight and reporting, other enforcement actions, disgorgement
of profits, significant fines, damages, other civil and criminal penalties or injunctions or other administrative remedies, suspension
and/or debarment from contracting with certain governments or other persons, the loss of privileges, reputational harm, contract damages,
adverse media coverage and other collateral consequences. In addition, corporate directors, officers, employees, and other representatives
who engage in violations of these and other laws may face imprisonment, fines, and penalties. If any subpoenas or investigations are launched,
or governmental or other sanctions are imposed, or if a company does not prevail in any possible civil or criminal litigation, business,
financial condition, and results of operations could be materially harmed. In addition, responding to any action will likely result in
a materially significant diversion of management&#8217;s attention and resources and significant defense costs and other professional
fees. Enforcement actions and sanctions could further harm business, financial condition, and results of operations. Any of the consequences
contained in this paragraph and section could adversely affect the ability to operate the business, financial condition, and the results
of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Sunshine Act</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Sunshine Act requires manufacturers of products
reimbursed by Medicare, Medicaid or the Children&#8217;s Health Insurance Program (&#8220;CHIP&#8221;) to collect and annually report
detailed data to the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) regarding payments or other transfers of value to
physicians, certain other health care providers (such as physicians assistants and nurse practitioners) and teaching hospitals (&#8220;covered
recipients&#8221;), as well as any ownership or investment interest held by physicians and their immediate family members. The reporting
data must be accompanied by an attestation as to the accuracy of the data and failure to timely and accurately submit required information
may result in civil monetary penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Health Insurance Portability and Accountability
Act </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Besides enacting the program integrity provisions
described above, HIPAA, also created a new set of privacy and security requirements. As amended by the Health Information Technology for
Economic and Clinical Health Act, and implementing regulations thereunder, HIPAA requires certain healthcare providers, health plans and
healthcare clearinghouses who conduct specified electronic healthcare transactions (&#8220;covered entities&#8221;), as well as their
independent contractors and agents who conduct certain activities involving protected health information on their behalf (&#8220;business
associates&#8221;) to comply with enumerated requirements relating to the privacy, security and transmission of protected health information.
Failure to comply with HIPAA can result in corrective action, as well as civil fines and penalties and government oversight. Among other
changes, HITECH made HIPAA security standards directly applicable to business associates, increased the tiered civil and criminal fines
and penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general
new authority to file actions to enforce HIPAA. Further, the breach notification rule implemented under HITECH requires covered entities
to notify affected individuals, the U.S. Department of Health and Human Services Office of Civil Rights (&#8220;OCR&#8221;), the agency
that enforces HIPAA, and for breaches affecting more than 500 individuals, the media, of any breaches of unsecured protected health information.
HIPAA does not create a private right of action for individuals, though individuals may submit complaints related to HIPAA to OCR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 31; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Legislative Activities Aimed at Controlling Drug
Costs </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, there have been, and continue
to be proposed and enacted legislation at the federal and state levels designed to, among other things, bring more transparency to drug
pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform
government program reimbursement methodologies for drugs. For example, in July 2021, the Biden administration released an executive order,
&#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s
executive order, on September 9, 2021, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) released a Comprehensive Plan
for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies
that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the Inflation
Reduction Act (&#8220;IRA&#8221;) passed on August 16, 2022. The IRA, among other things, (1) directs HHS to negotiate the price of certain
highly-utilized single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part
D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although
they may be subject to legal challenges. It is currently unclear how the IRA will be implemented but is likely to have a significant impact
on the pharmaceutical industry. Further, the Biden administration released an additional executive order on October 14, 2022, directing
HHS to submit a report within 90 days on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models
for lowering drug costs for Medicare and Medicaid beneficiaries. We expect that additional U.S. federal healthcare reform measures will
be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services,
which could result in reduced demand for our product candidates or additional pricing pressures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Research and Development Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Historically, a significant portion of our operating
expenses related to research and development. See our Consolidated Financial Statements contained elsewhere in this Annual Report for
costs and expenses related to research and development, and other financial information for fiscal years 2025, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Scientific Advisors </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are advised by scientists and physicians with experience
relevant to our Company and our product candidates. Our scientific advisors include clinicians and scientists who are affiliated with
a number of highly regarded medical institutions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employees</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently have approximately thirty-four full-time
employees, and we retain several independent contractors on a regular or as-needed basis. We believe that we have good relations with
our employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Available Information</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our internet website address is www.anavex.com. Our
Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished
pursuant to section 13(a) or 15(d) of the Exchange Act are available there free of charge. We include our website address in this report
only as an inactive textual reference and do not intend it to be an active link to our website. The contents of our website are not incorporated
into this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_003"></span>ITEM 1A. RISK FACTORS</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risk Factor Summary<span style="font-family: Times New Roman, Times, Serif; line-height: 115%"><sup></sup></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a summary of the risks and uncertainties
that could cause our business, financial condition or operating results to be harmed. We encourage you to carefully review the full risk
factors contained in this report in their entirety for additional information regarding these risks and uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Our history of losses and no revenue raises a risk regarding our ability to continue as a going concern
in the future;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">We have a very limited relevant operating history upon which an evaluation of our performance and prospects
can be made;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Our research and development plans will require substantial additional future funding;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">We may be unable to raise additional capital when needed, which would force us to delay, reduce or eliminate
our research and development activities;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">The marketing approval process is burdensome and may not be successful;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">If we or any companion diagnostic collaborator of ours are unable to timely develop and obtain regulatory
approval for companion diagnostic tests for our drug candidates, we may not realize the commercial potential of our drug candidates;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">The regulatory approval processes of the FDA, EMA and comparable foreign regulatory authorities are lengthy,
time-consuming and inherently unpredictable, which could lead to our inability to generate product revenue;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Regulatory authorities may not accept data from our trials conducted outside the United States;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Fast Track designation or breakthrough therapy designation that we have received or may seek out may not
actually lead to a faster FDA review and approval process;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">We may be unable to maintain any benefits associated with orphan drug designation, including market exclusivity;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">We may fail to demonstrate efficacy in our non-clinical studies and clinical trials;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">If a particular product candidate causes undesirable side effects, then we may be unable to receive regulatory
approval of or commercialize such product candidate;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Treatment of neurodegenerative and central nervous system, or CNS, disorders, is a field that has seen
very limited success in product development;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">The use of any of our products in clinical trials may expose us to liability claims, causing our business
to suffer;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">We are highly dependent on our key personnel and if we are not successful in attracting and retaining
highly qualified personnel, we may not be able to successfully implement our business strategy;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">If we do not obtain the support of qualified scientific collaborators, our revenue, growth and profitability
will likely be limited, which would have a material adverse effect on our business;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">We may not be able to develop, market or generate sales of our products to the extent anticipated;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Our technologies and future products may be rendered undesirable or obsolete if our competitors succeed
in developing products and technologies faster or that are more effective or with a better profile than our own, or if scientific developments
change our understanding of the potential scope and utility of our potential products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt"></p>

<!-- Field: Page; Sequence: 33; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Our reliance on third parties may result in delays in completing, or a failure to complete, non-clinical
testing or clinical trials if they fail to perform under our agreements with them or non-compliance with regulations;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">If we fail to compete with respect to partnering, licensing, mergers, acquisitions, joint venture and
other collaboration opportunities, our ability to research and develop our potential drug compounds may be limited;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Our business could be affected by litigation, government investigations and enforcement actions;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Loss of access to Australian government research and development income tax incentive refunds could have
a negative effect on our future cash flows and the funding of future research and development projects;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Our ability to use our net operating loss carryforwards and tax credit carryforwards may be subject to
limitation;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Healthcare laws and regulations could expose us to criminal sanctions, civil and administrative penalties,
contractual damages, reputational harm and diminished profits and future earnings, among other penalties;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved,
could limit our ability to market those products and decrease our ability to generate product revenue;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Issuing additional shares of common stock will result in the dilution of our existing stockholders and
may cause our stock price to fall;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Our stock price has been volatile at times in the past and may be volatile in the future and our common
stock may become the target of a &#8220;short squeeze&#8221;;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates,
our competitors could develop and commercialize product candidates similar or identical to ours, and our ability to successfully commercialize
our product candidates may be impaired;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Intellectual property infringement claims may adversely affect our development and commercialization efforts;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">We may be subject to claims that our employees, consultants or independent contractors have wrongfully
used or disclosed confidential information of third parties;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">We may become involved in lawsuits to protect or enforce our patents or other intellectual property;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt"></p>

<!-- Field: Page; Sequence: 34; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Obtaining and maintaining our patent protection depends on compliance with various requirements imposed
by governmental patent agencies. Changes in patent law could impair our ability to protect our product candidates; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">We may fail to protect our intellectual property rights or the confidentiality of our trade secrets.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to other information in this Annual Report
on Form 10-K, the following risk factors should be carefully considered in evaluating our business because such factors may have a significant
impact on our business, operating results, liquidity and financial condition. As a result of the risk factors set forth below, actual
results could differ materially from those projected in any forward-looking statements. Additional risks and uncertainties not presently
known to us, or that we currently consider to be immaterial, may also impact our business, operating results, liquidity and financial
condition. If any such risks occur, our business, operating results, liquidity and financial condition could be materially affected in
an adverse manner. Under such circumstances, the trading price of our securities could decline, and you may lose all or part of your investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to our Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We have had a history of losses and no revenue,
which raises a risk regarding our ability to continue as a going concern in the future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since inception through September 30, 2025, we have
accumulated a deficit of approximately $382 million. We can offer no assurance that we will ever operate profitably or that we will generate
positive cash flow in the future. To date, we have not generated any revenues from our operations. Our history of losses and no revenues
creates a greater risk of our continued ability to continue as a going concern in the future. As a result, our management expects the
business to continue to experience negative cash flows for the foreseeable future and cannot predict when, if ever, our business might
become profitable. We will need to raise additional funds, and such funds may not be available on commercially acceptable terms, if at
all. If we are unable to raise funds on acceptable terms, we may not be able to execute our business plan, take advantage of future opportunities,
or respond to competitive pressures or unanticipated requirements. This may seriously harm our business, financial condition and results
of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are a clinical stage pharmaceutical research
and development company and may never be able to successfully develop marketable products or generate any revenue. We have a very limited
relevant operating history upon which an evaluation of our future performance and prospects can be made. There is no assurance that our
future operations will result in profits. If we cannot generate sufficient revenues, we may suspend or cease operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a clinical stage company and have not generated
any revenues to date. Moreover, we cannot be certain that our research and development efforts will be successful or, if successful, that
our potential drug compounds will ever be approved for sale to pharmaceutical companies or generate commercial revenues. We have a very
limited relevant operating history upon which an evaluation of our performance and prospects can be made. We are subject to all of the
business risks associated with a pre-revenue company, including, but not limited to, risks of unforeseen capital requirements, failure
of potential drug compounds either in non-clinical testing or in clinical trials, failure to establish business relationships and competitive
disadvantages against larger and more established companies. If we fail to become profitable, we may suspend or cease operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may be unable to raise additional capital
when needed, which would force us to delay, reduce or eliminate our research and development activities.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To date, we have funded our operations primarily through issuances of shares
at-the-market sales agreements pursuant to which we offer and sell shares of common stock registered under an effective registration statement
from time to time through a sales agent and, historically, also through a Purchase Agreement with Lincoln Park Capital Fund, LLC (&#8220;Lincoln
Park&#8221;) pursuant to which the Company could direct Lincoln Park to purchase shares of common stock registered under an effective
registration. The Company will need to file a prospectus supplement in order to access funds under the 2023 Purchase Agreement and the
2023 Purchase Agreement will expire on February 3, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 35; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We will need to raise additional funding, and the
current economic conditions may have a negative impact on our ability to raise additional needed capital on terms that are favorable to
our Company or at all. We may not be able to generate significant revenues for several years, if at all. Until we can generate significant
revenues, if ever, we expect to satisfy our future cash needs through equity or convertible debt financing. We cannot be certain that
additional funding will be available on acceptable terms, or at all. If adequate funds are not available, we may be required to delay,
reduce the scope of, or eliminate one or more of our research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>A decline in the price of our common stock could
affect our ability to raise further working capital and adversely impact our operations and would severely dilute existing or future investors
if we were to raise funds at lower prices.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A prolonged decline in the price of our common stock
could result in a reduction in our ability to raise capital. Because our operations have been financed through the sale of equity securities,
a decline in the price of our common stock could be especially detrimental to our continued operations. Any reduction in our ability to
raise equity capital in the future would force us to reallocate funds from other planned uses and would have a significant negative effect
on our business plans and operations, including our ability to develop new products and continue our current operations. If our stock
price declines, we may be forced to sell equity securities at such lower prices resulting in significant dilution to existing investors.
We believe the following factors could cause the market price of our common stock to continue to fluctuate widely and could cause our
common stock to trade lower:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated variations in our quarterly operating results;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of new services, products, acquisitions or strategic relationships by us or our competitors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">the outcome of our clinical trials, which are inherently
    unpredictable;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in accounting treatments or principles;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in earnings estimates by securities analysts and in analyst recommendations; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general political, economic, regulatory and market conditions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The market price for our common stock may also be
affected by our ability to meet or exceed expectations of analysts or investors. Any failure to meet these expectations, even if minor,
could materially adversely affect the market price of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to the Discovery and Development
of Our Current and Future Product Candidates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The marketing approval process for pharmaceutical
products is a lengthy, complex and highly regulated process and we cannot predict the outcome of any interactions with the regulatory
authorities or when we will receive marketing approval, if at all.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The regulatory approval processes of the EMA, the FDA, and other comparable
foreign authorities are lengthy, time-consuming and inherently unpredictable, and the approval process can vary significantly depending
on the regulatory authority. Relevant health authorities may, at the time of the filing of the application for a marketing authorization,
or later during their review, impose requirements that can evolve over time, including requiring additional clinical trials, and such
authorities may delay or refuse to grant approval. On November 14, 2025, we announced that the CHMP of the EMA has rendered a negative
trend vote following an oral explanation of our MAA. The CHMP is expected to adopt a formal opinion on the MAA at its December meeting.
We plan to seek a re-examination of the MAA upon its formal adoption. However, we cannot predict the outcome of any interactions with
the regulatory authorities and when we will receive a marketing approval, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 36; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In recent years, health authorities have become increasingly
focused on product safety and on the risk/benefit profile of pharmaceutical products, which could lead to more burdensome and costly approval
processes and negatively affect our ability to obtain regulatory approval for products under development. For example, the FDA and the
EMA have been implementing strict requirements for approval, particularly in terms of the volume of data needed to demonstrate a product&#8217;s
efficacy and safety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Obtaining and maintaining regulatory approval
of blarcamesine or any future product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory
approval of those product candidates in other jurisdictions.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Obtaining and maintaining regulatory approval of blarcamesine
and any future product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval
in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on
the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative
review periods different from each other, including additional preclinical studies or clinical trials, as clinical trials conducted in
one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the U.S., including
Canada, and certain jurisdictions in the EU, a product candidate must be approved for reimbursement before it can be approved for sale
in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Regulatory authorities in jurisdictions outside of
the U.S. have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions and
such regulatory requirements can vary widely from country to country. Obtaining other regulatory approvals and compliance with other regulatory
requirements could result in significant delays, difficulties and costs for us and could require additional preclinical studies or clinical
trials, which could be costly and time-consuming and could delay or prevent the introduction of our products in certain countries. The
foreign regulatory approval process involves all of the risks associated with FDA approval. We do not have experience in obtaining regulatory
approval in international markets or within the United States. If we fail to comply with the regulatory requirements in international
or domestic markets and/or obtain and maintain applicable marketing approvals, our target market will be reduced and our ability to realize
the full market potential of blarcamesine or any future product candidates will be harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Even if we are able to develop our potential
drug compounds, we may not be able to receive regulatory approval, or if approved, we may not be able to generate significant revenues
or successfully commercialize our products, which will adversely affect our financial results and financial condition and we will have
to delay or terminate some or all of our research and development plans which may force us to cease operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of our potential drug compounds are exclusively
focused on SIGMAR1 which has not previously been the subject of any approved drug products and will require extensive additional research
and development, including non-clinical testing and clinical trials, as well as regulatory approvals, before we can market them. In particular,
human therapeutic products are subject to rigorous non-clinical and clinical testing and other approval procedures of the FDA and similar
regulatory authorities in other countries. Various federal statutes and regulations also govern or influence testing, manufacturing, safety,
labeling, storage, and record-keeping related to such products and their marketing. We cannot predict if or when any of the potential
drug compounds we intend to develop will be approved for marketing. There are many reasons that we may fail in our efforts to develop
our potential drug compounds. These include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possibility that non-clinical testing or clinical trials may show that our potential drug compounds are ineffective and/or cause harmful side effects;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators may not authorize us to commence or continue a clinical trial or may impose a clinical hold or may limit the conduct of a clinical trial through the imposition of a clinical hold;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of patients required for clinical trials for our drug candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or the duration of these clinical trials may be longer than we anticipate;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 37; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our third-party contractors, including investigators, may fail to meet their contractual obligations to us in a timely manner, or at all, or may fail to comply with regulatory requirements;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our potential drug compounds may prove to be too expensive to manufacture or administer to patients;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our potential drug compounds may fail to receive necessary regulatory approvals from the United States Food and Drug Administration or foreign regulatory authorities in a timely manner, or at all;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">even if our potential drug compounds are approved, we may not be able to produce them in commercial quantities or at reasonable costs;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">even if our potential drug compounds are approved, they may not achieve commercial acceptance;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory or governmental authorities may apply restrictions to any of our potential drug compounds, which could adversely affect their commercial success; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the proprietary rights of other parties may prevent us or our potential collaborative partners from marketing our potential drug compounds.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we fail to develop our potential drug compounds,
our financial results and financial condition will be adversely affected, we will have to delay or terminate some or all of our research
and development plans and may be forced to cease operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our research and development plans will require
substantial additional future funding which could impact our operations and financial condition. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">It may take several years before we can develop potentially
marketable products, if at all. Our research and development plans will require substantial additional capital, arising from costs to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conduct research, non-clinical testing and human clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish pilot scale and commercial scale manufacturing processes and facilities; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish and develop quality control, regulatory, marketing, sales, finance and administrative capabilities to support these programs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our future operating and capital needs will depend
on many factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the pace of scientific progress in our research and development programs and the magnitude of these programs;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope and results of pre-clinical testing and human clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the time and costs involved in obtaining regulatory approvals;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the time and costs involved in preparing, filing, prosecuting, securing, maintaining and enforcing patents;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing technological and market developments;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish additional collaborations;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in our existing collaborations;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of manufacturing scale-up; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effectiveness of our commercialization activities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 38; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We base our outlook regarding the need for funds on
many uncertain variables. Such uncertainties include the success of our research initiatives, regulatory approvals, the timing of events
outside our direct control such as negotiations with potential strategic partners and other factors. Any of these uncertain events can
significantly change our cash requirements as they may involve one-time events such as the receipt or payment of major milestones and
other payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additional funds will be required to support our operations,
including commercialization of our product candidates, and if we are unable to obtain them on favorable terms, we may be required to cease
or reduce certain further research and development and commercialization programs of our drug product platform, sell some or all our intellectual
property, merge with another entity or scale back operations.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we or any companion diagnostic collaborator
of ours are unable to successfully develop and obtain regulatory approval for companion diagnostic tests for our drug candidates, or experience
significant delays in doing so, we may not realize the commercial potential of our drug candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We analyze genomic data from clinical trials to identify
biomarkers, which we use in the analysis of our clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Identification of these patients will require the
use and development of companion diagnostics. According to the FDA&#8217;s 2014 guidance document on In Vitro Companion Diagnostic Devices,
for novel therapeutic products that depend on the use of a diagnostic test and where the diagnostic device could be essential for the
safe and effective use of the corresponding therapeutic product, the premarket application for the companion diagnostic device should
be developed and approved or cleared contemporaneously with the therapeutic.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not have experience or capabilities in developing
or commercializing diagnostics. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility,
or clinical validation of companion diagnostics during the development and regulatory approval processes. Moreover, even if data from
preclinical studies and early clinical trials appear to support development of a companion diagnostic for a drug candidate, data generated
in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future collaborators
may encounter difficulties in developing, obtaining regulatory approval for, manufacturing and commercializing companion diagnostics similar
to those we face with respect to our drug candidates, including issues with achieving regulatory clearance or approval, production of
sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are unable to
successfully develop companion diagnostics for our drug candidates, or experience delays in doing so, the development of these drug candidates
may be adversely affected, these drug candidates may not obtain marketing approval, and we may not realize the full commercial potential
of any of these therapeutics that have or may obtain marketing approval. We may not be able to enter into arrangements with another diagnostic
company to develop and obtain regulatory approval for an alternative diagnostic test for use in connection with the development and commercialization
of our drug candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization
of our therapeutic candidates or therapeutics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Companion diagnostics are subject to regulation by
the FDA, EMA and comparable foreign regulatory authorities as medical devices and will likely require separate regulatory approval prior
to commercialization. If we or third parties are unable to successfully develop companion diagnostics for our drug candidates, or experience
delays in doing so:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the development of these drug candidates may be delayed because it may be difficult to identify patients for enrollment in our clinical trials in a timely manner;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">these drug candidates may not receive marketing approval if their safe and effective use depends on a companion diagnostic; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not realize the full commercial potential of these drug candidates that receive marketing approval if, among other reasons, we are unable to appropriately identify patients targeted by these drug candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Even if our drug candidates and any associated companion
diagnostics are approved for marketing, the need for companion diagnostics may slow or limit adoption of our drug candidates. Our drug
candidates may be perceived negatively compared to alternative treatments that do not require the use of companion diagnostics, either
due to the additional cost of the companion diagnostic or the need to complete additional [testing?] prior to administering our drug candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 39; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If any of these events were to occur, our business
and growth prospects would be harmed materially.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The regulatory approval processes of the FDA,
EMA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, which could lead to our inability
to generate product revenue.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The time required to obtain approval by the FDA, EMA
and comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials
and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. Seeking foreign regulatory
approvals could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical
trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent
the introduction of our product candidates in those countries. In addition, approval policies, regulations or the type and amount of clinical
data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions,
which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion
in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require
additional preclinical, clinical or other data. Satisfying these and other regulatory requirements is costly, time consuming, uncertain
and subject to unanticipated delays. Our failure to obtain regulatory approval in any country may delay or have negative effects on the
process for regulatory approval in other countries. Even if we eventually complete clinical testing and receive approval of any regulatory
filing for our product candidates, the FDA, EMA and comparable foreign regulatory authorities may approve our product candidates for a
more limited indication or a narrower patient population than we originally requested. If we fail to comply with regulatory requirements
in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the
full market potential of our product candidates will be harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Applications for our product candidates could fail
to receive regulatory approval for many reasons, including but not limited to the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the FDA, EMA or comparable international regulatory authorities may disagree with the design, implementation
or results of our clinical trials;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the FDA, EMA or comparable international regulatory authorities may determine that our product candidates
are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics
that preclude our obtaining marketing approval or prevent or limit commercial use;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the population studied in the clinical program may not be sufficiently broad or representative to assure
efficacy and potency and safety in the full population for which we seek approval;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the FDA, EMA or comparable international regulatory authorities may disagree with our interpretation of
data from preclinical studies or clinical trials;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the data collected from clinical trials of our product candidates may not be sufficient to support the
submission of a Biologics License Application, New Drug Application or other submission or to obtain regulatory approval in the United
States or elsewhere;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">we may be unable to demonstrate to the FDA, EMA or comparable international regulatory authorities that
a product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the FDA or comparable international regulatory authorities may fail to approve the manufacturing processes,
test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;
and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the approval policies or regulations of the FDA, EMA or international foreign regulatory authorities may
significantly change in a manner rendering our clinical data insufficient for approval.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"></p>

<!-- Field: Page; Sequence: 40; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to market any product candidates outside
of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety
and efficacy and potency and approval standards. Clinical trials conducted in one country may not be accepted by regulatory authorities
in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ability of the FDA to review and approve new products
can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and
accept the payment of user fees, government shutdowns, including as a result of budget delays or other circumstances like the COVID-19
pandemic and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result.
This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain
regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #231F20"><b><i>All but one of our clinical
trials to date have been conducted outside the United States, and the FDA, EMA and other foreign regulatory authorities may not accept
data from such trials.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #231F20">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #231F20">The acceptance of study
data from clinical trials conducted outside the United States by the FDA may be subject to certain conditions or may not be accepted at
all. In cases where data from foreign clinical trials are intended to serve as the sole basis for regulatory approval in the United States,
the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the United
States population and United States medical practice; (ii) the trials were performed by clinical investigators of recognized competence
and pursuant to good clinical practice regulations; and (iii) the data may be considered valid without the need for an on-site inspection
by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection
or other appropriate means. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would
be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the
FDA</span>, EMA <span style="color: #231F20">or any other foreign regulatory authority will accept data from trials conducted outside
of the United States or the applicable jurisdiction. If the FDA</span>, EMA <span style="color: #231F20">or any comparable foreign regulatory
authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay
aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization
in the applicable jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #231F20">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We have received Fast Track designation for
one of our compounds and may seek such designation or breakthrough therapy and priority review for other compounds in the future. Fast
Track designation or breakthrough therapy designation may not actually lead to a faster FDA review and approval process.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For some of our compounds, including ANAVEX<sup>&#174;</sup>2-73,
we hope to benefit from the FDA&#8217;s Fast Track and priority review programs. In February 2020, the FDA granted Fast Track designation
for the ANAVEX<sup>&#174;</sup>2-73 clinical development program for the treatment of Rett syndrome. Programs with Fast Track designation
may benefit from early and frequent communications with the FDA, potential priority review and the ability to submit a rolling application
for regulatory review. Fast Track designation applies to both the product candidate and the specific indication for which it is being
studied. If any of our compounds receive Fast Track designation but do not continue to meet the criteria for Fast Track designation, or
if our clinical trials are delayed, suspended or terminated, or put on clinical hold due to unexpected adverse events or issues with clinical
supply, we will not receive the benefits associated with the Fast Track program. Furthermore, Fast Track designation does not change the
standards for approval. The receipt of Fast Track designation for a compound may not result in a faster development or regulatory review
or approval process compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval
by the FDA. In addition, even if any product candidate qualifies for Fast Track designation, the FDA may later decide that the product
candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.
Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 41; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under FDA policies, a compound is eligible for priority
review, or review within a six-month time frame from the time a complete NDA is accepted for filing, if the compound provides a significant
improvement compared to marketed drugs in the treatment, diagnosis or prevention of a disease. The FDA determines whether a drug qualifies
for Priority Review after an NDA for such drug is submitted to the FDA. Therefore, until NDAs are submitted for our compounds, we cannot
be assured that they will be granted Priority Review. Additionally, even if Priority Review is granted for one of our compounds, the FDA
does not always meet its six-month Prescription Drug User Fee Act (PDUFA) goal date for Priority Review and the review process is often
extended by FDA requests for additional information or clarification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may seek Breakthrough Therapy designation for one
or more of our current or future compounds. Designation as a Breakthrough Therapy is largely within the discretion of the FDA. Accordingly,
even if we believe that a compound meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine
not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in
a faster development process, review or approval compared to candidate products considered for approval under&#160;non-expedited&#160;FDA
review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more compounds qualify as breakthrough
therapies, the FDA may later decide that the product no longer meets the conditions for qualification and revoke the designation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fast Track or Breakthrough Therapy designation for
our compounds may not actually lead to a faster review process, and a delay in the review process or in the approval of our compounds
will delay revenue from their potential sales and will increase the capital necessary to fund these compound development programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We have received orphan drug designation for several of our compounds,
but we may be unable to maintain any benefits associated with orphan drug designation, including market exclusivity.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the Orphan Drug Act, the FDA may grant orphan
designation to a drug intended to treat a rare disease or condition or for which there is no reasonable expectation that the cost of developing
and making available in the United States a drug for a disease or condition will be recovered from sales in the United States for that
drug. If a product that has orphan drug designation subsequently receives the first FDA approval for the indication for which it has such
designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including
a full NDA, to market the same drug or biologic for the same indication for seven years, except in limited circumstances, such as a showing
of clinical superiority to the product with orphan drug exclusivity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have received orphan drug designation for several
of our compounds, but we may not be able to obtain or maintain orphan drug exclusivity in the United States for those compounds. We may
not be the first to obtain marketing approval of any compound for which we have obtained orphan drug designation for the orphan-designated
indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the
United States may be limited if we seek FDA marketing approval for an indication broader than the orphan designated indication. Additionally,
any compound with orphan drug designation may lose such designation if the FDA later determines that the request for designation was materially
defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare
disease or condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug with the same active moiety
for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective
or makes a major contribution to patient care.&#160;In addition, others may obtain orphan drug exclusivity for products addressing the
same diseases or conditions as products we are developing, thus limiting our ability to compete in the markets addressing such diseases
or conditions for a significant period of time.<b>&#160;</b><span style="background-color: white">Orphan drug designation neither shortens
the development time or regulatory review time of a drug nor gives the product candidate any advantage in the regulatory review or approval
process or entitles the product candidate to priority review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 42; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we fail to demonstrate efficacy in our non-clinical
studies and clinical trials our future business prospects, financial condition and operating results will be materially adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The success of our research and development efforts
will be greatly dependent upon our ability to demonstrate potential drug compound efficacy in non-clinical studies, as well as in clinical
trials. Non-clinical studies involve testing potential drug compounds in appropriate non-human disease models to demonstrate efficacy
and safety. Regulatory agencies evaluate these data carefully before they will approve clinical testing in humans. If certain non-clinical
data reveals potential safety issues or the results are inconsistent with an expectation of the potential drug compound&#8217;s efficacy
in humans, the regulatory agencies may require additional more rigorous testing before allowing human clinical trials. This additional
testing will increase program expenses and extend timelines. We may decide to suspend further testing on our potential drug compounds
if, in the judgment of our management and advisors, the non-clinical test results do not support further development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Moreover, success in non-clinical testing and early
clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the results of later clinical
trials will replicate the results of prior clinical trials and non-clinical testing. The clinical trial process may fail to demonstrate
that our potential drug compounds are safe for humans and effective for indicated uses. This failure would cause us to abandon a drug
candidate and may delay development of other potential drug compounds. Any delay in, or termination of, our non-clinical testing or clinical
trials will delay the filing of an IND and NDA with the FDA or the equivalent applications with pharmaceutical regulatory authorities
outside the United States and, ultimately, our ability to commercialize our potential drug compounds and generate product revenues. In
addition, we expect that our early clinical trials will involve small patient populations. Because of the small sample size, the results
of these early clinical trials may not be indicative of future results. Also, the IND process may be extremely costly and may substantially
delay the development of our potential drug compounds. Moreover, positive results of non-clinical tests will not necessarily indicate
positive results in subsequent clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following successful non-clinical testing, potential
drug compounds will need to be tested in a clinical development program to provide data on safety and efficacy prior to becoming eligible
for product approval and licensure by regulatory agencies. From the first human trial through to regulatory approval can take many years
and 10-12 years is not unusual for certain compounds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If any of our future clinical development potential drug compounds become
the subject of problems, our ability to sustain our development programs will become critically compromised. For example, efficacy or
safety concerns may arise, whether or not justified, that could lead to the suspension or termination of our clinical programs. Examples
of problems that could arise include, among others:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">efficacy or safety concerns with the potential drug compounds, even if not justified;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing difficulties or concerns;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory proceedings subjecting the potential drug compounds to potential recall;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publicity affecting doctor prescription or patient use of the potential drug compounds;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pressure from competitive products; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction of more effective treatments.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each clinical phase is designed to test attributes
of the drug and problems that might result in the termination of the entire clinical plan can be revealed at any time throughout the overall
clinical program. The failure to demonstrate efficacy in our clinical trials would have a material adverse effect on our future business
prospects, financial condition and operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 43; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If a particular product candidate causes undesirable
side effects, then we may be unable to receive regulatory approval of or commercialize such product candidate.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may experience numerous unforeseen events during,
or as a result of, the testing process that could delay or prevent commercialization of any of our product candidates, including the occurrence
of undesirable side effects. Such side effects could lead to clinical trial challenges, such as difficulties in subject recruitment, retention,
and adherence, potential product liability claims, and possible termination by health authorities. These types of clinical trial challenges
could in turn, delay or prevent regulatory approval of our product candidate. Side effects may also lead regulatory authorities to require
stronger product warnings on the product label, costly post-marketing studies, and/or a REMS, among other possible requirements. If the
product candidate has already been approved, such approval may be withdrawn. Any delay in, denial, or withdrawal of marketing approval
for one of our product candidates will adversely affect our business, including our results of operations and financial position. Even
if one or more of our product candidates receives marketing approval, undesirable side effects may limit such product&#8217;s commercial
viability. Patients may not wish to use our product, physicians may not prescribe our product, and our reputation may suffer. Any of these
events may significantly harm our business and financial prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Even if we receive regulatory approval for one
or more compounds, we will be subject to continuing regulatory obligations and ongoing regulatory review, which may result in significant
additional expense. Additionally, our compounds, if approved, could be subject to labeling and other restrictions on marketing or withdrawal
from the market, and we may be subject to penalties, if we fail to comply with regulatory requirements or if we experience unanticipated
problems with our compounds, when and if any of them are approved. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following potential approval of any our compounds,
the FDA may impose significant restrictions on a drug&#8217;s indicated uses or marketing or require potentially costly and time-consuming
post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy of the drug. The FDA may also require
a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) as a condition of approval of one or more of our compounds, which could
include requirements for a medication guide, physician communication plans or additional elements to ensure safe use of the drug. Additional
REMS elements may include restricted distribution methods, patient registries and other risk minimization tools.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, if the FDA, EMA or a comparable foreign
regulatory authority approves one or more of our compounds, the manufacturing processes, labeling, packaging, distribution, adverse event
reporting, storage, advertising, promotion, import, export and recordkeeping for the approved drug will be subject to additional and potentially
extensive ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports,
establishment registration, as well as continued compliance with cGMPs and GCP requirements for any clinical trials that we conduct post-approval.
Later discovery of previously unknown problems with our products, including adverse events of unanticipated severity or frequency, or
with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among
other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizure or detention, or refusal to permit the import or export of our products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions or the imposition of civil or criminal penalties; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 44; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The occurrence of any event or penalty described above
may limit our ability to commercialize our compounds and generate revenue and could require us to expend significant time and resources
in response or generate negative publicity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If any of our compounds are approved, our product
labeling, advertising and promotion will also be subject to regulatory requirements and ongoing regulatory review. The FDA strictly regulates
the promotional claims that may be made about drug products. In particular, a drug may not be promoted for uses that are not approved
by the FDA as reflected in the drug&#8217;s approved labeling. If we receive marketing approval for a compound, physicians may nevertheless
lawfully prescribe it to their patients in a manner that is inconsistent with the approved label. While the FDA recently clarified that
mere knowledge that a physician is prescribing an approved drug for off-label use is not sufficient to constitute unlawful off-label promotion,
if we are found to have actively promoted such off-label uses, we may become subject to significant liability under the Federal Food,
Drug, and Cosmetic Act (FDCA). The federal government has levied large civil and criminal fines against companies for alleged improper
promotion and has enjoined several companies from engaging in off-label promotion. Additionally, promotion for off-label uses could result
in significant liability under the False Claims Act. The FDA has also requested that companies enter into consent decrees or permanent
injunctions under which specified promotional conduct is changed or curtailed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA&#8217;s and other regulatory authorities&#8217;
policies are subject to change at any time, and additional government regulations may be enacted that could prevent, limit or delay regulatory
approval of our compounds. If we are unable to timely adapt to changes in existing requirements or the adoption of new requirements or
policies, or if we are not able to maintain regulatory compliance post-marketing, we may lose any marketing approval that we may have
obtained, and we may not achieve or sustain profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Finally, we cannot predict the likelihood, nature
or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United
States or abroad. It is difficult to predict how any such legislative, administrative or executive actions will be implemented, and the
extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these legislative or executive actions
impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business
may be negatively impacted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Material modifications in the methods of product
candidate manufacturing may result in additional costs or delay.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As product candidates progress from preclinical studies
to late-stage clinical trials to marketing approval and commercialization, it is common that various aspects of the development program,
such as manufacturing methods, materials and processes, are altered along the way in an effort to optimize yield, manufacturing batch
size, minimize costs and achieve consistent purity, identity, potency, quality and results. Such changes carry the risk that they will
not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and could affect
planned or other clinical trials conducted with product candidates produced using the modified manufacturing methods, materials, and processes.
This could delay completion of clinical trials and could require non-clinical or clinical bridging and comparability studies, which could
increase costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We have advanced our research and development
efforts on the treatment of neurodegenerative and central nervous system, or CNS, disorders, a field that has seen very limited success
in product development.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We have advanced our research
and development efforts on addressing neurodegenerative, neurodevelopmental and CNS disorders. Collectively, efforts by pharmaceutical
companies in the field of neurodegenerative,&#160;neurodevelopmental&#160;and CNS disorders have seen very limited successes in product
development. The development of neurodegenerative and CNS therapies presents unique challenges, including an imperfect understanding of
the biology, the presence of the blood brain barrier that can restrict the flow of drugs to the brain, a frequent lack of translatability
of preclinical study results in subsequent clinical trials and dose selection, and the product candidate having an effect that may be
too small to be detected using the outcome measures selected in clinical trials or if the outcomes measured do not reach statistical significance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 45; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The use of any of our products in clinical trials
may expose us to liability claims, which may cost us significant amounts of money to defend against or pay out, causing our business to
suffer.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The nature of our business exposes us to potential
liability risks inherent in the testing, manufacturing and marketing of our products. We currently have one drug compound in clinical
trials; however, when any of our products enter clinical trials or become marketed products, they could potentially harm people or allegedly
harm people possibly subjecting us to costly and damaging product liability claims. Some of the patients who participate in clinical trials
are already ill when they enter a trial or may intentionally or unintentionally fail to meet the exclusion criteria. The waivers we obtain
may not be enforceable and may not protect us from liability or the costs of product liability litigation. Although we intend to obtain
product liability insurance, which we believe is adequate, we are subject to the risk that our insurance will not be sufficient to cover
such claims. The insurance costs along with the defense or payment of liabilities above the amount of coverage could cost us significant
amounts of money and management distraction from other elements of the business, causing our business to suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are highly dependent on our key personnel,
and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our
business strategy.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our ability to compete in the highly competitive biotechnology
and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel.
We are highly dependent on our management, scientific and medical personnel. The loss of the services of any of our executive officers,
other key employees and other scientific and medical advisors, and an inability to find suitable replacements could result in delays in
product development and harm our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Competition for skilled personnel in our market is
intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. Despite our efforts to
retain valuable employees, members of our management, scientific and development teams may terminate their employment or service with
us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment,
which means that any of our employees could leave our employment at any time, with or without notice. Our success also depends on our
ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level
and senior scientific and medical personnel in an extremely competitive market for employees and other service providers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we do not obtain the support of qualified
scientific collaborators, our revenue, growth and profitability will likely be limited, which would have a material adverse effect on
our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While we have established relationships with leading scientists and research
institutions, we will need to continue to establish these relationships. We believe that such relationships are pivotal to establishing
products using our technologies as a standard of care for various indications. Additionally, although in discussion, there is no assurance
that our current research partners will continue to work with us or that we will be able to attract additional research partners. If we
are not able to maintain our existing scientific relationships and establish new scientific relationships to assist in our research and
development, we may not be able to successfully develop our potential drug compounds. If this happens, our business will be adversely
affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may not be able to develop, market or generate
sales of our products to the extent anticipated. Our business may fail and investors could lose all their investment in our Company.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Assuming that we are successful in developing our
potential drug compounds and receiving regulatory clearances to market our products, our ability to successfully penetrate the market
and generate sales of those products may be limited by a number of factors, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 46; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If our competitors receive regulatory approvals for and begin marketing similar products in the United States, the European Union, Japan and other territories before we do, greater awareness of their products as compared to ours will cause our competitive position to suffer;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information from our competitors or the academic community indicating that current products or new products are more effective or offer compelling other benefits than our future products could impede our market penetration or decrease our future market share; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The pricing and reimbursement environment for our future products, as well as pricing and reimbursement decisions by our competitors and by payers, may have an effect on our revenues.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If this happens, our business will be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>None of our potential drug compounds may reach
the commercial market for a number of reasons and our business may fail.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Successful research and development of pharmaceutical
products is high risk. Most products and development candidates fail to reach the market. Our success depends on the discovery of new
drug compounds that we can commercialize. It is possible that our products may never reach the market for a number of reasons. They may
be found ineffective or may cause harmful side effects during non-clinical testing or clinical trials or fail to receive necessary regulatory
approvals. We may find that certain products cannot be manufactured at a commercial scale and, therefore, they may not be economical to
produce. Our potential products could also fail to achieve market acceptance or be precluded from commercialization by proprietary rights
of third parties. Our patents, patent applications, trademarks and other intellectual property may be challenged, and this may delay or
prohibit us from effectively commercializing our products. Furthermore, we do not expect our potential drug compounds to be commercially
available for a number of years, if at all. If none of our potential drug compounds reach the commercial market, our business will likely
fail and investors will lose all of their investment in our Company. If this happens, our business will be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If our competitors succeed in developing products
and technologies faster or that are more effective or with a better profile than our own, or if scientific developments change our understanding
of the potential scope and utility of our potential products, then our technologies and future products may be rendered undesirable or
obsolete.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We face significant competition from industry participants
that are pursuing technologies in similar disease states to those that we are pursuing and are developing pharmaceutical products that
are competitive with our products. Nearly all of our industry competitors have greater capital resources, larger overall research and
development staffs and facilities, and a longer history in drug discovery and development, obtaining regulatory approval and pharmaceutical
product manufacturing and marketing than we do. With these additional resources, our competitors may be able to respond to the rapid and
significant technological changes in the biotechnology and pharmaceutical industries faster than we can. Our future success will depend
in large part on our ability to maintain a competitive position with respect to these technologies. Rapid technological development, as
well as new scientific developments, may result in our products becoming obsolete before we can recover any of the expenses incurred to
develop them. For example, changes in our understanding of the appropriate population of patients who should be treated with a targeted
therapy like we are developing may limit the drug&#8217;s market potential if it is subsequently demonstrated that only certain subsets
of patients should be treated with the targeted therapy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our reliance on third parties, such as university
laboratories, contract manufacturing organizations and contract or clinical research organizations, may result in delays in completing,
or a failure to complete, non-clinical testing or clinical trials if they fail to perform under our agreements with them or non-compliance
with regulations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the course of product development, we may engage
university laboratories, other biotechnology companies or contract or clinical manufacturing organizations to manufacture drug material
for us to be used in non-clinical and clinical testing and contract research organizations to conduct and manage non-clinical studies
and clinical trials. If we engage these organizations to help us with our non-clinical and clinical programs,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 47; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">many important aspects of
this process have been and will be out of our direct control. If any of these organizations we may engage in the future fail to perform
their obligations under our agreements with them or fail to perform non-clinical testing and/or clinical trials in a satisfactory manner,
we may face delays in completing our clinical trials, as well as commercialization of any of our potential drug compounds. Furthermore,
any loss or delay in obtaining contracts with such entities may also delay the completion of our clinical trials, regulatory filings and
the potential market approval of our potential drug compounds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, any of these third parties may engage
in misconduct or other improper activities, including non-compliance with regulatory standards and requirements. Misconduct by these parties
could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate the regulations
of any regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities;
healthcare fraud and abuse laws and regulations in the United States and abroad; or laws that require the reporting of financial information
or data accurately. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions
we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting
us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we fail to compete successfully with respect
to partnering, licensing, mergers, acquisitions, joint venture and other collaboration opportunities, we may be limited in our ability
to research and develop our potential drug compounds.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our competitors compete with us to attract established
biotechnology and pharmaceutical companies or organizations for partnering, licensing, mergers, acquisitions, joint ventures or other
collaborations. Collaborations include contracting with academic research institutions for the performance of specific scientific testing.
If our competitors successfully enter into partnering arrangements or license agreements with academic research institutions, we will
then be precluded from pursuing those specific opportunities. Since each of these opportunities is unique, we may not be able to find
a substitute. Other companies have already begun many drug development programs, which may target diseases that we are also targeting,
and have already entered into partnering and licensing arrangements with academic research institutions, reducing the pool of available
opportunities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Universities and public and private research institutions
also compete with us. While these organizations primarily have educational or basic research objectives, they may develop proprietary
technology and acquire patent applications and patents that we may need for the development of our potential drug compounds. In some instances,
we will attempt to license this proprietary technology, if available. These licenses may not be available to us on acceptable terms, if
at all. If we are unable to compete successfully with respect to acquisitions, joint venture and other collaboration opportunities, we
may be limited in our ability to develop new products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If our information systems or data, or those
of third parties upon whom we rely, are or were compromised, our business may be adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the course of our business, we, or third parties
upon whom we rely, may gather, collect, receive, use, transmit, store/retain or dispose of data and confidential information (such as
confidential employee information or health-related data), sensitive data, intellectual property and trade secrets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Cyberattacks, malicious internet-based
activity, online and offline fraud and other similar activities threaten the confidentiality, integrity, and availability of our sensitive
information and information technology systems, and those of the third parties upon whom we rely. We, and the third parties upon whom
we may rely, may be subject to a variety of these evolving threats.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Although we endeavor to protect
confidential information through the implementation of security technologies, processes and procedures, it is possible that an individual
or group could defeat security measures and access sensitive information about our business and employees. The existence of a remote workforce
also poses increased risks to our information technology systems and data, as more of our employees work from home, utilizing network
connections outside our premises.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 48; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any misappropriation, loss or other unauthorized disclosure
of confidential information gathered, stored or used by us or by third parties on our behalf, could have a material impact on the operation
of our business, including damaging our reputation with our employees, third parties and investors. We could also incur significant costs
implementing additional security measures and organizational changes, implementing additional protection technologies, training employees
or engaging consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our contracts with third
parties upon whom we may rely, may not contain limitations of liability, and even where they do, there can be no assurance that limitations
of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security
obligations. In addition, we could incur increased litigation as a result of any potential cyber-security breach and our insurance coverage
may not be adequate or sufficient in type or amount to protect us from or to mitigate liabilities arising out of our privacy and security
practices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are not aware that we have experienced any material
misappropriation, loss or other unauthorized disclosure of confidential or personally identifiable information as a result of a cyber-security
breach or other act; however, a cyber-security breach or other act and/or disruption to our information technology systems could have
a material adverse effect on our business, prospects, financial condition or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Changes in funding for the FDA, the SEC and
other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services
from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which
the operation of our business may rely, which could negatively impact our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ability of the FDA to review and approve new products
can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and
accept payment of user fees, statutory, regulatory and policy changes, and business disruptions, such as those caused by the COVID-19
pandemic. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and
other government agencies on which our operations may rely, including those that fund research and development activities is subject to
the political process, which is inherently fluid and unpredictable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Disruptions at the FDA and other agencies may
also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely
affect our business. For example, over the last several years, the U.S. government has shut down several times, including the
longest government shutdown that began on October 1, 2025 and ended November 13, 2025, and certain regulatory agencies, such as the
FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged
government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory
submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our
ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our business could be affected by litigation,
government investigations and enforcement actions.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently operate in a number of jurisdictions
in a highly regulated industry and we could be subject to litigation, government investigation and enforcement actions on a variety of
matters in the United States or foreign jurisdictions, including, without limitation, intellectual property, regulatory, product liability,
environmental, whistleblower, false claims, privacy, anti-kickback, anti-bribery, securities, commercial, employment and other claims
and legal proceedings which may arise from conducting our business. In the ordinary course as a public company, the SEC and other U.S.
and foreign regulatory and governmental agencies have initiated and may in the future initiate requests, comments and/or investigations
regarding legal, regulatory and compliance matters of the Company. We have cooperated, and will in the future cooperate, on any such matters
with such regulatory and governmental agencies, and such matters could require us to expend significant time, attention and resources.
Any determination that our operations or activities are not in compliance with existing laws or regulations could result in the imposition
of fines, civil and criminal penalties, equitable remedies, including disgorgement, injunctive relief and/or other sanctions against us,
and remediation of any such findings could have an adverse effect on our business operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 49; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Legal proceedings, government investigations and enforcement
actions can be expensive and time-consuming. An adverse outcome resulting from any such proceedings, investigations or enforcement actions
could result in significant damages, awards, fines, penalties, exclusion from the federal healthcare programs, healthcare debarment, injunctive
relief, product recalls, reputational damage and modifications of our business practices, which could have a material adverse effect on
our business and results of operations. Even if such a proceeding, investigation or enforcement action is ultimately decided in our favor,
the investigation and defense thereof could require substantial financial and management resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Changes in U.S. and international trade policies
may adversely impact our business and operating results.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The U.S. government has made statements and taken
actions that have led to certain changes and may lead to additional changes to U.S. and international trade policies. For example, President
Trump has imposed or signaled to impose a series of&#160;tariffs&#160;on certain products manufactured outside the United States, including
pharmaceutical products and raw materials and components for pharmaceutical products, and it is unknown whether and to what extent additional&#160;tariffs&#160;(or
other new laws or regulations) will be adopted, or the effect that any such actions would have on us or our industry. Such unfavorable
government policies on international trade, such as export controls, capital controls or&#160;tariffs, may affect the import and export
of materials and products used in our drug development. For example, we have already faced increased costs associated with our imports
of drug products due to newly imposed tariffs on Canada. These policies may also affect the demand for our product candidates, the competitive
position of our product candidates, and clinical manufacturing and future commercial activities. If any new&#160;tariffs, export controls,
legislation and/or regulations are implemented, or if existing trade agreements are renegotiated or if the U.S. government takes retaliatory
trade actions due to the ongoing trade tensions, such changes could have an adverse effect on our business, financial condition and results
of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We receive&#160;Australian&#160;government research
and development income&#160;tax&#160;incentive refunds. If our research and development expenditures are not deemed to be eligible for
the refund, proposed modifications to the&#160;tax&#160;incentive program are enacted, or the&#160;tax&#160;incentive program is discontinued
by the&#160;Australian&#160;government, it could have a negative effect on our future cash flows and the funding of future research and
development projects.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our subsidiary, Anavex Australia Pty Ltd., is incorporated
in Australia where we are currently engaged in research and development activities for ANAVEX<sup>&#174;</sup>2-73 and ANAVEX<sup>&#174;</sup>3-71.
Our subsidiary is eligible to participate in the&#160;Australian&#160;Federal Government&#8217;s Research and Development&#160;Tax&#160;Incentive
program, under which the government provides a cash refund for a portion of eligible research and development expenditures (currently
43.5% to 48.5% depending on the entity&#8217;s corporate tax rate) by small&#160;Australian&#160;entities, which are defined as&#160;Australian&#160;entities
with less than $20 million (Australian) in revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Research and Development&#160;Tax&#160;Incentive
refund is offered by the&#160;Australian&#160;federal government for eligible research and development purposes based on the filing of
an annual application. As part of this program, our subsidiary applied for and received cash refunds from the&#160;Australian&#160;Taxation
Office, or the ATO, for a percentage of the research and development costs expended by our subsidiary in Australia. Since the fiscal year
ended September 30, 2015, we have been receiving Research and Development&#160;Tax&#160;Incentive refunds related to research and development
expenditures made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain research and development expenses incurred
outside of Australia are also eligible for the&#160;Australian&#160;research and development&#160;tax&#160;incentive program, provided
we obtain an Advance Overseas Finding from AusIndustry, a division of the Australian Government&#8217;s Department of Industry, Innovation
and Science (&#8220;AusIndustry&#8221;).&#160;To receive an Advance Overseas Finding, the expenses must have been for eligible research
and development activities, as determined by AusIndustry, and the expenditures must have a scientific link to the&#160;Australian&#160;activities,
be unable to be conducted in Australia and the total actual and reasonably anticipated overseas costs must be expected to be less than
the total actual and reasonably anticipated expenditures for activities conducted within Australia, as determined by AusIndustry at the
time of application for an Advance Overseas Finding (&#8220;OSF&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">This OSF binds both AusIndustry
and the Commissioner of Taxation for three income years. However, for compliance purposes, specific issue guidance jointly issued by AusIndustry
and the ATO in 2014 provides that an OSF can apply for the duration of the overseas activity provided the activities are not new or materially
different than the activities described in the OSF. Currently, the Company is outside of the binding three-year period with respect to
OSF applicable to some of its programs being claimed in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 50; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the extent that some or all of our research and
development expenditures are deemed to be &#8220;ineligible,&#8221; then our refunds may decrease or be eliminated. In addition, the&#160;Australian&#160;government
may in the future modify the requirements of, reduce the amounts of the refunds available under, or discontinue the Research and Development&#160;Tax&#160;Incentive
program. Any such change to our anticipated refunds or change to the Research and Development&#160;Tax&#160;Incentive program would have
a negative effect on our future cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Additionally, although the
Company believes that it has complied with all the relevant conditions of eligibility under the program for all periods claimed, the ATO
has the right to review the Company&#8217;s qualifying programs and related expenditures for a period of four years. If such a review
were to occur, the ATO may have different interpretations of certain eligibility requirements. If the ATO disagreed with the Company&#8217;s
assessments and any related subsequent appeals, it could require adjustment to and repayment of current or previous years&#8217; claims
already received. Additionally, if the Company was unable to demonstrate a reasonably arguable position taken on such claims, the ATO
could also assess penalties and interest on any such adjustments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>A variety of risks are associated with operating
our business internationally which could materially adversely affect our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are presently conducting clinical development solely
in Australia, United Kingdom, The Netherlands, Germany and Canada and may choose to conduct additional international and U.S. clinical
trials in the future. Additionally, while we have not taken any steps to enter into any non-U.S. markets, we may do so in the future.
Accordingly, we are subject to risks related to operating in foreign countries, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">different standards of care in various countries that could complicate the evaluation of our product candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">different United States and foreign drug import and export rules;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced protection for intellectual property rights in certain countries;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with the FCPA and other anti-corruption and anti-bribery laws;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign taxes, including withholding of payroll taxes;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">different payor reimbursement regimes, governmental payors or patient self-pay systems and price controls;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential liability resulting from development work conducted by foreign partners;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business interruptions resulting from natural disasters, outbreaks of contagious diseases, such as COVID-19, or geopolitical actions, including war and terrorism, or systems failure including cybersecurity breaches; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with evolving and expansive foreign regulatory requirements, including data privacy laws (such as the GDPR).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 51; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, in connection with the ongoing conflict
between Russia and Ukraine, the U.S. government and European Union countries have imposed enhanced export controls on certain products
and sanctions on certain industry sectors and parties in Russia. The U.S. government has also indicated it will consider imposing additional
sanctions and other similar measures in the near future. Although we do not currently conduct any clinical trials in Russia or Ukraine,
further escalation of geopolitical tensions could have a broader impact that expands into other markets where we do business or conduct
certain research and development operations, which could adversely affect our business, our supply chain for our product candidates, our
collaborators or our ability to carry out our clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><b><i>Our ability
to use our net operating loss (&#8220;NOL&#8221;) carryforwards and certain tax credit carryforwards may be subject to limitation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2025, we had approximately $148.8
million of U.S. federal and $19.1 million of state and local NOL carryforwards. We had approximately $17.1 million of NOL carryforwards
in Australia as of the same period. Our NOL carryforwards are subject to review and possible adjustment by the U.S. and state tax authorities.
In addition, under Sections 382 and 383 of the Internal Revenue Code and corresponding provisions of state law, if a corporation undergoes
an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change (by value) in its equity ownership over a three-year
period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and research and development credits to offset its post-change
income may be limited. This could limit the amount of NOLs or research and development credit carryforwards that we can utilize annually
to offset future taxable income or tax liabilities. Subsequent ownership changes and changes to the U.S. tax rules in respect of the utilization
of NOLs and research and development credits carried forward may further affect the limitation in future years. In addition, at the state
level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase
state taxes owed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company conducts a Section 382 study annually
and has reduced its federal NOLs by $12.1 million and its Research and Development tax credit carryforwards by $0.8 million, which are
the amount of tax assets that will expire unutilized pursuant to Section 382. Subsequent ownership changes in future years could trigger
additional limitations of the Company&#8217;s NOLs<span style="background-color: white">. During the year ended September 30, 2025, the
Company determined that there were no changes in ownership pursuant to Section 382.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are subject to healthcare laws and regulations
which may require substantial compliance efforts and could expose us to criminal sanctions, civil and administrative penalties, contractual
damages, reputational harm and diminished profits and future earnings, among other penalties.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Healthcare providers, physicians and others will play
a primary role in the recommendation and prescription of our products, if approved. Our arrangements with such persons and third-party
payors and our general business operations will expose us to broadly applicable fraud and abuse and other healthcare laws and regulations
that may constrain the business or financial arrangements and relationships through which we research, market, sell and distribute our
drugs, if we obtain marketing approval. Restrictions under applicable U.S. federal, state and foreign healthcare laws and regulations
include, but are not limited to, the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, including any kickback, bribe or rebate, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase or lease, order or recommendation of, any item, good, facility or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. federal civil and criminal false claims laws and civil monetary penalties laws, including the civil False Claims Act, which impose criminal and civil penalties, including those from civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment that are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 52; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Stark Law prohibits a physician from making referrals for certain &#8220;designated health services&#8221; payable by Medicare to an entity in which the physician or an immediate family member of such physician has an ownership or investment interest or with which the physician has entered into a compensation arrangement, unless a statutory exception applies. There are a number of exceptions to the Stark Law. Such exceptions permit certain payments and arrangements that, although they would otherwise potentially implicate the Stark Law, are not treated as a violation under the same if the requirements of the specific exceptions are met.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA, which among other things, created additional federal criminal statutes that impose criminal and civil liability for, such actions as executing or attempting to execute a scheme to defraud any healthcare benefit program or knowingly and willingly falsifying, concealing or covering up a material fact or making false statements relating to healthcare matters;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The privacy and security provisions of HIPAA, which impose certain requirements on covered entities and their business associates, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. federal transparency requirements under the Physician Payments Sunshine Act, enacted as part of the Affordable Care Act that require applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to track and annually report to CMS payments and other transfers of value provided to physicians, certain other healthcare providers (such as physicians assistants and nurse practitioners),and teaching hospitals, as well as ownership and investment interests held by physicians or their immediate family members; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous state or foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state marketing and/or transparency laws applicable to manufacturers that may be broader in scope than the federal requirements, state laws that require biopharmaceutical companies to comply with the biopharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect as HIPAA, thus complicating compliance efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ensuring that our business arrangements with third
parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will
conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud
and abuse or other healthcare laws and regulations. If our operations were found to be in violation of any of these laws or any other
governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages,
fines, disgorgement, imprisonment, possible exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual
damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could substantially
disrupt our operations. If the physicians or other providers or entities with whom we expect to do business are found not to be in compliance
with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded
healthcare programs. We may incur significant costs achieving and maintaining compliance with applicable federal and state privacy, security,
and fraud laws. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur
significant legal expenses and divert our attention from the operation of our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We expect current and future legislation affecting
the pharmaceutical industry, including drug pricing reform, to impact our business generally, which could adversely affect our business
operations. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, there have been, and continue
to be proposed and enacted legislation at the federal and state levels designed to, among other things, bring more transparency to drug
pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform
government program reimbursement methodologies for drugs. For example, in July 2021, the Biden administration released an executive order,
&#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s
executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for
drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative
actions HHS can take to advance these principles. In addition, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;),</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 53; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">among other things,
(1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under
Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively
starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented
but is likely to have a significant impact on the pharmaceutical industry. If any of our products are subject to such negotiation, we
may lose a significant amount of the revenues expected during the full life cycle of these products. In addition, the current administration
is pursuing other measures to reduce the cost of drugs in the United States. For example, on July 4, 2025, the 2025 Reconciliation Act,
which reduces funding to federal healthcare programs and imposes additional requirements to be eligible for healthcare, was signed into
law. Additionally, in April 2025, an executive order was signed directing the Secretary of HHS to take appropriate steps to, among other
things, modify certain provisions of the Medicare Drug Price Negotiation Program, develop and implement a payment model to reduce the
price of high-cost prescription drugs and biological products covered by Medicare, accelerate approval of generic and biosimilar products,
and facilitate the ability of states to import pharmaceuticals from other countries, and in May 2025, an executive order was signed, among
other things, directing the Secretary of HHS to propose rules that impose &#8220;most-favored-nation&#8221; pricing and take other measures
to reduce the cost of prescription drugs. It is currently unclear whether and to what extent these measures will be implemented and what
impact any such implementation would have on our business. Further, there can be no assurance that the current administration or future
administrations will not pursue different or additional measures, such as those intended to more closely align U.S. drug prices with international
drug prices (often referred to as &#8220;reference&#8221; or &#8220;international price index&#8221; drug pricing). Future price controls
or other changes in pricing regulation or negative publicity related to the pricing of pharmaceutical drugs could restrict the amount
that we are able to charge for our drug products, which could render our product candidates, if approved, commercially unviable and materially
adversely affect our ability to raise additional capital on acceptable terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The coverage and reimbursement status of newly
approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved,
could limit our ability to market those products and decrease our ability to generate product revenue.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Significant uncertainty exists as to the coverage
and reimbursement status of any compound for which we may seek regulatory approval. Sales in the United States will depend in part on
the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health programs such
as Medicare, Medicaid, CHIP, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers.
Prices at which we or our customers seek reimbursement for our therapeutic compounds can be subject to challenge, reduction or denial
by payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The process for determining whether a payor will provide
coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product.
A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be available. Additionally,
in the United States there is no uniform policy among payors for coverage or reimbursement. Third-party payors often rely upon Medicare
coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and
approval processes. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. If coverage and adequate
reimbursement are not available, or are available only at limited levels, successful commercialization of, and obtaining a satisfactory
financial return on, any product we develop may not be possible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Third-party payors are increasingly challenging the
price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy.
In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to conduct expensive studies
in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended
to obtain regulatory approvals. Third-party payors may not consider our compounds to be medically necessary or cost-effective compared
to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost
or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development. Additionally,
we or our collaborators may develop companion diagnostic tests for use with our product candidates. Companion diagnostic tests require
coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products.
Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion
diagnostics. Our inability to promptly obtain coverage and adequate reimbursement from third-party payors for the product candidates,
and for us or our collaborators to obtain coverage and adequate reimbursement for related companion diagnostic tests that may be developed,
could have a material and adverse effect on our business, financial condition, results of operations and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 54; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to our Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we issue additional shares of common stock
in the future, it will result in the dilution of our existing stockholders and may cause the share price of our common stock to fall.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have 200,000,000 shares of common stock authorized
for issuance and we also have 10,000,000 shares of preferred stock authorized. Our Board of Directors has the authority to issue additional
shares of preferred and common stock up to the authorized capital stated in the articles of incorporation. Our Board of Directors may
choose to issue some or all such shares of common stock to acquire one or more businesses or to provide additional financing in the future.
The issuance of any such shares of common stock will result in a reduction of the book value or market price of the outstanding shares
of our common stock. If we do issue any such additional shares of common stock, such issuance also will cause a reduction in the proportionate
ownership and voting power of all other stockholders. Further, any such issuance may result in a change of control of our corporation.
In the event we do issue or sell additional shares of common or preferred stock, it may result in stockholder dilution and may cause our
share price to fall.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our stock price has been volatile and may be
volatile in the future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our stock price has been volatile at certain times
historically, and may be volatile in the future. We may incur rapid and substantial increases or decreases in our stock price in the foreseeable
future that do not coincide in timing with the disclosure of news or developments by us. The stock market in general, and the market for
biotechnology and pharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating
performance of particular companies. The market price for our common stock may be influenced by many factors, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of new data, clinical trial results or those of companies that are perceived to be similar to us;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements related to any delays in any preclinical or clinical trials related to our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements related to our products&#8217; ability to demonstrate efficacy or an acceptable safety profile of our product candidates or similar announcements by companies that are perceived to be similar to us;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to meet or exceed expectations of analysts or investors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">news that the number of patients required for clinical trials for our drug candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or the duration of these clinical trials may be longer than we anticipate;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions taken by regulatory agencies with respect to our product candidates or the progress of our clinical trials, including with respect to any fast track or orphan drug designations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic collaboration partners or our competitors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">grants awarded to us or companies that are perceived to be similar to us from outside entities;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading volume of our common stock;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments concerning our collaborations or partners;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the perception of the biotechnology or pharmaceutical industries by the public, legislatures, regulators and the investment community;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 55; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments or disputes concerning intellectual property rights;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant lawsuits, including patent or stockholder litigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability or inability to raise additional capital and the terms on which we raise it;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our common stock by us or our stockholders;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">declines in the market prices of stocks generally or of companies that are perceived to be similar to us; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general economic, industry and market conditions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, companies trading in the stock market
in general, and The Nasdaq Capital Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated
or disproportionate to the operating performance of these companies. These broad market and industry factors may seriously harm the market
price of our common stock, regardless of our operating performance. In the past, following periods of volatility in the market, securities
class-action litigation has often been instituted against companies. Such litigation, if instituted against us, could result in substantial
costs and diversion of management&#8217;s attention and resources, which could materially and adversely affect our business, financial
condition, results of operations and growth prospects. There can be no guarantee that our stock price will remain at current prices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our common stock may become the target of a
&#8220;short squeeze.&#8221;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Securities of certain companies have experienced significant
and extreme volatility in stock price due to short sellers of shares of common stock, known as a &#8220;short squeeze.&#8221; These short
squeezes have caused extreme volatility in those companies and in the market and have led to the price per share of those companies to
trade at a significantly inflated rate that is disconnected from the underlying value of the company. Many investors who have purchased
shares in those companies at an inflated rate face the risk of losing a significant portion of their original investment as the price
per share has declined steadily as interest in those stocks has abated. There can be no assurance that we will not in the future be a
target of a short squeeze, and you may lose a significant portion or all of your investment if you purchase our shares at a rate that
is significantly disconnected from our underlying value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Risks Related to our Intellectual Property </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we are unable to obtain and maintain sufficient
intellectual property protection for our product candidates, or if the scope of the intellectual property protection obtained is not sufficiently
broad, our competitors could develop and commercialize product candidates similar or identical to ours, and our ability to successfully
commercialize our product candidates that we may pursue may be impaired. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our success depends in large part on our ability to
obtain and maintain protection of our intellectual property, particularly patents, in the United States and other countries with respect
to our product candidates and technology. We seek to protect our proprietary position by filing patent applications in the United States
and abroad related to our product candidates and/or by in-licensing intellectual property. U.S. patents related to ANAVEX<sup>&#174;</sup>2-73
are directed to ANAVEX&#174;2-73 in its various optical or crystal forms, its therapeutic indications, and dosage forms comprising certain
doses of ANAVEX<sup>&#174;</sup>2-73 combined with another therapeutic agent. We may not be able to obtain broader scope patent protection
for ANAVEX<sup>&#174;</sup>2-73 as a single drug or in other jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The patent position of biotechnology and pharmaceutical
companies generally is highly uncertain, involves complex legal, technological and factual questions and has in recent years been the
subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the
United States, or vice versa. Further, we may not be aware of all third-party intellectual property rights potentially relating to and/or
interfering with our product candidates. Publications of discoveries in the scientific literature often lag behind the actual discoveries,
and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some
cases, not at all until issuance. Therefore,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 56; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">we cannot know with certainty whether we were the first to make the inventions claimed in
our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the
issuance, scope, validity, enforceability and/or commercial value of our patent rights are highly uncertain. Our pending and future patent
applications may not result in patents being issued that protect our product candidates, in whole or in part, or which could effectively
prevent others from commercializing competitive product candidates. Even if our patent applications issue as patents, they may not issue
in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with
any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative product candidates
in a non-infringing manner.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Moreover, we may be subject to a third-party pre-issuance
submission of prior art to the United States Patent and Trademark Office, or the USPTO, or become involved in opposition, derivation,
reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of
others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent
rights, allow third parties to commercialize our product candidates and compete directly with us, without payment to us, or result in
our inability to manufacture or commercialize drugs without infringing on third-party patent rights. In addition, if the breadth or strength
of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from
collaborating with us to license, develop or commercialize current or future product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, while U.S. patents have a presumption
of validity, our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result
in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part,
which could limit our ability to stop others from using or commercializing similar or identical product candidates, or limit the duration
of the patent protection of our product candidates. Given the amount of time required for the development, testing and regulatory review
of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.
As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical
to ours.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We hold ownership or exclusive rights to thirty (30)
U.S. patents, seventeen (17) pending U.S. patent applications, and numerous PCT and ex-U.S. patents and patent applications relating to
our drug candidates, methods associated therewith, and to our research programs. Neither patents nor patent applications necessarily ensure
the protection of our intellectual property for a number of reasons, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr>
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors may interfere with our patenting process in a variety of ways. Competitors may claim that we are not entitled to an issued patent for a variety of legal reasons. Competitors may also claim that we are infringing their patents and restrict our freedom to operate. If a court or, in some circumstances, a board of a national patent authority, agrees, we would lose some or all of our patent protection. As a company, we have no meaningful experience with competitors interfering with our patents or patent applications.</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because of the time, money and effort involved in obtaining and enforcing patents, our management may spend less time and resources on developing potential drug compounds than they otherwise would, which could increase our operating expenses and delay product programs.</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of a patent may not provide significant practical protection. If we receive a patent of narrow scope, then it may be possible for competitors to design products that do not infringe our patent(s).</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have patents covering, and are seeking patent protection for a number of indications, combination products and drug regimens. The lack of patent protection in global markets for a specific end product or indication may inhibit our ability to advance our compounds and may make us less attractive to potential partners.</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defending a patent lawsuit takes significant time and can be very expensive.</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a court decides that an Anavex compound, its method of manufacture or use, infringes on a competitor&#8217;s patent, we may have to pay substantial damages for infringement.</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A court may prohibit us from making, selling or licensing the potential drug compound unless the patent holder grants a license. A patent holder is not required to grant a license. If a license is available, we may have to pay substantial royalties or grant cross licenses to our patents, and the license terms may be unacceptable.</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redesigning our potential drug compounds so that they do not infringe on other patents may not be possible or could require substantial funds and time.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 57; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While we use reasonable efforts to protect our trade
secrets, our employees or consultants may unintentionally or willfully disclose our information to competitors. Enforcing a claim that
someone illegally obtained and is using our trade secrets, like patent litigation, is expensive and time consuming, and the outcome is
unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Our competitors may
independently develop equivalent knowledge, methods and know-how.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may also support and collaborate in research conducted
by government organizations, hospitals, universities or other educational institutions. These research partners may be unable or unwilling
to grant us exclusive rights to technology or products derived from these collaborations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we do not obtain required intellectual property
licenses or rights, we could encounter delays in our product development efforts while we attempt to design around other patents or even
be prohibited from developing, manufacturing or selling potential drug compounds requiring these rights or licenses. There is also a risk
that legal disputes may arise as to the rights to technology or potential drug compounds developed in collaboration with other parties,
all with attendant risk, distraction, expense, and lack of predictability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Patent terms may be inadequate to protect our
competitive position on our product candidates for an adequate amount of time.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patents have a limited lifespan. In the United States,
if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional
filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents
covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products,
including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product
candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our
owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar
or identical to ours.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depending upon the timing, duration and specifics
of FDA marketing approval of product candidates that we identify, one of the U.S. patents covering such product candidate or the use thereof
may be eligible for up to five years of patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act allows a maximum of one
patent to be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory review process. A patent
term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those
claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension
also may be available in certain foreign countries upon regulatory approval of our product candidates. Nevertheless, we may not be granted
patent term extension either in the United States or in any foreign country because of, for example, failing to exercise due diligence
during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration
of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of
patent protection during any such extension, afforded by the governmental authority could be less than what we request. If we are unable
to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we
will have the right to exclusively market our product may be shortened and our competitors may obtain approval of competing products following
our patent expiration sooner, and our revenue could be reduced, possibly materially.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Also, there are detailed rules and requirements regarding
the patents that may be submitted to the FDA for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations, or the
Orange Book. We may be unable to obtain patents covering our product candidates that contain one or more claims that satisfy the requirements
for listing in the Orange Book. Even if we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or
a manufacturer of generic drugs may challenge the listing. If one of our product candidates is approved and a patent covering that product
candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any abbreviated
new drug application filed with the FDA to obtain permission to sell a generic version of such product candidate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 58; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we fail to comply with our obligations in
the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business
relationships with our licensors, we could lose intellectual property rights that are important to our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are party to an exclusive license agreement with
Life Science Research Israel Ltd., with respect to certain in-licensed intellectual property related to our ANAVEX<sup>&#174;</sup>3-71
product candidate, and we may need to obtain additional licenses from others in the future. Our license agreement with Life Science Research
Israel Ltd. imposes, and we expect that future license agreements will impose, various development, diligence, commercialization, and
other obligations on us. In spite of our efforts, our licensors might conclude that we have materially breached our obligations under
such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and
commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents
fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and
to market, products identical to ours and we may be required to cease our development and commercialization of ANAVEX<sup>&#174;</sup>3-71
or other product candidates covered by any such future licenses. Any of the foregoing could have a material adverse effect on our competitive
position, business, financial conditions, results of operations, and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Moreover, disputes may arise regarding intellectual
property subject to a licensing agreement, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr>
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr>
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr>
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">the priority of invention of patented technology.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the agreements under which we currently
license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible
to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to
be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other
obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results
of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to
maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected
product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we do not obtain required intellectual property
licenses or rights, we could encounter delays in our product development efforts while we attempt to design around other patents or even
be prohibited from developing, manufacturing or selling potential drug compounds requiring these rights or licenses. There is also a risk
that legal disputes may arise as to the rights to technology or potential drug compounds developed in collaboration with other parties,
all with attendant risk, distraction, expense, and lack of predictability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 59; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Third-party claims of intellectual property
infringement may prevent or delay our development and commercialization efforts.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our success will also depend in part on our ability
to commercialize our compounds without infringing the proprietary rights of others. However, our research, development and commercialization
activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled
by third parties. We have not conducted extensive freedom of use patent searches and no assurance can be given that patents do not exist
or could be issued which would have an adverse effect on our ability to market our technology or maintain our competitive position with
respect to our technology. Because patent applications can take many years to issue, there may be currently pending patent applications
which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the
future and claim that use of our technologies infringes upon these patents. If our compounds or other subject matter are claimed under
other United States patents or other international patents or are otherwise protected by third party proprietary rights, we may be subject
to infringement actions. In such event, we may challenge the validity of such patents or other proprietary rights, or we may be required
to obtain licenses from such companies in order to develop, manufacture or market our technology. There can be no assurances that we would
be successful in a challenge or be able to obtain such licenses or that such licenses, if available, could be obtained on commercially
reasonable terms. Furthermore, the failure to succeed in a challenge, develop a commercially viable alternative or obtain needed licenses
could be materially adverse. Adverse consequences include delays in marketing some or all of our potential drug compounds based on our
drug technology or the inability to proceed with the development, manufacture or sale of potential drug compounds requiring such licenses.
If we defend ourselves against charges of patent infringement or to protect our proprietary rights against third parties, substantial
costs will be incurred regardless of whether we are successful. Such proceedings are typically protracted with no certainty of success.
An adverse outcome could subject us to significant liabilities to third parties and force us to curtail or cease the research and development
of our technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Parties making claims against us may obtain injunctive
or other equitable relief, which could effectively block our ability to further develop and commercialize ANAVEX<sup>&#174;</sup>2-73 or
our other product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would
be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we
may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign
our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary
expenditure. Additionally, parties making claims against us may be able to sustain the costs of complex patent litigation more effectively
than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in
connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information
could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could
have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results
of operations, financial condition and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we are unable to protect the confidentiality
of our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While we use reasonable efforts to protect our trade
secrets, our employees or consultants may unintentionally or willfully disclose our information to competitors. Enforcing a claim that
someone illegally obtained and is using our trade secrets, like patent litigation, is expensive and time consuming, and the outcome is
unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Our competitors may
independently develop equivalent knowledge, methods and know-how.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We seek to protect our confidential proprietary information,
in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors
and collaborators. These agreements are designed to protect our proprietary information. However, we cannot be certain that such agreements
have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information
will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent
information and techniques. For example,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 60; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">any of these parties may breach the agreements and disclose our proprietary information, including
our trade secrets, and we may not be able to obtain adequate remedies for such breaches. We also seek to preserve the integrity and confidentiality
of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our
information technology systems, but it is possible that these security measures could be breached. If any of our confidential proprietary
information were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor
from using that technology or information to compete with us, which could harm our competitive position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may be subject to claims that our employees,
consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees
have wrongfully used or disclosed alleged trade secrets of their former employers.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As is common in the biotechnology and pharmaceutical
industry, we employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including
our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not
use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants
or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary
information, of any of our employee&#8217;s former employer or other third parties. Litigation may be necessary to defend against these
claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights
or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could
result in substantial costs and be a distraction to management and other employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may become involved in lawsuits to protect
or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful and could harm our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Competitors may infringe our patents or other intellectual
property. Although we are not currently involved in any litigation, if we were to initiate legal proceedings against a third party to
enforce a patent covering ANAVEX<sup>&#174;</sup>2-73 or our other product candidates, the defendant could counterclaim that the patent
covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging
invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several
statutory requirements, including lack of novelty, obviousness, written description or non-enablement. Grounds for an unenforceability
assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or
made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Interference or derivation proceedings provoked by
third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents
or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights
to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable
terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation
or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management
and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to
raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties,
or enter into development partnerships that would help us bring ANAVEX<sup>&#174;</sup>2-73 or our other product candidates to market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 61; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may be subject to claims challenging the
inventorship of our patents and other intellectual property.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We or our licensors may be subject to claims that
former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets, or other intellectual
property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations
of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against
these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets
or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may
lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to
our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be
a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial
condition, results of operations and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Obtaining and maintaining our patent protection
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent
agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Periodic maintenance fees, renewal fees, annuity fees
and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent
agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place
to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent
agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee
payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help
us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable
rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting
in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the
market and this circumstance would have a material adverse effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may not be able to protect our intellectual
property rights throughout the world.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Filing, prosecuting and defending patents on our product
candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries
outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not
protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able
to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products
made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions
where we have not obtained patent protection to develop their own products and may also export infringing products to territories where
we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products
and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Changes in patent law could diminish the value
of our patents and patent applications in general, thereby impairing our ability to protect our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Changes in either the patent laws or interpretation
of the patent laws in the United States and other countries could increase the uncertainties and costs surrounding the prosecution of
patent applications and the enforcement or defense of issued patents. After March 2013, under the Leahy-Smith America Invents Act, or
the America Invents Act, enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming
that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an
invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application
in the USPTO after March 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the
invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent
application. Since patent applications in the United States and most other countries are confidential for a period of time after filing
or until issuance,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 62; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our
product candidates or (ii) invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. The America
Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect
patent litigation. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the
prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents,
all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the patent positions of companies in
the development and commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the
scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination
of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions
by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways
that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property
in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The risk factors disclosed in this Annual Report on
Form 10-K could materially and adversely affect our business, financial condition and results of operations. The risks described herein
are not the only risks we face. Our operations could also be affected by additional factors that are not presently known to us or by factors
that we currently consider immaterial to our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_004"></span>ITEM 1B. UNRESOLVED STAFF
COMMENTS</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_005"></span>ITEM 1C. CYBERSECURITY<span style="font-weight: normal">&#160;</span></span></p>

<div id="xdx_980_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20241001__20250930_z9nJGKLxlzJl" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000044" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Risk management and strategy </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have implemented and maintain various information
security processes designed to identify, assess and manage <span id="xdx_906_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20241001__20250930_zdv53dXGo97l" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:booleantrue" id="Fact000045" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">material</ix:nonNumeric> </span>risks from cybersecurity threats to our cloud networks, <span id="xdx_90E_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20241001__20250930_zRxyuWweayrh" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:booleantrue" id="Fact000046" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">third party</ix:nonNumeric></span>
hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information
that is proprietary, strategic or competitive in nature, and data related to our clinical trials and products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have processes designed to protect our information
systems, data, assets, infrastructure, and computing environments from cybersecurity threats and risks. Our cybersecurity strategy includes
the use of third-party IT professionals to assess the effectiveness of our cybersecurity practices for possible cybersecurity threats
and to manage our IT systems to mitigate these threats. We also use multi-factor authentication, maintain logical, physical and technical
controls designed to deter, prevent, mitigate and respond to cybersecurity threats. Further, we provide periodical cybersecurity reminders
to our employees and subscribe to a third-party cybersecurity training program required for all employees, to emphasize the importance
of adherence to our security policies and awareness of evolving cybersecurity threats. We also carry a separate cybersecurity commercial
insurance policy covering the potential financial losses that may occur in the event we experience a cybersecurity incident.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_905_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20241001__20250930_zlJZVmtouZA1" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000047" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock">Our assessment and management of material risks from
cybersecurity threats are <span id="xdx_90A_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20241001__20250930_zTtCiHPGKa8l" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:booleantrue" id="Fact000048" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">integrated</ix:nonNumeric> </span>into the Company&#8217;s overall risk management processes.</ix:nonNumeric></span> We conduct organizational risk assessments
commensurate with our size and complexity of our operations. We are in a continuous process of reviewing and implementing incremental
information technology strategies to mitigate cybersecurity risks as new risks arise and as our operations evolve. This has led us to
engage third party professionals to assist in the implementation of processes to manage these risks. We also use third-party service providers
across a variety of functions throughout our business, such as application providers, hosting companies, contract research organizations,
contract manufacturing organizations, distributors, and supply chain resources. We have a vendor management process to help manage cybersecurity
risks associated with our use of certain of these providers. For certain vendors, these processes include a comprehensive vendor audit
process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 63; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of the date of this Annual Report, we do not believe
that any past cybersecurity incidents that have been detected have materially affected, or are reasonably likely to materially affect,
our business strategy, results of operations, or financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See &#8220;<i>Risk Factors - Risks Related to Our
Business and Operations</i>&#8221; for additional information about the risks to our business associated with cybersecurity or a breach
or compromise to our information security systems.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Governance </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<div id="xdx_980_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20241001__20250930_zu38dIlHJAS2" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000049" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_904_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20241001__20250930_zqfCSDYTZXkh" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000050" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">Our Board of Directors addresses the Company&#8217;s
cybersecurity risk management as part of its general oversight function. <span id="xdx_90B_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20241001__20250930_zOSArugJT6Vg" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000051" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">The audit committee of the Board of Directors is responsible
for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity
<span id="xdx_908_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20241001__20250930_zdM05lQaYVC9" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:booleantrue" id="Fact000052" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">threats</ix:nonNumeric></span>.</ix:nonNumeric></span></ix:nonNumeric></span> <span id="xdx_90D_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20241001__20250930_z6KSwD07O2Ba" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000053" name="cyd:CybersecurityRiskRoleOfManagementTextBlock">The audit committee receives periodic updates as required from senior management concerning updates to the Company&#8217;s significant
cybersecurity threats and <span id="xdx_901_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20241001__20250930_zzhFYYiJaqYj" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:booleantrue" id="Fact000054" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">risk</ix:nonNumeric></span> and the processes the Company has implemented to address them.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Currently we have two cybersecurity experts on our
Audit Committee.</p>

</ix:nonNumeric></div>

</ix:nonNumeric></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_006"></span>ITEM 2. PROPERTIES</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not own any real property. We maintain a corporate
head office at 630 5th Avenue, 20th Floor, New York, NY, USA. During the fiscal year 2025, our costs for our physical office were approximately
$11,000 per month. We believe our offices are suitable and adequate to operate our business currently, as they provide us with sufficient
space to conduct our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_007"></span>ITEM 3. LEGAL PROCEEDINGS</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to claims and legal proceedings
that arise during the course of business. The Company is currently subject to the following lawsuits:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On <span style="background-color: white">March 13, 2024, a shareholder class
action complaint was filed in the United States District Court for the Southern District of New York, and it named the Company and an
officer of the Company as Defendants. The complaint was amended on July 12, 2024 (the &#8220;Initial Action&#8221;). The complaint alleged
violations of the Securities and Exchange Act of 1934 associated with disclosures and statements made with respect to certain clinical
trials for ANAVEX<sup>&#174;</sup>2-73 related to Rett syndrome. This lawsuit was dismissed by the United States District Court for the
Southern District of New York on June 18, 2025. The plaintiff filed a notice of appeal on July 17, 2025. Briefing on the appeal concluded
October 30, 2025. No decision has been entered. No amount has been recorded in our consolidated financial statements for any loss contingencies
associated with this lawsuit as the Company believes that it is not probable that any loss will</span>
occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On May 8, 2024,
a similar complaint was filed in the same court by Kenneth Downing, a purported shareholder of the Company, against the same defendants.
The Company believed that this lawsuit was without merit and filed a motion to dismiss the complaint. Plaintiff Downing voluntarily dismissed
this complaint subsequent to the filing of the motion to dismiss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On <span style="background-color: white">or about May 13, 2024, a derivative
lawsuit was filed against the Company (as nominal defendant), an officer of the Company, and members of the Company&#8217;s Board of Directors
in the U.S. District Court for the District of Nevada by another purported shareholder. The complaint asserts various common law claims
(including breach of fiduciary duty) and violation of Section 14(a)of the Securities Exchange Act regarding the same or similar allegations
at issue in the purported class action lawsuit related to disclosures and statements made about certain clinical trials related to Rett
syndrome. On January 22, 2025, pursuant to a stipulation of the parties, the Court entered an order staying this purported derivative
lawsuit until the motion to dismiss filed by defendants in the Initial Action is decided by the U.S. District Court for the Southern District
of New York. The stay has been extended throughout the appeal.&#160;No amount has been recorded in our consolidated financial statements
for any loss contingencies associated with this lawsuit as the Company believes that it is not probable that any loss will</span> occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 64; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On <span style="background-color: white">February 14, 2025, another derivative
lawsuit asserting state law breach of fiduciary duty and unjust enrichment claims based upon similar allegations was filed against the
Company (as nominal defendant), an officer of the Company, and members of the Company&#8217;s Board of Directors in the Supreme Court
for the State of New York, County of New York, by another purported shareholder. On August 18, 2025, pursuant to a stipulation of the
parties, the Court entered an order staying this purported derivative lawsuit until the appeal in the Initial Action is resolved. No amount
has been recorded in our consolidated financial statements for any loss contingencies associated with this lawsuit as the Company believes
that it is not probable that any loss will</span> occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">We know of no
other material pending legal or governmental proceedings, other than ordinary routine litigation incidental to our business, to which
our Company or our subsidiaries are a party or of which any of their property is subject. There are no other proceedings in which any
of our directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, or any associate
of such persons, is an adverse party or has a material interest adverse to our or our subsidiaries&#8217; interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_008"></span>ITEM 4. MINE SAFETY DISCLOSURES</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_009"></span>PART II</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_010"></span>ITEM 5. MARKET FOR REGISTRANT&#8217;S
COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Market information</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock is quoted on the Nasdaq Global Select
Stock Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;AVXL.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Holders of Common Stock </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of November 24, 2025, there were approximately
49 stockholders of record, and 89,348,107 shares of our common stock were issued and outstanding. Most of our stockholders hold their
shares in street name.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Dividends </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have not paid any cash dividends on our common
stock and have no intention of paying any dividends on the shares of our common stock. Our current policy is to retain earnings, if any,
for use in our operations and in the development of our business. Our future dividend policy will be determined from time to time by our
Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Performance Graph </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following graph compares the performance of our
Common Stock for the periods indicated with the performance of the NASDAQ Composite Index and the NASDAQ Biotechnology Index. This graph
assumes an investment of $100 after the market closed September 30, 2020 in each of our common stock, the NASDAQ Composite Index and the
NASDAQ Biotechnology Index, and assumes reinvestment of dividends, if any. The stock price performance shown on the graph below is not
necessarily indicative of future stock price performance. This graph is not &#8220;soliciting material,&#8221; is not deemed &#8220;filed&#8221;
with the SEC and is not to be incorporated by reference into any of our filings under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language
in any such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 65; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><img src="image_004.jpg" alt="" style="height: 215.25pt; width: 451.5pt"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">NASDAQ Biotechnology Index (NBI)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">100.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">119.46</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">88.51</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">92.88</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">112.01</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">114.64</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">S&amp;P Biotech ETF (XBI)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112.82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65.53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88.67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89.92</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">AVXL</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">394.51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">226.81</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">143.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">124.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">195.60</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Recent Sales of Unregistered Securities </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since the beginning of our fiscal year ended September
30, 2025, we have not sold any equity securities that were not registered under the Securities Act of 1933 that were not previously reported
in a quarterly report on Form 10-Q or in a current report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Repurchases of Equity Securities by Our Company
and Affiliated Purchasers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_011"></span>ITEM 6 [Reserved]</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal"><span id="a_012"></span>ITEM 7 MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>The following discussion should be read in conjunction
with our consolidated financial statements and related notes thereto included elsewhere in this report. Past operating results are not
necessarily indicative of results that may occur in future periods. This discussion contains forward-looking statements, which involve
a number of risks and uncertainties. See &#8220;Forward Looking Statements&#8221; included elsewhere in this report. For discussion and
analysis pertaining to 2024 overview and highlights as compared to 2023, please refer to the Company&#8217;s Annual Report on Form 10-K,
filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on December 23, 2024.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Financial Operations Overview</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">We are in
the pre-revenue stage and have not earned any revenues since our inception in 2004. We do not anticipate earning any revenues until we
can establish an alliance with other companies to develop, co-develop, license, acquire or market our products.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal"></span></p>

<!-- Field: Page; Sequence: 66; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">Our operating costs consist primarily of research and development
activities including the cost of clinical studies and clinical supplies as well as clinical drug manufacturing and formulation. Research
and development expenses also include personnel related costs such as salaries and wages, and third-party contract research organization
(CRO) expenses in support of these clinical studies. Personnel costs include salaries and wages, benefits, and non-cash share-based compensation
charges associated with options and other equity awards granted to employees and consultants who are directly engaged in support of our
research and development activities.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">General and administrative expenses consist of personnel costs,
expenses for outside professional services and expenses associated with operating as a public company. Personnel costs consist of salaries
and wages, benefits and share-based compensation for general and administrative personnel. Outside professional services and public company
expenses include expenses related to compliance and reporting, additional insurance expenses, audit and SOX compliance, expenses associated
with patent research, applications and filings, investor and stockholder relations activities and other administrative expenses and professional
services.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b>Comparison of fiscal year 2025 to fiscal years 2024 </b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b>&#160;</b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>Operating Expenses</i></b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">Our operating expenses for fiscal 2025 decreased to $51.4 million,
from $52.9 million in fiscal 2024. The decrease is attributable to research and development expenses, as more fully described below.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">The following table summarizes our research and development expenses for
the years ended September 30, 2025, 2024, and 2023 (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Costs of external service providers</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">16,348</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">21,974</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">22,542</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Personnel costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,264</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,013</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,813</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,812</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other common costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">765</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">375</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">99</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total research and development costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37,592</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">41,838</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">43,717</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">External service provider cost by product candidate
was as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">ANAVEX<sup>&#174;</sup>2-73</span></td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">10,292</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">17,572</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">19,540</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">ANAVEX<sup>&#174;</sup>3-71</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.408</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,748</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,624</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other product candidates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">297</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other external service provider costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">351</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">504</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">372</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total external service provider costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,348</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">21,974</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,542</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During fiscal 2025, we experienced an overall decrease
in total research and development expenses over the comparable fiscal 2024 financial year. The main factors driving this decrease were
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px">(i)</td><td style="text-align: justify">a decrease of approximately $3.6 million related to the Alzheimer&#8217;s program due to the completion
of the ATTENTION-AD trial in the third quarter of fiscal 2024 and an overall decrease in related trial data analysis activities;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px">(ii)</td><td style="text-align: justify">a decrease of approximately $1.7 million associated with the Parkinson&#8217;s program related to planning
activities for a future clinical trial in the comparable period;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px">(iii)</td><td style="text-align: justify">a decrease of approximately $1.5 million over the comparable period relating to manufacturing activities
of ANAVEX<sup>&#174;</sup>2-73 for potential commercial use, and to support the MAA;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -36pt"></p>

<!-- Field: Page; Sequence: 67; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px">(iv)</td><td style="text-align: justify">a decrease of approximately $0.9 million related to the completion of a production run of ANAVEX<sup>&#174;</sup>3-71
in fiscal 2024.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px">(v)</td><td style="text-align: justify">a decrease of approximately $0.8 million associated with our Rett syndrome program, due to the completion
of the ANAVEX<sup>&#174;</sup>2-73 EXCELLENCE OLE in the third quarter of fiscal 2024.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">The above decreases were partially offset by an increase
of approximately $3.0 million related to completion of Part B of the <span style="background-color: white">ANAVEX<sup>&#174;</sup>3-71-SZ-001
</span>trial during fiscal 2025, which was substantially larger in size than the preceding Part A during fiscal 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">General and administrative expenses were $13.8 million
for the fiscal 2025 financial year, as compared to $11.0 million in fiscal 2024. The primary reason for the increase in general and administrative
expenses was an increase in legal fees of $1.7 million, related to legal/regulatory matters, a new shelf registration statement, and various
class action lawsuits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">We expect to see our research and development expenditures increase
from current levels as we continue to advance our pipeline compounds.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>Other income (net)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">Net other income for the year ended September 30, 2025 was $5.0
million as compared to $9.9 million for fiscal 2024. The primary reason for the decrease in other income was due to a decrease of $2.6
million in interest income as a result of withdrawals in principal balance applied to excess funds invested in a money market as well
as a market wide decrease in interest rates.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">During fiscal 2025, we recorded $0.6 million in research and development incentive
income, consisting of the Australian research and development incentive credit administered through the ATO, in connection with fiscal
2025 eligible expenditures. In comparison, research and development incentive income for fiscal 2024 was $2.3 million in connection with
fiscal 2024 eligible expenditures. This income is driven by the clinical trial expenditures incurred in Australia, and the decrease year
over year is a result of the completion of eligible R&amp;D clinical trials in Australia. We expect to continue to receive support from
the Australian government for future clinical trials which we plan to conduct, in part, within Australia.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>Net loss</i></b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">Net loss for fiscal 2025 was $46.4 million, or $0.54
per share, compared to a net loss of approximately $43.0 million, or $0.52 per share for fiscal 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b>Liquidity and Capital Resources </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>Working Capital (in thousands)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Current Assets</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">103,815</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">135,567</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Current Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,946</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,304</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Working Capital</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">94,869</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">120,263</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">At September 30, 2025, we had $102.6 million in cash and cash
equivalents, a decrease from $132.2 million at September 30, 2024.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">We intend to continue to use our capital resources to advance
our clinical trials for ANAVEX<sup>&#174;</sup>2-73 and ANAVEX<sup>&#174;</sup>3-71, and to perform work necessary to prepare for future
development of our pipeline compounds.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"></p>

<!-- Field: Page; Sequence: 68; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><i>Cash Flows </i></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-weight: normal">Following is a summary
of sources of cash flows for the years ended September 30, 2025, 2024 and 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2025</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Cash flows used in operating activities</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(39,044</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(30,812</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(27,785</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash flows provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,434</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,651</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">(Decrease)/increase in cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(29,610</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(18,837</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,866</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">Cash flow used in operating activities</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">There was an increase in cash used in operating activities of
$8.2 million during fiscal 2025. The principal reason for this is due to a large decrease in accounts payable during the year, as compared
to a large increase in the comparable financial year, principally due to timing of payments for a large manufacturing campaign of ANAVEX<sup>&#174;</sup>2-73.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">Cash flow provided by financing activities</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">Cash provided by financing activities in fiscal 2025 was $9.4
million, comprised primarily of net cash received of $9.2 million related to the issuance of common shares pursuant to the at-the-market
offering and $2.9 million in cash from the exercise of stock options by our employees. We utilized $2.7 million to satisfy tax withholding
obligations associated with the net exercise of two expiring employee stock options to our CEO, in exchange for the withholding of shares.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">Cash provided by financing activities in fiscal 2024 was $12.0
million, comprised of $11.3 million attributable to cash received from the issuance of common shares under the 2023 Purchase Agreement
and $0.7 million received pursuant to the exercise of stock options.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">Other Financings</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b>Sales Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">On July 25, 2025, we entered into a Sales Agreement
(the &#8220;Sales Agreement&#8221;) with TD Securities (USA) LLC (the &#8220;Sales Agent&#8221;). Pursuant to the Sales Agreement, the
Company may offer and sell up to an aggregate offering price of $150 million (the &#8220;Offering&#8221;) in shares of common stock from
time to time through the Sales Agent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon delivery of a placement notice based on our instructions
and subject to the terms and conditions of the Sales Agreement, the Sales Agent may sell shares of common stock by methods deemed to be
an &#8220;at the market offering&#8221;, in negotiated transactions at market prices prevailing at the time of sale or at prices related
to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to our prior written
consent. We are not obligated to make any sales of shares under the Sales Agreement. We or the Sales Agent may suspend or terminate the
Offering upon notice to the other party, subject to certain conditions. The Sales Agent will act as sales agent on a commercially reasonable
efforts basis consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations and the
rules of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have agreed to pay the Sales Agent commissions
for its services of up to 3.0% of the gross proceeds from the sale of shares of Common Stock pursuant to the Sales Agreement. We have
also agreed to provide the Sales Agent with customary indemnification and contribution rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2025, the Company
issued an aggregate of 927,910 shares of Common Stock under the Sales Agreement for net proceeds of $9.2 million, after deducting commissions
and offering expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2025, there was an unused amount
of $140.4 million under the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 69; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2023 Purchase Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 3, 2023, we entered into a $150,000,000
purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant
to which we have the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $150.0 million in value
of our shares of Common Stock from time to time over a three-year period until February 3, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On any business day and subject to having an effective
registration statement and subject to certain customary conditions, we may direct Lincoln Park to purchase up to 200,000 shares of Common
Stock (such purchases, &#8220;Regular Purchases&#8221;). The amount of a Regular Purchase may increase under certain circumstances based
on the market price of the Common Stock; provided, however, that Lincoln Park&#8217;s committed obligation under any Regular Purchase
shall not exceed $4.0 million. The purchase price of shares of Common Stock will be based on the then prevailing market prices of such
shares at the time of sales as described in the 2023 Purchase Agreement. There are no limits on the price per share that Lincoln Park
may pay to purchase Common Stock under the 2023 Purchase Agreement. In addition, if we have directed Lincoln Park to purchase the full
amount of Common Stock available as a Regular Purchase on a given day, we may direct Lincoln Park to purchase additional amounts as &#8220;accelerated
purchases&#8221; and &#8220;additional accelerated purchases,&#8221; each as set forth in the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2023 Purchase Agreement limits the Company&#8217;s
sale of shares of Common Stock to Lincoln Park to 15,606,426 shares of Common Stock, representing 19.99% of the shares of the Common Stock
outstanding on the date of the 2023 Purchase Agreement unless (i) stockholder approval is obtained to issue more than such amount or (ii)
the average price of all applicable sales of Common Stock to Lincoln Park under the 2023 Purchase Agreement equals or exceeds the lower
of (A) the closing price of the Common Stock on the Nasdaq Capital Market immediately preceding the Execution Date or (B) the average
of the closing price of the Common Stock on the Nasdaq Capital Market for the five Business Days immediately preceding the Execution Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2023 Purchase Agreement also prohibits the Company
from directing Lincoln Park to purchase any shares of Common Stock if those shares, when aggregated with all other shares of Common Stock
then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial ownership,
at any single point in time, of more than 4.99% of the then total outstanding shares of Common Stock, as calculated pursuant to Section
13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the 2023 Purchase
Agreement, the Company issued to Lincoln Park 75,000 shares of Common Stock as a commitment fee (the &#8220;initial commitment shares&#8221;)
during the year ended September 30, 2023 and agreed to issue up to 75,000 shares pro rata (collectively with the initial commitment shares,
the &#8220;commitment shares&#8221;), when and if, Lincoln Park purchased, at the Company&#8217;s discretion, the $150.0 million aggregate
commitment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2025, the Company
did not issue any shares of common stock under the 2023 Purchase Agreement. During the year ended September 30, 2024, the Company issued
to Lincoln Park an aggregate of 2,455,646 shares of Common Stock under the 2023 Purchase Agreement, including 2,450,000 shares of Common
Stock for an aggregate purchase price of $11.3 million and 5,646 commitment shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 30, 2025, there was an unused amount
of $110.8 million under the 2023 Purchase Agreement. The Company will need to file a prospectus supplement in order to access funds under
the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Off-Balance Sheet Arrangements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have no off-balance sheet arrangements that have
or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses,
results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 70; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><span style="text-transform: uppercase"><b>Application
of Critical Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States.
Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities,
revenue and expenses. These estimates and assumptions are affected by management</span>&#8217;<span style="font-family: Times New Roman, Times, Serif">s
application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with
the following aspects of our financial statements is critical to an understanding of our financial statements.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">We base our assumptions and estimates on historical experience
and other sources that we believe to be reasonable at the time. Actual results may vary from our estimates due to changes in circumstances,
politics, global economics, general business conditions and other factors. Our significant estimates are related to the valuation of warrants
and options.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">There are accounting policies that we believe are significant
to the presentation of our financial statements. The most significant of these accounting policies relates to the accounting for our research
and development expenses and share-based compensation expense.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><i>Research and Development Expenses</i></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><i>&#160;</i></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Research
and development costs are expensed as incurred. These expenses are comprised of the costs of the Company</span>&#8217;<span style="font-family: Times New Roman, Times, Serif">s
proprietary research and development efforts, including preclinical studies, clinical trials, manufacturing costs, employee salaries and
benefits and share-based compensation expense, contract services including external research and development expenses incurred under arrangements
with third parties such as contract research organizations (</span>&#8220;<span style="font-family: Times New Roman, Times, Serif">CROs</span>&#8221;<span style="font-family: Times New Roman, Times, Serif">),
facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when
the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification
(</span>&#8220;<span style="font-family: Times New Roman, Times, Serif">ASC</span>&#8221;<span style="font-family: Times New Roman, Times, Serif">)
730, <i>Research and Development</i>, as these materials have no alternative future use outside of their intended use.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">Nonrefundable advance payments for goods or services that will
be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered,
or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs incurred in relation
to external CROs, and clinical site costs. The Company analyzes the progress of clinical trials, including levels of patient enrollment,
invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability.
Significant judgments and estimates must be made and used in determining the accrued balance and expense in any accounting period. The
Company reviews and accrues CRO expenses and clinical trial study expenses based on work performed and relies upon estimates of those
costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion.
Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical
site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these
contracts may be uneven and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion
of portions of the clinical trial or similar conditions. The objective of our policy is to record expenses in our financial statements
based on actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based
on our estimate of the degree of completion of the event or events specified in the specific clinical trial contract.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">In addition, we incur expenses in respect of the acquisition
of intellectual property relating to patents and trademarks. The probability of success and length of time to develop commercial applications
of the drugs subject to the acquired patents and trademarks is difficult to determine and numerous risks and uncertainties exist with
respect to the timely completion of the development projects. There is no assurance the acquired patents and trademarks will ever be successfully
commercialized. Due to these risks and uncertainties, we expense the acquisition of patents and trademarks.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><i>Share-based Compensation</i></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><i>&#160;</i></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">We account for all share-based payments and awards under the
fair value-based method.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">The fair value of all share purchase options and warrants are
expensed over their contractual vesting period, or over the expected performance period for only the portion of awards expected to vest,
in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 71; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">Compensation costs for share-based payments with graded vesting
are recognized on a straight-line basis. Share-based compensation expense is adjusted for actual forfeitures of unvested awards as they
occur.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">We have granted share purchase option awards that vest upon
achievement of certain performance criteria, or milestone-based awards. We estimate an implicit service period for achieving performance
criteria for each award and recognize the resulting fair value as expense over the implicit service period when we conclude that achieving
the performance criteria is probable. We periodically review and update as appropriate our estimates of implicit service periods and conclusions
on achieving the performance criteria. Performance awards vest upon achievement of the performance criteria.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
use the Black-Scholes option valuation model to calculate the fair value of share purchase options and warrants at the date of the grant.
This model requires the input of subjective assumptions, including the expected price volatility, and expected life of each&#160;award.
These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management</span>&#8217;<span style="font-family: Times New Roman, Times, Serif">s
judgment. Changes in these assumptions can materially affect the fair value estimates.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b>RECENT ACCOUNTING PRONOUNCEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">For a discussion of recent accounting pronouncements and their
possible effect on our results, see Note 2 to our Consolidated Financial Statements found elsewhere in this Annual Report.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-style: normal"><span id="a_013"></span>ITEM 7A QUANTITATIVE AND QUALITATIVE
DISCLOSURES ABOUT MARKET RISK</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b>Interest Rate Risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We invest our excess cash in investment-grade, interest-bearing
securities. The primary objective of our investment policy is to preserve principal and liquidity. To achieve this objective, our investment
policy allows for investments in domestic money market certificates, certificates of deposit, money market funds, bonds or commercial
papers, and establishes diversification and credit quality requirements and limits investments by maturity and issuer. At September 30,
2025 and 2024, the majority of our excess cash was held in a JP Morgan Chase Prime Money Market Fund. The average amount invested at any
given time throughout the year ended September 30, 2025 was $109.3 million (high: $127.0 million; low: $90.6 million) and the average
rate of return was 4.28%. A hypothetical 100 basis point change in interest rates during any of the periods presented would not have a
material impact on the fair market value of our cash and cash equivalents as of September 30, 2025 and 2024 and would impact our net loss
by approximately $1.1 million. To date, we have not experienced a loss of principal on any of our investments and as of September 30,
2025, we did not have any allowance for credit losses from our cash and cash equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Foreign Exchange Risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We face foreign exchange risk as a result of entering
into transactions denominated in currencies other than U.S. dollars and as a result of the existence of sales and incentive tax receivables
denominated in other than U.S. dollars. Due to the uncertain timing of expected payments in foreign currencies, we do not utilize any
forward exchange contracts. All foreign transactions settle on the applicable spot exchange basis at the time such payments are made.
Volatile market conditions and supply chain shortages may result in significant changes in exchange rates, and in particular a change
in foreign currencies values relative to the U.S. dollar may affect our operating expenses as expressed in U.S. dollars. An adverse movement
in foreign exchange rates could have a material effect on payments made to foreign suppliers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended September 30, 2025, a majority
of our expenses were denominated in U.S. dollars. A hypothetical 10% change in foreign exchange rates applied to foreign currency transactions
for the year ended September 30, 2025 would not have had a material impact on our consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2025, we held net assets of $1.9
million (AUD $2.9 million) denominated in Australian dollars. A hypothetical 10% change in foreign exchange rates at September 30, 2025
would result in a change in reported net assets of +/- $0.19 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Inflation Risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inflation generally may affect us by increasing our
cost of labor and clinical trial costs. We do not believe that inflation has had a material impact on our results of operations during
the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 72; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_014"></span>ITEM 8. FINANCIAL STATEMENTS
AND SUPPLEMENTARY DATA</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ANAVEX LIFE SCIENCES CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONSOLIDATED FINANCIAL STATEMENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2025</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 73; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM &#160; &#160;</b></p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">Board of Directors and Stockholders</span><br/>
Anavex Life Sciences Corp.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Opinion on the financial statements</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have audited the accompanying consolidated balance sheets of Anavex
Life Sciences Corp. (a Nevada corporation) and subsidiaries (the &#8220;Company&#8221;) as of September&#160;30, 2025 and 2024, the related
consolidated statements of operations and comprehensive loss, changes in stockholders&#8217; equity, and cash flows for each of the three
years in the period ended September&#160;30, 2025, and the related notes (collectively referred to as the &#8220;consolidated financial
statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position
of the Company as of September&#160;30, 2025 and 2024, and the results of its operations and its cash flows for each of the three years
in the period ended September&#160;30, 2025, in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We also have audited, in accordance with the standards of the Public Company
Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the Company&#8217;s internal control over financial reporting as of
September&#160;30, 2025, based on criteria established in the 2013 <i>Internal Control&#8212;Integrated Framework</i> issued by the Committee
of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;), and our report dated November&#160;25, 2025 expressed an
unqualified opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Basis for opinion</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">These consolidated financial statements are the responsibility of the Company&#8217;s
management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits.
We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We conducted our audits in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free
of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement
of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included
examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating
the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial
statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Critical audit matters</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Critical audit matters are matters arising from the current period audit
of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts
or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.
We determined that there are no critical audit matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">/s/ GRANT THORNTON LLP</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have served as the Company&#8217;s auditor since 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Melville, New York<br/>
November 25, 2025</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 74 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">Board of Directors and Stockholders</span><br/>
Anavex Life Sciences Corp.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Opinion on internal control over financial reporting</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; color: #3A215E">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have audited the internal control over financial reporting of Anavex
Life Sciences Corp. (a Nevada corporation) and subsidiaries (the &#8220;Company&#8221;) as of September 30, 2025, based on criteria established
in the 2013 <i>Internal Control&#8212;Integrated Framework</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission
(&#8220;COSO&#8221;). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting
as of September 30, 2025, based on criteria established in the 2013 <i>Internal Control&#8212;Integrated Framework</i> issued by COSO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We also have audited, in accordance with the standards of the Public Company
Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the consolidated financial statements of the Company as of and for the
year ended September 30, 2025, and our report dated November 25, 2025 expressed <span style="color: windowtext">an unqualified opinion</span>
on those financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Basis for opinion</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company&#8217;s management is responsible for maintaining effective
internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included
in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an
opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered
with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We conducted our audit in accordance with the standards of the PCAOB. Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial
reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting,
assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control
based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our
audit provides a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Definition and limitations of internal control over financial reporting</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">A company&#8217;s internal control over financial reporting is a process
designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting
includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded
as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts
and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
(3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s
assets that could have a material effect on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Because of its inherent limitations, internal control over financial reporting
may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk
that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures
may deteriorate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">/s/ <span id="xdx_90A_edei--AuditorName_c20241001__20250930_zSdI8aRMfXGd"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000055" name="dei:AuditorName">GRANT THORNTON LLP</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_902_edei--AuditorLocation_c20241001__20250930_zBiMPGZK2C57"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000056" name="dei:AuditorLocation">Melville, New York</ix:nonNumeric></span><br/>
November 25, 2025</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<span id="xdx_904_edei--AuditorFirmId_c20241001__20250930_zYjGnvQhCrZc" style="display: none"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact000057" name="dei:AuditorFirmId">248</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 75 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands, except share and per share amounts)</b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_111_pn3n3_zr86I1gFktyg" summary="xdx: Statement - Consolidated Balance Sheets" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20250930_zcERCmwD9Qpa" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20240930_zn6LaHss1Zdh" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsAbstract_iB_z055gYRKuGs6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsCurrentAbstract_i01B_zcrgHqXM4RIa" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzZMy_zDbANgn2vDRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; width: 56%; text-align: left; text-indent: -10pt">Cash and cash equivalents</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 8%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-09-30" id="Fact000065" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">102,577</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-09-30" id="Fact000066" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">132,187</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxesReceivable_i02I_maCzZMy_zojqdKqVGBV7" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Incentive and tax receivables</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2025-09-30" id="Fact000068" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">809</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2024-09-30" id="Fact000069" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,449</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzZMy_zdtHDJ8mHuaf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Prepaid expenses and other current assets</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-09-30" id="Fact000071" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">429</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-09-30" id="Fact000072" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">931</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Assets_i01TI_mtCzZMy_zZcwyzQPFEPf" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Assets</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-09-30" id="Fact000074" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">103,815</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-09-30" id="Fact000075" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135,567</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_ztCpz76Er4Wd" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrentAbstract_i01B_zN79PpTmQoD" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableCurrent_i02I_maCz0Cc_zzI7HDJMgP3k" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accounts payable</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-09-30" id="Fact000083" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,249</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-09-30" id="Fact000084" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,627</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCz0Cc_zFdAB1Q6RF7g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accrued liabilities - Note 3</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-09-30" id="Fact000086" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,892</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-09-30" id="Fact000087" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,835</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredRentCredit_i02I_maCz0Cc_zH8ZXbQHA4Gk" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Deferred grant income - Note 4</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredRentCredit" contextRef="AsOf2025-09-30" id="Fact000089" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">805</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredRentCredit" contextRef="AsOf2024-09-30" id="Fact000090" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">842</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Liabilities_i02TI_mtCz0Cc_maCzJC3_zhGT9P6qXwKh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-09-30" id="Fact000092" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,946</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-09-30" id="Fact000093" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,304</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CommitmentsAndContingencies_i01I_zh2JwxhRFepd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Commitments and Contingencies - Note 6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Capital stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Authorized:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20250930_zACrnDpqlQre" title="Preferred stock, authorized"><span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20240930_z2XX9lbn2eVd" title="Preferred stock, authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-09-30" id="Fact000098" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-09-30" id="Fact000100" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> preferred stock, par value $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20250930_zqZlot2Nhgfh" title="Preferred stock, par value"><span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20240930_zjULkwBIUtQ6" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-09-30" id="Fact000102" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30" id="Fact000104" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--PreferredStockValue_i01I_pp0p0_maCzWHW_c20250930_zFCaXMHUPjV8" title="Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share" style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0106">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--PreferredStockValue_i01I_pp0p0_maCzWHW_c20240930_z3CtXi7eu6Xh" title="Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share" style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0108">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20250930_z8gwvNE3NRzj" title="Common shares, authorized"><span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20240930_z5Nl1bOgZLEe" title="Common shares, authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-09-30" id="Fact000110" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-09-30" id="Fact000112" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span> common stock, par value $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20250930_zVthLNrt58Ub" title="Common shares, par value"><span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20240930_z0LWDOQJZhk5" title="Common shares, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-09-30" id="Fact000114" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30" id="Fact000116" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Issued and outstanding:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pip0_c20250930_zJrKVDUEnp3k" title="Common shares, issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pip0_c20250930_z6ZRKEohc1P4" title="Common shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-09-30" id="Fact000118" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-09-30" id="Fact000120" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">86,668,521</ix:nonFraction></ix:nonFraction></span></span> common shares (2024 - <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pip0_c20240930_zvWYsl1UQNfb" title="Common shares, issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_pip0_c20240930_zLgv0AizMdJk" title="Common shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-09-30" id="Fact000122" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-09-30" id="Fact000124" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">84,795,517</ix:nonFraction></ix:nonFraction></span></span>)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--CommonStockValue_iI_maCzWHW_c20250930_zwiG1FdDDjzi" title="Capital stock Authorized: 200,000,000 common stock, par value $0.001 per share Issued and outstanding: 86,668,521 common shares (2024 - 84,795,517)" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-09-30" id="Fact000126" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">87</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--CommonStockValue_iI_maCzWHW_c20240930_zb25xWayx2H9" title="Capital stock Authorized: 200,000,000 common stock, par value $0.001 per share Issued and outstanding: 86,668,521 common shares (2024 - 84,795,517)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-09-30" id="Fact000128" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">85</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_maCzWHW_zQoxIGJvitth" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Additional paid-in capital</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2025-09-30" id="Fact000130" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">477,230</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2024-09-30" id="Fact000131" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">456,249</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maCzWHW_zKPKdanYtSB5" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accumulated deficit</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-09-30" id="Fact000133" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">382,448</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-09-30" id="Fact000134" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">336,071</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--StockholdersEquity_iTI_mtCzWHW_maCzJC3_z6fh46qV12T" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Stockholders&#8217; Equity</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30" id="Fact000136" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">94,869</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000137" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120,263</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzJC3_zxnl5mVwriY6" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-09-30" id="Fact000139" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">103,815</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000140" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135,567</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 76 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Operations and Comprehensive Loss</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands, except share and per share amounts)</b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_113_pn3n3_zhRnoVtjpQfh" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_492_20241001__20250930_zGy8BiJhBR93" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20231001__20240930_zCHJqQpX7Uz7" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20221001__20230930_zUNYGGBUczza" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="11" style="font-weight: bold; text-align: center">Years Ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpensesAbstract_iB_zDIGErUJ706k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzeWD_zOYxwkvgd9Zd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 5%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 11%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-10-01to2025-09-30" id="Fact000146" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,816</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-10-012024-09-30" id="Fact000147" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,039</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-10-012023-09-30" id="Fact000148" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,046</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzeWD_zAOfhL8XBnj8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-10-01to2025-09-30" id="Fact000150" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37,592</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-10-012024-09-30" id="Fact000151" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41,838</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-10-012023-09-30" id="Fact000152" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43,717</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingExpenses_i01T_mtCzeWD_msCz8Vx_zMcVbIRG9zOb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total operating expenses</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-10-01to2025-09-30" id="Fact000154" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51,408</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-10-012024-09-30" id="Fact000155" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">52,877</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-10-012023-09-30" id="Fact000156" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55,763</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_i01T_mtCz8Vx_maCzyS5_z4a5plMwM0w9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Operating loss</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-10-01to2025-09-30" id="Fact000158" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">51,408</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-10-012024-09-30" id="Fact000159" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">52,877</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-10-012023-09-30" id="Fact000160" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">55,763</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zXyQQF5SKski" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--NonOperatingIncomeFromGrants_i01_maCzwDm_zRvpZUvQl0I7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Grant income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2024-10-01to2025-09-30" id="Fact000166" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2023-10-012024-09-30" id="Fact000167" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2022-10-012023-09-30" id="Fact000168" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ResearchAndDevelopmentIncentiveIncome_i01_maCzwDm_z8rDHRv2E3L" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development incentive income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2024-10-01to2025-09-30" id="Fact000170" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">648</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2023-10-012024-09-30" id="Fact000171" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,291</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2022-10-012023-09-30" id="Fact000172" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,718</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestIncomeExpenseNet_i01_maCzwDm_zhX38G20LUQc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Interest income, net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2024-10-01to2025-09-30" id="Fact000174" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,678</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-10-012024-09-30" id="Fact000175" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,320</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-10-012023-09-30" id="Fact000176" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,519</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--OtherFinancingExpense_i01N_di_msCzwDm_z1E6fH6meuV5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other financing expense</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0178">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0179">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:OtherFinancingExpense" contextRef="From2022-10-012023-09-30" id="Fact000180" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">964</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maCzwDm_zocv9p1xCbJl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign exchange gain (loss)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-10-01to2025-09-30" id="Fact000182" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">332</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-10-012024-09-30" id="Fact000183" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">189</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-10-012023-09-30" id="Fact000184" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">40</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NonoperatingIncomeExpense_i01T_mtCzwDm_maCzyS5_z4sarpbvau46" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total other income, net</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-10-01to2025-09-30" id="Fact000186" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,031</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-10-012024-09-30" id="Fact000187" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,875</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-10-012023-09-30" id="Fact000188" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,258</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_mtCzyS5_zg17DNKmkMC4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss and comprehensive loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-10-01to2025-09-30" id="Fact000190" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">46,377</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-09-30" id="Fact000191" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">43,002</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-09-30" id="Fact000192" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47,505</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--EarningPerShareBasicAndDilutedAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Net Loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Basic and diluted</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_pip0_c20241001__20250930_zpNp3HDwJFdk" title="Net Loss per share, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pip0_c20241001__20250930_zZhZ0cpN8zy" title="Net Loss per share, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-10-01to2025-09-30" id="Fact000198" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-10-01to2025-09-30" id="Fact000200" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.54</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_pip0_c20231001__20240930_z0J0lufuLll" title="Net Loss per share, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_pip0_c20231001__20240930_z57HDqt3TIPa" title="Net Loss per share, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-10-012024-09-30" id="Fact000202" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-10-012024-09-30" id="Fact000204" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.52</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pip0_c20221001__20230930_zOMZ52HyxOFd" title="Net Loss per share, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_pip0_c20221001__20230930_zRbuE470vdtg" title="Net Loss per share, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-10-012023-09-30" id="Fact000206" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-10-012023-09-30" id="Fact000208" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.60</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Weighted average number of shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Basic and diluted</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pip0_c20241001__20250930_zXI11u02ogil" title="Weighted average number of shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pip0_c20241001__20250930_z06Ou5cRwiZb" title="Weighted average number of shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-10-01to2025-09-30" id="Fact000214" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-10-01to2025-09-30" id="Fact000216" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">85,289,447</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pip0_c20231001__20240930_ztajpZte9Ql5" title="Weighted average number of shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pip0_c20231001__20240930_z1VgBl91A2Jh" title="Weighted average number of shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-10-012024-09-30" id="Fact000218" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-10-012024-09-30" id="Fact000220" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">83,468,049</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pip0_c20221001__20230930_zqIZG3jSUzla" title="Weighted average number of shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pip0_c20221001__20230930_zFxTweoh7fIg" title="Weighted average number of shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-10-012023-09-30" id="Fact000222" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-10-012023-09-30" id="Fact000224" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">79,787,596</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 77 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands, except share and per share amounts)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160; &#160; &#160; &#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_112_pn3n3_zKY0309I7oqk" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_490_20241001__20250930_zuohar0RQd9f" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20231001__20240930_zzH6ZjKS58L5" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20221001__20230930_zdpYd17zhT21" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="11" style="font-weight: bold; text-align: center">Years ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_zItZqCSLon6i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Cash Flows used in Operating Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_i01_maCzv40_zkZh00cMzWHj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Net loss</td><td style="width: 5%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 11%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-10-01to2025-09-30" id="Fact000230" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">46,377</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-09-30" id="Fact000231" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">43,002</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-09-30" id="Fact000232" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47,505</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_ziQrTKcpUog5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Adjustments to reconcile net loss to net cash used in operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--NoncashFinancingRelatedCharges_i01_maCzv40_ztwbSTg7wrM8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Non cash financing related charges</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0238">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0239">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:NoncashFinancingRelatedCharges" contextRef="From2022-10-012023-09-30" id="Fact000240" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">845</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_i01_maCzv40_zEBxMM9Bo3vk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Share based compensation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-10-01to2025-09-30" id="Fact000242" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,549</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-012024-09-30" id="Fact000243" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,438</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-10-012023-09-30" id="Fact000244" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,370</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zqtzTHZ9H9G7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Changes in working capital balances related to operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInIncomeTaxesReceivable_i02N_di_msCzv40_zh0Lj7lNp01k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Incentive and tax receivables</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2024-10-01to2025-09-30" id="Fact000250" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,640</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2023-10-012024-09-30" id="Fact000251" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">260</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2022-10-012023-09-30" id="Fact000252" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">484</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msCzv40_z2pmchUk1Rac" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Prepaid expenses and deposits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2024-10-01to2025-09-30" id="Fact000254" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">502</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2023-10-012024-09-30" id="Fact000255" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">278</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-10-012023-09-30" id="Fact000256" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">299</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maCzv40_zkJZHazMQ42e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accounts payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-10-01to2025-09-30" id="Fact000258" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,378</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-10-012024-09-30" id="Fact000259" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,305</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-10-012023-09-30" id="Fact000260" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">497</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maCzv40_zSRRSpYplBy3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accrued liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2024-10-01to2025-09-30" id="Fact000262" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">943</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-10-012024-09-30" id="Fact000263" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,460</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-10-012023-09-30" id="Fact000264" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,350</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredGrantIncome_i02N_di_msCzv40_zpVpKzfMAxN2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Deferred grant income</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="avxl:DeferredGrantIncome" contextRef="From2024-10-01to2025-09-30" id="Fact000266" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="avxl:DeferredGrantIncome" contextRef="From2023-10-012024-09-30" id="Fact000267" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:DeferredGrantIncome" contextRef="From2022-10-012023-09-30" id="Fact000268" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">473</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i02T_mtCzv40_maCzAAZ_zO6fuDiSlsT2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net cash used in operating activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-10-01to2025-09-30" id="Fact000270" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">39,044</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-10-012024-09-30" id="Fact000271" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">30,812</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-10-012023-09-30" id="Fact000272" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">27,785</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_iB_zCorR0Y9kbPg" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Cash Flows provided by Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--IssuanceOfCommonSharesNetOfShareIssueCosts_i01_maCzRiu_zHuphZUvnKw4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Issuance of common shares, net of share issue costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:IssuanceOfCommonSharesNetOfShareIssueCosts" contextRef="From2024-10-01to2025-09-30" id="Fact000278" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,198</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:IssuanceOfCommonSharesNetOfShareIssueCosts" contextRef="From2023-10-012024-09-30" id="Fact000279" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,284</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:IssuanceOfCommonSharesNetOfShareIssueCosts" contextRef="From2022-10-012023-09-30" id="Fact000280" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,875</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsForDelayedTaxExemptExchange_i01N_di_msCzRiu_zu1HUkpyeKnk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Payment for taxes related to cashless exercise of options</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForDelayedTaxExemptExchange" contextRef="From2024-10-01to2025-09-30" id="Fact000282" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,707</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0283">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromStockOptionsExercised_i01_maCzRiu_z1w6av5cJrH5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Proceeds from exercise of stock options</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2024-10-01to2025-09-30" id="Fact000286" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,943</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2023-10-012024-09-30" id="Fact000287" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">691</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-10-012023-09-30" id="Fact000288" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,776</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzRiu_maCzAAZ_z3P2Hur6zJUi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net cash provided by financing activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-10-01to2025-09-30" id="Fact000290" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,434</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-10-012024-09-30" id="Fact000291" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,975</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-10-012023-09-30" id="Fact000292" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,651</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzAAZ_zQwe4FJT9Gtj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">(Decrease) Increase in cash and cash equivalents during the year</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2024-10-01to2025-09-30" id="Fact000294" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29,610</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-10-012024-09-30" id="Fact000295" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,837</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-10-012023-09-30" id="Fact000296" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,866</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_z3O7unN6XbOc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash and cash equivalents, beginning of year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-09-30" id="Fact000298" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">132,187</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-09-30" id="Fact000299" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">151,024</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-09-30" id="Fact000300" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">149,158</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zKzqcZXEZ7m3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Cash and cash equivalents, end of year</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-09-30" id="Fact000302" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">102,577</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-09-30" id="Fact000303" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">132,187</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-09-30" id="Fact000304" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">151,024</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z9cQFOrhtUC9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Supplemental Cash Flow Information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--CashPaidForStateAndLocalFranchiseTaxes_i01_z9gaZxJ6u9Gf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash paid for state and local franchise taxes</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="avxl:CashPaidForStateAndLocalFranchiseTaxes" contextRef="From2024-10-01to2025-09-30" id="Fact000310" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">125</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="avxl:CashPaidForStateAndLocalFranchiseTaxes" contextRef="From2023-10-012024-09-30" id="Fact000311" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">300</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="avxl:CashPaidForStateAndLocalFranchiseTaxes" contextRef="From2022-10-012023-09-30" id="Fact000312" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">136</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--CommonStockIssuedUponCashlessExerciseOfStockOptions_i01_zH3KWR9CMKSi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Common stock issued upon cashless exercise of stock options</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="avxl:CommonStockIssuedUponCashlessExerciseOfStockOptions" contextRef="From2024-10-01to2025-09-30" id="Fact000314" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,493</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 78 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>Anavex Life Sciences Corp.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>Consolidated Statements of Changes in Stockholders&#8217; Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>(in thousands, except share and per share amounts)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_114_pn3n3_zZON3mtX4ZZ9" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z3RHQpNZZgag" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zmVhufWlhr15" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z6ujd137hot7" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BD_zDX2eBPdODE7" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Additional Paid-in</td><td>&#160;</td>
    <td colspan="7" style="text-align: center">&#160;<b>Accumulated</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Par Value</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_430_c20221001__20230930_eus-gaap--StockholdersEquity_iS_zyXNxT7cQu64" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 35%; font-weight: bold; text-indent: -10pt">Balance, October 1, 2022</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pip0_c20221001__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIxvh6fc2LQ6" title="Balance at beginning, shares" style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" id="Fact000323" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">77,942,815</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" id="Fact000318" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">78</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000319" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">387,977</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" id="Fact000320" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">245,564</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" id="Fact000321" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">142,491</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--SharesIssuedUnderPurchaseAgreement_z8Qf45RQGHd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under 2023 Purchase Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--InitialCommitmentShares_zntfCJLed7Ac" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;Initial Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--InitialCommitmentSharesShares_pip0_c20221001__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxVQVwWiCzMk" title="Initial commitment shares, shares" style="text-align: right"><ix:nonFraction name="avxl:InitialCommitmentSharesShares" contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember" id="Fact000335" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">75,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000331" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">845</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-012023-09-30" id="Fact000333" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">845</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockRepurchasedDuringPeriodValue_z7adEJVA4khl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;Purchase shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockRepurchasedDuringPeriodShares_pip0_c20221001__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUZ7KHbwLyai" title="Purchase shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember" id="Fact000342" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,275,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember" id="Fact000337" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000338" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,872</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0339">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012023-09-30" id="Fact000340" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,875</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--CommitmentShares_zzJ2xIvGbwPi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--CommitmentSharesShares_pip0_c20221001__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z23krprwBNmj" title="Commitment shares, shares" style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesShares" contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember" id="Fact000349" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">13,943</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_zFkCLX6KKyhi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued pursuant to exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsShares_pip0_c20221001__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zc0C5Ox1rc95" title="Shares issued pursuant to exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares" contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember" id="Fact000356" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">759,753</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember" id="Fact000351" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="font-style: italic; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000352" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,775</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012023-09-30" id="Fact000354" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,776</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zrZTME7NHNt6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000359" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,370</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0360">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012023-09-30" id="Fact000361" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,370</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zqFeXEYMHnO9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember" id="Fact000365" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47,505</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-09-30" id="Fact000366" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47,505</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_435_c20231001__20240930_eus-gaap--StockholdersEquity_iS_zCZ4lQ4GktQh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Balance, September 30, 2023</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pip0_c20231001__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztXobvtikZsd" title="Balance at beginning, shares" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact000373" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">82,066,511</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact000368" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000369" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">434,839</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" id="Fact000370" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">293,069</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" id="Fact000371" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">141,852</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--SharesIssuedUnderPurchaseAgreement_zH5Vt0v4mS3e" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under 2023 Purchase Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockRepurchasedDuringPeriodValue_z1fJkOHWBb2f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;Purchase shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockRepurchasedDuringPeriodShares_pip0_c20231001__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYpf53Fvn94g" title="Purchase shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember" id="Fact000385" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,450,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember" id="Fact000380" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000381" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,281</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0382">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-10-012024-09-30" id="Fact000383" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,284</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--CommitmentShares_zRQDV0a3WE3d" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--CommitmentSharesShares_pip0_c20231001__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8rZ4eXb3xVe" title="Commitment shares, shares" style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesShares" contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember" id="Fact000392" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">5,646</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0390">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_zEnobbT9b1il" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued pursuant to exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsShares_pip0_c20231001__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z40VtUteN64i" title="Shares issued pursuant to exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares" contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember" id="Fact000399" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">273,360</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000395" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">691</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0396">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-10-012024-09-30" id="Fact000397" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">691</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zry0Z1ypiJoj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0401">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000402" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,438</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-10-012024-09-30" id="Fact000404" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,438</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zfDoECRFIXCa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0406">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember" id="Fact000408" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">43,002</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-09-30" id="Fact000409" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">43,002</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_430_c20241001__20250930_eus-gaap--StockholdersEquity_iS_z2crimctKfP1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Balance, September 30, 2024</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pip0_c20241001__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMkAwCyJ43E9" title="Balance at beginning, shares" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000416" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">84,795,517</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000411" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">85</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000412" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">456,249</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" id="Fact000413" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">336,071</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000414" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120,263</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--SharesIssuedUnderSalesAgreement_iP3us-gaap--SharesOutstanding_zghbSXKqPYXb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under 2025 Sales Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--SharesIssuedUnderSalesAgreementShares_iP3custom--SharesIssuedUnderSalesAgreement_c20241001__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbbHrFKipYyi" title="Shares issued under Sales Agreement, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreementShares" contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember" id="Fact000423" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">927,910</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreement" contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember" id="Fact000418" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreement" contextRef="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000419" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,197</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreement" contextRef="From2024-10-01to2025-09-30" id="Fact000421" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,198</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_zIaeMKPElb8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued pursuant to exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsShares_pip0_c20241001__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwJAUNMDfkik" title="Shares issued pursuant to exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares" contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember" id="Fact000430" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">646,488</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember" id="Fact000425" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000426" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,942</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2024-10-01to2025-09-30" id="Fact000428" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,943</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--SharesIssuedPursuantToCashlessExerciseOfStockOptions_iP3custom--SharesIssuedPursuantToExerciseOfStockOptionsShares_zzXdqQ4mksVj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued pursuant to cashless exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--SharesIssuedPursuantToCashlessExerciseOfStockOptionsShares_iP3custom--SharesIssuedPursuantToCashlessExerciseOfStockOptions_pip0_c20241001__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEANL4h3Wvb3" title="Shares issued pursuant to cashless exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfStockOptionsShares" contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember" id="Fact000437" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">737,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfStockOptions" contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember" id="Fact000432" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfStockOptions" contextRef="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000433" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,492</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0434">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfStockOptions" contextRef="From2024-10-01to2025-09-30" id="Fact000435" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,493</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--SharesWithheldRelatedToCashlessExerciseOfStockOption_iP3custom--SharesIssuedPursuantToCashlessExerciseOfStockOptionsShares_zZIbAZ9q1bw7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares withheld related to cashless exercise of stock option</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--SharesWithheldRelatedToCashlessExerciseOfStockOptionShares_iP3custom--SharesWithheldRelatedToCashlessExerciseOfStockOption_pip0_c20241001__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zh8XMJrUOhvd" title="Shares withheld related to cashless exercise of stock option, shares" style="text-align: right">(<ix:nonFraction name="avxl:SharesWithheldRelatedToCashlessExerciseOfStockOptionShares" contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember" id="Fact000444" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="Shares">438,894</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:SharesWithheldRelatedToCashlessExerciseOfStockOption" contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember" id="Fact000439" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:SharesWithheldRelatedToCashlessExerciseOfStockOption" contextRef="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000440" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,199</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0441">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:SharesWithheldRelatedToCashlessExerciseOfStockOption" contextRef="From2024-10-01to2025-09-30" id="Fact000442" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,200</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ztVFo3ZI7QPh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000447" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,549</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-10-01to2025-09-30" id="Fact000449" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,549</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_z5AKk7hDP1da" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0451">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0452">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember" id="Fact000453" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">46,377</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-10-01to2025-09-30" id="Fact000454" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">46,377</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_434_c20241001__20250930_eus-gaap--StockholdersEquity_iE_zmGM63FYj7Zd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Balance, September 30, 2025</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pip0_c20241001__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqu7aZfmCCy6" title="Balance at ending, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-09-30_us-gaap_CommonStockMember" id="Fact000461" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">86,668,521</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_CommonStockMember" id="Fact000456" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">87</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000457" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">477,230</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember" id="Fact000458" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">382,448</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30" id="Fact000459" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">94,869</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 79 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2025 &#8211; Page 1</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000463" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zGqPc0XbeUT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Note 1 	<span id="xdx_823_zLqv9QImUj4f">Business Description and Basis of Presentation
</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i>Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. (&#8220;Anavex&#8221; or
the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex analyzes genomic data
from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative
and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s focus is on developing innovative
treatments for Alzheimer&#8217;s disease, Parkinson&#8217;s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases,
including Rett syndrome, and other central nervous system (CNS) disorders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i>Basis of Presentation </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements have been
prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and the instructions to Form
10-K and have been prepared under the accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain immaterial amounts from prior periods have
been reclassified to conform to the current year&#8217;s presentation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Liquidity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Company&#8217;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, the Company has not generated any revenue from our operations. The Company expects the business to continue to experience negative
cash flows from operations for the foreseeable future and cannot predict when, if ever, its business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials
are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change.&#160;The
actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including but not limited to the design,
timing and duration of future clinical trials, the progress of the Company&#8217;s research and development programs and the level of
financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future
clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the 2025 Sales Agreement
and the 2023 Purchase Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available when
needed or, if available, that it can be obtained on commercially reasonable terms. The Company will need to file a prospectus supplement
in order to access funds under the 2023 Purchase Agreement. If the Company is not able to obtain the additional financing on a timely
basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 80 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zQvQBaTImNSd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zvpYg5yJ4PTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zFQhfks4RLR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zomK06yQnnNf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2025 &#8211; Page 2</span></p></ix:exclude>


<ix:exclude><p id="xdx_230_zvHeF74wJQtk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000470" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_803_eus-gaap--SignificantAccountingPoliciesTextBlock_z5taQo9J6NA" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 2	<span id="xdx_826_zDMJqvHfGSmi">Summary of Significant Accounting Policies</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000472" name="us-gaap:UseOfEstimates"><p id="xdx_841_eus-gaap--UseOfEstimates_zxon4wP4Wia2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_zde3wXM9zkBb">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive and tax receivables, valuation and recoverability
of deferred tax assets, share based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000474" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zVD4XzL1tzEb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_zpCBy5brpQk2">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000476" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zD8NNHkBuK9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zLtybN7cq6Qd">Cash and equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>The Company considers only
those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to
be cash equivalents</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">Highly
liquid investments that are considered cash equivalents include money market&#160;accounts, money market&#160;funds&#160;and&#160;certificates
of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities. The Company&#8217;s
investment policy allows for investments in domestic money market certificates, certificates of deposit, money market funds, bonds or
commercial papers, and establishes diversification and credit quality requirements and limits investments by maturity and issuer. The
Company currently maintains the majority of its investments at one large well known financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the
Federal Deposit Insurance Corporation (FDIC) up to $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_pp0p0_c20250930_zE1i1FXPrd3j" title="Federal deposit insurance corporation"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2025-09-30" id="Fact000478" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span>, under current regulations. At September 30, 2025 and 2024, substantially
all of the Company&#8217;s cash balances were in excess of these federally insured limits. The Company mitigates this risk by maintaining
the majority of its cash balances in a large well-known financial institution. The Company has not experienced any losses in such accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000480" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_844_eus-gaap--ResearchAndDevelopmentExpensePolicy_zApC1CPXlzx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_zfNu11ZjOfR9">Research and Development Expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed as incurred.
These expenses are comprised of the costs of the Company&#8217;s proprietary research and development efforts, including preclinical studies,
clinical trials, manufacturing costs, employee salaries and benefits and share-based compensation expense, contract services including
external research and development expenses incurred under arrangements with third parties such as contract research organizations (&#8220;CROs&#8221;),
facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when
the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification
(&#8220;ASC&#8221;) 730, <i>Research and Development</i>, as these materials have no alternative future use outside of their intended
use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 81 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zuYhfumqBitd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zRTfcr5A0jy7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_238_zHiNFX4DnSbh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zTmyTBnx1Icj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2025 &#8211; Page 3</span></p></ix:exclude>


<ix:exclude><p id="xdx_236_zKzcGESLoZu2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nonrefundable advance payments for goods or services
that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods
are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs
incurred in relation to external CROs, and clinical site costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes
progress of the trials and studies including the phase or completion of events, invoices received and contracted costs. Judgments and
estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s
estimates. The Company&#8217;s historical accrual estimates have not been materially different from actual costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the Company incurs expenses in respect
of intellectual property costs relating to patents and trademarks. The probability of success and length of time to develop commercial
applications of the drugs subject to the underlying patent and trademark costs is difficult to determine and numerous risks and uncertainties
exist with respect to the timely completion of the development projects. There is no assurance the drugs subject to the underlying patents
and trademarks will ever be successfully commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to these risks and uncertainties, the patent and
trademark costs do not meet the definition of an asset and thus are expensed as incurred within general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000487" name="us-gaap:RevenueRecognitionIncentives"><p id="xdx_84B_eus-gaap--RevenueRecognitionIncentives_zqniuP8zbxt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_863_zaSKSRZ4JeZ8">Research and Development Incentive Income</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is eligible to obtain certain research
and development tax credits, including, through its wholly owned subsidiary Anavex Australia, the Australian research and development
tax incentive credit (the &#8220;Australia R&amp;D credit&#8221;) through a program administered through the Australian Tax Office (the
&#8220;ATO&#8221;) and AusIndustry, a division of the Australian Government&#8217;s Department of Industry, Innovation and Science (&#8220;AusIndustry&#8221;).
The Australia R&amp;D credit program provides for a cash refund based on a percentage of eligible research and development activities
undertaken in Australia by Anavex Australia. Anavex Australia is also eligible under the Australia R&amp;D credit program to receive the
cash refund for certain research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses
are pre-approved by AusIndustry pursuant to an advanced overseas finding application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Australia R&amp;D credit program is available
to eligible companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period at a rate
of 18.5% above the claimant&#8217;s company tax rate in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The tax incentives are available on the basis of specific
criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company
has accounted for the incentives outside of the scope of ASC Topic 740, <i>Income Taxes</i> (&#8220;ASC 740&#8221;), since the incentives
are not linked to the Company&#8217;s taxable income and can be realized regardless of whether the Company has generated taxable income
in the respective jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With respect to the Australia R&amp;D credit, as there
is no authoritative guidance under GAAP for accounting for grants to for-profit business entities, the Company accounts for the grant
by analogy to IAS20 <i>Accounting for Government Grants and Disclosure of Government Assistance</i> (&#8220;IAS 20&#8221;). The Company
recognizes the research and development incentive income as it incurs costs eligible for reimbursement under the Australia R&amp;D credit
program when it is reasonably assured that the cash incentive will be received, as evidenced through enrollment in the program and when
the applicable conditions under the program have been met. The Company accrues for the amount of cash refund it expects to receive in
relation to research and development expenses outside of Australia only to the extent it has received advanced approval from AusIndustry,
pursuant to an approved advanced overseas finding application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, Anavex Australia and Anavex Canada incur
Goods and Services Tax (GST) on certain services provided by local vendors. As a domestic entity in those jurisdictions, Anavex Australia
and Anavex Canada are entitled to a refund of the GST paid. Similarly, Anavex Germany incurs Value Added Tax (VAT) on certain services
provided by local vendors, to which it is entitled to a refund of such VAT paid. The Company&#8217;s estimate of the amount of cash refund
it expects to receive related to GST and VAT incurred is included in Incentive and tax receivables in the accompanying consolidated balance
sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 82 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zzn0aDtJGaP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_z7Va1fOYeIYd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zWkHoxqzBJY6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zT0atx7wwIlg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2025 &#8211; Page 4</span></p></ix:exclude>


<ix:exclude><p id="xdx_23F_zskpeHo13dVf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000494" name="avxl:LicenseFeesPolicyTextBlock"><p id="xdx_844_ecustom--LicenseFeesPolicyTextBlock_zd34ancWC3ii" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_zrfDP49gLz2k">License Fees</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company expenses amounts paid to acquire licenses associated with products under development when the ultimate recovery of the amounts
paid is uncertain and the technology has no alternative future use when acquired. Acquisitions of technology licenses are charged to expense
or capitalized based on management&#8217;s assessment regarding the ultimate recoverability of the amounts paid and the potential for
alternative future use. The Company has determined that the technological feasibility for its product candidates is reached when the requisite
regulatory approvals are obtained to make the product available for sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000496" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zEDn9LOkfxBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_zkqk8L0aChs9">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2025, diluted loss per share excludes
<span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241001__20250930_zki1oXWZpULk" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-10-01to2025-09-30" id="Fact000498" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,971,583</ix:nonFraction></span> potentially dilutive common shares (2024 - <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20231001__20240930_zM4mHEQ3JuJ5" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-10-012024-09-30" id="Fact000500" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,047,754</ix:nonFraction></span>; 2023 &#8211; <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230930_pdd" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-10-012023-09-30" id="Fact000502" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,271,780</ix:nonFraction></span>) related to outstanding options and warrants,
as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000504" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zceoKf43s8ij" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_863_zClX3phJ8r49">Financial Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The book value of the Company&#8217;s financial instruments,
consisting of cash and equivalents, incentive and tax receivables, accounts payable and accrued liabilities approximate their fair value
due to the short-term maturity of such instruments. Unless otherwise noted, it is management&#8217;s opinion that the Company is not exposed
to significant interest, currency or credit risks arising from these financial instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000506" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_847_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zQ4n5Kxzx4L9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_zOW8TWby7Rkj">Foreign Currency Translation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The functional currency of the Company is the US dollar.
Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date
and non-monetary items are translated at exchange rates prevailing when the assets were acquired, or obligations incurred. Foreign currency
denominated expense items are translated at exchange rates prevailing on the transaction date. Unrealized gains or losses arising from
the translations are credited or charged to income in the period in which they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has determined that the functional currency
of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd. is also the US dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000508" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ze2L1H2uNjul" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86A_zRKtUWWLX863">Segment and Geographic Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determines and presents operating segments
based on the information that is internally provided to the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), its Chief
Executive Officer, in accordance with ASC 280, Segment Reporting. The Company has determined that it operates in a single business segment,
which is a clinical-stage biopharmaceutical company developing differentiated therapeutics by applying precision medicine to central nervous
system (&#8220;CNS&#8221;) diseases with high unmet need. Refer to Note 8 &#8211; Segmented Information for further information related
to the Company&#8217;s segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 83 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zaQ5rIAVNQs5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zKDESQId8jQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zMJIq5m9PB2e" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zfgG03LLFu3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2025 &#8211; Page 5</span></p></ix:exclude>


<ix:exclude><p id="xdx_230_zl8N0CqzRc0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000515" name="avxl:GrantIncomePolicyTextBlock"><p id="xdx_84F_ecustom--GrantIncomePolicyTextBlock_zEftaHZ3lpN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_z8TzpgSXhhE9">Grant Income</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Grant income is recognized at the fair value of the
grant when it is received, and all substantive conditions have been satisfied. Grants received from government and other agencies in advance
of the specific research and development costs to which they relate are deferred and recognized in the consolidated statements of operations
and comprehensive loss in the period they are earned, typically when the related research and development costs are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000517" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zDoEUYITEGC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zVQe3W1QkAn4">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC 740, which
requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and
liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying
amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC 740 regarding
accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more
likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently
measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax
authority assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information.
The Company considers many factors when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions
and tax benefits may not accurately anticipate actual outcomes. As additional information is obtained, there may be a need to periodically
adjust the recognized tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements
of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes interest and penalties related
to current income tax expense on the interest income, net line, in the accompanying consolidated statements of operations and comprehensive
loss. Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000519" name="us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock"><p id="xdx_841_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zzoJR4HR6L54" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_zbECW6HHmcb4">Share-based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for all share-based payments
and awards under the fair value method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of all share-based payments are expensed
over their contractual vesting period, or over the expected performance period for only the portion of awards expected to vest, in the
case of milestone-based vesting, with a corresponding increase to additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compensation costs for share-based payments with graded
vesting are recognized on a straight-line basis. Stock based compensation expense is adjusted for actual forfeitures of unvested awards
as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has granted share purchase option awards
that vest upon achievement of certain performance criteria, or milestone-based awards. The Company estimates an implicit service period
for achieving performance criteria for each award and recognizes the resulting fair value as expense over the implicit service period
when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its
estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest upon achievement
of the performance criteria.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 84 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zRy1L1JeU60l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zLHnQYLnq7ad" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zt9ytDNVQ057" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zOCEc2QoWcVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2025 &#8211; Page 6</span></p></ix:exclude>


<ix:exclude><p id="xdx_23F_zSlE9RCiXppj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the Black-Scholes option valuation
model to calculate the fair value of share-based awards at the date of the grant. This model requires the input of subjective assumptions,
including the expected price volatility and expected life of each&#160;award. The Company uses the U.S. Treasury daily treasury yield
curve rates for the expected term of the option as the risk-free rate. The expected term represents the period that options granted are
expected to be outstanding using the simplified method. Historically, the Company&#8217;s historical share option exercise experience
did not provide sufficient basis for estimating the expected term. Expected volatility is based on the average of the daily share price
changes over the expected term. The Company does not estimate forfeitures and elects to record actual forfeitures as they occur. The Company
has not paid any dividends on its common stock historically, therefore no assumption of dividend payments is made in the model. These
assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#8217;s
judgment. Changes in these assumptions can materially affect the fair value estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The purchase price of share-based compensation awards
may be paid in cash or, if approved by the Company&#8217;s compensation committee (or in the case of warrants by the Board of Directors)
in advance, &#8220;net settled&#8221; in shares of the Company&#8217;s common stock. In a net settlement of an share-based award, the
Company does not receive payment of the exercise price from the holder but reduces the number of shares of common stock issued upon the
exercise of the award by the smallest number of whole shares that have an aggregate fair market value equal to or over the aggregate exercise
price for the option shares covered by the instrument exercised. Shares issued pursuant to the exercise of options and warrants are issued
from the Company&#8217;s treasury.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000526" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z92M6wRNMox" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_zxkKj0wYCM0h">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the exchange price that would
be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair
value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes
the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities that the Company has the ability to access at the measurement date;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2025 and 2024, the Company did not
have any Level 2 or Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000528" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zyxIcg1Lt1u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_z5CZrOPiGmE6">Recently Adopted Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2023, the Financial Accounting Standards
Board (FASB) issued ASU No. 2023-07, &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221; This guidance requires
disclosure of incremental segment information on an annual and interim basis, including disclosure of the title and position of the Chief
Operating Decision Maker and requires that a public entity that has a single reportable segment to provide all the disclosures required
by the amendments in ASU No. 2023-07. The Company adopted the new standard effective September 30, 2025, and for subsequent interim periods.
Since ASU No. 2023-07 addresses only disclosures, the adoption of ASU No. 2023-07 did not have a significant impact on the Company&#8217;s
consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 85 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zre6XbhMF1Rj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zrp3MIs45dV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zqNkfZlIsoHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_238_zyiynpGVFYoa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2025 &#8211; Page 7</span></p></ix:exclude>


<ix:exclude><p id="xdx_236_znIRCrlTDao1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000535" name="avxl:RecentAccountingPronouncementsPolicyTextBlock"><p id="xdx_845_ecustom--RecentAccountingPronouncementsPolicyTextBlock_zpvzsd0U9Chf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_865_zVt6QSRQlqpi">Recent Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In December 2023, the FASB
issued ASU No. 2023-09, &#8220;Income Taxes:&#160;Improvements to Income Tax Disclosures.&#8221; This guidance requires consistent categories
and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment
is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2024, the FASB
issued ASU No. 2024-03, &#8220;Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures. The
amendments in ASU No. 2024-03 address investor requests for more detailed expense information and require additional disaggregated disclosures
in the notes to the financial statements for certain categories of expenses that are included on the face of the financial statements.
The guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after
December 15, 2027, with early adoption permitted. The Company is currently assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000537" name="avxl:AccuredLiabilitiesTextBlock"><p id="xdx_80D_ecustom--AccuredLiabilitiesTextBlock_zVboWXwlA6Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 3	<span id="xdx_82F_zQru5WRVent6">Accrued Liabilities</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The principal components of accrued liabilities consist of (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000539" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zEFXjdmOG7z5" summary="xdx: Disclosure - Accrued Liabilities (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BA_zI3it03iRoGk" style="display: none">Schedule of principal components of accrued liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20250930_zyqxLuwprtle" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20240930_znZa56PfFcAk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
  <tr id="xdx_408_ecustom--AccruedInvestigatorPayments_iI_pn3n3_z91BpzDoygW5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Accrued investigator payments</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="avxl:AccruedInvestigatorPayments" contextRef="AsOf2025-09-30" id="Fact000541" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">96</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="avxl:AccruedInvestigatorPayments" contextRef="AsOf2024-09-30" id="Fact000542" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">860</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccruedBonusesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2025-09-30" id="Fact000544" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,562</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2024-09-30" id="Fact000545" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,527</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--MilestoneBasedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Milestone-based contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:MilestoneBasedContractAccruals" contextRef="AsOf2025-09-30" id="Fact000547" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">523</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:MilestoneBasedContractAccruals" contextRef="AsOf2024-09-30" id="Fact000548" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">557</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherAccountsPayableAndAccruedLiabilities_iI_pn3n3_z7ckRxVrVmq4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="AsOf2025-09-30" id="Fact000550" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,711</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="AsOf2024-09-30" id="Fact000551" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,891</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--TotalAccruedLiabilities_iTI_pn3n3_zK1vlMEb0Dl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total accrued liabilities</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="avxl:TotalAccruedLiabilities" contextRef="AsOf2025-09-30" id="Fact000553" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,892</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="avxl:TotalAccruedLiabilities" contextRef="AsOf2024-09-30" id="Fact000554" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,835</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000556" name="avxl:OtherIncomeDisclosureTextBlock"><p id="xdx_805_ecustom--OtherIncomeDisclosureTextBlock_z0okJWlDII35" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 4	<span id="xdx_82F_zfaCasMrBFNe">Other Income</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Grant income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of September 30, 2025,
the Company had received a $<span id="xdx_907_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20241001__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxFoundationMember_zFb5BginfwW5" title="Research and development incentive income"><ix:nonFraction name="avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" contextRef="From2024-10-012025-09-30_custom_MichaelJFoxFoundationMember" id="Fact000558" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1</ix:nonFraction></span>.0 million research grant awarded by the Michael J. Fox Foundation for Parkinson&#8217;s Research. The grant
will be used to fund a clinical trial of the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) related to Parkinson&#8217;s
disease. Of the total, $<span id="xdx_906_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20221001__20230930_zKQ4v4iMvXh4" title="Research and development incentive income"><ix:nonFraction name="avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" contextRef="From2022-10-012023-09-30" id="Fact000560" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million was received during the year ended September 30, 2023 and $<span id="xdx_90B_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20201001__20210930_zbwgyCM3Qd8b" title="Research and development incentive income"><ix:nonFraction name="avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" contextRef="From2020-10-012021-09-30" id="Fact000562" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million was received during the year
ended September 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The grant income has been
deferred when received and is being amortized to other income as the related research and development expenditures are incurred. During
the year ended September 30, 2025, the Company recognized $<span id="xdx_90E_ecustom--NonOperatingIncomeFromGrant_pn5n6_c20241001__20250930_z2wVNObUC3r4" title="Non operating income from grant"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2024-10-01to2025-09-30" id="Fact000564" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">37,000</ix:nonFraction></span> (2024: $<span id="xdx_902_ecustom--NonOperatingIncomeFromGrant_pn5n6_c20231001__20240930_zo7Pgibr0eDg" title="Non operating income from grant"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2023-10-012024-09-30" id="Fact000566" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">75,000</ix:nonFraction></span>; 2023: $<span id="xdx_909_ecustom--NonOperatingIncomeFromGrant_c20221001__20230930_pn5n6" title="Non operating income from grant"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2022-10-012023-09-30" id="Fact000568" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">25,000</ix:nonFraction></span>) of this grant on its statements of operations
within grant income. At September 30, 2025 an amount of $<span id="xdx_90D_ecustom--DeferredGrantIncome1_pn5n6_c20241001__20250930_zfjzuMk2QZs2" title="Deferred grant income"><ix:nonFraction name="avxl:DeferredGrantIncome1" contextRef="From2024-10-01to2025-09-30" id="Fact000570" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million (2024: $<span id="xdx_909_ecustom--DeferredGrantIncome1_pn5n6_c20231001__20240930_zsed7MY5Qs05" title="Deferred grant income"><ix:nonFraction name="avxl:DeferredGrantIncome1" contextRef="From2023-10-012024-09-30" id="Fact000572" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million) of this grant is recorded as deferred grant
income, representing the amount of this grant which has not yet been amortized to other income. The Company will recognize this income
on its statements of operations as the related expenditures are incurred to offset the income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Research and development
incentive income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Research and development
incentive income represents the income earned by Anavex Australia of the Australia R&amp;D credit. This cash incentive is received by
Anavex Australia, upon filing of a claim in connection with Anavex Australia&#8217;s annual income tax return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<ix:exclude><!-- Field: Page; Sequence: 86 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zHYMDoNyo6S4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zidVwBCEJzEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zelor1H70To9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zndqF6oqKUWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2025 &#8211; Page 8</span></p></ix:exclude>


<ix:exclude><p id="xdx_237_zA0rWeyTZf7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the year ended September
30, 2025, the Company recorded research and development incentive income of $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20241001__20250930_zyhXZ2WjcWVd" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2024-10-01to2025-09-30" id="Fact000579" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million (AUD <span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20241001__20250930__srt--CurrencyAxis__currency--AUD_z0G6WBCwBb82" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2024-10-012025-09-30_currency_AUD" id="Fact000581" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million) (2024: $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240930_zboRkqIm1B" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2023-10-012024-09-30" id="Fact000583" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.3</ix:nonFraction></span> million (AUD <span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240930__srt--CurrencyAxis__currency--AUD_zTiZVTCD76Ek" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2023-10-012024-09-30_currency_AUD" id="Fact000585" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.5</ix:nonFraction></span>
million); 2023: $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230930_zA7F2CU7m0Ni" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-10-012023-09-30" id="Fact000587" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.7</ix:nonFraction></span> million (AUD <span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230930__srt--CurrencyAxis__currency--AUD_zT5bn2jEk2bh" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-10-012023-09-30_currency_AUD" id="Fact000589" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.1</ix:nonFraction></span> million)) in respect of the Australia R&amp;D credit for eligible research and development expenses
incurred during the year. This amount is included within Other income (expense) on the consolidated statements of operations and comprehensive
loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">At September 30, 2025, Incentive
and tax receivables includes $<span id="xdx_90A_eus-gaap--OtherReceivables_iI_pn5n6_c20250930_zpsCBrNkE8Hj" title="Incentive and tax receivables"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2025-09-30" id="Fact000591" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span> million (AUD <span id="xdx_902_eus-gaap--OtherReceivables_iI_pn5n6_c20250930__srt--CurrencyAxis__currency--AUD_z5EWVo5e36be" title="Incentive and tax receivables"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2025-09-30_currency_AUD" id="Fact000593" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million) (2024: $<span id="xdx_903_eus-gaap--OtherReceivables_iI_pn5n6_c20240930_zmIXkejQmyke" title="Incentive and tax receivables"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2024-09-30" id="Fact000595" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.3</ix:nonFraction></span> million (AUD <span id="xdx_909_eus-gaap--OtherReceivables_iI_pn5n6_c20240930__srt--CurrencyAxis__currency--AUD_zu9mNr4hNgP3" title="Incentive and tax receivables"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2024-09-30_currency_AUD" id="Fact000597" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.3</ix:nonFraction></span> million)) relating to Australia R&amp;D credits
earned during the year that are expected to be reimbursed upon filing of the Company&#8217;s annual claim under this program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Australia R&amp;D credit
program is a self-assess program whereby the Company must assess its eligibility each year to determine (i) if the entity is eligible
(ii) if the specific R&amp;D activities are eligible and (iii) if the individual R&amp;D expenditures have nexus to such R&amp;D activities.
The Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Anavex Australia is able to continue to claim the R&amp;D tax incentive for as long as it remains eligible and continues
to incur eligible research and development expenditures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Although the Company believes
that it has complied with all the relevant conditions of eligibility under the program for all periods claimed, the ATO has the right
to review the Company&#8217;s qualifying programs and related expenditures for a period of four years. If such a review were to occur,
the ATO may have different interpretations of certain eligibility requirements. If the ATO disagreed with the Company&#8217;s assessments
and any related subsequent appeals, it could require adjustment to and repayment of current or previous years&#8217; claims already received.
Additionally, if the Company was unable to demonstrate a reasonably arguable position taken on such claims, the ATO could also assess
penalties and interest on any such adjustments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Currently, the Company&#8217;s
tax incentive claims from 2020 to 2025 are open to potential review by the ATO. Additionally, the period open for review is indefinite
if the ATO suspects fraud. The Company has not provided any allowance for any such potential adjustments, should they occur in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000599" name="avxl:EquityOfferingTextBlock"><p id="xdx_80F_ecustom--EquityOfferingTextBlock_zRYeKkgxLVs9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 5	<span id="xdx_821_zQTXlbtIMU17">Equity Offerings</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Board of Directors&#160;(the &#8220;Board&#8221;)&#160;has
the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number
of shares constituting any series or the designation of the series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2025 Sales Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 25, 2025, the Company entered into a Sales
Agreement (the &#8220;2025 Sales Agreement&#8221;) with TD Securities (USA) LLC (the &#8220;Sales Agent&#8221;). Pursuant to the 2025
Sales Agreement, the Company may offer and sell up to an aggregate offering price of $<span id="xdx_90B_ecustom--ValueOfSharesObligatedToPurchase_pn3n3_dm_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zj8GB2AoXg8a" title="Value of shares obligated to purchase"><ix:nonFraction name="avxl:ValueOfSharesObligatedToPurchase" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000601" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">150</ix:nonFraction></span> million (the &#8220;Offering&#8221;) in shares
of common stock from time to time through the Sales Agent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon delivery of a placement notice based on the Company&#8217;s
instructions and subject to the terms and conditions of the 2025 Sales Agreement, the Sales Agent may sell shares of common stock by methods
deemed to be an &#8220;at the market offering&#8221;, in negotiated transactions at market prices prevailing at the time of sale or at
prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to
the Company&#8217;s prior written consent. The Company is not obligated to make any sales of shares under the 2025 Sales Agreement. The
Company or the Sales Agent may suspend or terminate the Offering upon notice to the other party, subject to certain conditions. The Sales
Agent will act as sales agent on a commercially reasonable efforts basis consistent its normal trading and sales practices, applicable
state and federal law, rules and regulations and the rules of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 87 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zfKRLawjzPXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_z1TrTCEahh69" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zfvfftfggL2a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zkvzRgQ0EUEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2025 &#8211; Page 9</span></p></ix:exclude>


<ix:exclude><p id="xdx_237_z1PcoAbcL9m5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has agreed to pay the Sales Agent commissions
for its services of up to&#160;3.0% of the gross proceeds from the sale of shares of common stock pursuant to the Sales Agreement. The
Company has also agreed to provide the Sales Agent with customary indemnification and contribution rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2025, the Company
issued <span id="xdx_903_eus-gaap--SharesIssued_iI_c20250930_zyjvy8YZOYv4" title="Common stock issued shares"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2025-09-30" id="Fact000608" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">927,910</ix:nonFraction></span> shares of common stock for net proceeds of $<span id="xdx_908_eus-gaap--RedemptionPremium_pn3n3_dm_c20241001__20250930_zBHwAG4gwVa2" title="Common stock net proceeds"><ix:nonFraction name="us-gaap:RedemptionPremium" contextRef="From2024-10-01to2025-09-30" id="Fact000610" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">9.2</ix:nonFraction></span> million pursuant to the 2025 Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2023 Purchase Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 3, 2023, the Company entered into a $150.0
million purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;),
pursuant to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $<span id="xdx_90F_ecustom--ValueOfSharesObligatedToPurchase_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z7EqpYMKIk1j" title="Value of shares obligated to purchase"><ix:nonFraction name="avxl:ValueOfSharesObligatedToPurchase" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000612" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">150.0</ix:nonFraction></span>
million in value of its shares of common stock from time to time over a three-year period until February 3, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the 2023 Purchase
Agreement, the Company issued to Lincoln Park <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zQcYwUOS2Lod" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000614" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">75,000</ix:nonFraction></span> shares of common stock as a commitment fee (the &#8220;initial commitment shares&#8221;)
and agreed to issue up to an additional <span id="xdx_907_ecustom--StockIssuedDuringPeriodValueNewIssues1_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zU6fyfMArFzi" title="Pro rata basic number of shares obligated to purchase"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000616" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">75,000</ix:nonFraction></span> shares pro rata, when and if, Lincoln Park purchased, at the Company&#8217;s discretion,
the $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn3n3_dm_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zz4L6KMbsd98" title="Proceeds from issuance or sale of equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000618" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">150.0</ix:nonFraction></span> million aggregate commitment. The Company determined the fair value of the initial commitment shares was $<span id="xdx_909_ecustom--FairValueOfInitialCommitment_iI_pn5n6_c20230930_zJBqs5uOEhtk" title="Fair value of the initial commitment"><ix:nonFraction name="avxl:FairValueOfInitialCommitment" contextRef="AsOf2023-09-30" id="Fact000620" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million with
reference to the closing price of the Company&#8217;s shares on the Purchase Agreement date. In addition, the Company incurred third party
expenses of $<span id="xdx_90B_ecustom--IncurredExpenses_iI_pn5n6_c20230930_zlAL1dQJV4F1" title="Incurred expenses"><ix:nonFraction name="avxl:IncurredExpenses" contextRef="AsOf2023-09-30" id="Fact000622" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million in connection with entering into the Purchase Agreement. These amounts were expensed to other financing expense
on the statements of operations during the year ended September 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2025, the Company
did not issue any shares of common stock under the 2023 Purchase Agreement. During the year ended September 30, 2024, the Company issued
to Lincoln Park an aggregate of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20231001__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockIncludingCommitmentSharesMember_zG4l7ZvjtNE3" title="Number of shares issued, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockIncludingCommitmentSharesMember" id="Fact000624" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,455,646</ix:nonFraction></span> shares of common stock under the 2023 Purchase Agreement, including <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockExcludingCommitmentSharesMember_zDEJXtBLySoe" title="Number of shares issued, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-10-012025-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockExcludingCommitmentSharesMember" id="Fact000626" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,450,000</ix:nonFraction></span> shares of common
stock for an aggregate purchase price of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_dm_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zuy4NyY9D1N3" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-10-012025-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000628" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">11.3</ix:nonFraction></span> million and <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommitmentSharesMember_zO3MTIC3nZj8" title="Number of shares issued, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-10-012025-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommitmentSharesMember" id="Fact000630" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">5,646</ix:nonFraction></span> commitment shares. During the year ended September 30, 2023, the Company
issued to Lincoln Park an aggregate of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockIncludingCommitmentSharesMember_zefqrGFq41vd" title="Number of shares issued, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockIncludingCommitmentSharesMember" id="Fact000632" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,288,943</ix:nonFraction></span> shares of common stock under the 2023 Purchase Agreement, including <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockExcludingCommitmentSharesMember_zRKoC3QKcy4b" title="Number of shares issued, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockExcludingCommitmentSharesMember" id="Fact000634" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,275,000</ix:nonFraction></span> shares
of common stock for aggregate proceeds of $<span id="xdx_901_ecustom--StockIssuedDuringPeriodValueNewIssues2_pn5n6_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zEchpl1UyS6c" title="Number of shares issued, value"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues2" contextRef="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000636" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">27.9</ix:nonFraction></span> million and&#160;<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommitmentSharesMember_zirlILwWijVk" title="Number of shares issued, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommitmentSharesMember" id="Fact000638" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">13,943</ix:nonFraction></span>&#160;commitment shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2025, there was an unused amount
of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueOther_pn5n6_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zsvFtqHHMK29" title="Amount of shares remain available"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-10-012025-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000640" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">110.8</ix:nonFraction></span> million under the 2023 Purchase Agreement. The Company will need to file a prospectus supplement in order to access funds under
the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Exercise of Stock Options</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2025, the Company
issued&#160;<span id="xdx_90F_eus-gaap--SharesIssued_iI_pip0_c20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zKA4X7e03q83" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2025-09-30_srt_ChiefExecutiveOfficerMember" id="Fact000642" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">217,503</ix:nonFraction></span>&#160;shares of common stock to the Company&#8217;s Chief Executive Officer upon a net exercise of an option to purchase&#160;<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zHCh2lYflJAh" title="Exercise option shares purchase"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-10-012025-09-30_srt_ChiefExecutiveOfficerMember" id="Fact000644" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">500,000</ix:nonFraction></span>&#160;shares
of common stock at an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z0K8goYCYl5l" title="Common stock exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-30_srt_ChiefExecutiveOfficerMember" id="Fact000646" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.92</ix:nonFraction></span>&#160;per share. In connection with the exercise, the Company withheld&#160;<span id="xdx_901_ecustom--CommonStockConsiderationExerciseShares_c20241001__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zptS1rPbLdAg" title="Common stock consideration exercise shares"><ix:nonFraction name="avxl:CommonStockConsiderationExerciseShares" contextRef="From2024-10-012025-09-30_srt_ChiefExecutiveOfficerMember" id="Fact000648" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">47,745</ix:nonFraction></span>&#160;shares
of common stock as consideration of the exercise price of $<span id="xdx_908_eus-gaap--StockOptionExercisePriceIncrease_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zXN8FJ0MntRl" title=" exercise price"><ix:nonFraction name="us-gaap:StockOptionExercisePriceIncrease" contextRef="From2024-10-012025-09-30_srt_ChiefExecutiveOfficerMember" id="Fact000650" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.46</ix:nonFraction></span>&#160;million and&#160;<span id="xdx_904_eus-gaap--NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zZ4qo5NmjuGa" title="Consideration shares issued"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" contextRef="From2024-10-012025-09-30_srt_ChiefExecutiveOfficerMember" id="Fact000652" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">234,752</ix:nonFraction></span>&#160;shares of common stock as consideration
for the payment of $<span id="xdx_90E_eus-gaap--OtherSignificantNoncashTransactionValueOfConsiderationGiven1_pn3n3_dm_c20241001__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zfJ8OqevFlq2" title="Consideration payment"><ix:nonFraction name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" contextRef="From2024-10-012025-09-30_srt_ChiefExecutiveOfficerMember" id="Fact000654" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.3</ix:nonFraction></span>&#160;million in connection with tax withholding obligations associated with the exercise. The number of shares
withheld were based upon a market price of $<span id="xdx_90E_ecustom--MarketPrice_iI_pip0_c20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zy2fbb4B83Ed" title="Market price"><ix:nonFraction name="avxl:MarketPrice" contextRef="AsOf2025-09-30_srt_ChiefExecutiveOfficerMember" id="Fact000656" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">9.63</ix:nonFraction></span>&#160;per share as determined by reference to the average high and low sales price reported
on the Nasdaq stock exchange on the date of exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2025, the Company
issued&#160;<span id="xdx_900_eus-gaap--SharesIssued_iI_pip0_c20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zlqHCxA1saph" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2025-09-30_srt_DirectorMember" id="Fact000658" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">38,651</ix:nonFraction></span>&#160;shares of common stock to a director of the Company upon a net exercise of an option to purchase&#160;<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_z2iMyzfF8dw8" title="Exercise option shares purchase"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-10-012025-09-30_srt_DirectorMember" id="Fact000660" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">50,000</ix:nonFraction></span>&#160;shares
of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20250930__srt--TitleOfIndividualAxis__custom--BoardMember_z5K9Xu1l2zXh" title="Common stock exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-30_custom_BoardMember" id="Fact000662" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1.76</ix:nonFraction></span>&#160;per share. The Company withheld <span id="xdx_90E_ecustom--CommonStockConsiderationExerciseShares_pn3n3_c20241001__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zKBP2n6qVJfi" title="Common stock consideration exercise shares"><ix:nonFraction name="avxl:CommonStockConsiderationExerciseShares" contextRef="From2024-10-012025-09-30_srt_DirectorMember" id="Fact000664" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">11,349</ix:nonFraction></span> shares of common stock as consideration of the
exercise price of $<span id="xdx_902_eus-gaap--OtherSignificantNoncashTransactionValueOfConsiderationGiven1_pn3n3_c20241001__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zi3z3HaXphyc" title="Consideration payment"><ix:nonFraction name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" contextRef="From2024-10-012025-09-30_srt_DirectorMember" id="Fact000666" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">88,000</ix:nonFraction></span>. The number of shares withheld were based upon a market price of $<span id="xdx_90D_ecustom--MarketPrice_iI_pip0_c20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zT6drhsIPPg3" title="Market price"><ix:nonFraction name="avxl:MarketPrice" contextRef="AsOf2025-09-30_srt_DirectorMember" id="Fact000668" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">7.75</ix:nonFraction></span>&#160;per share as determined by reference
to the average high and low sales price reported on the Nasdaq stock exchange on the date of exercise</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 88 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zBIgs92kyiC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_z6uuJIsTaiW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_232_z0SaFZNQFKvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_231_zeDS6msdZwCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2025 &#8211; Page 10</span></p></ix:exclude>


<ix:exclude><p id="xdx_23E_z0QBbNMQRIgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2025, the Company
issued&#160;<span id="xdx_90F_eus-gaap--SharesIssued_iI_pip0_c20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zeFZaTZ6dGf2" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2025-09-30_custom_ChiefExecutiveOfficer1Member" id="Fact000675" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">42,452</ix:nonFraction></span>&#160;shares of common stock to the Company&#8217;s Chief Executive Officer upon a net exercise of an option to purchase&#160;<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_z86Ta8DByNQ6" title="Exercise option shares purchase"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-10-012025-09-30_custom_ChiefExecutiveOfficer1Member" id="Fact000677" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">187,500</ix:nonFraction></span>&#160;shares
of common stock at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zprUIgjB3PRl" title="Common stock exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-30_custom_ChiefExecutiveOfficer1Member" id="Fact000679" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.04</ix:nonFraction></span>&#160;per share. In connection with the exercise, the Company withheld&#160;<span id="xdx_904_ecustom--CommonStockConsiderationExerciseShares_c20241001__20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOffice1rMember_zUPfuIALfIug" title="Common stock consideration exercise shares"><ix:nonFraction name="avxl:CommonStockConsiderationExerciseShares" contextRef="From2024-10-012025-09-30_custom_ChiefExecutiveOffice1rMember" id="Fact000681" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">98,643</ix:nonFraction></span>&#160;shares
of common stock as consideration of the exercise price of $<span id="xdx_90D_eus-gaap--StockOptionExercisePriceIncrease_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zempGZr7JFYd" title=" exercise price"><ix:nonFraction name="us-gaap:StockOptionExercisePriceIncrease" contextRef="From2024-10-012025-09-30_custom_ChiefExecutiveOfficer1Member" id="Fact000683" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.9</ix:nonFraction></span>&#160;million and&#160;<span id="xdx_904_eus-gaap--NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zTHUd0TFfjdk" title="Consideration shares issued"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" contextRef="From2024-10-012025-09-30_custom_ChiefExecutiveOfficer1Member" id="Fact000685" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">46,405</ix:nonFraction></span>&#160;shares of common stock as consideration
for the payment of $<span id="xdx_907_eus-gaap--OtherSignificantNoncashTransactionValueOfConsiderationGiven1_pn3n3_dm_c20241001__20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zXKWeicBVcI9" title="Consideration payment"><ix:nonFraction name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" contextRef="From2024-10-012025-09-30_custom_ChiefExecutiveOfficer1Member" id="Fact000687" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.4</ix:nonFraction></span>&#160;million in connection with tax withholding obligations associated with the exercise. The number of shares
withheld were based upon a market price of $<span id="xdx_906_ecustom--MarketPrice_iI_pip0_c20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zv3nATBsxgqc" title="Market price"><ix:nonFraction name="avxl:MarketPrice" contextRef="AsOf2025-09-30_custom_ChiefExecutiveOfficer1Member" id="Fact000689" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">9.58</ix:nonFraction></span>&#160;per share as determined by reference to the closing price reported
on the Nasdaq stock exchange on the date of exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000691" name="us-gaap:CommitmentsDisclosureTextBlock"><p id="xdx_804_eus-gaap--CommitmentsDisclosureTextBlock_zalZYt2KeFV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 6	<span id="xdx_82E_z9NKLvS885p2">Commitments and Contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Lease</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company leases office space under an operating lease with an initial term of <span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20250930_zG4Pg7b23bOh" title="Operating lease term"><ix:nonNumeric contextRef="AsOf2025-09-30" format="ixt-sec:durmonth" id="Fact000693" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">12</ix:nonNumeric></span> months or less. Under the terms of the office lease, the
Company is required to pay its proportionate share of operating costs. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
operating lease costs were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal"></span></p>

<ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000695" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--LeaseCostTableTextBlock_pn3n3_zLGK3MGNJdu8" summary="xdx: Disclosure - Commitments and Contingencies (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B4_zO1LJNj6anr4" style="display: none">Schedule of operating lease costs</span></td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49A_20241001__20250930_zIJOpFzaZD61" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49E_20231001__20240930_zZipdRTLjkMb" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_491_20221001__20230930_z67COQZbK2se" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="11" style="font-weight: bold; text-align: center">Years ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseCost_zWMuXvMMUw3a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Operating lease costs</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-10-01to2025-09-30" id="Fact000697" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">134</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-10-012024-09-30" id="Fact000698" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">125</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-10-012023-09-30" id="Fact000699" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">118</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zMgEw3HONocf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employee 401(k) Benefit Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based
employees. United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the
Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing
employees. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company made matching contributions under the 401(k) plan as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;&#160;</span></p>

<ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000701" name="us-gaap:DefinedContributionPlanDisclosuresTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_ze32GXQdn995" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B9_zV9yNdYZC4wk" style="display: none">Schedule of contributions under the plan</span></td><td style="color: black; font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_495_20241001__20250930_zOHLuBnpjGgk" style="color: black; font-weight: bold; text-align: center">&#160;</td><td style="color: black; font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49C_20231001__20240930_zHvshI3hnLy" style="color: black; font-weight: bold; text-align: center">&#160;</td><td style="color: black; font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49D_20221001__20230930_zjLfn9CR0Wtk" style="color: black; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold">&#160;</td>
    <td colspan="11" style="color: black; font-weight: bold; text-align: center">Years ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2025</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2024</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40C_eus-gaap--PensionContributions_z8DWIeNHh9s6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; color: black; text-align: left; text-indent: -10pt">Contributions to 401(k) plan</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2024-10-01to2025-09-30" id="Fact000703" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">255</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2023-10-012024-09-30" id="Fact000704" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">279</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2022-10-012023-09-30" id="Fact000705" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">232</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zQ6RHsNUWttd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Litigation </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company
is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there
can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter
will not have a material adverse effect upon the Company&#8217;s consolidated financial statements. The Company does not believe that
any of such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On March 13,
2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York and it
named the Company and an officer of the Company as Defendants. The complaint was amended on July 12, 2024 (the &#8220;Initial Action&#8221;).
The complaint alleged violations of the Securities and Exchange Act of 1934 associated with disclosures and statements made with respect
to certain clinical trials for ANAVEX<sup>&#174;</sup>2-73 related to Rett syndrome. This lawsuit was dismissed by the United States District
Court for the Southern District of New York on June 18, 2025. The plaintiff filed a notice of appeal on July 17, 2025. Briefing on the
appeal concluded October 30, 2025. No decision has been entered. No amount has been recorded in these consolidated financial statements
for any loss contingencies associated with this lawsuit as the Company believes that it is not probable that any loss will occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 89 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zkFlPYpaY3ld" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zUXubk55DF4j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zmtMiOwe57I6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zBCKPoRcohk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2025 &#8211; Page 11</span></p></ix:exclude>


<ix:exclude><p id="xdx_237_z5ClD10ZWyR7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On May 8, 2024,
a similar complaint was filed in the same court by Kenneth Downing, a purported shareholder of the Company, against the same defendants.
The Company believed that this lawsuit was also without merit and filed a motion to dismiss the complaint. Plaintiff Downing voluntarily
dismissed this complaint subsequent to the filing of the motion to dismiss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On or about
May 13, 2024, a derivative lawsuit was filed against the Company (as nominal defendant), an officer of the Company, and members of the
Company&#8217;s Board of Directors in the U.S. District Court for the District of Nevada by another purported shareholder. The complaint
asserts various common law claims (including breach of fiduciary duty) and violation of Section 14(a)of the Securities Exchange Act regarding
the same or similar allegations at issue in the purported class action lawsuit related to disclosures and statements made about certain
clinical trials related to Rett <span style="background-color: white">syndrome</span>. On January 22, 2025, pursuant to a stipulation of the parties, the Court entered an order staying
this purported derivative lawsuit until the motion to dismiss filed by defendants in the Initial Action is decided by the U.S. District
Court for the Southern District of New York.&#160;The stay has been extended through the appeal. No amount has been recorded in these
consolidated financial statements for any loss contingencies associated with this lawsuit as the Company believes that it is not probable
that any loss will occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On February
14, 2025, another derivative lawsuit asserting state law breach of fiduciary duty and unjust enrichment claims based upon similar allegations
was filed against the Company (as nominal defendant), an officer of the Company, and members of the Company&#8217;s Board of Directors
in the Supreme Court for the State of New York, County of New York, by another purported shareholder. On August 18, 2025, pursuant to
a stipulation of the parties, the Court entered an order staying this purported derivative lawsuit until the appeal in the Initial Action
is resolved. No amount has been recorded in these consolidated financial statements for any loss contingencies associated with this lawsuit
as the Company believes that it is not probable that any loss will occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">We know of no
other material pending legal or governmental proceedings, other than ordinary routine litigation incidental to our business, to which
our Company or our subsidiaries are a party or of which any of their property is subject. There are no other proceedings in which any
of our directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, or any associate
of such persons, is an adverse party or has a material interest adverse to our or our subsidiaries&#8217; interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Share Purchase Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2025 and 2024, the Company had <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pip0_c20250930_zo6jODIXnLS9" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-09-30" id="Fact000712" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">10,000</ix:nonFraction></span>
share purchase warrants outstanding exercisable at $<span id="xdx_90C_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_pip0_c20250930_zoHxLrcYIqDc" title="Warrants outstanding weighted average exercise price"><ix:nonFraction name="avxl:WarrantsOutstandingWeightedAverageExercise" contextRef="AsOf2025-09-30" id="Fact000714" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">12.00</ix:nonFraction></span> per share until April 21, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock&#8211;based Compensation
Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2015 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 18, 2015, the Company&#8217;s Board approved
a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pip0_c20250930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zChHJPklfVAb" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2025-09-30_custom_StockOptionPlan2015Member" id="Fact000716" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">6,050,553</ix:nonFraction></span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2019 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 90 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zP5nq93FqVK6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zLvtg9PZv232" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_236_zTyrGixuZ1Yi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zkxZgCjLrq46" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2025 &#8211; Page 12</span></p></ix:exclude>


<ix:exclude><p id="xdx_234_zGIBplrzA2c3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20241001__20250930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_z5JvNOjJID3i" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2024-10-012025-09-30_custom_StockOptionPlan2019Member" id="Fact000723" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">6,000,000</ix:nonFraction></span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2022, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pip0_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zlCzeT2zmxN9" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2021-10-012022-09-30_custom_StockOptionPlan2022Member" id="Fact000725" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">406,453</ix:nonFraction></span>
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2022 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20220324__20220325__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_ztuTolYVP7Dl" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2022-03-242022-03-25_custom_StockOptionPlan2022Member" id="Fact000727" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">10,000,000</ix:nonFraction></span> additional shares of Common Stock will be available for issuance under the plan, in addition to the shares available
under the 2019 Plan and the 2015 Plan. Any awards outstanding under a previous stock option plan will remain subject to and be paid under
such plan, and any shares subject to outstanding awards under a previous plan that subsequently cease to be subject to such awards (other
than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then
the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date. Stock
options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser
periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 17, 2025, the Board approved an amendment
to the 2022 Plan (the &#8220;Amendment&#8221;). The Amendment was approved by the stockholders on June 10, 2025. The Amendment increased
the number of shares of common stock reserved for issuance under the 2022 Plan by 4,000,000 shares for a total of&#160;<span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20250417_zrhURZu8OwRh" title="Number of shares of common stock reserved for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2025-04-17" id="Fact000729" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,000,000</ix:nonFraction></span>. In
addition, the Amendment established a minimum vesting period of one year for all awards granted under the 2022 Plan and limited the discretion
to accelerate the vesting of awards upon a separation from service, with limited exceptions permitted. Finally, the Amendment prohibited
liberal share recycling provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2025, <span id="xdx_907_ecustom--OptionIssued_pip0_c20241001__20250930_zf9Lq2z2KnQi" title="Option issued"><ix:nonFraction name="avxl:OptionIssued" contextRef="From2024-10-01to2025-09-30" id="Fact000731" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">6,504,829</ix:nonFraction></span> options had been
issued under the 2022 Plan and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pip0_c20250930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_z2K8OoxsPTs7" title="Option available issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-09-30_custom_StockOptionPlan2022Member" id="Fact000733" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">8,436,882</ix:nonFraction></span> options were available for issue under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock option
activity during the years ended September 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000735" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zMAuyzGA2ub8" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BA_zE5YjSoz9rzc" style="display: none">Schedule of stock option activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="color: white">&#160;</td>
    <td style="color: white; text-align: left">&#160;</td><td style="color: white; text-align: right">&#160;</td><td style="color: white; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price <br/> ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value <br/> ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Aggregate intrinsic value <br/> ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 44%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, September 30, 2024</span></td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrDrKVnujtdg" title="Number of options, Outstanding beginning balance" style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember" id="Fact000737" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">15,037,754</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3ZDZFyqWmI6" title="Weighted average exercise price, Outstanding beginning balance" style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember" id="Fact000739" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.80</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsE1B6uFOVd5" title="Weighted average grant date fair value, Outstanding beginning balance" style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember" id="Fact000741" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.12</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1errfXlh8Yg" title="Aggregate intrinsic value, Outstanding beginning balance" style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember" id="Fact000743" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,825,791</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAYcb0woC0k3" title="Number of options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember" id="Fact000745" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,488,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMNxguD2E3j5" title="Weighted average exercise price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember" id="Fact000747" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">8.58</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="color: white">&#160;</td>
    <td style="color: white; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znhJQVsdiI8d" title="Weighted average grant date fair value, Granted" style="text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember" id="Fact000749" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.22</ix:nonFraction></td><td style="color: white; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Expired</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zybc6fWFW7ha" title="Number of options, Expired" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember" id="Fact000751" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">100,100</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfJ264tHNym7" title="Weighted average exercise price, Expired" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember" id="Fact000753" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">16.23</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercised</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKTyWPdQWJcf" title="Number of options, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember" id="Fact000755" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,383,988</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsXbjubtAJjb" title="Weighted average exercise price, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember" id="Fact000757" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.21</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="color: white">&#160;</td>
    <td style="color: white; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfcBnIF9bMaj" title="Weighted average grant date fair value, Exercised" style="text-align: right"><span style="font-size: 10pt"></span> <span style="font-size: 10pt"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember" id="Fact000759" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1.31</ix:nonFraction></span></td><td style="color: white; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzfG4883Xg2g" title="Aggregate intrinsic value, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember" id="Fact000761" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,324,901</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFBlpfLp5kQe" title="Number of options, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember" id="Fact000763" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">80,583</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfjSLbhDqvtl" title="Weighted average exercise price, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember" id="Fact000765" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">4.56</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5ObKFMoJrWc" title="Weighted average grant date fair value, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember" id="Fact000767" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.55</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, September 30, 2025</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z19ucprLcgS7" title="Number of options, Outstanding ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember" id="Fact000769" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">14,961,583</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zV9rYvQy4sud" title="Weighted average exercise price, Outstanding ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember" id="Fact000771" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">7.25</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1rKyhJroJkc" title="Weighted average grant date fair value, Outstanding ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember" id="Fact000773" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.46</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z344IAKZum9l" title="Aggregate intrinsic value, Outstanding ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember" id="Fact000775" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,715,608</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercisable, September 30, 2025</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zPQI44vUCf11" title="Number of options, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember" id="Fact000777" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">10,418,213</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoSubcAxPJQk" title="Weighted average exercise price, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember" id="Fact000779" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.22</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsFc6cCSWnW3" title="Weighted average grant date fair value, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember" id="Fact000781" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">4.83</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbEMxWQ89kt1" title="Aggregate intrinsic value, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember" id="Fact000783" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">34,762,588</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zeMQOFGsKuK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 91 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_z4uzqnteVIqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zoc0nSkyVAB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zKrtVUzpgfF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zFxFmoEqkbUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2025 &#8211; Page 13</span></p></ix:exclude>


<ix:exclude><p id="xdx_230_zliTz3J8oeae" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock options
at September 30, 2025 by a range of exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000790" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zZvFeODwATQj" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_8B3_zXiu7b3JvkEl" style="display: none">Schedule of summarizes information about stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="7" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Range of exercises prices</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Number of outstanding</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted average remaining contractual life</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted average exercise</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Number of vested</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted average exercise</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">From</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">To</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">(in years)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">price</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">price</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zxYN7hHqR4B9" title="Range of exercise prices, Lower range limit" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000792" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.30</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zsqM0silFxBa" title="Range of exercise prices, Upper range limit" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000794" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zhkFOTBe0x44" title="Number of outstanding options" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000796" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">4,315,700</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zsBDyLEeDv1g" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt-sec:duryear" id="Fact000798" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.15</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zmX1s7evjBc3" title="Weighted average exercise price" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000800" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.02</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zxNeCJnLt3Ek" title="Number of vested options" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000802" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">4,220,283</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zWWJ8Ja45XEc" title="Weighted average exercise price options vested" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000804" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.99</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zXqfKH8v7tB4" title="Range of exercise prices, Lower range limit" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000806" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.01</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_ztKJ50TDZAaa" title="Range of exercise prices, Upper range limit" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000808" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">7.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zwtchAcDnVy5" title="Number of outstanding options" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000810" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,299,536</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zOD4KFHqLWFc" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt-sec:duryear" id="Fact000812" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.23</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zMXVApfwnbye" title="Weighted average exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000814" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.62</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z6QnwWX4Ditg" title="Number of vested options" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000816" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,325,162</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zZAVuBEYr4gh" title="Weighted average exercise price options vested" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000818" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.72</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zUht1UO2aex1" title="Range of exercise prices, Lower range limit" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000820" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">7.01</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zfqeQDM5ew0f" title="Range of exercise prices, Upper range limit" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000822" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">9.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z2UPuVTMYFS3" title="Number of outstanding options" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000824" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">4,372,347</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zTKSmHCQIUel" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt-sec:duryear" id="Fact000826" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.66</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zbO88lQNtoPj" title="Weighted average exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000828" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">8.09</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z5M04ry9PRAj" title="Number of vested options" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000830" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,222,101</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z2qn76qyieRk" title="Weighted average exercise price options vested" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000832" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">7.82</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_znVh8X6kNeCj" title="Range of exercise prices, Lower range limit" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000834" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">9.01</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z3RjfNfj6a07" title="Range of exercise prices, Upper range limit" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000836" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">13.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_ziNfLlIh6zNi" title="Number of outstanding options" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000838" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,609,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zZiMFdT9M54l" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt-sec:duryear" id="Fact000840" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.31</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zMJwqgNnrXte" title="Weighted average exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000842" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">10.29</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zlxWmYRpuc35" title="Number of vested options" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000844" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,120,667</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zzv1vXIqLBue" title="Weighted average exercise price options vested" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000846" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">10.37</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z1WTTJpPSKbb" title="Range of exercise prices, Lower range limit" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000848" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">13.01</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zH4K4ZLjlZC8" title="Range of exercise prices, Upper range limit" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000850" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">25.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z7on3N9dOCcc" title="Number of outstanding options" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000852" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,365,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zT4jk8nQvG57" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt-sec:duryear" id="Fact000854" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.91</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zktkXtOXgkH9" title="Weighted average exercise price" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000856" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">18.33</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zY3g27ILay83" title="Number of vested options" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000858" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">530,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zBp15L52zgqg" title="Weighted average exercise price options vested" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000860" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">18.67</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z88YIicqOvj6" title="Number of outstanding options" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember" id="Fact000862" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">14,961,583</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBaB9MhtDPrb" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact000864" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.22</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBXUBkfD88Fb" title="Weighted average exercise price" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember" id="Fact000866" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">7.25</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNZ6TnWEEXM8" title="Number of vested options" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember" id="Fact000868" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">10,418,213</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6okIJiIgxGk" title="Weighted average exercise price options vested" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_StockOptionMember" id="Fact000870" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.22</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AB_zwUrGWiovHth" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average per share fair value of options
vested at September 30, 2025 was $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20241001__20250930_zXe09v8Nrp0g" title="Weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-10-01to2025-09-30" id="Fact000872" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">4.83</ix:nonFraction></span> (2024: $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20231001__20240930_zDmfeLFZWZXg" title="Weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-10-012024-09-30" id="Fact000874" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">4.34</ix:nonFraction></span>; 2023: $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20221001__20230930_zimoxsiShoF5" title="Weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-10-012023-09-30" id="Fact000876" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.94</ix:nonFraction></span>). At September 30, 2025, the weighted average contractual life of options
outstanding was <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930_zEqoepsiaxR1" title="Weighted average contractual life of options outstanding"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt-sec:duryear" id="Fact000878" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.22</ix:nonNumeric></span> years (2024: <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930_zE1fHsCVaO78" title="Weighted average contractual life of options outstanding"><ix:nonNumeric contextRef="From2023-10-012024-09-30" format="ixt-sec:duryear" id="Fact000880" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.48</ix:nonNumeric></span> years; 2023: <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230930_zOkLtOJoSRe2" title="Weighted average contractual life of options outstanding"><ix:nonNumeric contextRef="From2022-10-012023-09-30" format="ixt-sec:duryear" id="Fact000882" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.0</ix:nonNumeric></span> years) and for options exercisable was <span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930_zpMC8suFkDw" title="Options exercisable"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt-sec:duryear" id="Fact000884" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">4.11</ix:nonNumeric></span> years (2024: <span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930_zyZwf0KNFeDh" title="Options exercisable"><ix:nonNumeric contextRef="From2023-10-012024-09-30" format="ixt-sec:duryear" id="Fact000886" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">4.03</ix:nonNumeric></span> years; 2023: <span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230930_zLZyD2LSSVWd" title="Options exercisable"><ix:nonNumeric contextRef="From2022-10-012023-09-30" format="ixt-sec:duryear" id="Fact000888" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">4.75</ix:nonNumeric></span>
years).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the options
that were in-the-money at September 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">	The Company recognized share-based compensation
expense of $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20241001__20250930_zZUO3WW2hmof" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-10-01to2025-09-30" id="Fact000890" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">11.5</ix:nonFraction></span> million during the year ended September 30, 2025 (2024: $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20231001__20240930_zSG8NjUafQmc" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-10-012024-09-30" id="Fact000892" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">9.4</ix:nonFraction></span> million; 2023: $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20221001__20230930_zItd0E1Ahml4" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-10-012023-09-30" id="Fact000894" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.4</ix:nonFraction></span> million) in connection with the issuance
and vesting 	of stock options in exchange for services. These amounts have been included in general and 	administrative expenses
and research and development expenses on the Company&#8217;s consolidated statements of 	operations as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000896" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zy1ul9YLEJZ4" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B6_znpz9vQT6TPl" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="11" style="font-weight: bold; text-align: center">Years ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zMMfe5cVuu5c" title="Total share based compensation" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-10-012025-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000898" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,536</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHWirUELtqqe" title="Total share based compensation" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000900" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,625</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zFn7iKSnTNkg" title="Total share based compensation" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-10-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000902" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,558</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zaiJwxtkDUMe" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-10-012025-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000904" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,013</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zqLuPraCrmB6" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000906" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,813</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zr4kWOUUKPc6" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-10-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000908" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,812</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total share-based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930_zI3bl7GkOB54" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-10-01to2025-09-30" id="Fact000910" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,549</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930_zjWKBnIfnP51" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-012024-09-30" id="Fact000912" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,438</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930_zViBeqdRp5qj" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-10-012023-09-30" id="Fact000914" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,370</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A9_zjfcyIweY4yh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An amount of approximately $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20250930_z6RQETTxpAQ2" title="Remaining stock based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2025-09-30" id="Fact000916" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.3</ix:nonFraction></span> million in share-based
compensation is expected to be recorded over the remaining term 	of such options and warrants through fiscal 2029.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">The fair value of each option and
warrant award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000918" name="avxl:ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_zkFvazW9RlF" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BB_zs6JLQseyw75" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20241001__20250930_zvlq3707ODsh" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-10-01to2025-09-30" id="Fact000920" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">3.98</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20231001__20240930_znVjDE6iMPAf" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-10-012024-09-30" id="Fact000922" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.28</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20221001__20230930_zRhCY04Mi2y2" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-10-012023-09-30" id="Fact000924" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">3.70</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20241001__20250930_zaWkTo9C2cj2" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt-sec:duryear" id="Fact000926" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.57</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240930_zBB0jUO5Ejr" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2023-10-012024-09-30" format="ixt-sec:duryear" id="Fact000928" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.78</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230930_zspTKYDKT6Ee" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2022-10-012023-09-30" format="ixt-sec:duryear" id="Fact000930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.64</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20241001__20250930_zRD3GocNYn87" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-10-01to2025-09-30" id="Fact000932" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">86.49</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20231001__20240930_zJlr6T9OaP24" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-10-012024-09-30" id="Fact000934" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">84.81</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20221001__20230930_zoZva1sCuFIk" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-10-012023-09-30" id="Fact000936" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">85.13</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20241001__20250930_z6KTW8JNaUX9" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-10-01to2025-09-30" id="Fact000938" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20231001__20240930_zaiICJexi8Ml" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-10-012024-09-30" id="Fact000940" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20221001__20230930_z3tTbZw1FGa8" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-10-012023-09-30" id="Fact000942" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zyyYVoRU9ir3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of stock compensation charges recognized
during the years ended September 30, 2025, 2024 and 2023 was determined with reference to the quoted market price of the Company&#8217;s
shares on the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 92 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zCGRs31Xsrz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zGa6wDpaoNY9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zxiyD8KKehp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_238_zruXysEGFuo7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2025 &#8211; Page 14</span></p></ix:exclude>


<ix:exclude><p id="xdx_23A_zu7nUzoxehq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000949" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80C_eus-gaap--IncomeTaxDisclosureTextBlock_ziHkRR5Bh728" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 7	 	<span id="xdx_82F_zCiWeAJSiPml">Income Taxes </span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s U.S. and foreign losses before income
taxes are set forth below (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000951" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_pn3n3_zgKs5dfVY5l5" summary="xdx: Disclosure - Income Taxes (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"><span id="xdx_8B7_zzFnLgkQPPoi" style="display: none">Schedule of loss before income taxes</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20241001__20250930_z5MJb7OW8u69" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20231001__20240930_zFTtjaLIsDAh" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20221001_20230930" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">United States</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2024-10-01to2025-09-30" id="Fact000953" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">44,500</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2023-10-012024-09-30" id="Fact000954" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">39,195</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2022-10-012023-09-30" id="Fact000955" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">41,198</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2024-10-01to2025-09-30" id="Fact000957" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,877</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2023-10-012024-09-30" id="Fact000958" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,807</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2022-10-012023-09-30" id="Fact000959" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,300</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-10-01to2025-09-30" id="Fact000961" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">46,377</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-10-012024-09-30" id="Fact000962" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">43,002</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-10-012023-09-30" id="Fact000963" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47,498</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zV0AvDCRTxC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended September 30, 2025, 2024 and 2023, there were no
current or deferred income tax provisions (benefits) for any U.S. federal, state &amp; local, and foreign jurisdictions. The components
of net deferred income tax assets as of September 30, 2025 and 2024 are as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000965" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_z6GPFZ33krw8" summary="xdx: Disclosure - Income Taxes (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt">Schedule of components of net deferred income tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20250930_zOY5k9iTWpFk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20240930_zjQgJ3N6VP5j" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net operating loss carryforwards</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2025-09-30" id="Fact000967" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54,752</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-09-30" id="Fact000968" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48,134</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development tax credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2025-09-30" id="Fact000970" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,288</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-09-30" id="Fact000971" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,203</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2025-09-30" id="Fact000973" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,185</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-09-30" id="Fact000974" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,091</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsResearchAndDevelopmentCapitalization_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development capitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:DeferredTaxAssetsResearchAndDevelopmentCapitalization" contextRef="AsOf2025-09-30" id="Fact000976" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,737</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:DeferredTaxAssetsResearchAndDevelopmentCapitalization" contextRef="AsOf2024-09-30" id="Fact000977" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,104</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Unpaid charges</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:DeferredTaxAssetsUnpaidCharges" contextRef="AsOf2025-09-30" id="Fact000979" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,843</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:DeferredTaxAssetsUnpaidCharges" contextRef="AsOf2024-09-30" id="Fact000980" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,197</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Intangible asset costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2025-09-30" id="Fact000982" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">946</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2024-09-30" id="Fact000983" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">758</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ForeignExchangeAndOther_iNI_pn3n3_di_zOVd3Vxooh6e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign exchange and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:ForeignExchangeAndOther" contextRef="AsOf2025-09-30" id="Fact000985" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">259</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:ForeignExchangeAndOther" contextRef="AsOf2024-09-30" id="Fact000986" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">254</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_zYf0Q9J5VkZ4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Valuation allowance of deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2025-09-30" id="Fact000988" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">108,492</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-09-30" id="Fact000989" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">92,233</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0991">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0992">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zN93NJrimqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of income tax expense at the statutory
federal income tax rate and income taxes as reflected in the consolidated financial statements for the years ended September 30, 2025,
2024 and 2023 is as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact000994" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_pn3n3_z4dOHPfPkGL9" summary="xdx: Disclosure - Income Taxes (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zKPJn14YVjM9" style="display: none">Schedule of reconciliation of income tax expense</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20241001__20250930_zHrqqR1Sedf8" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20231001__20240930_z8d0FFMP0se1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20221001__20230930_znWxur4eJxqc" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Income tax benefit at statutory federal rate</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2024-10-01to2025-09-30" id="Fact000996" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,739</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2023-10-012024-09-30" id="Fact000997" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,030</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2022-10-012023-09-30" id="Fact000998" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,975</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign income taxed at other rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1000">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2023-10-012024-09-30" id="Fact001001" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">61</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--PermanentDifferencesRelatingToStockBasedCompensation_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Permanent differences relating to share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:PermanentDifferencesRelatingToStockBasedCompensation" contextRef="From2024-10-01to2025-09-30" id="Fact001004" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,219</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:PermanentDifferencesRelatingToStockBasedCompensation" contextRef="From2023-10-012024-09-30" id="Fact001005" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:PermanentDifferencesRelatingToStockBasedCompensation" contextRef="From2022-10-012023-09-30" id="Fact001006" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">601</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationGiltiAmount_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Permanent differences relating to GILTI inclusion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1009">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount" contextRef="From2022-10-012023-09-30" id="Fact001010" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">165</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2024-10-01to2025-09-30" id="Fact001012" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">130</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2023-10-012024-09-30" id="Fact001013" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">276</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2022-10-012023-09-30" id="Fact001014" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">273</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development credits, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" contextRef="From2024-10-01to2025-09-30" id="Fact001016" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">941</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" contextRef="From2023-10-012024-09-30" id="Fact001017" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">860</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" contextRef="From2022-10-012023-09-30" id="Fact001018" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">37</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">State and local taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-10-01to2025-09-30" id="Fact001020" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,672</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-10-012024-09-30" id="Fact001021" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,821</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-10-012023-09-30" id="Fact001022" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,122</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Adjustment to true up to prior years&#8217; tax provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="From2024-10-01to2025-09-30" id="Fact001024" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">182</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="From2023-10-012024-09-30" id="Fact001025" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,128</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="From2022-10-012023-09-30" id="Fact001026" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">206</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance_zahCpujyiQi2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Change in valuation allowances</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance" contextRef="From2024-10-01to2025-09-30" id="Fact001028" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,259</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance" contextRef="From2023-10-012024-09-30" id="Fact001029" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,186</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance" contextRef="From2022-10-012023-09-30" id="Fact001030" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,098</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Income tax expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1032">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2022-10-012023-09-30" id="Fact001034" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zs7Ty23yYUHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2025, the Company had U.S. federal
net operating loss carryforwards of approximately $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_pn5n6_c20250930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zIT809G1wVXi" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-09-30_custom_FederalMember" id="Fact001036" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">148.8</ix:nonFraction></span> million (2024: $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_pn5n6_c20240930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zDDBNxm6IMIh" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-09-30_custom_FederalMember" id="Fact001038" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">128.5</ix:nonFraction></span> million) of which <span id="xdx_903_ecustom--OperatingLossCarryforwardsDescription_c20241001__20250930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_z6ZDzmnCuXh1" title="Operating loss carryforwards description"><ix:nonNumeric contextRef="From2024-10-012025-09-30_custom_FederalMember" id="Fact001040" name="avxl:OperatingLossCarryforwardsDescription">$37.7</ix:nonNumeric></span> million will begin to expire in
2026 and $111.2 million can be carried forward indefinitely, state and local net operating loss carryforwards of approximately $ <span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_pn5n6_c20250930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z3WXKe40ojNj" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-09-30_us-gaap_StateAndLocalJurisdictionMember" id="Fact001042" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">19.1</ix:nonFraction></span>
million (2024: $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_pn5n6_c20240930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zj8nZX6iACK" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-09-30_us-gaap_StateAndLocalJurisdictionMember" id="Fact001044" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.9</ix:nonFraction></span> million) which will begin to expire in <span id="xdx_901_ecustom--OperatingLossCarryForwardsExpirationYear_c20241001__20250930_zxVIrL1KmEI" title="Operating loss carry forwards expiration year"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact001046" name="avxl:OperatingLossCarryForwardsExpirationYear">2036</ix:nonNumeric></span>, and Research and Development tax credits of approximately $<span id="xdx_90B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_pn5n6_c20241001__20250930_zq9QfxYlsJu5" title="Research and Development tax credits"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="From2024-10-01to2025-09-30" id="Fact001048" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.3</ix:nonFraction></span> million
(2024: $<span id="xdx_90A_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20221001__20230930_pn5n6" title="Research and Development tax credits"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="From2022-10-012023-09-30" id="Fact001050" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.3</ix:nonFraction></span> million) which will begin to expire in <span id="xdx_906_ecustom--ResearchAndDevelopmentTaxCreditsYear_c20241001__20250930_zvGoZpeSY8g1" title="Research and development tax credits year"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" id="Fact001052" name="avxl:ResearchAndDevelopmentTaxCreditsYear">2029</ix:nonNumeric></span>. The calculation of the Research and Development tax credits, by their nature,
involve estimates and subjectivity. If examined by the U.S. federal and state tax authorities, it is possible that some portion of these
credit carryforwards would be disputed by the tax authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 93 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_znslnnYi55m1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_z7uStgNEqj16" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zR0oCT4JbJyb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zuy8wkWWQzs8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2025 &#8211; Page 15</span></p></ix:exclude>


<ix:exclude><p id="xdx_23F_zKpvCM2H6Gzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company had approximately $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_pn5n6_c20250930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zsNPX58GEVUg" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-09-30_us-gaap_ForeignCountryMember" id="Fact001059" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">17.1</ix:nonFraction></span> million (approximately
AU$<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_pn5n6_c20250930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_z4k1lkTZXCJh" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-09-30_us-gaap_ForeignCountryMember_currency_AUD" id="Fact001061" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">25.9</ix:nonFraction></span> million) (2024: $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_pn5n6_c20240930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zx7knFevFoXe" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-09-30_us-gaap_ForeignCountryMember" id="Fact001063" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.6</ix:nonFraction></span> million (approximately AU$<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_pn5n6_c20240930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_znwFH72WmEX9" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-09-30_us-gaap_ForeignCountryMember_currency_AUD" id="Fact001065" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">23.9</ix:nonFraction></span> million)) of net operating loss carryforwards in Australia, which have an
indefinite life, available to offset future taxable income in those jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates its valuation allowance
requirements based on available evidence. When circumstances change, and this causes a change in management&#8217;s judgment about
the recoverability of deferred tax assets, the impact of the change on the valuation allowance is reflected in current income.
Because management of the Company does not currently believe that it is more likely than not that the Company will receive the
benefit of these assets, a full valuation allowance has been established at September 30, 2025 and 2024. During the year ended
September 30, 2025, the valuation allowance increased by $<span id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20241001__20250930_z9rGW6yiJXwa" title="Decrease in valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2024-10-01to2025-09-30" id="Fact001067" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.3</ix:nonFraction></span>
million (2024: $<span id="xdx_907_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20231001__20240930_zYd0Viq4W3rd" title="Decrease in valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2023-10-012024-09-30" id="Fact001069" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">15.2</ix:nonFraction></span>
million; 2023: $<span id="xdx_90B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20221001__20230930_zQg4RSi4E1N2" title="Decrease in valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2022-10-012023-09-30" id="Fact001071" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">14.1</ix:nonFraction></span>
million).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Tax Cuts and Jobs Act of 2017 (TCJA) has
modified the treatment of IRC 174 expenses related to research and development for tax years beginning after December 31, 2021.
Under the TCJA, the Company must capitalize the expenditures related to research and development activities and amortize them over
 5 years for U.S. activities and over 15 years for non-U.S. activities using a mid-year convention. Therefore, the capitalization of
research and development costs in accordance with IRC 174 has resulted in a net deferred tax assets at September 30, 2025 of $<span id="xdx_901_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_dm_c20250930_z5eSnKSjyeR3" title="Gross deferred tax asset"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2025-09-30" id="Fact001073" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">20.7</ix:nonFraction></span>
million (2024: $<span id="xdx_900_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_dm_c20240930_zPXHgII3Xyia" title="Gross deferred tax asset"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-09-30" id="Fact001075" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">15.1</ix:nonFraction></span>
million). On July 4, 2025, the United States President signed into law the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;), a
budget reconciliation package that changes many key provisions of the U.S. federal income tax code, including extensions of various
expiring provisions from the TCJA. The new legislation, which will be effective for the Company beginning in fiscal 2026, will now
allow for more tax-payer favorable treatment of domestic research and development expenditures for US income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Uncertain Tax Positions</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company files income tax returns in the U.S. federal
jurisdiction and various state and local and foreign jurisdictions. The Company&#8217;s tax returns are subject to tax examinations by
U.S. federal and state tax authorities, or examinations by foreign tax authorities until the respective statutes of limitation expire.
The Company is subject to tax examinations by tax authorities for all taxation years commencing on or after 2005.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the provisions of the Internal Revenue Code,
the net operating loss (&#8220;NOL&#8221;) carryforwards are subject to review and possible adjustment by the Internal Revenue Service
and state tax authorities. Under Section 382 of the Internal Revenue Code, NOL and tax credit carryforwards may become subject to an annual
limitation in the event of an over 50% cumulative change in the ownership interest of significant stockholders over a three-year period,
as well as similar state tax provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company conducts a Section 382 study annually
and has reduced its federal NOLs by $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20250930_zHiwV7YXLFM7" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-09-30" id="Fact001077" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">12.1</ix:nonFraction></span> million and its Research and Development tax credit carryforwards by $<span id="xdx_902_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_dm_c20250930_zz1wK7r4ljPf" title="Research and development tax credit carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2025-09-30" id="Fact001079" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million, which are
the amount of tax assets that will expire unutilized pursuant to Section 382. Subsequent ownership changes in future years could trigger
additional limitations of the Company&#8217;s NOLs<span style="background-color: white">. During the year ended September 30, 2025, the
Company determined that there were no changes in ownership pursuant to Section 382.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2025, the Company did not provide
any foreign withholding taxes related to its foreign subsidiaries&#8217; undistributed earnings, as such earnings have been retained and
are intended to be indefinitely reinvested to fund ongoing operations of the foreign subsidiaries. It is not practicable to estimate the
amount of taxes that would be payable upon remittance of these earnings, because such tax, if any, is dependent upon circumstances existing
if and when remittance occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2025 and 2024, the Company had determined that no liabilities
for uncertain tax positions, interest or penalties were required to be recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact001081" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_80C_eus-gaap--SegmentReportingDisclosureTextBlock_zzQV2YJU41o2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 8	<span id="xdx_821_zn5pQPMSkFpj">Segmented Information</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating segments are defined as components of an
entity for which separate financial information is available and regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;)
in deciding how to allocate resources and assess performance. The Company&#8217;s CODM is the Chief Executive Officer. The Company has
determined that it operates in a single operating segment, which consists of the development of clinical and preclinical product candidates
focused on advancing novel therapeutics for CNS diseases and disorders, and related administrative activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 94 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zIxn5xwZ73G8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zdaRDfGluVy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zTOJ9wZ4Opqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zmUUKQK8aEOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2025 &#8211; Page 16</span></p></ix:exclude>


<ix:exclude><p id="xdx_23C_zQmkYMTOv3Gg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accounting policies of the segment are the same
as those described in the summary of significant accounting policies. The CODM evaluates performance and allocates resources based on
consolidated net loss, as presented in the Company&#8217;s consolidated statement of operations, and monitors forecast-to-actual variances
for significant expense categories given their direct relationship to cash burn. The CODM also reviews the consolidated balance sheet
to assess liquidity, funding capacity, and segment assets, which are reported as total consolidated assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The CODM receives and reviews financial information
on a consolidated basis and does not assess performance or allocate resources based on geographic regions. In addition, management does
not internally organize or evaluate operating results by geography. Accordingly, management has determined that it is not required to
present financial information disaggregated by geographic region under ASC 280.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below summarizes the significant expense categories regularly
reviewed by the CODM for the years ended September 30, 2025, 2024 and 2023 (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact001088" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_pn3n3_zjxBEOPR4tqc" summary="xdx: Disclosure - Segmented Information (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span id="xdx_8BF_zYgw4UzcBeSd" style="display: none">Schedule of summarizes the significant expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20241001__20250930_zLHHUDIGsfxd" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20231001__20240930_zKk7pL1wdZwe" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20221001__20230930_zMYAJn06VFw8" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; width: 46%; text-align: left; text-indent: -10pt">Preclinical studies</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zFrZBm3FoeY9" title="Research and development costs" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2024-10-012025-09-30_custom_PreclinicalStudiesMember" id="Fact001090" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">543</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zxp07xxy7yY7" title="Research and development costs" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2023-10-012024-09-30_custom_PreclinicalStudiesMember" id="Fact001092" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">663</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zH9KDDhEzkph" title="Research and development costs" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2022-10-012023-09-30_custom_PreclinicalStudiesMember" id="Fact001094" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">627</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Clinical trials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_z1WONuLox7we" title="Research and development costs" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2024-10-012025-09-30_custom_ClinicalTrialsMember" id="Fact001096" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,805</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_zuj3PHG4gT9a" title="Research and development costs" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2023-10-012024-09-30_custom_ClinicalTrialsMember" id="Fact001098" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,301</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_zcUamCUFHlx8" title="Research and development costs" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2022-10-012023-09-30_custom_ClinicalTrialsMember" id="Fact001100" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,873</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Personnel costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_z2yP8sByQ5me" title="Research and development costs" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2024-10-012025-09-30_custom_PersonnelCostsMember" id="Fact001102" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,466</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zpO21lKV8dJ5" title="Research and development costs" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2023-10-012024-09-30_custom_PersonnelCostsMember" id="Fact001104" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,676</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zQXUpJcSUJy2" title="Research and development costs" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2022-10-012023-09-30_custom_PersonnelCostsMember" id="Fact001106" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,264</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Non-cash share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z60xdm80O0He" title="Research and development costs" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2024-10-012025-09-30_custom_NonCashShareBasedCompensationMember" id="Fact001108" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,013</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z2I3TxlZGWl2" title="Research and development costs" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2023-10-012024-09-30_custom_NonCashShareBasedCompensationMember" id="Fact001110" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,813</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_zFJDZrcFbA51" title="Research and development costs" style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2022-10-012023-09-30_custom_NonCashShareBasedCompensationMember" id="Fact001112" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,812</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Other research and development costs<sup>(a)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zZTM1o5KWTAl" title="Research and development costs" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2024-10-012025-09-30_custom_OtherResearchAndDevelopmentCostsMember" id="Fact001114" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">765</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zY2z0BJ6cNu" title="Research and development costs" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2023-10-012024-09-30_custom_OtherResearchAndDevelopmentCostsMember" id="Fact001116" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">385</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zPV5eE24LOyd" title="Research and development costs" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2022-10-012023-09-30_custom_OtherResearchAndDevelopmentCostsMember" id="Fact001118" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">141</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total research and development costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930_znLAEUCsjnY4" title="Research and development costs" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2024-10-01to2025-09-30" id="Fact001120" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37,592</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930_zgxBsosS3X9f" title="Research and development costs" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2023-10-012024-09-30" id="Fact001122" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41,838</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930_zuC4GxaJ0iW2" title="Research and development costs" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2022-10-012023-09-30" id="Fact001124" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43,717</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">General and administrative costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Personnel costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zh6aOjZq8sT4" title="General and administrative costs" style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-10-012025-09-30_custom_PersonnelCostsMember" id="Fact001126" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,288</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zpYJz6yuFcz" title="General and administrative costs" style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-10-012024-09-30_custom_PersonnelCostsMember" id="Fact001128" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,177</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zRa7H2ZF3xv9" title="General and administrative costs" style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2022-10-012023-09-30_custom_PersonnelCostsMember" id="Fact001130" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,527</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Non-cash share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_zuYd8YPkHrFd" title="General and administrative costs" style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-10-012025-09-30_custom_NonCashShareBasedCompensationMember" id="Fact001132" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,536</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z97W6Cm3eqO" title="General and administrative costs" style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-10-012024-09-30_custom_NonCashShareBasedCompensationMember" id="Fact001134" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,625</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z05ZWu0DGffg" title="General and administrative costs" style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2022-10-012023-09-30_custom_NonCashShareBasedCompensationMember" id="Fact001136" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,558</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Other general and administrative costs<sup>(b)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zmqi0fztDEVc" title="General and administrative costs" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-10-012025-09-30_custom_OtherResearchAndDevelopmentCostsMember" id="Fact001138" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,992</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_z1zIttFFD8tg" title="General and administrative costs" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-10-012024-09-30_custom_OtherResearchAndDevelopmentCostsMember" id="Fact001140" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,237</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zWYlj8jzeV3k" title="General and administrative costs" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2022-10-012023-09-30_custom_OtherResearchAndDevelopmentCostsMember" id="Fact001142" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,961</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total general and administrative costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930_z84cBtzE4JTa" title="General and administrative costs" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-10-01to2025-09-30" id="Fact001144" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,816</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930_zRTSScKRdqce" title="General and administrative costs" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-10-012024-09-30" id="Fact001146" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,039</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930_zMzJBfRDgPl9" title="General and administrative costs" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2022-10-012023-09-30" id="Fact001148" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,046</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OtherIncome_c20241001__20250930_zSQrsMX0gtDl" title="Other income" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="From2024-10-01to2025-09-30" id="Fact001150" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,031</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--OtherIncome_c20231001__20240930_zBzEhImJe7Bb" title="Other income" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="From2023-10-012024-09-30" id="Fact001152" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,875</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--OtherIncome_c20221001__20230930_z7gQovPJrPY7" title="Other income" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="From2022-10-012023-09-30" id="Fact001154" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,258</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net loss</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--NetIncomeLoss_c20241001__20250930_zHoQRnoi8oKd" title="Net Loss" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-10-01to2025-09-30" id="Fact001156" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">46,377</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--NetIncomeLoss_c20231001__20240930_zBcrRhrJpkXd" title="Net Loss" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-09-30" id="Fact001158" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">43,002</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--NetIncomeLoss_c20221001__20230930_zUh6s7Tme0V" title="Net Loss" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-09-30" id="Fact001160" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47,505</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(a)</td><td style="text-align: justify">Other research and development costs include, but are not limited to, publications, sponsorships, membership fees, scientific conferences,
and medical affairs strategy and branding.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(b)</td><td style="text-align: justify">Other general and administrative expenses include, but are not limited to, office rent, public company reporting requirements including
professional fees, insurance, and other general operating expenses not otherwise included in research and development expenses.</td></tr></table>

</ix:nonNumeric><p id="xdx_8AA_zaEsEC3Uej16" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact001162" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_z809reeRPkY6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 9	<span id="xdx_82C_zREFbpQGHIe3">Subsequent Events</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates subsequent events occurring
between the most recent balance sheet date and the date the financial statements are available to be issued in order to determine whether
the subsequent events are to be recorded and/or disclosed in the Company&#8217;s financial statements and footnotes. The financial statements
are considered to be available to be issued at the time they are filed with the Securities and Exchange Commission (SEC).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no subsequent events or transactions that
required recognition or disclosure in the consolidated financial statements.</p>

</ix:nonNumeric><p id="xdx_81D_zFRbkHEvbqF" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 95 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_015"></span>ITEM 9. CHANGES IN AND DISAGREEMENTS
WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL MATTERS</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not Applicable</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_016"></span>ITEM 9A. CONTROLS AND PROCEDURES</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Disclosure Controls and Procedures</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We maintain disclosure controls and procedures that
are designed to provide reasonable assurance that material information required to be disclosed in our periodic reports filed under the
Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms and
to provide reasonable assurance that such information is accumulated and communicated to our management, our chief executive officer and
our principal financial officer, to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We carried out an evaluation, under the supervision
and with the participation of our management, including our Chief Executive Officer and Principal Financial Officer, of the effectiveness
of the design and operation of our disclosure controls and procedures, as defined in&#160;Rule&#160;13(a)-15(e) under the Exchange Act.
Based on this evaluation, our Chief Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures
were effective as of September 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Management&#8217;s Annual Report on Internal
Control over Financial Reporting </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our management is responsible for establishing and
maintaining adequate internal control over financial reporting as defined in Rules&#160;13a-15(f) and 15d-15(f) under the Exchange Act.
Under the supervision and with the participation of our management, including our Principal Executive Officer and Principal Financial
Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on criteria established
in the framework in&#160;Internal Control &#8212; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the
Treadway Commission (&#8220;COSO&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Because of its inherent limitations, internal control
over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods
are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the
policies or procedures may deteriorate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on this evaluation, our management concluded
that our internal controls over financial reporting were effective as of September 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The effectiveness of our internal controls over financial
reporting as of September 30, 2025 has been audited by Grant Thornton LLP, an independent registered public accounting firm, as stated
in their report which appears in this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Changes in Internal Control over Financial Reporting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the quarter ended September 30, 2025, there
were no material changes in our internal control over financial reporting identified in management&#8217;s evaluation pursuant to Rules
13a 15(d) or 15d 15(d) of the Exchange Act that materially affected, or are reasonably likely to materially affect, our internal controls
over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_017"></span>ITEM 9B OTHER INFORMATION</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_90B_eecd--MtrlTermsOfTrdArrTextBlock_c20241001__20250930_zRgrIJ7S9xV7"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact001163" name="ecd:MtrlTermsOfTrdArrTextBlock">None of our directors or Section 16 officers <span id="xdx_904_eecd--Rule10b51ArrAdoptedFlag_dbT_c20241001__20250930_zNeVxKmrq1Bg"><span id="xdx_904_eecd--NonRule10b51ArrAdoptedFlag_dbT_c20241001__20250930_zUVbq55qNoQj"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:booleantrue" id="Fact001164" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:booleantrue" id="Fact001165" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span>,
modified or <span id="xdx_909_eecd--Rule10b51ArrTrmntdFlag_dbT_c20241001__20250930_zbQWKfxMgypc"><span id="xdx_908_eecd--NonRule10b51ArrTrmntdFlag_dbT_c20241001__20250930_zRPFC994X9V1"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:booleantrue" id="Fact001166" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:booleantrue" id="Fact001167" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement&#8221; (in each case,
as defined in Item 408(a) of Regulation S-K) during the three-month period ended September 30, 2025.&#160;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_018"></span>ITEM 9C DISCLOSURE REGARDING
FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 96; Options: NewSection; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_019"></span>PART III</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_020"></span>ITEM 10 DIRECTORS, EXECUTIVE
OFFICERS AND CORPORATE GOVERNANCE</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Directors and Executive Officers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our directors are to be elected at our annual meeting
and each director elected is to hold office until his or her successor is elected and qualified. Our Board of Directors may remove our
officers at any time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our directors and executive officers, their ages,
positions held, and duration of such, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: #F2F2F2">
    <td style="border-bottom: Black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 10%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date first appointed</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director, President, Chief Executive Officer, Secretary</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 5, 2013</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiong Ma, PhD</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director, Chair</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 25, 2021</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Athanasios Skarpelos</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 9, 2013</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claus van der Velden, PhD</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2, 2018</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steffen Thomas, PhD</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 15, 2015</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter Donhauser, D.O.</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 8, 2017</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra Boenisch, CPA, CGA</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer, Treasurer</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44 </span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 1, 2015</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Board Leadership Structure</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board of Directors is composed of a majority of
independent directors and the Chief Executive Officer of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Board of Directors has appointed an independent
Board Chair, Dr. Jiong Ma. As Board Chair, Dr. Ma has the authority, among other things, to call and preside over meetings of our Board,
to set meeting agendas, and to determine materials to be distributed to the Board. The Company believes separation of the positions of
Board Chair and Chief Executive Officer reinforces the independence of our Board in its oversight of the business and affairs of the Company.
In addition, the Company believes that having an independent Board Chair creates an environment that is more conducive to objective evaluation
and oversight of management&#8217;s performance, increasing management accountability and improving the ability of our Board to monitor
whether management&#8217;s actions are in the best interests of the Company and its stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Audit Committee, Compensation Committee, and Nominating
and Corporate Governance Committee each have oversight over specific areas of responsibility, as discussed further below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Board of Directors&#8217; Role in Risk Oversight</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board of Directors is responsible for oversight
of the Company&#8217;s risk management process. The Board administers this oversight function directly through the Board of Directors
as a whole, as well as through the committees of the Board. Areas of focus include economic risk, operational risk, financial risk (accounting,
investment or liquidity, and tax), competitive risk, legal and regulatory risk, cybersecurity risk and compliance and reputational risks.
The Board of Directors is supported by regular reporting by management, which is designed to give the Board of Directors visibility over
the Company&#8217;s operations and activities to adequately identify key risks and understand management&#8217;s risk mitigation strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Business Experience</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a brief account of the education
and business experience of directors and executive officers during at least the past five years, indicating their principal occupations
during the period, and the names and principal businesses of the organizations by which they were employed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 97; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Christopher Missling, PhD</span>. Christopher Missling
has over twenty years of healthcare industry experience in big pharmaceutical, biotech and investment banking prior to joining Anavex.
Most recently, from March 2007 until his appointment by our Company, Dr. Missling served as the head of healthcare investment banking
at Brimberg &amp; Co. in New York, New York. In addition, Dr. Missling served as the Chief Financial Officer of Curis, Inc. (NASDAQ: CRIS)
and ImmunoGen, Inc. (NASDAQ: IMGN). Dr. Missling earned his MS and PhD from the University of Munich and an MBA from Northwestern University
Kellogg School of Management and WHU Otto Beisheim School of Management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Jiong Ma,
PhD.&#160;</span>Jiong Ma <span style="background-color: white">has over 25 years of experience in investing, building, and scaling of
companies with a focus on innovative product launches in digital health, technology and the new energy transition. Dr. Ma has been a General
Partner of Phoenix Venture Partners since July 2024. She has served as director of SES AI Corporation (NYSE: SES) since February 2022
and has served as Lead Independent Board Director beginning in 2023. She also chairs the Compensation Committee, and is a member of Audit,
Nominating, and Strategic Investment Committee of SES. Dr. Ma served as senior partner and a member of the investment committee at Braemar
Energy Ventures (&#8220;Braemar&#8221;) from 2008 to 2020. While at Braemar, Dr. Ma led investments in more than 15 companies involved
in either resource efficiency, e-mobility, industrial digitalization, renewable energy, or deep tech, and has achieved multiple successful
exits through M&amp;A and IPO. Dr. Ma has significant knowledge and expertise in the technology industry, including information security.
Prior to Braemar Energy Ventures, she was with the Venture Capital Group at 3i Group, a global private equity firm, from 2004 to 2007
where she led investments across multiple stages in Digital Health, TMT and Cleantech. Preceding the Venture Capital Group at 3i, Dr.
Ma held several senior positions at Lucent Technologies and Bell Labs from 1997 to 2004. Her responsibilities included lead roles in product
portfolio strategy, new product launches for Optical and Data Networking, and research and product development. Dr. Ma was also a founding
team member of Onetta Inc., a fiber networks company. She has a PhD in Electrical and Computer Engineering from the University of Colorado
Boulder and an MS in Electrical Engineering from Worcester Polytechnic Institute. Dr. Ma is a Kauffman Fellow</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Claus van der Velden, PhD</span>. Claus van der Velden,
PhD brings significant expertise in management, accounting, internal controls, information security and risk management. Since May 2021,
he has served as <span style="background-color: white">Managing Director (Chief Financial Officer) of NetCologne GmbH, a regional telecommunication
provider in Germany</span>. From July 2011 to May 2021, he served as corporate head of Management Accounting, Internal Audit and Risk
Management at Stroeer SE &amp; Co KGaA, a publicly listed German digital media company. As the prior head of internal audit at Stroeer
SE &amp; Co KGaA, Dr. van der Velden has experience in the area of information security risk assessment, and the internal control tools,
processes, and policies needed to counter information security threats. Previously, Dr. van der Velden served as the Director of Corporate
Business Controlling for the Nutrition &amp; Health business unit at Cognis, a worldwide supplier of global nutritional ingredients and
specialty chemicals. In this position, he was also a compliance representative and a member of the global leadership team. After the acquisition
of Cognis by BASF, he was responsible for the management accounting processes of the BASF Nutrition &amp; Health division, developing
and producing mostly natural-source ingredients for the food and healthcare industries. Dr. van der Velden started his career as a strategy
consultant at an international marketing and strategy consultancy firm. He studied in Kiel and Stockholm and received a degree in economics
from the University of Kiel and later obtained his doctorate in business management from the WHU-Otto Beisheim School of Management where
he also previously taught economics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Athanasios Skarpelos</span>. Athanasios (Tom) Skarpelos
is a self-employed investor with over 25 years of experience working with private and public companies with a focus on biotechnology companies
involved in drug discovery and drug development projects. His experience has led to relationships with researchers at academic institutes
in Europe and North America. Mr. Skarpelos is a founder of Anavex.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Steffen Thomas, PhD</span>. Steffen Thomas has over
25 years of experience as a European patent attorney and is currently practicing, since September 2011, at Epping Hermann Fischer, a major
intellectual property law firm in Europe. Previously, he worked for Japan-based Takeda Pharmaceutical Company, the largest pharmaceutical
company in Asia and a top firm worldwide, as an in-house patent attorney. Prior to that, he worked for Nycomed Pharma, acquired by Takeda
in 2011 for approximately USD $10 billion. Dr. Thomas&#8217; legal practice covers drafting of patent applications, prosecuting patent
applications before national and international patent offices, defending and challenging patents in opposition, appeal, and nullity proceedings,
enforcing patents before the infringement courts, and preparing opinions on patentability and infringement in the technical field of chemistry.
Dr. Thomas has particular expertise in small molecule pharmaceuticals. He holds MS and PhD degrees in Chemistry from the University of
Munich.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 98; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Peter Donhauser, D.O.</span> Peter Donhauser had more
than 20 years of expertise in clinical research prior to practicing osteopathic medicine with an integrated medical approach in private
practice beginning in 2000. He worked at the University Hospital of Munich in the fields of geriatrics and neuromusculoskeletal diseases.
During this time, he was a clinical trial investigator in multiple Phase 3 studies, including studies sponsored by Merck Sharp &amp; Dohme,
Merck, Boehringer Mannheim, Roche, Servier and Sanofi. He received his human medicine degree at the University of Munich and Doctor of
Osteopathic Medicine (D.O.) from the German-American Academy for Osteopathy, or DAAO, a member of the European Register for Osteopathic
Physicians, or EROP, at the Philadelphia College of Osteopathic Medicine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Sandra Boenisch, CPA, CGA.</span> Ms. Boenisch is
a Chartered Professional Accountant (CPA, CGA) with approximately 20 years of accounting, audit and financial reporting experience in
a variety of industries, both in the United States and Canada. Ms. Boenisch was an independent consultant, providing financial reporting
services to a range of public companies in the United States and Canada since January 2012. From 2008 until 2012, Ms. Boenisch was employed
at BDO Canada LLP (Vancouver, BC) where she was hired as a Senior Accountant and was later promoted to Manager, Audit Assurance. Ms. Boenisch
specialized in managing assurance engagements for public companies in the United States and Canada. Prior to that, Ms. Boenisch worked
for another public accounting firm from 2001 to 2008. As an independent consultant, Ms. Boenisch has acquired considerable experience
in finance, governance, and regulatory compliance. She holds a BComm from Laurentian University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Family Relationships</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are no family relationships between any director
or executive officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Involvement in Certain Legal Proceedings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are no material proceedings to which any director
or executive officer or any associate of any such director or officer is a party adverse to our Company or has a material interest adverse
to our Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Delinquent Section 16(a) Reports </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Section 16(a) of the Exchange
Act requires our officers and directors, and persons who beneficially own more than ten percent (10%) of our outstanding common stock,
to file initial reports of ownership and reports of changes in ownership with the SEC. Such persons are required by SEC regulations to
furnish us with all copies of Section 16(a) forms they file.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Based solely on our review
of the forms furnished to us and written representations from certain reporting persons, we believe that all filing requirements applicable
to our executive officers, directors and persons who own more than 10% of our common stock were complied with in fiscal year 2025, except
for the following late filings:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Form 4 filed December 6, 2024 for Sandra
                                                                                                         Boenisch; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -18pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Form 4 filed December 6, 2024 for Christopher
Missling.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -18pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Business Code of Conduct &amp; Ethics</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Board adopted a code of business ethics and conduct
(the &#8220;<span style="text-decoration: underline">Code of Ethics</span>&#8221;), applicable to all of our executives, directors and employees. The Code of Ethics is available
in print to any stockholder that requests a copy. Copies may be obtained by contacting Investor Relations at our corporate headquarters.
Our Code of Ethics is also available on our website at <i><span style="text-decoration: underline">www.anavex.com/corporate-governance</span></i>. We intend to make any disclosures
regarding amendments to, or waivers from, the Code of Business Conduct required under Form 8-K by posting such information on our website.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 99; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Insider Trading Policy</i></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have an Insider Trading Policy that provides guidelines
with respect to transactions in our securities by insiders and the handling of our confidential information and the confidential information
of the companies with which we engage in transactions or do business. The policy promotes compliance with U.S. federal, securities laws
that prohibit certain persons who are aware of material non-public information relating to us from (1) purchasing, selling, or otherwise
engaging in transactions in our securities, or (2) providing material non-public information to other persons who may trade on the basis
of that information. In addition, our Insider Trading Policy prohibits our directors, officers, employees and consultants from engaging
in short sales, transactions in publicly traded options such as put, calls or other derivative securities, hedging transactions and other
inherently speculative transactions with respect to our stock at any time. Our policy further prohibits such persons from engaging in
transactions involving any loan, pledge or other transfer of beneficial ownership of the Company&#8217;s securities without obtaining
advance clearance of the proposed transaction from our Insider Trading Compliance Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Information Regarding Committees of the Board
of Directors</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board has an Audit Committee, a Compensation Committee
and a Nominating and Corporate Governance Committee. The following table provides membership and meeting information for fiscal 2025:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><b>Name</b></td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>&#160;</b><b>&#160;</b><b>Audit Committee</b></td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>&#160;</b><b>&#160;</b><b>Compensation Committee</b></td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nominating and Corporate Governance Committee</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Christopher Missling, PhD</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Jiong Ma, PhD</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Claus van der Velden, PhD</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
<td style="padding-bottom: 1pt; text-align: left">*</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
<td style="padding-bottom: 1pt; text-align: left">*</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
<td style="padding-bottom: 1pt; text-align: left">*</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Athanasios Skarpelos</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Steffen Thomas, PhD</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Peter Donhauser, D.O.</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Meetings in 2025</td>
<td style="width: 5%; padding-bottom: 1pt">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 11%; text-align: right">4</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="width: 5%; padding-bottom: 1pt">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 11%; text-align: right">7</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="width: 5%; padding-bottom: 1pt">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 11%; text-align: right">3</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">*Committee Chair</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Audit Committee and Audit Committee Financial
Experts </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Audit Committee is composed of three directors,
each of whom is independent. The Audit Committee operates under a charter that was adopted by our Board of Directors. The Audit Committee
oversees and reports to our Board of Directors on various auditing and accounting-related matters, including, among other things, the
maintenance of the integrity of our financial statements, reporting process and internal controls; the selection, evaluation, compensation
and retention of our independent registered public accounting firm; legal and regulatory compliance, including our disclosure controls
and procedures; and oversight over our risk management policies and procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Board of Directors has determined that Claus van
der Velden is an &#8220;audit committee financial expert&#8221; as defined by applicable SEC and NASDAQ rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Audit Committee met four times during fiscal 2025
and also acted by written consent as required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Audit Committee has reviewed and discussed the
audited consolidated financial statements with management. The Audit Committee has discussed with the Company&#8217;s independent registered
public accounting firm the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight
Board (&#8220;PCAOB&#8221;) and the Securities and Exchange Commission (the &#8220;SEC&#8221;). In addition,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 100; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">the Audit Committee has received
the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the
PCAOB regarding the firm&#8217;s communications with the Audit Committee concerning independence and has discussed with the independent
registered accounting firm its independence from the Company and management. Based on the reviews and discussions referred to above, the
Audit Committee recommended to the Board that the audited consolidated financial statements for the Company for the fiscal year ended
September 30, 2025 be included in this Annual Report on Form 10-K for the year ended September 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">The foregoing report has been furnished by the Audit
Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Claus van der Velden (Chairman)&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Jiong Ma<br/>
Steffen Thomas<br/>
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Compensation Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee is composed of three directors,
each of whom is independent. The Compensation Committee operates under a charter that was adopted by our Board of Directors. The Compensation
Committee assists our Board of Directors in discharging its responsibilities relating to the compensation of our directors and executive
officers. Its responsibilities include, among other things: reviewing, approving and recommending compensation programs and arrangements
applicable to our officers; determining the objectives of our executive officer compensation programs; overseeing the evaluation of our
senior executives; administering our incentive compensation plans and equity-based plans, including reviewing and granting equity awards
to our executive officers; and reviewing and approving director compensation and benefits. The Compensation Committee can delegate to
other members of our Board of Directors, or an officer or officers of the Company, the authority to review and grant share-based compensation
for employees who are not executive officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee has the responsibilities
and authority designated by NASDAQ rules and the Compensation Committee Charter. Specifically, the Compensation Committee has the sole
discretion to select and receive advice from a compensation consultant, legal counsel or other adviser and is directly responsible for
oversight of their work. The Compensation Committee must also determine reasonable compensation to be paid to such advisors by us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee met seven times during
fiscal 2025 and also acted by written consent as required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Nominating and Corporate Governance Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Nominating and Corporate Governance Committee
(the &#8220;NCG Committee&#8221;) is appointed by the Board to oversee and evaluate the Board&#8217;s performance and the Company&#8217;s
compliance with corporate governance regulations, guidelines and principles, to identify individuals qualified to become Board members,
to recommend to the Board proposed nominees for Board membership, and to recommend to the Board directors to serve on each standing committee.
The NCG Committee seeks to assemble a Board that possesses the appropriate balance of professional and industry knowledge, financial expertise
and management experience that is necessary to oversee the Company&#8217;s business. The NCG also recognizes the importance of diversity
in Board composition, including diversity of experience, gender and ethnicity and seeks to continually strive towards optimal diversity.
The NCG Committee operates under a charter that was adopted by our Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The NCG Committee met three times during fiscal 2025
and also acted by written consent as required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_021"></span>ITEM 11. EXECUTIVE COMPENSATION</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Executive Compensation Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s compensation objectives are to
offer our named executive officers compensation and benefits that are competitive and meet our goals of attracting, retaining and motivating
highly skilled, talented management, which is necessary for the Company to achieve its financial and strategic objectives and create long-term
value for our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 101; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A significant portion of our named executive officer&#8217;s
compensation is related to factors that directly and indirectly influence stockholder value, including long-term stock performance and
operational performance. We believe the levels of compensation we provide should be competitive, reasonable and appropriate for our business
needs and circumstances. The named executive officers who are the subject of this CD&amp;A are Christopher Missling, PhD, our Chief Executive
Officer, and Sandra Boenisch, our Principal Financial Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Our Executive Compensation Program and Philosophy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The intent of the Company&#8217;s compensation program
for our named executive officers is to attract and retain talent, to create incentives for and to reward excellent performance. We seek
to compensate our named executive officers in a manner that is competitive, rewards performance that creates stockholder value, recognizes
individual contributions, and encourages long-term value creation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee meets at least once per
year to review and evaluate the compensation of our named executive officers and each officer&#8217;s performance. The Compensation Committee
utilizes quantitative and qualitative factors, including the accomplishment of initiatives, attitude, and leadership and applies overall
judgment to assess performance, taking into account the financial condition of the Company. In setting compensation, the Compensation
Committee considers the outcome of the most recent say-on-pay vote, as well as stockholder feedback throughout the year, when making compensation
decisions for our executive officers. In our most recent say-on-pay vote, conducted at our 2024 annual meeting of stockholders, held on
June 18, 2024, our stockholders approved the compensation of our named executive officers on an advisory basis, with 83.8% of the votes
cast in favor of the fiscal 2023 compensation of our named executive officers. Ultimately, the Compensation Committee seeks to evaluate,
based on the achievement of financial and nonfinancial objectives, the variable compensation, including special awards, of our named executive
officers and decide on the base salary and target discretionary bonus for such persons taking into account relevant benchmark data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee believes that a significant
portion of each named executive officer&#8217;s compensation opportunity should be tied to variable compensation and value creation for
stockholders. The Compensation Committee believes this mix provides an appropriate balance between the financial security required to
attract and retain qualified individuals, and the Compensation Committee&#8217;s goal of ensuring that the compensation of our named executive
officers rewards performance that benefits stockholders over the long term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Compensation Risk Oversight</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In administering the compensation program for our
named executive officers, the Compensation Committee strives to achieve a balance among the elements of compensation to accomplish the
objectives of the program. The Compensation Committee reviews the overall compensation program in the context of the risks that may be
presented by the structure of the compensation program and the metrics used to determine compensation under that program. Based upon this
review, the Compensation Committee believes that the compensation program for our named executive officers does not create a reasonable
likelihood of a material adverse effect on the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Compensation Consultants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee makes recommendations to
the Board regarding the compensation of our named executive officers, including the structure and design of the compensation programs.
The Compensation Committee is responsible for retaining and terminating compensation consultants and determining the terms and conditions
of their engagement. During fiscal 2025, the Compensation Committee did not engage any compensation consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Elements of Executive Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We focus our named executive officer compensation
program on three related but distinct elements: base salary, cash bonuses and stock-related compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 102; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Base Salary</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Base salaries take into consideration a number of
factors, including the named executive officer&#8217;s job performance, our corporate performance, and compensation practices observed
in the market. In its evaluation of performance for the renewal of our Chief Executive Officer&#8217;s and Principal Financial Officer&#8217;s
employment agreements, the Compensation Committee considered our corporate performance, increases in stockholder value and advances in
the Company&#8217;s clinical trials. In July 2025, after considering the above factors, the annualized base salary of our Chief Executive
Officer was increased from $700,000 to $800,000 and the annualized base salary of our Principal Financial Officer remained unchanged at
$279,840 Canadian dollars.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Annual Discretionary Cash Bonuses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has an annual discretionary cash bonus
program. We provide such bonuses to motivate executive officers to perform on behalf of general corporate goals and to perform in their
areas of responsibility. The Compensation Committee of our Board works with the Chief Executive Officer, on an annual basis, to evaluate
the Company&#8217;s financial performance of the prior year, and overall financial condition of the Company to determine if discretionary
bonuses are to be paid. Our Compensation Committee independently evaluates the performance of our Chief Executive Officer in the prior
year, as well as the overall financial condition of the Company to determine if a discretionary bonus of up to 20% of base salary shall
be paid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Equity Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Only our Board, acting in its sole discretion, or
the Compensation Committee may grant stock options to our named executive officers. We view stock options as one of the more important
components of our long-term, performance-based compensation philosophy. We provide stock options through initial grants at or near the
date of hire and subsequent periodic/annual grants. Generally, initial stock option grants vest over a three-year period and have an exercise
price equal to the fair market value of our stock at the time of grant. Initial grant amounts are based on ranges that take into consideration
a named executive officer&#8217;s job responsibilities and competitive market data. We grant periodic additional stock options to reflect
the individual&#8217;s ongoing contributions to the long-term success and growth of the Company, to incentivize individuals to remain
with the Company and to provide a long-term incentive to achieve or exceed our corporate goals. We do not have a program, plan or practice
to time stock option grants to our named executive officers in coordination with the release of material nonpublic information. We have
not re-priced any of our stock options and do not intend to re-price or otherwise adjust outstanding stock options at any time in the
future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Equity compensation includes stock option grants within
the terms of our 2022 Omnibus Incentive Plan. Each named executive officer is eligible for stock option grants under the 2022 Omnibus
Incentive Plans which may vest over a required service period, &#8220;Time Based Awards&#8221;, or upon achievement of certain performance
criteria, &#8220;Performance Awards&#8221;. Generally, our Compensation Committee grants Time Based Awards at or near the date of hire.
Such grants are intended to link compensation with stockholder value over time. Subsequent awards are generally granted as Performance
Awards, which are intended to align compensation with the Company&#8217;s short-term and long-term objectives. Our Compensation Committee
selects performance goals that reflect the Company&#8217;s short-term and longer-term objectives to ensure named executive officers are
rewarded for the successful and timely accomplishment of these objectives. Generally, these performance criteria include milestones in
connection with the successful execution and enrollment of the Company&#8217;s clinical trial programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2025, our Compensation Committee granted
options to our Chief Executive Officer and Principal Financial Officer, which vest in four equal tranches based on four performance milestones,
as described further below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other components of the compensation of our named
executive officers include employee medical benefit plans and retirement plan contributions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Employee Medical Benefit Plans</b>.&#160;Our
employee medical and welfare benefit plans include medical, dental, life, disability and accidental death&#160;and dismemberment insurance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 103; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>401(k) Plan</b>.&#160;We have
a defined-contribution savings plan with a cash or deferred arrangement under Section 401(k) of the Internal Revenue Code. The plan covers
all United States based employees. United States based employees eligible to participate in the plan may contribute up to the current
statutory limits under the Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions
on behalf of contributing employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Registered Retirement Savings
Plan (RRSP) Plan</b>.&#160;We have a defined-contribution savings plan governed by Section 146 (1) of the Income Tax Act of Canada. The
plan covers all Canadian based employees. Canadian based employees eligible to participate in the plan may contribute up to the current
statutory limits under the Canadian regulations. The RRSP plan permits the Company to make additional matching contributions on behalf
of contributing employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Compensation Committee Interlocks and Insider Participation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify"><span style="font-family: Tahoma, Helvetica, Sans-Serif"><b>&#65279;</b></span>No
member of the Compensation Committee has ever been an officer or employee of the Company.&#160;None of the named executive officers currently
serves or has served on the Compensation Committee or board of directors of any other entity that has one or more named executive officers
serving as a member of the Board or Compensation Committee of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Managing Compensation-Related
Risks</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Although a portion of the
compensation provided to our executive officers and other employees is performance-based, the executive compensation program does not
encourage excessive or unnecessary risk taking. This is primarily due to the fact that the compensation program is designed to encourage
executive officers and other employees to remain focused on both short-term and long-term strategic goals within the context of our pay-for-performance
compensation philosophy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_907_eecd--InsiderTrdPoliciesProcAdoptedFlag_dbT_c20241001__20250930_zXrCWeB76Mae"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:booleantrue" id="Fact001168" name="ecd:InsiderTrdPoliciesProcAdoptedFlag">Insider Trading Policy</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our insider trading policy prohibits short sales and
derivative transactions of our stock by our named executive officers, directors and all of our employees, including short sales of our
securities, including short sales &#8220;against the box&#8221; (a sale with a delayed delivery); purchases or sales of puts, calls or
other derivative securities of the Company; or other hedging or monetization transactions such as zero-cost collars and forward sale contracts,
as they involve the establishment of a short position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, our insider trading policy prohibits
our named executive officers, directors and all of our employees from purchasing our securities on margin, borrowing against Company securities
held in a margin account, or pledging our securities as collateral for a loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<div id="xdx_98C_eecd--ErrCompAnalysisTextBlock_c20241001__20250930__ecd--RestatementDateAxis__2023-11-30_zFnAyrD3eOuh"><ix:nonNumeric contextRef="From2024-10-012025-09-30_2023-11-30" escape="true" id="Fact001169" name="ecd:ErrCompAnalysisTextBlock">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Clawback Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2023, the Board adopted an executive officer
compensation clawback policy that may be applied in the event of a material financial restatement. The clawback policy covers all of the
named executive officers and includes all incentive-based compensation. Specifically, in the event of an accounting restatement, the Company
must recover, reasonably promptly, erroneously awarded compensation in amounts determined pursuant to the policy. Compensation that may
be recoverable under the policy includes cash or equity-based compensation for which the grant, payment or vesting (or any portion thereof)
is or was predicated upon the achievement of specified financial results that are impacted by the material financial restatement, and
the amount of compensation that may be impacted by the clawback policy is the difference between the amount paid or granted, and the amount
that should have been paid or granted, if calculated on the updated financials. Recovery under the policy with respect to an executive
officer will not require the finding of any misconduct by such executive officer or such executive officer being found responsible for
the accounting error leading to an accounting restatement. Our equity awards provide that the Company may annul an award if the grantee
incurs a separation from service for &#8220;cause&#8221; (as defined in the agreements). In such case, all awards and any amounts or benefits
received or outstanding shall be subject to cancellation, recoupment, rescission, payback and other action in accordance with the terms
of the Company Clawback Policy or any applicable law. <span style="background-color: white">In addition, in the event
of a restatement of the Company&#8217;s financial statements due to material noncompliance with any financial reporting requirement under
the law, whether such noncompliance is the result of misconduct or other circumstances, an employee shall be required to reimburse the
Company for any amounts earned or payable with respect to an award granted under the Company&#8217;s equity plan to the extent required
by law and the Company&#8217;s clawback policy.</span></p>

</ix:nonNumeric></div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #222222; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<span id="xdx_90A_eecd--RestatementDeterminationDate_dd_c20241001__20250930__ecd--RestatementDateAxis__2023-11-30_zbb0Gg2M7U32" style="display: none"><ix:nonNumeric contextRef="From2024-10-012025-09-30_2023-11-30" format="ixt:datemonthdayyearen" id="Fact001170" name="ecd:RestatementDeterminationDate">November 30, 2023</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 104; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Stock Ownership Guidelines</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not have any stock ownership guidelines, ownership
goals or holding requirements. If and as we succeed in achieving approval for and commercializing our product candidates, we expect that
we will adapt the elements of our compensation program as appropriate and may include or substitute other elements in our compensation
program. Changes in the elements of our compensation program may also reflect changes in the importance of tax or accounting treatments
of a particular element of our compensation program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<div id="xdx_98B_eecd--AwardTmgMnpiDiscTextBlock_c20241001__20250930_zsd0amUAvRF5"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact001171" name="ecd:AwardTmgMnpiDiscTextBlock">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Policies and Practices for <span id="xdx_903_eecd--AwardTmgPredtrmndFlag_dbT_c20241001__20250930_zE9N9TVCaIM7"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:booleantrue" id="Fact001172" name="ecd:AwardTmgPredtrmndFlag">Granting Certain Equity
Awards</ix:nonNumeric></span></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our policies and practices regarding the granting
of equity awards are carefully designed to ensure compliance with applicable securities laws and to maintain the integrity of our executive
compensation program. The Compensation Committee is responsible for the timing and terms of equity awards to executives and other eligible
employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The timing of equity award grants is determined with
consideration to a variety of factors, including but not limited to, the achievement of pre-established performance targets, market conditions
and internal milestones. The Company does not follow a predetermined schedule for the granting of equity awards&#894; although the Company
generally grants equity-based awards annually after the completion of annual calendar year performance review process. Each grant is considered
on a case-by-case basis to align with the Company&#8217;s strategic objectives and to ensure the competitiveness of our compensation packages.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In determining the timing and terms of an equity award, the Board or the Compensation
Committee may consider material nonpublic information to ensure that such grants are made in compliance with applicable laws and regulations,
but does not take material nonpublic information into account when determining the terms of awards. The Board&#8217;s or the Compensation
Committee&#8217;s procedures to prevent the improper use of material nonpublic information in connection with the granting of equity awards
include oversight by legal counsel and, where appropriate, delaying the grant of equity awards until the public disclosure of such material
nonpublic information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_907_eecd--AwardTmgMethodTextBlock_c20241001__20250930_z3FZVQqnEI88"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact001173" name="ecd:AwardTmgMethodTextBlock">For all stock option awards, the exercise price is
the closing price of the Company&#8217;s common stock on the Nasdaq on the date of the grant. If the grant date falls on a non-trading
day, the exercise price is the closing price of the Company&#8217;s common stock on the Nasdaq on the last trading day preceding the date
of grant.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During fiscal 2025, the Company did not grant equity
awards to its named executive officers during the four business days prior to or the one business day following the filing of its periodic
reports or the filing or furnishing of a Form 8-K that discloses material nonpublic information. <span id="xdx_90A_eecd--AwardTmgHowMnpiCnsdrdTextBlock_c20241001__20250930_zkSJb6166DMf"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" escape="true" id="Fact001174" name="ecd:AwardTmgHowMnpiCnsdrdTextBlock">The Company has not timed the disclosure
of <span id="xdx_902_eecd--AwardTmgMnpiCnsdrdFlag_dbF_c20241001__20250930_zJn2n2F4G4r8"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:booleanfalse" id="Fact001175" name="ecd:AwardTmgMnpiCnsdrdFlag">material nonpublic information</ix:nonNumeric></span> for the purpose of affecting the <span id="xdx_901_eecd--MnpiDiscTimedForCompValFlag_dbF_c20241001__20250930_zDuh5Qy8B9c6"><ix:nonNumeric contextRef="From2024-10-01to2025-09-30" format="ixt:booleanfalse" id="Fact001176" name="ecd:MnpiDiscTimedForCompValFlag">value of executive compensation</ix:nonNumeric></span> for named executive officer grants
in fiscal 2025.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is committed to maintaining transparency
in its executive compensation practices and to making equity awards in a manner that is not influenced by the timing of the disclosure
of material nonpublic information for the purpose of affecting the value of executive compensation. The Company regularly reviews its
policies and practices related to equity awards to ensure they meet the evolving standards of corporate governance and continue to serve
the best interests of the Company and its stockholders.</p>

</ix:nonNumeric></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Compensation Committee Report</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The members of the Company&#8217;s Compensation Committee hereby state:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Compensation Committee has reviewed and discussed with management the
foregoing Compensation Discussion and Analysis, required by Item 402(b) of Regulation S-K. Based on this review and discussion, we recommended
to the Board of Directors that the Compensation Discussion and Analysis be included in this Annual Report on Form 10-K for the fiscal
year ended September 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 105; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">The foregoing report has been furnished by the Compensation
Committee</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Claus van der Velden, Committee Chair</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Steffen Thomas</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Peter Donhauser</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Summary Compensation </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The particulars of compensation paid to our named
executive officers for the last three completed fiscal years:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">All other</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Option</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Compen-</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Name and Principal</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Salary</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Bonus</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Awards</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">sation</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Position</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Year</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">($)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">($)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">($)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)<sup>(1)</sup></b></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">Christopher Missling, PhD</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">2025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">723,485</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">140,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">3,083,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">12,600</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">3,959,085</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">President, Chief Executive Officer, and</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">700,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,927,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,783,700</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">700,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">124,753</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,066,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,894,453</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Sandra Boenisch<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199,858</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,709</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">308,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,503</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">555,270</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Principal Financial Officer and Treasurer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">201,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">192,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,059</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">402,227</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; font-size: 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">186,883</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">306,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,475</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">501,058</td><td style="text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px">(1)</td><td>Comprised of employer matching of defined contribution savings plans.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1cm; text-indent: -21.8pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px">(2)</td><td>Compensation to Ms. Boenisch denominated in Canadian Dollars and has been translated to US dollars at an exchange rate of 0.714188
during the year ended September 30, 2025 (2024: 0.73733; 2023: 0.7416).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1cm; text-indent: -21.8pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employment Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Christopher Missling</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We and Dr. Missling entered into an employment agreement
dated July 5, 2013, as amended and extended most recently by the fourth amendment effective July 5, 2025 (the &#8220;CEO Employment Agreement&#8221;),
whereby we currently pay Dr. Missling an annual base salary of $800,000. In addition, Dr. Missling is eligible to earn an annual cash
bonus for each whole or partial calendar year of up to twenty percent of his base salary, and to participate in our employee benefit plans.
We have agreed to indemnify Dr. Missling in connection with his provision of services to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Sandra Boenisch</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We and Ms. Boenisch entered into an amended and restated
employment agreement dated October 4, 2017, as amended and extended most recently by the third amendment effective July 5, 2025, whereby
we currently pay Ms. Boenisch an annual base salary of $279,840 Canadian dollars. In addition, Ms. Boenisch is eligible to earn an annual
cash bonus for each whole or partial calendar year of up to twenty percent of her base salary, and to participate in our employee benefit
plans. Ms. Boenisch is eligible for discretionary salary increases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Grants of Plan Based Awards</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the awards granted
for each named executive officer during the year ended September 30, 2025 under our 2022 Omnibus Incentive Plan:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 106; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="11" style="font-weight: bold; text-align: center">All other option awards</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Name</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Grant Date</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of securities underlying options (#)<sup>(1)</sup></b></span></td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Exercise or base price of option award ($/sh)</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center"><b>&#160;</b><b>&#160;</b><b>Grant date fair value of option awards ($) <sup>(2)</sup></b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 31%; text-align: left; text-indent: -10pt">Christopher Missling, PhD</td><td style="width: 3%">&#160;</td>
    <td style="width: 15%; text-align: center; padding-left: 2.25pt">March 31, 2025</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">500,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8.58</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,083,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Sandra Boenisch <sup>&#160;</sup> &#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 2.25pt">March 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">308,200</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(1) <span style="letter-spacing: -0.05pt">Represents</span><span style="letter-spacing: -0.45pt">&#160;</span><span style="letter-spacing: -0.05pt">shares</span><span style="letter-spacing: -0.4pt">&#160;</span><span style="letter-spacing: -0.05pt">of</span><span style="letter-spacing: -0.4pt">&#160;</span><span style="letter-spacing: -0.05pt">our</span><span style="letter-spacing: -0.4pt">&#160;</span><span style="letter-spacing: -0.05pt">common</span><span style="letter-spacing: -0.4pt">&#160;</span><span style="letter-spacing: -0.05pt">stock</span><span style="letter-spacing: -0.4pt">&#160;</span><span style="letter-spacing: -0.05pt">underlying</span><span style="letter-spacing: -0.4pt">&#160;</span><span style="letter-spacing: -0.05pt">options</span><span style="letter-spacing: -0.4pt">&#160;</span><span style="letter-spacing: -0.05pt">awarded,</span><span style="letter-spacing: -0.45pt">&#160;</span><span style="letter-spacing: -0.05pt">each</span><span style="letter-spacing: -0.4pt">&#160;</span><span style="letter-spacing: -0.05pt">of</span><span style="letter-spacing: -0.4pt">&#160;</span><span style="letter-spacing: -0.05pt">which</span><span style="letter-spacing: -0.4pt">&#160;</span><span style="letter-spacing: -0.05pt">vest</span><span style="letter-spacing: -0.4pt">&#160;</span><span style="letter-spacing: -0.05pt">over</span><span style="letter-spacing: -0.4pt">&#160;</span><span style="letter-spacing: -0.05pt">time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(2) <span style="letter-spacing: -0.05pt">Represents</span><span style="letter-spacing: 0.15pt">&#160;</span><span style="letter-spacing: -0.05pt">the</span><span style="letter-spacing: 0.15pt">&#160;</span><span style="letter-spacing: -0.05pt">fair</span><span style="letter-spacing: 0.2pt">&#160;</span><span style="letter-spacing: -0.05pt">value</span><span style="letter-spacing: 0.15pt">&#160;</span><span style="letter-spacing: -0.05pt">of</span><span style="letter-spacing: 0.15pt">&#160;</span><span style="letter-spacing: -0.05pt">each</span><span style="letter-spacing: 0.2pt">&#160;</span><span style="letter-spacing: -0.05pt">equity</span><span style="letter-spacing: 0.15pt">&#160;</span><span style="letter-spacing: -0.05pt">award</span><span style="letter-spacing: 0.2pt">&#160;</span><span style="letter-spacing: -0.05pt">on</span><span style="letter-spacing: 0.15pt">&#160;</span><span style="letter-spacing: -0.05pt">the</span><span style="letter-spacing: 0.15pt">&#160;</span><span style="letter-spacing: -0.05pt">date</span><span style="letter-spacing: 0.2pt">&#160;</span><span style="letter-spacing: -0.05pt">of</span><span style="letter-spacing: 0.15pt">&#160;</span><span style="letter-spacing: -0.05pt">grant,</span><span style="letter-spacing: 0.2pt">&#160;</span><span style="letter-spacing: -0.05pt">as</span><span style="letter-spacing: 0.15pt">&#160;</span><span style="letter-spacing: -0.05pt">computed</span><span style="letter-spacing: 0.15pt">&#160;</span><span style="letter-spacing: -0.05pt">in</span><span style="letter-spacing: 0.2pt">&#160;</span><span style="letter-spacing: -0.05pt">accordance</span><span style="letter-spacing: 0.15pt">&#160;</span><span style="letter-spacing: -0.05pt">with</span><span style="letter-spacing: 0.2pt">&#160;</span><span style="letter-spacing: -0.05pt">FASB</span><span style="letter-spacing: 0.15pt">&#160;</span><span style="letter-spacing: -0.05pt">ASC</span><span style="letter-spacing: 0.15pt">&#160;</span><span style="letter-spacing: -0.05pt">718.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Outstanding Equity Awards at Fiscal Year-End
</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth for each named executive
officer and director certain information concerning the outstanding equity awards as of September 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="21" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Awards</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Equity</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Incentive</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Plan</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Awards:</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Securities</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Securities</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Securities</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Underlying</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Underlying</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Underlying</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Option</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Exercisable<br/>
Options</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Unexercisable<br/>
Options</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Unexercised<br/>
Unearned<br/>
Options</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Exercise <br/>
Price</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Option<br/>
 Expiration</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Name</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center">(#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center">(#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center">(#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center">($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; width: 27%; text-indent: -10pt">Christopher</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">379,625</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">6.26</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 5, 2026</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Missling</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">861,429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.06</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 18, 2026</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 22, 2026</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 12, 2027</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 13, 2027</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 15, 2028</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">409,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 1, 2028</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">750,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 3, 2029</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">550,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 6, 2030</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">550,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.49</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 30, 2030</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2, 2031</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">333,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.54</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2032</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.09</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 27, 2032</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2033</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">375,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 20, 2034</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">125,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">375,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">8.58</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2035</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Sandra Boenisch</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 13, 2027</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 15, 2028</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 1, 2028</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 4, 2029</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 6, 2030</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.49</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 30, 2030</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2, 2031</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.09</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 27, 2032</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2033</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 20, 2034</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2035</span></td><td style="text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 107; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 31, 2025, our Compensation Committee granted
options to our Chief Executive Officer and Principal Financial Officer, which vest in four equal tranches based on four performance milestones
including 1) the Company engaging in a second Regulatory dialogue for blarcamesine, 2) the publication of preclinical blarcamesine prevention
Alzheimer&#8217;s disease data, 3) the publication of blarcamesine clinical/biomarker Alzheimer&#8217;s disease data and 4) the Company
entering into a collaboration or licensing agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Option Exercises and Stock Vested</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth for each named executive
officer awards that were exercised during the year ended September 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Awards</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Name</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of shares acquired on exercise (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value realized on exercise ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Christopher Missling</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">687,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">5,161,206</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Sandra Boenisch</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Nonqualified Defined Contribution and Other
Nonqualified Deferred Compensation Plans</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There was no nonqualified deferred compensation for
our named executive officers in fiscal 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>CEO Pay Ratio Disclosure</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are providing the following information about the
relationship of the annual total compensation of our employees and the annual total compensation of our CEO. Based on the information
for fiscal 2025, we reasonably estimate that the ratio of our CEO&#8217;s annual total compensation to the annual total compensation of
our median employee was 16:1. Our pay ratio estimate has been calculated in a manner consistent with Item 402(u) of Regulation S-K using
the data and assumptions summarized below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We identified the median employee by examining the
2025 annual base salary compensation for all individuals,<span style="letter-spacing: -0.3pt">&#160;</span>excluding<span style="letter-spacing: -0.3pt">&#160;</span>our
<span style="letter-spacing: -0.25pt">CEO</span>. We excluded independent contractors retained on an as needed basis, whose compensation
is determined by an unaffiliated third party, and who are therefore are not considered our employees for purposes of the pay ratio calculation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We<span style="letter-spacing: -0.3pt">&#160;</span>included<span style="letter-spacing: 0.05pt">&#160;</span>all
employees who were employed by us as of September 30, 2025. We selected the determination date and measurement period because this was
the most recent period for which employee census and compensation information was readily available. Salaries and wages were annualized
for those employees who were not employed for the full year of fiscal 2025. We selected annual base salary as our compensation measure
because it is readily available in our existing payroll systems, it is consistently calculated for each employee, and because it is a
reasonable proxy for total compensation for purposes of determining the median employee. We did not apply any cost-of-living adjustments
to the compensation of employees in jurisdictions other than the jurisdiction in which the CEO resides.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Once we identified our median employee, we calculated
such employee&#8217;s annual total compensation for fiscal 2025 in accordance with the requirements of Item 402(c)(2)(x) of Regulation
S-K, resulting in that employee&#8217;s annual total compensation of $248,195. The median employee&#8217;s annual total compensation includes
annualized base salary, annualized bonus, annualized 401(k) or RRSP matching contributions, and the fair value of awards granted during
the fiscal year ended September 30, 2025 under our 2022 Omnibus Incentive Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With respect to the CEO, we used the amount reported
as total compensation in the Summary Compensation Table included above. Any estimates and assumptions used to calculate total annual compensation
are described in footnotes to the Summary Compensation Table.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 108; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Compensation of Directors </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below shows the compensation of our directors
who were not our named executive officers for the fiscal year ended September 30, 2025:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Name</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fees Earned or Paid in Cash<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center">Stock&#160;<br/> Awards&#160;<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>&#160;</b><b>&#160;</b><b>Option&#160;<br/> Awards&#160;<br/> ($) <sup>(1)</sup></b></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-Equity Incentive Plan Compensation ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nonqualified Deferred Compensation Earnings ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All Other Compensation&#160;($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Total&#160;<br/> ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 37%; text-align: left; text-indent: -10pt">Jiong Ma</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">41,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">323,060</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">364,060</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Claus van der Velden</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">323,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">364,060</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Athanasios Skarpelos</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">323,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">348,060</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Steffen Thomas</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">323,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">348,060</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Peter Donhauser</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">323,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">348,060</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Includes stock option awards valued based on the
aggregate grant date fair value of the award computed in accordance with FASB ASC Topic 718. The amounts shown in the table above do not
necessarily reflect the actual value that may be realized by the&#160;non-employee&#160;director upon vesting. On September 30, 2025,
the aggregate number of outstanding vested and unvested stock option awards held by each director was as follows: Dr. Ma possessed options
to purchase 260,000 shares, Dr. van der Velden possessed options to purchase 405,500 shares, Mr. Skarpelos possessed options to purchase
455,500 shares, Dr. Thomas possessed options to purchase 455,500 shares and Dr. Donhauser possessed options to purchase 405,500 shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently compensate non-employee directors $25,000
per year, paid quarterly. We compensate Dr. Ma an additional $4,000 per quarter for acting as Chair. We compensate Claus van der Velden
an additional $4,000 per quarter for performing the functions of Chairman of the Audit Committee, Compensation Committee and Nominating
and Corporate Governance Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We regularly grant members of the Board of Directors
awards of options. Each Board member is granted options initially when they join the Board of Directors, which typically vest over a three-year
period. Additionally, we grant awards on an annual basis. Annual awards of options typically vest over three years. In 2025, the annual
grant was 50,000 options to each director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, directors are entitled to reimbursement
for reasonable travel and other out-of-pocket expenses incurred in connection with attendance at meetings of our Board of Directors. Our
Board of Directors may award further special remuneration to any director undertaking any special services on our behalf other than services
ordinarily required of a director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Retirement or Similar Benefit Plans</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are no arrangements or plans in which we provide
retirement or similar benefits for our directors. Executive officers are eligible for the broad-based retirement plans described more
fully above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Resignation, Retirement, Other Termination,
or Change in Control Arrangements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Potential Payments Upon Termination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is a party to employment contracts with
our Chief Executive Officer and Principal Financial Officer that contain provisions for payment of severance upon termination by either
the Company without cause or by the employee for good reason. General terms of these arrangements are described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 109; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our CEO Employment Agreement with Dr. Missling contains
provisions regarding our obligations upon his termination and upon a Change in Control. Any capitalized term not defined herein is used
as defined in the CEO Employment Agreement. If Dr. Missling&#8217;s employment is terminated by us without Cause, he is entitled to receive
payments by us consisting of (i) reimbursement of any unpaid business expenses to which he is entitled to reimbursement that were incurred
prior to the effective date of his termination, (ii) all vested compensation and benefits to which he is entitled as of the Termination
Date, (iii) a severance payment consisting of the three times the sum of (a) his annual salary in effect at the time of termination and
(b) the average of the annual Bonuses payable to him for the last three completed calendar years prior to the Termination Date, (iv) all
outstanding and unvested stock options and all options previously vested will become and remain exercisable for no less than three years
from the Termination Date; (v) all of his unvested and outstanding restricted stock, restricted stock units or other equity awards that
are unvested and outstanding as of the Termination Date shall vest and be settled within ten business days after the Termination Date,
(vi) life insurance coverage until the end of the term of the CEO Employment Agreement; and (vii) continued participation in all medical,
dental and hospitalization benefits plans or programs for Dr. Missling and his eligible dependents for 36 months or until he receives
similar benefits at a new employer, at his sole cost. If Dr. Missling&#8217;s employment is terminated by him for Good Reason, he is entitled
to receive the same as the above, however the severance payment will consist of three times his annual salary in effect at the time of
termination and two times the average annual Bonuses payable to him for the last three completed calendar years prior to the Termination
Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If Dr. Missling was terminated by the Company without
cause on September 30, 2025, he would have been entitled to a severance payment of $2.8 million. If Dr. Missling terminated his employment
for Good Reason on September 30, 2025, he would have been entitled to a severance payment of $2.7 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our CFO Employment Agreement with Ms. Boenisch contains
provisions regarding our obligations upon her termination. Any capitalized term not defined herein is used as defined in the CFO Employment
Agreement. Under the CFO Employment Agreement, if Ms. Boenisch is terminated without Cause, the Company shall pay Ms. Boenisch severance
compensation equal to twelve months base salary payable by the Company for the twelve-month period following the Termination. In addition,
the Company must provide Ms. Boenisch thirty (30) day notice of her Termination. If the Company opts to have Ms. Boenisch cease providing
services to the Company prior to the expiration of the thirty (30) day notice-period (the &#8220;Notice Period&#8221;), Ms. Boenisch shall
receive the Compensation and Benefits for the full length of the Notice Period as if such period was not waived. In addition, any unvested
stock options or stock awards vesting in the contract year of Termination held by Ms. Boenisch as of the Date of Termination shall immediately
vest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If Ms. Boenisch was terminated by the Company without
cause on September 30, 2025, she would have been entitled to continued salary payments equal to $0.2 million in total.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents accelerated vesting for
certain equity awards outstanding at the time of the executive&#8217;s termination for each Named Executive Officer, if employment were
terminated by either the Company without cause or by Dr. Missling for good reason on September 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">Vesting Upon Termination</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Named Executive Officer</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Unvested Stock Options (#)</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center"><b>Stock Option Awards</b> <b>&#160;</b> <b>Estimated Benefit ($)<sup>(1)</sup></b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Dr. Christopher Missling</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">2,083,333</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">1,983,333</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Sandra Boenisch</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Estimated benefit based on the closing stock price
of $8.90 at September 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) Ms. Boenisch&#8217;s unvested stock options at
September 30, 2025 all contained performance based vesting conditions, therefore such options would not automatically vest upon Termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 110; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Potential Payments Upon Change in Control</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the Company is subject to a Change in Control,
then the CEO Employment Agreement and the CFO Employment Agreement provide that all previously granted but unvested stock options held
by Dr. Missling and Ms. Boenisch shall vest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents accelerated vesting for
certain equity awards outstanding to the Named Executive Officer, if a change in control had occurred at September 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">Vesting Due to Change in Control</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Named Executive Officer</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Unvested Stock Options (#)</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center"><b>Stock Option Awards<br/> Estimated Benefit ($)<sup>(1)</sup></b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Dr. Christopher Missling</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">2,083,333</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">1,983,333</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Sandra Boenisch</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">160,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">153,000</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Estimated benefit based on the closing stock price
of $8.90 at September 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>For a complete description of these terms and conditions please refer
to the CEO Employment Agreement and CFO Employment Agreement (and their amendments) filed as exhibits to this Annual Report on Form 10-K.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_022"></span>ITEM 12. SECURITY OWNERSHIP
OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth, as of November 24, 2025, certain information
with respect to the beneficial ownership of our common stock by each stockholder known by us to be the beneficial owner of more than 5%
of our common stock and by each of our current directors and our named executive officers and by our current directors and executive officers
as a group. We have determined the number and percentage of shares beneficially owned by such person in accordance with Rule 13d-3 under
the Securities Exchange Act of 1934. This information does not necessarily indicate beneficial ownership for any other purpose.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Title of class</td>
<td>&#160;</td>
<td style="text-align: center">Name and address of<br/> beneficial owner</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">Amount and nature of<br/> beneficial ownership</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percent of<br/> class <sup>(1)</sup></span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="11" style="font-weight: bold; text-align: left">Directors and Named Executive Officers</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 22%; text-align: left; text-indent: -10pt">Common Stock</td>
<td style="width: 5%">&#160;</td>
<td style="width: 21%; text-align: left; padding-left: 2.25pt">Christopher Missling (CEO/Director)</td>
<td style="width: 5%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 19%; text-align: right">7,727,386</td>
<td style="width: 1%; text-align: left"><sup>(2)</sup></td>
<td style="width: 5%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 19%; text-align: right">8.1</td>
<td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Common Stock</td>
<td>&#160;</td>
<td style="text-align: left; padding-left: 2.25pt">Jiong Ma (Director, Chair)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">160,001</td>
<td style="text-align: left"><sup>(3)</sup></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Common Stock</td>
<td>&#160;</td>
<td style="text-align: left; padding-left: 2.25pt">Claus van der Velden (Director)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">305,501</td>
<td style="text-align: left"><sup>(4)</sup></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Common Stock</td>
<td>&#160;</td>
<td style="text-align: left; padding-left: 2.25pt">Athanasios Skarpelos (Director)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,661,959</td>
<td style="text-align: left"><sup>(5)</sup></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1.9</td>
<td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Common Stock</td>
<td>&#160;</td>
<td style="text-align: left; padding-left: 2.25pt">Steffen Thomas (Director)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">399,152</td>
<td style="text-align: left"><sup>(6)</sup></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Common Stock</td>
<td>&#160;</td>
<td style="text-align: left; padding-left: 2.25pt">Peter Donhauser (Director)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">310,501</td>
<td style="text-align: left"><sup>(7)</sup></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Common Stock</td>
<td>&#160;</td>
<td style="text-align: left; padding-left: 2.25pt">Sandra Boenisch (Principal Financial Officer)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">335,262</td>
<td style="text-align: left"><sup>(8)</sup></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Common Stock</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left; padding-left: 2.25pt">Directors &amp; Executive Officers as a group (7 persons)</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right">10,899,762</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right">11.2</td>
<td style="font-weight: bold; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; font-weight: bold; text-indent: -10pt">5% Holders</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Common Stock</td>
<td>&#160;</td>
<td style="text-align: left; padding-left: 2.25pt">BlackRock, Inc.<br/> 55 East 52<sup>nd</sup> Street<br/> New York, NY 10055</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">6,671,075</td>
<td style="text-align: left"><sup>(9)</sup></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">7.5</td>
<td style="text-align: left">%</td></tr>
</table>



<p style="margin: 0"></p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">*Less than 1%</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 111; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">(1)</td><td style="text-align: justify">Percentage of ownership is based on 89,348,107 of our common stock issued and outstanding as of November
24, 2025. Except as otherwise indicated, we believe that the beneficial owners of the common stock listed above, based on information
furnished by such owners, have sole investment and voting power with respect to such shares, subject to community property laws where
applicable. Beneficial ownership is determined in accordance with the rules of the Commission and generally includes voting or investment
power with respect to securities. Shares of common stock subject to options or warrants currently exercisable or exercisable within 60
days, are deemed outstanding for purposes of computing the percentage ownership of the person holding such option or warrants but are
not deemed outstanding for purposes of computing the percentage ownership of any other person.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">(2)</td><td style="text-align: justify">Includes options to purchase 379,625 shares of our common stock at $6.26 per share, options to purchase
861,429 shares of our common stock at $7.06 per share, options to purchase 500,000 shares of our common stock at $3.28 per share, options
to purchase 450,000 shares of our common stock at $5.92 per share, options to purchase 400,000 shares of our common stock at $3.30 per
share, options to purchase 450,000 shares of our common stock at $2.30 per share, options to purchase 409,500 shares of our common stock
at $2.58 per share, options to purchase 750,000 shares of our common stock at $3.15 per share, options to purchase 550,000 shares of our
common stock at $2.96 per share, options to purchase 550,000 shares of our common stock at $5.49 per share, options to purchase 166,667
shares of our common stock at $7.54 per share, options to purchase 250,000 shares of our common stock at $10.09 per share, options to
purchase 250,000 shares of our common stock at $8.57 per share, options to purchase 125,000 shares of our common stock at $5.36 per share
and options to purchase 125,000 shares of our common stock at $8.58 per share that are vested or are vesting within 60 days. Excludes
options to purchase 500,000 shares of our common stock at $18.11 per share, options to purchase 333,333 shares of our common stock at
$7.54 per share, options to purchase 250,000 shares of our common stock at $10.09 per share, options to purchase 250,000 shares at $8.57
per share, options to purchase 375,000 shares of common stock at $5.36 per share and options to purchase 375,000 shares of our common
stock at $8.58 per share that do not vest within 60 days.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">(3)</td><td style="text-align: justify">Includes options to purchase 35,000 shares of our common stock at $13.01 per share, options to purchase
25,000 shares of our common stock at $18.11 per share, options to purchase 50,000 shares of our common stock at $10.09 per share, options
to purchase 33,334 shares of our common stock at $8.57 per share and options to purchase 16,667 shares of our common stock at $5.36 per
share that have vested or are vesting within 60 days. Excludes options to purchase 16,666 shares of our common stock at $8.57 per share,
options to purchase 33,333 shares of our common stock at $5.36 per share and options to purchase 50,000 shares of common stock at $8.58
per share that do not vest within 60 days.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">(4)</td><td style="text-align: justify">Includes options to purchase 50,000 shares of our common stock at $2.60 per share, options to purchase
45,500 shares of our common stock at $2.58 per share, options to purchase 50,000 shares of our common stock at $2.96 per share, options
to purchase 35,000 shares of our common stock at $5.49 per share, options to purchase 25,000 shares of our common stock at $18.11 per
share, options to purchase 50,000 shares of our common stock at $10.09 per share, options to purchase 33,334 shares of our common stock
at $8.57 per share and options to purchase 16,667 shares of our common stock at $5.36 per share that have vested or are vesting within
60 days. Excludes options to purchase 16,666 shares of our common stock at $8.57 per share, options to purchase 33,333 shares of our common
stock at $5.36 per share and options to purchase 50,000 shares of common stock at $8.58 per share that do not vest within 60 days.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">(5)</td><td style="text-align: justify">Includes options to purchase 100,000 shares of our common stock at $3.28 per share, options to purchase
45,500 shares of our common stock at $2.58 per share, options to purchase 50,000 shares of our common stock at $2.96 per share, options
to purchase 35,000 shares of our common stock at $5.49 per share, options to purchase 25,000 shares of our common stock at $18.11 per
share, options to purchase 50,000 shares of our common stock at $10.09 per share, options to purchase 33,334 shares of our common stock
at $8.57 per share and options to purchase 16,667 shares of our common stock at $5.36 per share that have vested or are vesting within
60 days. Excludes options to purchase 16,666 shares of our common stock at $8.57 per share, options to purchase 33,333 shares of our common
stock at $5.36 per share and options to purchase 50,000 shares of common stock at $8.58 per share that do not vest within 60 days.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"></p>

<!-- Field: Page; Sequence: 112; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">(6)</td><td style="text-align: justify">Includes options to purchase 100,000 shares of our common stock at $3.28 per share, options to purchase
45,500 shares of our common stock at $2.58 per share, options to purchase 50,000 shares of our common stock at $2.96 per share, options
to purchase 35,000 shares of our common stock at $5.49 per share, options to purchase 25,000 shares of our common stock at $18.11 per
share, options to purchase 50,000 shares of our common stock at $10.09 per share, options to purchase 33,334 shares of our common stock
at $8.57 per share and options to purchase 16,667 shares of our common stock at $5.36 per share that have vested or are vesting within
60 days. Excludes options to purchase 16,666 shares of our common stock at $8.57 per share, options to purchase 33,333 shares of our common
stock at $5.36 per share and options to purchase 50,000 shares of common stock at $8.58 per share that do not vest within 60 days.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">(7)</td><td style="text-align: justify">Includes options to purchase 50,000 shares of our common stock at $5.39 per share, options to purchase
45,500 shares of our common stock at $2.58 per share, options to purchase 50,000 shares of our common stock at $2.96 per share, options
to purchase 35,000 shares of our common stock at $5.49 per share, options to purchase 25,000 shares of our common stock at $18.11 per
share, options to purchase 50,000 shares of our common stock at $10.09 per share, options to purchase 33,334 shares of our common stock
at $8.57 per share and options to purchase 16,667 shares of our common stock at $5.36 per share that have vested or are vesting within
60 days. Excludes options to purchase 16,666 shares of our common stock at $8.57 per share, options to purchase 33,333 shares of our common
stock at $5.36 per share and options to purchase 50,000 shares of common stock at $8.58 per share that do not vest within 60 days.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">(8)</td><td style="text-align: justify">Includes options to purchase 30,000 shares of our common stock at $3.30 per share, options to purchase
30,000 shares of our common stock at $2.30 per share, options to purchase 27,300 shares of our common stock at $2.58 per share, options
to purchase 35,000 shares of our common stock at $2.93 per share, options to purchase 70,000 shares of our common stock at $2.96 per share,
options to purchase 50,000 shares of our common stock at $5.49 per share, options to purchase 20,000 shares of common stock at $10.09
per share, options to purchase 25,000 shares of our common stock at $8.57 per share, options to purchase 12,500 shares of our common
stock at $5.36 per share and options to purchase 12,500 shares of our common stock at $8.58 per share that have vested or are vesting
within 60 days. Excludes options to purchase 40,000 shares of our common stock at $18.11 per share, options to purchase 20,000 shares
of our common stock at $10.09 per share, options to purchase 25,000 shares of our common stock at $8.57 per share, options to purchase
37,500 shares of common stock at $5.36 per share and options to purchase 37,500 shares of our common stock at $8.58 per share that do
not vest within 60 days.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">(9)</td><td>Based on Schedule 13G/A as filed with the SEC and dated on January 25, 2024.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Change in Control</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are unaware of any contract or other arrangement, the operation of which
may at a subsequent date result in a change of control of our Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Securities Authorized for Issuance under Equity Compensation Plans
or Individual Compensation Arrangements </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes certain information regarding our equity
compensation plan or individual compensation arrangements at September 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 113; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="13" style="font-weight: bold; text-align: left">Equity Compensation Plan Information</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Plan Category</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Number of securities to be issued upon exercise of outstanding options, warrants and rights<br/> (a)</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted-average exercise price of outstanding options, warrants and rights<br/> (b)</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Number of securities remaining available for future issuances under equity compensation plans (excluding securities reflected in column (a))<br/> (c)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Equity compensation plans approved by security holders</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">26,050,553</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">7.25</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">8,436,882</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Equity compensation plans not approved by security holders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; font-weight: bold; text-indent: -10pt">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">26,050,553</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">7.25</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">8,436,882</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2022 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, 10,000,000 additional shares of Common Stock will be available for issuance under the 2022 Plan, in addition to the shares available
under the 2019 Plan and the 2015 Plan. Any awards outstanding under a previous stock option plan will remain subject to and be paid under
such plan, and any shares subject to outstanding awards under a previous plan that subsequently cease to be subject to such awards (other
than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant and shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date,
then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date.
Stock options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such
lesser periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 17, 2025, the Board approved an amendment
to the 2022 Plan (the &#8220;Amendment&#8221;). The Amendment was approved by the stockholders on June 10, 2025. The Amendment increased
the number of shares of common stock reserved for issuance under the 2022 Plan by 4,000,000 shares for a total of 14,000,000. In addition,
the Amendment established a minimum vesting period of one year for all awards granted under the 2022 Plan and limited the discretion to
accelerate the vesting of awards upon a separation from service, with limited exceptions permitted. Finally, the Amendment prohibited
liberal share recycling provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The purpose of the 2022 Plan is to retain the services
of valued key employees and consultants of our Company and such other persons, and to encourage such persons to acquire a greater proprietary
interest in our Company, thereby strengthening their incentive to achieve the objectives of the stockholders of our Company. The purpose
is also to serve as an aid and inducement in the hiring of new employees and to provide an equity incentive to consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 114; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_023"></span>ITEM 13. CERTAIN RELATIONSHIPS
AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Transactions with related persons</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There has not been nor is there currently proposed
any transaction or series of similar transactions requiring disclosure in this Annual Report to which we were or are a party in which
any director, executive officer, holder of more than 5% of our Common Stock or any member of the immediate family of any of the foregoing
persons had or will have a direct or indirect material interest, other than compensation for legal services, described below, and compensation
agreements and other arrangements which are described in &#8220;Item 11. Executive Compensation&#8221; and &#8220;Item 12. Security Ownership
of Certain Beneficial Owners and Management&#8221;. In accordance with the charter of the Company&#8217;s Audit Committee, the Company&#8217;s
policy is to require that any related party transactions be reviewed and approved by the Audit Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Legal Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2025, the brother
of our CEO provided legal services to the Company. In exchange for these services, the Company paid $88,541 to the brother of our CEO
and issued options to purchase 50,000 shares of our common stock at $8.58 per share. The grant date fair value of the options was $308,200
computed in accordance with FASB ASC Topic 718. The value does not necessarily reflect the actual value that may be realized by the&#160;related
party upon vesting. The options vest in four equal tranches based on four performance milestones.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All such services provided by the related party to
the Company were made in the ordinary course of business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Compensation of Named Executive Officers and
Directors</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For information regarding compensation of named executive
officers and directors, please see &#8220;Item 11. Executive Compensation.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Director Independence</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the NASDAQ Stock Market Rules, the Board has
a responsibility to make an affirmative determination that those members of its Board that serve as independent directors do not have
any relationships with the Company and its businesses that would impair their independence. The Board has determined that that Christopher
Missling, PhD is not independent, as that term is defined by NASDAQ 5605(a)(2), because Mr. Missling serves as our President, Chief Executive
Officer, and Secretary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board has determined that that Claus van der Velden,
Athanasios Skarpelos, Steffen Thomas, Peter Donhauser and Jiong Ma are independent, as that term is defined by NASDAQ 5605(a)(2) and the
applicable rules of the Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_024"></span>ITEM 14. PRINCIPAL ACCOUNTING
FEES AND SERVICES</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Fees Paid to Our Independent Registered Public
Accounting Firm </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the aggregate fees
billed or expected to be billed to our Company for professional services rendered by our independent registered public accounting firm,
Grant Thornton, LLP for the fiscal years ended September 30, 2025 and 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Audit Fees</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">523,950</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">446,250</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Audit Related Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Tax Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All Other Fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Fees</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">523,950</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">446,250</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 115; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Audit Fees.</i></b> Consist of fees billed for
professional services rendered for the audits of our financial statements, reviews of our interim financial statements included in quarterly
reports, services performed in connection with regular filings with the Commission, including comfort and consent letters for the fiscal
years ended September 30, 2025 and 2024 in connection with statutory and regulatory filings or engagements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Policy on Pre-Approval by Audit Committee of
Services Performed by Independent Registered Public Accounting Firm </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Audit Committee pre-approves all services provided
by our independent registered public accounting firm. All of the above services and fees were reviewed and approved by our Audit Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Audit Committee has considered the nature and
amount of fees billed or expected to be billed by Grant Thornton LLP and believes that the provision of services for activities unrelated
to the audit was compatible with maintaining Grant Thornton LLP&#8217;s independence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 116; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_025"></span>PART IV</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_026"></span>ITEM 15. EXHIBITS, FINANCIAL
STATEMENT SCHEDULES</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="border-bottom: Black 1pt solid; width: 10%; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit <br/> Number </b></span></td>
<td style="border-bottom: Black 1pt solid; padding: 0pt; text-align: justify; width: 90%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><br/>Description</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(1)</b></span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underwriting Agreement</b></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.1</b></span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112225001033/e6735_ex1-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales Agreement, dated July 25, 2025, by and between the Company and TD Securities (USA) LLC (incorporated by reference to our Current Report on Form 8-K filed on July 28, 2025)</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(3) </b></span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Articles of Incorporation and Bylaws </b></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1 </span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112221002062/e3306_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Articles of Incorporation, as amended (incorporated by reference to our Annual Report on Form 10-K for the year ended September 30, 2021 filed on November 24, 2021)</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112223000651/e4593_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated <span style="background-color: white">Bylaws (incorporated by reference to our Current Report on Form 8-K filed on April 14, 2023)</span></span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(4)</b></span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Instruments Defining the Rights of Security Holders</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">4.1</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112222002062/e4251_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Description of Registrant</span><span style="background-color: white">&#8217;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s Securities (incorporated by reference to our Annual Report on Form 10-K filed on November 28, 2022)</span></span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">4.2</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112223000152/e4385_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Registration Rights Agreement, dated February 3, 2023, by and between the Company and Lincoln Park Capital Fund, LLC</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to our Quarterly Report on Form 10-Q filed on February 7, 2023)</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(10) </b></span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material Contracts</b></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1&#x5E;</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577415003756/s102397_ex10-91.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015 Omnibus Incentive Plan (incorporated by reference to our Annual Report on Form 10-K filed on December 29, 2015)</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2&#x5E;</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577419002242/s115994_def14a.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019 Omnibus Incentive Plan (incorporated by reference to our Proxy Statement, dated February 11, 2019, as filed on February 11, 2019)</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3&#x5E;</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/0001314052/000173112222000703/e3687_def14a.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022 Omnibus Incentive Plan (incorporated by reference to our Registration Statement on Form S-8, as filed on June 10, 2022)</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112225000878/e6659_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No.1 to 2022 Omnibus Incentive Plan (incorporated by reference to our Current Report on Form 8-K filed on June 13, 2025)</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5&#x5E;</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000106299313004163/exhibit10-7.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated as of July 5, 2013, by and between the Company and Christopher Missling, PhD (incorporated by reference to our Quarterly Report on Form 10-Q filed on August 14, 2013)</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6&#x5E;</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577416006259/s103666_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to Employment Agreement, dated as of July 5, 2016, by and between the Company and Christopher Missling, PhD (incorporated by reference to our Current Report on Form 8-K filed on July 7, 2016)</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7&#x5E;</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577416006410/s103735_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated First Amendment to Employment Agreement, dated as of July 18, 2016, by and between the Company and Christopher Missling, PhD (incorporated by reference to our Current Report on Form 8-K filed on July 22, 2016)</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8&#x5E;</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/s118023_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amendment to Employment Agreement, dated as of May 3, 2019 by and between the Company and Christopher Missling, PhD (incorporated by reference to our Quarterly Report on Form 10-Q filed on May 9, 2019) </span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9&#x5E;</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112222000700/e3692_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third Amendment to Employment Agreement, dated April 7, 2022 by and between the Company and Christopher Missling, PhD (incorporated by reference to our Current Report on Form 8-K filed on April 8, 2022)</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10&#x5E;</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112225000935/e6684_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fourth Amendment to Employment Agreement, dated July 3, 2025, by and between the Company and Christopher Missling, PhD (incorporated by reference to our Current Report on Form 8-K filed on July 3, 2025)</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11&#x5E;</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577417007272/s108360_ex10-7.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Employment Agreement by and between the Company and with Sandra Boenisch (incorporated by reference to our Annual Report on Form 10-K filed on December 11, 2017)</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12&#x5E;</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112220000103/e1699_10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Amended and Restated Employment Agreement between the Company and Sandra Boenisch, dated February 4, 2020 (incorporated by reference to our Quarterly Report on Form 10-Q filed on February 6, 2020)</span></a></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 117; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 2.25pt; padding-left: 2.25pt; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13&#x5E;</span></td>
<td style="padding: 0pt; text-align: justify; width: 90%; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112222000366/e3562_10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 2 to Amended and Restated Employment Agreement between the Company and Sandra Boenisch, dated February 28, 2022 (incorporated by reference to our Current Report on Form 8-K filed on March 4, 2022)</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14&#x5E;</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112225000935/e6684_ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 3 to Amended and Restated Employment Agreement between the Company and Sandra Boenisch, dated July 3, 2025 (incorporated by reference to our Current Report on Form 8-K filed on July 3, 2025)</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112223000152/e4385_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase Agreement dated February 3, 2023 by and between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to our Quarterly Report on Form 10-Q filed on February 7, 2023)</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(14)</b></span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code of Ethics</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112223002197/e5240_ex14-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Ethics Adopted on August 1, 2023 (incorporated by reference to our Annual Report on Form 10-K filed on November 27, 2023)</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112224002041/e6219_ex19-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider Trading Policy (incorporated by reference to our Annual Report on Form 10-K filed on December 23, 2024)</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(21)</b></span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsidiaries</b></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="e7052_ex21-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries of the Registrant</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(23)</b></span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consent</b></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="e7052_ex23-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Independent Registered Public Accounting Firm</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(31) </b></span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 302 Certifications</b></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="e7052_ex31-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 302 Certification of Christopher Missling, PhD.</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="e7052_ex31-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 302 Certification of Sandra Boenisch</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(32) </b></span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 906 Certifications</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="e7052_ex32-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 906 Certification of Christopher Missling, PhD and Sandra Boenisch</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(97)</b></span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Policy Relating to Recovery of Erroneously Awarded Compensation</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112223002197/e5240_ex97-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex Life Sciences Corp. Compensation Clawback Policy (incorporated by reference to our Annual Report on Form 10-K filed on November 27, 2023)</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(101)</b></span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>XBRL</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL INSTANCE DOCUMENT</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL TAXONOMY EXTENSION SCHEMA</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL TAXONOMY EXTENSION CALCULATION LINKBASE</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL TAXONOMY EXTENSION DEFINITION LINKBASE</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL TAXONOMY EXTENSION LABEL LINKBASE</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr>
</table>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">* Filed herewith.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">** The certification attached as Exhibit 32.1 that accompanies
this Form 10-K is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Registrant under the
Securities Act or the Exchange Act, whether made before or after the date of this Form 10-K, irrespective of any general incorporation
language contained in such filing.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#x5E; Denotes a management contract or compensatory plan or arrangement.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><span style="font-style: normal"><span id="a_027"></span>ITEM 16. FORM 10-K SUMMARY</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">Not Applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"></p>

<!-- Field: Page; Sequence: 118; Value: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify; background-color: white"><span style="background-color: white">Pursuant
to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="background-color: white">
<td style="width: 50%">&#160;</td>
<td style="width: 7%">&#160;</td>
<td style="width: 43%">&#160;</td></tr>
<tr style="background-color: white">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date: November 25, 2025</b></span></td>
<td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANAVEX LIFE SCIENCES CORP.</b></span></td></tr>
<tr style="background-color: white">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="background-color: white">
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
<td style="border-bottom: Black 1pt solid; vertical-align: top"><i>/s/ Christopher Missling, PhD</i></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
<td style="vertical-align: bottom">Chief Executive Officer (Principal Executive Officer)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 28%">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Signatures</b></p></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 43%">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Title(s)</b></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 27%">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Date</b></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><i>/s/ Christopher Missling, PhD</i></p></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 25, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer (Principal Executive Officer) and Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 10pt; line-height: 115%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><i>/s/ Sandra Boenisch</i></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 25, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra Boenisch, CPA, CGA</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer and Treasurer (Principal Accounting Officer)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 10pt; line-height: 115%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><i>/s/ Jiong Ma, PhD</i></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 25, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiong Ma, PhD</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director, Chair</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 10pt; line-height: 115%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><i>/s/ Claus van der Velden, PhD</i></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 25, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claus van der Velden, PhD</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 10pt; line-height: 115%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><i>/s/Athanasios Skarpelos</i></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 25, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Athanasios Skarpelos</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 10pt; line-height: 115%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><i>/s/ Steffen Thomas, PhD</i></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 25, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steffen Thomas, PhD</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 10pt; line-height: 115%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><i>/s/ Peter Donhauser, D.O.</i></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 25, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter Donhauser, D.O.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 10pt; line-height: 115%">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">96</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p>



<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>e7052_ex21-1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-indent: 0pt; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21.1</B></FONT></P>

<P STYLE="text-indent: 0pt; font: 12pt/12pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSIDIARIES
OF THE REGISTRANT</B></FONT></P>

<P STYLE="font: 12pt/12pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; width: 2%; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="width: 48%; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.75pt; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of Subsidiary</B></FONT></TD>
<TD STYLE="line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.75pt; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction of Incorporation or Organization</B></FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex Australia Pty Limited</FONT></TD>
<TD STYLE="vertical-align: bottom; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex Germany GmbH</FONT></TD>
<TD STYLE="vertical-align: bottom; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex Canada Ltd.</FONT></TD>
<TD STYLE="vertical-align: bottom; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ontario, Canada</FONT></TD></TR>
</TABLE>

<P STYLE="text-indent: 0pt; font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>e7052_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-indent: 0pt; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 23.1</B>&nbsp;</FONT></P>

<P STYLE="margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have issued our reports dated November 25, 2025, with respect to the consolidated financial statements and internal control over
financial reporting included in the Annual Report of Anavex Life Sciences Corp. on Form 10-K for the year ended September&nbsp;30,
2025. We consent to the incorporation by reference of said reports in the Registration Statements of Anavex Life Sciences Corp. on
Form S-3 File No. 333-288661 and on Forms S-8 (File No. 333-219934, File No. 333-255166 and File No. 333-265537).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
GRANT THORNTON LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melville,
New York</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
25, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>e7052_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 31.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Christopher Missling, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this Annual Report on Form 10-K of Anavex Life Sciences Corp.;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify; width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and </FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions): </FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and </FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November
    25, 2025<BR>
    <BR>
    <I>/s/ Christopher Missling</I></FONT></TD>
    <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD
    </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer,
    President, Secretary<BR>
    (Principal Executive Officer)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>e7052_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 31.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Sandra Boenisch, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed
this Annual Report on Form 10-K of Anavex Life Sciences Corp.;</FONT></TD></TR>
<TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge,
this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;</FONT></TD></TR>
<TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge,
the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
<TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s
other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
<TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: top; width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles; &nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any
change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal
quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s
other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to
the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent
functions):</FONT></TD></TR>
<TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
                           November 25, 2025</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Sandra Boenisch</I></FONT></P></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra
    Boenisch, CPA, CGA</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Financial Officer, Treasurer<BR>
    (Principal Financial and Accounting Officer)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>e7052_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 32.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>18 U.S.C. SECTION 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Annual Report of Anavex Life
Sciences Corp. (the &ldquo;Company&rdquo;) on Form 10-K for the fiscal year ending September 30, 2025 as filed with the Securities and
Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), each of the undersigned, in the capacities and on the date indicated
below, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that
to the best of his or her knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
<TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 25, 2025 &nbsp;</FONT></TD>
<TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Christopher Missling</I></FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
Missling, PhD</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, President, Secretary<BR>
(Principal Executive Officer)<BR>
<BR>
<I>/s/ Sandra Boenisch&#9;</I></FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; &nbsp; &nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra
Boenisch, CPA, CGA</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
Financial Officer, Treasurer<BR> (Principal Financial and Accounting Officer)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing certification is being furnished solely
to accompany the Report pursuant to 18 U.S.C. &sect; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date
hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section
906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic
version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished
to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ;D$+0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@"$3$W9@V\!-V<^]354'_(5;_KE_6K= !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%->1(D9Y'5$49+,< "@!U%9H\0Z*TOE#6-/,G]P7*9_+-:*LKJ&
M1@RD9!!R"* %HHI&944LQ 4#))/ % "T5##=VUPQ6"XBE(&2$<-C\JFH **C
MEGBMTWS2I&N<;G8 9_&EBFBG3?%(DB'^)&!% #Z**AEN[:!PDUQ%&Y&0KN 3
M^= $U%-DD2)"\CJB#JS' %5_[3L/^?ZV_P"_J_XT 6J*KI?V<K!8[N!V/99
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[J.[FFD5I'B.Y$4'/WNA)('3WK1\$Z=-I_PLNVF0HUU%/< '^Z4P#^(4'\:
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M_@'_ /9US'@[7K'P[XTN[[4&=82LL>47<<EAV_"O2/\ A:_A?_GM=?\ ?@T
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M]A[&N'DC2'XYQQQ(J1I.BJJC  $0X H ]HHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /%_C+_R,.G_]>G_L[5>C^"X>-7_M_&X X^Q__9U1^,O_ ",.G_\
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M;'2&,CYCZ9Q^; 4 >YT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!)X;\,3WL !N7810Y&0&/?\   G\*Q_A5K?]I^%OL4CYGL&\OGJ8SRI_F/\
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M>A9B6./;)- &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M  I0?]# ?_ /_P"SKUCJ,BB@#YPD\+;/'(\-?;,_OQ#]H\KU&<[<_P!:[?\
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MH1FOM&T.2\%POE^<UI)(  >0I4@=>OT%=#\7-5>^URRT.VR_D ,Z+WD?[H_
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M (]NMM?C'HSVP:ZL+Z*?'*1A77/L21_*@#N-9U>UT+29]2O-_D0@%@@!8Y(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHV$-S(EQL5I 3@;0<5WG_""^%_\ H"VO_?)_QKE_@U_R+^H?]?7_ +(*])H
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M/C/XD0:WIK:-H4$\AN2$DE9,$C/W57J2:[#X<^&Y_#OAO;=KMN[I_.D3'*#
M 4^_?\: .OHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS:9:3Z2VEO"#9M#Y'ECLF,8'X5XJ\&O?"WQ"\\49GL)3MW'/ES)G@$_PL/\
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M3KCQEHMMXA70I+AQ?M(L>SRS@,P!'/3G(KSSX?Z-J7B#Q:_BK4D*PJ[2*Y7
MDD(P H_NCU]@*M_%'PM>_P!I1^)-,1W*A?/$8)9&7[K_ $P /;% '>:GX0\/
MZPS/>Z5;O(W61!L<_5EP37">)/A):Q6,]WHES*LD:E_L\Q#!@.<*W4'ZY_"C
M1OC'"MJD>LV$S3*,&:UP0_N5)&/SJ#Q!\7%O=/FL]'L9HY)E,?G3$94'CA1G
MG\: -'X1:_=7UG=Z3=2-(MJ%>!F.2%.05^@.,?6N>\0_\EQA_P"OVT_]!CKK
M/A9X7NM%TVXO[^-HKB\VA(F&&1!G&1V))Z>PKD_$/_)<8?\ K]M/_08Z .T^
M+-H]SX*:1%)%M<)*V.PY7_V84OPHOH[KP5%;*P\RTE>-E[C)+@_^/?I78WMG
M!J%C/9W*;X)T*.OJ#7B+P:]\+?$+SQ1F>PE.W<<^7,F> 3_"P_SD4 >ZUG:]
M?QZ7H%_>R.$$4#$$_P![' _$X%<9#\8M":W#36=_'+CE%16&?8[A_2N1\0>*
MM7^(=W%I&DV$B6N_<(@<LQ_O.W0 ?E]>* +WP9M';5]2O=IV1P"+=[LP./\
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M"-U% %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 4KW1],U*19+[3K2Z=1M5IX%<@>@)%70,# Z444 %
M%%% %*?1]+NKM;NXTVSEN5(*S20*SC'3#$9XJ[110 $9&#TJC::-I>GN[V6F
MV=LSKM9H8%0L/0X'(J]10!1L]%TK3IC-8Z99VLI7:7@@5&(],@=.!5ZBB@ J
M@="T@WOVPZ58FZW^9YYMTW[NN[=C.?>K]% #9(HYHVCE171AAE89!^HK#E\%
M>&II-[:)99_V8PH_(5O44 4M/TC3M*0K86-O; ]?*C"D_4CK5VBB@#*;PQH#
MN6;0],9F.23:1DD_E2?\(MX>_P"@#I?_ (!Q_P"%:U% &3_PBWA[_H Z7_X!
MQ_X5I000VL"06\210H,)'&H55'H .E244 %9DWAS0[B9YIM%TZ261BSN]JA9
MB>I)(Y-:=% &3_PBWA[_ * .E_\ @''_ (4J>&= C=730]-5U(*LMI&"#ZCB
MM6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:Z)+&T<BJZ,"K*PR"#U!%
M.HH J66E:=II<V%A:VIDQO\ (A5-V.F<#GJ:MT44 %1SV\-U \%Q#'-"XPT<
MBAE8>X/6I** *UEIUEIT;1V-G;VL;'<RP1*@)]2 *LT44 5+W2M.U(H;^PM;
MHQYV>?"K[<]<9''04RZT;2[U(DN]-LYUA7;$LL"L$'HN1P.!T]*O44 ,BBC@
MA2&&-(XD4*B(,*H'0 #H*?110!!=V-IJ$'DWMK!<Q9W>7-&'7/K@TEG86>G0
MF&QM(+:(MN*01A%)]<#OP*L44 9^H:'I6JD-?Z=:W+#HTD0+#\>M4X/!OANV
MD$D6BV89>06C#8_.MRB@!%4*H50 H& !T%5KW3;#4D1;ZRMKI4.5$\2N%/MD
M<5:HH R?^$6\/?\ 0!TO_P  X_\ "C_A%O#W_0!TO_P#C_PK6HH H6FAZ383
M^?9Z796TV,>9#;HC8],@5?HHH *H:CH>E:O@ZAI]M<LHPK2Q@L!['J*OT4 9
MFG^'=&TEQ)8:9:P2 8$B1C?_ -]=:TZ** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU?\ Y][;_OHT>;J__/O;?]]&@#2HK-\W5_\ GWMO^^C1YNK_ //O;?\ ?1H
MTJ*S?-U?_GWMO^^C1YNK_P#/O;?]]&@#2HK-\W5_^?>V_P"^C1YNK_\ /O;?
M]]&@#2HK-\W5_P#GWMO^^C1YNK_\^]M_WT: -*BLWS=7_P"?>V_[Z-'FZO\
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M17'_ /":-_SRC_(_XT?\)HW_ #RC_(_XT?7,/_.OO#ZK7_D9V%%<?_PFC?\
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M&=A17'_\)HW_ #RC_(_XT?\ ":-_SRC_ "/^-'US#_SK[P^JU_Y&=A17'_\
M":-_SRC_ "/^-'_":-_SRC_(_P"-'US#_P Z^\/JM?\ D9V%%<?_ ,)HW_/*
M/\C_ (T?\)HW_/*/\C_C1]<P_P#.OO#ZK7_D9V%%<?\ \)HW_/*/\C_C1_PF
MC?\ /*/\C_C1]<P_\Z^\/JM?^1G845Q__":-_P \H_R/^-'_  FC?\\H_P C
M_C1]<P_\Z^\/JM?^1G845Q__  FC?\\H_P C_C1_PFC?\\H_R/\ C1]<P_\
M.OO#ZK7_ )&=A17'_P#":-_SRC_(_P"-'_":-_SRC_(_XT?7,/\ SK[P^JU_
MY&=A17'_ /":-_SRC_(_XT?\)HW_ #RC_(_XT?7,/_.OO#ZK7_D9V%%<?_PF
MC?\ /*/\C_C1_P )HW_/*/\ (_XT?7,/_.OO#ZK7_D9V%%<?_P )HW_/*/\
M(_XT?\)HW_/*/\C_ (T?7,/_ #K[P^JU_P"1G845Q_\ PFC?\\H_R/\ C1_P
MFC?\\H_R/^-'US#_ ,Z^\/JM?^1G845Q_P#PFC?\\H_R/^-'_":-_P \H_R/
M^-'US#_SK[P^JU_Y&=A17'_\)HW_ #RC_(_XT?\ ":-_SRC_ "/^-'US#_SK
M[P^JU_Y&=A17'_\ ":-_SRC_ "/^-'_":-_SRC_(_P"-'US#_P Z^\/JM?\
MD9V%%<?_ ,)HW_/*/\C_ (T?\)HW_/*/\C_C1]<P_P#.OO#ZK7_D9V%%<?\
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M%%<?_P )HW_/*/\ (_XT?\)HW_/*/\C_ (T?7,/_ #K[P^JU_P"1G845Q_\
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M*/\ (_XT?\)HW_/*/\C_ (T?7,/_ #K[P^JU_P"1G845Q_\ PFC?\\H_R/\
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M\H_R/^-'_":-_P \H_R/^-'US#_SK[P^JU_Y&=A17'_\)HW_ #RC_(_XT?\
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M)HW_ #RC_(_XT?7,/_.OO#ZK7_D9V%%<?_PFC?\ /*/\C_C1_P )HW_/*/\
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M?\\H_P C_C1]<P_\Z^\/JM?^1G845Q__  FC?\\H_P C_C1_PFC?\\H_R/\
MC1]<P_\ .OO#ZK7_ )&=A17'_P#":-_SRC_(_P"-'_":-_SRC_(_XT?7,/\
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M>PJ?RLZ6BN:_X2.Z_P">,/Z_XT?\)'=?\\8?U_QH^L4OYD'L*G\K.EHKFO\
MA([K_GC#^O\ C1_PD=U_SQA_7_&CZQ2_F0>PJ?RLZ6BN:_X2.Y_YXP_K_C1_
MPD=S_P \8?U_QH^L4OYD'L*G\K.EHKFO^$CN?^>,/Z_XT?\ "1W/_/&']?\
M&CZQ2_F0>PJ?RLZ6BN9_X22Y_P">,7Z_XT?\))<_\\8OU_QH^L4OYD'L*O\
M*SIJ*YG_ (22Y_YXQ?K_ (T?\))<_P#/&+]?\:/K%+^9!["K_*SIJ*YG_A)+
MG_GC%^O^-'_"27/_ #QB_7_&CZQ2_F0>PJ_RLZ:BN9_X26Y_YXQ?K_C1_P )
M+<_\\8OU_P :/K%+^9!["K_*SIJ*YG_A);G_ )XQ?K_C1_PDMS_SQB_7_&CZ
MQ2_F0>PJ_P K.FHKF?\ A);G_GC%^O\ C1_PDMS_ ,\8OU_QH^L4?YD'L*O\
MK.FHKF/^$EN?^>,7Z_XT?\)-<?\ /&+]?\:/K-'^9!["K_*SIZ*YC_A)KC_G
MC%^O^-'_  DUQ_SQB_7_ !H^LT?YD'L*O\K.GHKF/^$FN/\ GC%^O^-'_"37
M'_/&+]?\:/K-'^9!["K_ "LZ>BN8_P"$GN/^>,7Z_P"-'_"3W'_/&+]?\:/K
M-'^9!]7J_P K.GHKE_\ A)[C_GC%^O\ C1_PD]Q_SQB_7_&CZS1_F0?5ZO\
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M_P )A)_SRC_(_P"-'UNA_.OO#ZM6_E9UM%<C_P )B_\ SRC_ "/^-'_"8O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** ./\ '7_+A_VT_P#9:X^NP\=?\N'_ &T_]EKC
MZ^-S/_>I?+\D?4Y?_N\?G^84445YYW!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDI:2@8E%%%( -)2FDI#$I#2TAI#"DI:2D,2@T4&D E)2TE(85K^%O^1DM/\
M@?\ Z U9%:_A;_D9+3_@?_H#5T87^/#U7YF.(_@S]'^1Z11117W)\>%%%% !
M1110 445A^+]:_L#PO>WZL!,$V0_]=&X'Y=?PH W**^<O^$_\5?]!F?\E_PK
MWGPYJZ:[X>LM27&Z:,;P.SCAA^8- &I117COQ$\6:[I'BZ:TL-2E@@6)&"*!
MC)'/44 >Q45YS\,_&MQK7G:7JMP9;U,R0R-@&1.X^HZ_0^U>C4 %%?/VG>.?
M$TVM6D,FKSM&]PB,I"\@L 1TKZ!H **IZMJ,6DZ3=ZA-_J[>)I"/7 X'XGC\
M:^?W^(/BEW9O[8F7)S@*N!^E 'T917,^ ]??Q#X6M[B>3?=Q$PSGN6'0_B"#
M^==*PW*1DC(QD=10 M%?/VJ^+_%VDZM=Z?-K-QOMY6C)VKS@\'IW'->V>&M6
M&N>'+#4<@M-$/,QV<<-^H- &K1399$AB>61@J(I9F/8#J:^?+SXA>);G49Y+
M74YXHI)6,42JORJ3PHX_"@#Z%HKA/&>H:QH'P^LYEOI%U)6B2:< 99B#N[8Z
MUY;_ ,)_XJ_Z#,_Y+_A0!]&T5\Y?\)_XJ_Z#,_Y+_A1_PG_BK_H,S_DO^% '
MT;17.ZW#J]]X0232;R2#4EA292N/WIV\J<CO_/%>/Z?\1O$EEJ<$UW?RW$,;
MCS8' &Y>XZ<'^M 'T%15>ROK?4+"&]MI ]O,@=&]C7BWBSXD:K<:_.NBW[V]
MC%^[CV ?O,=7Y'<]/;% 'N-96K^)-&T(#^TM0A@8C(0DLY'KM&3C\*X33O$.
MNZ'X N?$.L7LEQ<795+&&4# SG#' [C)QZ*/6L,V)\/W>F7&K:0-=UK5QYFR
MYFXC)(PN""">1G/3H* /1;+XA>%KZ80Q:M&CDX'G(T8/XL /UKI@0RAE(((R
M".]>427>E:GJ]OH/B+P9'I,MW\L$\)56#'@8(4=^.IY[5I^$+F]\,>*YO!VH
M3M/;.AEL)6/.WKM^F >.Q4^M 'HM%>7>-_B;/INH3:5H@C\V$[)KEQNVOW50
M>./4Y[\5PW_"PO%@D\W^V)<Y_P">:;?RVXH ^BJ*\S\"_$J75[Z/2=9$8N).
M(;E1M$C?W6'0$]B/IBO3* "BBN+^)6OZEX>T.UN=,G$,LER(V8HK97:QQR#W
M H [2BOGW_A9WBW_ *":_P#@/'_\31_PL[Q;_P!!-?\ P'C_ /B: /H*BO,/
MAKXPUOQ#KMU:ZG=K-"EL9% B5<-N4=0!V)J]X^^(3^'9QIFF)&]\5#22.,K$
M#T&.[8Y]N.N: /0:*^=&\?\ BQF,O]L3]>R*%S],8KO_  '\2)]7ODTG6O+^
MT2<07"C;O;^ZPZ9]",>E 'IE%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"I]:U>ZU*+6=DMPY<QRPY ]!D'H!@=*])HH Y?56\/>&_"$VFW36RVT=N8Q
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M/;TTEM;F?Y+\;F$/^1Y_[>_ZU-XNN;B'6@L<\B+Y2G"N0.IJ$?\ (\_]O?\
M6M[6_$G]E7XM_L:S?(&W%\=<^WM41470JJ4N5<^_W]BI.2JT^6/-[NWW'$_;
MKO\ Y^I_^_AJWHLCR^(+-Y'9V\T<L<FMG_A-O^H:G_?S_P"M67I]S]L\507.
MP)YDX;:#G%<?+352')4YM5T:Z^9T\TW"7-#ET?5%SQ?/*FM!4E=1Y2\!B.YK
M*T^]U%;V(6DTS2EAA-Q(;ZCTKK];UVTT[4!!-IZW#; V\X]^.15O3;^VU"QD
MFTR&)+A1@QNH7![9QVKT)X:-3$RY:MG>]E>_R.*->5/#QO3TMOI8QO'*QXLF
MX\SYQ^'%9&I:G#+HMEI\#RR^7AY'D['!&T>PS5/5;N\O+^1[[B93M*8P$QV
MJE7G8G%.=6<H*REI]W_#'?A\/RTX*3NUJ=W;)<OX*B72SB8KSM.&^]\V/>N/
M,NH6-P&9[B&8'/S$@_K5VSO-7T!%D$;QP2G(65#M8ULP>,X)E\N_L?E/4H0P
M_(UU2G2K**G-PDDEL[>OD<\8U*3DXQ4XMM^9GZYKMKJVF6R>7(+N,@LQ4!>G
MS <^N/RKGJZOQ#I%BVF+JVG )&<%E7A2#QD#L<]JY2N/'*HJO[VS=EJNJ[G3
MA'3=/]WHKO1]&=3X'_X_KK_KD/YUBWM[=KJ%P%NI@!*V )#QR:VO _\ Q_77
M_7(?SKGK_P#Y"%S_ -=6_F:UJR:P=.SZR,Z:3Q52_9'0^&-=N3?I974S2Q2Y
M"ESDJWU]#5;4;%+#Q?!'&NV-YHY% [ L/ZYJAH$;2:]9A>HD#?@.3_*MOQ X
M;QA8J.J&('_OLG^M:PDZF%3GJXR5OF9SBH8AJ&EXNY%XW_Y"=O\ ]<?_ &8U
MK:K'>2>&[1=)W%-B[A$?F*[>U97C52VJVRJ"28L #O\ ,:IVNJ:OX?"PR1LL
M3<K%.IQ[X[BMJE6-/$5E.]I:7738RA3E.A2<;76MGU*$%[?:;=K('ECD4Y*.
M2,^Q%:'B35K/5I+>2VCD61 5<NH&1V[_ %_.M:'Q?8W@$6HV6%/!. Z_D?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB>^CG!N&6:(GYDV@<>V*O2V$-KXDL+BW $-QE@!T!QV_,5RZ1O+(L:*6=C@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M--]!T;M%(LB'#*0P/H16M<>())+V*[@A$,BKL<%MP<9Z'@5CT4X59P5HNW_
M"5*$W>2-YO$%G(WFR:3"TW7<2.3^59NH:K<:A<K,YV;/]6J_P_\ UZI4E7/$
MU)JS?Z?D1"A3@[I&\GB))HD2_L8KDJ/OG&?RQ5>^UU[FU^RV]NEM >JIW_2L
MFDHEBJLE9O\ *_W[A'#4D[I?UZ&@=3SHHT[R>C[O,W>^>F*73-:GTY6BVK+
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M,+_'AZK\S'$?P9^C_(](HHHK[D^/"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ./\
M'7_+A_VT_P#9:X^NP\=?\N'_ &T_]EKCZ^-S/_>I?+\D?4Y?_N\?G^84445Y
MYW!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP/\ ] :NC"_QX>J_,QQ'\&?H_P CTBBBBON3X\**** "BBB@ K+U#Q'HVDW
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MC_Y\'_[^#_"O-KUL%&HU5MS>G_ .^C2Q<H)T[V]?^":O_"+:-_SY_P#D5_\
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M?\ /8X[S^_\ X)J_\(MHW_/G_P"17_QH_P"$6T;_ )\__(K_ .-97_"<Q_\
M/@__ '\'^%'_  G,?_/@_P#W\'^%'UC+O+[O^ 'L<=Y_?_P35_X1;1O^?/\
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M5_\ &LK_ (3F/_GP?_OX/\*/^$YC_P"?!_\ OX/\*/K&7>7W?\ /8X[S^_\
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MPBVC?\^?_D5_\:RO^$YC_P"?!_\ OX/\*/\ A.8_^?!_^_@_PH^L9=Y?=_P
M]CCO/[_^":O_  BVC?\ /G_Y%?\ QH_X1;1O^?/_ ,BO_C65_P )S'_SX/\
M]_!_A1_PG,?_ #X/_P!_!_A1]8R[R^[_ ( >QQWG]_\ P35_X1;1O^?/_P B
MO_C1_P (MHW_ #Y_^17_ ,:RO^$YC_Y\'_[^#_"C_A.8_P#GP?\ [^#_  H^
ML9=Y?=_P ]CCO/[_ /@FK_PBVC?\^?\ Y%?_ !H_X1;1O^?/_P BO_C65_PG
M,?\ SX/_ -_!_A1_PG,?_/@__?P?X4?6,N\ON_X >QQWG]__  35_P"$6T;_
M )\__(K_ .-'_"+:-_SY_P#D5_\ &LK_ (3F/_GP?_OX/\*/^$YC_P"?!_\
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M_P#P35_X1;1O^?/_ ,BO_C1_PBVC?\^?_D5_\:RO^$YC_P"?!_\ OX/\*/\
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M?\ /8X[S^_\ X)J_\(MHW_/G_P"17_QH_P"$6T;_ )\__(K_ .-97_"<Q_\
M/@__ '\'^%'_  G,?_/@_P#W\'^%'UC+O+[O^ 'L<=Y_?_P35_X1;1O^?/\
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M5_\ &LK_ (3F/_GP?_OX/\*/^$YC_P"?!_\ OX/\*/K&7>7W?\ /8X[S^_\
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MPBVC?\^?_D5_\:RO^$YC_P"?!_\ OX/\*/\ A.8_^?!_^_@_PH^L9=Y?=_P
M]CCO/[_^":O_  BVC?\ /G_Y%?\ QH_X1;1O^?/_ ,BO_C65_P )S'_SX/\
M]_!_A1_PG,?_ #X/_P!_!_A1]8R[R^[_ ( >QQWG]_\ P35_X1;1O^?/_P B
MO_C1_P (MHW_ #Y_^17_ ,:RO^$YC_Y\'_[^#_"C_A.8_P#GP?\ [^#_  H^
ML9=Y?=_P ]CCO/[_ /@FK_PBVC?\^?\ Y%?_ !H_X1;1O^?/_P BO_C65_PG
M,?\ SX/_ -_!_A1_PG,?_/@__?P?X4?6,N\ON_X >QQWG]__  35_P"$6T;_
M )\__(K_ .-'_"+:-_SY_P#D5_\ &LK_ (3F/_GP?_OX/\*/^$YC_P"?!_\
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M_P#P35_X1;1O^?/_ ,BO_C1_PBVC?\^?_D5_\:RO^$YC_P"?!_\ OX/\*/\
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M?\ /8X[S^_\ X)J_\(MHW_/G_P"17_QH_P"$6T;_ )\__(K_ .-97_"<Q_\
M/@__ '\'^%'_  G,?_/@_P#W\'^%'UC+O+[O^ 'L<=Y_?_P35_X1;1O^?/\
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M5_\ &LK_ (3F/_GP?_OX/\*/^$YC_P"?!_\ OX/\*/K&7>7W?\ /8X[S^_\
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MPBVC?\^?_D5_\:RO^$YC_P"?!_\ OX/\*/\ A.8_^?!_^_@_PH^L9=Y?=_P
M]CCO/[_^":O_  BVC?\ /G_Y%?\ QH_X1;1O^?/_ ,BO_C65_P )S'_SX/\
M]_!_A1_PG,?_ #X/_P!_!_A1]8R[R^[_ ( >QQWG]_\ P35_X1;1O^?/_P B
MO_C1_P (MHW_ #Y_^17_ ,:RO^$YC_Y\'_[^#_"C_A.8_P#GP?\ [^#_  H^
ML9=Y?=_P ]CCO/[_ /@FK_PBVC?\^?\ Y%?_ !H_X1;1O^?/_P BO_C65_PG
M,?\ SX/_ -_!_A1_PG,?_/@__?P?X4?6,N\ON_X >QQWG]__  35_P"$6T;_
M )\__(K_ .-'_"+:-_SY_P#D5_\ &LK_ (3F/_GP?_OX/\*/^$YC_P"?!_\
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M_P#P35_X1;1O^?/_ ,BO_C1_PBVC?\^?_D5_\:RO^$YC_P"?!_\ OX/\*/\
MA.8_^?!_^_@_PH^L9=Y?=_P ]CCO/[_^":O_  BVC?\ /G_Y%?\ QH_X1;1O
M^?/_ ,BO_C65_P )S'_SX/\ ]_!_A1_PG,?_ #X/_P!_!_A1]8R[R^[_ ( >
MQQWG]_\ P35_X1;1O^?/_P BO_C1_P (MHW_ #Y_^17_ ,:RO^$YC_Y\'_[^
M#_"C_A.8_P#GP?\ [^#_  H^L9=Y?=_P ]CCO/[_ /@C?$/AVV@M(FTZUVR&
M3#?O">,'^\:\R_X5MJ?_ #U7\A_\573>/_$QU/PX8X8I+=TE5MPDZ]L<5#X'
MEDE\-HTDC.WFORQR:$Z48NM0=D[+2W3U06J2:I5E=K76_P"C.?\ ^%;:G_SU
M7\A_\56_I?AG4-.L$MC&'*DG<&4=3GUKI<GUHR?6N:M45>/+4;:^7^1T4J;I
M2YH6O\_\S&_L:_\ ^>'_ (^O^-<I_P *VU/_ )ZK^0_^*KT3)]:,GUJ:#A0O
M[.ZOYK_(JLI5K<]G;U_S/._^%;:G_P ]5_(?_%5NZ5X7U'3;(6[1AR&)W!E'
M7\:Z?)]:3)]:JM45:/)4;:^7^1-*FZ4N:%K_ #_S,?\ L:__ .>'_CZ_XURK
M?#C4V=F\U1DYZ#_XJO0LGU-&3ZFHH.%"_L[J_FO\BJRE6MSV=O7_ #///^%;
M:G_SU7\A_P#%5NZ5X7U'3;(6[1AR&)W!E'7\:Z;)]31D^M76J*M'DJ-M?+_(
MFE3=*7-"U_G_ )F/_8U__P \/_'U_P :Y5OAQJ;.S>:HR<]!_P#%5Z%D^M&3
MZU%!PH7]G=7\U_D564JUN>SMZ_YGGG_"MM3_ .>J_D/_ (JMW2O"^HZ;9"W:
M,.0Q.X,HZ_C739/K1D^M76J*M'DJ-M?+_(FE3=*7-"U_G_F8_P#8U_\ \\/_
M !]?\:Y5OAQJ;.S>:HR<]!_\57H63ZT9/K44'"A?V=U?S7^1592K6Y[.WK_F
M>>?\*VU/_GJOY#_XJMS2/"VHZ99F!D$AWELAE'I[UTV3ZT9/J:NM55:/)-MK
MY?Y$TJ3I2YH6O\_\S(_L:_\ ^>'_ (^O^-<M+\.=3DF=Q(H#,3C _P#BJ] R
M?4T9/J:B@X4&W3NK^:_R+K*=:RG9V]?\SSW_ (5MJ?\ SU7\A_\ %5N:1X6U
M'3+,P,@D.\MD,H]/>NFR?4T9/J:NM55:/)-MKY?Y$4J3I2YH6O\ /_,R/[&O
M_P#GA_X^O^-<M+\.=3DF=Q(H#,3C _\ BJ[_ "?4T9/J:B@X4&W3NK^:_P B
MZRG6LIV=O7_,\^_X5MJ?_/5?R'_Q5;FD>%M1TRS,#()#O+9#*/3WKI<GU-&3
MZFKK556CR3;:^7^1%*DZ4N:%K_/_ #,G^QK_ /YX?^/K_C7+2_#G4Y)G<2*
MS$XP/_BJ[[)]31D^IK.@X4&W3NK^:_R+K*=9+GL[>O\ F>?_ /"MM3_YZK^0
M_P#BJVM'\*:CI=H\#()"TA?(*CL!Z^U=-D^IHR?4UI6K*M'DFVU\O\B*5)TI
M<T+7^?\ F97]C7__ #P_\?7_ !KF+CX=ZG-<RRB10'<MC XR?]ZN[R?4T9/J
M:SH.%!MT[J_FO\BZRG624[.WD_\ ,X#_ (5MJ?\ SU7\A_\ %5M:/X4U'2[1
MX&02%I"^05'8#U]JZ7)]31D^IK2M65:/)-MKY?Y$4J3I2YH6O\_\S+_L:_\
M^>'_ (^O^-<Q<?#O4YKF642* [EL8'&3_O5W1)]31D^IK*A*%!MT[J_FO\C2
MM&=9)3L[>3_S.!_X5MJ?_/5?R'_Q5;6C^%-1TNT>!D$A:0OD%1V ]?:NDR?4
MT9/J:TK5U6CR3NU\O\B*5%TI<T+7^?\ F9G]C7__ #P_\?7_ !KF+CX=ZG-<
MRRB10'<MC XR?]ZNZR?4TA8^IK.A*%!MT[J_FO\ (NM&=9)3L[>3_P S@O\
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M ,>KJ-S?WC^=)N;^\?SK&A5IT&Y4TT_5?Y&U:G.LK3L_D_\ ,Y#_ (5MJ?\
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MY/\ S+/]C7__ #P_\?7_ !K U3P)J6HW[W(*H& &TX/08]:U=[?WC^=)O?\
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M%<?\\_\ QX5W>Q?[H_*C8O\ ='Y4?V=2[L/K]3LC@_L5Q_SS_P#'A1]BN/\
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MY4;%_NC\J/[(H=W^'^0?VG5[+^OF>9_V3??\\/\ Q]?\:/[)OO\ GA_X^O\
MC7IFQ?[H_*C8O]T?E1_9%#N_P_R'_:=;LOZ^9YE_9%]_SP_\?7_&C^R+[_GA
M_P"/K_C7INQ?[H_*C8O]T?E2_LBAW?X?Y!_:=;LOZ^9YC_9%]_SP_P#'U_QI
M/['O_P#GA_X^O^->G[%_NC\J-B_W1^5']CT.[_#_ "#^U*W9?U\SS#^Q[_\
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M%T_A?3(([$+]MNRP1V&1&JXR<=SR,5Y9I?A_Q1XW6>\CF>XC5]KRW$^ 6QG
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MX^NP\=?\N'_;3_V6N/KXW,_]ZE\OR1]3E_\ N\?G^84445YYW!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 9'B7_D!R_P"\O\Q6SX$_Y%E/^NK_ ,Z%TRWU
M=)+2YW^65W?(<'((K8TK2[?2+(6EL7,88M\YR>:]K#5(_5?9];GDUZ;^L\_2
MQ=HHHH&%%%% !0:*#0 E%%% !1110 4444 %%%% !1110 &DI324AA1110 4
M444 )1110 4444@"DI:2@84444 %)2TE !1112 0T4&B@84444@"@T4&@!*2
MEI* "BBBD,****  TE*:2D,*2EI* "@T4&@!****0Q**** $HHHI %(:6D-
MPHHHI#"DI:2D 4E+24 %)2TE(84E+24 %)2TE(84444AB4E+24 %%%%(!*#1
M0:0Q*2EI* "DI:2D,#24II*0!24M)0,*2EI*D84E+24 )1112&)1112&)111
M2&(:2E-)0 4E+24AB4&B@T@$I*6DI# TE*:2D,]&L=:TJSL+"UN=3LX+@V\6
M(I9U5SE1C@G/-;5>">+?^1VTG_KWM/Y"O>Z^^I?PX^B_)'Q=3XY>K_-A1116
MA 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4$=C&/\ XJMZ>"KU$W%;.VZW,9XNC!I2>^NS.2HKK?\ A#;?_H+I_P!^Q_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M+^D_\?3?[A_F*V*X/Q%))%HTK1NR-E>5.#U%;/@B227PXC2.SMYK\L<FO8PU
M+_9_:7ZV/,KU/W_)Y'1T4451(4444 %!HH- "4444 %%%% !1110 4444 %%
M%%  :2E-)2&%%%% !1110 E%%% !1112 *2EI*!A1110 4E+24 %%%%(!#10
M:*!A1112 *#10: $I*6DH ****0PHHHH #24II*0PI*6DH *#10: $HHHI#$
MHHHH 2BBBD 4AI:0T#"BBBD,*2EI*0!24M)0 4E+24AA24M)0 4E+24AA111
M2&)24M)0 4444@$H-%!I#$I*6DH *2EI*0P-)2FDI %)2TE PI*6DJ1A24M)
M0 E%%%(8E%%%(8E%%%(8AI*4TE !24M)2&)0:*#2 2DI:2D,#24II*0S$\6_
M\CMI/_7O:?R%>]USUKX;T;4;73[Z[T^&:Z6WBQ*P.1A1BNAK[ZE_#CZ+\D?%
MU/CEZO\ -A1116A 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR0')A(&%Q]/6KC"EA\/*K2;ES*W:WJ3*52M6C3J)1MKZ^AI:>"W@.X5023O
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M=?\ T)JRJT'0P]1;KFBUYHNG65:O![.S3\F9VHZHNHZM'<O%LA3:JIUP@/\
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MEK+EU73ROU/#IU(TW"IK?7FT?7_(Q? __'[=?]<Q_.M*_@B\3:0[P@"[MV8
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M +HY_P#K?C5_Q???:=5%NIRENNW_ ($>3_0?A5[PO&NG:3>ZK,N, JH/H/\
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M KL;W_D0(/HO_H54]0T31;>PFFM]4$LR+E4\Y#D_05LVU]'I_@^VN)8!,H4
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ML<51*,*\8[:?\$YZ_P#^0A<_]=6_F:V/"NIS6VIQVI<F"8[=I/ ;L16/?_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH R/$O_(#E_WE_F*V? G_ "+*?]=7_G0NF6^KI):7
M._RRN[Y#@Y!%;&E:7;Z19"TMBYC#%OG.3S7M8:I'ZK[/K<\FO3?UGGZ6+M%%
M% PHHHH *#10: $HHHH **** "BBB@ HHHH ****  TE*:2D,**** "BBB@!
M**** "BBBD 4E+24#"BBB@ I*6DH ****0"&B@T4#"BBBD 4&B@T )24M)0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXXKFZ*U^N5/8*B^CNGUT,_JL/;>U[K8[B6?0_$L$;7,PM[E1CEPK#VR>"/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3)\6O#<<C(4OB5)!Q"/_ (JDLJPKVO\ >#S'$+>WW"?\(3J7_/>T_P"^V_\
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M$ZE_SWM/^^V_^)I/^%N^&O[E_P#]^1_\570Z!XMTOQ':RW%F[QI&^PB?"$G
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MO4?[-9_B_P /^(#I,7]C[GN//&X02;6V;6SUQQG%3?\ "W?#7]R__P"_(_\
MBJV?#_CC1_$D\T5FTT;0J&;SU" @G'')KIIX&A2VZ=V85,96J;GEG_"/?$3_
M )XW_P#X$+_\54]AX=\?_P!HVWGQ7HA\U?,+7"X"Y&<_-TQ7M?VJW_Y[Q?\
M?8KE]:^(NA:%J<EA=?:7E0 DPH&7D9ZYKIY*;TLOP.?FFM;O\2S_ ,(_=_\
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M/7D5@L'1B^;]39XJK)6/+_\ A'/B'_SQOO\ P(7_ .*H_P"$<^(?_/&^_P#
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M_P#Q5>Y_;K/_ )^H/^_@K#U_QQHWAR2!+MY93,"5-N X&,=>>.M=*A1>B2_
MP<JJW;_$S++PKJ9L+<S20K*8EWAF.0V!G/'6H-8\)ZQ_9%U]C>)[G9F-8Y"&
M)]B0!^M+_P +=\-?W+__ +\C_P"*J[I'Q)T'6=4AL+?[3'++NVM,@51A2>3G
MVKF^H4$^:WXG1]=K-<OZ'FG_  C'Q _Y]KW_ +_K_P#%4?\ ",?$#_GVO?\
MO^O_ ,57N?V^S_Y^X/\ OX*P]?\ '&C>')($NWEE,P)4VX5P,8Z\\=:Z5"B]
M$E^!SN55;M_B9=EX4U,V%N9I(%E,2[PS'(;'.>.M0:QX3UC^R+G[&\3W 3,:
MQR$,3[$@#]:=_P +=\-?W+__ +\C_P"*J[I/Q)T'6=3AL+?[3'++NVM,@51A
M2>3GVKE_L^@GS6_$Z/KM9KE_0\T_X1?Q_P#\^U[_ -_U_P#BJ/\ A%_'_P#S
M[7O_ '_7_P"*KW/[?9_\_<'_ '\%8>O^.=&\.20)=O+*9@2IMPK@8QUYXZUU
M*%%Z)+\#G<JJW;_$Q].\):J=,M#<20K.84\Q7<E@VT9!P.N:;JGA+5QI5T;5
MX6N!$WEK&Y#%L<8R!S2_\+=\-?W+_P#[\C_XJKFE_$S0-6U*&Q@%TDLQ(5I8
MU51P3R=WM7+_ &?AT^:WXG1]>K-<M_P/-?\ A%_'_P#SZWO_ '_7_P"*H_X1
M;Q__ ,^M[_W_ %_^*KW/[?9_\_<'_?P?XUB^(/&VC^'/L_VN227S]VW[. ^-
MN,YYX^\*Z5"B]$E^!SN55;M_B8FG>$=5.F6AN)(5G,*>8KN2P; R#@=<TW5/
M".KC2[HVKPM.(V\M8W(8MCC&0.:=_P +=\-?W+__ +\C_P"*JYI?Q,T#5M2A
ML8/M22S$A6EC55'&>3N]JYO[.PZ?-;\3I^O5FN6_X'FG_"+>/_\ GUO?^_Z_
M_%4?\(MX^_Y];S_O^O\ \57NGV^R_P"?N#_OX/\ &L3Q!XVT;PY]G^UR22^?
MNV_9P'QMQG//'45TJ%%Z)+\#G<JJW;_$Q-/\(:L=,M3<20+.84\Q7<E@V!D'
M ZYIFJ>$-7&EW1M9(7G$;>6L;D,3CC&0!FI/^%N^&O[E_P#]^1_\55S2_B9H
M&K:E#8P?:DEF)"M+&JJ.,\G=[5R_V=AU+FMY[G1]>KM<M_P/-/\ A%?'W_/K
M>?\ ?]?_ (JC_A%?'W_/K>?]_P!?_BJ]T_M"R_Y^[?\ [^#_ !K$\0>-M&\.
M?9_M<DDOG[MOV<!\;<9SSQU%=2A1>B2_ YW.JMV_Q,#3/!^L'2[4W4D*3F-3
M(LCDL#CG. 1FG:AX/U8:;=&WD@:80OY:HY#%L' &1US3_P#A;OAK^Y?_ /?D
M?_%5:TWXG>']3U&"RA^U)),VU6EC"J#[G/%<KRW#\W-9]]SH6/KVY;_@>;?\
M(KX^_P"?2\_[_K_\51_PBOC[_GTO/^_Z_P#Q5>Y_VA9?\_EO_P!_1_C6/K_C
M31_#L<#W<KRB8D*+?#D8QUYXZUU*%%Z)+\#G<ZJW;_$YW3/!NL'2[4W,D"3F
M-3(LCDL#CG. 1FG:AX-U<:;=&WD@:80OY:HY#%L' &1US4G_  MWPU_<O_\
MOR/_ (JK6F_$[P_J>HP64/VI))FVJTL850?<YXKD>6X?FYK/ON=*Q]>W+?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR]7^;"BBBM" HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLG;[RW5BIJF]WJ9%%=9;^&+*SM%N-9NO*+=$5@ /;U)^E21Z#H&I!H["^83
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ME<6T>XK'(47/).#7,Z,E357HW8V56+J.GU2N5:*ZRW\,65G:+<:S=>46Z(K
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MERZA,,@K #\S_P!![UC"$IRY8K4VG.,%S2V,\TE7-4M8[/4)((RQ1<8W'GD
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MAIU%S+;S=C*I7A!V>YS5%6]1T^33KHQ2$,",JP[BM&ST. 60N]0G,,;#*J,
MX[?_ *J4</4E-PMJM_(<JT(Q4KZ/8PJ*WKO0[=[)KK39S,JY+*Q!Z=<?X5@U
M-6E*D[2*IU8U%>(4E;&CZ(]^_F3ADMP.HX+'VK.O(5M[V>%,E8Y&49ZX!I2H
MSC!3:T81JQE)P6Z(****Q-0I*6DH&)1110 4444@$HHHH&%)2TE( I*6DH *
M#10:0Q**** $HHHI %%%% Q****0PI#2TAI %%%% "4444 )1112&!I*4TE
M!1112&)1110 4444AB4E+24 %%%%( I*6DH&%)2TE( H-%!H 2BBBD,2BBB@
M I*6DI#"BBB@#$\6_P#([:3_ ->]I_(5[W7/6OAO1M1M=/OKO3X9KI;>+$K
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSU=#K'[K0;*(\-\N1]%Y_G6-#^'4OV_4UK?Q*=N_Z!KA\C2;.W7A3C/O@?\
MUZH^'Y3'JT:@\."I_+/]*O>(/WFG64R_=_Q _P *S]!0MK$)'10Q/Y&MJM_K
M4;>1E3M]6E?S&:O&L.L3@#Y=P8CZ@$_SK7MM;^TZC;VMM$(H,D'(&2,'MVK(
MUMP^L7!'0$#\@!2:+_R&+?ZG^1K.-24*[C'9R_4TE3C*BI2W2_0?K_\ R&9_
M^ _^@BLRM/7_ /D,S_\  ?\ T$5F5RXC^++U9O1_AQ]$%%%%8FPE%%%(8&DI
M324@ TE*:2@!#10:*0Q****  TE*:2D,*0TM(:0Q****  TE*:2D,2@T4&D
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MIO=ZE:XTB_>YE=;<E6<D'<.F?K4+:/?HI9K<@ 9)W#_&IKC5[]+J5%N"%5R
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M4=3\E(Q' L9(7J3TKF=3_P"0K=_]=G_F:T?"_P#R%C_UR/\ ,5G:G_R%;O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MIQ3I)K2*41/=2;CV I9I;2!T22ZDRXR !FA\C6KV&O:)MQ6K\B.+[3IL\JH
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MV&_C,MKT4XR5![$'J*YRBN:.*JQJNJGJ]S>6&IRIJFUHCKC;^$7;S?M#*O\
M<!8#\L9J+5/$MNMD;#2(O+B(VF3&WCV'OZFN6HK:6.ERM0BHWWLM3)8.-TYR
M<K=V:WAR]M[#5UGN9/+C",-V">?PJMJ]Q%=:M<SPMNC=R5.,9'XU2HKF=:3I
M*ET3N="I)5'4ZVL;OAK6QI=RT5PQ%K+][C.UO7'Z4WQ1?VVHZG'-:2>9&L(4
MG:1SDGO]:Q**T>*J.A[![$?5X*K[9;CHY'AE26-BKH0RD=B*[%==T;6;5(]6
MB$<J]\'&?8CD?2N,HI4,3.C=*S3W3V"MAXU;-Z-;-;G91'PKIT@N$D\V1>5'
MS/@^PZ?G6!K>KOK%Z)=I2)!MC0]AZGWK,HJZV+E4A[-)1CV1-+#1A+G;;?F%
M=9H>JZ5#H+V-_/MWLVY=C'@^X%<G16>'KRH2YHI/2VII6HJM'E;MUT.MQX/3
MG<[X[?O*BU7Q- ;$V&E0F*(C:S[=O'< >_K7+T5O+'3Y7&$5&_9:F*P<.9.;
M<K=V;/AB_MM.U1IKJ3RXS$5SM)YR/3Z53O[L/K,]W;.<&8O&^,=\@U2HKG=>
M7LE2Z)W-E1C[1U.K5CLUUW1M9M4CU:(1RKWP<9]B.1]*2(^%=.D%PDGFR+RH
M^9\'V'3\ZXVBNO\ M";LY0BY=VM3F^HQ6D9-+M?0UM5UEM5U2.=E,<,9 13S
M@9Y)]ZZ/4-1\,ZHT;75RS&,$+A)!U^@KAJ*SAC:D>;F2ES;W-)X2$N7E;7+M
M8ZWR_!W_ #U?\I/\*JRCP['JMA):SD0*S-.2KGI@J,$=SFN<HHEC+_\ +N*^
M7_!!86WVY?>;?B?58M4OT^SOO@B3"G!&2>IY_ ?A6)117-6JRJS=26[-Z5.-
M."A'9'5W.L6&H^%UMKF?;>QJ"H*,<LO3G&.1_.I+/Q%IVH6"VFM1_,N!O()#
M>_'(-<A176LPJ\W-9;6?GZG,\%3M;7>Z\O0[%8O"5N_G>:),<A"68?EC^=9'
MB#7?[6E2.%"EM%]T'JQ]36+145<9*<'3C%13WLMRJ>%C&:G)N36USLK+5-$E
M\/06%_<$87YT"/P0<]0*B\OP=_SU?\I/\*Y*BK^OMI*4(NRMJO\ @D_4TFW&
M<E?71G0ZFGAL:?*=/D8W7&P$/SR,]1CIFN>HHKEK5?:2ORI>AT4J?LU:[?J%
M%%%8FH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 97B&"6YTEHX8VD?>IVJ,F
MMOP7;3VOAY([B)XG\QCM<8.#T-0UT5M_QZP_[B_RKT\+7?LG1MI>YY^(HKVB
MJWUV):***W,@K8L[ZWL]*D59/])?)QM/!Z#G]:QZ*TIU'3=T9SIJ:LPJ]I5X
MMG=YD;$;##'&<>E4:*4)N$E)="IQ4HN+-V"]L8-3N)A-^[D4'.T]>_:L.5@T
MKL.A8D4VBKJ57-6?G^)$*2@[K^K&OI&II;*T-PQ$753@G!]*FAO;(:M<W3S8
M!"A#M// SV]JPJ*N.)G%*.]B)8>+;?<FNIS<W4DQ_B;(^G:FP3-!.DJ]48&H
MZ*PYGS<W4WY5;EZ&MK-S:78BD@DW2#@C:1Q_G^=5--NA:7J2,<(?E;Z&JE%:
M2K2=3VG4SC22AR=#8U?4(;B&.&V;*9+-@$<_YS6/1145:CJ2YF53IJG'E1T+
MWFEW-K#%<2D[ . K#!Q]*@VZ#_?;_P ?_P *Q**W>*;WBG\C)8=+:3-6YCTA
MO+$$Q7Y_G.&.%P?;Z4_4M2A:V2ULC^ZQAB 1QZ<UCT5#KNS44E?L4J*NFVW8
MDAF>WF66,X93D5JZE=V-_:+()-ERHX7:?Q&<5C4E1"JXQ<.C+E34I*75!111
M6)H;^DWUA:60627;*Q)?Y2?IV]*8W]A,Q9I7+$Y)._G]*PZ2NI8I\JBXII'/
M]77,Y*35R]J(L 8_L+$]=^<^V.OXU1HHKGG+F=[6-XQY5:]RS821Q7\,DQVH
MK9)QFI=8NH[N^WQ-N0*%!P1_GK5&DJE4:AR=-R>1<_/U $@Y'6M_[?8:G;)'
M?$Q2K_$!W]C_ (U@44Z=5T[K=/H*I34[/9HWQ?:?I<#K9$RRM_$?ZG_"L!F+
ML68Y8G)-!I**E5U++9+HATZ2A=[MA6Q-?6[Z!';+)F88RNT^OK6/140J.":7
M56'.FIVOTU"DI:2LS0Z&WO=-?28K6ZE/ ^90K>N>H%1[?#W_ #T;_P ?_P *
MPC25U_6FTDXIV\CF^KI-M2:N:UZNC"T<VCL9^-H^;UYZ^U9-%%<]2?.[V2]#
M>$.16NWZFS=WUM)H4%LDF9EVY7:>,>]8II:0T5*CJ--]K!3IJ"L@J]I>H'3[
MDN06C88<#^=4:*F$W"2E'=%2BI)Q>QT)&@O<?:C,>NXQX.,_3%9NK:C_ &A<
M H"(D&%!Z^YK/HK:IB'./*DDGO;J90H*,N9MNW<V['4[66P^PZ@"$'"OC/TZ
M="*GCN]*TF)VM':>9A@9_P <#BN<HIQQ4TEHKK9]1/#1;>KL^G0=([2R-(YR
MS$DGWJQI<\=OJ4,LK;44G)QG'!JJ:2N:,G&2D;RBG%Q+NKW$5UJ4LT+;HVVX
M.".P'>J-*:2B<G.3D^H1BHQ45T"BBBH+$HHHI# TE*:2D &DI324 (:*#12&
M)1110 &DI324AA2&EI#2&)1110 &DI324AB4&B@T@$I*6DH&%)2TE( H-%!I
M#$I*6DI# TE*:2D E)2TE(84&B@TAB4E+24#$-%!HJ0$I*6DH&!I#2FD-(8E
M%%%("]I/_'TW^X?YBM<UD:3_ ,?3?[A_F*US7HX;^&<5?XPHHHKH,"[I<EO#
M>B6X?:J D<$Y/X4S4KH7=\\BG*#Y5^@JH:*OVCY/9]-R/9KGY^HH8JP93@@Y
M!K8U.]M+ZPC(D_TA<';M/?J,_P">E8U)1"JXQE'HPE34I*75&MJM[;W-I;1P
MR;F3[PP1CCWK,AF>"998SAE.13*2E.K*<N=[CA348\O0Z"_U6UN]*>-7Q*X7
MY"IXY&>:@U*_MCIL5I:2;E& WRD<#Z^]8U!K:>*G*]^JL9QP\(VMT=Q*VM(U
M&WAM);:[?"'[O!.0>HX_SS6+16-.JZ<N9&E2FJD>5BN%$C!&W*"<'U%=!IVK
MVL=A&ER^)8LA1M)R.W^%<[13I5I4I<T0J4HU(VD/FE:>=Y7^\[$FM'1+N"SN
M)6G?8K)@'!/?VK+HJ(5'"?.MRIP4H\CV-Y_[ DD9VD;<Q)/#]?RINWP]_P ]
M&_\ '_\ "L*DK?ZS_<C]QC]7_O/[S=TZXTRQ:>;S2TA9A&NTY"YX[=361=W,
MEY<O-(>6Z#T'I4-%8SK2E%0V2-84E&3ENV;.CZK';QO;79_<D':2"<>H^E9M
MXL"W+BVDWPGE3@C'MS4%%$JTI04'T"-)1FY+J)5G3S M]$UR<0J<MP3]/UJM
M1647RM,UDKIHZF[O]'O559[ABJ\@ .!_*JA3P[CB1O\ Q_\ PK HKJEBW)WE
M%/Y'+'"J*LI/[P-)2FDKB.PV[;4+:#P_+;B3_2'##;M/?CKTZ5ATM)6M2JYI
M)]%8SA34&VNNII:/J8TZ9A(I:&3[V.H/K5XQ>'S-]H,[;<Y\OG'Y8S7/T&KA
MB'&*BTFEM<B=!2ES)M-]C3UC51J#I'$I6"/H#U)]:RZ**QJ5)5).4MS2$%"/
M+$U]!O;>RN)6N)-@90 =I/?VK+N'$ES*ZG*LY(^F:924Y56X*'1 J:4W/JPK
M0T6YAM-166=]B!2,X)_E6?14PFX24ET*G%3BXOJ=+<2>'KF=YI96+L<D@./Z
M4B:II&G(QLH2\A'7!_F><5S=)72\9*]U%)]['/\ 58VLY-KM<FN;F2[N'GE.
M78_E[5!2TE<;;;NSJ225D7])U(Z;=%RI:-QAU'7ZUJD>'WN/M9F/7<8\'&?I
MBN;HK>GB'"/*TFO/H8SH*4N9-I^1HZSJ?]I7*E 5AC&$!ZGU-:$.IV&HV"6V
MI$I(F )!W]\]JYVBB.)FIN3UOO?8'AX.*BM+;'1OJ.G:5920Z:QDF?JY[>Y/
M^%<W1145:SJ6NK);)%TZ2IWMJWU-/0;N"RU RW#[$\LC.">>/2J=](DU_<2Q
MG*/(S*<=034%)4NJW35/HG<I4TIN?5Z!1116)H%)2TE Q**** "BBBD E%%%
M PI*6DI %)2TE !0:*#2&)1110 E%%%( HHHH&)1112&%(:6D-( HHHH 2BB
MB@!****0P-)2FDH ****0Q**** "BBBD,2DI:2@ HHHI %)2TE PI*6DI %!
MHH- "4444AB4444 %)2TE(84444 8GBW_D=M)_Z][3^0KWNN>M?#>C:C:Z??
M7>GPS72V\6)6!R,*,5T-??4OX<?1?DCXNI\<O5_FPHHHK0@**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M .^319A=#**?Y,G_ #S?_ODT>3)_SS?_ +Y-%F%T,HI_DR?\\W_[Y-'DR?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW_X2G6?^?S_R$G^%'_"4ZS_S^?\ D)/\*/[8H=G^'^8?V76[K^OD>D45YO\
M\)3K/_/Y_P"0D_PH_P"$IUG_ )_/_(2?X4?VQ0[/\/\ ,/[+K=U_7R/2**\W
M_P"$IUG_ )_/_(2?X4?\)3K/_/Y_Y"3_  H_MBAV?X?YA_9=;NOZ^1Z117F_
M_"4ZS_S^?^0D_P */^$IUG_G\_\ (2?X4?VQ0[/\/\P_LNMW7]?(](HKS?\
MX2G6?^?S_P A)_A1_P )3K/_ #^?^0D_PH_MBAV?X?YA_9=;NOZ^1Z117F__
M  E.L_\ /Y_Y"3_"C_A*=9_Y_/\ R$G^%']L4.S_  _S#^RZW=?U\CTBBO-_
M^$IUG_G\_P#(2?X4?\)3K/\ S^?^0D_PH_MBAV?X?YA_9=;NOZ^1Z117F_\
MPE.L_P#/Y_Y"3_"C_A*=9_Y_/_(2?X4?VQ0[/\/\P_LNMW7]?(](HKS?_A*=
M9_Y_/_(2?X4?\)3K/_/Y_P"0D_PH_MBAV?X?YA_9=;NOZ^1Z117F_P#PE.L_
M\_G_ )"3_"C_ (2G6?\ G\_\A)_A1_;%#L_P_P P_LNMW7]?(](HKS?_ (2G
M6?\ G\_\A)_A1_PE.L_\_G_D)/\ "C^V*'9_A_F']EUNZ_KY'I%%>;_\)3K/
M_/Y_Y"3_  H_X2G6?^?S_P A)_A1_;%#L_P_S#^RZW=?U\CTBBO-_P#A*=9_
MY_/_ "$G^%'_  E.L_\ /Y_Y"3_"C^V*'9_A_F']EUNZ_KY'I%%>;_\ "4ZS
M_P _G_D)/\*/^$IUG_G\_P#(2?X4?VQ0[/\ #_,/[+K=U_7R/2**\W_X2G6?
M^?S_ ,A)_A1_PE.L_P#/Y_Y"3_"C^V*'9_A_F']EUNZ_KY'I%%>;_P#"4ZS_
M ,_G_D)/\*/^$IUG_G\_\A)_A1_;%#L_P_S#^RZW=?U\CTBBO-_^$IUG_G\_
M\A)_A1_PE.L_\_G_ )"3_"C^V*'9_A_F']EUNZ_KY'I%%>;_ /"4ZS_S^?\
MD)/\*/\ A*=9_P"?S_R$G^%']L4.S_#_ ##^RZW=?U\CTBBO-_\ A*=9_P"?
MS_R$G^%'_"4ZS_S^?^0D_P */[8H=G^'^8?V76[K^OD>D45YO_PE.L_\_G_D
M)/\ "C_A*=9_Y_/_ "$G^%']L4.S_#_,/[+K=U_7R/2**\W_ .$IUG_G\_\
M(2?X4?\ "4ZS_P _G_D)/\*/[8H=G^'^8?V76[K^OD>D45YO_P )3K/_ #^?
M^0D_PH_X2G6?^?S_ ,A)_A1_;%#L_P /\P_LNMW7]?(](HKS?_A*=9_Y_/\
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M*=9_Y_/_ "$G^%'_  E.L_\ /Y_Y"3_"C^V*'9_A_F']EUNZ_KY'I%>8>,_
MGB'7?$UQ?V%Q ELZH%#S,IX4 \ >M3_\)3K/_/Y_Y"3_  H_X2G6?^?S_P A
M)_A1_;%#L_P_S#^RZW=?U\CF?^%6>+?^?NU_\"7_ ,*[#X?^$=:\-W]Y+J<T
M4D<T05!'*7P0>^0*J_\ "4ZS_P _G_D)/\*/^$IUG_G\_P#(2?X4?VQ0[/\
M#_,/[+K=U_7R/2*\P\9^!/$.N^)KB_L+B!+9U0*'F93PH!X ]:G_ .$IUG_G
M\_\ (2?X4?\ "4ZS_P _G_D)/\*/[8H=G^'^8?V76[K^OD<S_P *L\6_\_=K
M_P"!+_X5UG@#P=K?AS5KFXU.>&2*2#8H24M\VX'H0/0U#_PE.L_\_G_D)/\
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M[!>:9/#'"ELL3!Y64[@S'H!Z$4S_ (2G6?\ G\_\A)_A1_PE.L_\_G_D)/\
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M0\ ^(M%\4V>H7UQ ]M#OWJD[,3E&4<$>I%6_^$IUG_G\_P#(2?X4?\)3K/\
MS^?^0D_PH_MBAV?X?YA_9=;NOZ^1Z17"?$+PGJ_B6>P?2YH8Q"KB3?*4SDC'
M0'T-4O\ A*=9_P"?S_R$G^%'_"4ZS_S^?^0D_P */[8H=G^'^8?V76[K^OD<
MS_PJSQ;_ ,_=K_X$O_A6WX0\ ^(M%\4V>H7UQ ]M#OWJD[,3E&4<$>I%6_\
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MD_PH_P"$IUG_ )_/_(2?X4?VQ0[/\/\ ,/[+K=U_7R.9_P"%6>+?^?NU_P#
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MT#4?$>A06>F21QS)<K*Q=RHVA6'4#U(K _X2G6?^?S_R$G^%'_"4ZS_S^?\
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MV76[K^OD<S_PJSQ;_P _=K_X$O\ X4?\*L\6_P#/W:_^!+_X5TW_  E.L_\
M/Y_Y"3_"C_A*=9_Y_/\ R$G^%']L4.S_  _S#^RZW=?U\CTBL#QGH]YKOAFX
ML+!T2Y=D*L[%1PP)Y'M7+?\ "4ZS_P _G_D)/\*/^$IUG_G\_P#(2?X4?VQ0
M[/\ #_,/[+K=U_7R.9_X59XM_P"?NU_\"7_PH_X59XM_Y^[7_P "7_PKIO\
MA*=9_P"?S_R$G^%'_"4ZS_S^?^0D_P */[8H=G^'^8?V76[K^OD>D5@>,]'O
M-=\,W%A8.B7+LA5G8J.&!/(]JY;_ (2G6?\ G\_\A)_A1_PE.L_\_G_D)/\
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MO^%'_"0:I_S]?^0U_P */[3H]G_7S#^SZO='<45PW_"0:I_S]?\ D-?\*/\
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M^?O_ ,AI_A2?\))JW_/W_P"0T_PH_M6CV?X?YA_9M7NCOZ*X#_A)-6_Y^_\
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M_P AI_A1_P )-J__ #]_^0T_PH_M>CV?X?YA_9E7NOZ^1Z%17GO_  DVK_\
M/W_Y#3_"D_X2;6/^?O\ \AI_A1_:]#L_P_S#^S*O=?U\CT.BO//^$FUC_G[_
M /(:?X4?\)-K'_/W_P"0T_PH_M>AV?X?YA_9E;NOZ^1Z'17GG_"3:Q_S^?\
MD-/\*3_A)]8_Y_/_ "$G^%']KT.S_#_,?]F5NZ_KY'HE%>=_\)/K'_/Y_P"0
MD_PH_P"$GUC_ )_/_(2?X4?VO0[/\/\ ,/[,K=U_7R/1**\[_P"$GUC_ )_/
M_(2?X4G_  D^L?\ /Y_Y"3_"E_:]#L_P_P P_LRMW7]?(]%HKSK_ (2?6/\
MG\_\A)_A1_PE&L?\_G_D)/\ "C^V*'9_A_F']EUNZ_KY'HM%><_\)1K/_/Y_
MY"3_  H_X2C6?^?S_P A)_A1_;%#L_P_S#^RZW=?U\CT:BO.?^$HUG_G\_\
M(2?X4?\ "4:S_P _G_D)/\*/[8H=G^'^8?V76[K^OD>C45YQ_P )3K/_ #^?
M^0D_PH_X2G6?^?S_ ,A)_A1_;%#L_P /\P_LNMW7]?(]'HKSC_A*=9_Y_/\
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M9T/;4TU9I6;OOV"%6K"M[*HT[J^FA'_PA.H_\][7_OIO_B:/^$)U'_GO:_\
M?3?_ !-7/&EQ-#-9B*62/*MG:Q&>E<M]NN_^?J?_ +^&M,1'"4:KIN#=O/\
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MW1=2IB*"YYM2CUTLSD=-T^74[Q;:%D5R"<N3CCZ5M?\ "$ZC_P ][7_OIO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA(QO'G]Y=+6^YF,,3*24N7W7UO\ FCG#0:Z^"]&F^$K2Y2WBD=G*'>/]IO\
M"J/_  EDO_/A:?\ ?)I2P]*"7/.S:3V?7YA&O4DWRPNDVM^QSM%23RFXN)9B
MH4R.7(7H,G/%1UPO?0ZUMJ%)2TE(84&B@TAB4444 )1112&)1110 4E+24AA
M6QX6_P"1DM/^!_\ H#5CUL>%O^1DM/\ @?\ Z U=&%_CP]5^9AB/X,_1GI%%
M%%?='QX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5U'@C_D(7/_7(
M?S%<O74>"/\ D(7/_7(?S%=V7_[U#U_1G'C?]WD6;GQCY%U-%_9R-L=ESYG7
M!QZ57F\9>=!)%_9R+O4KGS.F1]*L7/@N6>ZFF%Z@$CEL>6>,G/K4?_"#2_\
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MA4C6G*ZV>EM&5]/_ .1"NO\ @?\ ,4GA?4H[RU?1KS#*RD1Y[CNOX=118?\
M(A77_ OYBN3BE>&5)8V*NA#*P[&E4KN@Z,EMRZKNKCA15958]>;3U.Z\-Z;)
MI>H:G;/DK^[*-_>7YL&N:\,V/V[6HMPS'%^];\.GZXKM]&U./5=/6X&!(/EE
M7T/^'>L3PXBZ5X=N=3D W."5SW X _$YKLG0IMT>5^XN:7RW_P" <L:TTJO,
MO>=E\]BSKOA^YUB]65;F-(T3:JD'\34^I:5+<>&/LLK++<0("K+W*_XCC\:\
M]=VD=G8Y9CDD]S71^#;[R-1>T8_+.N5_WA_];-<]'%T:M9Q<+<^C=[^FAO5P
MU6E24E*_)JE8YR.1HI4D0X="&4^A%==XF1=2T2SU6(=  ^.P/^!X_&L+Q!8_
MV?K,T2C$;GS$^A_^OD?A6YX4ECO]-NM)N.5^\H_V3UQ]#@_C7-A8/GJ86?7\
MUL;XB2Y88F/3\GN.)_L3P6!]VXN_S^;_  7]:Y[0O^0[9?\ 745I>,+X3ZFM
MJA_=VZXP/[QZ_IBLW0O^0[9?]=117FGB84X[1LOQ5_Q"C%_5Y3EO*[_!V_ Z
M[6_$G]E7XM_L:S?(&W%\=<^WM6;_ ,)M_P!0U/\ OY_]:M+6_#3ZM?BY6Z6,
M; NTIGIGW]ZSO^$&E_Y_D_[]G_&O1K_VA[67L_AOIL<-'ZE[-<^_7<YJ^N?M
ME[-<[ GF,6V@YQ72^$K!K9)=6N)#%"$(7)P&'<GVXJO#X3D&M):22B2!8Q+(
MZC'!)&WZG!J3Q5JZ'&E6A"PQ8$FWH2.B_0?YZ5PT:3H.6(K[IZ+N_P#)'95J
M*LE0H[-:OLBYXGLQJNFPZI9R&1(TR5'3;W./4=__ *U<C9W<UC=1W,#;9$.1
MZ'V-;OA76?LEQ]AN&_T>8_*3T5O\#5?Q+HW]F7OF1#_1IB2G^R>ZU.)7MHK%
MT]_M>3[CH?NI/#5-NGFNQ-<:KI&HM%+=QWT$L9R%MW4J#U)&>G-5]6UXWUO]
MDMD>.WR"[2-N>0CH6/Y?E6+0!DX%<LL75DFM-=[+?^OD=,<-3BT^VWD6].TV
MYU.Y$%NF3U9CT4>IKJ[BYL_">GFUM2);Z098GU]3Z#T%:UGI3:?H_P!ELW2.
MX*_-*RYRW<_X5A2>"KB61I)-15G8Y+,A))_.O5A@ZV'IWI1O-]=-/3S\SS98
MJE7G^\E:"Z=_7R,G1]%DUY[F1KD1LA!8LNXL6S[^U7+_ ,(O8V$UT;Q7$:[M
MOEXS^M8NI63:;J$MH9 YCQ\P&,Y /]:J9/K7F<]*$7"I3O+76_4]#EJ2DIPG
M[NFENA?T6R&H:M;V[#*%MS_[HY/^%:WC*_,U^EDA_=P#) _O'_ 8_,U)X(B#
M7]S,>J1A1^)_^M7/ZC-]HU*ZFSD/*Q'TSQ6K_=X)6WF_P1G_ !,6[[17XLK5
MJ:/KDVC"80PQOYI7)?/;/I]:9H=]'IVK0SS+F+E7XS@'O^%=#JGA@ZI=F^T^
MY@,<WS-N)QGU! -1AJ-5Q]K0?O)[=;=RL15IJ7LZR]U]>GH27RV_B7P^^H*C
M1W%NK<;L@$<D>^169IGA-]1T^*[%XL8DS\OEYQ@D>OM6C?26OAWP_)IL<PEN
MI@0P'7YA@D^G%<7D^M=.+G3C4BZL>:5O>L[:_+R,,-"I*$E2E:-]-+Z?\.;V
MI>'VT:2TD-R)?,E"X"8Q^M=-K^KV^F20+/9+<EP2"V/EQCU!K@+<_P"E0_[X
M_G73^.?^/BS_ -UOYBG1K*%"K4I+E^'S_,56DY5J<*KOOY?D;6C:I8:FK_9;
M>."Y09V%0/QR.HKC_$%YJ%QJ#17X"-$<*BCY0/4>N?6J-E>2V%Y'<PG#H<X]
M1W!KL-=M(M=T6/4[09EC3=CN5[J?<?X^M4ZL\9AG%.THZV75?\ 2IQPM=2:]
MV6E^S.?L[S5] 19!&\<$IR%E0[6-;,'C."9?+O['Y3U*$,/R-365Q8^(]%CT
M^YE$=S& !S@Y P&'KQU%51X'E\S!OD\OU\LY_+-7"&*A%/"RYH/T^:L1.>'F
MVL0N62]?O&^(=(L6TQ=6TX!(S@LJ\*0>,@=CGM3+7P8]S:0S_;57S$5]OEYQ
MD9]:F\07MG8Z,FC6<@D(P'(.=H!SR?4FN1R?6N?$RP\*SYH)Z*]G9)]3;#QK
M3I:2MJ[75W;H=GI.CG1?$<433B4RP.00NW'(]ZYS7 5UR]!_Y[,?UIFDWW]G
M:I!=')5&^8?[)X/\ZZ?5?#RZW<+J&G7,)64#?N)QQQD8'Z4^58G#N%%:J5[7
MZ-!S>PK\U5Z-6OYID6@?+X/U1CT/FX_[X%&J_-X&L2O0%,_D12ZQ+;:)X?&D
M02B2>3_6$=0,Y)/IZ8]*;H5Q;:KH;Z+<RB.09\LGN,Y&/<'MZ5U72MAK^]R6
M^=[V.?5_[1;3FO\ *UKG.:4"VKV0'7ST_P#0A6SXU(.LQ#T@'_H35?TOPU_9
M-W]OU"YA\N'E<$XSZG/\JQ+O65F\2#40FZ))!M4CJ@X_7^M<<J3H8;V=71RD
MON74Z5457$<]/513^]]"MI.JRZ1<//#&CLR;/GSP,@]OI75PS0>+]*ECEC,5
MS">,,< D<'Z<&H]6T2/Q T>H:;<Q990K!CP<?3H?:G0I;^$M*F,LZR7LPR%7
MN1TQ[#)YKKH4JM%N%1WI6>NEGZ>9SUJE.JE*"M5T]5Z^1PY&#@T4=3DT5\^>
MT%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 =%;?\>D/^XO\JDJ.V_X](?]
MQ?Y5)7L1^%'ERW84&B@U0C8T&%5:6[D(5$&T$] >_P#GWJW81107<CF_AE,W
M!0$<DGZUEO?Q#2$LXE<.3F0D#![_ .%4%8HX93AE.0:[57C344E>VOS9R.C*
MHY-NU]#7LK8VGB(1=AN*_3!Q3[6\5=1NK.?F&65P,]CG^M-?5[9[ZVNO+E#(
MI5^!SD=N?6LJXD$MU+*N0'<L,]>31*K&FER.^K^YH(TY5'[ZMHOON;<EHUEH
MU]$W(\S*GU'RTFEP+!I,DCRK"T^55V[#M_6J\NL+/I36TJN9B -P P>>M0:E
M?Q74<$-NKK%$,8;'6KE4I1?/'HM%Z_Y$*G4DN675ZOT-6RM(/L<UD+R*<2 D
M!2,K[]?I6+83-8:DA?C:VQQ[=#45G<FTO(YN2%/('<=Z?J,\-U>-- KJK $A
M@!S6,JL7",HZ.+_ VC3DI2B]4_S-9-/"^(7<C$2CSL]O\YS^54;>X-WXA2;L
MTG'TQQ4TFM*^E>0%?[04",^!C'U^E9MC.MM>Q3."50Y('6JJ5*:E%0>E[O\
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MQ9RK*>6V]_R(J8M1NH5-;]=FON').5G*&ENFZ_$+^PLI[6WO;4^3')($?/0
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MX/W9CQY0'.W!S6MJ=&E*+DI<UMNR=S.\ZM2,E%JU]^[-0>(;_3G-CJ5M'<%
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M,EI_P/\ ] :NC"_QX>J_,PQ'\&?HSTBBBBONCX\**** "BBB@ HHHH ****
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MH **** "BBB@ HHHH 4$J<@D'U%*\CR'+NS'W.:;11<+!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 *K,ARK%3Z@XH9V<Y9BQ]2<TE%%PL%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !3ED=,['9<]<'&:;11L 4444 %%%% !1110 4\S2
ME=IE?;Z;CBF44[M"L%%%%(84Y9'3.QV7/7!Q3:* #K1110 YI'< ,[,!T!.<
M4VBB@!R.\9RC,I]0<4TDDY)R:**+@%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]&>D4445]T?'A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY+_W\H_X1#2?[DO_ '\H_LC$>7W_ / #^TZ'G]QY[17H7_"(:3_<E_[^4?\
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M8CR^_P#X ?VG0\_N//:*]"_X1#2?[DO_ '\H_P"$0TG^Y+_W\H_LC$>7W_\
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MV1B/+[_^ ']IT//[CSVBO0O^$0TG^Y+_ -_*/^$0TG^Y+_W\H_LC$>7W_P#
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MY+_W\H_X1#2?[DO_ '\H_LC$>7W_ / #^TZ'G]QY[17H7_"(:3_<E_[^4?\
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MHJU_9UW_ ,\'I/[.N_\ G@]+V%7^5_<Q^VI_S+[T5J2K7]G7?_/!Z/[.O/\
MGW>CV%7^5_<P]M3_ )E]Z*M%6O[.O/\ GW>C^SKS_GW>E["K_*_N8_;4_P"9
M?>BH:#5K^SKS_GW>D_LZ\_Y]WH]A5_E?W,/;4_YE]Z*M%6O[-O/^?=Z/[-O/
M^?=Z7L*O\K^YA[:G_,OO15I*M_V;>?\ /N])_9MY_P ^[T>PJ_RO[F/VU/\
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M('4T@%HIOF(1G<,>N::EQ#(Y1)59AU - $E%(S*BEF( '<T@D1DWA@5]<\4
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MY_X3>R_Y]KC_ ,=_QH_X3>R_Y]KC_P =_P :X:BC^U<3W7W!_9N'[/[SN?\
MA-[+_GVN/_'?\:/^$WLO^?:X_P#'?\:X:BC^U<3W7W!_9N'[/[SN?^$WLO\
MGVN/_'?\:/\ A-[+_GVN/_'?\:X:BC^U<3W7W!_9N'[/[SN?^$WLO^?:X_\
M'?\ &C_A-[+_ )]KC_QW_&N&HH_M7$]U]P?V;A^S^\[G_A-[+_GVN/\ QW_&
MC_A-[+_GVN/_ !W_ !KAJ*/[5Q/=?<']FX?L_O.Y_P"$WLO^?:X_\=_QH_X3
M>R_Y]KC_ ,=_QKAJ*/[5Q/=?<']FX?L_O.Y_X3>R_P"?:X_\=_QH_P"$WLO^
M?:X_\=_QKAJ*/[5Q/=?<']FX?L_O.Y_X3>R_Y]KC_P =_P :/^$WLO\ GVN/
M_'?\:X:BC^U<3W7W!_9N'[/[SN?^$WLO^?:X_P#'?\:/^$WLO^?:X_\ '?\
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MX_\ '?\ &N&HH_M7$]U]P?V;A^S^\[G_ (3>R_Y]KC_QW_&C_A-[+_GVN/\
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M\:/^$WLO^?:X_P#'?\:X:BC^U<3W7W!_9N'[/[SN?^$WLO\ GVN/_'?\:/\
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M_'?\:/\ A-[+_GVN/_'?\:X:BC^U<3W7W!_9N'[/[SN?^$WLO^?:X_\ '?\
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MX_\ '?\ &C_A-[+_ )]KC_QW_&N&HH_M7$]U]P?V;A^S^\[G_A-[+_GVN/\
MQW_&C_A-[+_GVN/_ !W_ !KAJ*/[5Q/=?<']FX?L_O.Y_P"$WLO^?:X_\=_Q
MH_X3>R_Y]KC_ ,=_QKAJ*/[5Q/=?<']FX?L_O.Y_X3>R_P"?:X_\=_QH_P"$
MWLO^?:X_\=_QKAJ*/[5Q/=?<']FX?L_O.Y_X3>R_Y]KC_P =_P :/^$WLO\
MGVN/_'?\:X:BC^U<3W7W!_9N'[/[SN?^$WLO^?:X_P#'?\:/^$WLO^?:X_\
M'?\ &N&HH_M7$]U]P?V;A^S^\[G_ (3>R_Y]KC_QW_&C_A-[+_GVN/\ QW_&
MN&HH_M7$]U]P?V;A^S^\[G_A-[+_ )]KC_QW_&C_ (3>R_Y]KC_QW_&N&HH_
MM7$]U]P?V;A^S^\[G_A-[+_GVN/_ !W_ !H_X3>R_P"?:X_\=_QKAJ*/[5Q/
M=?<']FX?L_O.Y_X3>R_Y]KC_ ,=_QH_X3>R_Y]KC_P =_P :X:BC^U<3W7W!
M_9N'[/[SN?\ A-[+_GVN/_'?\:/^$WLO^?:X_P#'?\:X:BC^U<3W7W!_9N'[
M/[SN?^$WLO\ GVN/_'?\:/\ A-[+_GVN/_'?\:X:BC^U<3W7W!_9N'[/[SN?
M^$WLO^?:X_\ '?\ &C_A-[+_ )]KC_QW_&N&HH_M7$]U]P?V;A^S^\[G_A-[
M+_GVN/\ QW_&C_A-[+_GVN/_ !W_ !KAJ*/[5Q/=?<']FX?L_O.Y_P"$WLO^
M?:X_\=_QH_X3>R_Y]KC_ ,=_QKAJ*/[5Q/=?<']FX?L_O.Y_X3>R_P"?:X_\
M=_QH_P"$WLO^?:X_\=_QKAJ*/[5Q/=?<']FX?L_O.Y_X3>R_Y]KC_P =_P :
M/^$WLO\ GVN/_'?\:X:BC^U<3W7W!_9N'[/[SN?^$WLO^?:X_P#'?\:/^$WL
MO^?:X_\ '?\ &N&HH_M7$]U]P?V;A^S^\[G_ (3>R_Y]KC_QW_&C_A-[+_GV
MN/\ QW_&N&HH_M7$]U]P?V;A^S^\[G_A-[+_ )]KC_QW_&C_ (3>R_Y]KC_Q
MW_&N&HH_M7$]U]P?V;A^S^\[G_A-[+_GVN/_ !W_ !H_X3>R_P"?:X_\=_QK
MAJ*/[5Q/=?<']FX?L_O.Y_X3>R_Y]KC_ ,=_QH_X3>R_Y]KC_P =_P :X:BC
M^U<3W7W!_9N'[/[SN?\ A-[+_GVN/_'?\:/^$WLO^?:X_P#'?\:X:BC^U<3W
M7W!_9N'[/[SN?^$WLO\ GVN/_'?\:/\ A-[+_GVN/_'?\:X:BC^U<3W7W!_9
MN'[/[SN?^$WLO^?:X_\ '?\ &C_A-[+_ )]KC_QW_&N&HH_M7$]U]P?V;A^S
M^\[G_A-[+_GVN/\ QW_&C_A-[+_GVN/_ !W_ !KAJ*/[5Q/=?<']FX?L_O.Y
M_P"$WLO^?:X_\=_QH_X3>R_Y]KC_ ,=_QKAJ*/[5Q/=?<']FX?L_O.Y_X3>R
M_P"?:X_\=_QH_P"$WLO^?:X_\=_QKAJ*/[5Q/=?<']FX?L_O.Y_X3>R_Y]KC
M_P =_P :/^$WLO\ GVN/_'?\:X:BC^U<3W7W!_9N'[/[SN?^$WLO^?:X_P#'
M?\:/^$WLO^?:X_\ '?\ &N&HH_M7$]U]P?V;A^S^\[G_ (3>R_Y]KC_QW_&C
M_A-[+_GVN/\ QW_&N&HH_M7$]U]P?V;A^S^\ZN2Z-S(TZ%E64EP">0#S3-[_
M -]OSJ&V_P"/2'_<7^525NJDGJV8\D5HD.WO_?;\Z/,?^^WYTV@T^:7<.6/8
M7S'_ +[?G1YC_P!]OSIM%+FEW#ECV%\Q_P"^WYT>8_\ ?;\Z;12YI=PY8]A?
M,?\ OM^='F/_ 'V_.FT4<TNX^6/8<9'_ +[?G2>9)_?;\Z0TE'-+N'+'L.\R
M3^^WYTGF2?WV_.DI*7/+N/ECV'>9)_?;\Z/,D_OM^=-HI<\NX<L>PXRR?WV_
M.D\V3^^WYTAI#1SR[ARQ[#O-D_YZ-^='FR?\]&_.F44<\NX^6/8?YLG_ #T;
M\Z/-D_YZ-^=,HI<\NX<L>P[S9/\ GHWYT>;)_P ]&_.F44N>7<?+'L.\V3_G
MHWYT>;)_ST;\Z8:*.>7<.6/8=YLG_/1OSH\V3_GH_P#WT:::2CGEW'RQ[#_-
MD_YZ/_WT:3SI/^>C_P#?1IM)2YY=PY8]A_G2?\]'_P"^C2>=)_ST?_OHTVDH
MYY=PY8]A_G2?\]'_ .^C1YTG_/1_^^C3**7/+N'+'L/,TO\ ST?_ +Z-)YTO
M_/1_^^C3324<\NX^6/8?YTO_ #T?_OHT>=+_ ,]'_P"^C3**7/+N/ECV'>=+
M_P ]'_[Z-'G2_P#/1_\ OHTRBESR[ARQ[#S-+_ST?_OHTGG2_P#/1_\ OHTT
MTE'/+N'+'L/\Z7_GH_\ WT:3SI?^>K_]]&FTE+GEW'RQ[#_.E_YZO_WT:/.E
M_P">K_\ ?1IE)1SR[AR1[$GG2_\ /5_^^C2>?+_SU?\ [Z-,HHYY=V')'L/\
M^7_GJ_\ WT://E_YZO\ ]]&HZ*7/+NQ\D>Q)Y\O_ #U?_OHTGGR_\]7_ .^C
M3*0T<\N['R1[#_/E_P">K_\ ?1H\^;_GJ_\ WT:8:2ESR[O[PY(]B3SYO^>K
M_P#?1H\^;_GJ_P#WT:CHHYY=W]X<D>P_SYO^>K_]]&CSYO\ GJ__ 'T:8:2E
MSR[O[Q\D>Q)Y\W_/5_\ OHTGGS?\]9/^^C3*2CGEW?WAR1[$GGS?\]9/^^C2
M?:)O^>TG_?1IE)2YY=W]X<D>Q)]HF_Y[2?\ ?1H-Q-_SVD_[Z-1T&CGEW?WC
MY(]A_P!HF_Y[2?\ ?1H^T3?\]I/^^C4=%'/+N_O#DCV'_:)O^>TG_?1H^T3?
M\]I/^^C4=%+GEW?WL.2/8D^T3?\ /:3_ +Z-!N)O^>TG_?1J.@TN>7=_>Q\D
M>P_[1/\ \]I/^^C1]HG_ .>TG_?1J.BCGEW?WL?)'L2?:)_^>TG_ 'T:/M$_
M_/:3_OHU'24N>?=_>PY(]B7[1/\ \]I/^^C2?:9_^>TG_?1J.DHYY]W][#DC
MV)?M,_\ SVD_[Z-(;F?_ )[2?]]&HZ0TN>?=_>PY(]B7[3/_ ,]I/^^C2?:9
M_P#GM)_WT:CH-'M)]W]['R1[$GVF?_GM)_WT:/M,_P#SVD_[Z-144O:3[O[W
M_F')'L2_:9_^>TG_ 'V:3[3/_P ]Y/\ OLU'24>TGW?WO_,?)'L2_:9_^>\G
M_?9H^TS_ //>3_OLU%12]I/N_O8<D>R)#<S_ //>3_OLTAN9_P#GO)_WV:C-
M!H]I/N_O?^8^2/9$GVF?_GO)_P!]FC[3/_SWD_[[-144O:3[O[W_ )AR1[(E
M^TS_ //>3_OLTGVFX_Y[R_\ ?9J.DH]I/N_O?^8<D>R)?M-Q_P ]Y?\ OLT&
MZN/^>\O_ 'V:BH-+VD^[^]_YCY(]E]Q)]JN/^>\O_?9H^U7'_/>7_OLU%11[
M2?=_>_\ ,.2/9?<2?:KC_GO+_P!]FC[5<?\ />7_ +[-144O:3[O[W_F')'L
MON)/M5Q_SWE_[[-'VJX_Y[R_]]FHJ*/:3[O[W_F')'LON)?M5Q_SWE_[[-'V
MJX_Y[R_]]FHJ2E[2?=_>_P#,?)'LON)OM5Q_SWE_[[-:WAF>63Q%:*\KL/GX
M9B?X&K#K8\+?\C):?\#_ /0&KHPTY.O!-O==?,QQ$(JC+3HSTBBBBOMSY$**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *\^^(GC0Z/#_9UDW^E2#YB#]T&N\N9EM[:29NB#-?-.N7TFHZW=7$K
M$D2,HSZ9K:C#F=V7!792EDDGE::=S)(QR6;J:LV$)>=9-P55/K3[;2;R=4F,
M++:L0#-V&:V]>\$WVD6T=Y:N;RT89,B# %=%3WH\J=KFDM58BNK>$0L\:(9"
M.]<VRY;YAR*TK)+C6=2AM;=BLA 6DUS2;K1=3DM+L'>#PV/O5SX6E*DK2=[D
M4HN.C.G\!^-KC2;^.PO93):2G:I8_=KW".198UD0Y5AD&OE9L@94X(Z&OH#X
M?:H^J>&8BYRT.(_R%76@OB0374SKOCXDVI]%?^58^BZ3=:\FHW4^J7"&-W\L
M#^'!K7O"/^%DVH[[7_E3? Y!TW5,?WY/YU-[1N'09IQGU[P?J=O=W,@:T9D$
M@ZL .]4O#D;Z'\/9]4MIG:5APAZ+SBKWA4@^'/$/_763^55K)7E^$DJQ*68C
MI_P*GY>8&?();72(M8CUR>2[W;VASP1Z5I>(K[4=0DT1+>[DM6NK<-(4/K6:
ML?A:V\.0SHAFO2=HC#');TK2U=]VK>'F*&,FV!V?W>>E/J!<\265SH'@ZX6'
M49Y92 !*W4<UF7NEW6A:7IFJ0:G<22R,AD5NA!&<5T/Q#('A28GT'\Q5'Q01
M_P (?I.>F4_E4Q;LA(DUPZCJUQIJ_:S9:?+%NFE5L'=6=I$TL'B.XT2+4I;J
MTE 4.QY7CM46L-#/JVA6NIN4TQK8EN2 3VYHTF'2[?XA+'I1S%QG!)[4TM!]
M!/!VBI'XDOW6YDS&S<>N#5BTUR]M;?Q)<&5G,5P$C!/W0?2K7A$@^(=5Q_>?
M^=8D4;SZ=XI2)2S"[4X]J-WKY 2RV&H6?AH>(1J]RUPI+F,]#STJQKTUYJVI
MZ1"MY);K/;H\FP]<]:CO=8T^;X=&TCN%:X8%5CQR3FI+D&/7=!1P0WV6/(I^
MOF!;M8[KPWXRM=-CO);BWN49MK]B!Q56XLKZ_N;NYU75WLF&?)BC8'%:.MMC
MXCZ5C[WE/C\JPM.CTF_O=1E\0RD7:@X4DC SQ27</,E?4KC4O LPN)#(;>\$
M2N>K =Z[WP[_ ,@"T_W*\TLS$O@:_$)_<C4,)]*]+\.<Z!:?[E34V%(U****
MQ("BBB@#C_'7_+A_VT_]EKCZ[#QU_P N'_;3_P!EKCZ^-S/_ 'J7R_)'U.7_
M .[Q^?YA1117GG<%%%.:-U179&"MT)'!HL VBCK2[3Z&@!**,8HH **7:?0T
M;3Z&@!**,'.,4NT^AH 2BEVGT-&#Z&@!**7:?0T;3Z&@!**** "BE56=MJJ6
M/H!FG/%)%_K(W3_>4BG9[BNMAE% !/2BD,***,'TH **,$=J* "BC!QG'%+@
MGH#0 E%+@CL:2@ HHZTNT^AH 2BC&** "BBI#;S*NYH9 OJ5.*:3>PKI$=%%
M !/04AA11THH **7!QG!HP3T!H 2BEVGT-&".QH 2BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ** ">@HH **,'&<<44 %%%'2@ HH )Z44 %% !/04NT^AH 2BEVGT
M-)0 44 $]!10 44 $]*7:?0T )1110 4444 %%&#Z44 %%&#C.** "B@ GH*
M* "B@ GH** "BC!]** "BBEP<XP: $HI=I]#1M/H: $HHP?2B@ HHH((ZB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU&]^OG?R.(HHHKP3V0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^?PC.&_@E&WVY7_$UT2IT[RI):I7OYV3,(U)V51O1NUOP(X=(MX[..XU"Z,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,?<UH:?KUUIME+:VZ0@2$DN5.X$C'!S2AB(2Q7MJNU[_ .02H3CAO94]]O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .B
MMO\ CTA_W%_E4E1VW_'I#_N+_*I*]B/PH\N6["@T4&J$;<#'3=#,RG$TS?*?
M3_(S^=5(]:O5E0O-N0$;EVCD?E6=16[KRT479(Q5&.KEJV=*\"KKUM<IC9,I
MY]PO^&*Q)IWM]6FFC.&69B/S-5***E?FV5M;A3H\N[OI8Z>\FBN=#FGB 'F
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'L!!X1M;FQ\):K>"\D<)Y@$9Z9'>GMX@U'_A&]+M;9RMS=H"9 >1S5C0"/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#HK;_CTA_W%_E4E1VW
M_'I#_N+_ "J2O8C\*/+ENPH-%!JA"4444AB4444@$HHHH&!I*4TE !24M)2&
M%%%%( -(:4TAH 2BBB@84444@$HHHI#$-%!HH #24II*0PI*6DH *2EI*0!1
M110 &DI324AA1110,2BBBD &DI324 %)2TE(84E+24 %%%%(!****!A2&EI#
M2&!I*4TE !1112 #24II*!A24M)2 *2EI* "@T4&D,2BBB@!****0PH-%!H
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M.:X: ,#<,6?)[FM*BAR;"YGZ;H]KI<D[VX(,[;GR>]:%%%)NX@HHHH ****
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M[%'VNV_Y^(O^^Q1_9>$[O[P_M'$]OP.&_P"$-U3^];_]]G_"C_A#=4_O6_\
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MPANJ?WK?_OL_X5W/VNV_Y^(O^^Q1]KMO^?B+_OL4?V7A.[^\/[1Q/;\#AO\
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MS_A7<_:[;_GXB_[[%'VNV_Y^(O\ OL4?V7A.[^\/[1Q/;\#AO^$-U3^];_\
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M&_X0W5/[UO\ ]]G_  H_X0W5/[UO_P!]G_"NY^UVW_/Q%_WV*/M=M_S\1?\
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M_P *[G[7;?\ /Q%_WV*/M=M_S\1?]]BC^R\)W?WA_:.)[?@<-_PANJ?WK?\
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M_"NY^UVW_/Q%_P!]BC[7;?\ /Q%_WV*/[+PG=_>']HXGM^!PW_"&ZI_>M_\
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M#?\ "&ZI_>M_^^S_ (4?\(;JG]ZW_P"^S_A7<_:[;_GXB_[[%'VNV_Y^(O\
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M_P"%=S]KMO\ GXB_[[%'VNV_Y^(O^^Q1_9>$[O[P_M'$]OP.&_X0W5/[UO\
M]]G_  H_X0W5/[UO_P!]G_"NY^UVW_/Q%_WV*/M=M_S\1?\ ?8H_LO"=W]X?
MVCB>WX'#?\(;JG]ZW_[[/^%'_"&ZI_>M_P#OL_X5W/VNV_Y^(O\ OL4?:[;_
M )^(O^^Q1_9>$[O[P_M'$]OP.&_X0W5/[UO_ -]G_"C_ (0W5/[UO_WV?\*[
MG[7;?\_$7_?8H^UVW_/Q%_WV*/[+PG=_>']HXGM^!PW_  ANJ?WK?_OL_P"%
M'_"&ZI_>M_\ OL_X5W/VNV_Y^(O^^Q1]KMO^?B+_ +[%']EX3N_O#^T<3V_
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M]BC[7;?\_$7_ 'V*/[+PG=_>']HXGM^!PW_"&ZI_>M_^^S_A1_PANJ?WK?\
M[[/^%=S]KMO^?B+_ +[%'VNV_P"?B+_OL4?V7A.[^\/[1Q/;\#AO^$-U3^];
M_P#?9_PH_P"$-U3^];_]]G_"NY^UVW_/Q%_WV*/M=M_S\1?]]BC^R\)W?WA_
M:.)[?@<-_P (;JG]ZW_[[/\ A1_PANJ?WK?_ +[/^%=S]KMO^?B+_OL4?:[;
M_GXB_P"^Q1_9>$[O[P_M'$]OP.&_X0W5/[UO_P!]G_"C_A#=4_O6_P#WV?\
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MO6__ 'V?\*/^$-U3^];_ /?9_P *[^BC^R,-Y_>']IU_+[C@/^$-U3^];_\
M?9_PH_X0W5/[UO\ ]]G_  KOZ*/[(PWG]X?VG7\ON. _X0W5/[UO_P!]G_"C
M_A#=4_O6_P#WV?\ "N_HH_LC#>?WA_:=?R^XX#_A#=4_O6__ 'V?\*/^$-U3
M^];_ /?9_P *[^BC^R,-Y_>']IU_+[C@/^$-U3^];_\ ?9_PH_X0W5/[UO\
M]]G_  KOZ*/[(PWG]X?VG7\ON. _X0W5/[UO_P!]G_"C_A#=4_O6_P#WV?\
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M_P#WV?\ "N_HH_LC#>?WA_:=?R^XY:'P]>I!&A,654 _,?3Z4_\ L&\]8O\
MOK_ZU=-170L#26FOWF+QE5]CF?[!O/6+_OK_ .M1_8%YZQ?]]?\ UJZ:BG]1
MI>?WB^N53F/[ O/6+_OK_P"M1_8%YZQ?]]?_ %JZ>BE]1I>?WC^N5?(YC_A'
M[SUB_P"^C_A1_P (_>>L7_?1_P *Z>BCZC2\_O#ZY5\CE_\ A'[WUB_[Z/\
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MJ']Z#_OL_P"%)_PBNH_WH/\ OL_X5VM%']F4//[P_M"MY?<<5_PBFH_WH/\
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M"M-.,K6?D/HHHKU#S@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#I/!/_(9F_Z]V_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN:O?\)=\2?\ H"W/_@M?_"@#V*BL[0+B]NM!LI]2C,5Y)$&F0IL*MZ8[5HT
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M%GZ'(KT'PCXSL/%EL_DJ8+R( RV[-D@>JGN* .EHHHH **** "BBB@ HHHH
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M$?B* /0:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-1XI_P"1CN_^ ?\ H"UIV>E-I/C.VC )A?>T3'TVGCZBLWQ.I?Q+=*H)8E
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M;_RV1%XQL8;;4(IXE"^>I+ >H[_K7-UMZO>2^(M95+2,NJ@I$O0D#DGFHO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF*STUF:UR70L^_.[G(/I0!X3X5\0W^C^);S4;+3&O)YHW5H%#$J&<$G@9X(
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MO%>$+%#;?&6.+2PJQ+J*@!.@!QO QV^\,5H377Q3U%# 8KR-7&#LBCB/_?6
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MR/>@#/UOXK+%J+:?H.GF_E5BGF-G:S#^ZJ\L/?BLN7XH^)]-D5M5\/1PQ,>
M\4L)/T+9_E6OI<'@[X<W]TTNK^;=RJ$VNOF21@=1\@XSQUQT%4O%7Q+\/:IH
M-[IL%M=7#3Q%49HPJ*W\+<G/!P>E '6VGB^/5/!UQKNF6KS2Q*P-J>6$@Q\O
M'7J#]*\=MO$-_'\0&UM-,9[TRNWV,!LY*%2.F> <].U=S\&"?[+U5>PF0_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH Z3P3_P AF;_KW;_T):[RN#\$_P#(9F_Z]V_]"6N\KZW*?]V7JSYG,O\
M>'Z(****]4\X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,OC/\ \@C3/^N[
M?^@UUW@C_D2='_Z]EJ#QGX0_X2^SM;?[=]D\B0ON\KS-V1C&,BM?1-,_L;1+
M/3O-\[[-$(_,V[=V.^,G% %^LCQ3>SZ=X6U.[MLB>*W<HPZJ<8S^'7\*UZCG
MABN8)()D62*12CHPR&!&"#0!XK\-?"VD^)9+ZZU9FN9(6&(#(1G.27;')Y]_
M6NQ\86?AKPMX4O1!I]E!=7,+00!8P9&+#!()YP <YK*NOA%+;WS7&B:W):J3
M\JN#N0>F]2,_E5W3_A/:"Y-SKFIW&IR$8VG*#\3DD_F* ,_X/RM%HVMO'&99
M$9&6,'!8[6P/QQ6MX=\8:3X]N;C3M3TJVC9%#013L)2XYW8RHP1QT_I5_P %
M^!Y/"%S=N-5^U17"*#']GV8(/!SN/J?SK,\0_"FSU/4'O],O3832-O:/9N3=
MZK@@KSSWH H^.O /AS3M NM3M2UC-$,H@D)21L_=P<G)]C5[X/W%S-X9NHYF
M9H8KDK#N/3*@D#VR<_C69%\(KZZF0ZKX@:6)>R*S-CT!8\?D:])TG2;/1--B
ML+&+RX(AP.I)[DGN30!Y+\-Y8X?B3J:R.JEXYT4$XR?,4X'X _E7L^<C(KS7
M7_A)#J>KSWUEJ7V59W,CQ/%O 8\D@Y'&>U=SH6FOH^AV>G//Y[6\8C\S;MW
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M"#P<[CZG\ZH^+/AE!XBU9]2MKXVD\H'FJT>]6(&,CD8. * +?Q2(/@.[P?\
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M]<UB>./!VD>$?#]LD4\EQJ-Q< [Y#C$:J=V%';)7KF@#TGX=_P#(A:5_N/\
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M #8XTAB2.-%2- %55&  .@ IU%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH JMIMHUZMXT(,Z]'[BIY8DGB:*10R,,$'O3Z*
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M\BHKUWR8_P#GFG_?(H\F/_GFG_?(H_L5_P _X?\ !#^UE_)^)Y%17KODQ_\
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M 'R*/[%?\_X?\$/[67\GXGD5%>N^3'_SS3_OD4>3'_SS3_OD4?V*_P"?\/\
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M* -&BBN?N_''ANQNY;6YU6..>%BCH4<[2.HX% '045S'_"P_"G_09B_[]O\
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M_P 36AI/B?1==G>#3+]+B6-=[*JL,#.,\@4 :]%%8FI^+]!T>]:SU#44@N%
M8HR,>#TZ"@#;HKF/^%A^%/\ H,Q?]^W_ /B:T-)\3Z+KL[P:9?I<2QKO955A
M@9QGD"@#7HHK$U/Q?H.CWK6>H:BD%PH#%&1CP>G04 ;=%<Q_PL/PI_T&8O\
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MC^=_>'U6A_(C>_X2_5O[\7_?NC_A+]6_OQ?]^ZP:*/KF(_G?WA]5H?R(WO\
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M]JWS126)K+[3&Z%)_9.1_P"%?Z?_ ,_=S_X[_A6_X8TQ?"DER]E.[FX"AO-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPSK$:EC9,0/[KJQ_(&MGA:Z^P_N9C]8HO[2^\R:*=Y;^;Y94A\[=IX.:U_\
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M_I%[IBHUW#Y8<D*=P.<?0U<L/6@N:46EZ$1KTI.T9)OU*5%.1&DD6- 2S$
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MXQ,H"C> 3S7=5]]!WBGY(^*FK2:"BBBK)"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@"@,/]ZN<_X2+5_^?Z3\A_A756MQ:VO@ZVEO(/.A"C*;0<_-QP:S?[=\._\
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M)XD1R[$$-FN]\/W;7WA^QN74*SPC('3CC^E>:>+_ /CTMO\ ?/\ *O0_"/\
MR*>F_P#7$?S-?0X2E!8:,TM6V>)B:DG7<&]%8VJ***W,0HHHH **** "BBB@
M HHHH 2BBBD 4444 %%%%, HHHH ****0!1110 4444 %%%% !24M)0,****
M "BBBD 4444 %(:6D- !1110 4444 %%%%  :2E-)0 4444 %%%%(84E+24
M%%%% !1110 4E+24AA1110 4444 %%%% !24M)2 ****!A1110 4E+24 %%%
M%( I*6DH **** "DI:2@84444@"DI:2@84444 %%%%( -)2FDH ****!A111
M2 2BBB@ I*6DH **** $HHHI#"@T4&@!****0P-)2FDH **** "BBBD,0T4&
MB@ I#2TAI %%%% "4444#"DI:2D 4&B@T#$HHHI %)2TE PHHHI %(:6D- !
M0:*#2 2BBB@8AHH-% !24M)2&%)2TE( HHHH&%)2TE !24M)2&%%%%( -)2F
MDH #24II*!A24M)2 *2EI*0PHHHH #24II*0P-)2FDH *0TM(:0!0:*#0,2@
MT4&D E%%%(8AH-!H- Q****0!2&EI#0 4E+24AA24M)2 ****!B4E+24@"@T
M4&@8E%%%(8&DI324@$-%!HH&)1112 2BBBD,2BBB@ I*6DI#"DI:2D,#24II
M*  TE*:2D E%%%(84E+24#/5-)_Y UC_ ->\?_H(JY7C?PYU[5KOQH+&XU"Y
MEM%BD"PO(2H Z<>U>R5]]35H)>2_)'Q<W>3?F_S"BBBK("BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ./\=?\ +A_VT_\
M9:X^NP\=?\N'_;3_ -EKCZ^-S/\ WJ7R_)'U.7_[O'Y_F%%%%>>=Q-:7!M;R
M"X R8I%?'K@YKM-;T@>(88+^PFC9]FW!/##K^!&37"U/;WMU:$FWN)8L]=C$
M9KLP^(C"$J=2-XO[[G+7H2G)5*;M)'1Z;X0NQ>1R7C1I$C!BJMDMCM5;Q=J,
M5[J*10N'2!2"PZ%CUQ^0K*FU;4+A"DMY.R'JN\X-4ZNKB*2I.E1BTGNV]2:=
M"HZBJ597:VL=AJ'_ "(5K_P#^9KF],U"73+^.YBYV\,O]Y>XJ%KNY>!8&N)6
MA7I&7)4?ATJ&LZV)YYQG#1Q27W%TJ'+"4):IMO[STV\E@N?#UY<V^"DUN[Y'
M?Y,<^_&/PK%\&*7T^^0=68 9^AKDTO+J. P)<S+"<@QJY"G/7BB"\NK4$6]S
M-"&Y(C<KG\J[99E&5:%5QV33^9R+ 2C2E34MVG]QM#P9JA/WK<?\#/\ A6U8
M6%KX5LY;N[G5YW7&%_\ 05]?K7('5=1(P=0NB/\ KLW^-59)9)6W2.SMZL<F
ML88G#T7STH/FZ7=[&LL/7JKEJ35O)&UH=P]WXLAN)/OR2.Q_%32^*',?B621
M>JA"/P K%BEDAD$D4C1NO1E."/QHEFEGD,DTCR.>K.Q)/XFL/K'[ATWOS7N;
M>P_?*ITM:QW.H64/BK3H+FTF19D!X;MGJI]*Q8O!FI-,%D>%(\\N&SQ["L*"
MYGMGWP321-ZHQ!_2K3ZUJ<B;6OI\>SD5TSQ.&K/GK0?-UL]&81P]>DN2E)<O
MFM4;WBZ[@CL[72XGWO$0S'.2N!@9]^:MVKV_BC05M)) EY"!]01P&]P>]<.2
M222<D]Z<CM&X=&*L.05."*GZ^W5E.4;QDK->70?U-*FHQ?O)WOYF[_PA^J>=
MLQ#MS_K-_'^/Z5L7\MOX:\/FPADW74H(XZY/5CZ<=*Y?^VM4V;?M]QC_ *Z'
M/YU2=VD<N[%F)R68Y)H6)HTHOV$6I/2[>WH#P]6HU[:2LNB6_J=CX/0R:1?(
MO5FP,_[M9O\ PANJ>MO_ -]G_"L6"]NK52MO<S1*3DB.0KG\JE_M;4O^@A=_
M]_F_QH6(P\J4(58MN/9I!["M&I*=.27-W18O]&OM%\F>9HP2_P A1LX(YKII
M4M?%VEQLDBQ7D0R1_=/<'V/K7&3WMU=*%N+F:4 Y DD+8_.HHY'B</&[(XZ,
MIP144\33IRE&,;PENF]?O*GAYSBI.5IKJO\ (WD\':HTNUO)5?[^_(_QK7OI
M[7PSHC6%O('NY <GOD]6/I[5RYUK4V38;^XQ_P!=#G\ZHLQ9BS$DGJ3WJUBJ
M-)/V$6F]+M[>A+P]6HU[:2LNB6_J=-X/U&""6:RN&55GP4+=">A'XT7G@R\2
M9C:21R1$_*&;# >_:N8J[#J^HP($CO9U4=!O) J:>)I2I*E7BW;9IZE3H5%4
M=2C*U]TSK=$TG_A'HI[Z_N$7*;<*> .OXFL?PY/]I\6-<8QYID?'IG)K$N+R
MYNR#<7$DN.F]B<4R&>6WD$D,KQN.C(Q!_,53QD%*FH1M&+OYLE863C-SE>4E
M;R.JUCPQJ%]JUQ<PF'RY""-SD'H!Z52_X0W5/6W_ .^S_A65_:VI?]!"[_[_
M #?XT?VMJ7_00N_^_P W^-$ZV$G)R<)7?FO\@C2Q48J*DM/)FSX>LY=/\5_9
M9]OF(ASM.1RN?ZU9U?POJ%[JMQ<Q&'RY&R-SD'H/:N8%Y="X-P+F83G@R;SN
M/;KUJ7^UM2_Z"%W_ -_F_P :(8BA[+V4XMJ[:U02H5O:>TC)7M9Z'4:3X7&F
MSB^U&XBQ#\RJI^4'U)-8'B'5%U74S)'GR4&R//<>M9\US<7'^NGDDQ_?<G^=
M15E6Q,'3]E2CRQW?5LTI8>2G[6I*[V[)!78Z5_R(U[])/Y"N.J9;NY2!H$N)
M5A;K&'(4_ATK/#5U1DVU>Z:^\O$475BDGLT_N(:[K2;J+Q'H<EC=G,\8P6/7
M_98>_P#GO7"U)#<36S[X)I(GQC<C%3C\*K"XGV$G=7B]&NXL10]M'1V:V9VF
M@6#:'8W]Y>+M="0/=5]/J?Z5RCZQJ3NS&_N1N.<"5@!^M1RZC?3QF.6\N)$;
MJKRL0?PS5:KK8I2A&G2NDO/OZ$TL.U*4ZEFWY?YG7>$=6FFO);2ZGDE\Q=R&
M1BW(ZCGV_E3=*L?[.\:O;@80*S)_ND9'^'X5RT4LD,@DBD:-UZ,IP1^-2F_O
M#.)S=SF8#:)/,.X#TSUJX8U*$%--N+O?R[$3PK<IN#LI*UO/N7?$G_(P7G^\
M/Y"K?A;6/L%[]FF;%O.<<]%;L?Z5@R2232-)*[.[=68Y)_&FUSK$2A7]M#O?
M_@&SH*5'V4NUCI?$6C_8-5BNH5Q;SR#@=%;/(_'K^=;/B;1+O5I+=K8QXC#!
MM[8ZXKB9+^\F0)+=SN@((5I"0"/QJ3^UM2_Z"%W_ -_F_P :[%B\/[\7!\LK
M/='-]6K>XU)7C?HS5_X0W5/6W_[[/^%9VJ:-=:08OM/E_O<[=C9Z8S_.H_[6
MU+_H(7?_ '^;_&H9[NYNMOVBXEFVYV^8Y;'TS7+4EAG%JG%I^;1O3CB%+WY)
MKT(:[?0K9[OP?/;QXWR%U7<>,UQ%6(;^\MX_+@NYXDSG:DA4?D#1A*\:,W*2
MNFFOO'B:,JL$HNS33^XVE\&:F3@O;J/4N?\ "ME5M?".DR#S1+=R\@8Y8]N/
M05QYU746&&O[HCT,S?XU59V=BSL68]23DFMXXJA1O*A!J7=N]C&6'JU;*K)6
M[)6N:WAHEO$EJQ.268D_\!-7=<NOL7C$7.,B,QL1ZC S7/12R0R"2*1HW7HR
MG!'XT2S2SR&2:1Y'/5G8DG\36$<3RT?9K?FO<VE0YJO.]K6.WUG1$\0+%?V%
MQ&6*;3NZ,/Z&LNR\'7QND-R\<<2MDE6R3]*P+>\N;0DV]Q+$3UV,1FII=8U&
M="DE[.RGJ-Y -=,L3A:DO:5(/F\GHSGCA\1"/LX35O-:FQXQU"&ZO8;>%@_D
M!MS#IN../TK9U;2[C5=#L(K8IN0*QWG'&VN!JVNJ:BJA5O[H*!@ 3-@#\Z4<
M;&4JDJL;J?8<L))1@J;MR]S6_P"$-U3UM_\ OL_X5&WA6^AN+9)O+V32B/*-
MDC@DGIZ UG?VMJ7_ $$+O_O\W^-(=4U!BI-_=$J<@F9N#T]?<UFYX/I"7WK_
M "-%#%=9+[F=+XMU*6TEMK&SF>'8FYO+8KQT X^AKFQJ^I*P(O[K@YYF8_UJ
MM+-+/(9)I'D<]6=B2?Q-,K/$8J=6HYIM+M<NCAX4Z:@TF_0[;Q#&NK^'(-2B
M'SQ@.<>AX8?@?Y5(D<'BCP]%"LJI<P@9S_"P&.1Z'_/2N,2]NHX# ES,L)!!
MC$A"D'KQTJ.*62%P\4CQN.C(<&NIX^+FY2C=224EW\T<RP4E#E4K-.Z\O)F\
M/!NJ>;M)@V_W]YQ_+-:6OR0:5X;BT@2^9,V![X!W$^W-<V=<U0KM^WW&/]\Y
M_.J+NTCEW8LQZDG)-9O$T*<)1H1:<E:[?0T5"M.476DK+71=3N8K&;4?!5O;
M0;?,8 C<<#ALUC?\(;JGK;_]]G_"LB/4KZ&-8XKVX1%Z*LK #\,T[^UM2_Z"
M%W_W^;_&JGB<-54?:0=TDM&NA,*%>FWR25FV]GU+E]X:O]/LWNIC"8TQG:V3
MR<>GO6/5F74;V>,QS7EQ)&>JO*Q!_ FJU<59TG+]TFEYNYUTE42_>--^0444
M5B:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8WB+3[
MG4+>%;9 S(Y)!8#M7?>&K>6T\-V$$R[9$B&1G-<U79V7_'A;?]<E_D*]C UY
M2A[)[+4\O%T8J7M%NR>BBBO0.(**** "BBB@ HHHH **** $HHHI %%%% !1
M113 **** "BBBD 4444 %%%% !1110 4E+24#"BBB@ HHHI %%%% !2&EI#0
M 4444 %%%% !1110 &DI324 %%%% !1112&%)2TE !1110 4444 %)2TE(84
M444 %%%% !1110 4E+24@"BBB@84444 %)2TE !1112 *2EI* "BBB@ I*6D
MH&%%%%( I*6DH&%%%% !1112 #24II* "BBB@84444@$HHHH *2EI* "BBB@
M!****0PH-%!H 2BBBD,#24II* "BBB@ HHHI#$-%!HH *0TM(:0!1110 E%%
M% PI*6DI %!HH- Q****0!24M)0,****0!2&EI#0 4&B@T@$HHHH&(:*#10
M4E+24AA24M)2 ****!A24M)0 4E+24AA1112 #24II*  TE*:2@84E+24@"D
MI:2D,****  TE*:2D,#24II* "D-+2&D 4&B@T#$H-%!I )1112&(:#0:#0,
M2BBBD 4AI:0T %)2TE(84E+24@"BBB@8E)2TE( H-%!H&)1112&!I*4TE(!#
M10:*!B4444@$HHHI#$HHHH *2EI*0PI*6DI# TE*:2@ -)2FDI )1112&%)2
MTE S*^&/_)0S_P!<YJ]UKA?"'@*UT>_@UV.]FDEEAW&)E 4;P">:[JOOH.\4
M_)'Q4U:3044459(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!Q_CK_ )</^VG_ ++7'UV'CK_EP_[:?^RUQ]?&YG_O4OE^
M2/J<O_W>/S_,****\\[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** ,O6M5?2H8G2-7+L1ACC%=YX?NVOM L;EE"EXAD
M#MVKS3Q?_P >EM_OG^5>A^$?^13TW_KB/YFOH<'2@L,JB6K;/$Q523KN#>BL
M;5%%%;F(4444 %%%% !1110 4444 )1112 **** "BBBF 4444 %%%%( HHH
MH **** "BBB@ I*6DH&%%%% !1112 **** "D-+2&@ HHHH **** "BBB@ -
M)2FDH **** "BBBD,*2EI* "BBB@ HHHH *2EI*0PHHHH **** "BBB@ I*6
MDI %%%% PHHHH *2EI* "BBBD 4E+24 %%%% !24M)0,****0!24M)0,****
M "BBBD &DI324 %%%% PHHHI )1110 4E+24 %%%% "4444AA0:*#0 E%%%(
M8&DI324 %%%% !1112&(:*#10 4AI:0T@"BBB@!****!A24M)2 *#10:!B44
M44@"DI:2@84444@"D-+2&@ H-%!I )1110,0T4&B@ I*6DI#"DI:2D 4444#
M"DI:2@ I*6DI#"BBBD &DI324 !I*4TE PI*6DI %)2TE(84444 !I*4TE(8
M&DI324 %(:6D-( H-%!H&)0:*#2 2BBBD,0T&@T&@8E%%%( I#2TAH *2EI*
M0PI*6DI %%%% Q*2EI*0!0:*#0,2BBBD,#24II*0"&B@T4#$HHHI )1112&)
M1110 4E+24AA24M)2&!I*4TE  :2E-)2 2BBBD,*2EI*!GJFD_\ (&L?^O>/
M_P!!%7*\;^'.O:M=^-!8W&H7,MHL4@6%Y"5 '3CVKV2OOJ:M!+R7Y(^+F[R;
M\W^844459 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/^$RTO\ NW'_ 'P/\:+9;_="^/\ [PS_ (0G3?\ GO=_]]K_ /$T?\(3IO\
MSWN_^^U_^)I__"9:7_=N/^^!_C1_PF6E_P!VX_[X'^-%LM_NA?'_ -X9_P (
M3IO_ #WN_P#OM?\ XFC_ (0G3?\ GO=_]]K_ /$T_P#X3+2_[MQ_WP/\:/\
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M)TW_ )[W?_?:_P#Q-'_"$Z;_ ,][O_OM?_B:?_PF6E_W;C_O@?XT?\)EI?\
M=N/^^!_C1;+?[H7Q_P#>&?\ "$Z;_P ][O\ [[7_ .)H_P"$)TW_ )[W?_?:
M_P#Q-/\ ^$RTO^[<?]\#_&C_ (3+2_[MQ_WP/\:+9;_="^/_ +PS_A"=-_Y[
MW?\ WVO_ ,31_P (3IO_ #WN_P#OM?\ XFG_ /"9:7_=N/\ O@?XT?\ "9:7
M_=N/^^!_C1;+?[H7Q_\ >&?\(3IO_/>[_P"^U_\ B:/^$)TW_GO=_P#?:_\
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M_P#PF6E_W;C_ +X'^-'_  F6E_W;C_O@?XT6RW^Z%\?_ 'AG_"$Z;_SWN_\
MOM?_ (FC_A"=-_Y[W?\ WVO_ ,33_P#A,M+_ +MQ_P!\#_&C_A,M+_NW'_?
M_P :+9;_ '0OC_[PS_A"=-_Y[W?_ 'VO_P 31_PA.F_\][O_ +[7_P")I_\
MPF6E_P!VX_[X'^-'_"9:7_=N/^^!_C1;+?[H7Q_]X9_PA.F_\][O_OM?_B:/
M^$)TW_GO=_\ ?:__ !-/_P"$RTO^[<?]\#_&C_A,M+_NW'_? _QHMEO]T+X_
M^\,_X0G3?^>]W_WVO_Q-'_"$Z;_SWN_^^U_^)I__  F6E_W;C_O@?XT?\)EI
M?]VX_P"^!_C1;+?[H7Q_]X9_PA.F_P#/>[_[[7_XFC_A"=-_Y[W?_?:__$T_
M_A,M+_NW'_? _P :/^$RTO\ NW'_ 'P/\:+9;_="^/\ [PS_ (0G3?\ GO=_
M]]K_ /$T?\(3IO\ SWN_^^U_^)I__"9:7_=N/^^!_C1_PF6E_P!VX_[X'^-%
MLM_NA?'_ -X9_P (3IO_ #WN_P#OM?\ XFC_ (0G3?\ GO=_]]K_ /$T_P#X
M3+2_[MQ_WP/\:/\ A,M+_NW'_? _QHMEO]T+X_\ O#/^$)TW_GO=_P#?:_\
MQ-'_  A.F_\ />[_ .^U_P#B:?\ \)EI?]VX_P"^!_C1_P )EI?]VX_[X'^-
M%LM_NA?'_P!X9_PA.F_\][O_ +[7_P")H_X0G3?^>]W_ -]K_P#$T_\ X3+2
M_P"[<?\ ? _QH_X3+2_[MQ_WP/\ &BV6_P!T+X_^\,_X0G3?^>]W_P!]K_\
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M$)TW_GO=_P#?:_\ Q-/_ .$RTO\ NW'_ 'P/\:/^$RTO^[<?]\#_ !HMEO\
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MPA.F_P#/>[_[[7_XFG_\)EI?]VX_[X'^-'_"9:7_ ';C_O@?XT6RW^Z%\?\
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M"=-_Y[W?_?:__$T__A,M+_NW'_? _P :/^$RTO\ NW'_ 'P/\:+9;_="^/\
M[PS_ (0G3?\ GO=_]]K_ /$T?\(3IO\ SWN_^^U_^)I__"9:7_=N/^^!_C1_
MPF6E_P!VX_[X'^-%LM_NA?'_ -X9_P (3IO_ #WN_P#OM?\ XFC_ (0G3?\
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M I_^*KT#PA9Q>&-"737G-P5D9_,6/;G/MFA.BMK#:JO>YYK_ &'\2/[FH?\
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MN=]YWA[_ *#-K_X%1UY);:=X]O49[2:ZG53@M%>(P!_!JO\ _"K1_P!!H?\
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MD7_@7%_A7!^*-,U.;Q%Y/AR]^TVSHNP1WL1);'( W#^54/\ A K;_H--_P"
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MU&-SAEX&2>Q->B?\)=IO]V?_ +X'^-<AXY@L?&'V#R[R6U^R^9G=!NW;MO\
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M +_K_P#%5L>&?#^KVNL_\55++9631-L>:ZC4,^1@#).>,UZ-_P )?IG]V?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S\WQO\
M$5QK=WIVGZ/'.\,KH &/(5B,U:'Q4\=Y_P"1:3_OHUS_ ,'1GXNZIE P\R?J
M/]HU])>3'G_4I_WR* ///"_C?7M0\,:IJ6JZ8MK):PM(BY^]BN%LOC/XNU1)
M)+#0(Y8T;!8,:]D\7HJ>#-8VH%_T5^@]JX#X!HC^%+_<BG_2!U'M0!C#XO>+
MK5@][X="Q?Q$$FO2?!/CS3?&=D7MFV7"</$1@BNG>U@D7:T$;*>H*BO!=&CA
MTOXXSP:4V(G3]XBG@'/- 'T!7(>/?&T7@O2H[J0*[N<!2:ZQF"*[-]U1FOG7
MQ7%<?%'Q]<:59R'[+:8.1R* />]"U:/6M&M;^(@K-&&(!Z$CI5VXG6W@:5\[
M5Y.*\<^"^M2:?=7_ (3OF(FMY6*;CU XXKV5T61"KC(/!IKS$[VT//M4\9RR
MZ@B6S%(E;'UKO+.4S6D,I.=R DUYAXOTM=/U4/&,1L<UMV7B80>&0D;9N<B-
M5[U[.(PL9T:<J*W/F,'CZE+$UH8J6VOW=C1\2:K/+,NFZ?DRMPQ':J.C^#)X
M;]+J[D+$'=CWK8\,Z2UK UW<_-<S<G/:K7B36(]"\/WFHR.!Y49903U-<LL3
M[%.E2VZON=]/!+$R6(Q&^Z71?\$Y?5?B39Z9XWMO#PV%9$Y?/W3GI7?*<@$=
M",U\F?\ "-:KKVG:AXW5G5TNMZ*>NWK7T/\ #G7QXA\&65V7W3;</]17GGLG
M6T444 %%%% !1110!Q_CK_EP_P"VG_LM<?78>.O^7#_MI_[+7'U\;F?^]2^7
MY(^IR_\ W>/S_,****\\[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** ,;Q1_P @5O\ ?6NH^'?_ "*<?_79_P"=9%Y9
MPW]N8)P2A(/!Q77Z!IMOI>CP6]L&$942'<<\D9->[@*T70=+K>YX^,I2]LJG
M2UC3HHHKK.8**** "BBB@ HHHH **** $HHHI %%%% !1113 **** "BBBD
M4444 %%%% !1110 4E+24#"BBB@ HHHI %%%% !2&EI#0 4444 %%%% !111
M0 &DI324 %%%% !1112&%)2TE !1110 4444 %)2TE(84444 %%%% !1110
M4E+24@"BBB@84444 %)2TE !1112 *2EI* "BBB@ I*6DH&%%%%( I*6DH&%
M%%% !1112 #24II* "BBB@84444@$HHHH *2EI* "BBB@!****0PH-%!H 2B
MBBD,#24II* "BBB@ HHHI#$-%!HH *0TM(:0!1110 E%%% PI*6DI %!HH-
MQ****0!24M)0,****0!2&EI#0 4&B@T@$HHHH&(:*#10 4E+24AA24M)2 **
M**!A24M)0 4E+24AA1112 #24II*  TE*:2@84E+24@"DI:2D,****  TE*:
M2D,#24II* "D-+2&D 4&B@T#$H-%!I )1112&(:#0:#0,2BBBD 4AI:0T %)
M2TE(84E+24@"BBB@8E)2TE( H-%!H&)1112&!I*4TE(!#10:*!B4444@$HHH
MI#$HHHH *2EI*0PI*6DI# TE*:2@ -)2FDI )1112&%)2TE S6\#^/+[6-=B
MT.>UMDABA95D3=N.P #.3BO2J\*^&/\ R4,_]<YJ]UK[^&D5Z'Q4_B844451
M(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?(7A2+7Y?B)J:^'B@N_/F^^<#&\UZ;]B^*V>7MO^^S7,?!TG_A;VIX_P">
MD_\ Z$:^EN<]: /,+"'Q1%X%UT>)&C+&U?;L)->0>#?'OB?PAH%XVFZ='-8^
M=EY&0G!KZ2\8Y_X0W5\G_EU?^5>;?!73[?5_ 6JV-TBO%+/@@COB@##L?B%\
M1/&%F4TVRM4BDX\Q 01^-=K\-OAQ<>'+J;6=9E$VIS@Y.=P /-<EI%Y>_"3Q
M@^G:@Q.B7CXA<CA:]SMKF&ZMH[F%PT4BA@P]* .9^(?B6/PUX6N)RX$D@V(/
MKQ7'?![3[#1M&DU*]O+87MT26)<9QFN:^(=S<?$/Q[!X8TURT$&5F(Z BMU/
M@;*D:JFO3* !P%Z4 8WQ':V\->.;#Q1I=U"8Y'6.98W'//)KW'2=1AU?2[>_
M@(,<R;A7C>K_  +FDTR<_P!KR7#HA9$*]35_X,>)'MX+SPUJ<A2ZLFV(K>@H
M [CQQ!#+I2O)M#@G![UR/@V&VN-8"W).U>5'O5_5[B?Q/KBV=L3Y"M@D5AQK
M)HFO!&)'EO@GU&:^EPU)K#NBW[S5_0^'QM>,L;'$J/N)VOWL>R# X'&*\1^,
M_B :EJVG^$K>8)YLH\Y@<#!]:]6U/7[;3?#DFK3,%C$>>O>O!/"_@B^^)>J7
MGB"YNGMXB[+$^,]#7S;33LS[=--71[+I5KH5AX0BT,W=IL$'EO\ ..6QC-><
M_#G6D\,^/;_PTT\;6KN!!M;(]:TO^%(3YS_PD$W_ 'S7(^,_AO?^!FM_$=E=
MR73P-ND;&,4AGTB#FEK!\(:]!XB\.6M] X?*!7]FQS6]0 4444 %%%% ''^.
MO^7#_MI_[+7'UV'CK_EP_P"VG_LM<?7QN9_[U+Y?DCZG+_\ =X_/\PHHHKSS
MN"G-&ZHKLC!6Z$C@U<TE;![S;J+.L)4@% 2=W;I^-=K?:38)HUO'=RS_ &2U
M^;('S$>^![UWX?!2KPE--:?UKV1QU\6J,U%IZ_UH>>=:7:?0UO\ ASR1XK'V
M<DP9D\O/7;@XK8U7Q7+IVI36BVJ.(R!N+D9R ?ZT4\+3=+VE2=E>VUQ3Q$U4
M]G"%]+[V.(VGT-( 3T%=9_PG$W_/C'_WV?\ "K'@Q\6=_)CHP./P-53PM*K4
M5.G4O>_3:PIXFI3IN<X6M;J<9M/H:2NI_P"$WNO^?2'\S6GIFJVGB59;2[LT
M$@3=ZY'3(/4'D4X86A5ER4ZFKVNFA3Q-:FN:=/3R9P= !/2K%];?8[^>VSGR
MG*@^H!KJ_"T<6FZ//JEQ\JR,%!_V0<?S/Z5SX?#.K5]FW:U[OM8WK5U3I\Z5
M[VMYW.,HKHO&%A]GU-;I!^[N!D_[PZ_T-8,$+W$\<,8R\C!5'N:BM1E2JNF]
MT72JJI351=2/K4A@F5-QBD"^I4XKM9#IWA*SC_<B>]<9SW)[G/851C\;W'F_
MO+.(QYY"L<X^M=<L)1I>[6J6EV2O;U.58FK4]ZE"Z[MVOZ'*4 $]!77:_86=
M]I"ZS8($Z%P!C(S@Y'J#1X&_UE]]$_\ 9JE8%_6%1;T>J?D4\6O8NJEMNCD<
M9HKHO"G_ ",;?[CUG^(/^0]>?]=*PE0M156_5HU5:]5T[=+F;2X)Z TE=QX=
MN39^$Y[D*&,3.P4GK@"GA:"KS<6[63?W!B*SHQ4DKZI?><1M/H:,$=C75_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KL[+_CPMO^N2
M_P A7F?B<E=&8@D'>O(KJ?AZ[/X4C+,6(E<<G/>O:P%"U-UK^1Y6,K7J*E;S
M.JHHHKN.,**** "BBB@ HHHH **** $HHHI %%%% !1113 **** "BBBD 44
M44 %%%% !1110 4E+24#"BBB@ HHHI %%%% !2&EI#0 4444 %%%% !1110
M&DI324 %%%% !1112&%)2TE !1110 4444 %)2TE(84444 %%%% !1110 4E
M+24@"BBB@84444 %)2TE !1112 *2EI* "BBB@ I*6DH&%%%%( I*6DH&%%%
M% !1112 #24II* "BBB@84444@$HHHH *2EI* "BBB@!****0PH-%!H 2BBB
MD,#24II* "BBB@ HHHI#$-%!HH *0TM(:0!1110 E%%% PI*6DI %!HH- Q*
M***0!24M)0,****0!2&EI#0 4&B@T@$HHHH&(:*#10 4E+24AA24M)2 ****
M!A24M)0 4E+24AA1112 #24II*  TE*:2@84E+24@"DI:2D,****  TE*:2D
M,#24II* "D-+2&D 4&B@T#$H-%!I )1112&(:#0:#0,2BBBD 4AI:0T %)2T
ME(84E+24@"BBB@8E)2TE( H-%!H&)1112&!I*4TE(!#10:*!B4444@$HHHI#
M$HHHH *2EI*0PI*6DI# TE*:2@ -)2FDI )1112&%)2TE RYX#\%ZQI?B9-8
MN4A%I+$Y4K)EOF&1Q7JE4])_Y UC_P!>\?\ Z"*N5]]3=X1?DOR1\745IM>;
M_-A1115D!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_".C+8V?VF5?WTG7-<YX[T\Q7ZSQ*=KC)/O7I"A54*N-H&!56_TZWU"(1W"
M@'/2E2QDHXCVTNH\1ED9X/ZM#2VWJ>*^)1J_B30;;1;2*4Q-@.R].M>M^%-#
MA\/^'[:QA3;M4%OKCFM&VL+6TC58844#N!5G(K#$5(U)N458[,'0G1I*%25V
M@JAK6EPZSI-Q83@&.5<<UH9I,YKG.L\:^$T6L>&_$.H>';RSF6R#-)#*1\O)
MKV:H_*C\W?Y:[O[W>I* "BBB@ HHHH X_P =?\N'_;3_ -EKCZ[#QU_RX?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!C>*/^0*W^^M=1\._^13C_ .NS
M_P ZR+ZRBU"V,$V[82#\IP>*Z[P]ID&DZ-#;VY<HP\SYSDY(!->[@*T70=+K
M>YX^,I2]LJG2UC4HHHKK.8**** "BBB@ HHHH **** $HHHI %%%% !1113
M**** "BBBD 4444 %%%% !1110 4E+24#"BBB@ HHHI %%%% !2&EI#0 444
M4 %%%% !1110 &DI324 %%%% !1112&%)2TE !1110 4444 %)2TE(84444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK:IYQ!<C)(J>D'3C'I6?=ZI]FU".T"@LX!JHQ<G9$3J1@KR-&BBBI+"BBB@
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M#FO.O^$?^(O_ #RO_P#P(7_XJBGA9S5WH$\3"+TU/0Z2O//^$?\ B+_SRO\
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MX&I!76OH*GC(3=GIZB4E:4F@:D8G"Q#=@X^<=:\X_P"$;^(7_/"^_P# A?\
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M_P#Q5=?X=\.>(1I2C48'%P';/FR*3CMWJJN7U*<;K7T%3QM.<K/3U"@UJ_\
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M>/C(Q6VO=N3C]^O3_OJHHX"K4O?3U+JXRG3M;7T.JI#7*?\ ",?$#_GVO?\
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M^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\
MA_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3
MV"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO
M'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/
M[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N
M?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P
M _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG
M^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\
MA_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3
MV"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO
M'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/
M[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N
M?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P
M _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG
M^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\
MA_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3
MV"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO
M'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/
M[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N
M?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P
M _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG
M^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\ A_P3V"BO'Z*/[:_N?C_P _LG^_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMGPWHMMK'VK[0\J^5MV^60.N>N0?2M7Q#8Q:OID>L60W,J9<#J5_Q%1^!O\
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MJ%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5ZII/_(&L?^O>/_T$5Y77
MJFD_\@:Q_P"O>/\ ]!%>[DO\2?HOS/'S;X(^OZ%RBBBOI3P HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7JFD_\@:Q_Z]X__017E=>J:3_R!K'_ *]X_P#T$5[N2_Q)
M^B_,\?-O@CZ_H7****^E/ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%% !1110 4444 %%%% !1110 4444 %>J:3_ ,@:Q_Z]X_\ T$5Y77JFD_\
M(&L?^O>/_P!!%>[DO\2?HOS/'S;X(^OZ%RBBBOI3P HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]\"C[);?\^\7_? H_L67\_X!_:T?Y/Q/):*]:^R6W_/O%_WP*/LEM_S[Q?\
M? H_L67\_P" ?VM'^3\3R6BO6OLEM_S[Q?\ ? H^R6W_ #[Q?]\"C^Q9?S_@
M']K1_D_$\EHKUK[);?\ /O%_WP*/LEM_S[Q?]\"C^Q9?S_@']K1_D_$\EHKU
MK[);?\^\7_? H^R6W_/O%_WP*/[%E_/^ ?VM'^3\3R6BO6OLEM_S[Q?]\"C[
M);?\^\7_ 'P*/[%E_/\ @']K1_D_$\EHKUK[);?\^\7_ 'P*/LEM_P ^\7_?
M H_L67\_X!_:T?Y/Q/):*]:^R6W_ #[Q?]\"C[);?\^\7_? H_L67\_X!_:T
M?Y/Q/):*]:^R6W_/O%_WP*/LEM_S[Q?]\"C^Q9?S_@']K1_D_$\EHKUK[);?
M\^\7_? H^R6W_/O%_P!\"C^Q9?S_ (!_:T?Y/Q/):*]:^R6W_/O%_P!\"C[)
M;?\ /O%_WP*/[%E_/^ ?VM'^3\3R6BO6OLEM_P ^\7_? H^R6W_/O%_WP*/[
M%E_/^ ?VM'^3\3R6BO6OLEM_S[Q?]\"C[);?\^\7_? H_L67\_X!_:T?Y/Q/
M):*]:^R6W_/O%_WP*/LEM_S[Q?\ ? H_L67\_P" ?VM'^3\3R6BO6OLEM_S[
MQ?\ ? H^R6W_ #[Q?]\"C^Q9?S_@']K1_D_$\EKU32?^0-8_]>\?_H(J;[);
M?\^\7_? J4 *H50  , #M7?@< \-)R<KW.+&8Q8B*25K"T445ZAYX4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 8'B;6;K2/LOV81GS=^[>N>F,?SKG_^$RU3^[;_ /?!
M_P :O^.O^7#_ +:?^RUQ]?+8_%5Z>(E&$FEI^1]%@L/2G0C*44W_ ,$Z'_A,
MM4_NV_\ WP?\:/\ A,M4_NV__?!_QKGJ*X?KV)_G9V?5*'\B.A_X3+5/[MO_
M -\'_&C_ (3+5/[MO_WP?\:YZBCZ]B?YV'U2A_(CH?\ A,M4_NV__?!_QH_X
M3+5/[MO_ -\'_&N>HH^O8G^=A]4H?R(Z'_A,M4_NV_\ WP?\:/\ A,M4_NV_
M_?!_QKGJ*/KV)_G8?5*'\B.A_P"$RU3^[;_]\'_&C_A,M4_NV_\ WP?\:YZB
MCZ]B?YV'U2A_(CH?^$RU3^[;_P#?!_QH_P"$RU3^[;_]\'_&N>HH^O8G^=A]
M4H?R(Z'_ (3+5/[MO_WP?\:/^$RU3^[;_P#?!_QKGJ*/KV)_G8?5*'\B.A_X
M3+5/[MO_ -\'_&C_ (3+5/[MO_WP?\:YZBCZ]B?YV'U2A_(CH?\ A,M4_NV_
M_?!_QH_X3+5/[MO_ -\'_&N>HH^O8G^=A]4H?R(Z'_A,M4_NV_\ WP?\:/\
MA,M4_NV__?!_QKGJ*/KV)_G8?5*'\B.A_P"$RU3^[;_]\'_&C_A,M4_NV_\
MWP?\:YZBCZ]B?YV'U2A_(CH?^$RU3^[;_P#?!_QH_P"$RU3^[;_]\'_&N>HH
M^O8G^=A]4H?R(Z'_ (3+5/[MO_WP?\:/^$RU3^[;_P#?!_QKGJ*/KV)_G8?5
M*'\B.A_X3+5/[MO_ -\'_&C_ (3+5/[MO_WP?\:YZBCZ]B?YV'U2A_(CH?\
MA,M4_NV__?!_QH_X3+5/[MO_ -\'_&N>HH^O8G^=A]4H?R(Z'_A,M4_NV_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTJI4RC*#Y9*S*C)25XNZ"BM*+0=2FLA=I;Y@*E]Q=1P.^,YK.56=@J@LQ.
M,DTY4YQMS*UQ1G&5^5WL)16U%X4U:5 _D*F>@=P#5.^T>_TT W-NRH> X(*_
MF*TEAZT8\THM+T(C7I2?+&2OZE&BBBL#8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KU32?^0-8_\ 7O'_ .@BO*Z]4TG_ ) U
MC_U[Q_\ H(KW<E_B3]%^9X^;?!'U_0N4445]*> %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %>J:3_P @:Q_Z]X__ $$5Y77JFD_\
M@:Q_Z]X__017NY+_ !)^B_,\?-O@CZ_H7****^E/ "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKS&VW=GH)65D%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %>J:3_P @:Q_Z]X__ $$5Y77JFD_\@:Q_Z]X__017NY+_ !)^B_,\
M?-O@CZ_H7****^E/ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C_'7_ "X?]M/_ &6N
M/KL/'7_+A_VT_P#9:X^OC<S_ -ZE\OR1]3E_^[Q^?YA1117GG<%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ZII/\
MR!K'_KWC_P#017E=>J:3_P @:Q_Z]X__ $$5[N2_Q)^B_,\?-O@CZ_H7****
M^E/ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX*/M]G_S]P?]_!4?]E6'_/LE']E6'_/LE $GV^S_ .?N#_OX*/M]G_S]P?\
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M^>EQ_P!^C1_8B_Y\?A_P0_M2?_/W\?\ @$__  A.F_\ />[_ .^U_P#B:/\
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M_M2?_/W\?^ 3_P#"$Z;_ ,][O_OM?_B:/^$)TW_GO=_]]K_\34'_  L30/\
MGI<?]^C1_P +$T#_ )Z7'_?HT?V(O^?'X?\ !#^U)_\ /W\?^ 3_ /"$Z;_S
MWN_^^U_^)H_X0G3?^>]W_P!]K_\ $U!_PL30/^>EQ_WZ-'_"Q- _YZ7'_?HT
M?V(O^?'X?\$/[4G_ ,_?Q_X!/_PA.F_\][O_ +[7_P")H_X0G3?^>]W_ -]K
M_P#$U!_PL30/^>EQ_P!^C1_PL30/^>EQ_P!^C1_8B_Y\?A_P0_M2?_/W\?\
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M ,34'_"Q- _YZ7'_ 'Z-'_"Q- _YZ7'_ 'Z-']B+_GQ^'_!#^U)_\_?Q_P"
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M+_GQ^'_!#^U)_P#/W\?^ 3_\(3IO_/>[_P"^U_\ B:/^$)TW_GO=_P#?:_\
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M_P"^U_\ B:/^$)TW_GO=_P#?:_\ Q-0?\+$T#_GI<?\ ?HT?\+$T#_GI<?\
M?HT?V(O^?'X?\$/[4G_S]_'_ (!/_P (3IO_ #WN_P#OM?\ XFC_ (0G3?\
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M'_"Q- _YZ7'_ 'Z-'_"Q- _YZ7'_ 'Z-']B+_GQ^'_!#^U)_\_?Q_P" 3_\
M"$Z;_P ][O\ [[7_ .)H_P"$)TW_ )[W?_?:_P#Q-0?\+$T#_GI<?]^C1_PL
M30/^>EQ_WZ-']B+_ )\?A_P0_M2?_/W\?^ 3_P#"$Z;_ ,][O_OM?_B:/^$)
MTW_GO=_]]K_\34'_  L30/\ GI<?]^C1_P +$T#_ )Z7'_?HT?V(O^?'X?\
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MYZ7'_?HT?\+$T#_GI<?]^C1_8B_Y\?A_P0_M2?\ S]_'_@$__"$Z;_SWN_\
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M]H_^^A3EFB<X21&/H&!J/[%;?\\5IT=O#$VY(PIZ9% $M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'G7Q4_YA/\ VV_]DKSFO1OBI_S"?^VW_LE><U]GEG^Z
MQ^?YL^?QG\:7]= HHHKT3E"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH [3X
M8_\ (R7'_7FW_H:5ZO7E'PQ_Y&2X_P"O-O\ T-*]7KY#-_\ >7Z(]W _P?FP
MHHHKRCM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HKJYBLK2:ZG<)#"A
MD=CV4#)-2UP'Q9UK^S_#*:?&V)K]]IQU\M<%OUVC\30!;_X6IX5_Y^I_^_#5
MV4<B31)+&P9'4,K#H0>AKY0QQGM7O?PNUO\ M7PG';2-F>P;R6SUV=4/Y<?\
M!H [:N:UGQWH6@ZBUA?SRI.JAB%B+#!Z<BNEKP3XJ_\ (\S_ /7&/^5 'M.B
M:]I_B&Q-YITWF1!RC94J5([$'\*TJ^?/A[XI/AO7U6=\6%WB.?/13_"_X?R)
MKZ#!!&1R* ./A^)OAF>ZCMX[F<R2.$4&!NI.!785\NZ5_P C!9?]?4?_ *&*
M^HJ  G R>E<8_P 4O"R.R_:YC@XR(&(-6OB#K7]B>$+MT;;/<#[/%ZY;J?P7
M)KYWQQGM0!]4:??V^IZ?!?6C[X)T#HV,<&K#':I."<#.!UKS3X/ZW]HTJZT:
M5OGM6\V('^XQY'X-_P"A5Z90!Q9^*GA8'!N;@$?].[5V,,T=Q!'-$P:.10Z,
M.X(R#7SQ\0-'_L;QC>Q*NV&<_:(OHW)_)MP_"O5_AAJ_]I^#8(G;,UDQMV_W
M1ROZ$#\* .SKD;OXE^&;*\GM9KJ7S89&C?;"Q&0<'![UN>(-471?#]]J)(S!
M"63/=NBC\217S?I&GRZWKEI8J6,EU,%9NI )Y;\!DT ?1%YXITNQT"#6YY)%
MLI]NQO+.3N&1QUK%_P"%J>%?^?J?_OPU5?BI#';^ XX(E"QQSQ(BCL " *\I
M\)^&G\5:N^GQW2VY6%I=[)NZ$#&,CUH ]@_X6IX5_P"?J?\ [\-1_P +4\*_
M\_4__?AJY7_A2US_ -!N+_P'/_Q5'_"EKG_H-Q?^ Y_^*H ])U7Q#8:-I,>I
MWAE%K(5 =(RV-PR,@=*R=/\ B-X;U*_@LH+N033-L3?$5!)Z#)]:W9=+M[K1
M3I=THE@:$0OD8R,8S['O7SGXBT.Y\,Z[-83$YC.Z*4<;T/W6'^>H- 'TU7.Z
MWXXT+P]?"RO[EUGV!RJ1EL ],XZ5BZ!\0K:;P--J=^X-Y8J(YH\X,K_P$?[W
M]#Z5XW))?^)->+D&>^O9N .[$\#V _0"@#Z"TCQCHVMVUW<VD[B"T7=-)+&4
M51R>I^E<D?%WB;Q7=2)X8A@L=/1MOVV[QEC^.1^ !-5_&.E+X6^'5CH5FPWW
M=TB7$@&/,;!8G\POX"J/Q!T[2M(U/PO83H5TR",I*$')3<-QX[GDT ;3Q_$C
M2HS=1ZC8:Q&G+VZJ-Q^F%4G\#^%=-X3\6VOBFRD9(VM[R [;BV<\H?4>HZ_E
M7FFAQ6,GQ TU_!:WWV1"IO&DSM"9^;/MCU[XQ73ZA"NA_&'3;BU 1-4A9;A%
M'WFYY_,*?J#0!VVJZWINAVPGU*\BMXSPNX\M] .3^%<VOQ2\*M(%-Y,H)QN,
M#8_EFO(O%6HWWB+Q;.\B2EGE\FVB8$83.% !Z9Z_4FNAUKX576C^')=3_M&.
M:>!/,F@$> !WVMGG'T&: /9K&_M-3M$NK*XCN('Z/&V1]/K[59KP?X6:U<6'
MBN+3PY^RWP970] P4E6'OQC\:]XH *SM8US3=!MDN-3N1;Q.^Q6*,V6P3C@'
ML#6C7)^/_#%[XIT:WM+&2!)(K@2DS,0,;6'8'GD4 ._X61X2_P"@PO\ WXD_
M^)H_X61X2_Z#"_\ ?B3_ .)KSG_A3WB+_GZTW_OZ_P#\17+^(_#=SX8ODL[R
MYM99V3>5MW9M@[9R!UH ]_T?Q7HFOW+V^F7ZW$J)O91&RX7(&>0.Y%;->4_"
M#0+N![C7)AY=O-$8(5(Y?Y@2WT^7'OSZ5UOBOQWIGA;,$@>XORFY+=!C@]"S
M= /S/M0!>\0^*]*\,+ =2E=3.3L6-=Q..IQZ<BIM \06'B2P>]TYI&A20Q'>
MFT[@ ?Y$5\[:[KM]XBU22_OY-TC<*@^[&O95'I7KGP=_Y%"Z_P"OY_\ T".@
M#T*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#SKXJ?\PG_MM_[)7G->C?%3_F$_\ ;;_V
M2O.:^SRS_=8_/\V?/XS^-+^N@4445Z)RA15O2[%]3U2VLD;:TT@3=Z#N?RKT
M34+SPWX*\NQCTP7=WL#,S*I;'J6(_0"N2OB?9R4(Q<I/HC>G1YTY-V2/,**]
M0TW4?#7C%WL)M+2VNBI*$* 3C^ZPP<CK@UY]K6EOH^LW.GLV\Q/A6Q]X$9!_
M(BE0Q7M)NG*+C):V?8*E'DBI1=T4**]'L?#NB^%M'34_$"">Z?&(6&X*?[H7
MH3ZD\5''XY\/S2B"Y\/QI;$XW;$;'OMQ_6LOKKFW[&FY)==%]W<OZNHVYY)/
ML>>45VWC+PM:65G%K&D8^Q2XW(IR%ST8'T/^%6;RPLU^%D-VMI +DA<S",;S
M^\Q][&:M8Z#C"45\3MZ/S%]7DG)/HKG 445W_A>PLY_A_K%Q-:023IY^R1XP
M67$0(P2,CFML175&*DU?5+[S.E3=25D<!176?#VTMKSQ%)'=6\4\8MF.V5 P
MSN7G!JM/<6.D^.[J6XLDFLX;B4&W"+MQ@@#!XX)'Y5+Q'[R5)*[2OZ^0U2]Q
M3;T;L<Y17H'_  F7A;_H6HO^_$5=+HHT36-.>_.@6MK;#.UYH(QN ZGIT'K7
M+5Q\Z4>:=)I>J-X86,W:,T_O/&J*Z.+2X_$_C"X@TM5ALVD+[@F D8[@?R'O
M75WM]X5\'D64.GI=WBCYR5#,/]YCT^@K:IC.5J$8MR:O;MZF<*%TY-V2ZGF-
M%>E6.N^%_$\PL;[28[6:4XC; &3V <8(-<EXI\.2>'=2$08R6TH+0R$<D=P?
M<<?F*=+%\\_93BXR\^OHQ3H<L>>+NC"HKU*Q&CZ5X$LM3O-)MKD[%#'R4+,2
MV,Y(K.'C#PHQ ?PW&%[D6\1K)8Z<F^2DVDVMUT+>'BDN::5_4\^HKOO%7AO2
MYM 37]$41P\,Z+G:RDXR >A![4NA6%G+\-]2N9+2![A!+ME:,%AA1C!QFK^O
M0=-5$GO:W5,GZM+GY6^ES@***[[X:V%G>KJ?VNT@N-ABV^;&'VYWYQD>U;XF
MNJ%)U&KV,Z5-U)J".!HKM?AS96M[JMZEU;0SJL(($L88 [O>KUWXL\.6MY/;
MGPS;L8I&3=Y4?.#CTK">+DJKI0@Y-6ZKKZFD:"<%.4K7//**].TF]\)^*)FL
M#HT5K<,I*@1JA;'7#+W[US$.BII?Q M],F"S0BX7&]00Z'D9'T-.&-3<HRBX
MR2O9]@EAVDG%IINQS%%>J:_J_AS0-1%G-X?MY7,8?<EO'C!SZCVK+_X3+PM_
MT+47_?B*LX8VI.*E&DVGYHJ6'A%V<U?YGG]%;6H7ECJGB6*>RLUMK9WC7R=H
M [ \#CFO0_%GA"TO](9]-LX8+N#+H(8POF#NIQU]O?ZU=7&QI2A&HK<WX>I,
M,.YJ3B[V_$\BHH(P<'K7>^*+"S@^'^BW$-I!'/)Y.^5(P&;,3$Y(Y/-=%6NJ
M<H1:^)V_"YG"FYJ3['!45W]O86;?"F2[-I ;D!L3&,;_ /6X^]C/2N I4:ZJ
MN5E;E=@J4W"WFKA17J'@S1-.MO#T%UJ=K;R2WLO[OSXPV >% R.^"?QKB/%6
MD_V-XAN;95Q"Q\R+TV-R!^'(_"LJ6,A5K2I);?C;<N>'E"FIOJ8U%%%=ISA1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 445T_@31TU;Q K3Q+);6Z&216&58]%!_'G\*
MRK552INI+9%TX.<E%=3F**]"\=Z-8OH]KJ^E00QQ(Q23R4"@@G )QZ$8_&N$
ML5#7]LK %3*H((X(R*SP^(C6I^T2MOIZ%U:3ISY6045Z[XL\(6E_I#/IMG#!
M=P9=!#&%\P=U..OM[_6O(B,'!ZU.$Q<,3#FCI;H.O0E1E9A17>^*+"S@^'^B
MW$-I!'/)Y.^5(P&;,3$Y(Y/-<)'&\TJ1QJ6=V"J!W)Z5="NJT'-*UFU]Q-2F
MZ<N7T_$;17L@\,:1_9']BFWM?MWV7)F\H;\]-^<9^]7CTL4EO.\,B[9(V*LI
M[$'!%987&0Q',HJUOQ7<NM0E2M?J,HKT77M/L=6\!V^L6%G;P31A9)/)B"Y_
MA<<#L>?PKSJM</B%6BW:S3::]"*M)TVE>]]0HKT#P;IEC:>&+_7-3M89TY,:
MS(&&%],^K''X4_X?6EE>V>J3WEC;3E9 P#Q*VW@G R.*YZF.C!3?+=1:7JW_
M )&L<,Y.*OOJ>>45Z!_PF7A;_H6HO^_$5177B[PS-:311^'8T=XV56$,8VDC
M@\4UBJU_X+^]"=&G_P _%^)PE%=7X'U#3HM0-AJ=G:RQ7##RY9HE8H_IDCH?
MY_C4'C+PV=!U3?"I^Q3DM$?[I[K^';VK58E>V]C)6>Z\R/9/V?M$[]_(YN@
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MU?\ EV_,\THKO] \(64%SJEYJYWV=A*\:JW1MO)8^HQCBK&GZ[X6UO4%TM]
MA@CF.R*01J"3VSM *Y]B:UECE=^SBY);M6]?R(6&=ES22;V/.**V?%.BC0=<
MELXV+0E1)$6Z[3V/T((_"L:NVG.-2*G'9G/*+C)Q?0**ZWP_K?AJQTI8-4TE
MKFY#L3((4;([<D@UT6D:AX3UO4$LK/PZQD8$EFMXPJ@=R=W2N.KC)TV[TW9=
M=+?F;PH1G:TU=]-3S"BNR^(":/:WMO9:;;0Q3Q!C/Y2@#G& ??K^=4?#?@Z^
MUYTG<&"QS\TS=6'<*._UZ5K'%0=%5I^ZGW(=&7M/9QU9S=%=Y\1=-LM-M])C
ML[:*$ 2*2B@%@ F,GO\ C7!U>'KJO351*UQ5:;IS<&%%%>@^'M%T?2/#2^(=
M9B^T%QE(F4, ,X "G@D^]+$8B-&*;5V]$EU84J3J.RT//J*]$C\=>'YY!#<Z
M"B6YX+;$; _W<5G>-_#5GIL-OJNF86TN"%* Y4$C(*^Q&:PABW[14ZL'%O;9
M_D:2H+E<H2O;<XRBNXL/%GANVTZV@G\/1RS1Q*CR&&,[F  )R?4ULZ-K.@ZY
MJ"6=IX8BR>7<P1[47U/%34QE2";=)V76Z'&A"5DIJ[]3RZBN[^(HTFV:ULK*
MVMXKI27E\F)5PI' ./SQ7"5U8>M[:FJEK7,JM/V<W&]PHKI/!GAU/$&JL+C/
MV2W4/* <%B>BY[9Y_*NB;Q'X0BU Z=_8EN;0-Y9N?*4^V>F2/?.:QJXODFZ<
M(N36KMT+A0YH\TI))GG-%=-XT\.1Z#J$<EIDV=R"T8)SL(ZKGN.1BNACTW1/
M!N@V]WJUDMYJ%P.(W4-@]2 #P .Y]:)8V')&<$VY;+K_ $@6'ES.,M+;L\XH
MKTD6.A^-M'N)=-LDL=1MQG8BA<GG .."#CKU'\_.8X999EACC9Y6;:J*,DGT
MQ6E#$*K=-6:W3)J4G"S3NGL,HKTWPEX$-HXOM8CC>3'[NV8!@N>[=B?:N#UZ
M-(O$.I1QHJ(MU(%51@ ;CP!4T<73K594X:VZCJ4)4X*4NIG4445UF 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!VGPQ_Y&2X_Z\V_]#2O5Z\H^&/_ ",EQ_UYM_Z&E>KU\AF_^\OT1[N!_@_-
MA1117E':%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?/?Q'UK^V?&%R$;
M,%I_H\?I\OWC_P!]9_ "O;/%6LC0?#5]J&0)(X]L7NYX7]3G\*^: Y\S>XWG
M.2&/WOK0!Z3?^#O)^$5K>"/_ $R-_MK\<['P"/P78?P-9'PPUO\ LGQ;';R-
MB"^'D-GINZH?SX_X%5Z?XMZG<6<EI)I6GF"2,QLF'QM(P1U]*\_CD>*19(V*
MNA#*PZ@CO0!]7UX)\5?^1YG_ .N,?\J]G\-ZNFN^'K+4EQNFC&\#LXX8?F#7
MC'Q5_P"1YG_ZXQ_RH YF_P!'N=/L=/O9!FWOHC)$X'&02"OU&!^8KV+X7>*?
M[7T?^RKJ3-Y9* I)YDBZ _AT_*H]*\.Q>)OA)86+8681L\$A_@D#-C\#T/L:
M\FTO4+[POXACND1H[FTE*R1-QG'#*?U% $.E?\C!9?\ 7U'_ .ABOJ*OES2#
MNUZQ/K=1G_QX5]-:C?1:9IMS?3G$5O&TC>X SB@#QKXN:U]M\0PZ7&V8K),N
M!_ST;!/Y#;^M6/#O@[[?\+=3NC'F[N6\^WXYQ%G 'U^<?B*\\OKR74;^XO9S
MF6>1I'/N3FNWT_XL:GING6UC!IM@(K>-8UX?H!C^]0!SW@S6_P"P/%5E>LVV
M MY4WIL;@G\.#^%?2=?*5Q*)[F698UB61RPC3HN3G ]A7T)\/M;_ +;\(6LC
MMNN+<?9Y?7*]#^*X/YT <[\8='^T:1::M&OSVK^5(1_<;H3]& _[ZKF_A%J_
MV/Q+-ISMB.]B^4?[:9(_3=^E>P:WID>LZ)>:=)C%Q$R GL>Q_ X/X5\UV5S<
M:)K<-R%*W%G.&*GU4\@_EB@#U?XQ:MY&D6>E(WS7,AED _N+T!^I/_CM8GP>
MT?[1K-UJTB_):Q^7&3_?;J1]%!_[ZKF_'NO1^(/%4]U ^^UC18H3_L@9/_CQ
M:O8_A]H_]C>#K*-EVS7 ^T2_5N1^2[1^% &9\6_^1*_[>H_Y&O)?"GB67PKJ
MSW\5LEPS0F+8[%1R0<_I7K7Q;_Y$K_MZC_D:\V^'6A6'B'Q))9ZE$TL"VS2!
M5<K\P91U'U- '1_\+HO?^@-;_P#?X_X5;TOXNW>H:M9V3:3 BW$Z1%A*21N8
M#/3WKI?^%7>$_P#GPE_\"'_QJ6T^&_ABRO(;J&QD$L,BR(3.YPP.1QGUH ZR
MN,^(_A=-?T![J%5%]9*9(VZ;DZLI/X9'N/>NSKS'XK>+/LEK_P (_9R?OYUW
M73*?NIV7ZGO[?6@#QW)QC/![5Z]\)O"RQ6Q\172@R2Y2U!_A7HS?4\CZ9]:\
MG2SN)+.6[2%VMXF5)) /E4MG /Y&O0_A7XM^PWO]@WDF+:X;-NS'[DA_A^C?
MS^M '>_$+0IM>\*2Q6JEKJV<7$2KU8C((^N"<>^*Y"VO9/'6M^&KZ#R3/IY'
MV^&1PK###+!3]X'!/'3I7K-<GKOP\T37+LW@66RO"=QFMFV[CZD=,^XP: ,;
M5M NO#'C&/Q)I MX=-=?].B:58E _BQG YX(]Q46@S2>-/B(_B"-'72M,C,-
MNS#'F,01_P"S$^WRU<B^%6GR3(^IZKJ-^B=(Y),#_'\B*[>SLK;3K2.ULX$@
M@C&%1!@"@"1XHY2IDC1]IRNX9P?45XIXW^(FH:BVH:);PQ06BS/"\BDEY%5L
M?@#BO9&U/3TF2%[ZV65V"JAE4,Q/0 9Y-<]J?P[\.ZA9W$:6"07$NYEG0G<K
MGG/7GGM0!POPE\.Q7&I'6Y;F%FM@5BMU<%P2"-S#L,9QZ_AS[+7S%H6JW.@:
M_;7L$A5HI ' /#+GYE/J"*]:^+6I7VFZ5ISV-[<6K/.P9H)60L-O0X- 'H=%
M?,G_  E/B'_H/:G_ .!<G^->T_#&]N]0\(+/>W4US-]H<>9-(7;''&30!T>M
M:K#HFBW>I3_<@C+8S]X] /Q.!^-?/^BV%YXV\8HES(S/<R&6YD'\*#DX].,
M?A7>?&35C':Z?I,;X\UC/*!Z#A?U+?E4WP<T@0Z7>ZLZ_/<2>3&3_<7DX^I/
M_CM 'I-O;Q6EM%;P1K'#$H1$7HH P!7!^*OAW<>*?%8OY+V.WLA B':"TA()
MR .@Z]<_A7H%% 'A/Q+T#3O#L^E6>G0"-/(8NYY:0[NK'N:[3X._\BA=?]?S
M_P#H$=<]\9_^0MI?_7!__0JZ'X._\BA=?]?S_P#H$= 'H5%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPQ)"Y1OJ#4%?1IIJZ/*:MHPHHHIB"BBB@ HHHH **** "BBB@ HHHH ****
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M[&KV:@VMR<R;>BN><_0]?KGVJ?XH_P#(3L/^N+?^A5;\%:M!K6DS>&]3^?\
M=D19/+)Z#W7J/_K5ST(NA1IXJ':TEW5]_D:U&JE25&7R]1OBW_DFVA?]L/\
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MV>A^.XM'T>"P.D+,8MV9/."[LL3TVGUJCXG\5IXBM[>)-/%KY3ELB3=NR/\
M=%=T:M9U.5T[1[W7Y',X4U"ZEKVL5/"NC?VYKT-LX)@3]Y-C^Z.WXG _&MKX
MA:W]JU)=*MV MK3[P7H9,?T''YUI_#^--.\.:KK+KDC=C/\ =1=WZD_I7G<T
MKSS232-NDD8LQ/<DY-<\%[;%RD]H:+U>[-9?NZ"2WEK\B_HVNWFA33361C$D
ML?EEG7.T9!R/?CO7;^&+NXOO!7B*XNIGEF<2EG<Y)_=5YM7H?@[_ )$+7_\
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MY?\ T(T48QAC)QBK+E7YL*DG*A%ONS,HHHKTCD"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JWI=A)J>J6UE
M']Z:0+GT'<_@,FJE=Y\---#WEUJLH CMU\M&/3<>2?P'_H5<V*K>QHRG_5^A
MK1I^TJ*)-\0=4^PSZ9IED=@M-LX _A(X3\@#^8J;QS;QZUX9L-?MUY11OQV5
MNQ^C<?B:@N/B-9R7#L= AFYP)'E&6'8_<K=\/Z]9^+K"^TUK%;11'M\M7# J
MV02.!C!_F*\1QJX>%.HZ=N3=W6M]ST;PJRE%2OS;+TV.>^%W_(3O_P#KBO\
MZ%6MH&IP>)+/4/#VIG=(C.(V/5DSP1[J<?I[U0^'=I+8>(-6M)AB2%-C?4-7
M%F]GT[7Y+RV?;-%<,RG\3P?:NB=!8BO5Y7K:+3\S*-1TJ<+[7:9O^&M,GT?X
MBVMC<#YXVDP>S#RVP1[&J?CO_D<]0_[9_P#HM:]'L!8^)'TOQ!!A)[?<K#OR
MI!0_0G(_^O7):AI?]K_%:6W9<Q*T<LO^ZL:G'XG _&IH8KFQ#J5%9Q@[^J95
M2C:DHQU3EI\T7+\?\(O\-8[3[MU>C#COE^6S]%^6GZ.!XI^'<VG'YKJU&Q/7
M*\I^GR_G5CQ)XWM=-U:33VTJ.]\D#+O(!AB,D ;3[4SP]XZM+_5XK!=)CLA.
M=OF)(#EL' (VCZ?C7/RUW0]IR:WY[W7Y;[&MZ?M.3FTMRV_KS/+P6C<$$JRG
M(/<&O2/%&/$?@2SUE #-!AI,=L_*X_, _05S/C?2?[*\23[%Q#<?OH_3GJ/S
MS^E;GP[O([NUU'0;DYCF0N@]B-K#^1_.O1Q4U.E#%0^S9_)[G)1CRSE1EUT^
M?0S?AYI?V[Q$+EUS%9KYA_WCPO\ 4_A6;XMU7^U_$=U.K9B0^5%_NKQG\3D_
MC78VT#^#? E])+\E]<2-&O8YR57'X M7F=7AFJU>=?HO=7ZDU?W=*-/J]7^A
M[%JWA_\ X2+PUIEO]K6V\M(WW,F[/R8QU'K7._\ "L?^HU%_WY_^RJ?QW_R)
MVC?5/_19KSBN3!4J\J5X5+*[TLGU-\1.FIVE&[LNOD;?B7P]_P ([=0P?:UN
M?-3?N5-N.<8ZFI?!VLW.DZ["L*/+%<L(I(EY+9/!'N/\:Y^O2/!^C6^@:3)X
MCU4;&\O,2D<JI[_[S=!['WKMQ4E3P_+5]YO3U9ST8N=6\-$M?0Z'Q!,GAO1]
M0U+3K,?:KAP9'4=&/&]O8?S/N:\<CNI8[U+LL7F602;F.26SG)_&O1_#/C(:
MWJ5WINJJGE79/D*1P!C'EGUX_7/J*X[Q3X?D\/ZJT(!:UDRT#GNOH?<?X>M<
MN7Q]C.5"JO>>M^ZMM\C;%/VD54ALOP?_  3LG+M8ZKKF@F>9]22,A+<9>"53
M\P(Z_E_*HVLEU5K#7]:CGT][)0;LSIM$Q4Y7:"<Y/T[X%>>6M[=6,ADM+F:!
MSU:)RI/Y4ZZU"]OBOVN[GGV_=\V0MCZ9K58&:>DOGUM:UNVW^>Y'UF+6J^72
M^]^Y8U+5[F^U"]G2:6.*YD9C&'(&"> 1WXQ7=>$?">EQ7%IJ#ZG'=70C69;=
M"H\MB,\X))QGVKF--\(RZIX;N-6@N@SP[A]G6/))7DC.>N#GI6+IOVO^T[;[
M#N^U>8/*V]=V:TJPC6IRIT9\O+H_NZ_YD0DX24ZD;WV-GQO/>W'B65KVU-N5
M4+$A.<H,X.1P<G/\NU<Y7JGC758-&UW1;YK=;B6)9LQ[MN00 .<'N3^M9W_"
MSH?^@$O_ ($#_P"(K'#XBM["'LZ5U;O;\S2K2A[27/.S]#SRO2]"CC\(^")M
M8F0?;+I0R!O?[B_^S'_ZU<'90?VMKL, 4J+FX ('\(9N?R%=A\3;W;/8:9'A
M8XX_-*CIS\J_D ?SK3%WJU*>'Z/5^BZ?>30]R,JO;1>K.#FFDN)Y)IG+R2,6
M9CU)/4UK-XHU3^Q8=)CF$-K&I4B,89P23R?Q[8K&HKT)4X2MS*]MCE4Y*]GN
M>A_$S_CTT7_=D_DE>>5Z'\3/^/31?]V3^25SWA?Q/'X<%UOL!=&?;@F3;MQG
MV/K^E>=@92C@TX*[UTVZLZ\0DZ[4G9?\ YVO0_#FO:-J?AQ= UMEBV#:KN=J
ML,Y!W=B/>J6K^/XM4TJYLAI"PF9-OF><#M_#:*-9\'VT?A>UU72!/.S*KR@G
M=\I')  ['_/%*M)58QCB$X-O1WOKZA3BX-ND^96U+]S\-+>=/-TO5=R'[HD
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MQW@(^1X5UNY3B0!L'_=0D?SKSJO3_!^HQZ[_ ,)!#Y8@-T?,$><X#*5//'3
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#M/AC_P C)<?]>;?^AI7J]>4?#'_D9+C_ *\V_P#0TKU>OD,W_P!Y?HCW
M<#_!^;"BBBO*.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \B^,>M;Y[+
M18FX0?:)@/4Y"C\MQ_$52^&/@ZPUZ"^OM5M?/MT810J691NZL>".@*_G7I.I
M^!_#FLZA+?W^G>=<RXWOY\BYP !P& Z 5J:5I-CHE@EEIT @MU)(0,6Y)R>2
M230!A_\ "N/"7_0'7_O])_\ %5YQ\3O"-GX?FLKO2[?R;28&-T#%@''(.22>
M0?\ QVO<*H:OHVGZ[9?8]2MQ/!N#[2Q7!'0Y!![T >:_!S6\&]T25NO^D0@_
M@&'_ *"?SKG?BK_R/,__ %QC_E7K6F>!_#FCZA'?6&GF&YCSL?SY&QD$'@L0
M>":=JW@OP_KE\;W4=/\ .N&4*7\Z1>!TX5@* (/A[_R(>D_]<V_]#:N)^+7A
M79(OB&TC^5L)=A1T/17_ !Z'\*]3T_3[72K"*QLHO*MH1A$W$X&<]3D]Z?=V
ML%]:2VMS&LL$R%'1NC ]: /F'1O^0YI__7S'_P"A"O7OB]K7V30H-*C;$EX^
MZ0#_ )YKS^K8_(UNP?#GPI;SQSQ:5MDC8.A^T2G!!R.K5=UCP?H6OWBW>IV)
MN)E01JWG2+A02<85@.YH \@^&OA>V\1ZQ</J$'FV5M%EEW$!G;A1D$'H&/X5
MZE_PKCPE_P! =?\ O])_\56OHWA_2_#UO)!I=J+>.1][C>S$G&.K$FM*@#Q_
MXE>"--T?1[?4M'M/(2.39.H=FR&^Z?F)Q@C'_ JH?"36_L/B*33)6Q#?)\N>
MTBY(_,;A^5>S:AI]KJEA-97L(FMIAM="2,CKU'(K!M?A[X7L;N&[MM,,<\+B
M2-Q<2G:P.0>6H Z>O OB?H_]E^,)ID7$-ZHG7'3<>&_49_&O?:RM:\-:1XB$
M(U6S%QY.?+_>,A7.,_=(]!0!\]^%=(.N^)K#3RN8Y)09?]P<M^@-?3(    P
M!T K#T?P=H.@WC7>F6 @G*%"_FN_RD@G[Q/H*W* .$^+?_(E?]O4?\C7DGA?
MQ)/X6U5[^W@CF=HC%MD) P2#GCZ5]$:MHUAKME]CU*W\^WW!]F]EY'0Y4@U@
M_P#"L_"'_0(_\F9?_BZ .%_X7-JG_0+L_P#OIO\ &C_A<VJ?] NS_P"^F_QK
MNO\ A6?A#_H$?^3,O_Q='_"L_"'_ $"/_)F7_P"+H EO/%T6G>!K?7[I$$T]
MNCQP@\-(RY"CV_H#7@9-]X@UK)W7%]>3?BS,?T'\A7T/?^$-"U.RL[.\LC);
MV2;((_.D4(, =F&> .3FF:5X*\.Z)?+>Z?IRQ7*@JKF5WP#UP&8C\: (])\'
MV&G^$3H$J++',A^TN!R[GJP^AQCTP*\%U[1KKPWKD]A.2'A;,<@XWK_"P_SP
M:^G:Q]:\*Z+XADBDU2Q6X>(%4;S&0@'M\I&?QH RO 'BL>)M# G<?VA:@)..
M[>C_ (_SS76UA:1X.T'0;PW>F6)MYRA0L)Y&RI[8+$=A6[0 4C*'4JPRI&"/
M44M% 'S1KVD7OA3Q&]NVZ-X9!+;RC^)<Y5A^7Y@UV-U\8KZ?1FMXM.CAOG38
M;D2DJI_O*N.OX\>]>KZKHNFZY:_9M2M([B+J-PP5/L1R/PKF?^%5>%O.W_9K
MC;_SS\]MO^/ZT >2>#?#MQXC\0V\"1L;:)Q)<28X5 >F?4]!_P#6KZ,FMX+@
M 3PQR@<@.H;'YU!INEV.D6@M=/M8[>$<[4'4^I/4GW-6Z *O]F6'_/C;?]^E
M_P *GBAB@39%&D:#^%% %/HH \!^*5R;CQW=(3D01QQCV^4-_-C7KO@6T6R\
M$:1&H^];B4_5_G_]FINH^!/#6JW\M]>Z;YMS,07?SY%R<8Z!@.@K>MK:*SM(
M;6W39#"BQQKDG:H& .?84 2T444 >.?&?_D+:7_UP?\ ]"KH?@[_ ,BA=?\
M7\__ *!'74ZUX5T7Q#-%+JEE]H>)2J'S73 /^Z15G1]#T[0+-K33+;R(&D,A
M7>S98@#.6)/0"@#0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \Z^*G_,)_[;?^R5YS7H
MWQ4_YA/_ &V_]DKSFOL\L_W6/S_-GS^,_C2_KH%%%%>B<HZ.1X94EC=DD0AE
M93@@CN*[NP^)<ZVXAU*P2Y.,&1&V[OJN"/Y5P5%<];#4JZM45[&M.K.G\+/0
M)_B4D4#1Z9I,<#'HSL,#_@( S^=<+=W<]]=RW5S(9)I6W,Q[FH:*5'"TJ%W3
M6K"I6G4^)G3^'O&U_H4(MFC6ZM >(W8@I_NGL/;!K;'Q%T^ F:WT"-+@]6#J
MOZA<FO/:*SJ8'#U).4HZOS:O]Q<<35BK)FKKGB"^\070FNV4*@Q'$G"H/;W]
MZO3^*S-X0CT'[%C9C]_YO7#;ONX_K7.45L\/2M&-M(ZHS]K.[=]]PKH])\5_
MV5X;O=(^Q>;]J\S][YN-NY O3'.,9ZUSE%74I0JKEFKK?[A0G*#O$V?#6O?\
M([J;7OV;[1NB,>S?LZD'.<'TK0TKQD=,US4M2^P>;]M8GR_.V[.<]=IS^5<M
M16=3#4JC;DMU9^A4:TXI)/8]";XFQ.Q9M!1B>YN ?_9*3_A9<'_0OQ_]_P ?
M_$5Y]17/_9N&_E_%_P"9K];K=_P1I:MJQU'7)=3MXOL;,RLJ(_W" !D$ >F:
MZ>Q^)$PMA;ZKI\5X ,;P0I/U!!!/Y5PU%;U,)1J1491VV_X?<SC7J1;:>YWM
MQ\2!#;F+2M)AMB>C,1@?\! '\ZXB[N[B^NI+FZE:6:0Y9VZFH:*='#4J-W!:
MO[Q5*TZGQ,Z.Y\5_:/"4.A?8MOE[?W_FYS@Y^[C^M<Y116E.E"FFH+=W^9,Y
MRG;F"NCT_P 5FP\+76B_8M_G[_WWFXV[@!]W'/YUSE%%2E"HDIJ]M?N"$Y0=
MXA71^%?%?_",B['V+[3]HV?\M=FW;GV.>M<Y115I0JP<)JZ80G*$N:.YO>%_
M$G_"-WD]Q]D^T>:FS;YFS'.<]#6/=S_:KR>XV[?-D9]N<XR<XJ&BA4H*;J):
MO] <Y.*B]D7]&U:?1=4AOK?ED/S)G =>X-;FI>,8=0UO3]572O*GM6RV)\^8
MHZ _+QCGGWKE**B>'ISGSR6MK?(<:LXQY4]#T)_B=%(<OH*,?4W /_LE)_PL
MN#_H7X_^_P"/_B*\^HKF_LW#?R_B_P#,V^MUN_X(W-<\0)K&M6^HI8K;"%54
MQJ^=Q5B<YP/7'3M3O%'B3_A);J";[)]F\I"FWS-^><^@K!HKICAZ<7%I?#HC
M%U9NZ;WW)K6ZFLKJ*YMW*31,&1AV(KI/$OC1O$>EPV;6 @*2B4N)=V2%(QC
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M44 ;'AO6X_#^IF^>S^TL(RB+YFS:3CGH>V1^-5M9U236=6N+^1=AE;(3.=H
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M(3E"7-'<DG>.2XE>*/RHV<E8\YV@G@9[XKKH/B#<P^'!I8M,S+ 85N?-Z#&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_C1]<P_\Z^\/85?Y6<Q173_\*_\ $7_/I'_W^7_&C_A7_B+_ )](_P#O\O\
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M #K[P]A5_E9S%%=/_P *_P#$7_/I'_W^7_&C_A7_ (B_Y](_^_R_XT?7,/\
MSK[P]A5_E9S%%=/_ ,*_\1?\^D?_ '^7_&C_ (5_XB_Y](_^_P O^-'US#_S
MK[P]A5_E9S%%=/\ \*_\1?\ /I'_ -_E_P :/^%?^(O^?2/_ +_+_C1]<P_\
MZ^\/85?Y6<Q173_\*_\ $7_/I'_W^7_&C_A7_B+_ )](_P#O\O\ C1]<P_\
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M ,*_\1?\^D?_ '^7_&C_ (5_XB_Y](_^_P O^-'US#_SK[P]A5_E9S%%=/\
M\*_\1?\ /I'_ -_E_P :/^%?^(O^?2/_ +_+_C1]<P_\Z^\/85?Y6<Q173_\
M*_\ $7_/I'_W^7_&C_A7_B+_ )](_P#O\O\ C1]<P_\ .OO#V%7^5G,45T__
M  K_ ,1?\^D?_?Y?\:/^%?\ B+_GTC_[_+_C1]<P_P#.OO#V%7^5G,45T_\
MPK_Q%_SZ1_\ ?Y?\:/\ A7_B+_GTC_[_ "_XT?7,/_.OO#V%7^5G,45T_P#P
MK_Q%_P ^D?\ W^7_ !H_X5_XB_Y](_\ O\O^-'US#_SK[P]A5_E9S%%=/_PK
M_P 1?\^D?_?Y?\:/^%?^(O\ GTC_ ._R_P"-'US#_P Z^\/85?Y6<Q173_\
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M1?\ /I'_ -_E_P :/^%?^(O^?2/_ +_+_C1]<P_\Z^\/85?Y6<Q173_\*_\
M$7_/I'_W^7_&C_A7_B+_ )](_P#O\O\ C1]<P_\ .OO#V%7^5G,45T__  K_
M ,1?\^D?_?Y?\:/^%?\ B+_GTC_[_+_C1]<P_P#.OO#V%7^5G,45T_\ PK_Q
M%_SZ1_\ ?Y?\:/\ A7_B+_GTC_[_ "_XT?7,/_.OO#V%7^5G,45T_P#PK_Q%
M_P ^D?\ W^7_ !H_X5_XB_Y](_\ O\O^-'US#_SK[P]A5_E9S%%=/_PK_P 1
M?\^D?_?Y?\:/^%?^(O\ GTC_ ._R_P"-'US#_P Z^\/85?Y6<Q173_\ "O\
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M^D?_ '^7_&C_ (5_XB_Y](_^_P O^-'US#_SK[P]A5_E9S%%=/\ \*_\1?\
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M_?Y?\:/^%?\ B+_GTC_[_+_C1]<P_P#.OO#V%7^5G,45T_\ PK_Q%_SZ1_\
M?Y?\:/\ A7_B+_GTC_[_ "_XT?7,/_.OO#V%7^5G,45T_P#PK_Q%_P ^D?\
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MHHKS3K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ>J:E;Z/I=SJ%TV
MV&!"[>I] /<G _&@#COB'XZG\-/;66F^4U[)^\D,B[@B= ,>I/\ +WKFO#7Q
M.US4?$FGV5Z;7[/<3")MD6#SP.<^N*XH_P!H>,_%? W7=]-]0@_P51^0JJ ^
MB>(0"<R6-UR<8R4?_P"M0!]0U#>7*6=E/=2?<AC:1OH!D_RJ56#*&4Y!&0:Y
MCXB7WV#P-J3 X:5! OON(!_3- 'F'_"VO$WK9_\ ?G_Z]'_"VO$WK9_]^?\
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M* "BBB@ HHHH **** "BBB@ HHHH **\\^*,CQ_V5L=ESYV<'']RO._M$_\
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MZ[IXO;:]A2,N4Q)(X.1] :SGEM*%^:JE;?3OL5'%SE:T-_,]BHKR[_A7.O\
M_01M?^_LG_Q-'_"N=?\ ^@A:_P#?V3_XFLOJ>&_Y_K[F:>WJ_P#/MGJ-%?/D
M;7<LZP1/,\K-M55)))]!7867P]UVXB$EQ>1VV?X&=F8?7''ZUM5RRG15ZE5+
MY&<,9*I\,+GJ=%>2ZGX%U^PA::*87:*,D0N=P'T/7\,UAZ-I]]K>I+8V]SLE
M*ELRNP''TS1#+:4X.<:J:6^@2Q<XR47#5GNU%>7?\*YU_P#Z"-K_ -_9/_B:
M/^%<Z_\ ]!&U_P"_LG_Q-8_4\-_S_7W,T]O5_P"?;/4:*\6OO#>J6&N6FDRW
M<9GN@"CK(VT9)'/&>WI6Q_PKG7_^@C:_]_9/_B:N6 H12<JRUVT)6)J-M*F]
M#U&BO+O^%<Z__P!!&U_[^R?_ !-8<^@ZG;^(X]$>[3[1(0 XD;9R,^F?THAE
M]&=U&LG;78)8JI'>F_O/;:*\9U[POJ_AZTCN;FZCDC=]F8I&.#C/.0/0USWV
MB?\ Y[2?]]&MJ>4QJQYH5+KT,YXYP=I0L_4^AZ*\=T7PCK.N:<M]!=Q1Q,Q5
M1+(X)QWX!XS_ "K-TG3+_6-6.G07024!CND=@O'7IFH_LRG[W[U>[OIL5]<E
MI[F^Q[I17EW_  KG7_\ H(VO_?V3_P")JM>> _$EK"9$ECN<=5AF;=^3 5DL
M%AV[*NON+>(JK7V;/6J*^>3/<*Q5I900<$%CQ73:1X,U[5H%N#)]F@895IG(
M+#U '/YXK>KE4*4>:=5)>G_!,X8V4W:,+GL%%>777P[UN*(O;W\4[ ?<WLI/
MTSQ^M<?=+?65R]O<F:*9#AD8D$5-++*=;^'53^0YXN=/XH6/H&BO'-$\)ZOK
MVG_;;:]A2/>4Q)(X.1] :TO^%<Z__P!!&T_[^R?_ !-9SP-"$G&59)KR*CB:
MDE=4V>HT5XWJWA'7](M6N96$T*#+O!*6VCU(.#BN<^T3_P#/:3_OHUO3RF-5
M<T*J:]/^"9SQS@[2A8^AZ*\8T'PQJ_B&UDN;:Z2.)'V9ED89.,\8!]16+="[
ML[N:VFDD66)RC#<>H.*4<IA*3A&JKK?0;QLE%2<-&?0-%>%:)IU]KVH"RMKD
M))L+YD=@,#Z9JOJ4%WIFHSV4UP6DA;:Q1S@GVS5?V1'GY/::[VL+Z\^7FY-/
M4]]HKYX^T3_\]I/^^C1]HG_Y[2?]]&K_ +$?\_X?\$G^T5_+^)]#T5\\?:)_
M^>TG_?1H^T3_ //:3_OHT?V(_P"?\/\ @A_:*_E_$^AZ*^>/M$__ #VD_P"^
MC1]HG_Y[2?\ ?1H_L1_S_A_P0_M%?R_B?0]%?/'VB?\ Y[2?]]&C[1/_ ,]I
M/^^C1_8C_G_#_@A_:*_E_$^AZ*^>/M$__/:3_OHT?:)_^>TG_?1H_L1_S_A_
MP0_M%?R_B?0]%?/'VB?_ )[2?]]&C[1/_P ]I/\ OHT?V(_Y_P /^"']HK^7
M\3Z'HKYX^T3_ //:3_OHT?:)_P#GM)_WT:/[$?\ /^'_  0_M%?R_B?0]%?/
M'VB?_GM)_P!]&C[1/_SVD_[Z-']B/^?\/^"']HK^7\3Z'HKYX^T3_P#/:3_O
MHT?:)_\ GM)_WT:/[$?\_P"'_!#^T5_+^)]#T5\\?:)_^>TG_?1H^T3_ //:
M3_OHT?V(_P"?\/\ @A_:*_E_$^AZ*^>/M$__ #VD_P"^C1]HG_Y[2?\ ?1H_
ML1_S_A_P0_M%?R_B?0]%?/'VB?\ Y[2?]]&C[1/_ ,]I/^^C1_8C_G_#_@A_
M:*_E_$^AZ*^>/M$__/:3_OHT?:)_^>TG_?1H_L1_S_A_P0_M%?R_B?0]%?/'
MVB?_ )[2?]]&C[1/_P ]I/\ OHT?V(_Y_P /^"']HK^7\3Z'HKYX^T3_ //:
M3_OHT?:)_P#GM)_WT:/[$?\ /^'_  0_M%?R_B?0]%?/'VB?_GM)_P!]&C[1
M/_SVD_[Z-']B/^?\/^"']HK^7\3Z'HKYX^T3_P#/:3_OHT?:)_\ GM)_WT:/
M[$?\_P"'_!#^T5_+^)]#T5\\?:)_^>TG_?1H^T3_ //:3_OHT?V(_P"?\/\
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M2>8_]]OSH^I^8>W\CM+U97L+A8,^<T3!,'!W8XY[<UXQ_9WQ0_OZI_X%+_\
M%5V?F/\ WV_.@R/_ 'V_.G]3\P]OY'&?V=\4/[^J?^!2_P#Q5>K>%4U&/PS9
M)JYD-^%/G>:VYL[CC)^F*YOS'_OM^='F/_?;\Z/J?F'UCR.UO5E>PN%@SYS1
M,$P<'=CCGMS7C']G?%#^_JG_ (%+_P#%5V/F/_?;\Z/,?^^WYT?4_P"\'UCR
M.._L[XH?W]4_\"E_^*KU+PA'JD/A:S36C*=0&_S3*^YOOMC)_P!W%<[YC_WV
M_.CS'_OM^='U+^\'UCR.[F#-!($SO*D+@XYQ7BG]G?%#^_JG_@4O_P 577^8
M_P#?;\Z/,?\ OM^=/ZE_>#ZQY'(?V=\4/[^J?^!2_P#Q5>I>$(]4A\+6::T9
M3J W^:97W-]]L9/^[BN;\Q_[[?G09'_OM^='U)_S"^L>1WLP9H) F=Y4A<''
M.*\4_L[XH?W]4_\  I?_ (JNM\Q_[[?G2>8_]]OSH^I?W@^L>1R?]G?%#^_J
MG_@4O_Q5>I>$(]4A\+6::T93J W^:97W-]]L9/\ NXKF?,?^^WYTGF/_ 'V_
M.CZD_P"8/K'D>@3!F@D"9WE2%P<<XKQ3^SOBA_?U3_P*7_XJNK,C_P!]OSI/
M,?\ OM^=/ZB_Y@^L>1RO]G?%#^_JG_@4O_Q5>G^#(M6A\,VZ:X9C?[G+^<^]
ML;CCG)[8KF?,?^^WYT&1_P"^WYT?47_,'UGR/1:\1_L[XH?W]4_\"E_^*KJ/
M,?\ OM^=)YC_ -]OSH^HO^87UGR.8_L[XH?W]4_\"E_^*KT_P9%JT/AFW37#
M,;_<Y?SGWMC<<<Y/;%<MYC_WV_.CS)/[[?G3^H/^8/K/D>D5XC_9WQ0_OZI_
MX%+_ /%5TIDD_OM^=(9)/[[?G1]0?\WX!]9\CF_[.^*']_5/_ I?_BJ]/\&1
M:M#X9MTUPS&_W.7\Y][8W''.3VQ7)^9)_?;\Z/-D_OM^=/Z@_P";\ ^L^1Z7
M7B/]G?%#^_JG_@4O_P 570^;)_?;\Z/-D_OM^=']GO\ F_ 7UKR.>_L[XH?W
M]4_\"E_^*KTOP3'K,/AQ$UXS&^$KY,SAFV]N:Y0RR?WV_.D\V3^^WYT?V>_Y
MOP#ZUY'I]>*3:?\ $TSR&-]3V%CMQ=*.,_[U;9ED_P">C?G2&63_ )Z-^=/^
MSW_-^ ?6O(PO[.^*']_5/_ I?_BJ]+\$QZS#X<1->,QOA*^3,X9MO;FN0,LG
M_/1OSI/-D_YZ-^=']G/^;\ ^M>1ZG7BDVG_$TSR&-]3V%CMQ=*.,_P"]6QYL
MG_/1OSI/-D_YZ-^=/^SG_-^ OK7D8O\ 9WQ0_OZI_P"!2_\ Q5>E^"8]9A\.
M(FO&8WPE?)F<,VWMS7&^;)_ST;\Z3S9/^>C?G1_9S_F_ /K?D>K5XI-I_P 3
M3/(8WU/86.W%THXS_O5J>;)_ST?\Z3S9/^>C_P#?1I_V:_YOP#ZWY&3_ &=\
M4/[^J?\ @4O_ ,57I'@6+6X?#[)KYG-[Y[$><X=MF!CG)]ZXSS9/^>C_ /?1
MI/-D_P">C_\ ?1H_LU_S?@+ZWY'K5>+WNG?$O[=<>0^I>3YK;,72XVYX_B]*
MN^=)_P ]'_[Z-)YTG_/1_P#OHT_[,?\ -^ ?6_(S?[.^*']_5/\ P*7_ .*K
MTCP+%K</A]DU\SF]\]B/.<.VS QSD^]<1YTG_/1_^^C3?.E_YZ/_ -]&C^S'
M_-^ ?7/(]?KQ>]T[XE_;KCR'U+R?-;9BZ7&W/'\7I5CSI?\ GH__ 'T:0S2_
M\]'_ .^C3_LQ_P WX"^N>12_L[XH?W]4_P# I?\ XJO2/ L6MP^'V37S.;WS
MV(\YP[;,#'.3[UP?G2_\]'_[Z-)YTO\ ST?_ +Z-']EO^;\ ^N>1['7B][IW
MQ+^W7'D/J7D^:VS%TN-N>/XO2I/.E_YZ/_WT:0S2_P#/1_\ OHT_[+?\WX!]
M<_NE;^SOBA_?U3_P*7_XJO1? ,.O0:%.OB$SF[-RQ3SY [;-JXY!/&=U<#YT
MO_/1_P#OHTGG2_\ /5_^^C1_93_G_ /KO]T]HKQO4]/^)#:M>&U?4OLQG<Q;
M;H ;-QQCYO3%1&:7_GJ__?1I#-+_ ,]7_P"^C3_LI_S_ ("^N_W2/^SOBA_?
MU3_P*7_XJO1? ,.O0:%.OB$SF[-RQ3SY [;-JXY!/&=U>>^=+_SU?_OHTGG2
M_P#/5_\ OHT_[)?\_P" ?7?[I[97C>IZ?\2&U:\-J^I?9C.YBVW0 V;CC'S>
MF*JF>7_GJ_\ WT:0SR_\]7_[Z-']DO\ G_ 7UY?RB_V=\4/[^J?^!2__ !5>
MB^ 8=>@T*=?$)G-V;EBGGR!VV;5QR">,[J\X,\O_ #U?_OHTGGR_\]7_ .^C
M3_LA_P _X?\ !#Z\OY3W&O&]3T_XD-JUX;5]2^S&=S%MN@!LW'&/F],50\^;
M_GJ__?1I#/-_SU?_ +Z-']D/^?\ #_@A]>7\I-_9WQ0_OZI_X%+_ /%5Z#X
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ;2\!(.#VR*U/^$G\5_]!;5/^_KUZC\(;'[/X4FNB/FNKEB#ZJH 'Z[J] H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,\]M(C&19'+!< D$9Z<X'XUMZWJWA"#6;F+4-,>6[5@)'$8.3@?[7I54>.M
MTJ!QHND,DK#J46,'ZD$DUT<\JF'5.-%W:2OI;;<RY5"KSNIU\Q6T.UU'XI7*
M-&I@A1;B5,<%MJ\'ZD@_G6;XV\5WL^JSZ;:3O#:P-L;RS@NPZY/H#QCVJW\/
M-0DOO$^HSW+[KBXA+D^OS#@?F*Y+Q%"\'B34HW!!^TR'GN"Q(/Y&M*%*^)Y*
MFO)%6_5DU)VH\T-.9L;INN:CI-TL]K=2*0<LA8E7]B.]=SXR@M]>\(VOB"!
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M^1LU+_KL?Y"O7C_OTO\ "OS.%_[LO5F+1117HG(%%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"WF2N=\\Q&-[8_0#L*W:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#SKXJ?\PG_MM_[)7G->C?%3_F
M$_\ ;;_V2O.:^SRS_=8_/\V?/XS^-+^N@4445Z)RA1110!T_P_\ ^1PM?]R3
M_P!!-0>-_P#D<=0_WD_] 6N?HKF]A^_]M?I:WS-?:?N_9VZW"O1_AO\ \@;5
M_J/_ $$UYQ11B:'MZ;IWML%&I[.?-8*]#^'VO)-%)H%\0\;JWD!^A!^\G\S^
M=>>44\3AXUZ;A+_AF%*JZ4N9'4W]O<>!_%Z30 M"#OBR?OQG@J??J/R-=3J.
MD:-X[C2_TZ]6&]"@.I )QZ.O7/O_ #KRVE!*D$$@CN*PGA)2Y9J=II6O;?U1
MI&NE>+C>+Z'H=E\.(;.7[3K&HQ?9H^65/E!^K'H*SO''BBWU3RM,TX@V4!RS
M@8#L. ![ 5Q\DTLN/,D=\=-S$TRBGA).HJM:?,UMI9()5URN%.-D]ST72?\
MDD]_]7_F*\^@GEMKB.>%RDL;!D8=014=%;4:'LW-MWYG<SJ5>=1\E8]S\-ZY
M#KVD)=KM691LG0?PL/Z=Q]:\,HHK+"X..&E-Q>C_  -*V(=5136QZ/X#_P"1
M/UGZO_Z+KSBBBM:5#V=2<[_$[F<ZG-&,;;'3^#/$R^'[]TN=QLKC DP,E".C
M?X__ %JZ+4O =EK4K:AH>H0K'*2Q3[R GT(Z?2O-J?'+)$VZ-V0^JG%95<+)
MU/:TI<LGOU3^1I"LE'DFKH],TKPMI?A%QJFL:A&\T>3$.@!QV'5C7$^)]=;Q
M!K#W6TI"HV0H>H4>ON>M8[.SMN=BS>I.:2G1PKA/VM27-+;M;T0JE92CR05D
M;W@S_D;]._ZZ'_T$U;^(7_(W3_\ 7-/Y5RU%:.A>NJU^EK$>T_=^SMUN;'A7
M_D:M,_Z[K7H7B?P3+X@U87J7R0@1!-IC+=">>OO7DM%95\-.=55:<^5I6VN:
M4ZT8P<)1NO4]!_X5;/\ ]!6/_OR?\:HVF@/X=\?:59O.LY?$H95V\'<,?I7&
M44*A7::G4NFFMK;@ZM-6<8V:\SK_ !U</:^-_M$1Q)$L3J?0@9%=QK6J6UMX
M8N-=MP%GNK5$C?OSG:/PW$_A7C%%9SR^,XTXM_#^*[%1Q3BY-+?\#O\ X6_\
M?NH_]<T_F:H>!>?'!_W9:X^BM)X3F=1W^-)>A$:]E!6^%F[XR_Y&[4?^N@_]
M!%85%%==.')!0[*QC.7-)R[E_1M5FT75H+Z$9,9^93_$IX(_*O0]1TC1O'<:
M7^G7JPWH4!U(!./1UZY]_P"=>6TH)4@@D$=Q7-7POM)*I"7+)=?T9K3K<L7"
M2NF>AV7PXALY?M.L:C%]FCY94^4'ZL>@K.\<>*+?5/*TS3B#90'+.!@.PX '
ML!7'R32RX\R1WQTW,33*BGA).HJM:?,UMI9(J5=<KA3C9/<]'T'_ ))9J7TF
M_D*\XHHK:C0]E*<KWYG<SJ5.=15ME8]/\&ZK!XBT*?0=2.^2./:,GEX^Q'NI
MQ^E6-#TH^"]"U:]NMK2AF*-_>5>$^F2?U%>445R3R_F<E&5HR:;5OZW.B.*L
MDVKM=1TDCRRO)(Q9W)9B>Y/6NT^&VJ?9=9ET]VQ'=)E<_P!]>?Y9_(5Q-%=M
M>BJU)TWU.:E4=.:FCTG1]*&D?$ZX@08ADA>6(?[+=OP.1^%3:S\/)M4UBZOE
MU&.,3/N"&(G'XYKS"BN-X.JIJI&I9V2VOM\S?V\.7E<=+WW.UU7X>3Z7I=Q?
M'48Y!"F\H(B,_CFN*HHKMHPJ15JDN9^EC"I*$G[JL%%%%;&84444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6QX9T7^WM<BLW
M+K#@O*R=0H_^O@?C6/7HW@>%-%\,:CK\Z\LI$>>ZKV'U;C\*Y,96=*BW'=Z+
MU9OAX*=1)[+5F/XR\)0>'X;:YLGFDMY"4<RD$JW4= .HS^5<M:Q+-=PQ-D*\
MBJ<=<$UZ/H3GQ7X$O--F;?=P$[2>N?O(?SR/H*\\L05U.V5@01,H(/;YA6.$
MJS<)TZCO*-_^ RZ\(\T9Q6C.S\4^ X=*TLWVFR3RB(YF24@G;ZC '3O_ /6K
M@Z]PU#6X;+Q#:Z7=!?(O8B%9NF_.,'V/3\J\O\7^'FT#5BL:G['-EX&]!W7\
M/Y8KGR[%SFE3K/5ZI]U_P#7%T(Q]ZGLM&7-<\,V6F^$=-U6&2<W%UY6]78%1
MNC+' QGJ/6N3KT7Q;_R3;0O^V'_HEJY?PAI?]K>);6)ES%&?.E_W5[?B<#\:
MZ,+7:H2J5'>SE^#,ZU->U4(K=(ZD?#FW/AX3>;<?VGY'F>7N&W?C.W&,^W6O
M.>AYKU5O$H7XE"RW_P"C>5]E//'F?>S]<_+7%^-=)_LKQ)<*BXAG_?1^F#U'
MX'/Z5C@:]7GY*S^)<R_R_(O$TX<O-36SLS1\0^%+"R\-VVLZ7+<21R;2XE8'
M"L.#P!WP/QKC:])\%3)KGA._T&=ANC4A,]E;D'\&R?RKSF2)XIGA=2)$8JR]
MP1QBNC!U)\TZ51W<7^#V,Z\8VC.*T:_$ZOPEX5L]8T^]U#4I9HK:#A6C8#H,
ML3D'H,4_PAX7TWQ!#?374MS&D#@)L=1\I!/.0?2MCQ W_"-> +325.VYNAMD
MQU_O/^I"_0TGPT4OI6JJHR2R@#_@)KAJ8BJZ%2O&5E=)>B=K_,Z(4H*I"FUK
M;4K_ /".^!O^@[+_ -_T_P#B:BNO#_@M+29X-;D:98V**9D.6QP/N^M8G_"$
M>(_^@8W_ ']3_P"*J&[\)ZY86DEU<V#1PQC+L9$.!^!K>,8MJV(;^<3-MV_A
M?@R[X/T;1]=N);._FN8KK[T7ENH#CN.0>1U^GTK*UW1I]"U66RFY ^:-\<.O
M8_Y[U2M[B6TN8[B!RDL;!D8=017JJ0V'Q"T&VEE;R;J!P)"@R5/\0^C#I_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSQRBK.HV;Z=J-S9R?>AD9"?7!ZUU'P\T:'4M5GN;J!)K>WCQMD4,I9NG!Z\
M_I756KQI4G5>QA"FYS4.IQU%=G\1K.ULM6M$M;:&!6@R5BC"@G<?2NFOY="T
M#0-.N[K1;:?SD1?E@3.=F<G(KE>.]R$XP;Y]EH;K#>]*+E;E/)J*] _X3+PM
M_P!"U%_WXBK"\3:WI.K16ZZ;I:V3QL2Y6-5W X_NUK3Q%64E&5)I=[HB=*$5
M=33^\YRBO8;[PGI^J^&8XH+2W@NC"CQRI&%.[;W('(/>O(9H9+>>2&9"DD;%
M64]01U%&%QD,3?ET:Z!6H2I6OU&45WOV"S_X5+]L^R0?:O\ GMY8W_Z_'WNO
M3BJND>*/#]EI5O;7>@QSSQKAY3#&=QSUR>:GZW*2DX0;LVNG3J/V"32E*UU<
MXRBO7H+GP_/X8DUP:%:B%,YC-O'NX./3%<U>^+/#5Q87$,/AZ..62)E1Q#&-
MK$8!R/2LJ>.G4;4:3T=GJM"YX:,5=S6OJ<-17?V]A9M\*9+LVD!N0&Q,8QO_
M -;C[V,]*X"NNC755RLK<KL85*;A;S5PHKU[0/#VE6NAV-IJ%G;/>74;.3)&
M"^2,D D9& 17ENJ6$FEZI<V,GWH9"N?4=C^(P:RP^,A7G*$5M^/2Z+JX>5.*
MD^I3HHHKM.<**[FZM(?"W@A5EB1]3U0<EU!,:8Y SZ _FWM5_P '6^FQ^"[K
M4;W3[>Y,#R.2\2LQ 4' )%>?/'*--U%&ZO9>?],ZHX9N2BW9VOZ'F]%>@?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^O4[()4N9N5XV=E?]"'0X_!)T> ZM*POCN\T?O>/F./NC'3%4?$Z>%UM[?\
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M"BBB@ I*6DH **** $HHHI@%%%% !24M)0(*2EI* "DI:2F 4&B@T"$HHHH
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M)"ML4VPJ"V2Z>I%>K>'M?M?$NE+J-G'-'"SLFV90&R/H37@UU_R#+W_KFO\
MZ,2O5_A1_P B/%_UWD_G7R.;_P"\OT1[F!_@_-G;T445Y1VA1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!YU\5/\ F$_]MO\ V2O.
M:]&^*G_,)_[;?^R5YS7V>6?[K'Y_FSY_&?QI?UT"BBBO1.4V?"?_ "->F_\
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MMU#!]K6Y\U-^Y4VXYQCJ:Q**]BE2KQE>=2Z[62."<Z;5HQL_4]9U_6YM!L=
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M )\[?_OT/\*/[/LO^?.W_P"_0_PH_MN/\GXA_9S_ )CY]HKZ"_L^R_Y\[?\
M[]#_  H_L^R_Y\[?_OT/\*/[;C_)^(?V<_YCY]HKZ"_L^R_Y\[?_ +]#_"C^
MS[+_ )\[?_OT/\*/[;C_ "?B']G/^8^?:*^@O[/LO^?.W_[]#_"C^S[+_GSM
M_P#OT/\ "C^VX_R?B']G/^8^?:*^@O[/LO\ GSM_^_0_PH_L^R_Y\[?_ +]#
M_"C^VX_R?B']G/\ F/GVBOH+^S[+_GSM_P#OT/\ "C^S[+_GSM_^_0_PH_MN
M/\GXA_9S_F/GVBOH+^S[+_GSM_\ OT/\*/[/LO\ GSM_^_0_PH_MN/\ )^(?
MV<_YCY]HKZ"_L^R_Y\[?_OT/\*/[/LO^?.W_ ._0_P */[;C_)^(?V<_YCY]
MHKZ"_L^R_P"?.W_[]#_"C^S[+_GSM_\ OT/\*/[;C_)^(?V<_P"8^?:*^@O[
M/LO^?.W_ ._0_P */[/LO^?.W_[]#_"C^VX_R?B']G/^8^?:*^@O[/LO^?.W
M_P"_0_PH_L^R_P"?.W_[]#_"C^VX_P GXA_9S_F/GVBOH+^S[+_GSM_^_0_P
MH_L^R_Y\[?\ []#_  H_MN/\GXA_9S_F/GVBOH+^S[+_ )\[?_OT/\*/[/LO
M^?.W_P"_0_PH_MN/\GXA_9S_ )CY]HKZ"_L^R_Y\[?\ []#_  H_L^R_Y\[?
M_OT/\*/[;C_)^(?V<_YCY]HKZ"_L^R_Y\[?_ +]#_"C^S[+_ )\[?_OT/\*/
M[;C_ "?B']G/^8^?:*^@O[/LO^?.W_[]#_"C^S[+_GSM_P#OT/\ "C^VX_R?
MB']G/^8^?:*^@O[/LO\ GSM_^_0_PH_L^R_Y\[?_ +]#_"C^VX_R?B']G/\
MF/GVBOH+^S[+_GSM_P#OT/\ "C^S[+_GSM_^_0_PH_MN/\GXA_9S_F/GVBOH
M+^S[+_GSM_\ OT/\*/[/LO\ GSM_^_0_PH_MN/\ )^(?V<_YCY]HKZ"_L^R_
MY\[?_OT/\*/[/LO^?.W_ ._0_P */[;C_)^(?V<_YCY]HKZ"_L^R_P"?.W_[
M]#_"C^S[+_GSM_\ OT/\*/[;C_)^(?V<_P"8^?:*^@O[/LO^?.W_ ._0_P *
M/[/LO^?.W_[]#_"C^VX_R?B']G/^8^?:*^@O[/LO^?.W_P"_0_PH_L^R_P"?
M.W_[]#_"C^VX_P GXA_9S_F/GVBOH+^S[+_GSM_^_0_PH_L^R_Y\[?\ []#_
M  H_MN/\GXA_9S_F/GVBOH+^S[+_ )\[?_OT/\*/[/LO^?.W_P"_0_PH_MN/
M\GXA_9S_ )CY]HKZ"_L^R_Y\[?\ []#_  H_L^R_Y\[?_OT/\*/[;C_)^(?V
M<_YCY]HKZ"_L^R_Y\[?_ +]#_"C^S[+_ )\[?_OT/\*/[;C_ "?B']G/^8^?
M:*^@O[/LO^?.W_[]#_"C^S[+_GSM_P#OT/\ "C^VX_R?B']G/^8^?:*^@O[/
MLO\ GSM_^_0_PH_L^R_Y\[?_ +]#_"C^VX_R?B']G/\ F/GVBOH+^S[+_GSM
M_P#OT/\ "C^S[+_GSM_^_0_PH_MN/\GXA_9S_F/GVBOH+^S[+_GSM_\ OT/\
M*/[/LO\ GSM_^_0_PH_MN/\ )^(?V<_YCY]HKZ"_L^R_Y\[?_OT/\*/[/LO^
M?.W_ ._0_P */[;C_)^(?V<_YCY]HKZ"_L^R_P"?.W_[]#_"C^S[+_GSM_\
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M()[?2N6_X3V__P"?6V_\>_QKWZ:WM1$S26\3*H+8* ]*X+_A9O@W_GPG_P#
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MYJZ6,E&_-J3.@GMH>9:_J<NDZ<+F)$=C(%P^<<Y_PKF/^$WO?^?6W_\ 'O\
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M[6=JR[6MH2#V*"N"D^)'@V.1D.GRY4D'%HG;\:FKC9RE>+:0X8>*5I:GFO\
MPF%Y_P ^\'Z_XUV-:_\ PLOP9_T#IO\ P$3_ !KK/#^JZ5XDTTWUC;8A$AC_
M 'L04Y&/KZU5''2A?GU)GAE+X=#RW5[U]/TY[F-59E(&&Z<G%<W_ ,)?=_\
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MS854[@ ??^\*NAF,X7Y[R)J82,K<NAY%J-RUG8R3HH9EQ@'IR0*PO^$DN?\
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M['P]K-AKVE+?:<C) SLN'0*<CKP*\VK5G5ES3=V=<(1@K15C5HHHK(L****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\
MC7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<
M-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUO
MYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +
M)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]
M^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PL
MG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_W
MZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T
M4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@
M^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A
M_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^
MY9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C
M1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[
MEG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\
MC7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<
M-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUO
MYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +
M)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]
M^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PL
MG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_W
MZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T
M4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@
M^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A
M_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^
MY9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C
M1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[
MEG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\
MC7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<
M-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUO
MYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +
M)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]
M^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PL
MG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_W
MZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T
M4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@
M^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A
M_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^
MY9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C
M1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[
MEG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\
MC7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<
M-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUO
MYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +
M)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]
M^C_C1_PLG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PL
MG7?[EG_WZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_W
MZ/\ C7'T4?4<-_(@^LUOYF=A_P +)UW^Y9_]^C_C1_PLG7?[EG_WZ/\ C7'T
M4?4<-_(@^LUOYF='J?C*]UFU-OJ%CIUQ&00/,@R5R,$J<Y4^XYJW9^$=!N+&
MWF?3QNDC5SB:3&2,_P!ZN.>5(@"[A0>F37I6DNLFCV3(P93 G(.>PKS\;A\/
M%)0BKG5AZM5W<F[&;_PAGA__ *!__D:3_P"*KJK'49=.L8+.VCC2"!!'&I!.
M .G)-4Z*\WV-/L=?M)=R[=ZG-?64]I<)&T,\;12* 1E6&",Y]#7*?\(9X?\
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M;&T2-8(5VHIR<#ZDU5HI^QI]@]I+N7[G5[B[M9K:98S%*AC< $9!&#WKD_\
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M -_9/_BJZ'1]1?0; 6.GPQ1VX8L%.YL$]>2:IFDI_5Z7\J#VL^YN?\)7J/\
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MVR>TTVWMXH7D,K*0S?,0!G);T K*-)3^IX?^1"]O5_F.G_X3[6/[MK_W[/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDFDL $C4LQ\Y#@ 9/>L_K5!_;7WHOV-3^5_<<]111709!1110 4444 %%%%
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M*AN;>6TNI;:==LL3E'7.<$'!I\T>;EOJ*SM?H144450@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,[5O\ 51_[QKTWPO\
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M/*SQD [@ ..:XJ^&6&PT4M9.2;\W<Z*=7VM5]%9GEU>C_"O[NJ_6+_V>H?\
MA-_#O_0MQ_\ ?N/_  KI?"6MZ=K(N_L&FK9>5LW[54;\[L=/3!_.GCZ]6>'E
M&5-I::W7<6&IPC534T_O.4^&'_(8OO\ K@/_ $(5E:GXMUZ'5;R*/4I51)W5
M5 ' #'':M7X8?\AB^_ZX#_T(5<O?$WA**^N(YM WRI*RN_V>,[F!Y/6G-VQD
M_P!WSZ+MI]XHK]Q'WN75]_T.4_X3'Q#_ -!2;\E_PJ7P4S/XTL'8Y9G<D^IV
M-6U<^)_",MK-'%X?V2,C*C?9XQ@D<'K6)X(_Y''3_P#>?_T!JZ79T*C]GR:/
MMKH^QE_R\A[_ #:^?ZFCXN_Y*(/^ND'\EKTC5H(=4L[S2&(\R6WW#/N2 ?P(
M%>;^+O\ DH@_ZZ0?R6NLUK4O[-\>Z.6;$<\+0/\ \";C_P >Q7F5X2G"CR[J
M+:^5F=E.2C*I?9NWWGDCHT;LC@AE."#V->Q^#+2/2?#UC!)Q<7@:<CN<C/Z+
MMKC==\.F3XAI9(I$5[()N/[IY?\ DU=4FHBZ^)"V49'E6=HR #H&.TG]-H_"
MNC'U?;THJ.UN9_+;\?R,L-#V4VWWM_7R.1'_ "5/_M__ *UI^.O$.K:9X@%O
M97LD,7D*VU0.I)]JS!_R5/\ [?\ ^M=7XGUSP]IVK"#4](^UW'E!O,\E&^7)
MP,DY]:51VK4O<YO<VT\NX1_AS]ZWO;G _P#"8^(?^@I-^2_X5+H5_=:EXTTZ
MYO)FFF,R@NW7 K?_ .$J\&_]"[_Y+Q_XUA:1/;77CZUGM(?)MWN@T<> -H],
M#BNM-.$_W7)H]=.WD8.ZE'W^;5=S=\>:[JFG>(1!9WTT,7D*VU#@9R>:P].\
M9^((+V(_;)+D%P##( =_/3U%=KXGU#PM;:N(]8L'GNO*4[U3("Y.!U'O5S2;
M?0&L&U70=.@GE0':H&'#?W?F^Z:X(5Z<,/%3HWTM>RL_F=4J<Y57RS^6OY'/
M?%&VA5]/N@ )GWHQ[LHP1^63^=9'B#6(9?".DZ2+U;NXCVRNR+@1J%(5/J <
M>O'-97B/7KO7]1\ZZ3R5BRB0C/R<\Y]_6L>O2PV%<:5-5'K'7^OO..M73G)P
MV9ZG8/<Z3\-(KG1HM]RZ[V95W$$M\S8[D=/PKB(?%^OV]P)AJ4SD')20[E/M
M@U:\/>+M1\.0B$P^?9,<B.3*X/?:W;]:Z8>+/"6MG;JFGB*1N"\L0;_QY>?Y
M5R>SE0E-SI<Z;;NK-^EF;\T:D8\L^5I;&5XSUO1]>T>QN()5_M),;XPC952/
MF7.,'!QW]:XBNU\7>$;33K!-6TF3?9.1N3=N"@]"I[C_ !KBJ[\#[/V*]DW;
M7?IY'-B>?VGO[G>?"_\ Y"E__P!<1_Z%63J'B[7H=3NHX]2E5$F=5&%X 8X[
M5K?"_P#Y"E__ -<1_P"A5QVJ_P#(8O?^OB3_ -"-<\*<)XRISI/2.YK*4HX>
M'*[:L[WP?XQN=5O/[)U?9.)U(CD* 9XY5@."",_Y-<_?Z2NB^/[:TB!$)NHI
M(L]E+ X_#D?A6?X45V\5:8$Z^>I_ =?TS74>+W5OB+I(7JOD!OKYA/\ (BLY
M0C1Q+C3T4HMM>:*4G4HIRW317^)__(;L_P#KV_\ 9C6_KEQ>Z'X*L!HB%4V(
M))8UW%5*YW?B>]8/Q/\ ^0Y9_P#7M_[,:JZ#XXU#0K:.SNK8W%LH_=AB5=1Z
M ]Q64*,ZF%HR@E+EUL^NYI*I&-:HI.U^O8HZ?XTUNRO$FDOI;B,-\\4IW!AW
M'/3\*O>/-1T?5;NUN]-G66;:5GPC+P,;3R!GN/RK?37_  9K[!+ZR2WE?C?+
M'MY_WU_KBN;\9>%$T!XKFTD9[*<E0&.2C=<9[C'3Z5M2E2>(BY0<)Z]K/[C.
M<9JD[24H_BCI6OKG3OA9:W-I,T4RJH#KU&7P:XS_ (3'Q#_T%)OR7_"N^L+R
MQL/AQ9W&HVOVFV5 &BVALDN<<'BL7_A*O!O_ $+O_DO'_C7/AVDY_N>?WGKI
M^IK57P^_RZ+N<E?>(=6U.V^SWM[)-%D-M8#&1^%0:58/JFJVUC'G,T@4D=AW
M/X#)K7\3:OHFIPVZZ3IGV-T8F0^4J[ACC[IK;^&6E^;>7.J.ORPCRHS_ +1Y
M)_ 8_P"^J]"=94<,ZBCR^6F_R.6--U*RC>_F=C_:5HNO#PWL3ROL>0OZ;/\
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M!DCW!&>*YJ[T(1^,6T59/+1KD1JY&=JMR/KP14O@8$^,M/QZO_Z U.\=D?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC%5*>%I3I4U";O;;T"M.,Y\T5:YZI'%:>.O!]O;)<+%>VP7(/)5P,<C^Z?\
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ME*HI6T2M8Z;_ (5OKO\ >M/^_I_PH/PWUT G-H?;S3_A6#_PD&M?]!>__P#
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M]]N[_P"'M]:PH]4U"*T^RQW]TEM@CR5F8)@]1C..<FJE:1PS==UJCO;9=O\
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MZ$&K_P#PD.M?]!>__P# A_\ &LVBMI0C+XDF9J36S.Z^'^M)_:5[9:A.7-\
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M+ZXF0'(1W)&?ITJC6M"A.-1U:KO)Z:;)$5*L7%0@K)'8?#;_ )&A_P#KV?\
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M(2DI:2F E)2TE,0E)2TE,!*2EI*8A*2EI*8"4TTZFFF(2D-+2&F(2D-+2&F
MVD-+2&F(2DI:2F(0TAI32&J$-I*6DIB$-(:4TAI@--)2FDIB&FD-*:0U0A#3
M:<:;30A#2&E-(:8#33:<:;5$B&FFG&FFF AI#2FD-4A#:::=333$/%[=6%G>
MSV=S-;3"(#S(9"C8\Q.,BO5_AG>W5_X.CGO+F:YF,T@\R:0NV,],FO(;K_D&
M7O\ US7_ -&)7J_PH_Y$>+_KO)_.OD<W_P!Y?HCW,#_!^;.WHHHKRCM"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SKXJ?\ ,)_[
M;?\ LE><UZ-\5/\ F$_]MO\ V2O.:^SRS_=8_/\ -GS^,_C2_KH%%%%>B<H4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\*O?\+"T'_GI/_WZ-'_"PM!_YZ3_ /?HT?VABOYW_7R#ZK1_E*/_  K#3/\
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M_P!>?^._X5>_X6%H/_/2?_OT:/\ A86@_P#/2?\ []&C^T,5_._Z^0?5:/\
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M/JM'^4H_\*PTS_G^O/\ QW_"C_A6&F?\_P!>?^._X5>_X6%H/_/2?_OT:/\
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M_E.'_P"%8:9_S_7G_CO^%'_"L-,_Y_KS_P =_P *[BBC^T,5_._Z^0?5:/\
M*</_ ,*PTS_G^O/_ !W_  H_X5AIG_/]>?\ CO\ A7<44?VABOYW_7R#ZK1_
ME.'_ .%8:9_S_7G_ ([_ (4?\*PTS_G^O/\ QW_"NXHH_M#%?SO^OD'U6C_*
M</\ \*PTS_G^O/\ QW_"C_A6&F?\_P!>?^._X5W%%']H8K^=_P!?(/JM'^4X
M?_A6&F?\_P!>?^._X4?\*PTS_G^O/_'?\*[BBC^T,5_._P"OD'U6C_*</_PK
M#3/^?Z\_\=_PH_X5AIG_ #_7G_CO^%=Q11_:&*_G?]?(/JM'^4X?_A6&F?\
M/]>?^._X4?\ "L-,_P"?Z\_\=_PKN**/[0Q7\[_KY!]5H_RG#_\ "L-,_P"?
MZ\_\=_PH_P"%8:9_S_7G_CO^%=Q11_:&*_G?]?(/JM'^4X?_ (5AIG_/]>?^
M._X4?\*PTS_G^O/_ !W_  KN**/[0Q7\[_KY!]5H_P IP_\ PK#3/^?Z\_\
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M?&UI%#*,$'D#'I7-_P#"EKC_ *#<7_@.?_BJ]>HI5*LZCO-W80A&"M%'D/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -D)$9
M(JMYC_WC^=69/]6WTJI0 [S'_O'\Z/,?^\?SIM% #O,?^\?SH\Q_[Q_.FT4
M.\Q_[Q_.CS'_ +Q_.FT4 .\Q_P"\?SH\Q_[Q_.FT4 .\Q_[Q_.CS'_O'\Z;1
M0 [S'_O'\Z/,?^\?SIM% #O,?^\?SH\Q_P"\?SIM% #O,?\ O'\Z/,?^\?SI
MM% #O,?^\?SH\Q_[Q_.FT4 .\Q_[Q_.CS'_O'\Z;10 [S'_O'\Z/,?\ O'\Z
M;10 [S'_ +Q_.CS'_O'\Z;10 [S'_O'\Z/,?^\?SIM% #O,?^\?SH\Q_[Q_.
MFT4 .\Q_[Q_.CS'_ +Q_.FT4 .\Q_P"\?SH\Q_[Q_.FT4 .\Q_[Q_.CS'_O'
M\Z;10 [S'_O'\Z/,?^\?SIM% #O,?^\?SH\Q_P"\?SIM% #O,?\ O'\Z/,?^
M\?SIM% #O,?^\?SH\Q_[Q_.FT4 .\Q_[Q_.CS'_O'\Z;10 [S'_O'\Z/,?\
MO'\Z;10 [S'_ +Q_.CS'_O'\Z;10 [S'_O'\Z/,?^\?SIM% #O,?^\?SH\Q_
M[Q_.FT4 .\Q_[Q_.CS'_ +Q_.FT4 .\Q_P"\?SH\Q_[Q_.FT4 .\Q_[Q_.CS
M'_O'\Z;10 [S'_O'\Z/,?^\?SIM% #O,?^\?SH\Q_P"\?SIM% #O,?\ O'\Z
M/,?^\?SIM% #O,?^\?SH\Q_[Q_.FT4 .\Q_[Q_.CS'_O'\Z;10 [S'_O'\Z/
M,?\ O'\Z;10 [S'_ +Q_.CS'_O'\Z;10 [S'_O'\Z/,?^\?SIM% #O,?^\?S
MH\Q_[Q_.FT4 .\Q_[Q_.CS'_ +Q_.FT4 .\Q_P"\?SH\Q_[Q_.FT4 .\Q_[Q
M_.CS'_O'\Z;10 [S'_O'\ZL1$E,DYJK5F'_5_C0!)1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'GGQ2_YA7_;;_P!DKSNO1/BE_P PK_MM_P"R5YW0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'HGPM
M_P"8K_VQ_P#9Z]#KSSX6_P#,5_[8_P#L]>AT %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#TSCI6+H'Q"MIO TVIW[@WEBHCFCS@RO_ 1_O?T/I7C<DE_XDUXN09[Z]FX
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M)65AD$%AD$4 4**ZWXA6EM9Z_!':V\4"&U5BL2!03N?G KDJ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /1/A;_S%?\ MC_[/7H=>>?"W_F*_P#;'_V>
MO0Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ;)_JV^E5*MR?ZMOI52@ HHHH ***\YU7XB:A8>+Y-
M'2SMFA6X2+>V[=@XYZ^] 'HU%%% !1110 4444 %%%% !1110 4444 %%%%
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M'!/'3I7K-<GKOP\T37+LW@66RO"=QFMFV[CZD=,^XP: ,;5M NO#'C&/Q)I
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M[(0(AV@M(2"<@#H.O7/X5G_#SQVEPVE>&/[/966-D^T>;Q\JLWW<>V.M>H4
M>$_$O0-.\.SZ59Z= (T\AB[GEI#NZL>YKM/@[_R*%U_U_/\ ^@1USWQG_P"0
MMI?_ %P?_P!"KH?@[_R*%U_U_/\ ^@1T >A4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'IDYQ]ZJES\.?L]K-/\ VQ&WEHS[?)ZX&<?>KD=7_P"0U?\ _7Q)_P"A&J=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 V3_5M]*J5;D_U;?2JE !1110 5X1XC_Y
M*A-_U^Q_^RU[O7A'B/\ Y*A-_P!?L?\ [+0![O2$@ DG '4FEK/UYI%\.ZFT
M7^L%I*5^NPXH \XU?XB:SJFLMI_AF$;0Q1'6,2/+C^( \ 4FG_$+7M%UA+'Q
M/;Y0X#LT81T!_B&.&%<MX,.O#5ICX>2-KL0G?OV<)D9QN]\5MZ[X=\;>(+N
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MG_H(H M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJPBL;*+RK:$81-Q.!G/4Y/>GW=K!?6DMK<QK+!,A1T;HP/6@#YAT;_D.:?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!YY\4O^85_VV_\ 9*\[KT3XI?\ ,*_[;?\ LE>=
MT %%%% %S2K_ /LS5;:^\OS?)</LW;=WX\UVK_$R.0Y?0D8^IN ?_9*\^HH
M[JX^)EV8BEGIT$![%G+X_# KB[JZGO;J2YN96DFD.69NIJ&B@#M-)\?+IFCV
M^GMI0G$*[=QGQNYSTVFK?_"R8/\ H 1_]_Q_\17 44 =?K?C:'6-(FL5T=(&
MDVXE$H8KA@>FT>F.O>J5SXJ^T>$XM"^Q[?+V_OO-SG!S]W']:YVB@ HHHH Z
M*P\5?8O"]SHOV/?YV_\ ?>;C&[_9Q_6N=HHH W_#/BF?PY),!#]H@E',1?;A
MAW!P:MZ?XPATW7[W4X-+PMTN#")\!6SDG.WN>V.]<K10!WY^)4)))T&,D_\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V3_ %;?2JE6Y/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *LP_P"K
M_&JU68?]7^- $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5T7_  @OB3_H'?\ D>/_ .*H_P"$%\2?] [_ ,CQ_P#Q5 '.T5T7_""^)/\
MH'?^1X__ (JC_A!?$G_0._\ (\?_ ,50!SM%=%_P@OB3_H'?^1X__BJ/^$%\
M2?\ 0._\CQ__ !5 '.T5T7_""^)/^@=_Y'C_ /BJ/^$%\2?] [_R/'_\50!S
MM%=%_P (+XD_Z!W_ )'C_P#BJ/\ A!?$G_0._P#(\?\ \50!SM%=%_P@OB3_
M *!W_D>/_P"*H_X07Q)_T#O_ "/'_P#%4 <[171?\(+XD_Z!W_D>/_XJC_A!
M?$G_ $#O_(\?_P 50!SM%=%_P@OB3_H'?^1X_P#XJC_A!?$G_0._\CQ__%4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** &R?ZMOI52K<G^K;Z54H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ JS#_J_QJM5F'_5_C0!)1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !17GWQ/D>/^RMCLN?.S@X_N5Y[]HF_P">TG_?1H ^
M@Z*^?/M$W_/:3_OHT?:)O^>TG_?1H ^@Z*^?/M$W_/:3_OHT?:)O^>TG_?1H
M ^@Z*^?/M$W_ #VD_P"^C1]HF_Y[2?\ ?1H ^@Z*^?/M$W_/:3_OHT?:)O\
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MZ*^?/M$W_/:3_OHT?:)O^>TG_?1H ^@Z*^?/M$W_ #VD_P"^C1]HF_Y[2?\
M?1H ^@Z*^?/M$W_/:3_OHT?:)O\ GM)_WT: /H.BOGS[1-_SVD_[Z-'VB;_G
MM)_WT: /H.BOGS[1-_SVD_[Z-'VB;_GM)_WT: /H.BOGS[1-_P ]I/\ OHT?
M:)O^>TG_ 'T: /H.BOGS[1-_SVD_[Z-'VB;_ )[2?]]&@#Z#HKY\^T3?\]I/
M^^C1]HF_Y[2?]]&@#Z#HKY\^T3?\]I/^^C1]HF_Y[2?]]&@#Z#HKY\^T3?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!LG^K;Z54JW)_JV^E5* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *LP_P"K_&JU68?]7^- $E%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >>?%+_F%?\ ;;_V2O.Z]$^*7_,*_P"VW_LE>=T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!Z)\+?^8K_ -L?_9Z]#KSSX6_\Q7_MC_[/7H= !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -
MD_U;?2JE6Y/]6WTJI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5F
M'_5_C5:K,/\ J_QH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M642K"Y02 8W8[U)_8NJ_] R]_P"_#?X52(*D@@@C@@T )1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'HGPM_YB
MO_;'_P!GKT.O//A;_P Q7_MC_P"SUZ'0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #9/\ 5M]*J5;D
M_P!6WTJI0 4444 %5=0U&STJT:ZOKB."!>KN>_H/4^PJU7COQ!FGUCQ[:Z*\
MWE0(T4*9^ZI?&6(_$?E0!U4_Q6\.Q2%42^F&?OQQ  _]],#^E:>C^.] UJ=;
M>"Z,-PQPL5PNPM]#T)]LYI+/X?\ AJTMUB.FI.P&#),Q9F]_0?A7&>/O EII
MEFFIZ-#)&!(%E@4E@,]&7N.?YT >LT5@>"[^[U'PK9RWZ2+=(#&YD!!;:< G
M/J,5K7VHV>F6_GWUU%;Q9QND8#)]!ZT 6:*YV+QWX8FF\I=7A#9QEU95_,C%
M= CK(BNC!D89#*<@B@#$'B[2CXB_L+?+]NW;-OEG;G&[K]*=KWBK2_#;P+J+
MR*9PQ38A;IC/\Q7GB_\ );_^W@_^BJ[+QEIGAO4)+-M?OS:L@<0@2A-P.,]C
M[4 =5'(LL22+]UU##Z&G5' $6WC6(YC"@*?48XK-U/Q-HNC2>7?ZC##)C/EY
M+,/J!DT 6=6U2UT73)=0O&98(MNXJN3R0!Q]2*9HVLV>NZ>M]8LS0EBN67:<
MCKQ7*>,M>TO6_ &J-IU[%<;/*W*IPR_O5Z@\BI_A=_R)B?\ 7>3^E ':444A
M(52S$  9)/:@!:*Y^X\<>&K68Q2:O 7!P=@9Q^:@BM73]3L=5@\^PNHKB/."
M8VS@^_I0!;HILDL<,322NJ1J,LS'  ]2:Y^3QYX8BE\MM7A+>JJS#\P,4 =%
M65KOB'3_  [;17&H/(L<C[%V)NYQFKME?6FHVXN+*YBN(3T>-@PK@_B]_P @
M*P_Z^3_Z": .\L;V'4;""\MR3#.@="1@X/M5BL7PC_R*&D?]>L?\JL:GX@TG
M1R%U"_@@<C(1FRQ'K@<T :5%8FG^+] U2<06>J0/*W"HV4+'V# 9K:)"J22
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M.: -"BN=D\=>&(IS"VKPEP<94,R_]] 8_6MVVNK>\MUGM9HYH7Y5XV# _B*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#SSXI?\PK_MM_[)7G=>B?%+_F%?\
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M_6N0OF5[^Y=2&5I6(([C)KN_!WB2SN=+ET36I8EB5"(WF8*K)_=)/<=O_K4
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MQ7_MC_[/7H= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M>?%+_F%?]MO_ &2O.Z]$^*7_ #"O^VW_ +)7G= !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >B?"W_ )BO_;'_
M -GKT.O//A;_ ,Q7_MC_ .SUZ'0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYKWBB@"KIJ,FEVB.I5EA0%2,$':*M444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %68?]7^-5JLP_ZO\: )**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M \%HKWK^R-,_Z!UI_P!^%_PH_LC3/^@=:?\ ?A?\* /!:*]Z_LC3/^@=:?\
M?A?\*/[(TS_H'6G_ 'X7_"@#P6BO>O[(TS_H'6G_ 'X7_"C^R-,_Z!UI_P!^
M%_PH \%HKWK^R-,_Z!UI_P!^%_PH_LC3/^@=:?\ ?A?\* /!:*]Z_LC3/^@=
M:?\ ?A?\*/[(TS_H'6G_ 'X7_"@#P6BO>O[(TS_H'6G_ 'X7_"C^R-,_Z!UI
M_P!^%_PH \%HKWK^R-,_Z!UI_P!^%_PH_LC3/^@=:?\ ?A?\* /!:*]Z_LC3
M/^@=:?\ ?A?\*/[(TS_H'6G_ 'X7_"@#P6BO>O[(TS_H'6G_ 'X7_"C^R-,_
MZ!UI_P!^%_PH \%HKWK^R-,_Z!UI_P!^%_PH_LC3/^@=:?\ ?A?\* /!:*]Z
M_LC3/^@=:?\ ?A?\*/[(TS_H'6G_ 'X7_"@#P6BO>O[(TS_H'6G_ 'X7_"C^
MR-,_Z!UI_P!^%_PH \%HKWK^R-,_Z!UI_P!^%_PH_LC3/^@=:?\ ?A?\* /!
M:*]Z_LC3/^@=:?\ ?A?\*/[(TS_H'6G_ 'X7_"@#P6BO>O[(TS_H'6G_ 'X7
M_"C^R-,_Z!UI_P!^%_PH \%HKWK^R-,_Z!UI_P!^%_PH_LC3/^@=:?\ ?A?\
M* /!:*]Z_LC3/^@=:?\ ?A?\*/[(TS_H'6G_ 'X7_"@#P6BO>O[(TS_H'6G_
M 'X7_"C^R-,_Z!UI_P!^%_PH \%HKWK^R-,_Z!UI_P!^%_PH_LC3/^@=:?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ;)_JV^E5*MR?ZMOI52@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F[%W;MHW>N.:=10 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !5F'_5_C5:K,/\ J_QH DHHHH ****
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MM_<6ZV%N5BE9 2QR0"10!1_X67K0ZVMA_P!^W_\ BJ/^%EZS_P ^UA_W[?\
M^*K=T+Q?;>)KP:7J.FQ!I5.S^-6P,D$$<< UQNM: UMXM?2+,%A)(HA!/0,
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M_P#BJS=(O3J/CNUO6C$9FN@Y4'(&:[+Q1XTN=!U86<-I%*OE*^YV.<DGT^E
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M.264@G&XX!K+_P"%GW/_ $#(O^_I_P * *Q^)6MCK:6/_?M__BJ3_A9>L_\
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M &:D_P"%EZS_ ,^UA_W[?_XJN@M9[#X@:+<I-:K!?0C 8<E"1\I!ZX.#D?\
MZZ\M(*D@C!'!H [+_A9>L_\ /M8?]^W_ /BJ/^%EZS_S[6'_ '[?_P"*KC**
M .S_ .%EZS_S[6'_ '[?_P"*H_X67K/_ #[6'_?M_P#XJN,HH ]=\&>)KWQ%
M]M^UQ6Z>1Y>WR5(SNW9SDGT%=57GGPM_YBO_ &Q_]GKT.@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M &R?ZMOI52K<G^K;Z54H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJS#_ *O\:K59A_U?XT 24444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "K,/^K_ !JM5F'_ %?XT 24444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!YY\4O^85_VV_]DKSNO1/BE_S"O^VW_LE>=T %%%% %G3[Z73=0@O8
M51I(6W*'!()]\5-K.KW&MZ@U[<I&DC*%Q&"!@?4FJ%% %BRO9]/O8;NV?9-$
MVY3_ $/M6CKWB6]\1&W^UQP)Y&[;Y*D9W8SG)/H*QJ* .HTWQYJFEZ=#9006
M;10KM4NC$GG/.&%6_P#A9>L_\^UA_P!^W_\ BJXRB@#IM6\<:GK&F36%Q!:+
M%+MW&-&#<$'C+'TK*TC7+_0[@S6,VS=PZ,,J_P!16=10!VX^)NI;,&QM-_K\
MV/RS7.:SXAU'795:]E!1.4B081?P_J:RZ* -70O$%WX>N)9K2.%VD381*I(Q
MG/8BLZXG:YN99W #RN7;'3).:CHH LV%]/IE]#>6S;98FW+GH?8^QZ5H:]XD
MNO$)A:[M[9'BR%>%6!(/8Y)XK&HH W-%\6:KH:>5;RK);YSY,HW*/IW'X&MF
M7XEZJ\>V.TM(V(^]ACCZ#-<510!:O]1N]4NFN;V=II3QENP] .@%:6@^*K[P
M]#-%:16[K*P9O-5B1CTP16'10!V1^)>M$8%O8CW$;_\ Q58VK^*=6UJ/R;JX
M @SGRHUVJ?KW/XUC44 7]'U:?1-16]MDC>55*@2 D<C'8BND_P"%EZS_ ,^U
MA_W[?_XJN,HH [/_ (67K/\ S[6'_?M__BJYG5=3FUC4YK^X6-99<;A&"%X
M'&2?2J5% &SHWBC5=#'EVLX:#.3#*-R_XC\#6\?B;J?EX%E:!_7YL?EFN(HH
M U-6\0ZGK;#[;<EHP<K$HVH/P_QJ]HOC/4="L/L=K#:O'O+YE5B<GZ,*YVB@
M#L_^%EZS_P ^UA_W[?\ ^*J"\^(6K7ME/:26]D(YXVC8JCY (P<?-[UR=% &
MSI'B6]T6QNK2VC@:.Y^^9%)(XQQ@BL:BB@#;T+Q3J'AY)4M!%)'*02DP) /J
M,$<U#9:_=V.NRZO%'"UQ(SNRLIV9;.> <]_6LJB@#L_^%EZS_P ^UA_W[?\
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MQ7_MC_[/7H= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M50W8#N?KZ56^#_\ R$-4_P"N2?S-<W8OKDGCF]GT:,-J0GF?:=O&20WWN.]
M'2GX6:PEO]I36E-\!NV ,!GTWYS^E7_ 7BO4#JLOAS7)':Y3<L3R\ON7[R$]
M^!D'V/M4/VGXI?\ /LOY0?XUGZ;X;\7OXUL]:U'3\,;A&GD#Q@!>%)P#Z>E
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MVJ?R//4>7YAVX\H=NE3?%F]N[2YTH6]S-""DA(CD*@\KUQ5&7_DMX_Z^%_\
M10J?XP_\?6D_[DO\UH BMO"GB7QM;?VMJ.J"".?YH(FW$;>V%'"CT[GK5+3=
M1USP1XOATR_NI)+9G570N61D8X#+GIC\.F*]?TV-8M+M(U^ZD**/H%%>5_%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** ///BE_S"O\ MM_[)7G=>B?%+_F%?]MO_9*\
M[H **** +FE6/]I:K;67F>7Y\@3?C.,^U=J_PUMXVVR:ZJ'T:$#_ -GKE?"W
M_(TZ;_UW6NA\?Z=?77B-9+>RN)D\A1NCB9AG)[@4 3_\*YM/^A@C_P"_0_\
MBZY+7=*31M5>SCN5N555(D QG(STR:C_ +%U7_H&7O\ WX;_  JG)%)#(T<J
M,DBG#*PP0?<4 7]#TF36]7AL8WV;\EGQG:H&2<5I>*/"DGAO[.XN#<139&_R
M]NUAVZGM_(UO> +:/3M)U'7KD855*(?]E>6Q]3@?A5NUD?QAX!N(I#OOK=F(
M]2P^9?S!VT >9UU>@>!KK5K07MU.MG:,-R,1EF'KC(P/<URE>JZUI]QXC\&V
M T>52BJC&+=@. N-N>F0>QH RO\ A7NGW2LMAKJ22J.F%?\ /!XKC=6TF[T6
M_:TO$ <#*LO*L/4'TJ:33=9T*Y2Y>TN;=XF#++L.T$>XXJ]XI\3Q^)#:D67V
M=H P+>9NW XXZ#T_6@#;@^',,EE!<2:R(A*BMAH!QD9QG=3O^%<VG_0P1_\
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M4 >B?"W_ )BO_;'_ -GKT.O//A;_ ,Q7_MC_ .SUZ'0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI5K'(#D/Y8)'T)Z4 <E\+O#=QIEK<:I>Q&*6Y4)$C##!.I)'N<?E[UB>!?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'HGPM_YBO_ &Q_]GKT.O//A;_S%?\ MC_[/7H= !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 -D_U;?2JE6Y/]6WTJI0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1_\ ?0JK_8^G_P#/LOYG_&C^Q]/_ .?9?S/^- %K[1#_ ,]H_P#OH4?:(?\
MGM'_ -]"JO\ 8^G_ //LOYG_ !H_L?3_ /GV7\S_ (T 6OM$/_/:/_OH4?:(
M?^>T?_?0JK_8^G_\^R_F?\:/['T__GV7\S_C0!:^T0_\]H_^^A1]HA_Y[1_]
M]"JO]CZ?_P ^R_F?\:/['T__ )]E_,_XT 6OM$/_ #VC_P"^A1]HA_Y[1_\
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M_P#/LOYG_&C^Q]/_ .?9?S/^- %K[1#_ ,]H_P#OH4?:(?\ GM'_ -]"JO\
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M 'P*/^%8V7_01N/^^!74_P!NZ?\ \]6_[X-']NZ?_P ]6_[X- '+?\*QLO\
MH(W'_? H_P"%8V7_ $$;C_O@5U/]NZ?_ ,]6_P"^#1_;NG_\]6_[X- '+?\
M"L;+_H(W'_? H_X5C9?]!&X_[X%=3_;NG_\ /5O^^#1_;NG_ //5O^^#0!RW
M_"L;+_H(W'_? H_X5C9?]!&X_P"^!74_V[I__/5O^^#1_;NG_P#/5O\ O@T
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M@T?V[I__ #U;_O@T <M_PK&R_P"@C<?]\"C_ (5C9?\ 01N/^^!74_V[I_\
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M74_V[I__ #U;_O@T?V[I_P#SU;_O@T <M_PK&R_Z"-Q_WP*/^%8V7_01N/\
MO@5U/]NZ?_SU;_O@T?V[I_\ SU;_ +X- %3PWX8A\-_:?)N))O/V9W@#&W/I
M_O5NU6M+^WO=_D.6V8SD$=?_ -56: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;)_JV^E5*MR?ZMO
MI52@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K,/^K_&JU68?]7^-
M $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 <_XG_Y=?\ @?\ 2N?KH/$__+K_ ,#_
M *5S] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 =!X8_Y>O^ ?UKH*Y_PQ_P O7_ /ZUT% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M-D_U;?2JE6Y/]6WTJI0 4444 %%%>8^,/&VNZ1XJETS3O*9,1^6AAW,68#@>
MO)H ].HKR3_A*_B&.3H]Q_X+W_PH@^*&NZ==+%K.EQE>Z^6T,@'KSQ^E 'K=
M%4='U>SUS38[ZQDWQ/U!X93W4CL:O4 %%%% !1110 445PGQ"\5ZGX;GL$T]
MH@)U<OYB;NA&/YT =W145L[2VL,C?>9%8_4BI: "BBB@ HHHH ***Y7Q_K]]
MX=T."[L#&)7N5B.]=PVE6/\ 04 =5165X:U"?5?#EA?7.WSIHMS[1@9SZ5JT
M %%<%\0O%FJ>&[JQCT]H@LR.S^8F[D$8_G6YXJU:^TKPG)J%B%-T/+QE-PY(
M!X_&@#H:*P/!NJWVL^'(KW4 !<,[@X3:, X'%;] !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%9GB&^FTWP]?WMN5$T$+.FX9&10!IT5R/P_
M\0W_ (CTFZN=0,9DCG\M=B;1C:#_ %KKJ "BBB@ HHHH **** "BBB@ HHHH
M **** "BBN5\?Z_?>'=#@N[ QB5[E8CO7<-I5C_04 =5165X:U"?5?#EA?7.
MWSIHMS[1@9SZ5JT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %68?]7^-5JLP_P"K_&@"2BBB@ HHHH *BNKF*RM)KJ=PD,*&1V/90,DU
M+7 ?%G6O[/\ #*:?&V)K]]IQU\M<%OUVC\30!;_X6IX5_P"?J?\ [\-791R)
M-$DL;!D=0RL.A!Z&OE#'&>U>]_"[6_[5\)QVTC9GL&\EL]=G5#^7'_ : .VK
MFM9\=Z%H.HM87\\J3JH8A8BPP>G(KI:\$^*O_(\S_P#7&/\ E0![3HFO:?XA
ML3>:=-YD0<HV5*E2.Q!_"M*OGSX>^*3X;U]5G?%A=XCGST4_PO\ A_(FOH,$
M$9'(H X^'XF^&9[J.WCN9S)(X108&ZDX%=A7R[I7_(P67_7U'_Z&*^HJ  G
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M#VG3OB-X8U*X6!-0\F5SA1.A0'_@1X_6NJ!R,CI7SYXN\!7GAFXMEAD>_AN
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MG7L!C!]\=1[U4T&W1[R=)XE8JO1U!P<T 8U%=!)JFFQ2O&=/0E6*YV+VIO\
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M*@TSPC9-&@$MS&)Y7QRQ;D?D"!7-_%O28/L%IJR(%G$OD2,!]Y2"1GZ;?UH
MZSP1_P B7I7_ %Q_J:WZP/!'_(EZ5_UQ_J:WZ /)OC#_ ,?VE?\ 7*3^8KN]
M?UM_#WA4ZE' LS1K& C-@') _K7"?&'_ (_M*_ZY2?S%=-\0?^2=S?2'_P!"
M6@#8\*:Y)XBT&/49(%A9W9=BMD#!Q7)O\5$M=3U&VN]/ 2V+I#Y;DM(X? !X
MP!C)S[5K_#'_ )$FW_ZZR?\ H5<'X:TV#4_BC<QW$8DBBN9YBAZ$JQQG\2*
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MD9]<;?UJ+X+W3F/5[0DE%,<JCL"=P/\ (?E0!ZO1110 4444 %%%% !1110
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MPZ^D_:?(W;/WNS=C:0>F1Z>M &1\,?\ D2;?_KK)_P"A5R/@C_DJ6I_6X_\
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M>.K9/%K>'=2TV..V\SRWGFD#*<C*DKC&#D=3WK6\+^#=/\+QNT!:>ZD&'GD
MSCT ["H/%?@:P\4,LYE:UO$7:)D4,&'HP[_F* (]5^'WAF^A>4VHLC@DRP/L
M"CUQ]W'X5Q/PODF@\7W5I;S&6T,+[R.%8*PVMC_/6M#_ (55JC*+>3Q /LH_
MAVL1C_=SBNU\,>$[#PO;.EL6EGEQYL[_ 'FQV'H/:@#>JGJFFV^KZ;/876[R
M)@ ^PX/7/7\*N44 <3_PJOPY_P!/G_?[_P"M1_PJOPY_T^?]_O\ ZU=M10!@
M:!X/TOPW<33V'G[Y5"-YC[N,Y]*WZ** .1^)?_(CWG^_'_Z&*S_A9K-O<>'O
M[+,BK<VKL0A/+(QSD?B2/_UUH?$O_D1[S_?C_P#0Q7$^'? *Z_X9M=3M+Y[2
M\WNK$@E6PQ (P00: .K^*&M6]IX:?3!(INKME 0'E4#!BQ]N,?C[5G:+I\EA
M\'=0:52K7,4L^".Q  _,*#^-2:3\*H8KQ;G6+]KW:0?*52 Q_P!HDY(]N*[?
M5M,74]$NM-5Q L\1B#!,A!C'3B@#B_A%_P B_??]?7_LBUR-G;)XM^)$\.KS
MNJ--( A;!PI.V,>G _0UZAX0\+_\(KI\]K]L^U>;+YF[RMF. ,8R?2L7Q)\-
M+;6-1?4;"\-E<2-OD79N5F]1@@@]^] &P?#7A30;1[N33K.**$;FDG&_'XMG
MFO./ ETEY\2WND78D[3R*OH#DXKHH/A=<74D9UG7[BYC0_ZI03^3,3C\JT;+
MX<PZ7XIAU?3M0-O!$X*VODEOEVX8;RW?GMWH YCQ[_R4O3/I!_Z,->O5R&O>
M!O[<\36NL?VCY/D",>3Y&[=M8G[VX8SGTKKZ /(=8_Y+7!_U\6__ * M3_&'
M_CZTG_<E_FM=1>>!OM?C6/Q'_:.S9)&_V?R,YVJ!C=N[X]*D\8^"_P#A+);1
M_P"T/LOV=6&/)W[LX_VACI0!TEE_QX6__7)?Y"O*/BA_R.FF?]>\?_HQJ];A
MC\F".+.=BA<^N!7)^*/ W_"2:U:ZC_:/V;R(U3R_(W[L,6SG<,=: .?^+^GR
M/%INH(A,:%XI&';."O\ )JWO"UGX7U_0K>YBTG36F5 LZ>0FY' P<\=^HKJ-
M0L+;5+&6RO(A+;RC#J?\]:\YN?A--#<M)I6M-$AZ"12& ]-RGG\A0!<\7ZAX
M6\+R00)X=TV[NI#EXA&B[%]2=IZ]OQJGXYLOMWP^TO4+;3ULHX6$IMD Q$CY
MYX [E>W>KVB_"RTM+U;O5;UK]U;<(]FU"?\ :R26_2N]GMX;FWDMYHUDAD4H
MZ,,@@]J .7^'NM6^J>%K6W21?M-H@AECSR .%/T(Q^M<_P#%K6+<V-KH\<BM
M<>:)I0ISL ! !^N[/X4M_P#"?;=M-H^JM;(V<1R*25]@P.<?6A?A'"UBXFU9
MS>NX;SO*RJCN-N[DGU)_"@#K/!'_ ")>E?\ 7'^IK?K/T33/[&T6TT[SO.^S
MIL\S;MW?ADXK0H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *LP_ZO\:K59A_U?XT 24444 %%%% 'D7QCUK?/9:+$W"#[1,!ZG(4?EN/
MXBJ7PQ\'6&O07U]JMKY]NC"*%2S*-W5CP1T!7\Z])U/P/X<UG4);^_T[SKF7
M&]_/D7.  . P'0"M32M)L=$L$LM.@$%NI)"!BW).3R22: ,/_A7'A+_H#K_W
M^D_^*KSCXG>$;/P_-97>EV_DVDP,;H&+ ..0<DD\@_\ CM>X50U?1M/UVR^Q
MZE;B>#<'VEBN".AR"#WH \U^#FMX-[HDK=?](A!_ ,/_ $$_G7._%7_D>9_^
MN,?\J]:TSP/X<T?4([ZPT\PW,>=C^?(V,@@\%B#P33M6\%^']<OC>ZCI_G7#
M*%+^=(O Z<*P% $'P]_Y$/2?^N;?^AM7$_%KPKLD7Q#:1_*V$NPHZ'HK_CT/
MX5ZGI^GVNE6$5C91>5;0C")N)P,YZG)[T^[M8+ZTEM;F-98)D*.C=&!ZT ?,
M.C?\AS3_ /KYC_\ 0A7KWQ>UK[)H4&E1MB2\?=(!_P \UY_5L?D:W8/ASX4M
MYXYXM*VR1L'0_:)3@@Y'5JNZQX/T+7[Q;O4[$W$RH(U;SI%PH).,*P'<T >0
M?#7PO;>(]8N'U"#S;*VBRR[B SMPHR"#T#'\*]2_X5QX2_Z Z_\ ?Z3_ .*K
M7T;P_I?AZWD@TNU%O'(^]QO9B3C'5B36E0!X_P#$KP1INCZ/;ZEH]IY"1R;)
MU#LV0WW3\Q.,$8_X%5#X2:W]A\12:9*V(;Y/ESVD7)'YC</RKV;4-/M=4L)K
M*]A$UM,-KH21D=>HY%8-K\/?"]C=PW=MIACGA<21N+B4[6!R#RU '3UX%\3]
M'_LOQA-,BXAO5$ZXZ;CPWZC/XU[[65K7AK2/$0A&JV8N/)SY?[QD*YQG[I'H
M* /GOPKI!UWQ-8:>5S')*#+_ +@Y;] :^F0   !@#H!6'H_@[0=!O&N],L!!
M.4*%_-=_E)!/WB?05N4 <)\6_P#D2O\ MZC_ )&O)/"_B2?PMJKW]O!',[1&
M+;(2!@D'/'TKZ(U;1K#7;+['J5OY]ON#[-[+R.ARI!K!_P"%9^$/^@1_Y,R_
M_%T <+_PN;5/^@79_P#?3?XT?\+FU3_H%V?_ 'TW^-=U_P *S\(?] C_ ,F9
M?_BZ/^%9^$/^@1_Y,R__ != $MYXNBT[P-;Z_=(@FGMT>.$'AI&7(4>W] :\
M#)OO$&M9.ZXOKR;\69C^@_D*^A[_ ,(:%J=E9V=Y9&2WLDV01^=(H08 [,,\
M <G-,TKP5X=T2^6]T_3EBN5!57,KO@'K@,Q'XT 1Z3X/L-/\(G0)466.9#]I
M<#EW/5A]#C'I@5X+KVC77AO7)["<D/"V8Y!QO7^%A_G@U].UCZUX5T7Q#)%)
MJEBMP\0*HWF,A /;Y2,_C0!E> /%8\3:&!.X_M"U 2<=V]'_ !_GFNMK"TCP
M=H.@WAN],L3;SE"A83R-E3VP6(["MV@ HHHH *\&^+'_ ".\G_7O'_(U[S6#
MJW@OP_KE\;W4=/\ /N"H4OYTB\#IPK 4 4?AI_R3[2_^VO\ Z->H_B3H$NN^
M%7^S1E[JT<3HH&2P (8#\#G\*Z73-,M-'T^*PL(?)MHL[$W%L9))Y))ZDU;H
M ^</"'BRX\(ZG)<1P"XAE39+"6VYP<@@X."/IW-1>*/$=UXMUO[;)!Y?RB*&
M%"6VC/3/<DD]J]MU?X?^'-9N6N;BQ\N=SEI('*;CZD#C/OBGZ-X$\/:%<+<V
MECNN%^[+,Q<K],\ ^X&: %\#:&_A_P *6MI,NVY?,TP]&;M^ P/PKR'XB^')
MM#\37%PL9^Q7KF:)P. 3RR_4'/X8KZ!JM?6%IJ=H]K>V\=Q _5)%R/K]?>@#
MQS2/BS?:;H*6$M@ES<0IY<-PTA P!@;EQSCZC-<MX>T:[\5>)(K<!G,LGF7,
MO]U<Y9C_ )ZFO8'^%7A9YMXMKA%S]Q9VQ^O/ZUTNDZ)INA6QM]-LX[>,\MMY
M+'W)Y/XT 8GQ \.R>(/"TD%JFZZMF$T*C^(@$%1]03^.*\5\,^([SPGK/VN&
M/?P8YH')7>N>1[$$=:^E:YW6O WA_7IS<7EB!<-]Z6%BC-]<<'ZF@#QWQIXY
MG\7&WB%J+6U@)81[]Y9CQDG [=/J:]#^$^@3Z7H<^H749CDOV4HK#D1KG!_$
MD_ABM;3?AQX9TRX6=+$SRJ<J;ARX!^G3]*ZN@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G_
M !/_ ,NO_ _Z5S]=!XG_ .77_@?]*Y^@ HHHH *MZ??-87/FA=X(*E<XS52B
M@"YJ6H-J$ZR%-BJN N<U3HHH T-2U3^T$B7R?+\O/\6<_I2Z?K$]BOEX$D77
M:3C'T-9U% '0?\)#!G>++Y_7(_GBLR_U*;4&&_"HOW4'2J5% $]K=S6<PEA;
M![@]"/>M?_A((9 #/9*S#OD'^8K!HH U;W7)KJ(PQ((8R,'!R2*KZ;J']G2N
M_E>9N7&-V,?I5*B@#>_X2-#_ ,N*_P#??_UJ/^$C3_GP7_OO_P"M6#10!=MK
M\6^I/=B'(8L=F[&,^^*AO+C[7=R3[=N\YVYSBH** 'PRO!,DL9PZG(-;)\0H
MTJ2M8@R(" WF=,]>U8=% $]Y<M=W4D[#!8\#.<#TJ"BB@#3N]7^V6"V\D'SK
MC]YO[COC%6E\1@1JALPVT <R?_6K"HH WO\ A(T_Y\%_[[_^M6/=3"XN9)@@
M0.<[0<XJ&B@!R-LD5L9VD'%7=3U+^T7C;RO+V C[V<_I5"B@ JWIUZMA<^<8
MO,.T@#=C'OTJI10!/>7+7=U).PP6/ SG ]*@HHH T[O5_ME@MO)!\ZX_>;^X
M[XQ3+C5/M&FQ6?D[?+Q\^[.<#'3%9]% &A%J?E:6]EY.=^?GW=/PQ6?110!K
M6&N26=L(6B\T#[IW8P/3I63110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 =!X8_P"7
MK_@']:Z"N?\ #'_+U_P#^M=!0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% #9/]6WTJI5N3_5M]*J4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8/C#1KG7
MO#=QI]HT:S2,A!D)"\,">@/I2>#=%N= \.0Z?=M$TR.[$Q$E>3D=0*WZ* "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JS#_ *O\:K59A_U?XT 2
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!S_B?_EU_X'_2N?KI]>L[B[^S^1&7V[LX
M(XSBL;^Q]0_Y]F_,?XT 4:*O?V/J'_/LWYC_ !H_L?4/^?9OS'^- %&BKW]C
MZA_S[-^8_P :/['U#_GV;\Q_C0!1HJ]_8^H?\^S?F/\ &C^Q]0_Y]F_,?XT
M4:*O?V/J'_/LWYC_ !H_L?4/^?9OS'^- %&BKW]CZA_S[-^8_P :/['U#_GV
M;\Q_C0!1HJ]_8^H?\^S?F/\ &C^Q]0_Y]F_,?XT 4:*O?V/J'_/LWYC_ !H_
ML?4/^?9OS'^- %&BKW]CZA_S[-^8_P :/['U#_GV;\Q_C0!1HJ]_8^H?\^S?
MF/\ &C^Q]0_Y]F_,?XT 4:*O?V/J'_/LWYC_ !H_L?4/^?9OS'^- %&BKW]C
MZA_S[-^8_P :/['U#_GV;\Q_C0!1HJ]_8^H?\^S?F/\ &C^Q]0_Y]F_,?XT
M4:*O?V/J'_/LWYC_ !H_L?4/^?9OS'^- %&BKW]CZA_S[-^8_P :/['U#_GV
M;\Q_C0!1HJ]_8^H?\^S?F/\ &C^Q]0_Y]F_,?XT 4:*O?V/J'_/LWYC_ !H_
ML?4/^?9OS'^- %&BKW]CZA_S[-^8_P :/['U#_GV;\Q_C0!1HJ]_8^H?\^S?
MF/\ &C^Q]0_Y]F_,?XT 4:*O?V/J'_/LWYC_ !H_L?4/^?9OS'^- %&BKW]C
MZA_S[-^8_P :/['U#_GV;\Q_C0!1HJ]_8^H?\^S?F/\ &C^Q]0_Y]F_,?XT
M4:*O?V/J'_/LWYC_ !H_L?4/^?9OS'^- %&BKW]CZA_S[-^8_P :/['U#_GV
M;\Q_C0!1HJ]_8^H?\^S?F/\ &C^Q]0_Y]F_,?XT 4:*O?V/J'_/LWYC_ !H_
ML?4/^?9OS'^- %&BKW]CZA_S[-^8_P :/['U#_GV;\Q_C0!1HJ]_8^H?\^S?
MF/\ &C^Q]0_Y]F_,?XT 4:*O?V/J'_/LWYC_ !H_L?4/^?9OS'^- %&BKW]C
MZA_S[-^8_P :/['U#_GV;\Q_C0!1HJ]_8^H?\^S?F/\ &C^Q]0_Y]F_,?XT
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!LG^K;Z54JW)_JV^E5*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *LP_ZO\:K59A_U?XT 244
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*$7 H =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5'FJ/O ?D17,UL^&P?M\A'01'/YB@"7P\C17US&PPRK@_4&J5QJM\ES*JW#
M!R ./6M33"#KFH8Z9/\ .HY8=#,SEYF#[CN&3U_*@!VB:C/>2R6]P1(NS<"1
M^&/UK#O8EAO9XT^ZKD#Z9K;&I:9IT+BR4O(WL>?J36+!&]]?*A.6E?+']2:
M-NP(TO1#=,,O(0<>HS@?IDU!XAMP6AO(^5D&TD?F#^7\JNZO8W-W'##;*OE)
MR<MCGH*>EC-+HAM+@#S%!"$'/3D?X4 <Q!<S6K%H9"A(P2*V=$O[JYO_ "YI
MF==A.#^%8)!!P1@BM;P]_P A,_\ 7,_TH -0U.\BU">-+AE17( &.*L:!-)<
M:A/)*Q9S&,D_45F:I_R$[G_?-:'AK_C[F_ZY_P!: ,J[_P"/V?\ ZZ-_.K>A
M_P#(7@_X%_Z":T)M7L4GD1K!696()VKSS4UAJ=G<7B1168C=LX8*..* ,^__
M .1F'_72/^0I_B3_ (_8O^N?]33+_P#Y&8?]=(_Y"G^)/^/V+_KG_4T 6K-8
M])T;[6R!II ",^_0?UK(DU:^DDWFY=?93@?E6KK/S:':E?NY3_T$USM '00Z
MG;WVF20W\BK(. V.OH1CO7/TY8W<$HC,!UP,XIM !1110 4444 %%%% !111
M0 4444 %%%% '0>&/^7K_@']:Z"N?\,?\O7_  #^M=!0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!S_B?_EU_P"!_P!*Y^N@\3_\NO\ P/\ I7/T %%%% &K
MH%MYU_YI'RQ#/X]O\^U-U/4IWU"7R9Y$C4[0%<@<50BN)H,^5-)'GKL8C-1T
M :.GZG<17T337$CQDX8,Y(P>]6O$%N8+R.Z3C?U/HP_S^E8E2R7,\RA99I'4
M<@,Q(% '1311:]8I)&ZI.G4'L>X/M6='X>O6DVOL1>[;LUEI(\3AHW9&'=3@
MU8.HWK+M-U+C_>- &OJUQ#9:>NG0-EL -[#KS[FETMHK_2'L'?:ZY ]<9R#^
M=<Z3DY/6E5F1@RD@CH0: -4^'KW?M'EE?[V[BKUWY>E:*;3>&ED!'USU/TK%
M_M*]VX^U2X_WJKN[2,6=BS'J2<F@!M=#H?\ R";SZG_T&N>J1)YHD9(Y9$5N
MJJQ - $==)I433^'YHDQN<L!FN;J6.ZN(5VQ3RHO7"N0* -'_A'KWUB_[Z_^
MM3)="O(87E8Q[44L<-V%5/M]Y_S]S_\ ?PTC7MTZE6N9BI&"#(<$4 05K>'[
MF."\9)"%$BX!/K6310!M7>@W1O':':T;MD,6QC/K6[$PBCCM9;@-.4Z]S[UR
M*:A>(FU;F4+Z;CQ4'FR>9YF]M^<[L\Y^M %B_LWL;IHG8-W##N*JT^25YI&D
MD8L[=2:90!T&N_\ (.L_\]JS-+OS8788Y\IN''MZU6DGFE55DE=U7H&8D"HZ
M .NUC9_8LQ3&UMK#'0Y8'-5=*B:?P_-$F-SE@,USYN)S%Y1FD,?]PL<?E2QW
M5Q"NV*>5%ZX5R!0!H_\ "/7OK%_WU_\ 6IDNA7D,+RL8]J*6.&["JGV^\_Y^
MY_\ OX:1KVZ=2K7,Q4C!!D."* -+P]=I#<20R,%$H&TGU';]:6Y\/7 G8VY1
MHR<C)P16+5E-0O(UVI<R@>FZ@#?L+-=&MY;BZD7<1C [>P]36;HKF76O,/5M
MS'\:S99YISF65W(Z;CFFQR21/OC=D;U4X- %S6/^0M<?[P_D*GT34/LMSY,C
M?NI#CG^$^M9CNTCEW8LQZECDFFT :VN:?]EN/.C7$4A[?PMZ5?MY8-:TX6TK
MA;A!U[\=QZUS\EU<2ILDGE=?[K.2*C!*D$$@CH10!J'P]>A]H\LC^]NXK200
M:!8MN</</SCU/^ K"&I7H7;]JEQ_O&JS.SL6=BS'J2<F@#<\.,7O+AF.25R3
M^-8]U_Q]S?\ 71OYTV*:6$DQ2O&3U*,1FFDDDDDDGJ30 E;OAVW&^6[?A4&T
M$^O?]/YUA5(EQ/'&8TFD5#U4,0#^% %FYU*YEN9)$N)41F)50Y  [5;T;49A
MJ"QSS2.D@V_.Q.#VK'I02K!E)!!R".U &CK=K]FU%F PDOSCZ]_UJ3P]_P A
M,_\ 7,_TK-EGFGQYLKR8Z;V)Q21RR0MNBD9&Z94X- %C5/\ D)W/^^:T/#7_
M !]S?]<_ZUBLS.Q9V+,>22<DTZ*:6%BT4CQDC!*L10 ^[_X_9_\ KHW\ZMZ'
M_P A>#_@7_H)K/)+$DDDGDDTJ2/$X>-V1AT93@B@#5O_ /D9A_UTC_D*?XD_
MX_8O^N?]360TLCR>8TC-)G.XG)_.B6:69@TLCR$# +,30!O:9-#J&FG3YVPX
M&%]2.Q'TJF_A^]63:NQU[-NQ64"0<C@U:&HWJKM%U+C_ 'C0!NQI%H.GN7<-
M._8=SV_ 5S))8DDY)Y)I7D>5R\CL['NQR:;0 4444 %%%% !1110 4444 %%
M%% !1110!T'AC_EZ_P" ?UKH*Y_PQ_R]?\ _K704 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 =!X8_Y>O^ ?UKH*Y_PQ_P O7_ /ZUT% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ_XT?V)J/_/O_P"/K_C0!GT5H?V)J/\ S[_^/K_C1_8FH_\ /O\ ^/K_ (T
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MC_S[_P#CZ_XT?V)J/_/O_P"/K_C0!GT5H?V)J/\ S[_^/K_C1_8FH_\ /O\
M^/K_ (T 9]%:']B:C_S[_P#CZ_XT?V)J/_/O_P"/K_C0!GT5H?V)J/\ S[_^
M/K_C1_8FH_\ /O\ ^/K_ (T 9]%:']B:C_S[_P#CZ_XT?V)J/_/O_P"/K_C0
M!GT5H?V)J/\ S[_^/K_C1_8FH_\ /O\ ^/K_ (T 9]%:']B:C_S[_P#CZ_XT
M?V)J/_/O_P"/K_C0!GT5H?V)J/\ S[_^/K_C1_8FH_\ /O\ ^/K_ (T 9]%:
M']B:C_S[_P#CZ_XT?V)J/_/O_P"/K_C0!GT5H?V)J/\ S[_^/K_C1_8FH_\
M/O\ ^/K_ (T 9]%:']B:C_S[_P#CZ_XT?V)J/_/O_P"/K_C0!GT5H?V)J/\
MS[_^/K_C1_8FH_\ /O\ ^/K_ (T 9]%:']B:C_S[_P#CZ_XT?V)J/_/O_P"/
MK_C0!H>&/^7K_@']:Z"L?0K&XL_M'VB/9OV[?F!SC/I]:V* "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
B*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M?#S3!J%];::=)U>_EL[2[>&*XEBEL$B\U4_UBJLTORM\OSU\V>+]4\/?V?\
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MEWXH7FO_  #\,:YXV\0P7%[>/=K::MJ CLI=3LX[B5+6Z9,_>E@6)SM_OYH
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M#_P3I_C7Q710!]J?\/=/VAO^@IH'_@G3_&C_ (>Z?M#?]!30/_!.G^-?%=%
M'VI_P]T_:&_Z"F@?^"=/\:/^'NG[0W_04T#_ ,$Z?XU\5T4 ?:G_  ]T_:&_
MZ"F@?^"=/\:/^'NG[0W_ $%- _\ !.G^-?%=% 'VI_P]T_:&_P"@IH'_ ()T
M_P :/^'NG[0W_04T#_P3I_C7Q710!]J?\/=/VAO^@IH'_@G3_&C_ (>Z?M#?
M]!30/_!.G^-?%=% 'VI_P]T_:&_Z"F@?^"=/\:/^'NG[0W_04T#_ ,$Z?XU\
M5T4 ?:G_  ]T_:&_Z"F@?^"=/\:/^'NG[0W_ $%- _\ !.G^-?%=% 'VI_P]
MT_:&_P"@IH'_ ()T_P :/^'NG[0W_04T#_P3I_C7Q710!]J?\/=/VAO^@IH'
M_@G3_&C_ (>Z?M#?]!30/_!.G^-?%=% 'VI_P]T_:&_Z"F@?^"=/\:/^'NG[
M0W_04T#_ ,$Z?XU\5T4 ?:G_  ]T_:&_Z"F@?^"=/\:/^'NG[0W_ $%- _\
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MDJ6.%I&VK77"$ZGN0)8BQ^8W!S6C9Z3+='Y$9JZGP7\+-=\67"_9--N9(?\
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M1117A&X4444 %%%% "M3XU+.%IG:KFGKNND_WJ[<'3]M7C F;Y8W/JS]D/\
M9Q3Q[??VSK-L\FF1-^[5EX9J_1R'PKX1^&=KI=I?*UH]RJ^6EK%\J_[]>?\
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M[O+4^'WES?=T+*;DL]NW^&N:U*PBN6AEG9D1:[:9(H8MM<Y>)LE?^-&K\/\
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M1114 %%%% !3XS3*F2/=712C*4O< [SX2ZLUGXLL&W?Q5^DVB:K/>>%;=?\
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M/NG[%P]PY0R>'-'XAK;=OS53EJW-]VJK5^?YA_*?=TR#H:0T^2F5\I*/+(Z
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M^T>Y9?+-QI]R\#E?[NY<5F33M-(TLC,\C-N9F_BJ*B@ HHHH **** "BBB@
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M%T5[I_PPS^T!_P!$D\4_^ #4?\,,_M ?]$D\4_\ @ U 'A=%>Z?\,,_M ?\
M1)/%/_@ U'_##/[0'_1)/%/_ ( -0!X717NG_##/[0'_ $23Q3_X -1_PPS^
MT!_T23Q3_P" #4 >%T5[I_PPS^T!_P!$D\4_^ #4?\,,_M ?]$D\4_\ @ U
M'A=%>Z?\,,_M ?\ 1)/%/_@ U'_##/[0'_1)/%/_ ( -0!X717NG_##/[0'_
M $23Q3_X -1_PPS^T!_T23Q3_P" #4 >%T5[I_PPS^T!_P!$D\4_^ #4?\,,
M_M ?]$D\4_\ @ U 'A=%>Z?\,,_M ?\ 1)/%/_@ U'_##/[0'_1)/%/_ ( -
M0!X717NG_##/[0'_ $23Q3_X -1_PPS^T!_T23Q3_P" #4 >%T5[I_PPS^T!
M_P!$D\4_^ #4?\,,_M ?]$D\4_\ @ U 'A=%>Z?\,,_M ?\ 1)/%/_@ U'_#
M#/[0'_1)/%/_ ( -0!X717NG_##/[0'_ $23Q3_X -1_PPS^T!_T23Q3_P"
M#4 >%T5[I_PPS^T!_P!$D\4_^ #4?\,,_M ?]$D\4_\ @ U 'A=%>Z?\,,_M
M ?\ 1)/%/_@ U'_##/[0'_1)/%/_ ( -0!X717NG_##/[0'_ $23Q3_X -1_
MPPS^T!_T23Q3_P" #4 >%T5[I_PPS^T!_P!$D\4_^ #4?\,,_M ?]$D\4_\
M@ U 'A=%>Z?\,,_M ?\ 1)/%/_@ U'_##/[0'_1)/%/_ ( -0!X717NG_##/
M[0'_ $23Q3_X -1_PPS^T!_T23Q3_P" #4 >%T5[I_PPS^T!_P!$D\4_^ #4
M?\,,_M ?]$D\4_\ @ U 'A=%>Z?\,,_M ?\ 1)/%/_@ U'_##/[0'_1)/%/_
M ( -0!X717NG_##/[0'_ $23Q3_X -1_PPS^T!_T23Q3_P" #4 >%T5[I_PP
MS^T!_P!$D\4_^ #4?\,,_M ?]$D\4_\ @ U 'A=%>Z?\,,_M ?\ 1)/%/_@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !17D/QI\2>*?#^K?#Z;1=6M;#1;WQ%96&J0M:^;<722OM\I&;Y
M8U_O';N]-M>*>)OC=X\\.Z+;>(8/$#/+XDGUNR_L^XM86M]%^RWZ6L5Q'\F[
M]TF[S?-9E9V_AH ^R:*\M^#^KZK-JWCWP]JNJW&OCP]K*6=KJ5XL:RRQ2V5M
M<;)?+15+(TS+N"_=VUZ-<7GDW$<2Q[VD5F^]_=H N455\VX_Y]O_ "+1YMQ_
MS[?^1: +5%5?-N/^?;_R+1YMQ_S[?^1: +5%5?-N/^?;_P BTR2ZFB7<UM\O
M_72@"[157S;C_GV_\BT>;<?\^W_D6@"U157S;C_GV_\ (M'FW'_/M_Y%H M4
M55\VX_Y]O_(M'FW'_/M_Y%H M452ANIIEW+;_+_UTI_FW'_/M_Y%H M455\V
MX_Y]O_(M'FW'_/M_Y%H M455\VX_Y]O_ "+1YMQ_S[?^1: +5%4ENIF9U%M]
MW_II3_-N/^?;_P BT 6J*J^;<?\ /M_Y%H\VX_Y]O_(M %JBJOFW'_/M_P"1
M:/-N/^?;_P BT 6J*I/=3HR+]F^9O^FE/\VX_P"?;_R+0!:HJKYMQ_S[?^1:
M/-N/^?;_ ,BT 6J*J^;<?\^W_D6CS;C_ )]O_(M %JBJ4UU-"FYK;_R)3_-N
M/^?;_P BT 6J*J^;<?\ /M_Y%H\VX_Y]O_(M %JBJOFW'_/M_P"1:/-N/^?;
M_P BT 6J*J^;<?\ /M_Y%ID-U/,B.MM\K?\ 32@"[144;,RY9-G_  *I: "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "O#OBW\<M7^#_CVUCU#1K34/">I6*?9)_[9L+"=;Y9
M7\U,7EQ$)5V&+[GW?^!5[C7R%\:/'5A_PNC6_P"QEM[O6;?18=+U.V\2^!M4
MU2WBB\ZX=6M98(OFW;WWI]V79%A_D:@#ZIT>]EU33+6[GM)M.N)XUE:UN&1W
MA9E^ZS(S+_WRU:E<-\&M.32?A1X-LHEODBM](M8475H/(N]JQ*/WL7\#_P"S
M_#TKN: ,O5=#L-<6T6_M(+S[+<K=P>:H;RI4)V.O^TM<\OPC\&KJ^MZE_P (
MSIAOM:B>#49FME)NHVX=']0^U=W][:-U=K10!SWA'P5HG@72%TO0=.M]*L%=
MI/)MTV!G;&YV_O,?[QK2N/\ D+67_7.7_P!DJ_5"X_Y"UE_USE_]DH OT444
M %%%% !56^_X]V_WE_\ 0A5JJM]_Q[M_O+_Z$* +5%%% !1110 4444 5=-_
MX\XZM55TW_CSCJU0 4444 %%%% %6W_X_+K_ 'E_]!JU56W_ ./RZ_WE_P#0
M:M4 %%%% !1110!6D_X^H/\ @56:K2?\?4'_  *K- !1110 4444 5;[_CW;
M_>7_ -"%6JJWW_'NW^\O_H0JU0 4444 %%%% !5:P_X\XOI5FJUA_P ><7TH
M LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH9&VUL?88O1O^_K?XT 6J*J_88O1O^_K?XT?88O1O^_K?XT 6J*J_88O1O\
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MDH OT444 %%%% !56^_X]V_WE_\ 0A5JJM]_Q[M_O+_Z$* +5%%% !24M(:
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MWE1K^W^7_IWGJ3Q3J?B+6-:M+;1M;C\)O%\3FTR>73+&(_;$_L_?NG_OO_\
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MY?\ V2J/A?QAHOC325U30=3M]7T]G:-;BTDWIN7[R_[U7KC_ )"UE_USE_\
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M 'LW\7\=6/L?_3>;_ONB3_CZ@_X%5F@"M]C_ .F\W_?='V/_ *;S?]]U9HH
MK?8_^F\W_?='V/\ Z;S?]]U9HH SKNTVP_ZV;[R_Q?[56/L?_3>;_ONDOO\
MCW;_ 'E_]"%6J *WV/\ Z;S?]]T?8_\ IO-_WW5FB@"M]C_Z;S?]]T?8_P#I
MO-_WW5FB@"M]C_Z;S?\ ?=5[&TW6L7[V;_ONM&JUA_QYQ?2@"6&/RUV[F?\
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MAA88V3TE]DZ;2]+CTN *"SNQW22-]Z1O[S5H55^TO_SPF_\ '?\ &E^TR?\
M/O-_X[_C7TT8QIQY8GF2E*3O(M56OO\ CW;_ 'E_]"%)]JD_Y]YO_'?\:@N[
MAF@;]S)]Y?[O]ZM"32HJI]JD_P"?>;_QW_&C[5)_S[S?^._XT 6Z*J?:I/\
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M;WX?_#;0/#NIZB^K7^G6HAENMSLN>NQ"WS%$SL7=\VU5KMZ* "BBB@ HHHH
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M"%6J "BBB@ HHHH *K6'_'G%]*LU6L/^/.+Z4 6:*** "BBB@ HHHH ****
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M_P!U_P!]+_\ $T?V6_\ S_W7_?2__$T 3Z;_ ,><=6JS4T=D3:M_=;?]Y/\
MXFE_LM_^?^Z_[Z7_ .)H T:*SO[+?_G_ +K_ +Z7_P")H_LM_P#G_NO^^E_^
M)H T:*SO[+?_ )_[K_OI?_B:/[+?_G_NO^^E_P#B: )[?_C\NO\ >7_T&K59
MO]CE6=OM]UENOS+_ /$TO]EO_P _]U_WTO\ \30!HT5G?V6__/\ W7_?2_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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H !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 9;#3L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M* /5:*S]#U0:UHEIJ2Q&$7$>_P LMNV^V>]:% !1110 4444 %%%% !1110
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M6L-:LEO-.N4G@;C<O4'T(/(/L: +M%%% !1110 4444 %%%% !1110 4444
M%%%% !17GWB?XHPZ!K<NFV^G"\,( DD\_8 _=?NG../QSZ5J>"?&Q\8?;LZ?
M]D^R^7_RVW[MV[_9&,;?UH ZVBBB@ HKBM>^)VA:+,]O$9+^X3@K!C8I]"QX
M_+-<Z/C4GF8.@ML]?M?/Y;* /5Z*Y3PY\0=$\1S+;1.]M>-]V"< %_\ =(X/
MTZ^U=70 4444 %%%% !16;K^LP^']#NM3G7>L*Y" X+L3@#/N37GG_"ZH_\
MH!/_ .!0_P#B* /5:*YGP;XR@\7VURZ6QMIK=P&B,F_Y2.&S@>A'X5TU !11
M7*>-/&J^#S9;K W7VKS.DNS;MV^QS][]* .KHKRK_A=4?_0"?_P*'_Q%'_"Z
MH_\ H!/_ .!0_P#B* /5:*\NB^-%H6_>Z-.H]4G#?T%=3H/C_0/$$BP07+07
M+'"P7(V,Q]CD@_0'- '44444 %%%% !114=Q<0VEO)<7$J10QJ6=W. H]2:
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M4?\ T G_ / H?_$4 >JT5Y5_PNJ/_H!/_P"!0_\ B*/^%U1_] )__ H?_$4
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MI0 4444 %%%% !1110 4444 %%%<IXS\;+X/-D&L#=?:M_279MV[?8Y^]^E
M'5T5YSH?Q7CUG6[33?['>'[1)L\S[0&V_AM%>C4 %%-=UC1G=@J*,EF. !67
MI/B32]<N[RWTVY%P;3;YCJ/D^;.,'O\ =/2@#6HHKS[Q'\48_#^OW6EG26G,
M!4>9]HV[LJ&Z;3ZT >@T5Q_@WQXGBZ[N;==/:U,$8?)FW[LG'H*["@ HHHH
M**** "BBB@ HK-U_68?#^AW6ISKO6%<A <%V)P!GW)KSS_A=4?\ T G_ / H
M?_$4 >JT5S/@WQE!XOMKETMC;36[@-$9-_RD<-G ]"/PKIJ "BBN?\8>*%\)
MZ3%?-:&Z$DXAV"39C*L<YP?[OZT =!17E7_"ZH_^@$__ (%#_P"(H_X75'_T
M G_\"A_\10!ZK17EL?QIMB1YFB2J/5;@'_V45T.B_$SP]K$JPM,]E.QP%N@%
M#'V8$C\\4 =C1110 45P'B;XG)X<U^XTLZ2UP80I\P3[<[E#=-I]:9X?^*UI
MK6M0:=/I[6?GG:DIG#C?V!&T=>GUQ0!Z%1110 45YYXA^*4>@Z[=:6=(:<V[
M >8+C;NRH/3:?6M;P9XW7Q?)>(M@;7[,$.3+OW;L^PQTH ZVBL;Q1KX\-:%+
MJ;6QN!&RKY8?;G)QUP:X/_A=4?\ T G_ / H?_$4 >JT56T^[%_IMK>*A07$
M*2A2<XW ''ZU9H ***1VVHS=<#- "T5Y5_PNJ/\ Z 3_ /@4/_B*/^%U1_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%R5Z'7GGQC_Y%*T_Z_D_]%R4 >(UV@^%?BEE#"VM\$9_UZUQ=?5T7^I3_=%
M'SW>?#GQ591&5]+:5!U\F19#_P!\@Y_2N6961BK A@<$$<@U]85Y'\7_  ]#
M ;;7;>,(TK^3<8'WFQE6^N 0?PH ?\+O&DTDZ^']1E:3</\ 1)'.2,#E"?3
MX_+TKUFOE2SNI;&]@NX&*S0R+(A]"#D5]36MPEW9PW,9S'-&LB_0C(H EHHH
MH *^>OB9_P E!U3_ +9?^BDKZ%KYZ^)G_)0=4_[9?^BDH QM"T&_\17[66G(
MCS+&9"'<*-H('4_45T7_  JKQ3_S[V__ '_6K7P@_P"1QF_Z\W_]"2O<J /
M_P#A57BG_GWM_P#O^M'_  JKQ3_S[V__ '_6O?** ,KPU83Z9X:TZQN0!/!
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M&$R1[UW [>2,?0&@#3HKP;_A;'B?_GI:?]^/_KU[1H&IC6= L=1&,SPJ[ =
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MR* / OB=_P C_J/^[%_Z+6N15BK!E)# Y!!Y!KKOB=_R/^H_[L7_ *+6N0H
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MT;3IK^^E$4$0R3W)[ #N30!<HKP_5_BYK=W,PTQ(;&#/RG8)'(]R>/R%8O\
MPL/Q7NS_ &Q+G_KFG_Q- 'T517A6E_%GQ#9RK]M,%]%GY@\81L>Q7 _,&O8M
M UZS\1Z3'J%DQV,=KHWWHV'53[T 1>*M2N-(\+ZA?VI43PQ;D+#(!R!T_&OG
M#4-2O=6NVNK^YDN)VZNYS^ ]!["N^^(GC/5UU?5?#ZM"+'Y4QY?S8VJW7ZUY
MO0!]->%/^10T7_KQA_\ 0!6O7@&G?$SQ%86=K8PO;>3 BQ(&AR=H  R<^E>_
MT %%>9^*_BO%I]Q)9:'%'<RH</<R$F,'N% ^]]<X^M<+-\2?%DSEO[5*#.0J
M0H /_': /H:BO!M/^*WB6UF5KF6&]C'WDDB521]5 YKUGPIXML?%=@TUN#%<
M1\36[-ED]#[@^M %CQ9_R)^L_P#7E-_Z :^9J^F?%G_(GZS_ ->4W_H!KYFH
M ^C_  )_R(^D?]<!_,UT5>,P_$Q="\):9IFEPI->QP 2RR@[(SD\ =S^GUKG
MG^)'BQY=_P#:S+Z*L,8 _#;0!]#T5Y!X8^+5T+N.U\0+')"Y"_:HUVLGNP'!
M'TQ^->O A@"""#R"* %HJGJFJ6>C:?+?7TPB@C&2QZD]@!W)]*\>UOXN:O=S
M,FD1QV-N/NLRAY#[G/RCZ8_&@#VVBOG=/B/XLC?<-7<^H:&,C_T&NR\,_%LS
M7"6NOPQQAS@74(("_P"\O]1^5 'JU%(K*Z!T8,K#((.01535-4L]&TZ6_OI1
M%!$,D]23V '<F@"Y17B&M?%O6KR=ETI8["W!^4E \A^I.0/P'XUE6WQ+\5VT
MP<ZD)ESDI+"A!_( _D: .Z^,W_(!T[_KY/\ Z":\HT'_ )&+3/\ K[B_]#%=
M3XO\<0^+?#=E#)!]GOH)]TB+DHPVD;E/U[']:Y;0?^1BTS_K[B_]#% 'U#11
M10 4UW6.-I'8*B@EF)X '>G5QWQ.U1],\%W"QOMDNW6W!'7!R6_\=!'XT >6
M>.?&=QXGU)XH9'32X6Q#%TWX_C;W/;T'XUS^EZ1?ZU>+::=:O<3'G"C@#U)Z
M >YJE7T7X$\/0Z!X8ME$8%U<(LUP^.2Q&0/H!Q^?K0!YD/A#XD, D,M@&_YY
MF9MW_H./UKD-7T74="O#:ZE:O!+U7=R&'J"."/I7U%7.^-?#:^)?#LUJD:&\
MC^>V=N,,.V?0CC_]5 'AGA3Q-=>%]9CO(2SP-\L\.>)$_P 1V-?2-O/'=6T5
MQ"P>*5 Z,.ZD9!KQW3_@WJ<N&U#4;:W']V)3(W]!_.O5="TH:)HMMIJW$EPM
MNNU9),9(R3CCTSC\* -&BL[6M<L/#^GM>ZC.(HAPHZL[>BCN:\DUCXO:O=2%
M=+@ALH0>&8"20_7/ ^F/QH ]LHKYW'Q'\6B3?_;#Y]/)CQ^6W%=+H/Q?O8IE
MBURVCGA. 9H%VNON1T/X8H ]CHJO8WUKJ5E%>6<R36\HRCH>#_GTJMKU[+IO
MA[4;V#;YUO;22)N&1D*2,T :-%>#?\+8\3_\]+3_ +\?_7KIM;^+/V2PM8-,
MCBN+YH$:>=A^[1RH)  /)R?H/>@#U.BOGB3XD>+))-_]K,OH%AC 'X;:Z7PU
M\6[Q+J.WU](Y8'(4W,:[63W('!'T _'I0![%7!_%'Q!J6A:1:+IT_D-<R,CR
M*/F  ['MUZ]:[AY1]G:5"&&S<I'(/%?./B+QAJWB>."/46A*0L601Q[>3_\
MJH K^')'E\8:1)([.[7\)9F.23Y@Y)KZ:KY5L[J6QOK>\@($L$BRID9&Y3D?
MJ*]1\%?$'7==\5VFG7K6YMY0^[9%@\(2.<^HH ]9HKSSXC>,M6\,W]C!IQA"
MS1,[^9'N.<XKG=!^*^H_;)GUEH6MHX&94BCVL[\;5!H ]EHKY_OOB=XHN[II
M8;Y;6/.5BBB4A1]2"3^->A?#7Q1K7B2*\&I^5)%;[0LZIM9F.>"!QP!V ZT
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MOXU]=#_[;_\ M.@#SKPW_P C1I'_ %^P_P#H8KZ>KYA\-_\ (T:1_P!?L/\
MZ&*^GJ "O-OC+&#X?T^3 RMUM_-#_A7I->8?&>Y5=+TNUS\SS/)CV5<?^S4
M>.U]66\GFVL4G]] WYBOE6.-YI4C0;G=@J@=R:^J'3RK%D7HD9 _ 4 3T5\L
M?VE?_P#/[<_]_6_QH_M*_P#^?VY_[^M_C0!]22OY<3O_ '5)KY1KUKX.W$]V
M=;6>>24;80-[EL9W^M>3,I1BK#!!P10![?\ !Y0/!]P?6]<_^.)77>(UW>&-
M64]#93#_ ,<-<A\'7#>$KI>ZWK_^@)76^)G$?A36'/:RF/\ XX: /F.O?OAI
M+CX>6;?\\S-_Z&Q_K7@-?07PUAQ\/=/5ACS/-)_&1J /GVO</@\H'@^X/K>N
M?_'$KQ!E*,588(."*]N^#KAO"5TO=;U__0$H Z_Q&N[PQJRGH;*8?^.&OF&O
MISQ,XC\*:PY[64Q_\<-?,= 'T#\+WW> ; ?W7E'_ )$8_P!:I_$SQ=_8>E_V
M;9R8O[M2"5/,4?0M]3T'XGM4O@2X&E?"R&^>,L(8KBX*#@L%9SC\0*\2U?5+
MK6M4N-0O'W33-N/HH[ >P'% $_A[0[GQ%K4&G6PP7.7?'$:#JQ_SUP*]$^*N
MG6VD^&=#L+2/9!!(R*/^ CD^YZFLOP)XP\-^%--D^T6]])J$Y_>R)$A 4=%4
MEAQW^I]JA^(7C;3/%=E90V$-TC02,S&=% P1CC#&@#G?!O\ R.>C_P#7W'_.
MOI6OF#P_?Q:5X@L+^=7:*WG61P@!8@'MFO=?#OQ TGQ/J9L+*&\241F3,R*%
MP"!V8^M %3XIZA]B\$S1 X>[E2$?3.X_HN/QKS/X8Z?]O\<6K$92U1YV_ 8'
M_CS"NB^,VH;[[3--4_ZN-IW'^\<#_P!!/YU9^#&GXAU34F7[S+ A^GS-_-:
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M_P#(I6G_ %_)_P"BY*[ZVN(KNUBN8&#Q2H)$8=U(R#7 _&/_ )%*T_Z_D_\
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M-='\-]$T_7O$LEIJ=OY\ MFD";V7Y@R@'*D'N:]6_P"%:>$?^@1_Y,2__%4
M>#?VOJ?_ $$;O_O^W^-7=(U746UJQ5M0NBIN(P09FP?F'O7MG_"M/"/_ $"/
M_)B7_P"*J2'X=>%+>>.:+2MLD;!U/VB4X(.1_%0!U%>(_&/_ )&ZT_Z\$_\
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MEK^HG5O$%_?YRL\[,O\ NY^7],5:UW0'T?3-$NV!_P!/M3*<_P![<3_Z"R4
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M#CTGPG::5+&#^YQ.I_B9N7'YDBOG33+Q-/U2UO)(!.L$JR>4QP&P<X)KT?\
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MH L45SFE>.O#FL;5M]2BCE/_ "RG_=MGTYX/X$UOS2%+:21.2J%A[\4 ?/\
M\0_$4FO>)YXUDS9V;&&!1TXX9OQ(_+%4_"'A.Z\6:FUO%((;>$!IYB,[0>@
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M?+DB/%(T;J5=2593U!%?5]>1?$?P#<F]EUS2(&E27+W,"#+*W=U'<'J??GZ
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M/AU@GB;2F8@*+R$DD\ ;Q7HWQKZZ'_VW_P#:=>3T ?5']HV/_/Y;_P#?U?\
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M&Z-KVFZ]9K<Z==)*I W(#\R'T8=0:^=-<\.ZGX=O#;:C;-'S\D@Y20>JGO\
MSK,5F5@RD@CH0: /J;4-2LM*M6N;^ZBMX5_BD;&?8>I]A7SEXLUF/Q!XGO=2
MB0I%*P$8;KM50H)^N,UCN[R-N=V9O5CDU;TO2-0UJ\6UTZUDN)3U"CA1ZD]
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MC;=_]>#_ /HR.J'Q4_Y'NY_ZY1_^@BK_ ,'/^1MN_P#KP?\ ]&1T >W4444
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M%4  #  KE? _@R'PI8,TK)-J$X_?2J.%']U?;^?Y5U= 'S[\3O\ D?\ 4?\
M=B_]%K6]\&/^0QJ?_7NO_H58/Q._Y'_4?]V+_P!%K6]\&/\ D,:G_P!>Z_\
MH5 'K]U;0WEK+;7$8DAE0HZ'H01@BOFWQ5X?F\-:]/I\F6B!WP2'^.,]#]>Q
M]P:^EZY#XA^%O^$CT%I+=,W]H#)#CJX_B3\>WN!0!\^UZK\%O^/C6?\ <A_F
M]>5$8.#7JOP6_P"/C6?]R'^;T =3\4_^1$NO^NL7_H0KP&O?OBG_ ,B)=?\
M76+_ -"%> T ?3WAS_D6-)_Z\H?_ $ 5IUF>'/\ D6-)_P"O*'_T 5IT %,F
M_P!3)_NG^5/IDW^ID_W3_*@#Y1KW[X7 'P%: C(,DO\ Z&:\!KW_ .%O_(AV
M?_727_T,T >(Z]IYTK7[^PQ@03NB_P"[G@_EBLZN]^+>G?9/%XNU7Y+R!7)_
MVE^4_H%_.N'M;>2[NX;:(9DF=8U'N3@4 >__  UT[^S_  /9$KA[DM<-[[CQ
M_P".A:\'U;_D,WW_ %\2?^A&OI^TMH[.S@M8AB.&-8U'L!@?RKY@U;_D,WW_
M %\2?^A&@#V3X/?\BA<_]?S_ /H"5QGQ;O9;CQ>MJS'RK:!0B]LMR3_+\J[/
MX/?\BA<_]?S_ /H"5D_%GPM=7%Q%KME"TJ+'Y=RJ#)7&</CTP<'TP* ..^'V
MAV.O^*4M-1.8$B:7R]V/-(Q\N>O<G\*]\L=*T[2X]MC96ULH'/E1A?S(ZU\O
MVUS/9W,=S;3/#-&=R2(<%3[&MR_\:^)=8MOL=SJ<TD3_ "F.-%3?[': 3]*
M(_&E_#J?C'4[NW</"TVU''1@H"Y'MQ7;_!8_Z3K([[(OYO7G6J:+J&C&W&H6
MSP-<1>:BOUVY(Y'8\=.M=I\(-12V\3W%G(V/M<!">[*<X_+=^5 'I?CT9\#:
MM_UQ_P#9A7SC7T_XATYM6\.ZA8)CS)X'1,_WL<?KBOF.:&6WF>&:-HY8V*NC
M#!4CJ"* /I7PBZOX.T8J00+*(<>H4 UQ7QFL'ETK3;]02L$KQMCMO ()_P"^
M/UKR07]X+46HNYQ; Y$/F'9GZ=*^E;JRMO$GAO[-=C=!>0*21U!(!!'N#@T
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M:,EE"0\S'?/-C_6/_@.@%9WQ-_Y)_J7UB_\ 1JT ?/E?4ND?\@6P_P"O>/\
M]!%?+5?4ND?\@6P_Z]X__010!<HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "D=%D0HZAE(P01D&EHH Y^Z\$>&;QV>;1K7<
MW4QJ8_\ T'%-@\!^%[>3>FBVQ/\ TTRX_)B17144 ,AABMXEBAC2.-1A410
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M5?;GKC(XZ#\JJ?\ "+>'O^@#I?\ X!Q_X5K44 9/_"+>'O\ H Z7_P" <?\
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M5B?\*\\*;]_]CQ9_ZZ/C\MV*Z>B@"I8:78:7#Y5A9P6R'J(HPN?KCK5NBB@
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M#((/4$4ZB@#)_P"$6\/?] '2_P#P#C_PK1MK6WLK=+>T@B@@3.V.) JKDY.
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M%51Z #I4E% #71)8VCD571@596&00>H(K+_X1;P]_P! '2__  #C_P *UJ*
M(K:UM[*W2WM8(H($SMCB0*JY.3@#@<FI:** .?O/ _AF_F,T^CV_F,<DQYCR
M??:15G3O"VA:3*);'2[:*4=)-F6'T)R16O10!3O=(TS4G5[[3K2Z9!A6G@5R
MH]LBHK;0-&LKA+BUTBP@F3.V2*V167C'! STK1HH **** "LW4?#^D:NP;4-
M.MKAQT=XQN_/K6E10!S4?P_\*QOO71H"<Y^9F8?D3BM^UM+:R@$-I;Q01#HD
M2!5'X"IJ* "H;JTMKVW:WN[>*X@?&Z.5 ZG!R,@\=:FHH R?^$6\/?\ 0!TO
M_P  X_\ "M1$6-%1%"HHPJJ, #T%.HH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!KQI(NUT5AZ,,TQ+6WC.8X(E/J
MJ 5+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 ,DBCE&)(T<?[2@TD=O#%_JX8T_W5 J2B@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'7\J />**Q_"LD\OAC3WN6D:8PC<9,[L^^:V* "BBB@ HHHH **** "BBB@
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M+1/#.G>0+:)8S,(_-=O7C! KVK7O%6IP_"C^WK*SN%U.:V4QQ"$ED<]RN,T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFH_]<D_F:]>KR'X0?\A34?\ KDG\S7KU !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 17*E[695&6*, /PKP.?P1XB:XD8:9-@L2./>OH&FNZQH
M7=@JCDDG % 'S[_P@WB/_H&3?E1_P@WB/_H&3?E7N=KK^E7M\;.UOX)K@ DQ
MHV2 *OR2)%&TDC!449+$X % 'S[_ ,(-XC_Z!DWY4?\ "#>(_P#H&3?E7JEY
M\2_#EI,T2SR3E?XH4RI_&K>D^/- U><00W1BE8@*LPV[CZ#UH YGX9^']4T?
M4;V2_M'A1XU"ENYR:]+HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-P:M @C@YK&6'IOH;1Q56/4Y"70;V+D1[A_LD&J3VES"?GAD7ZJ17>TA /4
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MJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 '2O#_B!XMN-6U6?3[>8K80-LVJ<;V'4GUYKV?49
M/*TR[D)QMA<_H:^:K>)K[48H<X:>4+GW8X_K0!UOPMR/&4?!P89 ?RK:^*GB
M.4W$>B6[E8@N^?!^\3T%>AZ-H>GZ%8QQ6MM%&43YI-OS,>Y)ZU\_Z_?_ -J:
M]>WO.)92P]A0!3M;2XO9A#;0O+(?X4&323P36DQBFC>.13RK#!%>Q_"G2DMO
M#\FH,H\VY<@$CD*#C'TJC\7--@-G9ZBJ 3A_+=O[RXXH T_AIXDFUG29;*Z<
MO<6F!O8\LAZ?E@UW->*_">8IXHEB!.'@)(^G_P"NO:J "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K:A$9]-NH
M@,EXG4#Z@U\U1O)8:BKE<2P2@X/JI_\ K5]/5Y%X\\!7:ZA-JFE0&:&8[Y8D
M&61NY]QWH W==^(6EOX2=K.Y#WMQ%Y:QC[R,1@D^F*\<C1IIE0<LQ 'UJ5;*
MZ>;R5MY3)TVA3FO1O ?@"Z6]BU;5HS%'&=T4##YF/J?04 >B:1;0Z'X>L[:=
MTB$$*J[,P W8Y.?K7EWQ+\5VFL2P:=82"6&!BSRKT9NF!ZBNH^+*,WAFW=21
MLN1G'H5(KR+3=+O=6NTMK*!Y9&./E' ]S[4 =S\([4R:U>7.TXBB"Y^I/^%>
MPU@>$?#B>&M$2U)#7#G?,X[MZ?05OT %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% #'BCD!#HK9]1FJ4VC64O_+/8?536A10!S\WAL<F&;Z!J
MH3Z+>0\^66'^SS77T4 <&T<L1(974^A!%217MS"1LF=<=LUVKQ1R AT5@?45
M3FT:SF_@*?[I_P : ,:'Q#<H?W@60>XQ_*K\/B&W? E1D/<CD5!-X;/6&<?1
ME_K6?-HUY#R8RP]5YH Z>'4+2?[DZ9]"<&K(.1D5P3))&V&!!'K4T-_<P?ZN
M5EH [>BN7A\0W*8$BHX^F#6C#XAMG'[Q&0^QS0!KT57BOK:? CF4D]L\U8H
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MHA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXO\ ]^#7J7ANZN[WP[97-\I6ZD0F0%<<Y/;Z4 :M%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[/[9;_\ /5:XCXAS1RPV>QPW)Z5[V7?[S'^NA\MG/^XS^7YHS?A]_P A]O\
MKD:]0KRWP%(D>NL78*/*/6O2_MEO_P ]5K7-?]X^2.?(/]S7JQFIR&'2;R48
MRD#L,^RFOF25S)*[GJQ).*^C/$-W WAW4 )5),#_ ,J^=8?^/B/_ 'Q_.NS*
M%[DWZ&></WX+U/?])MOL>D6EOQ\D2CCZ9_K57Q/<W-GX7U*>RC:2Y2!O+51D
MDGCC\ZTX?^/>+_<7^5/Z5Y,G=MGLQ5DD> ?"+X=IJ.H7NJ>)M/DD\D@10W*\
M.YY+$'K7HWCGP'X>U'PEJ#)IEK;7%O \L,T,85E*C(Y]*[HDGJ2:\E^,?Q M
M]*TF?PYI\HDU"Z39.5.?*C/4'W-9V21=VV87[/5[<"XUK3RS-;A4D [*WS _
MGQ^5>[5YG\%O"-QX<\-37]ZI2ZU+:_EL,%$7.W/H>37IE..P2W"OGCXT:O=Z
M_P".+3PQ9MN2W*H(P>LS^OX;:^AQUKY5\5ZS)I'QGO=86 32VUZLJQ,3ABH7
M XI3V'#<]^\-?#KP]X?TB*U73+>YGV_O;B:(,[D]?P]JX3Q?\';U_%-OJ_A)
M;2T12)'A=R@20$?= !X-9./C!XMC:^A$UG;2<QH'2' ],<-^=4](^)/C#P3X
MC72_%8DFM]P65)@"R@_Q*XZ_GBE==AV9Z3\6KF]M?A1=L6VW+B&.=D/') <?
M0\BN6^!GA?1;OPY<:Q<VD-U??:6BS(N[RU !& >A.3S7I?B:30[WP==R:Q.J
M:1/ &:4]E(RI'OR,>]?-7AG7/$'A_7KM/!<EW>6I?&T0%PZ]BRXX/O0]'<2U
M5CTGXZ^&M%L_#UKJUM:0VU^;D19B7;YBD$G([XP*[3X1W-Q=_#+2I+EF9U\R
M-2W]U6(7] *\"\0ZUKNO>(K-/',MY:VRM@KY&P(O<JN #]:^GO#0TI?#=@NB
M.CZ:L06!D[@#O[^OO1'5W!Z*QJ,H=2C=&&#7SQ?0FVO[B$YRDC#GZU]$#K7@
M.OE3K]^4!"^<< U[>5OWI(\/-5[L6=WX?\=ZA9:;;0R(D\4:!0#P< =,UUMA
M\0-/N!BZBD@?CI\RUQWA_P (G4/#EM=QWT22."=CY&!4%YX<U*S8Y@,B]0T9
M#9_ <UM.C@:TFKI2^[_@'DK$9KAES)-QZ75]/EJ>LVFKZ??+FVNXG]LX/Y&K
MM>#D2PN,AXV'(Z@BM2Q\4:O88\J\D91_#)\X_6N:ID[WIR^\ZZ/$:VK0MZ?Y
M,]DHKS^R^(SC"WMH&'=HN#^1KHK+QAHUZ /M/E/_ '901^O2O.JX*O3WC]VI
M[5#-,)6^&:OYZ?F;U%5TOK61=T<Z./53FE^V6_\ SU6N,]).^J)Z*@^V6_\
MSU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5
M: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\
MSU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5
M: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\
MSU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5
M: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\
MSU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5
M: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\
MSU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5
M: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\
MSU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5
M: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\
MSU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5
M: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\
MSU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5
M: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\
MSU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5
M: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\
MSU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5
M: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\
MSU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5
M: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\
MSU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5
M: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\
MSU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5
M: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\
MSU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5
M: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\
MSU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5
M: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\ SU6C[9;_ //5: )Z*@^V6_\
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M^$NGZ?9?#W3)[&-!+<QEYY /F9\D<G\!Q6CXS\&V?BSPN=')\DQ*#:N/^6;
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M'[+!_P \EH^RP?\ /):FHH A^RP?\\EH^RP?\\EJ:B@"'[+!_P \EH^RP?\
M/):FHH A^RP?\\EH^RP?\\EJ:B@"'[+!_P \EH^RP?\ /):FHH A^RP?\\EH
M^RP?\\EJ:B@"'[+!_P \EH^RP?\ /):FHH A^RP?\\EH^RP?\\EJ:B@"'[+!
M_P \EH^RP?\ /):FHH A^RP?\\EH^RP?\\EJ:B@"'[+!_P \EH^RP?\ /):F
MHH A^RP?\\EH^RP?\\EJ:B@"'[+!_P \EH^RP?\ /):FHH A^RP?\\EH^RP?
M\\EJ:B@"'[+!_P \EH^RP?\ /):FHH A^RP?\\EH^RP?\\EJ:B@"'[+!_P \
MEH^RP?\ /):FHH A^RP?\\EH^RP?\\EJ:B@"'[+!_P \EH^RP?\ /):FHH A
M^RP?\\EH^RP?\\EJ:B@"'[+!_P \EH^RP?\ /):FHH A^RP?\\EH^RP?\\EJ
M:B@"'[+!_P \EH^RP?\ /):FHH A^RP?\\EH^RP?\\EJ:B@"'[+!_P \EH^R
MP?\ /):FHH A^RP?\\EH^RP?\\EJ:B@"'[+!_P \EH^RP?\ /):FHH A^RP?
M\\EH^RP?\\EJ:B@"'[+!_P \EH^RP?\ /):FHH A^RP?\\EH^RP?\\EJ:B@"
M'[+!_P \EH^RP?\ /):FHH A^RP?\\EH^RP?\\EJ:B@"'[+!_P \EH^RP?\
M/):FHH A^RP?\\EH^RP?\\EJ:B@"'[+!_P \EH^RP?\ /):FHH A^RP?\\EH
M^RP?\\EJ:B@"'[+!_P \EH^RP?\ /):FHH A^RP?\\EH^RP?\\EJ:B@"'[+!
M_P \EH^RP?\ /):FHH A^RP?\\EH^RP?\\EJ:B@"'[+!_P \EH^RP?\ /):F
MHH A^RP?\\EH^RP?\\EJ:B@"'[+!_P \EH^RP?\ /):FHH A^RP?\\EH^RP?
M\\EJ:B@"'[+!_P \EH^RP?\ /):FHH A^RP?\\EH^RP?\\EJ:B@"'[+!_P \
MEH^RP?\ /):FHH A^RP?\\EH^RP?\\EJ:B@"'[+!_P \EH^RP?\ /):FHH A
M^RP?\\EH^RP?\\EJ:B@"'[+!_P \EH^RP?\ /):FHH A^RP?\\EH^RP?\\EJ
M:B@"'[+!_P \EH^RP?\ /):FHH A^RP?\\EH^RP?\\EJ:B@"'[+!_P \EH^R
MP?\ /):FHH A^RP?\\EH^RP?\\EJ:B@"'[+!_P \EH^RP?\ /):FHH A^RP?
M\\EH^RP?\\EJ:B@"'[+!_P \EH^RP?\ /):FHH A^RP?\\EH^RP?\\EJ:B@"
M'[+!_P \EH^RP?\ /):FHH A^RP?\\EH^RP?\\EJ:B@"'[+!_P \EH^RP?\
M/):FHH A^RP?\\EH^RP?\\EJ:B@"'[+!_P \EH^RP?\ /):FHH A^RP?\\EH
M^RP?\\EJ:B@"'[+!_P \EH^RP?\ /):FHH A^RP?\\EH^RP?\\EJ:B@"'[+!
M_P \EH^RP?\ /):FHH A^RP?\\EH^RP?\\EJ:B@"'[+!_P \EH^RP?\ /):F
MHH A^RP?\\EI1;0J01&H(J6B@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHK,U/Q#I.CC_3[Z*)O[F<M^0YH TZ*Y2#XB^'KF\BMH+B1WE<(O[I@,GZ
MBMN;7--MM373I[N.*Z=-ZHYQD?4\?A0!H4444 %%%% !1110 4444 %0S6EO
M<8\Z".3'3<H-344 -2-(D"1J%4= !@4ZBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 456EU&RAD,<MY;QNO57E4$?AFF?VMIW_ $$+7_O\O^- %RBJ?]K:=_T$
M+7_O\O\ C1_:VG?]!"U_[_+_ (T 7**J#5=.)P+^U/\ VV7_ !JQ'+'*NZ-U
M=?53D4 /HHHH **** "BBB@ HHHH *:TB(<,ZJ?<XIU><^./^0^O_7!?YF@#
MT/SHO^>J?]]"CSHO^>J?]]"O&**8SV?SHO\ GJG_ 'T*/.B_YZI_WT*\8HH
M]J!! (.0:*I:-_R ]/\ ^O:/_P!!%7:0@HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH YCQSXE/AO1-\/_ !]7!*0Y['')_#->%JM]J]\0JS75S(<X +,U
M=_\ %Z60ZE81$GRA$6 ]R>?Y"MGX36]D-"N)T"&\,NV0]PH'R_UH \RT6"6V
M\4V4$T;1RI<JK(PP5.>A%;7Q)EG/C2YW*Z*@01L1C(V@Y'XYJ*[_ .2GS?\
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M.'U"9?F/:,?W1_6NQHHKYVK5E5FYS>I]'2I1I04(+1!11169J%%%% !1110
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MZ;X:UG5FQ9:?-)@9+$;1CZFO0M"^$R(8Y]9N0Q!R;>+H?8M7IZ(J($10J@8
M P!2UQ5LSJSTC[J_$[:.54:>L_>?X%>RL+33K<6]G;QP1#HL:X%6***\QMMW
M9ZJ22L@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF,-I",NX0M@?0 FJ?AGQ=HOB^SENM$NS<PQ-L<F-DP?HP!H VZ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=JEHW_(#T_\ Z]H__015VD(**** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3X6YAE@;UQN7].:H7WPY'S-8W?N%E'Z9%<Y?>$]8L2=UF\BCHT7S9_+FM.3
M8C:R?W&/M<WP?Q)R7_@2^]:GJEIJ^GWRYMKN)_;.#^1J[7@^)H'Y#QL/J"*U
M+'Q1J]@0(KQV4<;9/F'ZUA4R=[TY?>=5'B..U:%O3_)GLE%>?V7Q%<86]M P
M[M%P?UKH['Q?HU]@"Z$3GC;*-OZGBO.JX*O3^*/W:GM4,TPE;X9J_GI^9NT4
MR.6.9=T4BNOJIR*?7&>DG?8**** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QKXJ:IHE
M]J+V9@NX]7LL()@BF.12 VTG=GC/!QZ^M<UX5\<ZGX5#PP!+BS=MS02YP#ZJ
M1T-:WCWPUK=[XUU&YM=)O)X)&0I)'"S*WR*.H]Q7.?\ "(>(_P#H!:A_X#M_
MA0!Z"GQJ3'[S0F!_V;K/_LE._P"%TP?] .3_ ,"1_P#$UYY_PB'B/_H!:A_X
M#M_A1_PB'B/_ * 6H?\ @.W^% 'H?_"Z8/\ H!R?^!(_^)KU&&3SH(Y,8WJ&
MQZ9%?-?_  B'B/\ Z 6H?^ [?X5](VBE+.!6!#"-00>W% $U%%% !1110 44
M44 %%%% !7G/CC_D/K_UP7^9KT:O.?''_(?7_K@O\S0!S=%%%,84444 >NZ-
M_P @/3_^O:/_ -!%7:I:-_R ]/\ ^O:/_P!!%7:0@HHHH **** "BBB@ HHH
MH **** "BBB@!#C!SC'?-9QMM%R<Q6.?HM7+O_CSG_ZYM_*OFFXN;C[3+B:3
M[Y_B/K0!]'S?V9<!1,;20+]T.5./I4/V71/^>5C^2U\X_:;C_GM)_P!]&C[3
M<?\ /:3_ +Z- 'T=]ET3_GE8_DM'V71/^>5C^2U\X_:;C_GM)_WT:/M-Q_SV
MD_[Z- 'TO:0V$;,;-+=3_$8@/UQ5JO)?A'-+)J>H!Y'8>4O!8GN:]:H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2U"S'VJ!U9G3CS0#]U_4?K5KQ;X'T?QGIEO8ZG$0ENX>-H^&7U /H?Z4 5O
M=AX1.BP:OX6T^UABN8]IECC D]T8]>#V]JZVJ6DZ18:%IL6GZ9:QVUK$,)&@
MX^ON?>KM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM;%;E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %07%G!=+B6,$]CT(J>B@#GK
MOP\>7MGSS]UJQ98);9]LBLC>XQ7=TR2&.9=LB*X]"* .1MM6NK8!5?<@.=K5
MN6>NV\^%EQ$_J3P:AO/#Z29:V;:W]UNGYUAW%A<6IQ(A'OVH [575UW*P8>H
MIU<1;WUQ:L#&Y&.V>*W+3Q#&XVW*%6_O+R#0!MT5'%/%.FZ)PP]JDH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"I=
MZ78WR[;FUCD'3D<_G7/ZAX"TVY^:V:2W?)X!W+^1KJZ*WIXBK3^"31RUL'AZ
M_P#$@G^?WGF%]X U*V!:WD2Y4>@VG\JYZ[TN^L/^/FUEA]W4BO<*:\:2H4=0
MRL,$$=17HTLWJQ^-)_@>)7X=H3UI2<?Q7^9X=!J%W:MNAN)$(]&KH;/Q[JUO
MA9O*G7N74AOS!_I7<WOA;1[[/F6BHQ_BC^4USE]\.5.6LKS!_N2K_4?X5V?7
M<'7TJQMZK]4>>\KS+":T)W7D_P!&7+'X@Z?/M6ZA>!NA(.X5T5EK&GZ@!]FN
MXI"?X0PR/PKRV]\(ZS99+6ID0?Q1G<*Q)S):1N[JRE1G!XI/+<-55Z4OU'#.
ML;AWRXB%_56?^1Z7XN\>6GAPM:0IY]^5R$_A3/0G_"O+-1U_Q'KH5KFX8HK;
MT4 * ?:J%BLE]=R7ERQD8GJQSDUK5V8;!4Z"O:[[G+F&:U:LG!;=OZW-#2?B
M-KNCSQQZB!=VW (<88#_ &2/ZBO6=#UVR\0:>+RR<E,[65NJGT->*/&LB%'
M*GK5GP5K\GAKQ&;>20_8ISMD'\C]:YL;E\)P<Z:M+\SMRO-Y\W)6>GY'LVLZ
MBFE:5/=N>57"CU8]*\?MM2GM]634 Y,HE\QCZ\\BM_QGXBBU=X+>T<FW0;R3
MQEO_ *U<G5Y=A?9TFYK67Y'%G./]MB$J3TAL_/N>Z65W'?64-U$04E4,,58K
M@/ 6N)'%+IUS*% .^(L?S%=V+B$])HS_ ,"%?/XG#RHU7#H?88'%QQ-"-2^O
M7U)**:'0]'4_C3LYKF.X**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D
M/&'@.+Q=>6UP^H/;&",IM6(-G)SGJ*K^%/AS%X6UDZBFI/<'RFCV&$+UQSG)
M]*[>B@#S_P 1?"Z#7]=N=4;59(&G*DQB$-C"@=<CTK,_X4M;_P#0;E_\!Q_\
M57HVJ:M8:+9-=ZC=);P#C<W4GT ')/L*XJX^,.@1N5BM;^8#^(1JH/YMG]*
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MP^AY_*I_"WPWTO\ L>&YU6)I[F= Y7<0(P1TX[UROCTF[^(0C)Z>7'^&:]M
M"J% P!P!0!XGXS\,-X.U.UU'2Y72W=\QY;YHW';/>O6]!U1-9T2UOD_Y:H-P
M]".#7-_%*!9/"#2D<Q2H1^)Q3?A3*TGA%U8YV7+J/IM4_P!: .XHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *1E#*58 @]0:6B@#)N]!MYLM#B)O
M0=*Q+S2+FT.2F]/[R\BNQH(R,&@#A(9YK9P\;LA]CBMFV\1,,"XCW?[2]:T[
MG1[2YYV;&]4XK"O-$N+8%D!E3U7K^5 '2V]Y!=+F*0-[="/PJ>N#5Y8'RI9&
M'X5J6FO3P[5FQ(@ZYZ_G0!U%%5+74K6Z7*2J&[JQP:MT %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$^DC#^M<']J8=_%#\$>Q_8.,C\%1??)'FZ>)]93.-0G.?5LU9C\::W%C%UG
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M > ?$O6Y=5\77%OO/V:R/D1IV!'WC]<Y_ "N/CCDF<)&C.QZ*HR:V_&EL]IX
MTUB.0$%KIY!GT<[A^A%>S?#C2[*Q\'V5Q;QIYUTGF32X^9CD\9]!TQ[4 >%#
M1M4(R--O"/:!O\*/[%U7_H&7O_?AO\*^HZ* /ES^Q=5_Z!E[_P!^&_PKZ=M
M190 C!$:Y!^E344 %%%% !1110 4444 %%%% !7G/CC_ )#Z_P#7!?YFO1J\
MY\<?\A]?^N"_S- '-T444QA1110!Z[HW_(#T_P#Z]H__ $$5=JEHW_(#T_\
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M'!>-OPS7MU>3_%C2I8K^TUB-249?*=NRD<K^?/Y5V'A3Q=I^LZ/"9+E([J-
MLR2-@Y Y(]C0!4^*$@3P;*A/+RIC\&%0?"="OA*5B/O73G_QU17,_$OQ/;:O
M-;Z5I[^<L3[G=.C,>,#UKT7PCI3:/X9L[20 2A=TF/4\_P"% &W1110 4444
M %5YY9T<"*+<,<FK%% %/S[O_GW'YT>?=_\ /N/SJY10!3\^[_Y]Q^='GW?_
M #[C\ZN44 4_/N_^?<?G1Y]W_P ^X_.KE% %/S[O_GW'YT>?=_\ /N/SJY10
M!3\^[_Y]Q^='GW?_ #[C\ZN44 4_/N_^?<?G1Y]W_P ^X_.KE% %/S[O_GW'
MYT>?=_\ /N/SJY10!3\^[_Y]Q^='GW?_ #[C\ZN44 4_/N_^?<?G1Y]W_P ^
MX_.KE% %/S[O_GW'YT>?=_\ /N/SJY10!3\^[_Y]Q^='GW?_ #[C\ZN44 4_
M/N_^?<?G1Y]W_P ^X_.KE% %/S[O_GW'YT>?=_\ /N/SJY10!3\^[_Y]Q^='
MGW?_ #[C\ZN44 4_/N_^?<?G1Y]W_P ^X_.KE% %/S[O_GW'YT>?=_\ /N/S
MJY10!3\^[_Y]Q^='GW?_ #[C\ZN44 4_/N_^?<?G1Y]W_P ^X_.KE% %/S[O
M_GW'YT>?=_\ /N/SJY10!3\^[_Y]Q^='GW?_ #[C\ZN44 4_/N_^?<?G1Y]W
M_P ^X_.KE% %/S[O_GW'YT>?=_\ /N/SJY10!3\^[_Y]Q^='GW?_ #[C\ZN4
M4 4_/N_^?<?G1Y]W_P ^X_.KE% %/S[O_GW'YT>?=_\ /N/SJY10!3\^[_Y]
MQ^='GW?_ #[C\ZN44 4_/N_^?<?G1Y]W_P ^X_.KE% %/S[O_GW'YT>?=_\
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M_/N/SH\^[_Y]Q^=7** *?GW?_/N/SH\^[_Y]Q^=7** *?GW?_/N/SI//N_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 'Q_.O:]8_Y ]W_UR;^5>*1?\?"?[X_G7T64?PY_UT/C.(_XU/T?YH]SMO\
MCUA_W!_*I:BMO^/6'_<'\JEKYY[L^QC\*"BBBD4%%%% !1110 4444 %%%%
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M65\=Z,S %Y5'J4-<5)X)UR/K:@_[KJ?ZU5?PQK* $V$QSZ+FCZE@9;2_$?\
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ML/K&P_I5A?%6BL0!?Q#/J<5D\-66\']QO'&X:6U1?>C6EECAC:25U1%&2S'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.B_S_.NOKF_#OC.Q\2W]S;V<,RI"H;?( -V<]L^U=)0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2-(^/4G)_G7TWH-JUEX>TVU==KPVL4;#T(4 T :%%%% !1110 4444 %%%%
M!7G/CC_D/K_UP7^9KT:O.?''_(?7_K@O\S0!S=%%%,84444 >NZ-_P @/3_^
MO:/_ -!%7:I:-_R ]/\ ^O:/_P!!%7:0@HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH \Z^*^LS6FFV^G02%/M))EQP2HQ@?SKR2&TN;D.T%O+*$&6*(6V
MCWQTKT+XO!O[6L3_  >20/KDUO?"Q+:7PG<QJJ^<TK+*<<X(XS^M 'CUO;3W
M<PBMX9)9#T1%))_"EN+2YM'"7-O+"QY D0J?UKH-&E_X1SX@1*20L%TT+?0D
MK_6O4?B-I]G>>$KBXF""6##12]P<],^] '/?";2;N 76I2*HMIE"(0X))!.>
M!TZ]Z]0KR'X2:G)'J=WII8F*5/,5<\ CJ?Y?E7KU !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !4<T$5PFR6-77W'2I** ,&[
M\/*=S6S?16_QK%N+*XM7*R1LOOV-=Q37C252KJ&4]B* .,M=0N;-OW<C8[J>
M1^5;EMXAAD;;.IC_ -H#(IUSH%O*"828V[#M6%=:9<VC?/&Q7^\!D4 =E'(D
MJ!HW#*>X-.KAH+NXMGS'(RD=JV;/Q#R%N5'7[RT =!144-S#<*&BD5L^AYJ6
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI:^5/OPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 8?PDTJ5KZZU1D(A1?*1CW)ZC^5>MU!:6=O86J6UK"D,*#"H@P!4] !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M -YF>GE'^Y4_3]6%%%%<1Z@4444 %%%% !1110 4444 %%%% !1110 4444
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M10 5YSXX_P"0^O\ UP7^9KT:O.?''_(?7_K@O\S0!S=%%%,84444 >NZ-_R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,LG_ %S7^M>KUY1XZ_Y&63_KFO\ 6O6RG^/\F?/<0_[HO5?J='\.O^0;=_\
M71?Y&NTKB_AU_P @V[_ZZ+_(UVE<V/\ ]YF=N4?[E3]/U84445Q'J!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'S1XNB:+QCK*L"";R5N?0L2
M/YUZC?>)[2#X/P203IY\MFEFJ!AN#[0C<=L $_E7/?%CPQ/;ZJ=>MXBUK<!1
M.5'^K<# )]B,?C]:\UH *^D/#\5MX8\$6*WLJ6\=O;AYF<X"LWS,/KDFO%_
MGAJ;Q%XB@!B)LK=Q)<.1\N!R%^IZ?GZ5UOQH@<3:1< ML99$(SP""I'\S^5
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M?X;>&M6T/4+V34;1H$DC4*2P.2"?2O2* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKUOXE1M)\.-="_PVK,?H!7@OPO\ AXOCF>[DN[QH;"S9!(B?>=FS@#TZ'FO
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M\&6^%QEV)XZU[.8_[K&_E^1X>6_[W.WG^9UU%%%?.GT@4444 %%%% !1110
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MLEM-.MD@A'.%ZL?4GJ3[FKM%% !1110 4444 %%%% !1110 5YSXX_Y#Z_\
M7!?YFO1J\Y\<?\A]?^N"_P S0!S=%%%,84444 >NZ-_R ]/_ .O:/_T$5=JE
MHW_(#T__ *]H_P#T$5=I""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\?SKZ+*/X<_ZZ'QG$?\ &I^C_-'N=M_QZP_[@_E3W4/&RGHP(IEM_P >L/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7E'CK_ )&63_KFO]:]7KRCQU_R,LG_ %S7^M>M
ME/\ '^3/GN(?]T7JOU.C^'7_ "#;O_KHO\C7:5Q?PZ_Y!MW_ -=%_D:[2N;'
M_P"\S.W*/]RI^GZL****XCU HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQI<TE_I41EL,%F0'+1?AU(KCM*U>\T6]%U92F.3H1V8>A%?3! 8$$ @\$&N
M\6?#6VU1C>:44M;C!+QX^60_T->[A<Q4E[.O]_\ F>#BLME%^UP^_;_(;X=\
M<Z=J\*174J6M[_$CG"GW!/'X5U78'L>E?/NI:3?:1<^1?6[PR#!^8?CUJ]I7
MBW6-(8>1=&2,#'ER_,I&<_6M:N7*7O47_7J94LR<?=K+7^NA[I17G5C\4D.%
MOM/(/=XFX'X&MRW^(7AZ<A3<2Q,?[\9 _.N"6$K1WB>C#&4);2.IHK _X37P
M]_T$$_*H9?'WAV+.;QVQ_<B+5FJ%5_9?W%O$45]I?>=+1C/2N#O?BA81\6=G
M+,?[SG:/RKDM5\=ZUJB^6)5MHNZP#&?J3713P%:>ZMZG-4S"A#9W]#U#6_$^
MFZ% S7$RO.!\L"'+$_T_&O)?$7BB]\0W.Z4F*W7A(%/RCZ^IK*AAN=0NDBB6
M2>>0X4#+,QKTGPQ\+'9UN=>.U!RMNC<G_>/]*]"-.A@US3=W_6R/.E5Q&-?)
M35H_UNSE/"_@S4/$=RC")HK+/SSL,#'MZFO==*TJTT;3X[*RB$<2#\6/J?>K
M%O;PVEND%O&L<2#"HHP *EKQ<5C)XAZZ+L>WA,%##K35]PHHHKB.X**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/'7
M_(RR?]<U_K7J]>4>.O\ D99/^N:_UKULI_C_ "9\]Q#_ +HO5?J='\.O^0;=
M_P#71?Y&NTKB_AU_R#;O_KHO\C7:5S8__>9G;E'^Y4_3]6%%%%<1Z@4444 %
M%%96J>)='T8,+Z_ACD49\K<"Y^B]:J,92=HJY,I1BKR=C5HK@KWXKZ) X6VA
MGN1W(&W^=9;_ !ACWGR]);;VW2\_RKKC@,1+[)R2S##1WF>HT5Y6OQA/.[2A
MUXQ)V_*KEM\7K!^+C3IHR!U5PV3^5-Y?B5]G\B5F.&?VOS/2**Y6Q^(GAR]"
M@WP@8XR)AMP?K7307$-U$)8)4EC;HR-D&N6=*=/XTT=<*M.I\#3)****S- H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]%_.HOL%O_SS%'V"W_YYB@"7SXO^>B_G1Y\7_/1?SJ+[!;_\\Q1]@M_^>8H
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M.O\ D99/^N:_UKU>O*/'7_(RR?\ 7-?ZUZV4_P ?Y,^>XA_W1>J_4Z/X=?\
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M#FZ***8PHHHH ]=T;_D!Z?\ ]>T?_H(J[5+1O^0'I_\ U[1_^@BKM(04444
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MLK<J6NGW&Y1117B'U(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV6,''W2_-<Y?Z=>:3=FWO('@F7G##%?3=<!\5[6U?P[%<2!1<1R@1GN0>HH
MF^&OB:76M+DLKMR]S:8 <]60]/Q&#^E=S7BOPG9QXHE49V&!MW]*]JH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** /+_&/Q-U'1-=N])L;*W!@*CSI26)RH/
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MC@"I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCS\G;Y)+S"BBBO%/<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "L;5O#GA_48WEU/3K1AC+2LH1A_P,8/ZUYUXZ^(6O:;XBO-
M)L)(;:& J!(L89SE0>2V1W["O.+_ %;4=4DWW]]<7+9R/-D+ ?0'I0!V_B70
MOA_:;_L6N3QS]HK<?:5_/C]6KSYPH=@A+)GY2PP2/<9.*DMK6XO)A#:P2SRG
MHD2%F/X"NOTKX6^)-1VO/#'8Q'^*X;YL?[HR?SQ0!Q5?55E_QXV__7)?Y5P6
ME?"#1K7:^HW,]\XZJ/W2?D.?UKT-$6-%11A5& /04 +1110 4444 %%%% !1
M110 5YSXX_Y#Z_\ 7!?YFO1J\Y\<?\A]?^N"_P S0!S=%%%,84444 >NZ-_R
M ]/_ .O:/_T$5=JEHW_(#T__ *]H_P#T$5=I""BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#R?XOPS"[T^8_Z@HRC_>!R?T(I/A"+;[9J#.^+D(@C4GJO
M.?Z5J?%C49K;3K2U5(FBN"^_>@8C&,$$]#S7D=O<SVDRS6\TD4J]'1BI'XB@
M#ZAHKY\B\=^(X5 &IS-_OG/\ZE_X6%XE_P"@@?\ OD?X4 >_45YQ\-_$VJZY
M?WL6H7/FI'&I4%0,')KT>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#@L1ZYR/PKT'Q[\*=#\3:'/]BL8+34XT+031(%R0.%;U%:OPPM5LOAMH<*C
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<\GC\!^=>MU6:5.:ORKHB<JI\M#F?5A1117EGJA1110 4444 %%%% !1110
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M*6.^ANI6F,*'$B9[8/WOPJO^SUX;FO?$MWX@F3-O:1F-"P^](W<?0#]:^EJ
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MOK>ODCQ?_P E[N?^PG%_): /K5/]6OT%.IJ?ZM?H*=0 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_015VJ6C?\@/3_\ KVC_ /015VD(**** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)?Y5S_\ PKSPI_T!XO\ OX__ ,573(BQHJ*,*HP!Z"@!:*** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S==T+3_$FE2:;
MJD!FM)""R!RN<>X.:H^&/!6@^#DN5T2R^S"Y*F7,C/NVYQ]XG'4UT%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#I7M- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9O\ TCH N453S?\ I'1F_P#2.@"Y15/-_P"D=&;_ -(Z +E%4\W_ *1T9O\
MTCH N453S?\ I'1F_P#2.@"Y15/-_P"D=&;_ -(Z +E%4\W_ *1T9O\ TCH
MN453S?\ I'1F_P#2.@"Y15/-_P"D=&;_ -(Z +E%4\W_ *1T9O\ TCH N453
MS?\ I'1F_P#2.@"Y15/-_P"D=&;_ -(Z +E%4\W_ *1T9O\ TCH N453S?\
MI'1F_P#2.@"Y15/-_P"D=&;_ -(Z +E%4\W_ *1T9O\ TCH N453S?\ I'1F
M_P#2.@"Y15/-_P"D=&;_ -(Z +E%4\W_ *1T9O\ TCH N453S?\ I'1F_P#2
M.@"Y15/-_P"D=&;_ -(Z +E%4\W_ *1T9O\ TCH N453S?\ I'1F_P#2.@"Y
M15/-_P"D=&;_ -(Z +E%4\W_ *1T9O\ TCH N453S?\ I'1F_P#2.@"Y15/-
M_P"D=&;_ -(Z +E%4\W_ *1T9O\ TCH N453S?\ I'1F_P#2.@"Y15/-_P"D
M=&;_ -(Z +E%4\W_ *1T9O\ TCH N453S?\ I'1F_P#2.@"Y15/-_P"D=&;_
M -(Z +E%4\W_ *1T9O\ TCH N453S?\ I'1F_P#2.@"Y15/-_P"D=&;_ -(Z
M +E%4\W_ *1T9O\ TCH N453S?\ I'1F_P#2.@"Y15/-_P"D=&;_ -(Z +E%
M4\W_ *1T9O\ TCH N453S?\ I'1F_P#2.@"Y15/-_P"D=&;_ -(Z +E%4\W_
M *1T9O\ TCH N453S?\ I'1F_P#2.@"Y15/-_P"D=&;_ -(Z +E%4\W_ *1T
M9O\ TCH N453S?\ I'1F_P#2.@"Y15/-_P"D=&;_ -(Z +E%4\W_ *1T9O\
MTCH N453S?\ I'1F_P#2.@"Y15/-_P"D=&;_ -(Z +E%4\W_ *1T9O\ TCH
MN453S?\ I'1F_P#2.@"Y15/-_P"D=&;_ -(Z +E%4\W_ *1T9O\ TCH N453
MS?\ I'1F_P#2.@"Y15/-_P"D=&;_ -(Z +E%4\W_ *1T9O\ TCH N453S?\
MI'1F_P#2.@"Y15/-_P"D=&;_ -(Z +E%4\W_ *1T9O\ TCH N453S?\ I'1F
M_P#2.@"Y15/-_P"D=&;_ -(Z +E%4\W_ *1T9O\ TCH N453S?\ I'1F_P#2
M.@"Y15/-_P"D=&;_ -(Z +E%4\W_ *1T9O\ TCH N453S?\ I'1F_P#2.@"Y
M15/-_P"D=&;_ -(Z +E%4\W_ *1T9O\ TCH N453S?\ I'1F_P#2.@"Y15/-
M_P"D=&;_ -(Z +E%4\W_ *1T9O\ TCH N453S?\ I'1F_P#2.@"Y15/-_P"D
M=&;_ -(Z +E%4\W_ *1T9O\ TCH N453S?\ I'1F_P#2.@"Y15/-_P"D=&;_
M -(Z +E%4\W_ *1T9O\ TCH N453S?\ I'1F_P#2.@"Y15/-_P"D=&;_ -(Z
M +E%4\W_ *1T9O\ TCH N453S?\ I'1F_P#2.@"Y15/-_P"D=&;_ -(Z +E%
M4\W_ *1T9O\ TCH N453S?\ I'1F_P#2.@"Y15/-_P"D=&;_ -(Z +E%4\W_
M *1T9O\ TCH N453S?\ I'1F_P#2.@"Y15/-_P"D=&;_ -(Z +E%4\W_ *1T
M9O\ TCH N453S?\ I'1F_P#2.@"Y15/-_P"D=&;_ -(Z +E%4\W_ *1T9O\
MTCH N453S?\ I'1F_P#2.@"Y15/-_P"D=&;_ -(Z +E%4\W_ *1T9O\ TCH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ72CHT-OJ!E6=BS6TD:!MK#&0>1P>*\Z\)^-+OPM)(BQBXM9#EHF;;SZ@]J
M/9AX3T%1@:7;_E2_\(IH/_0+M_\ OFN/3XO6) WZ;,I]!(#_ $I__"W=._Y\
M)_\ OL4 =O8Z/IVFN[V5I% SC#%!UJ]7,>%_&EKXHN)X8+>2)H5#'<<YSG_"
MNGH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *K3V%M< ^9$N2/O#@U9HH PKGPZC
M$M!*1Z*W^-9%SIEU:\O$V/[PY%=I1C/6@#@TFEB/RNRGV-:=OK]S%Q)MD'N,
M&MZXTVUN<[X\$]UX-9-QX<;.8)0?9AB@"];Z[:3'#MY1_P!H\5HHZ2('1@RG
MH0<BN*N+"YM>98RH)P#V-,ANI[=MT<C*1Z&@#NJ*YFV\0S)M69 X[G.#6M;Z
MS:3X!;8Q[-_C0!H44@8,,@@CVI: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\H\=?\C+)_US7^M>KUY1XZ_Y&63_ *YK
M_6O6RG^/\F?/<0_[HO5?J='\.O\ D&W?_71?Y&NTKB_AU_R#;O\ ZZ+_ "-=
MI7-C_P#>9G;E'^Y4_3]6%%%%<1Z@4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 45Q?CGQ['X55+2UB2XU&5=P5S\D:]BV.OT_R?+[CXE^+)W+#
M4Q$#T6.% !^F?UH ^A**^=/^%A>*_P#H,R_]\)_A1_PL+Q7_ -!F7_OA/\*
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M/_WF9VY1_N5/T_5A1117$>H%%%% !1110 4444 %%%% !1110 4444 %%%%
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M .%+WG_09@_[\G_&O7((_)MXXR<E%"Y]<"I** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ,DACE&)$5A[BLRXT"VE
MYB+1GTZBM:B@#D[G0KJ$$H/,'^SU_*L]EDA?:P96'8C%=Y44MM#.,2QJWUH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO56R>Q6);>Q>W\N,8"0L,*/H*M4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)R$  YQ[YH \M\V3^^WYT>;)_?;\Z^DAH&D@<:=;_P#? H_L'2?^@?;_ /?
MH \T^$3LVJ:AN8G]TO4^YKURJUKIUG9,S6UM%$S<$HN,U9H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY!-=]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !7:^#=!^YJMP/7R$(_#=_A^=9/A?0FU6\$\R_Z'"WSY_C/]W_&O2E4*H50
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M>C?G1_9\'HWYU:HH J_V?!Z-^=']GP>C?G5JB@"K_9\'HWYT?V?!Z-^=6J*
M*O\ 9\'HWYT?V?!Z-^=6J* *O]GP>C?G1_9\'HWYU:HH J_V?!Z-^=']GP>C
M?G5JB@"K_9\'HWYT?V?!Z-^=6J* *O\ 9\'HWYT?V?!Z-^=6J* *O]GP>C?G
M1_9\'HWYU:HH J_V?!Z-^=']GP>C?G5JB@"K_9\'HWYT?V?!Z-^=6J* *O\
M9\'HWYT?V?!Z-^=6J* *O]GP>C?G1_9\'HWYU:HH J_V?!Z-^=']GP>C?G5J
MB@"K_9\'HWYT?V?!Z-^=6J* *O\ 9\'HWYT?V?!Z-^=6J* *O]GP>C?G1_9\
M'HWYU:HH J_V?!Z-^=']GP>C?G5JB@"K_9\'HWYT?V?!Z-^=6J* *O\ 9\'H
MWYT?V?!Z-^=6J* *O]GP>C?G1_9\'HWYU:HH J_V?!Z-^=']GP>C?G5JB@"K
M_9\'HWYT?V?!Z-^=6J* *O\ 9\'HWYT?V?!Z-^=6J* *O]GP>C?G1_9\'HWY
MU:HH J_V?!Z-^=']GP>C?G5JB@"K_9\'HWYT?V?!Z-^=6J* *O\ 9\'HWYT?
MV?!Z-^=6J* *O]GP>C?G1_9\'HWYU:HH J_V?!Z-^=']GP>C?G5JB@"K_9\'
MHWYT?V?!Z-^=6J* *O\ 9\'HWYT?V?!Z-^=6J* *O]GP>C?G1_9\'HWYU:HH
M J_V?!Z-^=']GP>C?G5JB@"K_9\'HWYT?V?!Z-^=6J* *O\ 9\'HWYT?V?!Z
M-^=6J* *O]GP>C?G1_9\'HWYU:HH J_V?!Z-^=']GP>C?G5JB@"K_9\'HWYT
M?V?!Z-^=6J* *O\ 9\'HWYT?V?!Z-^=6J* *O]GP>C?G1_9\'HWYU:HH J_V
M?!Z-^=']GP>C?G5JB@"K_9\'HWYT?V?!Z-^=6J* *O\ 9\'HWYT?V?!Z-^=6
MJ* *O]GP>C?G1_9\'HWYU:HH J_V?!Z-^=']GP>C?G5JB@"K_9\'HWYT?V?!
MZ-^=6J* *O\ 9\'HWYT?V?!Z-^=6J* *O]GP>C?G1_9\'HWYU:HH J_V?!Z-
M^=']GP>C?G5JB@"K_9\'HWYT?V?!Z-^=6J* *O\ 9\'HWYT?V?!Z-^=6J* *
MO]GP>C?G1_9\'HWYU:HH J_V?!Z-^=']GP>C?G5JB@"K_9\'HWYT?V?!Z-^=
M6J* *O\ 9\'HWYT?V?!Z-^=6J* *O]GP>C?G1_9\'HWYU:HH J_V?!Z-^=']
MGP>C?G5JB@"K_9\'HWYT?V?!Z-^=6J* *O\ 9\'HWYT?V?!Z-^=6J* *O]GP
M>C?G1_9\'HWYU:HH J_V?!Z-^=']GP>C?G5JB@"K_9\'HWYT?V?!Z-^=6J*
M*O\ 9\'HWYT?V?!Z-^=6J* *O]GP>C?G1_9\'HWYU:HH J_V?!Z-^=']GP>C
M?G5JB@"K_9\'HWYT?V?!Z-^=6J* *O\ 9\'HWYT?V?!Z-^=6J* *O]GP>C?G
M1_9\'HWYU:HH J_V?!Z-^=']GP>C?G5JB@"K_9\'HWYT?V?!Z-^=6J* *O\
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MJGE/E/UZUH4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM% #418U"HH51T &!3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %233;261I'A#,Q
MR2:;_9-C_P \%J[10!%;VT-JA6% JDY(%2T44 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% $-U:Q7MK);3KNCD7:PKRO6=*ETC4'MY 2AYC<_P 2^M>M
M57NK&VO3$;B%9#$^],CH: .>\(Z +*%=0N!_I$J?(I'W%/\ 4_RKJ:** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \D^+[R_VA8(?]4(B1]<\
M_P!*J> _ EKX@LY-0U"600!RB1QG!)'4D_C76?$^TTZ[T:'[3=QV]W&6:WWY
M^?IN' ^E<3X'\=#PTLEG>1/+9.VX&/[R'O@'KG^E 'H(^&GAL#_42GZR4O\
MPK7PW_S[R_\ ?RF)\3O#C@'S9U]FC_\ KT[_ (67X;_Y[R_]^_\ Z] &KHGA
M72_#\TLMA$Z/( K;FSP*VJQ=$\4Z7X@EECL)69X@"P9<<&MJ@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!" 001D
M&N/N?A[8RW#O#<2Q(QR$P#CZ>U=C16U*O4HMNF[7.;$82CB4E5C>QQ'_  KF
MV_Y_9/\ OD4?\*YMO^?V3_OD5V]%=']H8G^8X_['P7_/M?C_ )G$?\*YMO\
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M6E9T'XIBO0[^T%]83VI<H)4*;@,XS6/X3\+KX6L9K9;LW/FR;]QCV8XQCJ:
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M0!@V_@+PK=VR7$$)>&1=RL)>"*Q-%7PFOC-+#3;"9[B!\I.LF5R!DG'M3O\
MA5]Y AM[;7Y5MF^\OED?H&KJ/#'@ZP\,1LT),URXP\SC!QZ =J .BHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /.OBGI5]J46G?8[62?87W;!G'2O-?^$6UW_H%W/\ WQ7T
M?69/XBT6V<I-JMFCCJIF7(_#- '@?_"+:[_T"[G_ +XH_P"$6UW_ *!=S_WQ
M7NP\6>'S_P QBS_[_"DD\7>'XU+'5[0X_NR@T <1\+=(U#3=2OFO+26!6C4*
M77&>37J-86B^+-+\07MQ;:>[R>2H8N5(!SGIGZ5NT %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!P/Q1UZ?3=)AL;60I)=$^8RG!"#_ !KQGYY"3\S'OWKT
M;XO;O[6L?[ODG'UR:V_A?96DOA2Z81H9Y9&20D<[<# _G0!X\JL[!5!8GL.:
M1@RG# @^]=-X>E_X1_Q_"CG"PW+0-GOG*_SQ7I?Q(T6SO?#4]ZR(ES; ,DF,
M$C/(- &!\)=-O();N^E@=+::-1'(1PQ!.<5ZG7DWPDU:1;N[TIV)B9?-C']T
MCK_2O6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "B@G R:X;5?&%W+>-;:5'\B'!D(R6_P%
M85J\**O(Z,/AJE>5H=#N:*\T&J>(H<O]K>3/.W=G&*Z?PYXG753]EN@([Q0?
M8-]/>L:6,A4ERM-/S.BME]2G#G332['24445VGGA1110 4444 %<'XG^(4OA
M_79--33Q/M52&WX)R,],5WE>2>(?^2OVG_72'^0H M_\+5O1UT-L?[Y_PK3T
M7XH:?J%XEK?6KV4CL%5R^Y<^_ Q7>;1Z"O*OBU9V4,MA=1*D=XY8-M'+@8Y/
MT_K0!V7C'Q0_A>PM[E+99S-+Y>"V,<$_TK=L;C[786UR5VF:)9-OID XKS#Q
MZ\DG@'PZ\W^L;RRWU\NO1=*E2'P[92R,%C2TC9F/0 (,F@#1HKSN?XF3W=Y)
M;Z'HTMXJ_P#+1FQ^@!_G3+'XG31:DEGK6E-:[SC>I)(_ @<>] 'H]%9^KZS9
M:+ICW]W)B%1QMY+$] *X,?$O5KPO-I_A]I+5"?F+DDC\!0!Z917+^$_&MIXG
M#PF(VU[&,M"QSD>H/>H/%'CVUT"Z%C;V[7E]WC4X"_4\\^U '7TC':A;T&:\
MW7XEZC931G5]!>"W<_ZQ6.0/H1S7?6E];ZGIBWEI()()4+*PH P/!WBY_%#W
MJO:"#[,5QA]V<Y_PKJJ\-\'>*U\-#452TDNKJX9!%&O .-V<G\175P?$VZM+
MV.'6]&>UBD/^L5B2!]".: /1Z*BCN89;5;I)%,#)O#YXVXSFN O_ (FM+?O:
M:'I;WI7@R$XY]@ >* /1**\_TKXF*^HK8ZUISV#L0H?)(S[@@8'YUZ "" 0<
M@T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\;:7->^$=%U>T4R&U@CW[1DA2HY_ UNZ+\1-#GT>)[NZ%O/&@62-@<Y [>M
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M_3-><^ O%,'AW5;I+S*VES@-(!G8PS@_J:Z3QSXWL-0T=M)TF0W,UT55B@/
MSG ]22* *5MJLZ?!NXPS%D?R,D_PLW/Z&NF^&>F06?A:.Z1%\ZY8L[XYQT ^
MG%06_A*<_#)M(8#[7(AFVX_CSN ^O05C^!/&5IH]B^C:PS6TD+G8SCC'<'TY
MH U?BIIL$WA^.^V*+B"4 /WVG.1_*M[P5=O>^$-.ED)+"/9D]3MX_I7"^//%
MEOXB2WT31MUR7E#,RJ>3V ]>M>B^'=-;2/#]E8O_ *R.(;_][J?UH U****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>B@#)TSPUH^COYEC8QQ2$8+]6_,UK444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-?#%-3TJ._U2YEC>==Z1IU /0G/>LWXA.UYX^2'LJQQ@?C7M4<:Q1+&@PJ@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^1K1HH SOMUQ_P \A^1H^W7'_/(?D:T:* ,[[=<?\\A^1H^W7'_/(?D:T:*
M,[[=<?\ /(?D:/MUQ_SR'Y&M&B@#.^W7'_/(?D:/MUQ_SR'Y&M&B@#.^W7'_
M #R'Y&C[=<?\\A^1K1HH SOMUQ_SR'Y&C[=<?\\A^1K1HH SOMUQ_P \A^1H
M^W7'_/(?D:T:* ,[[=<?\\A^1H^W7'_/(?D:T:* ,[[=<?\ /(?D:/MUQ_SR
M'Y&M&B@#.^W7'_/(?D:/MUQ_SR'Y&M&B@#.^W7'_ #R'Y&C[=<?\\A^1K1HH
M SOMUQ_SR'Y&C[=<?\\A^1K1HH SOMUQ_P \A^1H^W7'_/(?D:T:* ,[[=<?
M\\A^1H^W7'_/(?D:T:* ,[[=<?\ /(?D:/MUQ_SR'Y&M&B@#.^W7'_/(?D:/
MMUQ_SR'Y&M&B@#.^W7'_ #R'Y&C[=<?\\A^1K1HH SOMUQ_SR'Y&C[=<?\\A
M^1K1HH SOMUQ_P \A^1H^W7'_/(?D:T:* ,[[=<?\\A^1H^W7'_/(?D:T:*
M,[[=<?\ /(?D:/MUQ_SR'Y&M&B@#.^W7'_/(?D:/MUQ_SR'Y&M&B@#.^W7'_
M #R'Y&C[=<?\\A^1K1HH SOMUQ_SR'Y&C[=<?\\A^1K1HH SOMUQ_P \A^1H
M^W7'_/(?D:T:* ,[[=<?\\A^1H^W7'_/(?D:T:* ,[[=<?\ /(?D:/MUQ_SR
M'Y&M&B@#.^W7'_/(?D:/MUQ_SR'Y&M&B@#.^W7'_ #R'Y&C[=<?\\A^1K1HH
M SOMUQ_SR'Y&C[=<?\\A^1K1HH SOMUQ_P \A^1H^W7'_/(?D:T:* ,[[=<?
M\\A^1H^W7'_/(?D:T:* ,[[=<?\ /(?D:/MUQ_SR'Y&M&B@#.^W7'_/(?D:/
MMUQ_SR'Y&M&B@#.^W7'_ #R'Y&C[=<?\\A^1K1HH SOMUQ_SR'Y&C[=<?\\A
M^1K1HH SOMUQ_P \A^1H^W7'_/(?D:T:* ,[[=<?\\A^1H^W7'_/(?D:T:*
M,[[=<?\ /(?D:/MUQ_SR'Y&M&B@#.^W7'_/(?D:/MUQ_SR'Y&M&B@#.^W7'_
M #R'Y&C[=<?\\A^1K1HH SOMUQ_SR'Y&C[=<?\\A^1K1HH SOMUQ_P \A^1H
M^W7'_/(?D:T:* ,[[=<?\\A^1H^W7'_/(?D:T:* ,[[=<?\ /(?D:/MUQ_SR
M'Y&M&B@#.^W7'_/(?D:/MUQ_SR'Y&M&B@#.^W7'_ #R'Y&C[=<?\\A^1K1HH
M SOMUQ_SR'Y&C[=<?\\A^1K1HH SOMUQ_P \A^1H^W7'_/(?D:T:* ,[[=<?
M\\A^1H^W7'_/(?D:T:* ,[[=<?\ /(?D:/MUQ_SR'Y&M&B@#.^W7'_/(?D:/
MMUQ_SR'Y&M&B@#.^W7'_ #R'Y&C[=<?\\A^1K1HH SOMUQ_SR'Y&C[=<?\\A
M^1K1HH SOMUQ_P \A^1H^W7'_/(?D:T:* ,[[=<?\\A^1H^W7'_/(?D:T:*
M,[[=<?\ /(?D:/MUQ_SR'Y&M&B@#.^W7'_/(?D:/MUQ_SR'Y&M&B@#.^W7'_
M #R'Y&C[=<?\\A^1K1HH SOMUQ_SR'Y&C[=<?\\A^1K1HH SOMUQ_P \A^1H
M^W7'_/(?D:T:* ,[[=<?\\A^1H^W7'_/(?D:T:* ,[[=<?\ /(?D:/MUQ_SR
M'Y&M&B@#.^W7'_/(?D:/MUQ_SR'Y&M&B@#.^W7'_ #R'Y&C[=<?\\A^1K1HH
M SOMUQ_SR'Y&C[=<?\\A^1K1HH SOMUQ_P \A^1H^W7'_/(?D:T:* ,[[=<?
M\\A^1H^W7'_/(?D:T:* ,[[=<?\ /(?D:/MUQ_SR'Y&M&B@#.^W7'_/(?D:/
MMUQ_SR'Y&M&B@#.^W7'_ #R'Y&C[=<?\\A^1K1HH SOMUQ_SR'Y&C[=<?\\A
M^1K1HH SOMUQ_P \A^1H^W7'_/(?D:T:* ,[[=<?\\A^1H^W7'_/(?D:T:*
M,[[=<?\ /(?D:/MUQ_SR'Y&M&B@#.^W7'_/(?D:/MUQ_SR'Y&M&B@#.^W7'_
M #R'Y&C[=<?\\A^1K1HH SOMUQ_SR'Y&C[=<?\\A^1K1HH SOMUQ_P \A^1H
M^W7'_/(?D:T:* ,[[=<?\\A^1H^W7'_/(?D:T:* ,[[=<?\ /(?D:/MUQ_SR
M'Y&M&B@#.^W7'_/(?D:/MUQ_SR'Y&M&B@#.^W7'_ #R'Y&C[=<?\\A^1K1HH
M SOMUQ_SR'Y&C[=<?\\A^1K1HH SOMUQ_P \A^1H^W7'_/(?D:T:* ,[[=<?
M\\A^1H^W7'_/(?D:T:* ,[[=<?\ /(?D:/MUQ_SR'Y&M&B@#.^W7'_/(?D:/
MMUQ_SR'Y&M&B@#.^W7'_ #R'Y&C[=<?\\A^1K1HH SOMUQ_SR'Y&C[=<?\\A
M^1K1HH SOMUQ_P \A^1H^W7'_/(?D:T:* ,[[=<?\\A^1H^W7'_/(?D:T:*
M,[[=<?\ /(?D:/MUQ_SR'Y&M&B@#.^W7'_/(?D:/MUQ_SR'Y&M&B@#.^W7'_
M #R'Y&C[=<?\\A^1K1HH SOMUQ_SR'Y&C[=<?\\A^1K1HH SOMUQ_P \A^1H
M^W7'_/(?D:T:* ,[[=<?\\A^1H^W7'_/(?D:T:* ,[[=<?\ /(?D:/MUQ_SR
M'Y&M&B@#.^W7'_/(?D:/MUQ_SR'Y&M&B@#.^W7'_ #R'Y&C[=<?\\A^1K1HH
M SOMUQ_SR'Y&C[=<?\\A^1K1HH SOMUQ_P \A^1H^W7'_/(?D:T:* ,[[=<?
M\\A^1H^W7'_/(?D:T:* ,[[=<?\ /(?D:/MUQ_SR'Y&M&B@#.^W7'_/(?D:/
MMUQ_SR'Y&M&B@#.^W7'_ #R'Y&C[=<?\\A^1K1HH SOMUQ_SR'Y&C[=<?\\A
M^1K1HH SOMUQ_P \A^1H^W7'_/(?D:T:* ,[[=<?\\A^1H^W7'_/(?D:T:*
M,[[=<?\ /(?D:/MUQ_SR'Y&M&B@#.^W7'_/(?D:/MUQ_SR'Y&M&B@#.^W7'_
M #R'Y&C[=<?\\A^1K1HH SOMUQ_SR'Y&C[=<?\\A^1K1HH SOMUQ_P \A^1H
M^W7'_/(?D:T:* ,[[=<?\\A^1H^W7'_/(?D:T:* ,[[=<?\ /(?D:/MUQ_SR
M'Y&M&B@#.^W7'_/(?D:/MUQ_SR'Y&M&B@#.^W7'_ #R'Y&C[=<?\\A^1K1HH
M SOMUQ_SR'Y&C[=<?\\A^1K1HH SOMUQ_P \A^1H^W7'_/(?D:T:* ,[[=<?
M\\A^1H^W7'_/(?D:T:* ,[[=<?\ /(?D:/MUQ_SR'Y&M&B@#.^W7'_/(?D:/
MMUQ_SR'Y&M&B@#.^W7'_ #R'Y&C[=<?\\A^1K1HH SOMUQ_SR'Y&C[=<?\\A
M^1K1HH SOMUQ_P \A^1H^W7'_/(?D:T:* ,[[=<?\\A^1H^W7'_/(?D:T:*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 1SP17,#P3(KQ.I5E89!%>8ZG\*KB&]-QH=_Y2]51V(93Z!A7J5% 'DL7PQU
MS4)D;5=5!0'G=(TC8]L\5Z/H>A67A_3Q9V4>%SEF/)<^IK3HH S]9T:SUW3G
MLKV/?&W((ZJ>Q%>:2_##7+"5SI>J 1L<#;(T;8]\5ZW10!YOX>^%_P!EOTO=
M9N5N61MZQ+D@G_:)ZUZ0    , = *** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HJM>ZA9Z="9KRYC@3U=L5EP>,_
M#MS.(8M5@,A. #D?J1B@#=HI%974,I#*>00<@TM !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 445'<7$5K;R3SR+'%&-S.W0"@"2BL_
M2]<TW6A*=.NTN!$0'V@\9Z=16A0 453O]5L-+0/>W<4 /3>>3^%4+7Q?X?O9
M1';ZI SDXP25_F* -NB@$$ @Y!Z&B@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HK-E\0:5#JRZ7)>QB];&(<'//X8K2H **** "BLNW\2:/
M=ZD=.@OXI+L$@Q+G/'7MBM2@ HHJ"\O;;3[5[J[F6&!.6=N@H GHJEIFKV&L
MP-/I]REQ$C;&90>#UQS]:NT %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %17$\=K;23RL%CC4LQ/8"I:Y[QS.
M8/!VHE3@M'LS]: /+(DU'XC^+'#2M' ,MS]V*,'H!Z\UTNK_  GMXM->73+N
M9[J-<A),8?'T[T[X/VZBTU*X*C<71 ?;!)KTV@#R_P"%_B&X:XGT*]E9B@+0
M!SDKC[R_2O4*\0MU.F?%I(HOE!OE4X]&(S_.O;Z "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPZ,/\]Z]IKFO#?B+1?$X::W@B2\4;I(W4;Q[Y[CWKI: "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P
MGBKX;V^M79OM/F6TNG;,@8':Y]?8USO_  K'Q!=NL5YJBF%#QOD9^/85Z[10
M!C^'/#=EX:T_[+: LS',DK?><UL444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'\4:/)K_ (>N=-AE2)Y=N'<9 PP/]*V** .:\%>&9_"^ESVD]Q',TDWF H"
M!M QS]*Z6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **S]8UJPT*R-U?S"./
MH!U+'T [FN"NOB_ LC+:Z8[J.CO+C/X8H ]-HKS6R^+UG)*$O-.DB3NZ2;L?
MABN_TW4K35K)+NRF66%NC*>A]#[T 6Z*9++'!$TLKJD:C+,QP *H:3KMAK8N
M&L)?-2"3RV<#@G&>#W'- &E1110 4444 %%%% !17'ZCX_M].\5C0GL9'<RQ
MQ^<)!C+@<XQ_M5V% !1110 4444 %%<[XK\5IX6@@FDLI+A)6*Y5PNT_E5[P
M]K<7B'1HM1AC,2R%@48Y*D'']* -2BBO/+OXL6-M?RVRZ=+(J.4\P2@ ^^,4
M >AT5';SI<V\<\9RDBAE/L:@U34(]+TRYOI1E((RY4'&<#I0!;HKE?"GC6+Q
M5<7$45C) (%#,S.&'.>.GM754 %%%% !1110 4444 %%<IXI\<0>&+V&VELI
M)S*N[<KA<?I72VEP+JTAN I42H' /;(S0!-1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'BGQ'N
M9=1\;)8-)MBCV1IGHN[&3^M>CZ3X(T+3;../[##/*%&Z:5=Q8]_PKF/B/X-N
M]0NAK.FH99 H$T:GYN.A%<WI?Q%U_1$2UNH_M"1C:$G4JP'UZT >A>(/ .CZ
MII\HMK2*UN@I,<D8QD^_J*XKX77=Y8^();"1)!;SH<@J<!QT/\ZW].^+6F3E
M4OK2:W8]77#*/ZUW&G:C9:G:K<6$\<T+<Y3^H[4 <U\1=3LHO"M_8O<QK=2(
MI2(GYF^85S?POUK3=,TF\BO;V*"1[C*JYP2-HK4^)/AJTN-*N]<=Y!<P1J%4
M=#\P']:Y;P%X-L/$EA<W5W+*KPS!%"=,8!H ]9OM<TS37C2\O8H&D&5#GJ*O
M(ZR1JZ,&5AD$=Q7C_P 5E":[8H.BP ?K7JVE?\@FT_ZXK_*@!;_5+'2XTDOK
MF.!';:I<XR?2I;2[M[ZV2YM95EA?E77H:X#XO_\ ("L/^OD_^@FM[P$RIX%T
M]V("A'))[?,U &_>W]IIUN9[RXCAB'5G.*R8?&OAVXG$,>JPEV.%SD9/Y5Y/
M=S:A\0?&'V>.1EAW'RU8_+%&.IQ78W/PETXV!2VNYA= <._1C[CM0!S'B8@_
M%M2""#=6V"/HE>O:AK.FZ6R+?7D4!?[H<XS7@5E#=6_C*SM[QF:>*\BC8L2>
MC #KVP!7J/Q1T?[=X=6]C4F6S;<<?W#U_E0!VUO<175ND\$BR12#<CKT(ITC
MK%&TCL%1068GL!7"_"S5_MOA^2Q=B9+1\#/]T]/Y&KWQ&U?^R_"LR(VV:Z(A
M0CTZG] : -ZPUS2]3F:*RO8IY%&2J'.!6A7GOPHT<VNC3ZG(N)+I]J'_ &!_
M]?->A4 <I\1=.%_X/N3C+VY$R@>W'\B:P?A%?;].O;%FRT<@D4>@/7]:]#O(
M!=64]NP!$B%<'W%>._#J9M)\=3Z=(<&3S(&)]5R?_9: /5/$6H?V5X>OKP-A
MHX6*?[V./UKP*/2)KC0;K6#G9%,D>,==P))_# _.O4/BQJ/V?08+%3S<R9;V
M"\T_1/#V_P"%CV87][=1-,,CD,>G\J -7X>ZC_:'@^TW-EX!Y)'H%X'Z51^*
M5_\ 9?"9MP<-=2*@QZ Y/\JY_P"$6H[+F^TUC]]1,N?4'!_G47Q9O6N-7LM.
MC.[8FXJ/[Q/'Z8H Z#X5:;]E\.2WCKA[F4X/JH  _7-=M<W4%G TUS*D4:]6
M<X%4]#LDTO0+.U'"Q0C/\S_.O(=4OM1^('BP6%I*XM Q\M22%1!_&1ZT >H_
M\)OX;\WR_P"UH,^O./SQ6S;74%Y LUM*DL;=&0Y%<)_PJ72?L?E_:I_/Q_K?
M?Z5R>E7FH?#_ ,7_ -GW4K-9LX$B@G8RGHX'J/Z4 >VU0U#6],TK'V^]A@ST
M#GFJ7BG7ET'P[-J"_-(0%A&.K'I7E_A;PG>>-;J;4]4NI?(#8,A.6D/H/84
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4'@9HHH YVW\;:'=:RNE0W#FZ
M+M'@QD#<,Y&3]#6I>Z-INHJ1=V,$N>K,@S^?6O'?'&CW?AOQ6=4MP1#--Y\4
MG8-G)4_CG\*[+2/BGI-U;(-15[:XQAL#<I/KGM0 _5_A9HUY&S6!DLY<?* Q
M9,^^<FN(\'7E[X:\;C397VHTI@G3.03Z_6NZU'XHZ%;0O]E\VYF ^50NU2?K
M7%^"K"]\3>-&UB=/W4<AGF<#Y=QZ*/\ /:@#T;X@_P#(C:G_ +J_^AK7/_"#
M_D"7_P#U\_\ LHKH_'L;2^"=2502=BGCV8&N!^'/BO2]!LKNUU"1HVDE\Q6"
MY!X _I0 ?%G_ )&"R_ZX_P!:]5TK_D$6G_7%?Y5YE\6K20SZ=J*#="Z%-P['
M@C^=;_A?Q_H\F@V\=_=);7,$81U?^+ ZB@"I\7_^0'8#_IY/_H)J]X?++\)P
M4^\+6;'URU<)\0/%L/B.[A@L@WV.WYW,,;V]?85Z3X%A2X\ V,,@RCQNK#U!
M9J .'^$BH==O6;_6"' ^F>?Z5[#7A%C<W7@#QJXN(RT:DHX QOC)ZBO3Y_B#
MX=AT\W2WRR';D0K]\GTQVH \]\4HB_%J+;WNK<D>A^2O9+RUBO;.:UF7='*A
M1AZ@U\_Q:I+K/CJVU";AIKV(@>@W  ?D!7T-0!XGX,GE\,^/GTZ<X5V:W?TS
MG@_I^M6?B/>OK/BZVTB Y$)6/CD%VZ_EFI/BCIKZ=K]IK%N,"7J0. Z_X_TJ
M+X>VDNO^,KC6;L9\HM,3C@NW 'ZG\J /6=+L4TW2[:RC "PQA>/7O^M6Z**
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?X%4,Q]O@I5X_$D[KS18TOQ+INL71M[.1VD"%SN0@8&!_6M>O,?AY_R'Y?\
MKW;_ -"6O3JC'4(T*W)#:R-,KQ53%8?VM3>[V\@JIJ>HP:58O=W#81> .Y/H
M*MUYIX^U4W6II81M^[@'S =V/^']:G!X?V]50Z=2\RQGU3#NHM]EZG::-XAM
MM:AGEACD1(?O%A[52;QSH:L5,TN0<']V:E\.Z<-.\*HA'[R2(R/QSDC.*\J\
MKS]1\G.W?+MSZ9.*[\/A*%:I4WM'8\C&YCB\-1HO1RDM=/2W7S/4/^$ZT/\
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MV,K.<\-!<D-[[_F>C6]S#=P+-;RI)&W1E.14M>;_  \OI4U*:S+$Q/&6"^C
MCG^=>D5YF*P_L*KA>Y[N7XSZW056UGU^04445RG>%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO<@ H  P!6V/Q<\.HJ'4Y\HRZEC)5'5O9?\ !_R/,O&6KR"Y71[9V2VMD5&
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M@[=]AUO9][[&V/R-9^T>(P3E4WO^J_S-E2C@LT4*.BM_[:W^AF:OJ-WXBUG
MW,&?9#%G@=ABM'4? U[I^F&[\Z.1D&Z1%SP/;UKGK*.XFU"&.T)%PS@1D-M(
M/;GM732Z%XO:)EEEE\LCYMUT,8_.NRJ_8N,8344NCZGF8>*Q"J5*E.4Y/JNG
M]?D6? 6N2B[_ ++GD9HW4F$$YVD<X^F,U6\?ZA/+JXLBS"&)00O8D\YJ3PYX
M8U>SURUO'BC\F-B6=95;C!'8^];WBWPY#JI6Y2YB@N57!\Q\!A_C7#*IAX8U
M33T:^YGK0HXNKECI---/KI=?,Y72?"]IJFGK*FJPI<$<Q$8P?0\TNDZ!XAT_
M5$GMK9EV/AGW#:PSS]16==>&]7LL,UI(R]0\1W@^_%2:7XEU32;D#SY'C!PT
M4I+#'ISTKMDJLXR]G-23Z/\ X'ZGEP="G."KTY0:ZKKYV?Z,](\4$GPQ>DC!
M\L<?B*X+P+_R-$7^X_\ Z":[GQ#.MUX/N+A!A985<#V.#7#>!?\ D:(O]Q__
M $$UYV#5L'53\_R/:S)IYEAVO+\RU\1/^0U!_P!<1_.L_0_#M]XA0L)0EO#\
MH9R3^ %:'Q$_Y#4'_7$?SKI_ @ \,1'N9&_G6SKRHX&$X;_\.<JPL,5FM2G4
MVU?Y'G&K:7<:)J+6TQ!9,%77H1V(KT:PUYH?!:ZC/\\L:%>?XF' KF/B$/\
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M7%ENE.K?^M&>IG>M?#\O]:Q/:J***\ ^N"BBB@ HHHH **** "BBB@ HHHH
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MK"U"Z?6-9>:.,YED 1>_H*ZN;P);,^8;F103T89Q6EI/ABQTJ7SAF:8='?\
MA^@KI^L4(-U(;LX_JN*J1C2J644:=C!]FL8(<8*( ?K5BBBO*;N[GNI65D%%
M%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_JQWLKK+8R.ARK1D@^V*\0D=X[QI$.&5\@^AS7K/A'45U#P];Y(\R%1$X^G
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MR/:P6#AA*2I0^_NPHHHKG.P**** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %8]KX8TJTOQ>Q0'SP2P9F)Y/>MBBKC4E%
M-1=KF<Z5.HTYQ3MMY!1114&@4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %<IJ.J7L-]*B3L%#$ 5U=<1JW_(2G_WS7)BY-15F=V"BI3=UT.DT743>VQ6
M0YF3[WN/6IM5FD@L'DB8JP(Y%<E87;V5VDJ] >1ZBNGU:19M',B'*M@@BIIU
M>>DT]T55H*%:+6S91T/4+JZO62:4NH0G!]<BNAKE?#7_ "$&_P"N9_F*ZJM,
M,VZ=V98R*C5LD%9.NZ@;2W$49Q))W]!6M7%ZI,;O5'(.1G:OTHQ-1PAINPPE
M-3J7>R-S1?/.GR3RR,V[.W/;%8CZQ?AR!<-P?:NK2$6]@(AT2/'Z5Q47_'\G
M_70?SKGK\T(QBF=6&Y:DIR:+/]LZA_S\']*GM=?NXI!YK"53U!%=5Y<;)AD4
M@CTKC=8C@BU!UM\!1U Z TJD*E)<W,51G2K-Q<+'3W=WNTA[FW?&4#*1VK)T
M?4;NYU%8Y9F9.>#]#3[8D^%I,]!G'YU2T#_D*K^/\C5RJ2<X/N9PI1C3J*VU
MSKJ*J:A?QZ?!O8;F/"KGK7/GQ#>NQVA .P KIJ5X0=F<E+#5*BO'8ZNBN8M_
M$DXE GC5D)P=HP:Z,S(L'G%L1[=V?:G3JQFKHFK0G3:4NI)17-77B24R$6T:
MA.Q;DFHH_$=VCCS$1E[C&#6;Q5-.QLL'5:O8ZJBJ]G>1WMN)HSUX(]#6;J>N
MBUD,-NH9QU8]!6LJD8QYF]#"%&<I<B6IM45RB^(KU2"RQD>F*WM.U*/4(B5&
MV1?O*:BG7A-V1=3#5*:N]C-UZ_N;2ZC6"4HI3) ]<U>T6XENK#S)G+-O(R:R
M/$__ !^0_P#7/^IJ"TUB2RL1! @+[BQ9NE<WM>2L^9Z'9['GP\>5:_\ #G7T
M5RT/B.Y60>:B,F>0.#726]Q'=0+-$<JPKKIUHU/A.*K0G2^(EHK#U'Q ()&B
MME#L."YZ9K/'B*]!R1&1Z8J)8FG%V-(82K)7L=97.:Y)<VEZLL<KA'P0.P(K
M0TS5X[_]VPV38SC/!^E)K\ FTUFQ\T9##^M*JU4I-Q844Z591FBW87:WMHDH
MZ]&'H:LUS7AJX*SR6Y/##<![BNEK2C/G@F9XBG[.HXA1116I@%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1167KL\L-FIB<J6;!P:F<N6+D73@YR45U(M9U86R>3 _[
MXGDC^$5#H%[<W5S*LTI=0F0#ZYK%DL+A+7[5(NU"P SU.:TO#'_'W-_US_K7
MGQJ3E65]#TYTJ<*$N77S.GKG-3UZ196BM" !P7ZD_2MG4IC!I\[@X.P@'WKD
M+!8GO4,[ 1@Y;/I6V)J234(NUS#"4HM.<E>Q,NLZ@C F<GO@CK72:7J(U"WW
M$!9%^\!TJC=W>F:@HA:0Q[3D-MJ]I^G06>9(79MZXSD8Q2HJ:GI*Z'7=-PUC
MRR]"_7.:SK$B7 AM9-H3[S#N:T=8U'[%;%4/[YQA?;WKD6C?RQ*P.UC@'U-+
M$UFO<B/!T$_?EMT.IT&YFNK>5II"Y##&:UZP_#/_ !ZS?[P_E6Y710;=--G+
MB4E5DD%%%%;& 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9NK:FEE R(P\]
MAP/3WJ7597AT^1XV*MQR*Y3[%=2V\EVX(1>2S=^:Y:]64?=BM3MPU",O?F]#
M2T;4+JXU)8Y9F9"#P?I71RR+#$TCG"J,DUR?A_\ Y"R?[K?RKIK^W>ZM&A1P
MA;N12P\I.DWNQXJ,562V6ASEWX@NI9#Y#"),\8&2?K4*:UJ$3@M*6 _A8=:U
M=.T)[6\$LQ1U4'&/6F^)A$(81@>;N[=<5A*%51<Y2LSHC.BYJG&-UW-/3K]-
M0M]X&'!PR^E9VK:VUO*;>VQN'WG/./I4/A@-FX;^' _.L<#S;W#G[S<_G53K
M3]G&V[)IX>'MI7V18&LZ@I#&=CGU YK?TG5EOU\N0!9E';HU3:C:PR:;(A10
M$7*X'3%<MILI@U.$K_?"_GQ1>=&:3=TQVIXBFVHV:.WHHHKT#R@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSWU.97PS,6PTRA?7&:W+&PAL(MD>23]YCU-6J*4*,(.Z0ZF(J5%:3"BBBMC
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"RCJ1^=&]?[P_.@!:*3
M>O\ >'YTM !12,RK]Y@/J:175ONL#]#0 ZBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLIVVI.,_[0Q_.@"[1156ZU"WLV"S,02,C"DT 6J*KVM]!>!O)?=MZ@C%3D@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% ',ZQ;W,FHNT<;E2!@CZ50^R7G_/*2NUK*UR^-M;")#AY,\CL* .85G+
M 9)_&NK-R;#1XWD!\P( %/K69H-@)9#=2#*IPH/<U-XDD_=PQ]LYH R2UWJ=
MS@;I'/09Z?X4W%WI]S@[XY!SP:GTS4$L%D;9ND;@>@JXFKVMS,IO+9,]-PYQ
M0!MV-S]KM$FQ@D88>AJQ3(EC6)?*"A#R-HXI] !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1137=8T+NP51U)H =16<=<L V/-)]PIJY;W,-
MTF^&0,/;M0!+115.XU2SMGV22C=Z*,T 7**IV^JV=R^R.4;O1ABKE !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QNISF[U%R#D [
M5KK;E_+MI7'54)_2N2TY/.U.+/(W#- '5V=N+:TCB Z#GW-8WB53F%NV"*Z"
MLW6[1KFQR@RT9W8'<=Z ,C0K*&ZFD:9=P0< ]#1KEE':SH\0VJX/RCL1_P#K
MJMIU^^G3EMNY6X84NI:@VH3J0FU5& .M &[H,IDT\*23L.*U*H:/;-;V"!QA
MF^8BK] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.>()YFG
M6)0PB4>G4UT=! /44 <K!H4L]E]H\T*2-P7'4?6JNG7$EM?1E3U;:1ZBM76-
M3GMYFMX2JH5QD#FJ&C0137J-+(J[3D*>K&@#=UF\:TLB$.'?@'TKGM/L)-1F
M8!]JJ,LQYK1\2.?,B3MMS^M9EI?7%O&T5OP6.20.: 'W&FW%I=>6H9\<AE4\
MUU%@\LEE&TRLLF,$,,'CO7/6^MW<$H$W[Q<\ANM=/#*D\*2H<JPR* 'T444
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MB@ HHHH **** "BBB@ HHHH **** "F32"*%Y#_"I-/JCJ[%=+FQU. /Q(H
MYFWC-[J2@C[[Y;^M=F!@ #H*Y?0(R=0WD$8!ZUU- ',>(D(O$?LRU<\-JGV:
M5P!OW8)[XJSK&GF]MP8QF5.0/4>E<Y;75UI\K!-RGHRD4 6M?C2/4"4 !903
MCUYK=TAF;38MPZ<"N86.ZU.[)PS.QY..!786\(M[=(@<A1C- $M%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% $5Q*(+>24_P "DUR-C$;S
M445AD%LM71ZT2-+EQU.!^M9'AZ,_;F8@C"T =/6!XD0XA?MR*WZIZE9?;K1H
MQC>.5)]: ,CPVJ&:9B 6 &/:D\21HL\3@#>RG/X8K-C>ZTZZ.T,CKU!%++)=
M:E= L&=SP !T% &_X?8FP(/0-Q6M573[7['9I$3EARQ]ZM4 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 -EC66)HW&588/TJI!I=K;RB6-"''
M?-7:* "BBB@"A<:19W#EVCVN>Z\46^D6=NX=8]S#H6YJ_10 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %5)M2M+>0QR3 ..J@$U;KG]
M=TZ1I/M,2E@1AP!R/>@#7\BUNT$IBC<./O%>2*Y&YC6WOW2,\+)@8[<U-!J=
MY;P&)'.WMD9Q26-A-?W )#;,Y=S_ )ZT 7=;W26]K,W4QC/UJ3PTB%IVP-X
M ]A6EJ-@+NQ$28WH/DS7,127.G7)*[D<<$$4 :/B.-%N8W4#<R_-6CH#$Z:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D
M(##! (]#2T4 -5$4Y5%!]A3J** "HW@BD^_&K?45)10 U(T0810OT%.HHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $*AAA@"/0TBH
MB_=51]!3J* "BBB@!CQ1R##HK?44)%'&/D15^@I]% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $36T#-N,2$_2I%55&%
M  ] *6B@ ICPQR##HK?44^B@!B11QC"(J_04^BB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
4H **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '! ZP# 2(  A$! Q$!_\0
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M+_QX_P"-6:* *W]GVO\ SR_\>/\ C1_9]K_SR_\ 'C_C5FB@"M_9]K_SR_\
M'C_C1_9]K_SR_P#'C_C5FB@"M_9]K_SR_P#'C_C1_9]K_P \O_'C_C5FB@"M
M_9]K_P \O_'C_C1_9]K_ ,\O_'C_ (U9HH K?V?:_P#/+_QX_P"-']GVO_/+
M_P >/^-6:* *W]GVO_/+_P >/^-']GVO_/+_ ,>/^-6:* *W]GVO_/+_ ,>/
M^-']GVO_ #R_\>/^-6:* *W]GVO_ #R_\>/^-']GVO\ SR_\>/\ C5FB@"M_
M9]K_ ,\O_'C_ (T?V?:_\\O_ !X_XU9HH K?V?:_\\O_ !X_XT?V?:_\\O\
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M_/+_ ,>/^-']GVO_ #R_\>/^-6:* *W]GVO_ #R_\>/^-']GVO\ SR_\>/\
MC5FB@"M_9]K_ ,\O_'C_ (T?V?:_\\O_ !X_XU9HH K?V?:_\\O_ !X_XT?V
M?:_\\O\ QX_XU9HH K?V?:_\\O\ QX_XT?V?:_\ /+_QX_XU9HH K?V?:_\
M/+_QX_XT?V?:_P#/+_QX_P"-6:* *W]GVO\ SR_\>/\ C1_9]K_SR_\ 'C_C
M5FB@"M_9]K_SR_\ 'C_C1_9]K_SR_P#'C_C5FB@"M_9]K_SR_P#'C_C1_9]K
M_P \O_'C_C5FB@"M_9]K_P \O_'C_C1_9]K_ ,\O_'C_ (U9HH K?V?:_P#/
M+_QX_P"-']GVO_/+_P >/^-6:* *W]GVO_/+_P >/^-']GVO_/+_ ,>/^-6:
M* *W]GVO_/+_ ,>/^-']GVO_ #R_\>/^-6:* *W]GVO_ #R_\>/^-']GVO\
MSR_\>/\ C5FB@"M_9]K_ ,\O_'C_ (T?V?:_\\O_ !X_XU9HH K?V?:_\\O_
M !X_XT?V?:_\\O\ QX_XU9HH K?V?:_\\O\ QX_XT?V?:_\ /+_QX_XU9HH
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M\LUIZ'8RZ9H5C8S,C2V\"QL4)*D@8XS3=?T6#Q!HT^G3NR+( 5=>JL#D'\Z
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6V?_ )Z1_P#?L_XT;9_^>D?_ '[/^- $M%1;9_\ GI'_ -^S_C1MG_YZ1_\
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M_P ](_\ OV?\: ):*BVS_P#/2/\ []G_ !HVS_\ /2/_ +]G_&@"6BHML_\
MSTC_ ._9_P :-L__ #TC_P"_9_QH EHJ+;/_ ,](_P#OV?\ &C;/_P ](_\
MOV?\: ):*BVS_P#/2/\ []G_ !HVS_\ /2/_ +]G_&@"6BHML_\ STC_ ._9
M_P :-L__ #TC_P"_9_QH EHJ+;/_ ,](_P#OV?\ &C;/_P ](_\ OV?\: ):
M*BVS_P#/2/\ []G_ !HVS_\ /2/_ +]G_&@"6BHML_\ STC_ ._9_P :-L__
M #TC_P"_9_QH EHJ+;/_ ,](_P#OV?\ &C;/_P ](_\ OV?\: ):*BVS_P#/
M2/\ []G_ !HVS_\ /2/_ +]G_&@"6BHML_\ STC_ ._9_P :-L__ #TC_P"_
M9_QH EHJ+;/_ ,](_P#OV?\ &C;/_P ](_\ OV?\: ):*BVS_P#/2/\ []G_
M !HVS_\ /2/_ +]G_&@"6BHML_\ STC_ ._9_P :-L__ #TC_P"_9_QH EHJ
M+;/_ ,](_P#OV?\ &C;/_P ](_\ OV?\: ):*BVS_P#/2/\ []G_ !HVS_\
M/2/_ +]G_&@"6BHML_\ STC_ ._9_P :-L__ #TC_P"_9_QH EHJ+;/_ ,](
M_P#OV?\ &C;/_P ](_\ OV?\: ):*BVS_P#/2/\ []G_ !HVS_\ /2/_ +]G
M_&@"6BHML_\ STC_ ._9_P :-L__ #TC_P"_9_QH EHJ+;/_ ,](_P#OV?\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A(4$D@
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M2?85C6J^SCIJWLA-V&0I-XIU@RR!DLH3C'H/3ZGO_P#JKL418T5$4*JC  Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1@YR]M/?HNR)2OJR+[3!_P ]H_\ OH4?:8/^>T?_ 'T*EHKK*(OM,'_/:/\
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M/_OH5+10!%]I@_Y[1_\ ?0H^TP?\]H_^^A4M% $7VF#_ )[1_P#?0H^TP?\
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M%%'!"D42A40851V%<*_VB?,_A6WFR-V/HHHKN+"BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^0H T]/_ ./&/\?YFK-5M/\ ^/&/\?YFK- !15>]OK73K22ZO)XX((QEG<X
M_P#K^U1#5[$Z/_:PG_T'RO.\W8WW.N<8S^E %VBJ-GJUM?2%(4NUPN[=-9RQ
M+C_>=0*BM_$.F7-S'!%<.6E)6)VA=8Y2.NQR-K?@30!IT444 %%%% !1110
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M?PB*=IPF<_N9WB)^I0@D>U5;?P_IMKI[V$4<WV5U"^6]S(X4#IMRQVX_V<4
M8&OW^K:;8S:;<26UQ]JL)_(EMXFB9&1,G(+-D$'J",&I]=\O_A%=(^S;<_:+
M/[/L_P!Y>GX9_"MRTT:QLYWGCCDDF=/+,EQ.\S;>NT%R2!["HK7P]IEE/'-!
M X,1)B1IG=(L]=B,Q5?3@#CB@#4HHHH :Y<8V*I]=S8_H:9NG_YYQ_\ ?P_X
M5+10!%NG_P"><?\ W\/^%&Z?_GG'_P!_#_A4M% $6Z?_ )YQ_P#?P_X4;I_^
M><?_ '\/^%2T4 1;I_\ GG'_ -_#_A1NG_YYQ_\ ?P_X5+10!%NG_P"><?\
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M><?_ '\/^%2T4 1;I_\ GG'_ -_#_A1NG_YYQ_\ ?P_X5+10!%NG_P"><?\
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MM;I[JWL+6&X?.Z6.%5=LG)R0,G)H N4444 -<.<;&4>NY<_U%,VS_P#/2/\
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M* (ML_\ STC_ ._9_P :IW6CVM[G[5:V4Q/>2V!/YYK1HHM<:;6J9REU\/\
M1;G)$"P,>\18?H6(_2LB;X60YW6VJRH1R-\0;]017H5%9NG!]#IAC*\=I/\
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M -EI_P#PK31O^?F__P"_B?\ Q-'+0_F?W!S5OY5]YLGQ'I8./[:T_P#[Z_\
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M">@@Y_LNW_*I/^$9T/\ Z!5I_P!^A1?#]G]X6K=T<])\2--7[B7#G_K@ /\
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M93_]#!)_X#G_ .+J/_A5/_4:_P#)7_[.CFG_ "A[##_\_?P9Z%MG_P">D?\
MW[/^-&V?_GI'_P!^S_C7GO\ PJG_ *C7_DK_ /9T?\*I_P"HU_Y*_P#V='-/
M^7\0]AA_^?OX,]"VS_\ /2/_ +]G_&F&5E)#7-N".H*__95P:?"J, []88_2
MWQ_[-3O^%5P?]!:3_OP/\:.:?\OXA['#?\_?P9W/G_\ 3U;_ )?_ &5'G_\
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M7VF#_GM'_P!]"C[3!_SVC_[Z% $M%1?:8/\ GM'_ -]"C[3!_P ]H_\ OH4
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M!+147VF#_GM'_P!]"C[3!_SVC_[Z% $M%1?:8/\ GM'_ -]"C[3!_P ]H_\
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M/_OH4 2T5%]I@_Y[1_\ ?0H^TP?\]H_^^A0!+147VF#_ )[1_P#?0H^TP?\
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MC_5[MOZ5<HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQT_3+O3VM5@EC>YN#*C(XC(($8#%OF('4# S0!U-%%% !1110 4444 %%%%
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MW$T"E5=7!Q\I)VD8/<YJK<ZGJDFNZA96D]C!#:6T<VZX@9RQ;=G)#J /E]*
M.BHK L=8?4$T*Y>X^QM>QNYM/*W^=\N>&Q\H'7WJV?$6EBX,/VAN)/),HA<Q
M!^FWS,;,YXQGKQUH U**QH_$4,GB&?2#;7(:)$(E$$A!+%AS\N ./O$X.?:I
MTU_3)+T6BW#&1I#$K>4_ELXZJ),;2W!X!SP: -*BL^\UJPL+CR)Y)#*$\QEB
M@>78O]YM@.T=>3CH?2LT^(8[7Q'J%O=3NUO';PRPQPPF5N=^YL("Q'"Y/0<>
MM '145%;7,-W;1W%O(LD,JAD=3D,#WK"T6^UK5[<W9N;"*$7$D?E?9'9MJ.5
M^]YN,D#TH Z*BN:GO-?AU^TTP7FFD7$,DOF?89/EV%1C'G<YW?I4AOM8F\03
M:7!<V,?D6L4SR/:N^]F+ X D&!\OJ?K0!T-%,B$@B03,KR!1N9%V@GN0"3@>
MV33Z "BBB@ HHHH **** "BBB@ HK"\2ZQ>:9##%IL,4][)OD\N4$CRT4LQX
M(Y^Z![M3M1UTVVGZ=J=OY;V$\L8G<@DK&XP&!!XPQ7- &W16+K&I7L.H66G:
M8+<W5PLDC-.I9415ZX!'5BH_.J5IXGFU(Z?:6D,:ZC(["]BDR1;*AQ)G!ZDX
M"_7/:@#IZ*S-,U&:]OM5@D5 MI<B*,J#DC8K<\]<L:TZ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *P]0_P"/Z3\/Y"MRL/4/^/Z3\/Y"@#3T
M_P#X\8_Q_F:LU6T__CQC_'^9JS0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7)>(O!)U_4_MAU-X1M"B-HMX7'I\PQ76T5<*DH.\2)PC-6D>>
M?\*N_P"HQ_Y*_P#V='_"KO\ J,?^2O\ ]G7H=%;_ %NMW,OJU+L>>?\ "KO^
MHQ_Y*_\ V='_  J[_J,?^2O_ -G7H=%'UNMW#ZM2['(^'O!#:#JBW@U1Y0%(
M,2Q; V1CGYCFFC1+B_3Q FV2WN/[0%Q93,I&'5$VL">HR"#[9KL**PG4E-WD
M:PA&"M$\]M+;5;_PJ=.:RGM;C4]1D,WFPMMAC+;V+=.#C Y&<]:V)+35=/\
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M_?0H EHJ+[3!_P ]H_\ OH4?:8/^>T?_ 'T* ):*B^TP?\]H_P#OH4?:8/\
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M%'VF#_GM'_WT* ):*B^TP?\ /:/_ +Z%'VF#_GM'_P!]"@"6BHOM,'_/:/\
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9 4444 %%%% !1110 4444 %/7I110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>avxl-20250930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +KIpo7xRiXgen8uAZHZcOayMWbPtxZ97iekhsmR4bdmKfy8tQVOopCPgJn3GUQ4J -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:avxl="http://anavex.com/20250930" elementFormDefault="qualified" targetNamespace="http://anavex.com/20250930">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://anavex.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000005 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
          <link:definition>00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" id="BusinessDescriptionAndBasisOfPresentation">
          <link:definition>999014 - Disclosure - Business Description and Basis of Presentation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999015 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/AccruedLiabilities" id="AccruedLiabilities">
          <link:definition>999016 - Disclosure - Accrued Liabilities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/OtherIncome" id="OtherIncome">
          <link:definition>999017 - Disclosure - Other Income</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/EquityOfferings" id="EquityOfferings">
          <link:definition>999018 - Disclosure - Equity Offerings</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999019 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999020 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/SegmentedInformation" id="SegmentedInformation">
          <link:definition>999021 - Disclosure - Segmented Information</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999022 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999023 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/AccruedLiabilitiesTables" id="AccruedLiabilitiesTables">
          <link:definition>999024 - Disclosure - Accrued Liabilities (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
          <link:definition>999025 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999026 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/SegmentedInformationTables" id="SegmentedInformationTables">
          <link:definition>999027 - Disclosure - Segmented Information (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" id="AccruedLiabilitiesDetails">
          <link:definition>999029 - Disclosure - Accrued Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" id="OtherIncomeDetailsNarrative">
          <link:definition>999030 - Disclosure - Other Income (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" id="EquityOfferingsDetailsNarrative">
          <link:definition>999031 - Disclosure - Equity Offerings (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
          <link:definition>999032 - Disclosure - Commitments and Contingencies (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
          <link:definition>999033 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" id="CommitmentsAndContingenciesDetails2">
          <link:definition>999034 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" id="CommitmentsAndContingenciesDetails3">
          <link:definition>999035 - Disclosure - Commitments and Contingencies (Details 3)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" id="CommitmentsAndContingenciesDetails4">
          <link:definition>999036 - Disclosure - Commitments and Contingencies (Details 4)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" id="CommitmentsAndContingenciesDetails5">
          <link:definition>999037 - Disclosure - Commitments and Contingencies (Details 5)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999038 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
          <link:definition>999039 - Disclosure - Income Taxes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
          <link:definition>999040 - Disclosure - Income Taxes (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
          <link:definition>999041 - Disclosure - Income Taxes (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999042 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/SegmentedInformationDetails" id="SegmentedInformationDetails">
          <link:definition>999043 - Disclosure - Segmented Information (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="avxl-20250930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="avxl-20250930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="avxl-20250930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="avxl-20250930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd" />
    <element id="avxl_MichaelJFoxFoundationMember" name="MichaelJFoxFoundationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreement2023Member" name="PurchaseAgreement2023Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommonStockIncludingCommitmentSharesMember" name="CommonStockIncludingCommitmentSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommonStockExcludingCommitmentSharesMember" name="CommonStockExcludingCommitmentSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesMember" name="CommitmentSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_BoardMember" name="BoardMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ChiefExecutiveOfficer1Member" name="ChiefExecutiveOfficer1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ChiefExecutiveOffice1rMember" name="ChiefExecutiveOffice1rMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2015Member" name="StockOptionPlan2015Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2019Member" name="StockOptionPlan2019Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2022Member" name="StockOptionPlan2022Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice1Member" name="OptionPrice1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice2Member" name="OptionPrice2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice3Member" name="OptionPrice3Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice4Member" name="OptionPrice4Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice5Member" name="OptionPrice5Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_FederalMember" name="FederalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PreclinicalStudiesMember" name="PreclinicalStudiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ClinicalTrialsMember" name="ClinicalTrialsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PersonnelCostsMember" name="PersonnelCostsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonCashShareBasedCompensationMember" name="NonCashShareBasedCompensationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherResearchAndDevelopmentCostsMember" name="OtherResearchAndDevelopmentCostsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrants" name="NonOperatingIncomeFromGrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentIncentiveIncome" name="ResearchAndDevelopmentIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherFinancingExpense" name="OtherFinancingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EarningPerShareBasicAndDilutedAbstract" name="EarningPerShareBasicAndDilutedAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NoncashFinancingRelatedCharges" name="NoncashFinancingRelatedCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredGrantIncome" name="DeferredGrantIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IssuanceOfCommonSharesNetOfShareIssueCosts" name="IssuanceOfCommonSharesNetOfShareIssueCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CashPaidForStateAndLocalFranchiseTaxes" name="CashPaidForStateAndLocalFranchiseTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommonStockIssuedUponCashlessExerciseOfStockOptions" name="CommonStockIssuedUponCashlessExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUnderSalesAgreement" name="SharesIssuedUnderSalesAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUnderSalesAgreementShares" name="SharesIssuedUnderSalesAgreementShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUnderPurchaseAgreement" name="SharesIssuedUnderPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_InitialCommitmentShares" name="InitialCommitmentShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_InitialCommitmentSharesShares" name="InitialCommitmentSharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentShares" name="CommitmentShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesShares" name="CommitmentSharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfStockOptions" name="SharesIssuedPursuantToExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" name="SharesIssuedPursuantToExerciseOfStockOptionsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptions" name="SharesIssuedPursuantToCashlessExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptionsShares" name="SharesIssuedPursuantToCashlessExerciseOfStockOptionsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesWithheldRelatedToCashlessExerciseOfStockOption" name="SharesWithheldRelatedToCashlessExerciseOfStockOption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesWithheldRelatedToCashlessExerciseOfStockOptionShares" name="SharesWithheldRelatedToCashlessExerciseOfStockOptionShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureAccruedLiabilitiesAbstract" name="DisclosureAccruedLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AccuredLiabilitiesTextBlock" name="AccuredLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureOtherIncomeAbstract" name="DisclosureOtherIncomeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherIncomeDisclosureTextBlock" name="OtherIncomeDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureEquityOfferingsAbstract" name="DisclosureEquityOfferingsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingTextBlock" name="EquityOfferingTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LicenseFeesPolicyTextBlock" name="LicenseFeesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_GrantIncomePolicyTextBlock" name="GrantIncomePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_RecentAccountingPronouncementsPolicyTextBlock" name="RecentAccountingPronouncementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" name="ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AccruedInvestigatorPayments" name="AccruedInvestigatorPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_MilestoneBasedContractAccruals" name="MilestoneBasedContractAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_TotalAccruedLiabilities" name="TotalAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" name="ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrant" name="NonOperatingIncomeFromGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredGrantIncome1" name="DeferredGrantIncome1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ValueOfSharesObligatedToPurchase" name="ValueOfSharesObligatedToPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues1" name="StockIssuedDuringPeriodValueNewIssues1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_FairValueOfInitialCommitment" name="FairValueOfInitialCommitment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IncurredExpenses" name="IncurredExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues2" name="StockIssuedDuringPeriodValueNewIssues2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommonStockConsiderationExerciseShares" name="CommonStockConsiderationExerciseShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_MarketPrice" name="MarketPrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_WarrantsOutstandingWeightedAverageExercise" name="WarrantsOutstandingWeightedAverageExercise" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionIssued" name="OptionIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization" name="DeferredTaxAssetsResearchAndDevelopmentCapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredTaxAssetsUnpaidCharges" name="DeferredTaxAssetsUnpaidCharges" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ForeignExchangeAndOther" name="ForeignExchangeAndOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PermanentDifferencesRelatingToStockBasedCompensation" name="PermanentDifferencesRelatingToStockBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" name="IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance" name="IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OperatingLossCarryforwardsDescription" name="OperatingLossCarryforwardsDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OperatingLossCarryForwardsExpirationYear" name="OperatingLossCarryForwardsExpirationYear" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentTaxCreditsYear" name="ResearchAndDevelopmentTaxCreditsYear" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>avxl-20250930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#Cover" roleURI="http://anavex.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#BalanceSheets" roleURI="http://anavex.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#BalanceSheetsParenthetical" roleURI="http://anavex.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#StatementsOfOperationsAndComprehensiveLoss" roleURI="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#StatementsOfCashFlows" roleURI="http://anavex.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#StatementsOfChangesInStockholdersEquity" roleURI="http://anavex.com/role/StatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#BusinessDescriptionAndBasisOfPresentation" roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#AccruedLiabilities" roleURI="http://anavex.com/role/AccruedLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#OtherIncome" roleURI="http://anavex.com/role/OtherIncome" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#EquityOfferings" roleURI="http://anavex.com/role/EquityOfferings" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingencies" roleURI="http://anavex.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#IncomeTaxes" roleURI="http://anavex.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SegmentedInformation" roleURI="http://anavex.com/role/SegmentedInformation" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SubsequentEvents" roleURI="http://anavex.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#AccruedLiabilitiesTables" roleURI="http://anavex.com/role/AccruedLiabilitiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesTables" roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#IncomeTaxesTables" roleURI="http://anavex.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SegmentedInformationTables" roleURI="http://anavex.com/role/SegmentedInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#AccruedLiabilitiesDetails" roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#OtherIncomeDetailsNarrative" roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#EquityOfferingsDetailsNarrative" roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetails" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetails1" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetails2" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetails3" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetails4" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetails5" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#IncomeTaxesDetails" roleURI="http://anavex.com/role/IncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#IncomeTaxesDetails1" roleURI="http://anavex.com/role/IncomeTaxesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#IncomeTaxesDetails2" roleURI="http://anavex.com/role/IncomeTaxesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#IncomeTaxesDetailsNarrative" roleURI="http://anavex.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SegmentedInformationDetails" roleURI="http://anavex.com/role/SegmentedInformationDetails" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRentCredit" xlink:label="loc_us-gaapDeferredRentCredit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRentCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="loc_avxlNonOperatingIncomeFromGrants" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlNonOperatingIncomeFromGrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OtherFinancingExpense" xlink:label="loc_avxlOtherFinancingExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlOtherFinancingExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_NoncashFinancingRelatedCharges" xlink:label="loc_avxlNoncashFinancingRelatedCharges" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_avxlNoncashFinancingRelatedCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_DeferredGrantIncome" xlink:label="loc_avxlDeferredGrantIncome" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_avxlDeferredGrantIncome" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_IssuanceOfCommonSharesNetOfShareIssueCosts" xlink:label="loc_avxlIssuanceOfCommonSharesNetOfShareIssueCosts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_avxlIssuanceOfCommonSharesNetOfShareIssueCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForDelayedTaxExemptExchange" xlink:label="loc_us-gaapPaymentsForDelayedTaxExemptExchange" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForDelayedTaxExemptExchange" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="999014 - Disclosure - Business Description and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="999016 - Disclosure - Accrued Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="999017 - Disclosure - Other Income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="999018 - Disclosure - Equity Offerings" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="999019 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxes" xlink:title="999020 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SegmentedInformation" xlink:title="999021 - Disclosure - Segmented Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEvents" xlink:title="999022 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999023 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="999024 - Disclosure - Accrued Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="999025 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesTables" xlink:title="999026 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SegmentedInformationTables" xlink:title="999027 - Disclosure - Segmented Information (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="999029 - Disclosure - Accrued Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="999030 - Disclosure - Other Income (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="999031 - Disclosure - Equity Offerings (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="999032 - Disclosure - Commitments and Contingencies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="999033 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="999034 - Disclosure - Commitments and Contingencies (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="999035 - Disclosure - Commitments and Contingencies (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="999036 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="999037 - Disclosure - Commitments and Contingencies (Details 5)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999038 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails" xlink:title="999039 - Disclosure - Income Taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails1" xlink:title="999040 - Disclosure - Income Taxes (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails2" xlink:title="999041 - Disclosure - Income Taxes (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:title="999042 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SegmentedInformationDetails" xlink:title="999043 - Disclosure - Segmented Information (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>avxl-20250930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#Cover" roleURI="http://anavex.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#BalanceSheets" roleURI="http://anavex.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#BalanceSheetsParenthetical" roleURI="http://anavex.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#StatementsOfOperationsAndComprehensiveLoss" roleURI="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#StatementsOfCashFlows" roleURI="http://anavex.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#StatementsOfChangesInStockholdersEquity" roleURI="http://anavex.com/role/StatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#BusinessDescriptionAndBasisOfPresentation" roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#AccruedLiabilities" roleURI="http://anavex.com/role/AccruedLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#OtherIncome" roleURI="http://anavex.com/role/OtherIncome" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#EquityOfferings" roleURI="http://anavex.com/role/EquityOfferings" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingencies" roleURI="http://anavex.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#IncomeTaxes" roleURI="http://anavex.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SegmentedInformation" roleURI="http://anavex.com/role/SegmentedInformation" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SubsequentEvents" roleURI="http://anavex.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#AccruedLiabilitiesTables" roleURI="http://anavex.com/role/AccruedLiabilitiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesTables" roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#IncomeTaxesTables" roleURI="http://anavex.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SegmentedInformationTables" roleURI="http://anavex.com/role/SegmentedInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#AccruedLiabilitiesDetails" roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#OtherIncomeDetailsNarrative" roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#EquityOfferingsDetailsNarrative" roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetails" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetails1" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetails2" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetails3" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetails4" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetails5" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#IncomeTaxesDetails" roleURI="http://anavex.com/role/IncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#IncomeTaxesDetails1" roleURI="http://anavex.com/role/IncomeTaxesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#IncomeTaxesDetails2" roleURI="http://anavex.com/role/IncomeTaxesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#IncomeTaxesDetailsNarrative" roleURI="http://anavex.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SegmentedInformationDetails" roleURI="http://anavex.com/role/SegmentedInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedUnderSalesAgreement" xlink:label="loc_avxlSharesIssuedUnderSalesAgreement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnderSalesAgreement_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedUnderSalesAgreementShares" xlink:label="loc_avxlSharesIssuedUnderSalesAgreementShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnderSalesAgreementShares_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedUnderPurchaseAgreement" xlink:label="loc_avxlSharesIssuedUnderPurchaseAgreement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnderPurchaseAgreement_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_InitialCommitmentShares" xlink:label="loc_avxlInitialCommitmentShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlInitialCommitmentShares_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_InitialCommitmentSharesShares" xlink:label="loc_avxlInitialCommitmentSharesShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlInitialCommitmentSharesShares_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CommitmentShares" xlink:label="loc_avxlCommitmentShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentShares_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CommitmentSharesShares" xlink:label="loc_avxlCommitmentSharesShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesShares_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptions" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfStockOptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfStockOptions_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptionsShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfStockOptionsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfStockOptionsShares_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesWithheldRelatedToCashlessExerciseOfStockOption" xlink:label="loc_avxlSharesWithheldRelatedToCashlessExerciseOfStockOption_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesWithheldRelatedToCashlessExerciseOfStockOption_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesWithheldRelatedToCashlessExerciseOfStockOptionShares" xlink:label="loc_avxlSharesWithheldRelatedToCashlessExerciseOfStockOptionShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesWithheldRelatedToCashlessExerciseOfStockOptionShares_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="999014 - Disclosure - Business Description and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="999016 - Disclosure - Accrued Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="999017 - Disclosure - Other Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="999018 - Disclosure - Equity Offerings" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="999019 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxes" xlink:title="999020 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SegmentedInformation" xlink:title="999021 - Disclosure - Segmented Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEvents" xlink:title="999022 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999023 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="999024 - Disclosure - Accrued Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="999025 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesTables" xlink:title="999026 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SegmentedInformationTables" xlink:title="999027 - Disclosure - Segmented Information (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="999029 - Disclosure - Accrued Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="999030 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_MichaelJFoxFoundationMember" xlink:label="loc_avxlMichaelJFoxFoundationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlMichaelJFoxFoundationMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AUD" xlink:label="loc_currencyAUD_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" xlink:label="loc_avxlResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_DeferredGrantIncome1" xlink:label="loc_avxlDeferredGrantIncome1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlDeferredGrantIncome1_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapOtherReceivables_130" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="999031 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_PurchaseAgreement2023Member" xlink:label="loc_avxlPurchaseAgreement2023Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement2023Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CommonStockIncludingCommitmentSharesMember" xlink:label="loc_avxlCommonStockIncludingCommitmentSharesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_avxlCommonStockIncludingCommitmentSharesMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CommonStockExcludingCommitmentSharesMember" xlink:label="loc_avxlCommonStockExcludingCommitmentSharesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_avxlCommonStockExcludingCommitmentSharesMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CommitmentSharesMember" xlink:label="loc_avxlCommitmentSharesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_avxlCommitmentSharesMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_BoardMember" xlink:label="loc_avxlBoardMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_avxlBoardMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ChiefExecutiveOfficer1Member" xlink:label="loc_avxlChiefExecutiveOfficer1Member_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_avxlChiefExecutiveOfficer1Member_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ChiefExecutiveOffice1rMember" xlink:label="loc_avxlChiefExecutiveOffice1rMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_avxlChiefExecutiveOffice1rMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RedemptionPremium" xlink:label="loc_us-gaapRedemptionPremium_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRedemptionPremium_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues1_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_210" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_FairValueOfInitialCommitment" xlink:label="loc_avxlFairValueOfInitialCommitment_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlFairValueOfInitialCommitment_210" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_IncurredExpenses" xlink:label="loc_avxlIncurredExpenses_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlIncurredExpenses_210" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_210" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues2" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues2_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues2_210" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_210" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_210" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CommonStockConsiderationExerciseShares" xlink:label="loc_avxlCommonStockConsiderationExerciseShares_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommonStockConsiderationExerciseShares_210" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="loc_us-gaapStockOptionExercisePriceIncrease_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockOptionExercisePriceIncrease_210" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_210" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:label="loc_us-gaapOtherSignificantNoncashTransactionValueOfConsiderationGiven1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherSignificantNoncashTransactionValueOfConsiderationGiven1_210" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_MarketPrice" xlink:label="loc_avxlMarketPrice_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlMarketPrice_210" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="999032 - Disclosure - Commitments and Contingencies (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="999033 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="999034 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="999035 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OptionPrice1Member" xlink:label="loc_avxlOptionPrice1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OptionPrice2Member" xlink:label="loc_avxlOptionPrice2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OptionPrice3Member" xlink:label="loc_avxlOptionPrice3Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice3Member_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OptionPrice4Member" xlink:label="loc_avxlOptionPrice4Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice4Member_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OptionPrice5Member" xlink:label="loc_avxlOptionPrice5Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice5Member_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_130" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="999036 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensation_100" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="999037 - Disclosure - Commitments and Contingencies (Details 5)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999038 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_StockOptionPlan2022Member" xlink:label="loc_avxlStockOptionPlan2022Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2022Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="loc_avxlWarrantsOutstandingWeightedAverageExercise_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlWarrantsOutstandingWeightedAverageExercise_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OptionIssued" xlink:label="loc_avxlOptionIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlOptionIssued_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_110" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails" xlink:title="999039 - Disclosure - Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails1" xlink:title="999040 - Disclosure - Income Taxes (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails2" xlink:title="999041 - Disclosure - Income Taxes (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:title="999042 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_FederalMember" xlink:label="loc_avxlFederalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_avxlFederalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AUD" xlink:label="loc_currencyAUD_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OperatingLossCarryforwardsDescription" xlink:label="loc_avxlOperatingLossCarryforwardsDescription_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_avxlOperatingLossCarryforwardsDescription_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OperatingLossCarryForwardsExpirationYear" xlink:label="loc_avxlOperatingLossCarryForwardsExpirationYear_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_avxlOperatingLossCarryForwardsExpirationYear_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ResearchAndDevelopmentTaxCreditsYear" xlink:label="loc_avxlResearchAndDevelopmentTaxCreditsYear_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_avxlResearchAndDevelopmentTaxCreditsYear_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsGross_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_150" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SegmentedInformationDetails" xlink:title="999043 - Disclosure - Segmented Information (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaapScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="loc_us-gaapScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_PreclinicalStudiesMember" xlink:label="loc_avxlPreclinicalStudiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_avxlPreclinicalStudiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ClinicalTrialsMember" xlink:label="loc_avxlClinicalTrialsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_avxlClinicalTrialsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_PersonnelCostsMember" xlink:label="loc_avxlPersonnelCostsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_avxlPersonnelCostsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_NonCashShareBasedCompensationMember" xlink:label="loc_avxlNonCashShareBasedCompensationMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_avxlNonCashShareBasedCompensationMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OtherResearchAndDevelopmentCostsMember" xlink:label="loc_avxlOtherResearchAndDevelopmentCostsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_avxlOtherResearchAndDevelopmentCostsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="loc_us-gaapOtherIncome_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="loc_us-gaapNetIncomeLoss_190" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>avxl-20250930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_MichaelJFoxFoundationMember" xlink:label="avxl_MichaelJFoxFoundationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_MichaelJFoxFoundationMember" xlink:to="avxl_MichaelJFoxFoundationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_MichaelJFoxFoundationMember_lbl" xml:lang="en-US">Michael J Fox Foundation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AUD" xlink:label="currency_AUD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AUD" xlink:to="currency_AUD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AUD_lbl" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_PurchaseAgreement2023Member" xlink:label="avxl_PurchaseAgreement2023Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement2023Member" xlink:to="avxl_PurchaseAgreement2023Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreement2023Member_lbl" xml:lang="en-US">Purchase Agreement 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="avxl_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CommonStockIncludingCommitmentSharesMember" xlink:label="avxl_CommonStockIncludingCommitmentSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommonStockIncludingCommitmentSharesMember" xlink:to="avxl_CommonStockIncludingCommitmentSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommonStockIncludingCommitmentSharesMember_lbl" xml:lang="en-US">Common Stock Including Commitment Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CommonStockExcludingCommitmentSharesMember" xlink:label="avxl_CommonStockExcludingCommitmentSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommonStockExcludingCommitmentSharesMember" xlink:to="avxl_CommonStockExcludingCommitmentSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommonStockExcludingCommitmentSharesMember_lbl" xml:lang="en-US">Common Stock Excluding Commitment Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CommitmentSharesMember" xlink:label="avxl_CommitmentSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesMember" xlink:to="avxl_CommitmentSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesMember_lbl" xml:lang="en-US">Commitment Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_BoardMember" xlink:label="avxl_BoardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_BoardMember" xlink:to="avxl_BoardMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_BoardMember_lbl" xml:lang="en-US">Board [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ChiefExecutiveOfficer1Member" xlink:label="avxl_ChiefExecutiveOfficer1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ChiefExecutiveOfficer1Member" xlink:to="avxl_ChiefExecutiveOfficer1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ChiefExecutiveOfficer1Member_lbl" xml:lang="en-US">Chief Executive Officer 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ChiefExecutiveOffice1rMember" xlink:label="avxl_ChiefExecutiveOffice1rMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ChiefExecutiveOffice1rMember" xlink:to="avxl_ChiefExecutiveOffice1rMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ChiefExecutiveOffice1rMember_lbl" xml:lang="en-US">Chief Executive Office 1r [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_StockOptionPlan2015Member" xlink:label="avxl_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2015Member_lbl" xml:lang="en-US">Stock Option Plan 2015 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_StockOptionPlan2019Member" xlink:label="avxl_StockOptionPlan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2019Member_lbl" xml:lang="en-US">Stock Option Plan 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_StockOptionPlan2022Member" xlink:label="avxl_StockOptionPlan2022Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2022Member" xlink:to="avxl_StockOptionPlan2022Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2022Member_lbl" xml:lang="en-US">Stock Option Plan 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OptionPrice1Member" xlink:label="avxl_OptionPrice1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice1Member" xlink:to="avxl_OptionPrice1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice1Member_lbl" xml:lang="en-US">Option Price 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OptionPrice2Member" xlink:label="avxl_OptionPrice2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice2Member" xlink:to="avxl_OptionPrice2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice2Member_lbl" xml:lang="en-US">Option Price 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OptionPrice3Member" xlink:label="avxl_OptionPrice3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice3Member" xlink:to="avxl_OptionPrice3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice3Member_lbl" xml:lang="en-US">Option Price 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OptionPrice4Member" xlink:label="avxl_OptionPrice4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice4Member" xlink:to="avxl_OptionPrice4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice4Member_lbl" xml:lang="en-US">Option Price 4 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OptionPrice5Member" xlink:label="avxl_OptionPrice5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice5Member" xlink:to="avxl_OptionPrice5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice5Member_lbl" xml:lang="en-US">Option Price 5 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_FederalMember" xlink:label="avxl_FederalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FederalMember" xlink:to="avxl_FederalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_FederalMember_lbl" xml:lang="en-US">Federal [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_PreclinicalStudiesMember" xlink:label="avxl_PreclinicalStudiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PreclinicalStudiesMember" xlink:to="avxl_PreclinicalStudiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PreclinicalStudiesMember_lbl" xml:lang="en-US">Preclinical Studies [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ClinicalTrialsMember" xlink:label="avxl_ClinicalTrialsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ClinicalTrialsMember" xlink:to="avxl_ClinicalTrialsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ClinicalTrialsMember_lbl" xml:lang="en-US">Clinical Trials [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_PersonnelCostsMember" xlink:label="avxl_PersonnelCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PersonnelCostsMember" xlink:to="avxl_PersonnelCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PersonnelCostsMember_lbl" xml:lang="en-US">Personnel Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_NonCashShareBasedCompensationMember" xlink:label="avxl_NonCashShareBasedCompensationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonCashShareBasedCompensationMember" xlink:to="avxl_NonCashShareBasedCompensationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonCashShareBasedCompensationMember_lbl" xml:lang="en-US">Non Cash Share Based Compensation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OtherResearchAndDevelopmentCostsMember" xlink:label="avxl_OtherResearchAndDevelopmentCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherResearchAndDevelopmentCostsMember" xlink:to="avxl_OtherResearchAndDevelopmentCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherResearchAndDevelopmentCostsMember_lbl" xml:lang="en-US">Other Research And Development Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities - Note 3</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCredit" xlink:to="us-gaap_DeferredRentCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCredit_lbl" xml:lang="en-US">Deferred grant income - Note 4</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - Note 6</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Capital stock Authorized: 200,000,000 common stock, par value $0.001 per share Issued and outstanding: 86,668,521 common shares (2024 - 84,795,517)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common shares, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common shares, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="avxl_NonOperatingIncomeFromGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrants" xlink:to="avxl_NonOperatingIncomeFromGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrants_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OtherFinancingExpense" xlink:label="avxl_OtherFinancingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherFinancingExpense" xlink:to="avxl_OtherFinancingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avxl_OtherFinancingExpense_lbl" xml:lang="en-US">Other financing expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_EarningPerShareBasicAndDilutedAbstract" xlink:label="avxl_EarningPerShareBasicAndDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EarningPerShareBasicAndDilutedAbstract" xlink:to="avxl_EarningPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EarningPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net Loss per share, Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net Loss per share, Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of shares outstanding, Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of shares outstanding, Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows used in Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_NoncashFinancingRelatedCharges" xlink:label="avxl_NoncashFinancingRelatedCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NoncashFinancingRelatedCharges" xlink:to="avxl_NoncashFinancingRelatedCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NoncashFinancingRelatedCharges_lbl" xml:lang="en-US">Non cash financing related charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in working capital balances related to operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_DeferredGrantIncome" xlink:label="avxl_DeferredGrantIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncome" xlink:to="avxl_DeferredGrantIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avxl_DeferredGrantIncome_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_IssuanceOfCommonSharesNetOfShareIssueCosts" xlink:label="avxl_IssuanceOfCommonSharesNetOfShareIssueCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IssuanceOfCommonSharesNetOfShareIssueCosts" xlink:to="avxl_IssuanceOfCommonSharesNetOfShareIssueCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IssuanceOfCommonSharesNetOfShareIssueCosts_lbl" xml:lang="en-US">Issuance of common shares, net of share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForDelayedTaxExemptExchange" xlink:label="us-gaap_PaymentsForDelayedTaxExemptExchange" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForDelayedTaxExemptExchange" xlink:to="us-gaap_PaymentsForDelayedTaxExemptExchange_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForDelayedTaxExemptExchange_lbl" xml:lang="en-US">Payment for taxes related to cashless exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">(Decrease) Increase in cash and cash equivalents during the year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CashPaidForStateAndLocalFranchiseTaxes" xlink:label="avxl_CashPaidForStateAndLocalFranchiseTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CashPaidForStateAndLocalFranchiseTaxes" xlink:to="avxl_CashPaidForStateAndLocalFranchiseTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CashPaidForStateAndLocalFranchiseTaxes_lbl" xml:lang="en-US">Cash paid for state and local franchise taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CommonStockIssuedUponCashlessExerciseOfStockOptions" xlink:label="avxl_CommonStockIssuedUponCashlessExerciseOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommonStockIssuedUponCashlessExerciseOfStockOptions" xlink:to="avxl_CommonStockIssuedUponCashlessExerciseOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommonStockIssuedUponCashlessExerciseOfStockOptions_lbl" xml:lang="en-US">Common stock issued upon cashless exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance at beginning, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedUnderSalesAgreement" xlink:label="avxl_SharesIssuedUnderSalesAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUnderSalesAgreement" xlink:to="avxl_SharesIssuedUnderSalesAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUnderSalesAgreement_lbl" xml:lang="en-US">Shares issued under 2025 Sales Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedUnderSalesAgreementShares" xlink:label="avxl_SharesIssuedUnderSalesAgreementShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUnderSalesAgreementShares" xlink:to="avxl_SharesIssuedUnderSalesAgreementShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUnderSalesAgreementShares_lbl" xml:lang="en-US">Shares issued under Sales Agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedUnderPurchaseAgreement" xlink:label="avxl_SharesIssuedUnderPurchaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUnderPurchaseAgreement" xlink:to="avxl_SharesIssuedUnderPurchaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUnderPurchaseAgreement_lbl" xml:lang="en-US">Shares issued under 2023 Purchase Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_InitialCommitmentShares" xlink:label="avxl_InitialCommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_InitialCommitmentShares" xlink:to="avxl_InitialCommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_InitialCommitmentShares_lbl" xml:lang="en-US">&#160;Initial Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_InitialCommitmentSharesShares" xlink:label="avxl_InitialCommitmentSharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_InitialCommitmentSharesShares" xlink:to="avxl_InitialCommitmentSharesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_InitialCommitmentSharesShares_lbl" xml:lang="en-US">Initial commitment shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">&#160;Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Purchase shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CommitmentShares" xlink:label="avxl_CommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentShares" xlink:to="avxl_CommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentShares_lbl" xml:lang="en-US">&#160;Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CommitmentSharesShares" xlink:label="avxl_CommitmentSharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesShares" xlink:to="avxl_CommitmentSharesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesShares_lbl" xml:lang="en-US">Commitment shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:to="avxl_SharesIssuedPursuantToExerciseOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptions_lbl" xml:lang="en-US">Shares issued pursuant to exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:to="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares_lbl" xml:lang="en-US">Shares issued pursuant to exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptions" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptions" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptions_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptionsShares" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptionsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptionsShares" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptionsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptionsShares_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesWithheldRelatedToCashlessExerciseOfStockOption" xlink:label="avxl_SharesWithheldRelatedToCashlessExerciseOfStockOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesWithheldRelatedToCashlessExerciseOfStockOption" xlink:to="avxl_SharesWithheldRelatedToCashlessExerciseOfStockOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesWithheldRelatedToCashlessExerciseOfStockOption_lbl" xml:lang="en-US">Shares withheld related to cashless exercise of stock option</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesWithheldRelatedToCashlessExerciseOfStockOptionShares" xlink:label="avxl_SharesWithheldRelatedToCashlessExerciseOfStockOptionShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesWithheldRelatedToCashlessExerciseOfStockOptionShares" xlink:to="avxl_SharesWithheldRelatedToCashlessExerciseOfStockOptionShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesWithheldRelatedToCashlessExerciseOfStockOptionShares_lbl" xml:lang="en-US">Shares withheld related to cashless exercise of stock option, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance at ending, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrByIndTable_lbl" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis" xlink:label="ecd_TradingArrAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrAxis" xlink:to="ecd_TradingArrAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrAxis_lbl" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Business Description and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_DisclosureAccruedLiabilitiesAbstract" xlink:label="avxl_DisclosureAccruedLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureAccruedLiabilitiesAbstract" xlink:to="avxl_DisclosureAccruedLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureAccruedLiabilitiesAbstract_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_AccuredLiabilitiesTextBlock" xlink:label="avxl_AccuredLiabilitiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AccuredLiabilitiesTextBlock" xlink:to="avxl_AccuredLiabilitiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_AccuredLiabilitiesTextBlock_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="avxl_DisclosureOtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureOtherIncomeAbstract" xlink:to="avxl_DisclosureOtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureOtherIncomeAbstract_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="avxl_OtherIncomeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_OtherIncomeDisclosureTextBlock_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="avxl_DisclosureEquityOfferingsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureEquityOfferingsAbstract" xlink:to="avxl_DisclosureEquityOfferingsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureEquityOfferingsAbstract_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_EquityOfferingTextBlock" xlink:label="avxl_EquityOfferingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingTextBlock" xlink:to="avxl_EquityOfferingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_EquityOfferingTextBlock_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segmented Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionIncentives" xlink:label="us-gaap_RevenueRecognitionIncentives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionIncentives" xlink:to="us-gaap_RevenueRecognitionIncentives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionIncentives_lbl" xml:lang="en-US">Research and Development Incentive Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_LicenseFeesPolicyTextBlock" xlink:label="avxl_LicenseFeesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LicenseFeesPolicyTextBlock" xlink:to="avxl_LicenseFeesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LicenseFeesPolicyTextBlock_lbl" xml:lang="en-US">License Fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment and Geographic Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_GrantIncomePolicyTextBlock" xlink:label="avxl_GrantIncomePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GrantIncomePolicyTextBlock" xlink:to="avxl_GrantIncomePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_GrantIncomePolicyTextBlock_lbl" xml:lang="en-US">Grant Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:to="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl" xml:lang="en-US">Share-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_RecentAccountingPronouncementsPolicyTextBlock" xlink:label="avxl_RecentAccountingPronouncementsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_RecentAccountingPronouncementsPolicyTextBlock" xlink:to="avxl_RecentAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_RecentAccountingPronouncementsPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of principal components of accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of operating lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:label="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:to="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of contributions under the plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of summarizes information about stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of general and administrative expenses and research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" xlink:label="avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" xlink:to="avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions for fair value of each option award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of summarizes the significant expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Federal deposit insurance corporation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Loss per share for potentially dilutive common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_AccruedInvestigatorPayments" xlink:label="avxl_AccruedInvestigatorPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AccruedInvestigatorPayments" xlink:to="avxl_AccruedInvestigatorPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AccruedInvestigatorPayments_lbl" xml:lang="en-US">Accrued investigator payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued compensation and benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_MilestoneBasedContractAccruals" xlink:label="avxl_MilestoneBasedContractAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_MilestoneBasedContractAccruals" xlink:to="avxl_MilestoneBasedContractAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_MilestoneBasedContractAccruals_lbl" xml:lang="en-US">Milestone-based contract accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">All other accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_TotalAccruedLiabilities" xlink:label="avxl_TotalAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_TotalAccruedLiabilities" xlink:to="avxl_TotalAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="avxl_TotalAccruedLiabilities_lbl" xml:lang="en-US">Total accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" xlink:label="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" xlink:to="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="avxl_NonOperatingIncomeFromGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrant_lbl" xml:lang="en-US">Non operating income from grant</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_DeferredGrantIncome1" xlink:label="avxl_DeferredGrantIncome1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncome1" xlink:to="avxl_DeferredGrantIncome1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredGrantIncome1_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="avxl_ValueOfSharesObligatedToPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ValueOfSharesObligatedToPurchase_lbl" xml:lang="en-US">Value of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RedemptionPremium" xlink:label="us-gaap_RedemptionPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedemptionPremium" xlink:to="us-gaap_RedemptionPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedemptionPremium_lbl" xml:lang="en-US">Common stock net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues1_lbl" xml:lang="en-US">Pro rata basic number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from issuance or sale of equity</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_FairValueOfInitialCommitment" xlink:label="avxl_FairValueOfInitialCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FairValueOfInitialCommitment" xlink:to="avxl_FairValueOfInitialCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_FairValueOfInitialCommitment_lbl" xml:lang="en-US">Fair value of the initial commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_IncurredExpenses" xlink:label="avxl_IncurredExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncurredExpenses" xlink:to="avxl_IncurredExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IncurredExpenses_lbl" xml:lang="en-US">Incurred expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Number of shares issued, value</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues2" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues2" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues2_lbl" xml:lang="en-US">Number of shares issued, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Amount of shares remain available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise option shares purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Common stock exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CommonStockConsiderationExerciseShares" xlink:label="avxl_CommonStockConsiderationExerciseShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommonStockConsiderationExerciseShares" xlink:to="avxl_CommonStockConsiderationExerciseShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommonStockConsiderationExerciseShares_lbl" xml:lang="en-US">Common stock consideration exercise shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="us-gaap_StockOptionExercisePriceIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xml:lang="en-US">exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_lbl" xml:lang="en-US">Consideration shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:to="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_lbl" xml:lang="en-US">Consideration payment</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_MarketPrice" xlink:label="avxl_MarketPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_MarketPrice" xlink:to="avxl_MarketPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_MarketPrice_lbl" xml:lang="en-US">Market price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionContributions" xlink:label="us-gaap_PensionContributions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionContributions" xlink:to="us-gaap_PensionContributions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionContributions_lbl" xml:lang="en-US">Contributions to 401(k) plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options, Outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, Outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, Outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted_lbl" xml:lang="en-US">Weighted average grant date fair value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of options, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of options, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised_lbl" xml:lang="en-US">Weighted average grant date fair value, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of options, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited_lbl" xml:lang="en-US">Weighted average grant date fair value, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options, Outstanding ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted average grant date fair value, Outstanding ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value, Outstanding ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, Lower range limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, Upper range limit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of outstanding options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of vested options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Annualized volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="avxl_WarrantsOutstandingWeightedAverageExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WarrantsOutstandingWeightedAverageExercise" xlink:to="avxl_WarrantsOutstandingWeightedAverageExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_WarrantsOutstandingWeightedAverageExercise_lbl" xml:lang="en-US">Warrants outstanding weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Number of shares of common stock reserved for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares of common stock available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Option granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OptionIssued" xlink:label="avxl_OptionIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionIssued" xlink:to="avxl_OptionIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionIssued_lbl" xml:lang="en-US">Option issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Option available issue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value of options vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted average contractual life of options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Remaining stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">United States</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization" xlink:label="avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization" xlink:to="avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization_lbl" xml:lang="en-US">Research and development capitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_DeferredTaxAssetsUnpaidCharges" xlink:label="avxl_DeferredTaxAssetsUnpaidCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredTaxAssetsUnpaidCharges" xlink:to="avxl_DeferredTaxAssetsUnpaidCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredTaxAssetsUnpaidCharges_lbl" xml:lang="en-US">Unpaid charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangible asset costs</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ForeignExchangeAndOther" xlink:label="avxl_ForeignExchangeAndOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ForeignExchangeAndOther" xlink:to="avxl_ForeignExchangeAndOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avxl_ForeignExchangeAndOther_lbl" xml:lang="en-US">Foreign exchange and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance of deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income tax benefit at statutory federal rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign income taxed at other rates</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_PermanentDifferencesRelatingToStockBasedCompensation" xlink:label="avxl_PermanentDifferencesRelatingToStockBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PermanentDifferencesRelatingToStockBasedCompensation" xlink:to="avxl_PermanentDifferencesRelatingToStockBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PermanentDifferencesRelatingToStockBasedCompensation_lbl" xml:lang="en-US">Permanent differences relating to share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_lbl" xml:lang="en-US">Permanent differences relating to GILTI inclusion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" xlink:label="avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" xlink:to="avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_lbl" xml:lang="en-US">Research and development credits, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State and local taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Adjustment to true up to prior years&#8217; tax provision</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance" xlink:label="avxl_IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance" xlink:to="avxl_IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OperatingLossCarryforwardsDescription" xlink:label="avxl_OperatingLossCarryforwardsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OperatingLossCarryforwardsDescription" xlink:to="avxl_OperatingLossCarryforwardsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OperatingLossCarryforwardsDescription_lbl" xml:lang="en-US">Operating loss carryforwards description</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OperatingLossCarryForwardsExpirationYear" xlink:label="avxl_OperatingLossCarryForwardsExpirationYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OperatingLossCarryForwardsExpirationYear" xlink:to="avxl_OperatingLossCarryForwardsExpirationYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OperatingLossCarryForwardsExpirationYear_lbl" xml:lang="en-US">Operating loss carry forwards expiration year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">Research and Development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ResearchAndDevelopmentTaxCreditsYear" xlink:label="avxl_ResearchAndDevelopmentTaxCreditsYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentTaxCreditsYear" xlink:to="avxl_ResearchAndDevelopmentTaxCreditsYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentTaxCreditsYear_lbl" xml:lang="en-US">Research and development tax credits year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Decrease in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Gross deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xml:lang="en-US">Research and Development, Contract to Perform for Others [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherFinancingExpense" xlink:to="avxl_OtherFinancingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherFinancingExpense_2_lbl" xml:lang="en-US">OtherFinancingExpense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncome" xlink:to="avxl_DeferredGrantIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredGrantIncome_2_lbl" xml:lang="en-US">DeferredGrantIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForDelayedTaxExemptExchange" xlink:to="us-gaap_PaymentsForDelayedTaxExemptExchange_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForDelayedTaxExemptExchange_2_lbl" xml:lang="en-US">Payments for Delayed Tax Exempt Exchange</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_lbl" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AccuredLiabilitiesTextBlock" xlink:to="avxl_AccuredLiabilitiesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AccuredLiabilitiesTextBlock_2_lbl" xml:lang="en-US">AccuredLiabilitiesTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xml:lang="en-US">OtherIncomeDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingTextBlock" xlink:to="avxl_EquityOfferingTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingTextBlock_2_lbl" xml:lang="en-US">EquityOfferingTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_TotalAccruedLiabilities" xlink:to="avxl_TotalAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_TotalAccruedLiabilities_2_lbl" xml:lang="en-US">TotalAccruedLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" xlink:to="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_2_lbl" xml:lang="en-US">ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_2_lbl" xml:lang="en-US">Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues2" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues2_2_lbl" xml:lang="en-US">StockIssuedDuringPeriodValueNewIssues2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ForeignExchangeAndOther" xlink:to="avxl_ForeignExchangeAndOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ForeignExchangeAndOther_2_lbl" xml:lang="en-US">ForeignExchangeAndOther</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>avxl-20250930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#Cover" roleURI="http://anavex.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#BalanceSheets" roleURI="http://anavex.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#BalanceSheetsParenthetical" roleURI="http://anavex.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#StatementsOfOperationsAndComprehensiveLoss" roleURI="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#StatementsOfCashFlows" roleURI="http://anavex.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#StatementsOfChangesInStockholdersEquity" roleURI="http://anavex.com/role/StatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#BusinessDescriptionAndBasisOfPresentation" roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#AccruedLiabilities" roleURI="http://anavex.com/role/AccruedLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#OtherIncome" roleURI="http://anavex.com/role/OtherIncome" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#EquityOfferings" roleURI="http://anavex.com/role/EquityOfferings" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingencies" roleURI="http://anavex.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#IncomeTaxes" roleURI="http://anavex.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SegmentedInformation" roleURI="http://anavex.com/role/SegmentedInformation" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SubsequentEvents" roleURI="http://anavex.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#AccruedLiabilitiesTables" roleURI="http://anavex.com/role/AccruedLiabilitiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesTables" roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#IncomeTaxesTables" roleURI="http://anavex.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SegmentedInformationTables" roleURI="http://anavex.com/role/SegmentedInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#AccruedLiabilitiesDetails" roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#OtherIncomeDetailsNarrative" roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#EquityOfferingsDetailsNarrative" roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetails" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetails1" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetails2" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetails3" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetails4" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetails5" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#IncomeTaxesDetails" roleURI="http://anavex.com/role/IncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#IncomeTaxesDetails1" roleURI="http://anavex.com/role/IncomeTaxesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#IncomeTaxesDetails2" roleURI="http://anavex.com/role/IncomeTaxesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#IncomeTaxesDetailsNarrative" roleURI="http://anavex.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="avxl-20250930.xsd#SegmentedInformationDetails" roleURI="http://anavex.com/role/SegmentedInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRentCredit" xlink:label="loc_us-gaapDeferredRentCredit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRentCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="loc_avxlNonOperatingIncomeFromGrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlNonOperatingIncomeFromGrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OtherFinancingExpense" xlink:label="loc_avxlOtherFinancingExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlOtherFinancingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_EarningPerShareBasicAndDilutedAbstract" xlink:label="loc_avxlEarningPerShareBasicAndDilutedAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_avxlEarningPerShareBasicAndDilutedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_NoncashFinancingRelatedCharges" xlink:label="loc_avxlNoncashFinancingRelatedCharges" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_avxlNoncashFinancingRelatedCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_DeferredGrantIncome" xlink:label="loc_avxlDeferredGrantIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_avxlDeferredGrantIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_IssuanceOfCommonSharesNetOfShareIssueCosts" xlink:label="loc_avxlIssuanceOfCommonSharesNetOfShareIssueCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_avxlIssuanceOfCommonSharesNetOfShareIssueCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForDelayedTaxExemptExchange" xlink:label="loc_us-gaapPaymentsForDelayedTaxExemptExchange" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsForDelayedTaxExemptExchange" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CashPaidForStateAndLocalFranchiseTaxes" xlink:label="loc_avxlCashPaidForStateAndLocalFranchiseTaxes" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_avxlCashPaidForStateAndLocalFranchiseTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CommonStockIssuedUponCashlessExerciseOfStockOptions" xlink:label="loc_avxlCommonStockIssuedUponCashlessExerciseOfStockOptions" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_avxlCommonStockIssuedUponCashlessExerciseOfStockOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedUnderSalesAgreement" xlink:label="loc_avxlSharesIssuedUnderSalesAgreement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnderSalesAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedUnderSalesAgreementShares" xlink:label="loc_avxlSharesIssuedUnderSalesAgreementShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnderSalesAgreementShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedUnderPurchaseAgreement" xlink:label="loc_avxlSharesIssuedUnderPurchaseAgreement" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnderPurchaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_InitialCommitmentShares" xlink:label="loc_avxlInitialCommitmentShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlInitialCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_InitialCommitmentSharesShares" xlink:label="loc_avxlInitialCommitmentSharesShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlInitialCommitmentSharesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CommitmentShares" xlink:label="loc_avxlCommitmentShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CommitmentSharesShares" xlink:label="loc_avxlCommitmentSharesShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptions" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfStockOptions" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptionsShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfStockOptionsShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfStockOptionsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesWithheldRelatedToCashlessExerciseOfStockOption" xlink:label="loc_avxlSharesWithheldRelatedToCashlessExerciseOfStockOption" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesWithheldRelatedToCashlessExerciseOfStockOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_SharesWithheldRelatedToCashlessExerciseOfStockOptionShares" xlink:label="loc_avxlSharesWithheldRelatedToCashlessExerciseOfStockOptionShares" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesWithheldRelatedToCashlessExerciseOfStockOptionShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable" xlink:label="loc_ecdTradingArrByIndTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTradingArrByIndTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis" xlink:label="loc_ecdTradingArrAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdTradingArrAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember" xlink:label="loc_ecdAllTradingArrangementsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrAxis" xlink:to="loc_ecdAllTradingArrangementsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="999014 - Disclosure - Business Description and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="999016 - Disclosure - Accrued Liabilities">
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_DisclosureAccruedLiabilitiesAbstract" xlink:label="loc_avxlDisclosureAccruedLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_AccuredLiabilitiesTextBlock" xlink:label="loc_avxlAccuredLiabilitiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_avxlAccuredLiabilitiesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="999017 - Disclosure - Other Income">
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="loc_avxlOtherIncomeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_avxlOtherIncomeDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="999018 - Disclosure - Equity Offerings">
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_EquityOfferingTextBlock" xlink:label="loc_avxlEquityOfferingTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingsAbstract" xlink:to="loc_avxlEquityOfferingTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="999019 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxes" xlink:title="999020 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SegmentedInformation" xlink:title="999021 - Disclosure - Segmented Information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEvents" xlink:title="999022 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999023 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionIncentives" xlink:label="loc_us-gaapRevenueRecognitionIncentives" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionIncentives" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_LicenseFeesPolicyTextBlock" xlink:label="loc_avxlLicenseFeesPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_avxlLicenseFeesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_GrantIncomePolicyTextBlock" xlink:label="loc_avxlGrantIncomePolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_avxlGrantIncomePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:label="loc_us-gaapShareBasedCompensationForfeituresPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationForfeituresPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_RecentAccountingPronouncementsPolicyTextBlock" xlink:label="loc_avxlRecentAccountingPronouncementsPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_avxlRecentAccountingPronouncementsPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="999024 - Disclosure - Accrued Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_DisclosureAccruedLiabilitiesAbstract" xlink:label="loc_avxlDisclosureAccruedLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="999025 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:label="loc_us-gaapDefinedContributionPlanDisclosuresTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanDisclosuresTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" xlink:label="loc_avxlScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_avxlScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesTables" xlink:title="999026 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SegmentedInformationTables" xlink:title="999027 - Disclosure - Segmented Information (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="999029 - Disclosure - Accrued Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_DisclosureAccruedLiabilitiesAbstract" xlink:label="loc_avxlDisclosureAccruedLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_AccruedInvestigatorPayments" xlink:label="loc_avxlAccruedInvestigatorPayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_avxlAccruedInvestigatorPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_MilestoneBasedContractAccruals" xlink:label="loc_avxlMilestoneBasedContractAccruals" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_avxlMilestoneBasedContractAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_TotalAccruedLiabilities" xlink:label="loc_avxlTotalAccruedLiabilities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_avxlTotalAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="999030 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_MichaelJFoxFoundationMember" xlink:label="loc_avxlMichaelJFoxFoundationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlMichaelJFoxFoundationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" xlink:label="loc_avxlResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_DeferredGrantIncome1" xlink:label="loc_avxlDeferredGrantIncome1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlDeferredGrantIncome1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="999031 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_PurchaseAgreement2023Member" xlink:label="loc_avxlPurchaseAgreement2023Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement2023Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CommonStockIncludingCommitmentSharesMember" xlink:label="loc_avxlCommonStockIncludingCommitmentSharesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_avxlCommonStockIncludingCommitmentSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CommonStockExcludingCommitmentSharesMember" xlink:label="loc_avxlCommonStockExcludingCommitmentSharesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_avxlCommonStockExcludingCommitmentSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CommitmentSharesMember" xlink:label="loc_avxlCommitmentSharesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_avxlCommitmentSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_BoardMember" xlink:label="loc_avxlBoardMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_avxlBoardMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ChiefExecutiveOfficer1Member" xlink:label="loc_avxlChiefExecutiveOfficer1Member" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_avxlChiefExecutiveOfficer1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ChiefExecutiveOffice1rMember" xlink:label="loc_avxlChiefExecutiveOffice1rMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_avxlChiefExecutiveOffice1rMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RedemptionPremium" xlink:label="loc_us-gaapRedemptionPremium" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRedemptionPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_FairValueOfInitialCommitment" xlink:label="loc_avxlFairValueOfInitialCommitment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlFairValueOfInitialCommitment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_IncurredExpenses" xlink:label="loc_avxlIncurredExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlIncurredExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues2" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_CommonStockConsiderationExerciseShares" xlink:label="loc_avxlCommonStockConsiderationExerciseShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommonStockConsiderationExerciseShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="loc_us-gaapStockOptionExercisePriceIncrease" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockOptionExercisePriceIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:label="loc_us-gaapOtherSignificantNoncashTransactionValueOfConsiderationGiven1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_MarketPrice" xlink:label="loc_avxlMarketPrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlMarketPrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="999032 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="999033 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionContributions" xlink:label="loc_us-gaapPensionContributions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapPensionContributions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="999034 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="999035 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OptionPrice1Member" xlink:label="loc_avxlOptionPrice1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OptionPrice2Member" xlink:label="loc_avxlOptionPrice2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OptionPrice3Member" xlink:label="loc_avxlOptionPrice3Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OptionPrice4Member" xlink:label="loc_avxlOptionPrice4Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OptionPrice5Member" xlink:label="loc_avxlOptionPrice5Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="999036 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="999037 - Disclosure - Commitments and Contingencies (Details 5)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999038 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_StockOptionPlan2022Member" xlink:label="loc_avxlStockOptionPlan2022Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2022Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="loc_avxlWarrantsOutstandingWeightedAverageExercise" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlWarrantsOutstandingWeightedAverageExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OptionIssued" xlink:label="loc_avxlOptionIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlOptionIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails" xlink:title="999039 - Disclosure - Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails1" xlink:title="999040 - Disclosure - Income Taxes (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization" xlink:label="loc_avxlDeferredTaxAssetsResearchAndDevelopmentCapitalization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_avxlDeferredTaxAssetsResearchAndDevelopmentCapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_DeferredTaxAssetsUnpaidCharges" xlink:label="loc_avxlDeferredTaxAssetsUnpaidCharges" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_avxlDeferredTaxAssetsUnpaidCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ForeignExchangeAndOther" xlink:label="loc_avxlForeignExchangeAndOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_avxlForeignExchangeAndOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails2" xlink:title="999041 - Disclosure - Income Taxes (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_PermanentDifferencesRelatingToStockBasedCompensation" xlink:label="loc_avxlPermanentDifferencesRelatingToStockBasedCompensation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_avxlPermanentDifferencesRelatingToStockBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationGiltiAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" xlink:label="loc_avxlIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_avxlIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance" xlink:label="loc_avxlIncomeTaxReconciliationChangeInTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_avxlIncomeTaxReconciliationChangeInTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:title="999042 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_FederalMember" xlink:label="loc_avxlFederalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_avxlFederalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OperatingLossCarryforwardsDescription" xlink:label="loc_avxlOperatingLossCarryforwardsDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_avxlOperatingLossCarryforwardsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OperatingLossCarryForwardsExpirationYear" xlink:label="loc_avxlOperatingLossCarryForwardsExpirationYear" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_avxlOperatingLossCarryForwardsExpirationYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ResearchAndDevelopmentTaxCreditsYear" xlink:label="loc_avxlResearchAndDevelopmentTaxCreditsYear" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_avxlResearchAndDevelopmentTaxCreditsYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SegmentedInformationDetails" xlink:title="999043 - Disclosure - Segmented Information (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaapScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_PreclinicalStudiesMember" xlink:label="loc_avxlPreclinicalStudiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_avxlPreclinicalStudiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_ClinicalTrialsMember" xlink:label="loc_avxlClinicalTrialsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_avxlClinicalTrialsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_PersonnelCostsMember" xlink:label="loc_avxlPersonnelCostsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_avxlPersonnelCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_NonCashShareBasedCompensationMember" xlink:label="loc_avxlNonCashShareBasedCompensationMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_avxlNonCashShareBasedCompensationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250930.xsd#avxl_OtherResearchAndDevelopmentCostsMember" xlink:label="loc_avxlOtherResearchAndDevelopmentCostsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_avxlOtherResearchAndDevelopmentCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Nov. 24, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAVEX LIFE SCIENCES CORP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0608404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">630 5th Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">20th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">US<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">689-3939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock Par Value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVXL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 708,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,348,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">GRANT THORNTON LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Melville, New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 102,577<span></span>
</td>
<td class="nump">$ 132,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">809<span></span>
</td>
<td class="nump">2,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">931<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">103,815<span></span>
</td>
<td class="nump">135,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,249<span></span>
</td>
<td class="nump">9,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities - Note 3</a></td>
<td class="nump">3,892<span></span>
</td>
<td class="nump">4,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred grant income - Note 4</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">8,946<span></span>
</td>
<td class="nump">15,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Capital stock Authorized: 200,000,000 common stock, par value $0.001 per share Issued and outstanding: 86,668,521 common shares (2024 - 84,795,517)</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">477,230<span></span>
</td>
<td class="nump">456,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(382,448)<span></span>
</td>
<td class="num">(336,071)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">94,869<span></span>
</td>
<td class="nump">120,263<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 103,815<span></span>
</td>
<td class="nump">$ 135,567<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481178/840-20-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479341/842-30-25-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">86,668,521<span></span>
</td>
<td class="nump">84,795,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding</a></td>
<td class="nump">86,668,521<span></span>
</td>
<td class="nump">84,795,517<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 13,816<span></span>
</td>
<td class="nump">$ 11,039<span></span>
</td>
<td class="nump">$ 12,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">37,592<span></span>
</td>
<td class="nump">41,838<span></span>
</td>
<td class="nump">43,717<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">51,408<span></span>
</td>
<td class="nump">52,877<span></span>
</td>
<td class="nump">55,763<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(51,408)<span></span>
</td>
<td class="num">(52,877)<span></span>
</td>
<td class="num">(55,763)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrants', window );">Grant income</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">648<span></span>
</td>
<td class="nump">2,291<span></span>
</td>
<td class="nump">2,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">4,678<span></span>
</td>
<td class="nump">7,320<span></span>
</td>
<td class="nump">6,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OtherFinancingExpense', window );">Other financing expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(964)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain (loss)</a></td>
<td class="num">(332)<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">5,031<span></span>
</td>
<td class="nump">9,875<span></span>
</td>
<td class="nump">8,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (46,377)<span></span>
</td>
<td class="num">$ (43,002)<span></span>
</td>
<td class="num">$ (47,505)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_EarningPerShareBasicAndDilutedAbstract', window );"><strong>Net Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss per share, Basic</a></td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss per share, Diluted</a></td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding, Basic</a></td>
<td class="nump">85,289,447<span></span>
</td>
<td class="nump">83,468,049<span></span>
</td>
<td class="nump">79,787,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding, Diluted</a></td>
<td class="nump">85,289,447<span></span>
</td>
<td class="nump">83,468,049<span></span>
</td>
<td class="nump">79,787,596<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EarningPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EarningPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherFinancingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherFinancingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows used in Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (46,377)<span></span>
</td>
<td class="num">$ (43,002)<span></span>
</td>
<td class="num">$ (47,505)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NoncashFinancingRelatedCharges', window );">Non cash financing related charges</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">11,549<span></span>
</td>
<td class="nump">9,438<span></span>
</td>
<td class="nump">16,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in working capital balances related to operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">1,640<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and deposits</a></td>
<td class="nump">502<span></span>
</td>
<td class="num">(278)<span></span>
</td>
<td class="num">(299)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(5,378)<span></span>
</td>
<td class="nump">5,305<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(943)<span></span>
</td>
<td class="num">(2,460)<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DeferredGrantIncome', window );">Deferred grant income</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(39,044)<span></span>
</td>
<td class="num">(30,812)<span></span>
</td>
<td class="num">(27,785)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows provided by Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_IssuanceOfCommonSharesNetOfShareIssueCosts', window );">Issuance of common shares, net of share issue costs</a></td>
<td class="nump">9,198<span></span>
</td>
<td class="nump">11,284<span></span>
</td>
<td class="nump">27,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForDelayedTaxExemptExchange', window );">Payment for taxes related to cashless exercise of options</a></td>
<td class="num">(2,707)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">2,943<span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="nump">1,776<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">9,434<span></span>
</td>
<td class="nump">11,975<span></span>
</td>
<td class="nump">29,651<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">(Decrease) Increase in cash and cash equivalents during the year</a></td>
<td class="num">(29,610)<span></span>
</td>
<td class="num">(18,837)<span></span>
</td>
<td class="nump">1,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">132,187<span></span>
</td>
<td class="nump">151,024<span></span>
</td>
<td class="nump">149,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">102,577<span></span>
</td>
<td class="nump">132,187<span></span>
</td>
<td class="nump">151,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CashPaidForStateAndLocalFranchiseTaxes', window );">Cash paid for state and local franchise taxes</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommonStockIssuedUponCashlessExerciseOfStockOptions', window );">Common stock issued upon cashless exercise of stock options</a></td>
<td class="nump">$ 1,493<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CashPaidForStateAndLocalFranchiseTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CashPaidForStateAndLocalFranchiseTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommonStockIssuedUponCashlessExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommonStockIssuedUponCashlessExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IssuanceOfCommonSharesNetOfShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IssuanceOfCommonSharesNetOfShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NoncashFinancingRelatedCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NoncashFinancingRelatedCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDelayedTaxExemptExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow related to a property which is traded for the promise to provide a replacement like-kind property in the near future also known as a tax deferred exempt exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForDelayedTaxExemptExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2022</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 387,977<span></span>
</td>
<td class="num">$ (245,564)<span></span>
</td>
<td class="nump">$ 142,491<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning, shares at Sep. 30, 2022</a></td>
<td class="nump">77,942,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_InitialCommitmentShares', window );">&#160;Initial Commitment shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">845<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_InitialCommitmentSharesShares', window );">Initial commitment shares, shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">&#160;Purchase shares</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">27,872<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Purchase shares, shares</a></td>
<td class="nump">3,275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentShares', window );">&#160;Commitment shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesShares', window );">Commitment shares, shares</a></td>
<td class="nump">13,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">Shares issued pursuant to exercise of stock options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares', window );">Shares issued pursuant to exercise of stock options, shares</a></td>
<td class="nump">759,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,370<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(47,505)<span></span>
</td>
<td class="num">(47,505)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2023</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">434,839<span></span>
</td>
<td class="num">(293,069)<span></span>
</td>
<td class="nump">141,852<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at ending, shares at Sep. 30, 2023</a></td>
<td class="nump">82,066,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">&#160;Purchase shares</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">11,281<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Purchase shares, shares</a></td>
<td class="nump">2,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentShares', window );">&#160;Commitment shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesShares', window );">Commitment shares, shares</a></td>
<td class="nump">5,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">Shares issued pursuant to exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares', window );">Shares issued pursuant to exercise of stock options, shares</a></td>
<td class="nump">273,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,438<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(43,002)<span></span>
</td>
<td class="num">(43,002)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2024</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">456,249<span></span>
</td>
<td class="num">(336,071)<span></span>
</td>
<td class="nump">120,263<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at ending, shares at Sep. 30, 2024</a></td>
<td class="nump">84,795,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedUnderSalesAgreement', window );">Shares issued under 2025 Sales Agreement</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">9,197<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedUnderSalesAgreementShares', window );">Shares issued under Sales Agreement, shares</a></td>
<td class="nump">927,910,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">Shares issued pursuant to exercise of stock options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,942<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares', window );">Shares issued pursuant to exercise of stock options, shares</a></td>
<td class="nump">646,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptions', window );">Shares issued pursuant to cashless exercise of stock options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,492<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptionsShares', window );">Shares issued pursuant to cashless exercise of stock options, shares</a></td>
<td class="nump">737,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesWithheldRelatedToCashlessExerciseOfStockOption', window );">Shares withheld related to cashless exercise of stock option</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(4,199)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesWithheldRelatedToCashlessExerciseOfStockOptionShares', window );">Shares withheld related to cashless exercise of stock option, shares</a></td>
<td class="num">(438,894)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11,549<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(46,377)<span></span>
</td>
<td class="num">(46,377)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2025</a></td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">$ 477,230<span></span>
</td>
<td class="num">$ (382,448)<span></span>
</td>
<td class="nump">$ 94,869<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at ending, shares at Sep. 30, 2025</a></td>
<td class="nump">86,668,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_InitialCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_InitialCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_InitialCommitmentSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_InitialCommitmentSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedUnderSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedUnderSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedUnderSalesAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedUnderSalesAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesWithheldRelatedToCashlessExerciseOfStockOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesWithheldRelatedToCashlessExerciseOfStockOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesWithheldRelatedToCashlessExerciseOfStockOptionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesWithheldRelatedToCashlessExerciseOfStockOptionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (46,377)<span></span>
</td>
<td class="num">$ (43,002)<span></span>
</td>
<td class="num">$ (47,505)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recovery of Erroneously Awarded Compensation - Restatement Determination Date [Axis]: 2023-11-30<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ErrCompRecoveryTable', window );"><strong>Erroneously Awarded Compensation Recovery [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_RestatementDeterminationDate', window );">Restatement Determination Date</a></td>
<td class="text">Nov. 30,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ErrCompAnalysisTextBlock', window );">Erroneous Compensation Analysis</a></td>
<td class="text">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Clawback Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2023, the Board adopted an executive officer
compensation clawback policy that may be applied in the event of a material financial restatement. The clawback policy covers all of the
named executive officers and includes all incentive-based compensation. Specifically, in the event of an accounting restatement, the Company
must recover, reasonably promptly, erroneously awarded compensation in amounts determined pursuant to the policy. Compensation that may
be recoverable under the policy includes cash or equity-based compensation for which the grant, payment or vesting (or any portion thereof)
is or was predicated upon the achievement of specified financial results that are impacted by the material financial restatement, and
the amount of compensation that may be impacted by the clawback policy is the difference between the amount paid or granted, and the amount
that should have been paid or granted, if calculated on the updated financials. Recovery under the policy with respect to an executive
officer will not require the finding of any misconduct by such executive officer or such executive officer being found responsible for
the accounting error leading to an accounting restatement. Our equity awards provide that the Company may annul an award if the grantee
incurs a separation from service for &#8220;cause&#8221; (as defined in the agreements). In such case, all awards and any amounts or benefits
received or outstanding shall be subject to cancellation, recoupment, rescission, payback and other action in accordance with the terms
of the Company Clawback Policy or any applicable law. <span style="background-color: white">In addition, in the event
of a restatement of the Company&#8217;s financial statements due to material noncompliance with any financial reporting requirement under
the law, whether such noncompliance is the result of misconduct or other circumstances, an employee shall be required to reimburse the
Company for any amounts earned or payable with respect to an award granted under the Company&#8217;s equity plan to the extent required
by law and the Company&#8217;s clawback policy.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ErrCompAnalysisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br> -Paragraph 1<br> -Subparagraph i<br> -Sentence B<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 6<br> -Subsection F<br> -Paragraph 1<br> -Subparagraph i<br> -Sentence B<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Section 19<br> -Paragraph a<br> -Subparagraph 1<br> -Sentence ii<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-CSR<br> -Section 18<br> -Paragraph a<br> -Subparagraph 1<br> -Sentence ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ErrCompAnalysisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ErrCompRecoveryTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 6<br> -Subsection F<br> -Paragraph 1<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Section 19<br> -Paragraph a<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-CSR<br> -Section 18<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ErrCompRecoveryTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_RestatementDeterminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br> -Paragraph 1<br> -Subparagraph i<br> -Sentence A<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 6<br> -Subsection F<br> -Paragraph 1<br> -Subparagraph i<br> -Sentence A<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Section 19<br> -Paragraph a<br> -Subparagraph 1<br> -Sentence i<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-CSR<br> -Section 18<br> -Paragraph a<br> -Subparagraph 1<br> -Sentence i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_RestatementDeterminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_RestatementDateAxis=2023-11-30">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_RestatementDateAxis=2023-11-30</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardsCloseToMnpiDiscTable', window );"><strong>Awards Close in Time to MNPI Disclosures [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure</a></td>
<td class="text">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Policies and Practices for <span id="xdx_903_eecd--AwardTmgPredtrmndFlag_dbT_c20241001__20250930_zE9N9TVCaIM7">Granting Certain Equity
Awards</span></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our policies and practices regarding the granting
of equity awards are carefully designed to ensure compliance with applicable securities laws and to maintain the integrity of our executive
compensation program. The Compensation Committee is responsible for the timing and terms of equity awards to executives and other eligible
employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The timing of equity award grants is determined with
consideration to a variety of factors, including but not limited to, the achievement of pre-established performance targets, market conditions
and internal milestones. The Company does not follow a predetermined schedule for the granting of equity awards&#894; although the Company
generally grants equity-based awards annually after the completion of annual calendar year performance review process. Each grant is considered
on a case-by-case basis to align with the Company&#8217;s strategic objectives and to ensure the competitiveness of our compensation packages.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In determining the timing and terms of an equity award, the Board or the Compensation
Committee may consider material nonpublic information to ensure that such grants are made in compliance with applicable laws and regulations,
but does not take material nonpublic information into account when determining the terms of awards. The Board&#8217;s or the Compensation
Committee&#8217;s procedures to prevent the improper use of material nonpublic information in connection with the granting of equity awards
include oversight by legal counsel and, where appropriate, delaying the grant of equity awards until the public disclosure of such material
nonpublic information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_907_eecd--AwardTmgMethodTextBlock_c20241001__20250930_z3FZVQqnEI88">For all stock option awards, the exercise price is
the closing price of the Company&#8217;s common stock on the Nasdaq on the date of the grant. If the grant date falls on a non-trading
day, the exercise price is the closing price of the Company&#8217;s common stock on the Nasdaq on the last trading day preceding the date
of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During fiscal 2025, the Company did not grant equity
awards to its named executive officers during the four business days prior to or the one business day following the filing of its periodic
reports or the filing or furnishing of a Form 8-K that discloses material nonpublic information. <span id="xdx_90A_eecd--AwardTmgHowMnpiCnsdrdTextBlock_c20241001__20250930_zkSJb6166DMf">The Company has not timed the disclosure
of <span id="xdx_902_eecd--AwardTmgMnpiCnsdrdFlag_dbF_c20241001__20250930_zJn2n2F4G4r8">material nonpublic information</span> for the purpose of affecting the <span id="xdx_901_eecd--MnpiDiscTimedForCompValFlag_dbF_c20241001__20250930_zDuh5Qy8B9c6">value of executive compensation</span> for named executive officer grants
in fiscal 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is committed to maintaining transparency
in its executive compensation practices and to making equity awards in a manner that is not influenced by the timing of the disclosure
of material nonpublic information for the purpose of affecting the value of executive compensation. The Company regularly reviews its
policies and practices related to equity awards to ensure they meet the evolving standards of corporate governance and continue to serve
the best interests of the Company and its stockholders.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMethodTextBlock', window );">Award Timing Method</a></td>
<td class="text">For all stock option awards, the exercise price is
the closing price of the Company&#8217;s common stock on the Nasdaq on the date of the grant. If the grant date falls on a non-trading
day, the exercise price is the closing price of the Company&#8217;s common stock on the Nasdaq on the last trading day preceding the date
of grant.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgPredtrmndFlag', window );">Award Timing Predetermined</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiCnsdrdFlag', window );">Award Timing MNPI Considered</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgHowMnpiCnsdrdTextBlock', window );">Award Timing, How MNPI Considered</a></td>
<td class="text">The Company has not timed the disclosure
of <span id="xdx_902_eecd--AwardTmgMnpiCnsdrdFlag_dbF_c20241001__20250930_zJn2n2F4G4r8">material nonpublic information</span> for the purpose of affecting the <span id="xdx_901_eecd--MnpiDiscTimedForCompValFlag_dbF_c20241001__20250930_zDuh5Qy8B9c6">value of executive compensation</span> for named executive officer grants
in fiscal 2025.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MnpiDiscTimedForCompValFlag', window );">MNPI Disclosure Timed for Compensation Value</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgHowMnpiCnsdrdTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgHowMnpiCnsdrdTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMethodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMethodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiCnsdrdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiCnsdrdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgPredtrmndFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgPredtrmndFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardsCloseToMnpiDiscTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardsCloseToMnpiDiscTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MnpiDiscTimedForCompValFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MnpiDiscTimedForCompValFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">None of our directors or Section 16 officers <span id="xdx_904_eecd--Rule10b51ArrAdoptedFlag_dbT_c20241001__20250930_zNeVxKmrq1Bg"><span id="xdx_904_eecd--NonRule10b51ArrAdoptedFlag_dbT_c20241001__20250930_zUVbq55qNoQj">adopted</span></span>,
modified or <span id="xdx_909_eecd--Rule10b51ArrTrmntdFlag_dbT_c20241001__20250930_zbQWKfxMgypc"><span id="xdx_908_eecd--NonRule10b51ArrTrmntdFlag_dbT_c20241001__20250930_zRPFC994X9V1">terminated</span></span> a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement&#8221; (in each case,
as defined in Item 408(a) of Regulation S-K) during the three-month period ended September 30, 2025.&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text">

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Risk management and strategy </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have implemented and maintain various information
security processes designed to identify, assess and manage <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20241001__20250930_zdv53dXGo97l">material </span>risks from cybersecurity threats to our cloud networks, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20241001__20250930_zRxyuWweayrh">third party</span>
hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information
that is proprietary, strategic or competitive in nature, and data related to our clinical trials and products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have processes designed to protect our information
systems, data, assets, infrastructure, and computing environments from cybersecurity threats and risks. Our cybersecurity strategy includes
the use of third-party IT professionals to assess the effectiveness of our cybersecurity practices for possible cybersecurity threats
and to manage our IT systems to mitigate these threats. We also use multi-factor authentication, maintain logical, physical and technical
controls designed to deter, prevent, mitigate and respond to cybersecurity threats. Further, we provide periodical cybersecurity reminders
to our employees and subscribe to a third-party cybersecurity training program required for all employees, to emphasize the importance
of adherence to our security policies and awareness of evolving cybersecurity threats. We also carry a separate cybersecurity commercial
insurance policy covering the potential financial losses that may occur in the event we experience a cybersecurity incident.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20241001__20250930_zlJZVmtouZA1">Our assessment and management of material risks from
cybersecurity threats are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20241001__20250930_zTtCiHPGKa8l">integrated </span>into the Company&#8217;s overall risk management processes.</span> We conduct organizational risk assessments
commensurate with our size and complexity of our operations. We are in a continuous process of reviewing and implementing incremental
information technology strategies to mitigate cybersecurity risks as new risks arise and as our operations evolve. This has led us to
engage third party professionals to assist in the implementation of processes to manage these risks. We also use third-party service providers
across a variety of functions throughout our business, such as application providers, hosting companies, contract research organizations,
contract manufacturing organizations, distributors, and supply chain resources. We have a vendor management process to help manage cybersecurity
risks associated with our use of certain of these providers. For certain vendors, these processes include a comprehensive vendor audit
process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of the date of this Annual Report, we do not believe
that any past cybersecurity incidents that have been detected have materially affected, or are reasonably likely to materially affect,
our business strategy, results of operations, or financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See &#8220;<i>Risk Factors - Risks Related to Our
Business and Operations</i>&#8221; for additional information about the risks to our business associated with cybersecurity or a breach
or compromise to our information security systems.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Governance </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<div class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_980_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20241001__20250930_zu38dIlHJAS2">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20241001__20250930_zqfCSDYTZXkh">Our Board of Directors addresses the Company&#8217;s
cybersecurity risk management as part of its general oversight function. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20241001__20250930_zOSArugJT6Vg">The audit committee of the Board of Directors is responsible
for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity
<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20241001__20250930_zdM05lQaYVC9">threats</span>.</span></span> <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20241001__20250930_z6KSwD07O2Ba">The audit committee receives periodic updates as required from senior management concerning updates to the Company&#8217;s significant
cybersecurity threats and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20241001__20250930_zzhFYYiJaqYj">risk</span> and the processes the Company has implemented to address them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Currently we have two cybersecurity experts on our
Audit Committee.</p>

</div>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Our assessment and management of material risks from
cybersecurity threats are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20241001__20250930_zTtCiHPGKa8l">integrated </span>into the Company&#8217;s overall risk management processes.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20241001__20250930_zqfCSDYTZXkh">Our Board of Directors addresses the Company&#8217;s
cybersecurity risk management as part of its general oversight function. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20241001__20250930_zOSArugJT6Vg">The audit committee of the Board of Directors is responsible
for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity
<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20241001__20250930_zdM05lQaYVC9">threats</span>.</span></span> <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20241001__20250930_z6KSwD07O2Ba">The audit committee receives periodic updates as required from senior management concerning updates to the Company&#8217;s significant
cybersecurity threats and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20241001__20250930_zzhFYYiJaqYj">risk</span> and the processes the Company has implemented to address them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Currently we have two cybersecurity experts on our
Audit Committee.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our Board of Directors addresses the Company&#8217;s
cybersecurity risk management as part of its general oversight function. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20241001__20250930_zOSArugJT6Vg">The audit committee of the Board of Directors is responsible
for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity
<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20241001__20250930_zdM05lQaYVC9">threats</span>.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">The audit committee receives periodic updates as required from senior management concerning updates to the Company&#8217;s significant
cybersecurity threats and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20241001__20250930_zzhFYYiJaqYj">risk</span> and the processes the Company has implemented to address them.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">The audit committee of the Board of Directors is responsible
for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity
<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20241001__20250930_zdM05lQaYVC9">threats</span>.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business Description and Basis of Presentation</a></td>
<td class="text"><p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zGqPc0XbeUT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Note 1 	<span id="xdx_823_zLqv9QImUj4f">Business Description and Basis of Presentation
</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i>Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. (&#8220;Anavex&#8221; or
the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex analyzes genomic data
from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative
and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s focus is on developing innovative
treatments for Alzheimer&#8217;s disease, Parkinson&#8217;s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases,
including Rett syndrome, and other central nervous system (CNS) disorders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i>Basis of Presentation </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements have been
prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and the instructions to Form
10-K and have been prepared under the accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain immaterial amounts from prior periods have
been reclassified to conform to the current year&#8217;s presentation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Liquidity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Company&#8217;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, the Company has not generated any revenue from our operations. The Company expects the business to continue to experience negative
cash flows from operations for the foreseeable future and cannot predict when, if ever, its business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials
are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change.&#160;The
actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including but not limited to the design,
timing and duration of future clinical trials, the progress of the Company&#8217;s research and development programs and the level of
financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future
clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the 2025 Sales Agreement
and the 2023 Purchase Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available when
needed or, if available, that it can be obtained on commercially reasonable terms. The Company will need to file a prospectus supplement
in order to access funds under the 2023 Purchase Agreement. If the Company is not able to obtain the additional financing on a timely
basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>














<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_803_eus-gaap--SignificantAccountingPoliciesTextBlock_z5taQo9J6NA" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 2	<span id="xdx_826_zDMJqvHfGSmi">Summary of Significant Accounting Policies</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p id="xdx_841_eus-gaap--UseOfEstimates_zxon4wP4Wia2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_zde3wXM9zkBb">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive and tax receivables, valuation and recoverability
of deferred tax assets, share based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zVD4XzL1tzEb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_zpCBy5brpQk2">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zD8NNHkBuK9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zLtybN7cq6Qd">Cash and equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>The Company considers only
those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to
be cash equivalents</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">Highly
liquid investments that are considered cash equivalents include money market&#160;accounts, money market&#160;funds&#160;and&#160;certificates
of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities. The Company&#8217;s
investment policy allows for investments in domestic money market certificates, certificates of deposit, money market funds, bonds or
commercial papers, and establishes diversification and credit quality requirements and limits investments by maturity and issuer. The
Company currently maintains the majority of its investments at one large well known financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the
Federal Deposit Insurance Corporation (FDIC) up to $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_pp0p0_c20250930_zE1i1FXPrd3j" title="Federal deposit insurance corporation">250,000</span>, under current regulations. At September 30, 2025 and 2024, substantially
all of the Company&#8217;s cash balances were in excess of these federally insured limits. The Company mitigates this risk by maintaining
the majority of its cash balances in a large well-known financial institution. The Company has not experienced any losses in such accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p id="xdx_844_eus-gaap--ResearchAndDevelopmentExpensePolicy_zApC1CPXlzx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_zfNu11ZjOfR9">Research and Development Expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed as incurred.
These expenses are comprised of the costs of the Company&#8217;s proprietary research and development efforts, including preclinical studies,
clinical trials, manufacturing costs, employee salaries and benefits and share-based compensation expense, contract services including
external research and development expenses incurred under arrangements with third parties such as contract research organizations (&#8220;CROs&#8221;),
facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when
the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification
(&#8220;ASC&#8221;) 730, <i>Research and Development</i>, as these materials have no alternative future use outside of their intended
use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nonrefundable advance payments for goods or services
that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods
are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs
incurred in relation to external CROs, and clinical site costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes
progress of the trials and studies including the phase or completion of events, invoices received and contracted costs. Judgments and
estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s
estimates. The Company&#8217;s historical accrual estimates have not been materially different from actual costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the Company incurs expenses in respect
of intellectual property costs relating to patents and trademarks. The probability of success and length of time to develop commercial
applications of the drugs subject to the underlying patent and trademark costs is difficult to determine and numerous risks and uncertainties
exist with respect to the timely completion of the development projects. There is no assurance the drugs subject to the underlying patents
and trademarks will ever be successfully commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to these risks and uncertainties, the patent and
trademark costs do not meet the definition of an asset and thus are expensed as incurred within general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84B_eus-gaap--RevenueRecognitionIncentives_zqniuP8zbxt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_863_zaSKSRZ4JeZ8">Research and Development Incentive Income</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is eligible to obtain certain research
and development tax credits, including, through its wholly owned subsidiary Anavex Australia, the Australian research and development
tax incentive credit (the &#8220;Australia R&amp;D credit&#8221;) through a program administered through the Australian Tax Office (the
&#8220;ATO&#8221;) and AusIndustry, a division of the Australian Government&#8217;s Department of Industry, Innovation and Science (&#8220;AusIndustry&#8221;).
The Australia R&amp;D credit program provides for a cash refund based on a percentage of eligible research and development activities
undertaken in Australia by Anavex Australia. Anavex Australia is also eligible under the Australia R&amp;D credit program to receive the
cash refund for certain research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses
are pre-approved by AusIndustry pursuant to an advanced overseas finding application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Australia R&amp;D credit program is available
to eligible companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period at a rate
of 18.5% above the claimant&#8217;s company tax rate in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The tax incentives are available on the basis of specific
criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company
has accounted for the incentives outside of the scope of ASC Topic 740, <i>Income Taxes</i> (&#8220;ASC 740&#8221;), since the incentives
are not linked to the Company&#8217;s taxable income and can be realized regardless of whether the Company has generated taxable income
in the respective jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With respect to the Australia R&amp;D credit, as there
is no authoritative guidance under GAAP for accounting for grants to for-profit business entities, the Company accounts for the grant
by analogy to IAS20 <i>Accounting for Government Grants and Disclosure of Government Assistance</i> (&#8220;IAS 20&#8221;). The Company
recognizes the research and development incentive income as it incurs costs eligible for reimbursement under the Australia R&amp;D credit
program when it is reasonably assured that the cash incentive will be received, as evidenced through enrollment in the program and when
the applicable conditions under the program have been met. The Company accrues for the amount of cash refund it expects to receive in
relation to research and development expenses outside of Australia only to the extent it has received advanced approval from AusIndustry,
pursuant to an approved advanced overseas finding application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, Anavex Australia and Anavex Canada incur
Goods and Services Tax (GST) on certain services provided by local vendors. As a domestic entity in those jurisdictions, Anavex Australia
and Anavex Canada are entitled to a refund of the GST paid. Similarly, Anavex Germany incurs Value Added Tax (VAT) on certain services
provided by local vendors, to which it is entitled to a refund of such VAT paid. The Company&#8217;s estimate of the amount of cash refund
it expects to receive related to GST and VAT incurred is included in Incentive and tax receivables in the accompanying consolidated balance
sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>














<p id="xdx_844_ecustom--LicenseFeesPolicyTextBlock_zd34ancWC3ii" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_zrfDP49gLz2k">License Fees</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company expenses amounts paid to acquire licenses associated with products under development when the ultimate recovery of the amounts
paid is uncertain and the technology has no alternative future use when acquired. Acquisitions of technology licenses are charged to expense
or capitalized based on management&#8217;s assessment regarding the ultimate recoverability of the amounts paid and the potential for
alternative future use. The Company has determined that the technological feasibility for its product candidates is reached when the requisite
regulatory approvals are obtained to make the product available for sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zEDn9LOkfxBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_zkqk8L0aChs9">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2025, diluted loss per share excludes
<span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241001__20250930_zki1oXWZpULk" title="Loss per share for potentially dilutive common shares">14,971,583</span> potentially dilutive common shares (2024 - <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20231001__20240930_zM4mHEQ3JuJ5" title="Loss per share for potentially dilutive common shares">15,047,754</span>; 2023 &#8211; <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230930_pdd" title="Loss per share for potentially dilutive common shares">14,271,780</span>) related to outstanding options and warrants,
as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zceoKf43s8ij" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_863_zClX3phJ8r49">Financial Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The book value of the Company&#8217;s financial instruments,
consisting of cash and equivalents, incentive and tax receivables, accounts payable and accrued liabilities approximate their fair value
due to the short-term maturity of such instruments. Unless otherwise noted, it is management&#8217;s opinion that the Company is not exposed
to significant interest, currency or credit risks arising from these financial instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_847_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zQ4n5Kxzx4L9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_zOW8TWby7Rkj">Foreign Currency Translation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The functional currency of the Company is the US dollar.
Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date
and non-monetary items are translated at exchange rates prevailing when the assets were acquired, or obligations incurred. Foreign currency
denominated expense items are translated at exchange rates prevailing on the transaction date. Unrealized gains or losses arising from
the translations are credited or charged to income in the period in which they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has determined that the functional currency
of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd. is also the US dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84E_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ze2L1H2uNjul" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86A_zRKtUWWLX863">Segment and Geographic Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determines and presents operating segments
based on the information that is internally provided to the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), its Chief
Executive Officer, in accordance with ASC 280, Segment Reporting. The Company has determined that it operates in a single business segment,
which is a clinical-stage biopharmaceutical company developing differentiated therapeutics by applying precision medicine to central nervous
system (&#8220;CNS&#8221;) diseases with high unmet need. Refer to Note 8 &#8211; Segmented Information for further information related
to the Company&#8217;s segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>














<p id="xdx_84F_ecustom--GrantIncomePolicyTextBlock_zEftaHZ3lpN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_z8TzpgSXhhE9">Grant Income</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Grant income is recognized at the fair value of the
grant when it is received, and all substantive conditions have been satisfied. Grants received from government and other agencies in advance
of the specific research and development costs to which they relate are deferred and recognized in the consolidated statements of operations
and comprehensive loss in the period they are earned, typically when the related research and development costs are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zDoEUYITEGC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zVQe3W1QkAn4">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC 740, which
requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and
liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying
amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC 740 regarding
accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more
likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently
measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax
authority assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information.
The Company considers many factors when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions
and tax benefits may not accurately anticipate actual outcomes. As additional information is obtained, there may be a need to periodically
adjust the recognized tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements
of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes interest and penalties related
to current income tax expense on the interest income, net line, in the accompanying consolidated statements of operations and comprehensive
loss. Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_841_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zzoJR4HR6L54" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_zbECW6HHmcb4">Share-based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for all share-based payments
and awards under the fair value method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of all share-based payments are expensed
over their contractual vesting period, or over the expected performance period for only the portion of awards expected to vest, in the
case of milestone-based vesting, with a corresponding increase to additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compensation costs for share-based payments with graded
vesting are recognized on a straight-line basis. Stock based compensation expense is adjusted for actual forfeitures of unvested awards
as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has granted share purchase option awards
that vest upon achievement of certain performance criteria, or milestone-based awards. The Company estimates an implicit service period
for achieving performance criteria for each award and recognizes the resulting fair value as expense over the implicit service period
when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its
estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest upon achievement
of the performance criteria.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the Black-Scholes option valuation
model to calculate the fair value of share-based awards at the date of the grant. This model requires the input of subjective assumptions,
including the expected price volatility and expected life of each&#160;award. The Company uses the U.S. Treasury daily treasury yield
curve rates for the expected term of the option as the risk-free rate. The expected term represents the period that options granted are
expected to be outstanding using the simplified method. Historically, the Company&#8217;s historical share option exercise experience
did not provide sufficient basis for estimating the expected term. Expected volatility is based on the average of the daily share price
changes over the expected term. The Company does not estimate forfeitures and elects to record actual forfeitures as they occur. The Company
has not paid any dividends on its common stock historically, therefore no assumption of dividend payments is made in the model. These
assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#8217;s
judgment. Changes in these assumptions can materially affect the fair value estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The purchase price of share-based compensation awards
may be paid in cash or, if approved by the Company&#8217;s compensation committee (or in the case of warrants by the Board of Directors)
in advance, &#8220;net settled&#8221; in shares of the Company&#8217;s common stock. In a net settlement of an share-based award, the
Company does not receive payment of the exercise price from the holder but reduces the number of shares of common stock issued upon the
exercise of the award by the smallest number of whole shares that have an aggregate fair market value equal to or over the aggregate exercise
price for the option shares covered by the instrument exercised. Shares issued pursuant to the exercise of options and warrants are issued
from the Company&#8217;s treasury.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z92M6wRNMox" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_zxkKj0wYCM0h">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the exchange price that would
be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair
value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes
the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities that the Company has the ability to access at the measurement date;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2025 and 2024, the Company did not
have any Level 2 or Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zyxIcg1Lt1u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_z5CZrOPiGmE6">Recently Adopted Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2023, the Financial Accounting Standards
Board (FASB) issued ASU No. 2023-07, &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221; This guidance requires
disclosure of incremental segment information on an annual and interim basis, including disclosure of the title and position of the Chief
Operating Decision Maker and requires that a public entity that has a single reportable segment to provide all the disclosures required
by the amendments in ASU No. 2023-07. The Company adopted the new standard effective September 30, 2025, and for subsequent interim periods.
Since ASU No. 2023-07 addresses only disclosures, the adoption of ASU No. 2023-07 did not have a significant impact on the Company&#8217;s
consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>














<p id="xdx_845_ecustom--RecentAccountingPronouncementsPolicyTextBlock_zpvzsd0U9Chf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_865_zVt6QSRQlqpi">Recent Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In December 2023, the FASB
issued ASU No. 2023-09, &#8220;Income Taxes:&#160;Improvements to Income Tax Disclosures.&#8221; This guidance requires consistent categories
and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment
is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2024, the FASB
issued ASU No. 2024-03, &#8220;Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures. The
amendments in ASU No. 2024-03 address investor requests for more detailed expense information and require additional disaggregated disclosures
in the notes to the financial statements for certain categories of expenses that are included on the face of the financial statements.
The guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after
December 15, 2027, with early adoption permitted. The Company is currently assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureAccruedLiabilitiesAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_AccuredLiabilitiesTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><p id="xdx_80D_ecustom--AccuredLiabilitiesTextBlock_zVboWXwlA6Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 3	<span id="xdx_82F_zQru5WRVent6">Accrued Liabilities</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The principal components of accrued liabilities consist of (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zEFXjdmOG7z5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Liabilities (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BA_zI3it03iRoGk" style="display: none">Schedule of principal components of accrued liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20250930_zyqxLuwprtle" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20240930_znZa56PfFcAk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
  <tr id="xdx_408_ecustom--AccruedInvestigatorPayments_iI_pn3n3_z91BpzDoygW5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Accrued investigator payments</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">96</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">860</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccruedBonusesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,562</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,527</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--MilestoneBasedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Milestone-based contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">523</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">557</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherAccountsPayableAndAccruedLiabilities_iI_pn3n3_z7ckRxVrVmq4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,711</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,891</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--TotalAccruedLiabilities_iTI_pn3n3_zK1vlMEb0Dl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total accrued liabilities</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,892</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,835</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AccuredLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AccuredLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OtherIncomeDisclosureTextBlock', window );">Other Income</a></td>
<td class="text"><p id="xdx_805_ecustom--OtherIncomeDisclosureTextBlock_z0okJWlDII35" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 4	<span id="xdx_82F_zfaCasMrBFNe">Other Income</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Grant income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of September 30, 2025,
the Company had received a $<span id="xdx_907_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20241001__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxFoundationMember_zFb5BginfwW5" title="Research and development incentive income">1</span>.0 million research grant awarded by the Michael J. Fox Foundation for Parkinson&#8217;s Research. The grant
will be used to fund a clinical trial of the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) related to Parkinson&#8217;s
disease. Of the total, $<span id="xdx_906_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20221001__20230930_zKQ4v4iMvXh4" title="Research and development incentive income">0.5</span> million was received during the year ended September 30, 2023 and $<span id="xdx_90B_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20201001__20210930_zbwgyCM3Qd8b" title="Research and development incentive income">0.5</span> million was received during the year
ended September 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The grant income has been
deferred when received and is being amortized to other income as the related research and development expenditures are incurred. During
the year ended September 30, 2025, the Company recognized $<span id="xdx_90E_ecustom--NonOperatingIncomeFromGrant_pn5n6_c20241001__20250930_z2wVNObUC3r4" title="Non operating income from grant">37,000</span> (2024: $<span id="xdx_902_ecustom--NonOperatingIncomeFromGrant_pn5n6_c20231001__20240930_zo7Pgibr0eDg" title="Non operating income from grant">75,000</span>; 2023: $<span id="xdx_909_ecustom--NonOperatingIncomeFromGrant_c20221001__20230930_pn5n6" title="Non operating income from grant">25,000</span>) of this grant on its statements of operations
within grant income. At September 30, 2025 an amount of $<span id="xdx_90D_ecustom--DeferredGrantIncome1_pn5n6_c20241001__20250930_zfjzuMk2QZs2" title="Deferred grant income">0.8</span> million (2024: $<span id="xdx_909_ecustom--DeferredGrantIncome1_pn5n6_c20231001__20240930_zsed7MY5Qs05" title="Deferred grant income">0.8</span> million) of this grant is recorded as deferred grant
income, representing the amount of this grant which has not yet been amortized to other income. The Company will recognize this income
on its statements of operations as the related expenditures are incurred to offset the income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Research and development
incentive income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Research and development
incentive income represents the income earned by Anavex Australia of the Australia R&amp;D credit. This cash incentive is received by
Anavex Australia, upon filing of a claim in connection with Anavex Australia&#8217;s annual income tax return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the year ended September
30, 2025, the Company recorded research and development incentive income of $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20241001__20250930_zyhXZ2WjcWVd" title="Research and development incentive income">0.6</span> million (AUD <span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20241001__20250930__srt--CurrencyAxis__currency--AUD_z0G6WBCwBb82" title="Research and development incentive income">1.0</span> million) (2024: $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240930_zboRkqIm1B" title="Research and development incentive income">2.3</span> million (AUD <span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240930__srt--CurrencyAxis__currency--AUD_zTiZVTCD76Ek" title="Research and development incentive income">3.5</span>
million); 2023: $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230930_zA7F2CU7m0Ni" title="Research and development incentive income">2.7</span> million (AUD <span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230930__srt--CurrencyAxis__currency--AUD_zT5bn2jEk2bh" title="Research and development incentive income">4.1</span> million)) in respect of the Australia R&amp;D credit for eligible research and development expenses
incurred during the year. This amount is included within Other income (expense) on the consolidated statements of operations and comprehensive
loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">At September 30, 2025, Incentive
and tax receivables includes $<span id="xdx_90A_eus-gaap--OtherReceivables_iI_pn5n6_c20250930_zpsCBrNkE8Hj" title="Incentive and tax receivables">0.7</span> million (AUD <span id="xdx_902_eus-gaap--OtherReceivables_iI_pn5n6_c20250930__srt--CurrencyAxis__currency--AUD_z5EWVo5e36be" title="Incentive and tax receivables">1.1</span> million) (2024: $<span id="xdx_903_eus-gaap--OtherReceivables_iI_pn5n6_c20240930_zmIXkejQmyke" title="Incentive and tax receivables">2.3</span> million (AUD <span id="xdx_909_eus-gaap--OtherReceivables_iI_pn5n6_c20240930__srt--CurrencyAxis__currency--AUD_zu9mNr4hNgP3" title="Incentive and tax receivables">3.3</span> million)) relating to Australia R&amp;D credits
earned during the year that are expected to be reimbursed upon filing of the Company&#8217;s annual claim under this program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Australia R&amp;D credit
program is a self-assess program whereby the Company must assess its eligibility each year to determine (i) if the entity is eligible
(ii) if the specific R&amp;D activities are eligible and (iii) if the individual R&amp;D expenditures have nexus to such R&amp;D activities.
The Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Anavex Australia is able to continue to claim the R&amp;D tax incentive for as long as it remains eligible and continues
to incur eligible research and development expenditures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Although the Company believes
that it has complied with all the relevant conditions of eligibility under the program for all periods claimed, the ATO has the right
to review the Company&#8217;s qualifying programs and related expenditures for a period of four years. If such a review were to occur,
the ATO may have different interpretations of certain eligibility requirements. If the ATO disagreed with the Company&#8217;s assessments
and any related subsequent appeals, it could require adjustment to and repayment of current or previous years&#8217; claims already received.
Additionally, if the Company was unable to demonstrate a reasonably arguable position taken on such claims, the ATO could also assess
penalties and interest on any such adjustments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Currently, the Company&#8217;s
tax incentive claims from 2020 to 2025 are open to potential review by the ATO. Additionally, the period open for review is indefinite
if the ATO suspects fraud. The Company has not provided any allowance for any such potential adjustments, should they occur in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureEquityOfferingsAbstract', window );"><strong>Equity Offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_EquityOfferingTextBlock', window );">Equity Offerings</a></td>
<td class="text"><p id="xdx_80F_ecustom--EquityOfferingTextBlock_zRYeKkgxLVs9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 5	<span id="xdx_821_zQTXlbtIMU17">Equity Offerings</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Board of Directors&#160;(the &#8220;Board&#8221;)&#160;has
the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number
of shares constituting any series or the designation of the series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2025 Sales Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 25, 2025, the Company entered into a Sales
Agreement (the &#8220;2025 Sales Agreement&#8221;) with TD Securities (USA) LLC (the &#8220;Sales Agent&#8221;). Pursuant to the 2025
Sales Agreement, the Company may offer and sell up to an aggregate offering price of $<span id="xdx_90B_ecustom--ValueOfSharesObligatedToPurchase_pn3n3_dm_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zj8GB2AoXg8a" title="Value of shares obligated to purchase">150</span> million (the &#8220;Offering&#8221;) in shares
of common stock from time to time through the Sales Agent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon delivery of a placement notice based on the Company&#8217;s
instructions and subject to the terms and conditions of the 2025 Sales Agreement, the Sales Agent may sell shares of common stock by methods
deemed to be an &#8220;at the market offering&#8221;, in negotiated transactions at market prices prevailing at the time of sale or at
prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to
the Company&#8217;s prior written consent. The Company is not obligated to make any sales of shares under the 2025 Sales Agreement. The
Company or the Sales Agent may suspend or terminate the Offering upon notice to the other party, subject to certain conditions. The Sales
Agent will act as sales agent on a commercially reasonable efforts basis consistent its normal trading and sales practices, applicable
state and federal law, rules and regulations and the rules of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has agreed to pay the Sales Agent commissions
for its services of up to&#160;3.0% of the gross proceeds from the sale of shares of common stock pursuant to the Sales Agreement. The
Company has also agreed to provide the Sales Agent with customary indemnification and contribution rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2025, the Company
issued <span id="xdx_903_eus-gaap--SharesIssued_iI_c20250930_zyjvy8YZOYv4" title="Common stock issued shares">927,910</span> shares of common stock for net proceeds of $<span id="xdx_908_eus-gaap--RedemptionPremium_pn3n3_dm_c20241001__20250930_zBHwAG4gwVa2" title="Common stock net proceeds">9.2</span> million pursuant to the 2025 Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2023 Purchase Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 3, 2023, the Company entered into a $150.0
million purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;),
pursuant to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $<span id="xdx_90F_ecustom--ValueOfSharesObligatedToPurchase_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z7EqpYMKIk1j" title="Value of shares obligated to purchase">150.0</span>
million in value of its shares of common stock from time to time over a three-year period until February 3, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the 2023 Purchase
Agreement, the Company issued to Lincoln Park <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zQcYwUOS2Lod" title="Share issued for offering, shares">75,000</span> shares of common stock as a commitment fee (the &#8220;initial commitment shares&#8221;)
and agreed to issue up to an additional <span id="xdx_907_ecustom--StockIssuedDuringPeriodValueNewIssues1_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zU6fyfMArFzi" title="Pro rata basic number of shares obligated to purchase">75,000</span> shares pro rata, when and if, Lincoln Park purchased, at the Company&#8217;s discretion,
the $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn3n3_dm_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zz4L6KMbsd98" title="Proceeds from issuance or sale of equity">150.0</span> million aggregate commitment. The Company determined the fair value of the initial commitment shares was $<span id="xdx_909_ecustom--FairValueOfInitialCommitment_iI_pn5n6_c20230930_zJBqs5uOEhtk" title="Fair value of the initial commitment">0.8</span> million with
reference to the closing price of the Company&#8217;s shares on the Purchase Agreement date. In addition, the Company incurred third party
expenses of $<span id="xdx_90B_ecustom--IncurredExpenses_iI_pn5n6_c20230930_zlAL1dQJV4F1" title="Incurred expenses">0.1</span> million in connection with entering into the Purchase Agreement. These amounts were expensed to other financing expense
on the statements of operations during the year ended September 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2025, the Company
did not issue any shares of common stock under the 2023 Purchase Agreement. During the year ended September 30, 2024, the Company issued
to Lincoln Park an aggregate of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20231001__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockIncludingCommitmentSharesMember_zG4l7ZvjtNE3" title="Number of shares issued, shares">2,455,646</span> shares of common stock under the 2023 Purchase Agreement, including <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockExcludingCommitmentSharesMember_zDEJXtBLySoe" title="Number of shares issued, shares">2,450,000</span> shares of common
stock for an aggregate purchase price of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_dm_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zuy4NyY9D1N3" title="Number of shares issued, value">11.3</span> million and <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommitmentSharesMember_zO3MTIC3nZj8" title="Number of shares issued, shares">5,646</span> commitment shares. During the year ended September 30, 2023, the Company
issued to Lincoln Park an aggregate of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockIncludingCommitmentSharesMember_zefqrGFq41vd" title="Number of shares issued, shares">3,288,943</span> shares of common stock under the 2023 Purchase Agreement, including <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockExcludingCommitmentSharesMember_zRKoC3QKcy4b" title="Number of shares issued, shares">3,275,000</span> shares
of common stock for aggregate proceeds of $<span id="xdx_901_ecustom--StockIssuedDuringPeriodValueNewIssues2_pn5n6_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zEchpl1UyS6c" title="Number of shares issued, value">27.9</span> million and&#160;<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommitmentSharesMember_zirlILwWijVk" title="Number of shares issued, shares">13,943</span>&#160;commitment shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2025, there was an unused amount
of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueOther_pn5n6_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zsvFtqHHMK29" title="Amount of shares remain available">110.8</span> million under the 2023 Purchase Agreement. The Company will need to file a prospectus supplement in order to access funds under
the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Exercise of Stock Options</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2025, the Company
issued&#160;<span id="xdx_90F_eus-gaap--SharesIssued_iI_pip0_c20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zKA4X7e03q83" title="Shares issued">217,503</span>&#160;shares of common stock to the Company&#8217;s Chief Executive Officer upon a net exercise of an option to purchase&#160;<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zHCh2lYflJAh" title="Exercise option shares purchase">500,000</span>&#160;shares
of common stock at an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z0K8goYCYl5l" title="Common stock exercise price">0.92</span>&#160;per share. In connection with the exercise, the Company withheld&#160;<span id="xdx_901_ecustom--CommonStockConsiderationExerciseShares_c20241001__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zptS1rPbLdAg" title="Common stock consideration exercise shares">47,745</span>&#160;shares
of common stock as consideration of the exercise price of $<span id="xdx_908_eus-gaap--StockOptionExercisePriceIncrease_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zXN8FJ0MntRl" title=" exercise price">0.46</span>&#160;million and&#160;<span id="xdx_904_eus-gaap--NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zZ4qo5NmjuGa" title="Consideration shares issued">234,752</span>&#160;shares of common stock as consideration
for the payment of $<span id="xdx_90E_eus-gaap--OtherSignificantNoncashTransactionValueOfConsiderationGiven1_pn3n3_dm_c20241001__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zfJ8OqevFlq2" title="Consideration payment">2.3</span>&#160;million in connection with tax withholding obligations associated with the exercise. The number of shares
withheld were based upon a market price of $<span id="xdx_90E_ecustom--MarketPrice_iI_pip0_c20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zy2fbb4B83Ed" title="Market price">9.63</span>&#160;per share as determined by reference to the average high and low sales price reported
on the Nasdaq stock exchange on the date of exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2025, the Company
issued&#160;<span id="xdx_900_eus-gaap--SharesIssued_iI_pip0_c20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zlqHCxA1saph" title="Shares issued">38,651</span>&#160;shares of common stock to a director of the Company upon a net exercise of an option to purchase&#160;<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_z2iMyzfF8dw8" title="Exercise option shares purchase">50,000</span>&#160;shares
of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20250930__srt--TitleOfIndividualAxis__custom--BoardMember_z5K9Xu1l2zXh" title="Common stock exercise price">1.76</span>&#160;per share. The Company withheld <span id="xdx_90E_ecustom--CommonStockConsiderationExerciseShares_pn3n3_c20241001__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zKBP2n6qVJfi" title="Common stock consideration exercise shares">11,349</span> shares of common stock as consideration of the
exercise price of $<span id="xdx_902_eus-gaap--OtherSignificantNoncashTransactionValueOfConsiderationGiven1_pn3n3_c20241001__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zi3z3HaXphyc" title="Consideration payment">88,000</span>. The number of shares withheld were based upon a market price of $<span id="xdx_90D_ecustom--MarketPrice_iI_pip0_c20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zT6drhsIPPg3" title="Market price">7.75</span>&#160;per share as determined by reference
to the average high and low sales price reported on the Nasdaq stock exchange on the date of exercise</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2025, the Company
issued&#160;<span id="xdx_90F_eus-gaap--SharesIssued_iI_pip0_c20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zeFZaTZ6dGf2" title="Shares issued">42,452</span>&#160;shares of common stock to the Company&#8217;s Chief Executive Officer upon a net exercise of an option to purchase&#160;<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_z86Ta8DByNQ6" title="Exercise option shares purchase">187,500</span>&#160;shares
of common stock at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zprUIgjB3PRl" title="Common stock exercise price">5.04</span>&#160;per share. In connection with the exercise, the Company withheld&#160;<span id="xdx_904_ecustom--CommonStockConsiderationExerciseShares_c20241001__20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOffice1rMember_zUPfuIALfIug" title="Common stock consideration exercise shares">98,643</span>&#160;shares
of common stock as consideration of the exercise price of $<span id="xdx_90D_eus-gaap--StockOptionExercisePriceIncrease_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zempGZr7JFYd" title=" exercise price">0.9</span>&#160;million and&#160;<span id="xdx_904_eus-gaap--NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zTHUd0TFfjdk" title="Consideration shares issued">46,405</span>&#160;shares of common stock as consideration
for the payment of $<span id="xdx_907_eus-gaap--OtherSignificantNoncashTransactionValueOfConsiderationGiven1_pn3n3_dm_c20241001__20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zXKWeicBVcI9" title="Consideration payment">0.4</span>&#160;million in connection with tax withholding obligations associated with the exercise. The number of shares
withheld were based upon a market price of $<span id="xdx_906_ecustom--MarketPrice_iI_pip0_c20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zv3nATBsxgqc" title="Market price">9.58</span>&#160;per share as determined by reference to the closing price reported
on the Nasdaq stock exchange on the date of exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureEquityOfferingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureEquityOfferingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EquityOfferingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EquityOfferingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_804_eus-gaap--CommitmentsDisclosureTextBlock_zalZYt2KeFV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 6	<span id="xdx_82E_z9NKLvS885p2">Commitments and Contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Lease</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company leases office space under an operating lease with an initial term of <span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20250930_zG4Pg7b23bOh" title="Operating lease term">12</span> months or less. Under the terms of the office lease, the
Company is required to pay its proportionate share of operating costs. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
operating lease costs were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--LeaseCostTableTextBlock_pn3n3_zLGK3MGNJdu8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B4_zO1LJNj6anr4" style="display: none">Schedule of operating lease costs</span></td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49A_20241001__20250930_zIJOpFzaZD61" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49E_20231001__20240930_zZipdRTLjkMb" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_491_20221001__20230930_z67COQZbK2se" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="11" style="font-weight: bold; text-align: center">Years ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseCost_zWMuXvMMUw3a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Operating lease costs</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">134</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">125</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">118</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zMgEw3HONocf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employee 401(k) Benefit Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based
employees. United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the
Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing
employees. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company made matching contributions under the 401(k) plan as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_ze32GXQdn995" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B9_zV9yNdYZC4wk" style="display: none">Schedule of contributions under the plan</span></td><td style="color: black; font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_495_20241001__20250930_zOHLuBnpjGgk" style="color: black; font-weight: bold; text-align: center">&#160;</td><td style="color: black; font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49C_20231001__20240930_zHvshI3hnLy" style="color: black; font-weight: bold; text-align: center">&#160;</td><td style="color: black; font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49D_20221001__20230930_zjLfn9CR0Wtk" style="color: black; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold">&#160;</td>
    <td colspan="11" style="color: black; font-weight: bold; text-align: center">Years ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2025</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2024</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40C_eus-gaap--PensionContributions_z8DWIeNHh9s6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; color: black; text-align: left; text-indent: -10pt">Contributions to 401(k) plan</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">255</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">279</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">232</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zQ6RHsNUWttd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Litigation </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company
is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there
can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter
will not have a material adverse effect upon the Company&#8217;s consolidated financial statements. The Company does not believe that
any of such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On March 13,
2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York and it
named the Company and an officer of the Company as Defendants. The complaint was amended on July 12, 2024 (the &#8220;Initial Action&#8221;).
The complaint alleged violations of the Securities and Exchange Act of 1934 associated with disclosures and statements made with respect
to certain clinical trials for ANAVEX<sup>&#174;</sup>2-73 related to Rett syndrome. This lawsuit was dismissed by the United States District
Court for the Southern District of New York on June 18, 2025. The plaintiff filed a notice of appeal on July 17, 2025. Briefing on the
appeal concluded October 30, 2025. No decision has been entered. No amount has been recorded in these consolidated financial statements
for any loss contingencies associated with this lawsuit as the Company believes that it is not probable that any loss will occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On May 8, 2024,
a similar complaint was filed in the same court by Kenneth Downing, a purported shareholder of the Company, against the same defendants.
The Company believed that this lawsuit was also without merit and filed a motion to dismiss the complaint. Plaintiff Downing voluntarily
dismissed this complaint subsequent to the filing of the motion to dismiss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On or about
May 13, 2024, a derivative lawsuit was filed against the Company (as nominal defendant), an officer of the Company, and members of the
Company&#8217;s Board of Directors in the U.S. District Court for the District of Nevada by another purported shareholder. The complaint
asserts various common law claims (including breach of fiduciary duty) and violation of Section 14(a)of the Securities Exchange Act regarding
the same or similar allegations at issue in the purported class action lawsuit related to disclosures and statements made about certain
clinical trials related to Rett <span style="background-color: white">syndrome</span>. On January 22, 2025, pursuant to a stipulation of the parties, the Court entered an order staying
this purported derivative lawsuit until the motion to dismiss filed by defendants in the Initial Action is decided by the U.S. District
Court for the Southern District of New York.&#160;The stay has been extended through the appeal. No amount has been recorded in these
consolidated financial statements for any loss contingencies associated with this lawsuit as the Company believes that it is not probable
that any loss will occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On February
14, 2025, another derivative lawsuit asserting state law breach of fiduciary duty and unjust enrichment claims based upon similar allegations
was filed against the Company (as nominal defendant), an officer of the Company, and members of the Company&#8217;s Board of Directors
in the Supreme Court for the State of New York, County of New York, by another purported shareholder. On August 18, 2025, pursuant to
a stipulation of the parties, the Court entered an order staying this purported derivative lawsuit until the appeal in the Initial Action
is resolved. No amount has been recorded in these consolidated financial statements for any loss contingencies associated with this lawsuit
as the Company believes that it is not probable that any loss will occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">We know of no
other material pending legal or governmental proceedings, other than ordinary routine litigation incidental to our business, to which
our Company or our subsidiaries are a party or of which any of their property is subject. There are no other proceedings in which any
of our directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, or any associate
of such persons, is an adverse party or has a material interest adverse to our or our subsidiaries&#8217; interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Share Purchase Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2025 and 2024, the Company had <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pip0_c20250930_zo6jODIXnLS9" title="Warrants outstanding">10,000</span>
share purchase warrants outstanding exercisable at $<span id="xdx_90C_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_pip0_c20250930_zoHxLrcYIqDc" title="Warrants outstanding weighted average exercise price">12.00</span> per share until April 21, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock&#8211;based Compensation
Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2015 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 18, 2015, the Company&#8217;s Board approved
a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pip0_c20250930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zChHJPklfVAb" title="Maximum number of common shares reserved for future issuance">6,050,553</span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2019 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20241001__20250930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_z5JvNOjJID3i" title="Additional shares of common stock available for issuance">6,000,000</span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2022, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pip0_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zlCzeT2zmxN9" title="Option granted">406,453</span>
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2022 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20220324__20220325__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_ztuTolYVP7Dl" title="Additional shares of common stock available for issuance">10,000,000</span> additional shares of Common Stock will be available for issuance under the plan, in addition to the shares available
under the 2019 Plan and the 2015 Plan. Any awards outstanding under a previous stock option plan will remain subject to and be paid under
such plan, and any shares subject to outstanding awards under a previous plan that subsequently cease to be subject to such awards (other
than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then
the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date. Stock
options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser
periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 17, 2025, the Board approved an amendment
to the 2022 Plan (the &#8220;Amendment&#8221;). The Amendment was approved by the stockholders on June 10, 2025. The Amendment increased
the number of shares of common stock reserved for issuance under the 2022 Plan by 4,000,000 shares for a total of&#160;<span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20250417_zrhURZu8OwRh" title="Number of shares of common stock reserved for issuance">14,000,000</span>. In
addition, the Amendment established a minimum vesting period of one year for all awards granted under the 2022 Plan and limited the discretion
to accelerate the vesting of awards upon a separation from service, with limited exceptions permitted. Finally, the Amendment prohibited
liberal share recycling provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2025, <span id="xdx_907_ecustom--OptionIssued_pip0_c20241001__20250930_zf9Lq2z2KnQi" title="Option issued">6,504,829</span> options had been
issued under the 2022 Plan and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pip0_c20250930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_z2K8OoxsPTs7" title="Option available issue">8,436,882</span> options were available for issue under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock option
activity during the years ended September 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zMAuyzGA2ub8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BA_zE5YjSoz9rzc" style="display: none">Schedule of stock option activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="color: white">&#160;</td>
    <td style="color: white; text-align: left">&#160;</td><td style="color: white; text-align: right">&#160;</td><td style="color: white; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price <br/> ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value <br/> ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Aggregate intrinsic value <br/> ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 44%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, September 30, 2024</span></td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrDrKVnujtdg" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Number of options, Outstanding beginning balance">15,037,754</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3ZDZFyqWmI6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average exercise price, Outstanding beginning balance">6.80</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsE1B6uFOVd5" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average grant date fair value, Outstanding beginning balance">5.12</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1errfXlh8Yg" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Aggregate intrinsic value, Outstanding beginning balance">15,825,791</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAYcb0woC0k3" style="text-align: right" title="Number of options, Granted">1,488,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMNxguD2E3j5" style="text-align: right" title="Weighted average exercise price, Granted">8.58</td><td style="text-align: left">&#160;</td><td style="color: white">&#160;</td>
    <td style="color: white; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znhJQVsdiI8d" style="text-align: right" title="Weighted average grant date fair value, Granted">6.22</td><td style="color: white; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Expired</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zybc6fWFW7ha" style="text-align: right" title="Number of options, Expired">(100,100</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfJ264tHNym7" style="text-align: right" title="Weighted average exercise price, Expired">16.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercised</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKTyWPdQWJcf" style="text-align: right" title="Number of options, Exercised">(1,383,988</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsXbjubtAJjb" style="text-align: right" title="Weighted average exercise price, Exercised">3.21</td><td style="text-align: left">&#160;</td><td style="color: white">&#160;</td>
    <td style="color: white; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfcBnIF9bMaj" style="text-align: right" title="Weighted average grant date fair value, Exercised"><span style="font-size: 10pt"></span> <span style="font-size: 10pt">1.31</span></td><td style="color: white; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzfG4883Xg2g" style="text-align: right" title="Aggregate intrinsic value, Exercised">9,324,901</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFBlpfLp5kQe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Forfeited">(80,583</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfjSLbhDqvtl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited">4.56</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5ObKFMoJrWc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Forfeited">0.55</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, September 30, 2025</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z19ucprLcgS7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Outstanding ending balance">14,961,583</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zV9rYvQy4sud" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Outstanding ending balance">7.25</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1rKyhJroJkc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Outstanding ending balance">5.46</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z344IAKZum9l" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, Outstanding ending balance">39,715,608</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercisable, September 30, 2025</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zPQI44vUCf11" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Exercisable">10,418,213</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoSubcAxPJQk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable">6.22</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsFc6cCSWnW3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Exercisable">4.83</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbEMxWQ89kt1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Exercisable">34,762,588</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zeMQOFGsKuK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock options
at September 30, 2025 by a range of exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zZvFeODwATQj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_8B3_zXiu7b3JvkEl" style="display: none">Schedule of summarizes information about stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="7" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Range of exercises prices</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Number of outstanding</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted average remaining contractual life</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted average exercise</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Number of vested</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted average exercise</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">From</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">To</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">(in years)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">price</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">price</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zxYN7hHqR4B9" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Range of exercise prices, Lower range limit">2.30</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zsqM0silFxBa" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Range of exercise prices, Upper range limit">5.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zhkFOTBe0x44" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of outstanding options">4,315,700</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zsBDyLEeDv1g" title="Weighted average remaining contractual life">3.15</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zmX1s7evjBc3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price">3.02</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zxNeCJnLt3Ek" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of vested options">4,220,283</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zWWJ8Ja45XEc" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price options vested">2.99</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zXqfKH8v7tB4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit">5.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_ztKJ50TDZAaa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit">7.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zwtchAcDnVy5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options">3,299,536</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zOD4KFHqLWFc" title="Weighted average remaining contractual life">5.23</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zMXVApfwnbye" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price">5.62</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z6QnwWX4Ditg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options">2,325,162</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zZAVuBEYr4gh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested">5.72</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zUht1UO2aex1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit">7.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zfqeQDM5ew0f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit">9.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z2UPuVTMYFS3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options">4,372,347</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zTKSmHCQIUel" title="Weighted average remaining contractual life">6.66</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zbO88lQNtoPj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price">8.09</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z5M04ry9PRAj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options">2,222,101</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z2qn76qyieRk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested">7.82</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_znVh8X6kNeCj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit">9.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z3RjfNfj6a07" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit">13.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_ziNfLlIh6zNi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options">1,609,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zZiMFdT9M54l" title="Weighted average remaining contractual life">6.31</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zMJwqgNnrXte" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price">10.29</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zlxWmYRpuc35" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options">1,120,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zzv1vXIqLBue" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested">10.37</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z1WTTJpPSKbb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit">13.01</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zH4K4ZLjlZC8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit">25.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z7on3N9dOCcc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options">1,365,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zT4jk8nQvG57" title="Weighted average remaining contractual life">5.91</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zktkXtOXgkH9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price">18.33</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zY3g27ILay83" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options">530,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zBp15L52zgqg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested">18.67</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z88YIicqOvj6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options">14,961,583</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBaB9MhtDPrb" title="Weighted average remaining contractual life">5.22</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBXUBkfD88Fb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price">7.25</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNZ6TnWEEXM8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options">10,418,213</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6okIJiIgxGk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested">6.22</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AB_zwUrGWiovHth" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average per share fair value of options
vested at September 30, 2025 was $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20241001__20250930_zXe09v8Nrp0g" title="Weighted average grant date fair value of options vested">4.83</span> (2024: $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20231001__20240930_zDmfeLFZWZXg" title="Weighted average grant date fair value of options vested">4.34</span>; 2023: $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20221001__20230930_zimoxsiShoF5" title="Weighted average grant date fair value of options vested">3.94</span>). At September 30, 2025, the weighted average contractual life of options
outstanding was <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930_zEqoepsiaxR1" title="Weighted average contractual life of options outstanding">5.22</span> years (2024: <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930_zE1fHsCVaO78" title="Weighted average contractual life of options outstanding">5.48</span> years; 2023: <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230930_zOkLtOJoSRe2" title="Weighted average contractual life of options outstanding">6.0</span> years) and for options exercisable was <span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930_zpMC8suFkDw" title="Options exercisable">4.11</span> years (2024: <span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930_zyZwf0KNFeDh" title="Options exercisable">4.03</span> years; 2023: <span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230930_zLZyD2LSSVWd" title="Options exercisable">4.75</span>
years).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the options
that were in-the-money at September 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">	The Company recognized share-based compensation
expense of $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20241001__20250930_zZUO3WW2hmof" title="Share based compensation">11.5</span> million during the year ended September 30, 2025 (2024: $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20231001__20240930_zSG8NjUafQmc" title="Share based compensation">9.4</span> million; 2023: $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20221001__20230930_zItd0E1Ahml4" title="Share based compensation">16.4</span> million) in connection with the issuance
and vesting 	of stock options in exchange for services. These amounts have been included in general and 	administrative expenses
and research and development expenses on the Company&#8217;s consolidated statements of 	operations as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zy1ul9YLEJZ4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B6_znpz9vQT6TPl" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="11" style="font-weight: bold; text-align: center">Years ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zMMfe5cVuu5c" style="width: 11%; text-align: right" title="Total share based compensation">4,536</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHWirUELtqqe" style="width: 11%; text-align: right" title="Total share based compensation">3,625</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zFn7iKSnTNkg" style="width: 11%; text-align: right" title="Total share based compensation">5,558</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zaiJwxtkDUMe" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">7,013</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zqLuPraCrmB6" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">5,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zr4kWOUUKPc6" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">10,812</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total share-based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930_zI3bl7GkOB54" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">11,549</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930_zjWKBnIfnP51" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">9,438</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930_zViBeqdRp5qj" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">16,370</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8A9_zjfcyIweY4yh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An amount of approximately $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20250930_z6RQETTxpAQ2" title="Remaining stock based compensation">6.3</span> million in share-based
compensation is expected to be recorded over the remaining term 	of such options and warrants through fiscal 2029.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">The fair value of each option and
warrant award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_zkFvazW9RlF" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BB_zs6JLQseyw75" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20241001__20250930_zvlq3707ODsh" title="Risk-free interest rate">3.98</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20231001__20240930_znVjDE6iMPAf" title="Risk-free interest rate">4.28</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20221001__20230930_zRhCY04Mi2y2" title="Risk-free interest rate">3.70</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20241001__20250930_zaWkTo9C2cj2" title="Expected life of options (years)">5.57</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240930_zBB0jUO5Ejr" title="Expected life of options (years)">5.78</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230930_zspTKYDKT6Ee" title="Expected life of options (years)">5.64</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20241001__20250930_zRD3GocNYn87" title="Annualized volatility">86.49</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20231001__20240930_zJlr6T9OaP24" title="Annualized volatility">84.81</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20221001__20230930_zoZva1sCuFIk" title="Annualized volatility">85.13</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20241001__20250930_z6KTW8JNaUX9" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20231001__20240930_zaiICJexi8Ml" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20221001__20230930_z3tTbZw1FGa8" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8AE_zyyYVoRU9ir3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of stock compensation charges recognized
during the years ended September 30, 2025, 2024 and 2023 was determined with reference to the quoted market price of the Company&#8217;s
shares on the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>














<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--IncomeTaxDisclosureTextBlock_ziHkRR5Bh728" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 7	 	<span id="xdx_82F_zCiWeAJSiPml">Income Taxes </span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s U.S. and foreign losses before income
taxes are set forth below (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_pn3n3_zgKs5dfVY5l5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"><span id="xdx_8B7_zzFnLgkQPPoi" style="display: none">Schedule of loss before income taxes</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20241001__20250930_z5MJb7OW8u69" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20231001__20240930_zFTtjaLIsDAh" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20221001_20230930" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">United States</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(44,500</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(39,195</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(41,198</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,877</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,807</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,300</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(46,377</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(43,002</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(47,498</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A6_zV0AvDCRTxC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended September 30, 2025, 2024 and 2023, there were no
current or deferred income tax provisions (benefits) for any U.S. federal, state &amp; local, and foreign jurisdictions. The components
of net deferred income tax assets as of September 30, 2025 and 2024 are as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_z6GPFZ33krw8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt">Schedule of components of net deferred income tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20250930_zOY5k9iTWpFk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20240930_zjQgJ3N6VP5j" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net operating loss carryforwards</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">54,752</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">48,134</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development tax credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,288</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,203</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,185</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,091</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsResearchAndDevelopmentCapitalization_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development capitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,737</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,104</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Unpaid charges</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,843</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,197</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Intangible asset costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">946</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">758</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ForeignExchangeAndOther_iNI_pn3n3_di_zOVd3Vxooh6e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign exchange and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(259</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(254</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_zYf0Q9J5VkZ4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Valuation allowance of deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(108,492</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(92,233</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0991">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0992">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zN93NJrimqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of income tax expense at the statutory
federal income tax rate and income taxes as reflected in the consolidated financial statements for the years ended September 30, 2025,
2024 and 2023 is as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_pn3n3_z4dOHPfPkGL9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zKPJn14YVjM9" style="display: none">Schedule of reconciliation of income tax expense</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20241001__20250930_zHrqqR1Sedf8" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20231001__20240930_z8d0FFMP0se1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20221001__20230930_znWxur4eJxqc" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Income tax benefit at statutory federal rate</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(9,739</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(9,030</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(9,975</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign income taxed at other rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1000">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(61</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--PermanentDifferencesRelatingToStockBasedCompensation_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Permanent differences relating to share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,219</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(601</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationGiltiAmount_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Permanent differences relating to GILTI inclusion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1009">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(276</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">273</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development credits, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(941</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(860</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(37</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">State and local taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,672</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,821</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,122</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Adjustment to true up to prior years&#8217; tax provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">182</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,128</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance_zahCpujyiQi2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Change in valuation allowances</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">16,259</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,186</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14,098</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Income tax expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1032">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zs7Ty23yYUHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2025, the Company had U.S. federal
net operating loss carryforwards of approximately $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_pn5n6_c20250930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zIT809G1wVXi" title="Operating loss carryforwards">148.8</span> million (2024: $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_pn5n6_c20240930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zDDBNxm6IMIh" title="Operating loss carryforwards">128.5</span> million) of which <span id="xdx_903_ecustom--OperatingLossCarryforwardsDescription_c20241001__20250930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_z6ZDzmnCuXh1" title="Operating loss carryforwards description">$37.7</span> million will begin to expire in
2026 and $111.2 million can be carried forward indefinitely, state and local net operating loss carryforwards of approximately $ <span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_pn5n6_c20250930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z3WXKe40ojNj" title="Operating loss carryforwards">19.1</span>
million (2024: $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_pn5n6_c20240930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zj8nZX6iACK" title="Operating loss carryforwards">16.9</span> million) which will begin to expire in <span id="xdx_901_ecustom--OperatingLossCarryForwardsExpirationYear_c20241001__20250930_zxVIrL1KmEI" title="Operating loss carry forwards expiration year">2036</span>, and Research and Development tax credits of approximately $<span id="xdx_90B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_pn5n6_c20241001__20250930_zq9QfxYlsJu5" title="Research and Development tax credits">5.3</span> million
(2024: $<span id="xdx_90A_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20221001__20230930_pn5n6" title="Research and Development tax credits">4.3</span> million) which will begin to expire in <span id="xdx_906_ecustom--ResearchAndDevelopmentTaxCreditsYear_c20241001__20250930_zvGoZpeSY8g1" title="Research and development tax credits year">2029</span>. The calculation of the Research and Development tax credits, by their nature,
involve estimates and subjectivity. If examined by the U.S. federal and state tax authorities, it is possible that some portion of these
credit carryforwards would be disputed by the tax authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company had approximately $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_pn5n6_c20250930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zsNPX58GEVUg" title="Operating loss carryforwards">17.1</span> million (approximately
AU$<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_pn5n6_c20250930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_z4k1lkTZXCJh" title="Operating loss carryforwards">25.9</span> million) (2024: $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_pn5n6_c20240930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zx7knFevFoXe" title="Operating loss carryforwards">16.6</span> million (approximately AU$<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_pn5n6_c20240930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_znwFH72WmEX9" title="Operating loss carryforwards">23.9</span> million)) of net operating loss carryforwards in Australia, which have an
indefinite life, available to offset future taxable income in those jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates its valuation allowance
requirements based on available evidence. When circumstances change, and this causes a change in management&#8217;s judgment about
the recoverability of deferred tax assets, the impact of the change on the valuation allowance is reflected in current income.
Because management of the Company does not currently believe that it is more likely than not that the Company will receive the
benefit of these assets, a full valuation allowance has been established at September 30, 2025 and 2024. During the year ended
September 30, 2025, the valuation allowance increased by $<span id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20241001__20250930_z9rGW6yiJXwa" title="Decrease in valuation allowance">16.3</span>
million (2024: $<span id="xdx_907_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20231001__20240930_zYd0Viq4W3rd" title="Decrease in valuation allowance">15.2</span>
million; 2023: $<span id="xdx_90B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20221001__20230930_zQg4RSi4E1N2" title="Decrease in valuation allowance">14.1</span>
million).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Tax Cuts and Jobs Act of 2017 (TCJA) has
modified the treatment of IRC 174 expenses related to research and development for tax years beginning after December 31, 2021.
Under the TCJA, the Company must capitalize the expenditures related to research and development activities and amortize them over
 5 years for U.S. activities and over 15 years for non-U.S. activities using a mid-year convention. Therefore, the capitalization of
research and development costs in accordance with IRC 174 has resulted in a net deferred tax assets at September 30, 2025 of $<span id="xdx_901_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_dm_c20250930_z5eSnKSjyeR3" title="Gross deferred tax asset">20.7</span>
million (2024: $<span id="xdx_900_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_dm_c20240930_zPXHgII3Xyia" title="Gross deferred tax asset">15.1</span>
million). On July 4, 2025, the United States President signed into law the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;), a
budget reconciliation package that changes many key provisions of the U.S. federal income tax code, including extensions of various
expiring provisions from the TCJA. The new legislation, which will be effective for the Company beginning in fiscal 2026, will now
allow for more tax-payer favorable treatment of domestic research and development expenditures for US income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Uncertain Tax Positions</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company files income tax returns in the U.S. federal
jurisdiction and various state and local and foreign jurisdictions. The Company&#8217;s tax returns are subject to tax examinations by
U.S. federal and state tax authorities, or examinations by foreign tax authorities until the respective statutes of limitation expire.
The Company is subject to tax examinations by tax authorities for all taxation years commencing on or after 2005.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the provisions of the Internal Revenue Code,
the net operating loss (&#8220;NOL&#8221;) carryforwards are subject to review and possible adjustment by the Internal Revenue Service
and state tax authorities. Under Section 382 of the Internal Revenue Code, NOL and tax credit carryforwards may become subject to an annual
limitation in the event of an over 50% cumulative change in the ownership interest of significant stockholders over a three-year period,
as well as similar state tax provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company conducts a Section 382 study annually
and has reduced its federal NOLs by $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20250930_zHiwV7YXLFM7" title="Operating loss carryforwards">12.1</span> million and its Research and Development tax credit carryforwards by $<span id="xdx_902_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_dm_c20250930_zz1wK7r4ljPf" title="Research and development tax credit carryforwards">0.8</span> million, which are
the amount of tax assets that will expire unutilized pursuant to Section 382. Subsequent ownership changes in future years could trigger
additional limitations of the Company&#8217;s NOLs<span style="background-color: white">. During the year ended September 30, 2025, the
Company determined that there were no changes in ownership pursuant to Section 382.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2025, the Company did not provide
any foreign withholding taxes related to its foreign subsidiaries&#8217; undistributed earnings, as such earnings have been retained and
are intended to be indefinitely reinvested to fund ongoing operations of the foreign subsidiaries. It is not practicable to estimate the
amount of taxes that would be payable upon remittance of these earnings, because such tax, if any, is dependent upon circumstances existing
if and when remittance occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2025 and 2024, the Company had determined that no liabilities
for uncertain tax positions, interest or penalties were required to be recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmented Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segmented Information</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--SegmentReportingDisclosureTextBlock_zzQV2YJU41o2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 8	<span id="xdx_821_zn5pQPMSkFpj">Segmented Information</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating segments are defined as components of an
entity for which separate financial information is available and regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;)
in deciding how to allocate resources and assess performance. The Company&#8217;s CODM is the Chief Executive Officer. The Company has
determined that it operates in a single operating segment, which consists of the development of clinical and preclinical product candidates
focused on advancing novel therapeutics for CNS diseases and disorders, and related administrative activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accounting policies of the segment are the same
as those described in the summary of significant accounting policies. The CODM evaluates performance and allocates resources based on
consolidated net loss, as presented in the Company&#8217;s consolidated statement of operations, and monitors forecast-to-actual variances
for significant expense categories given their direct relationship to cash burn. The CODM also reviews the consolidated balance sheet
to assess liquidity, funding capacity, and segment assets, which are reported as total consolidated assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The CODM receives and reviews financial information
on a consolidated basis and does not assess performance or allocate resources based on geographic regions. In addition, management does
not internally organize or evaluate operating results by geography. Accordingly, management has determined that it is not required to
present financial information disaggregated by geographic region under ASC 280.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below summarizes the significant expense categories regularly
reviewed by the CODM for the years ended September 30, 2025, 2024 and 2023 (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_pn3n3_zjxBEOPR4tqc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segmented Information (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span id="xdx_8BF_zYgw4UzcBeSd" style="display: none">Schedule of summarizes the significant expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20241001__20250930_zLHHUDIGsfxd" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20231001__20240930_zKk7pL1wdZwe" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20221001__20230930_zMYAJn06VFw8" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; width: 46%; text-align: left; text-indent: -10pt">Preclinical studies</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zFrZBm3FoeY9" style="width: 11%; text-align: right" title="Research and development costs">543</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zxp07xxy7yY7" style="width: 11%; text-align: right" title="Research and development costs">663</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zH9KDDhEzkph" style="width: 11%; text-align: right" title="Research and development costs">627</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Clinical trials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_z1WONuLox7we" style="text-align: right" title="Research and development costs">15,805</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_zuj3PHG4gT9a" style="text-align: right" title="Research and development costs">21,301</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_zcUamCUFHlx8" style="text-align: right" title="Research and development costs">21,873</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Personnel costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_z2yP8sByQ5me" style="text-align: right" title="Research and development costs">13,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zpO21lKV8dJ5" style="text-align: right" title="Research and development costs">13,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zQXUpJcSUJy2" style="text-align: right" title="Research and development costs">10,264</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Non-cash share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z60xdm80O0He" style="text-align: right" title="Research and development costs">7,013</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z2I3TxlZGWl2" style="text-align: right" title="Research and development costs">5,813</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_zFJDZrcFbA51" style="text-align: right" title="Research and development costs">10,812</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Other research and development costs<sup>(a)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zZTM1o5KWTAl" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development costs">765</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zY2z0BJ6cNu" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development costs">385</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zPV5eE24LOyd" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development costs">141</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total research and development costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930_znLAEUCsjnY4" style="font-weight: bold; text-align: right" title="Research and development costs">37,592</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930_zgxBsosS3X9f" style="font-weight: bold; text-align: right" title="Research and development costs">41,838</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930_zuC4GxaJ0iW2" style="font-weight: bold; text-align: right" title="Research and development costs">43,717</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">General and administrative costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Personnel costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zh6aOjZq8sT4" style="text-align: right" title="General and administrative costs">2,288</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zpYJz6yuFcz" style="text-align: right" title="General and administrative costs">2,177</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zRa7H2ZF3xv9" style="text-align: right" title="General and administrative costs">2,527</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Non-cash share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_zuYd8YPkHrFd" style="text-align: right" title="General and administrative costs">4,536</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z97W6Cm3eqO" style="text-align: right" title="General and administrative costs">3,625</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z05ZWu0DGffg" style="text-align: right" title="General and administrative costs">5,558</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Other general and administrative costs<sup>(b)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zmqi0fztDEVc" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative costs">6,992</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_z1zIttFFD8tg" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative costs">5,237</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zWYlj8jzeV3k" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative costs">3,961</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total general and administrative costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930_z84cBtzE4JTa" style="font-weight: bold; text-align: right" title="General and administrative costs">13,816</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930_zRTSScKRdqce" style="font-weight: bold; text-align: right" title="General and administrative costs">11,039</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930_zMzJBfRDgPl9" style="font-weight: bold; text-align: right" title="General and administrative costs">12,046</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OtherIncome_c20241001__20250930_zSQrsMX0gtDl" style="border-bottom: Black 1pt solid; text-align: right" title="Other income">5,031</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--OtherIncome_c20231001__20240930_zBzEhImJe7Bb" style="border-bottom: Black 1pt solid; text-align: right" title="Other income">9,875</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--OtherIncome_c20221001__20230930_z7gQovPJrPY7" style="border-bottom: Black 1pt solid; text-align: right" title="Other income">8,258</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net loss</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--NetIncomeLoss_c20241001__20250930_zHoQRnoi8oKd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net Loss">(46,377</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--NetIncomeLoss_c20231001__20240930_zBcrRhrJpkXd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net Loss">(43,002</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--NetIncomeLoss_c20221001__20230930_zUh6s7Tme0V" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net Loss">(47,505</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(a)</td><td style="text-align: justify">Other research and development costs include, but are not limited to, publications, sponsorships, membership fees, scientific conferences,
and medical affairs strategy and branding.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(b)</td><td style="text-align: justify">Other general and administrative expenses include, but are not limited to, office rent, public company reporting requirements including
professional fees, insurance, and other general operating expenses not otherwise included in research and development expenses.</td></tr></table>

<p id="xdx_8AA_zaEsEC3Uej16" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_z809reeRPkY6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 9	<span id="xdx_82C_zREFbpQGHIe3">Subsequent Events</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates subsequent events occurring
between the most recent balance sheet date and the date the financial statements are available to be issued in order to determine whether
the subsequent events are to be recorded and/or disclosed in the Company&#8217;s financial statements and footnotes. The financial statements
are considered to be available to be issued at the time they are filed with the Securities and Exchange Commission (SEC).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no subsequent events or transactions that
required recognition or disclosure in the consolidated financial statements.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_841_eus-gaap--UseOfEstimates_zxon4wP4Wia2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_zde3wXM9zkBb">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive and tax receivables, valuation and recoverability
of deferred tax assets, share based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zVD4XzL1tzEb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_zpCBy5brpQk2">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and equivalents</a></td>
<td class="text"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zD8NNHkBuK9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zLtybN7cq6Qd">Cash and equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>The Company considers only
those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to
be cash equivalents</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">Highly
liquid investments that are considered cash equivalents include money market&#160;accounts, money market&#160;funds&#160;and&#160;certificates
of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities. The Company&#8217;s
investment policy allows for investments in domestic money market certificates, certificates of deposit, money market funds, bonds or
commercial papers, and establishes diversification and credit quality requirements and limits investments by maturity and issuer. The
Company currently maintains the majority of its investments at one large well known financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the
Federal Deposit Insurance Corporation (FDIC) up to $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_pp0p0_c20250930_zE1i1FXPrd3j" title="Federal deposit insurance corporation">250,000</span>, under current regulations. At September 30, 2025 and 2024, substantially
all of the Company&#8217;s cash balances were in excess of these federally insured limits. The Company mitigates this risk by maintaining
the majority of its cash balances in a large well-known financial institution. The Company has not experienced any losses in such accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ResearchAndDevelopmentExpensePolicy_zApC1CPXlzx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_zfNu11ZjOfR9">Research and Development Expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed as incurred.
These expenses are comprised of the costs of the Company&#8217;s proprietary research and development efforts, including preclinical studies,
clinical trials, manufacturing costs, employee salaries and benefits and share-based compensation expense, contract services including
external research and development expenses incurred under arrangements with third parties such as contract research organizations (&#8220;CROs&#8221;),
facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when
the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification
(&#8220;ASC&#8221;) 730, <i>Research and Development</i>, as these materials have no alternative future use outside of their intended
use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nonrefundable advance payments for goods or services
that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods
are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs
incurred in relation to external CROs, and clinical site costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes
progress of the trials and studies including the phase or completion of events, invoices received and contracted costs. Judgments and
estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s
estimates. The Company&#8217;s historical accrual estimates have not been materially different from actual costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the Company incurs expenses in respect
of intellectual property costs relating to patents and trademarks. The probability of success and length of time to develop commercial
applications of the drugs subject to the underlying patent and trademark costs is difficult to determine and numerous risks and uncertainties
exist with respect to the timely completion of the development projects. There is no assurance the drugs subject to the underlying patents
and trademarks will ever be successfully commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to these risks and uncertainties, the patent and
trademark costs do not meet the definition of an asset and thus are expensed as incurred within general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionIncentives', window );">Research and Development Incentive Income</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--RevenueRecognitionIncentives_zqniuP8zbxt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_863_zaSKSRZ4JeZ8">Research and Development Incentive Income</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is eligible to obtain certain research
and development tax credits, including, through its wholly owned subsidiary Anavex Australia, the Australian research and development
tax incentive credit (the &#8220;Australia R&amp;D credit&#8221;) through a program administered through the Australian Tax Office (the
&#8220;ATO&#8221;) and AusIndustry, a division of the Australian Government&#8217;s Department of Industry, Innovation and Science (&#8220;AusIndustry&#8221;).
The Australia R&amp;D credit program provides for a cash refund based on a percentage of eligible research and development activities
undertaken in Australia by Anavex Australia. Anavex Australia is also eligible under the Australia R&amp;D credit program to receive the
cash refund for certain research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses
are pre-approved by AusIndustry pursuant to an advanced overseas finding application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Australia R&amp;D credit program is available
to eligible companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period at a rate
of 18.5% above the claimant&#8217;s company tax rate in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The tax incentives are available on the basis of specific
criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company
has accounted for the incentives outside of the scope of ASC Topic 740, <i>Income Taxes</i> (&#8220;ASC 740&#8221;), since the incentives
are not linked to the Company&#8217;s taxable income and can be realized regardless of whether the Company has generated taxable income
in the respective jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With respect to the Australia R&amp;D credit, as there
is no authoritative guidance under GAAP for accounting for grants to for-profit business entities, the Company accounts for the grant
by analogy to IAS20 <i>Accounting for Government Grants and Disclosure of Government Assistance</i> (&#8220;IAS 20&#8221;). The Company
recognizes the research and development incentive income as it incurs costs eligible for reimbursement under the Australia R&amp;D credit
program when it is reasonably assured that the cash incentive will be received, as evidenced through enrollment in the program and when
the applicable conditions under the program have been met. The Company accrues for the amount of cash refund it expects to receive in
relation to research and development expenses outside of Australia only to the extent it has received advanced approval from AusIndustry,
pursuant to an approved advanced overseas finding application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, Anavex Australia and Anavex Canada incur
Goods and Services Tax (GST) on certain services provided by local vendors. As a domestic entity in those jurisdictions, Anavex Australia
and Anavex Canada are entitled to a refund of the GST paid. Similarly, Anavex Germany incurs Value Added Tax (VAT) on certain services
provided by local vendors, to which it is entitled to a refund of such VAT paid. The Company&#8217;s estimate of the amount of cash refund
it expects to receive related to GST and VAT incurred is included in Incentive and tax receivables in the accompanying consolidated balance
sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>














<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_LicenseFeesPolicyTextBlock', window );">License Fees</a></td>
<td class="text"><p id="xdx_844_ecustom--LicenseFeesPolicyTextBlock_zd34ancWC3ii" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_zrfDP49gLz2k">License Fees</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company expenses amounts paid to acquire licenses associated with products under development when the ultimate recovery of the amounts
paid is uncertain and the technology has no alternative future use when acquired. Acquisitions of technology licenses are charged to expense
or capitalized based on management&#8217;s assessment regarding the ultimate recoverability of the amounts paid and the potential for
alternative future use. The Company has determined that the technological feasibility for its product candidates is reached when the requisite
regulatory approvals are obtained to make the product available for sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss per Share</a></td>
<td class="text"><p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zEDn9LOkfxBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_zkqk8L0aChs9">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2025, diluted loss per share excludes
<span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241001__20250930_zki1oXWZpULk" title="Loss per share for potentially dilutive common shares">14,971,583</span> potentially dilutive common shares (2024 - <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20231001__20240930_zM4mHEQ3JuJ5" title="Loss per share for potentially dilutive common shares">15,047,754</span>; 2023 &#8211; <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230930_pdd" title="Loss per share for potentially dilutive common shares">14,271,780</span>) related to outstanding options and warrants,
as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text"><p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zceoKf43s8ij" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_863_zClX3phJ8r49">Financial Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The book value of the Company&#8217;s financial instruments,
consisting of cash and equivalents, incentive and tax receivables, accounts payable and accrued liabilities approximate their fair value
due to the short-term maturity of such instruments. Unless otherwise noted, it is management&#8217;s opinion that the Company is not exposed
to significant interest, currency or credit risks arising from these financial instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zQ4n5Kxzx4L9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_zOW8TWby7Rkj">Foreign Currency Translation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The functional currency of the Company is the US dollar.
Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date
and non-monetary items are translated at exchange rates prevailing when the assets were acquired, or obligations incurred. Foreign currency
denominated expense items are translated at exchange rates prevailing on the transaction date. Unrealized gains or losses arising from
the translations are credited or charged to income in the period in which they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has determined that the functional currency
of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd. is also the US dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographic Reporting</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ze2L1H2uNjul" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86A_zRKtUWWLX863">Segment and Geographic Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determines and presents operating segments
based on the information that is internally provided to the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), its Chief
Executive Officer, in accordance with ASC 280, Segment Reporting. The Company has determined that it operates in a single business segment,
which is a clinical-stage biopharmaceutical company developing differentiated therapeutics by applying precision medicine to central nervous
system (&#8220;CNS&#8221;) diseases with high unmet need. Refer to Note 8 &#8211; Segmented Information for further information related
to the Company&#8217;s segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>














<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_GrantIncomePolicyTextBlock', window );">Grant Income</a></td>
<td class="text"><p id="xdx_84F_ecustom--GrantIncomePolicyTextBlock_zEftaHZ3lpN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_z8TzpgSXhhE9">Grant Income</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Grant income is recognized at the fair value of the
grant when it is received, and all substantive conditions have been satisfied. Grants received from government and other agencies in advance
of the specific research and development costs to which they relate are deferred and recognized in the consolidated statements of operations
and comprehensive loss in the period they are earned, typically when the related research and development costs are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zDoEUYITEGC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zVQe3W1QkAn4">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC 740, which
requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and
liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying
amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC 740 regarding
accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more
likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently
measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax
authority assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information.
The Company considers many factors when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions
and tax benefits may not accurately anticipate actual outcomes. As additional information is obtained, there may be a need to periodically
adjust the recognized tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements
of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes interest and penalties related
to current income tax expense on the interest income, net line, in the accompanying consolidated statements of operations and comprehensive
loss. Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock', window );">Share-based Compensation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zzoJR4HR6L54" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_zbECW6HHmcb4">Share-based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for all share-based payments
and awards under the fair value method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of all share-based payments are expensed
over their contractual vesting period, or over the expected performance period for only the portion of awards expected to vest, in the
case of milestone-based vesting, with a corresponding increase to additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compensation costs for share-based payments with graded
vesting are recognized on a straight-line basis. Stock based compensation expense is adjusted for actual forfeitures of unvested awards
as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has granted share purchase option awards
that vest upon achievement of certain performance criteria, or milestone-based awards. The Company estimates an implicit service period
for achieving performance criteria for each award and recognizes the resulting fair value as expense over the implicit service period
when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its
estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest upon achievement
of the performance criteria.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the Black-Scholes option valuation
model to calculate the fair value of share-based awards at the date of the grant. This model requires the input of subjective assumptions,
including the expected price volatility and expected life of each&#160;award. The Company uses the U.S. Treasury daily treasury yield
curve rates for the expected term of the option as the risk-free rate. The expected term represents the period that options granted are
expected to be outstanding using the simplified method. Historically, the Company&#8217;s historical share option exercise experience
did not provide sufficient basis for estimating the expected term. Expected volatility is based on the average of the daily share price
changes over the expected term. The Company does not estimate forfeitures and elects to record actual forfeitures as they occur. The Company
has not paid any dividends on its common stock historically, therefore no assumption of dividend payments is made in the model. These
assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#8217;s
judgment. Changes in these assumptions can materially affect the fair value estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The purchase price of share-based compensation awards
may be paid in cash or, if approved by the Company&#8217;s compensation committee (or in the case of warrants by the Board of Directors)
in advance, &#8220;net settled&#8221; in shares of the Company&#8217;s common stock. In a net settlement of an share-based award, the
Company does not receive payment of the exercise price from the holder but reduces the number of shares of common stock issued upon the
exercise of the award by the smallest number of whole shares that have an aggregate fair market value equal to or over the aggregate exercise
price for the option shares covered by the instrument exercised. Shares issued pursuant to the exercise of options and warrants are issued
from the Company&#8217;s treasury.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z92M6wRNMox" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_zxkKj0wYCM0h">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the exchange price that would
be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair
value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes
the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities that the Company has the ability to access at the measurement date;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2025 and 2024, the Company did not
have any Level 2 or Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zyxIcg1Lt1u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_z5CZrOPiGmE6">Recently Adopted Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2023, the Financial Accounting Standards
Board (FASB) issued ASU No. 2023-07, &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221; This guidance requires
disclosure of incremental segment information on an annual and interim basis, including disclosure of the title and position of the Chief
Operating Decision Maker and requires that a public entity that has a single reportable segment to provide all the disclosures required
by the amendments in ASU No. 2023-07. The Company adopted the new standard effective September 30, 2025, and for subsequent interim periods.
Since ASU No. 2023-07 addresses only disclosures, the adoption of ASU No. 2023-07 did not have a significant impact on the Company&#8217;s
consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>














<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_RecentAccountingPronouncementsPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_845_ecustom--RecentAccountingPronouncementsPolicyTextBlock_zpvzsd0U9Chf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_865_zVt6QSRQlqpi">Recent Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In December 2023, the FASB
issued ASU No. 2023-09, &#8220;Income Taxes:&#160;Improvements to Income Tax Disclosures.&#8221; This guidance requires consistent categories
and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment
is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2024, the FASB
issued ASU No. 2024-03, &#8220;Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures. The
amendments in ASU No. 2024-03 address investor requests for more detailed expense information and require additional disaggregated disclosures
in the notes to the financial statements for certain categories of expenses that are included on the face of the financial statements.
The guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after
December 15, 2027, with early adoption permitted. The Company is currently assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_GrantIncomePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_GrantIncomePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_LicenseFeesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_LicenseFeesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_RecentAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_RecentAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for sales incentives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (m)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureAccruedLiabilitiesAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of principal components of accrued liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zEFXjdmOG7z5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Liabilities (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BA_zI3it03iRoGk" style="display: none">Schedule of principal components of accrued liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20250930_zyqxLuwprtle" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20240930_znZa56PfFcAk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
  <tr id="xdx_408_ecustom--AccruedInvestigatorPayments_iI_pn3n3_z91BpzDoygW5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Accrued investigator payments</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">96</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">860</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccruedBonusesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,562</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,527</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--MilestoneBasedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Milestone-based contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">523</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">557</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherAccountsPayableAndAccruedLiabilities_iI_pn3n3_z7ckRxVrVmq4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,711</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,891</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--TotalAccruedLiabilities_iTI_pn3n3_zK1vlMEb0Dl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total accrued liabilities</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,892</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,835</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of operating lease costs</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--LeaseCostTableTextBlock_pn3n3_zLGK3MGNJdu8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B4_zO1LJNj6anr4" style="display: none">Schedule of operating lease costs</span></td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49A_20241001__20250930_zIJOpFzaZD61" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49E_20231001__20240930_zZipdRTLjkMb" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_491_20221001__20230930_z67COQZbK2se" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="11" style="font-weight: bold; text-align: center">Years ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseCost_zWMuXvMMUw3a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Operating lease costs</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">134</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">125</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">118</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock', window );">Schedule of contributions under the plan</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_ze32GXQdn995" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B9_zV9yNdYZC4wk" style="display: none">Schedule of contributions under the plan</span></td><td style="color: black; font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_495_20241001__20250930_zOHLuBnpjGgk" style="color: black; font-weight: bold; text-align: center">&#160;</td><td style="color: black; font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49C_20231001__20240930_zHvshI3hnLy" style="color: black; font-weight: bold; text-align: center">&#160;</td><td style="color: black; font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49D_20221001__20230930_zjLfn9CR0Wtk" style="color: black; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold">&#160;</td>
    <td colspan="11" style="color: black; font-weight: bold; text-align: center">Years ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2025</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2024</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40C_eus-gaap--PensionContributions_z8DWIeNHh9s6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; color: black; text-align: left; text-indent: -10pt">Contributions to 401(k) plan</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">255</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">279</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">232</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zMAuyzGA2ub8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BA_zE5YjSoz9rzc" style="display: none">Schedule of stock option activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="color: white">&#160;</td>
    <td style="color: white; text-align: left">&#160;</td><td style="color: white; text-align: right">&#160;</td><td style="color: white; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price <br/> ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value <br/> ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Aggregate intrinsic value <br/> ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 44%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, September 30, 2024</span></td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrDrKVnujtdg" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Number of options, Outstanding beginning balance">15,037,754</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3ZDZFyqWmI6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average exercise price, Outstanding beginning balance">6.80</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsE1B6uFOVd5" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average grant date fair value, Outstanding beginning balance">5.12</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1errfXlh8Yg" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Aggregate intrinsic value, Outstanding beginning balance">15,825,791</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAYcb0woC0k3" style="text-align: right" title="Number of options, Granted">1,488,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMNxguD2E3j5" style="text-align: right" title="Weighted average exercise price, Granted">8.58</td><td style="text-align: left">&#160;</td><td style="color: white">&#160;</td>
    <td style="color: white; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znhJQVsdiI8d" style="text-align: right" title="Weighted average grant date fair value, Granted">6.22</td><td style="color: white; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Expired</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zybc6fWFW7ha" style="text-align: right" title="Number of options, Expired">(100,100</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfJ264tHNym7" style="text-align: right" title="Weighted average exercise price, Expired">16.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercised</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKTyWPdQWJcf" style="text-align: right" title="Number of options, Exercised">(1,383,988</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsXbjubtAJjb" style="text-align: right" title="Weighted average exercise price, Exercised">3.21</td><td style="text-align: left">&#160;</td><td style="color: white">&#160;</td>
    <td style="color: white; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfcBnIF9bMaj" style="text-align: right" title="Weighted average grant date fair value, Exercised"><span style="font-size: 10pt"></span> <span style="font-size: 10pt">1.31</span></td><td style="color: white; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzfG4883Xg2g" style="text-align: right" title="Aggregate intrinsic value, Exercised">9,324,901</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFBlpfLp5kQe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Forfeited">(80,583</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfjSLbhDqvtl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited">4.56</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5ObKFMoJrWc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Forfeited">0.55</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, September 30, 2025</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z19ucprLcgS7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Outstanding ending balance">14,961,583</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zV9rYvQy4sud" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Outstanding ending balance">7.25</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1rKyhJroJkc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Outstanding ending balance">5.46</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z344IAKZum9l" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, Outstanding ending balance">39,715,608</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercisable, September 30, 2025</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zPQI44vUCf11" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Exercisable">10,418,213</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoSubcAxPJQk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable">6.22</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsFc6cCSWnW3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Exercisable">4.83</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbEMxWQ89kt1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Exercisable">34,762,588</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of summarizes information about stock options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zZvFeODwATQj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_8B3_zXiu7b3JvkEl" style="display: none">Schedule of summarizes information about stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="7" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Range of exercises prices</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Number of outstanding</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted average remaining contractual life</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted average exercise</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Number of vested</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted average exercise</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">From</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">To</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">(in years)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">price</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">price</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zxYN7hHqR4B9" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Range of exercise prices, Lower range limit">2.30</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zsqM0silFxBa" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Range of exercise prices, Upper range limit">5.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zhkFOTBe0x44" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of outstanding options">4,315,700</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zsBDyLEeDv1g" title="Weighted average remaining contractual life">3.15</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zmX1s7evjBc3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price">3.02</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zxNeCJnLt3Ek" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of vested options">4,220,283</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zWWJ8Ja45XEc" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price options vested">2.99</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zXqfKH8v7tB4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit">5.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_ztKJ50TDZAaa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit">7.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zwtchAcDnVy5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options">3,299,536</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zOD4KFHqLWFc" title="Weighted average remaining contractual life">5.23</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zMXVApfwnbye" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price">5.62</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z6QnwWX4Ditg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options">2,325,162</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zZAVuBEYr4gh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested">5.72</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zUht1UO2aex1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit">7.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zfqeQDM5ew0f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit">9.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z2UPuVTMYFS3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options">4,372,347</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zTKSmHCQIUel" title="Weighted average remaining contractual life">6.66</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zbO88lQNtoPj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price">8.09</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z5M04ry9PRAj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options">2,222,101</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z2qn76qyieRk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested">7.82</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_znVh8X6kNeCj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit">9.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z3RjfNfj6a07" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit">13.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_ziNfLlIh6zNi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options">1,609,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zZiMFdT9M54l" title="Weighted average remaining contractual life">6.31</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zMJwqgNnrXte" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price">10.29</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zlxWmYRpuc35" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options">1,120,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zzv1vXIqLBue" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested">10.37</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z1WTTJpPSKbb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit">13.01</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zH4K4ZLjlZC8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit">25.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z7on3N9dOCcc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options">1,365,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zT4jk8nQvG57" title="Weighted average remaining contractual life">5.91</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zktkXtOXgkH9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price">18.33</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zY3g27ILay83" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options">530,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zBp15L52zgqg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested">18.67</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z88YIicqOvj6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options">14,961,583</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBaB9MhtDPrb" title="Weighted average remaining contractual life">5.22</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBXUBkfD88Fb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price">7.25</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNZ6TnWEEXM8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options">10,418,213</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6okIJiIgxGk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested">6.22</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of general and administrative expenses and research and development expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zy1ul9YLEJZ4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B6_znpz9vQT6TPl" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="11" style="font-weight: bold; text-align: center">Years ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zMMfe5cVuu5c" style="width: 11%; text-align: right" title="Total share based compensation">4,536</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHWirUELtqqe" style="width: 11%; text-align: right" title="Total share based compensation">3,625</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zFn7iKSnTNkg" style="width: 11%; text-align: right" title="Total share based compensation">5,558</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zaiJwxtkDUMe" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">7,013</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zqLuPraCrmB6" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">5,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zr4kWOUUKPc6" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">10,812</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total share-based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930_zI3bl7GkOB54" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">11,549</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930_zjWKBnIfnP51" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">9,438</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930_zViBeqdRp5qj" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">16,370</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions for fair value of each option award</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_zkFvazW9RlF" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BB_zs6JLQseyw75" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20241001__20250930_zvlq3707ODsh" title="Risk-free interest rate">3.98</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20231001__20240930_znVjDE6iMPAf" title="Risk-free interest rate">4.28</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20221001__20230930_zRhCY04Mi2y2" title="Risk-free interest rate">3.70</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20241001__20250930_zaWkTo9C2cj2" title="Expected life of options (years)">5.57</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240930_zBB0jUO5Ejr" title="Expected life of options (years)">5.78</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230930_zspTKYDKT6Ee" title="Expected life of options (years)">5.64</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20241001__20250930_zRD3GocNYn87" title="Annualized volatility">86.49</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20231001__20240930_zJlr6T9OaP24" title="Annualized volatility">84.81</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20221001__20230930_zoZva1sCuFIk" title="Annualized volatility">85.13</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20241001__20250930_z6KTW8JNaUX9" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20231001__20240930_zaiICJexi8Ml" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20221001__20230930_z3tTbZw1FGa8" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 70<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of loss before income taxes</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_pn3n3_zgKs5dfVY5l5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"><span id="xdx_8B7_zzFnLgkQPPoi" style="display: none">Schedule of loss before income taxes</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20241001__20250930_z5MJb7OW8u69" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20231001__20240930_zFTtjaLIsDAh" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20221001_20230930" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">United States</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(44,500</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(39,195</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(41,198</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,877</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,807</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,300</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(46,377</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(43,002</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(47,498</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_z6GPFZ33krw8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt">Schedule of components of net deferred income tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20250930_zOY5k9iTWpFk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20240930_zjQgJ3N6VP5j" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net operating loss carryforwards</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">54,752</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">48,134</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development tax credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,288</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,203</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,185</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,091</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsResearchAndDevelopmentCapitalization_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development capitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,737</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,104</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Unpaid charges</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,843</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,197</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Intangible asset costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">946</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">758</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ForeignExchangeAndOther_iNI_pn3n3_di_zOVd3Vxooh6e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign exchange and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(259</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(254</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_zYf0Q9J5VkZ4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Valuation allowance of deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(108,492</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(92,233</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0991">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0992">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of income tax expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_pn3n3_z4dOHPfPkGL9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zKPJn14YVjM9" style="display: none">Schedule of reconciliation of income tax expense</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20241001__20250930_zHrqqR1Sedf8" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20231001__20240930_z8d0FFMP0se1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20221001__20230930_znWxur4eJxqc" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Income tax benefit at statutory federal rate</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(9,739</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(9,030</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(9,975</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign income taxed at other rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1000">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(61</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--PermanentDifferencesRelatingToStockBasedCompensation_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Permanent differences relating to share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,219</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(601</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationGiltiAmount_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Permanent differences relating to GILTI inclusion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1009">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(276</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">273</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development credits, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(941</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(860</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(37</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">State and local taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,672</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,821</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,122</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Adjustment to true up to prior years&#8217; tax provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">182</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,128</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance_zahCpujyiQi2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Change in valuation allowances</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">16,259</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,186</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14,098</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Income tax expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1032">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmented Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of summarizes the significant expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_pn3n3_zjxBEOPR4tqc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segmented Information (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span id="xdx_8BF_zYgw4UzcBeSd" style="display: none">Schedule of summarizes the significant expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20241001__20250930_zLHHUDIGsfxd" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20231001__20240930_zKk7pL1wdZwe" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20221001__20230930_zMYAJn06VFw8" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; width: 46%; text-align: left; text-indent: -10pt">Preclinical studies</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zFrZBm3FoeY9" style="width: 11%; text-align: right" title="Research and development costs">543</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zxp07xxy7yY7" style="width: 11%; text-align: right" title="Research and development costs">663</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zH9KDDhEzkph" style="width: 11%; text-align: right" title="Research and development costs">627</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Clinical trials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_z1WONuLox7we" style="text-align: right" title="Research and development costs">15,805</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_zuj3PHG4gT9a" style="text-align: right" title="Research and development costs">21,301</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_zcUamCUFHlx8" style="text-align: right" title="Research and development costs">21,873</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Personnel costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_z2yP8sByQ5me" style="text-align: right" title="Research and development costs">13,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zpO21lKV8dJ5" style="text-align: right" title="Research and development costs">13,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zQXUpJcSUJy2" style="text-align: right" title="Research and development costs">10,264</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Non-cash share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z60xdm80O0He" style="text-align: right" title="Research and development costs">7,013</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z2I3TxlZGWl2" style="text-align: right" title="Research and development costs">5,813</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_zFJDZrcFbA51" style="text-align: right" title="Research and development costs">10,812</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Other research and development costs<sup>(a)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zZTM1o5KWTAl" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development costs">765</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zY2z0BJ6cNu" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development costs">385</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zPV5eE24LOyd" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development costs">141</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total research and development costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930_znLAEUCsjnY4" style="font-weight: bold; text-align: right" title="Research and development costs">37,592</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930_zgxBsosS3X9f" style="font-weight: bold; text-align: right" title="Research and development costs">41,838</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930_zuC4GxaJ0iW2" style="font-weight: bold; text-align: right" title="Research and development costs">43,717</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">General and administrative costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Personnel costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zh6aOjZq8sT4" style="text-align: right" title="General and administrative costs">2,288</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zpYJz6yuFcz" style="text-align: right" title="General and administrative costs">2,177</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zRa7H2ZF3xv9" style="text-align: right" title="General and administrative costs">2,527</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Non-cash share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_zuYd8YPkHrFd" style="text-align: right" title="General and administrative costs">4,536</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z97W6Cm3eqO" style="text-align: right" title="General and administrative costs">3,625</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z05ZWu0DGffg" style="text-align: right" title="General and administrative costs">5,558</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Other general and administrative costs<sup>(b)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zmqi0fztDEVc" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative costs">6,992</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_z1zIttFFD8tg" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative costs">5,237</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zWYlj8jzeV3k" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative costs">3,961</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total general and administrative costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930_z84cBtzE4JTa" style="font-weight: bold; text-align: right" title="General and administrative costs">13,816</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930_zRTSScKRdqce" style="font-weight: bold; text-align: right" title="General and administrative costs">11,039</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930_zMzJBfRDgPl9" style="font-weight: bold; text-align: right" title="General and administrative costs">12,046</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OtherIncome_c20241001__20250930_zSQrsMX0gtDl" style="border-bottom: Black 1pt solid; text-align: right" title="Other income">5,031</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--OtherIncome_c20231001__20240930_zBzEhImJe7Bb" style="border-bottom: Black 1pt solid; text-align: right" title="Other income">9,875</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--OtherIncome_c20221001__20230930_z7gQovPJrPY7" style="border-bottom: Black 1pt solid; text-align: right" title="Other income">8,258</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net loss</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--NetIncomeLoss_c20241001__20250930_zHoQRnoi8oKd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net Loss">(46,377</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--NetIncomeLoss_c20231001__20240930_zBcrRhrJpkXd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net Loss">(43,002</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--NetIncomeLoss_c20221001__20230930_zUh6s7Tme0V" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net Loss">(47,505</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(a)</td><td style="text-align: justify">Other research and development costs include, but are not limited to, publications, sponsorships, membership fees, scientific conferences,
and medical affairs strategy and branding.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(b)</td><td style="text-align: justify">Other general and administrative expenses include, but are not limited to, office rent, public company reporting requirements including
professional fees, insurance, and other general operating expenses not otherwise included in research and development expenses.</td></tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal deposit insurance corporation</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Loss per share for potentially dilutive common shares</a></td>
<td class="nump">14,971,583<span></span>
</td>
<td class="nump">15,047,754<span></span>
</td>
<td class="nump">14,271,780<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureAccruedLiabilitiesAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_AccruedInvestigatorPayments', window );">Accrued investigator payments</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">1,562<span></span>
</td>
<td class="nump">1,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_MilestoneBasedContractAccruals', window );">Milestone-based contract accruals</a></td>
<td class="nump">523<span></span>
</td>
<td class="nump">557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">All other accrued liabilities</a></td>
<td class="nump">1,711<span></span>
</td>
<td class="nump">1,891<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_TotalAccruedLiabilities', window );">Total accrued liabilities</a></td>
<td class="nump">$ 3,892<span></span>
</td>
<td class="nump">$ 4,835<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AccruedInvestigatorPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AccruedInvestigatorPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_MilestoneBasedContractAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_MilestoneBasedContractAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_TotalAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_TotalAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1', window );">Research and development incentive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Non operating income from grant</a></td>
<td class="nump">$ 37,000.0<span></span>
</td>
<td class="nump">$ 75,000.0<span></span>
</td>
<td class="nump">25,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DeferredGrantIncome1', window );">Deferred grant income</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Incentive and tax receivables</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Incentive and tax receivables</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxFoundationMember', window );">Michael J Fox Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1', window );">Research and development incentive income</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredGrantIncome1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredGrantIncome1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (m)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 03, 2023</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">927,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedemptionPremium', window );">Common stock net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_FairValueOfInitialCommitment', window );">Fair value of the initial commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_IncurredExpenses', window );">Incurred expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise option shares purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommonStockConsiderationExerciseShares', window );">Common stock consideration exercise shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1', window );">Consideration shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1', window );">Consideration payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_MarketPrice', window );">Market price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise option shares purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommonStockConsiderationExerciseShares', window );">Common stock consideration exercise shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,349,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1', window );">Consideration payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_MarketPrice', window );">Market price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=avxl_BoardMember', window );">Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=avxl_ChiefExecutiveOfficer1Member', window );">Chief Executive Officer 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise option shares purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1', window );">Consideration shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1', window );">Consideration payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_MarketPrice', window );">Market price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=avxl_ChiefExecutiveOffice1rMember', window );">Chief Executive Office 1r [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommonStockConsiderationExerciseShares', window );">Common stock consideration exercise shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2023Member', window );">Purchase Agreement 2023 [Member] | Lincoln Park Capital Fund L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ValueOfSharesObligatedToPurchase', window );">Value of shares obligated to purchase</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued, shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues1', window );">Pro rata basic number of shares obligated to purchase</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance or sale of equity</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues2', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Amount of shares remain available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2023Member', window );">Purchase Agreement 2023 [Member] | Lincoln Park Capital Fund L L C [Member] | Common Stock Including Commitment Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,455,646<span></span>
</td>
<td class="nump">3,288,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2023Member', window );">Purchase Agreement 2023 [Member] | Lincoln Park Capital Fund L L C [Member] | Common Stock Excluding Commitment Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,275,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2023Member', window );">Purchase Agreement 2023 [Member] | Lincoln Park Capital Fund L L C [Member] | Commitment Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,943<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommonStockConsiderationExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommonStockConsiderationExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_FairValueOfInitialCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_FairValueOfInitialCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IncurredExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IncurredExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_MarketPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_MarketPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ValueOfSharesObligatedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ValueOfSharesObligatedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedemptionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedemptionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=avxl_BoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=avxl_BoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=avxl_ChiefExecutiveOfficer1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=avxl_ChiefExecutiveOfficer1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=avxl_ChiefExecutiveOffice1rMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=avxl_ChiefExecutiveOffice1rMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avxl_CommonStockIncludingCommitmentSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avxl_CommonStockIncludingCommitmentSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avxl_CommonStockExcludingCommitmentSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avxl_CommonStockExcludingCommitmentSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avxl_CommitmentSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avxl_CommitmentSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 134<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contributions to 401(k) plan</a></td>
<td class="nump">$ 255<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 2) - Equity Option [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding beginning balance | shares</a></td>
<td class="nump">15,037,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding beginning balance</a></td>
<td class="nump">$ 6.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Outstanding beginning balance</a></td>
<td class="nump">$ 5.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding beginning balance | $</a></td>
<td class="nump">$ 15,825,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted | shares</a></td>
<td class="nump">1,488,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">$ 8.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted', window );">Weighted average grant date fair value, Granted</a></td>
<td class="nump">$ 6.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of options, Expired | shares</a></td>
<td class="num">(100,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Expired</a></td>
<td class="nump">$ 16.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, Exercised | shares</a></td>
<td class="num">(1,383,988)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">$ 3.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised', window );">Weighted average grant date fair value, Exercised</a></td>
<td class="nump">$ 1.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, Exercised | $</a></td>
<td class="nump">$ 9,324,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, Forfeited | shares</a></td>
<td class="num">(80,583)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">$ 4.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited', window );">Weighted average grant date fair value, Forfeited</a></td>
<td class="nump">$ 0.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding ending balance | shares</a></td>
<td class="nump">14,961,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding ending balance</a></td>
<td class="nump">$ 7.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Outstanding ending balance</a></td>
<td class="nump">$ 5.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding ending balance | $</a></td>
<td class="nump">$ 39,715,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Exercisable | shares</a></td>
<td class="nump">10,418,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable</a></td>
<td class="nump">$ 6.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Exercisable</a></td>
<td class="nump">$ 4.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable | $</a></td>
<td class="nump">$ 34,762,588<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-12<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-21<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-15<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 3) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 2 months 19 days<span></span>
</td>
<td class="text">5 years 5 months 23 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">14,961,583<span></span>
</td>
<td class="nump">15,037,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 2 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 7.25<span></span>
</td>
<td class="nump">$ 6.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">10,418,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 6.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Lower range limit</a></td>
<td class="nump">2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Upper range limit</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">4,315,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">3 years 1 month 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 3.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">4,220,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Lower range limit</a></td>
<td class="nump">5.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Upper range limit</a></td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">3,299,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 2 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 5.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">2,325,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 5.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Lower range limit</a></td>
<td class="nump">7.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Upper range limit</a></td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">4,372,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">6 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 8.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">2,222,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 7.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Lower range limit</a></td>
<td class="nump">9.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Upper range limit</a></td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">1,609,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">6 years 3 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 10.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">1,120,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 10.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Lower range limit</a></td>
<td class="nump">13.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Upper range limit</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">1,365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 10 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 18.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 18.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-12<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-21<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-15<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 4) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total share based compensation</a></td>
<td class="nump">$ 11,549<span></span>
</td>
<td class="nump">$ 9,438<span></span>
</td>
<td class="nump">$ 16,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total share based compensation</a></td>
<td class="nump">4,536<span></span>
</td>
<td class="nump">3,625<span></span>
</td>
<td class="nump">5,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total share based compensation</a></td>
<td class="nump">$ 7,013<span></span>
</td>
<td class="nump">$ 5,813<span></span>
</td>
<td class="nump">$ 10,812<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 5)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.98%<span></span>
</td>
<td class="nump">4.28%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 6 months 25 days<span></span>
</td>
<td class="text">5 years 9 months 10 days<span></span>
</td>
<td class="text">5 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Annualized volatility</a></td>
<td class="nump">86.49%<span></span>
</td>
<td class="nump">84.81%<span></span>
</td>
<td class="nump">85.13%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 25, 2022</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Apr. 17, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_WarrantsOutstandingWeightedAverageExercise', window );">Warrants outstanding weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OptionIssued', window );">Option issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,504,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="nump">$ 4.34<span></span>
</td>
<td class="nump">$ 3.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual life of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 2 months 19 days<span></span>
</td>
<td class="text">5 years 5 months 23 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 1 month 9 days<span></span>
</td>
<td class="text">4 years 10 days<span></span>
</td>
<td class="text">4 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 9.4<span></span>
</td>
<td class="nump">$ 16.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Remaining stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">Stock Option Plan 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member', window );">Stock Option Plan 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member', window );">Stock Option Plan 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Option available issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,436,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OptionIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OptionIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_WarrantsOutstandingWeightedAverageExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_WarrantsOutstandingWeightedAverageExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (44,500)<span></span>
</td>
<td class="num">$ (39,195)<span></span>
</td>
<td class="num">$ (41,198)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(1,877)<span></span>
</td>
<td class="num">(3,807)<span></span>
</td>
<td class="num">(6,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total</a></td>
<td class="num">$ (46,377)<span></span>
</td>
<td class="num">$ (43,002)<span></span>
</td>
<td class="num">$ (47,498)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 54,752<span></span>
</td>
<td class="nump">$ 48,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">5,288<span></span>
</td>
<td class="nump">4,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">23,185<span></span>
</td>
<td class="nump">21,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization', window );">Research and development capitalization</a></td>
<td class="nump">20,737<span></span>
</td>
<td class="nump">15,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DeferredTaxAssetsUnpaidCharges', window );">Unpaid charges</a></td>
<td class="nump">3,843<span></span>
</td>
<td class="nump">3,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible asset costs</a></td>
<td class="nump">946<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ForeignExchangeAndOther', window );">Foreign exchange and other</a></td>
<td class="num">(259)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance of deferred tax assets</a></td>
<td class="num">(108,492)<span></span>
</td>
<td class="num">(92,233)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredTaxAssetsUnpaidCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredTaxAssetsUnpaidCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ForeignExchangeAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ForeignExchangeAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at statutory federal rate</a></td>
<td class="num">$ (9,739)<span></span>
</td>
<td class="num">$ (9,030)<span></span>
</td>
<td class="num">$ (9,975)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign income taxed at other rates</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_PermanentDifferencesRelatingToStockBasedCompensation', window );">Permanent differences relating to share-based compensation</a></td>
<td class="num">(1,219)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount', window );">Permanent differences relating to GILTI inclusion</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other permanent differences</a></td>
<td class="nump">130<span></span>
</td>
<td class="num">(276)<span></span>
</td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet', window );">Research and development credits, net</a></td>
<td class="num">(941)<span></span>
</td>
<td class="num">(860)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local taxes</a></td>
<td class="num">(4,672)<span></span>
</td>
<td class="num">(3,821)<span></span>
</td>
<td class="num">(4,122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Adjustment to true up to prior years&#8217; tax provision</a></td>
<td class="nump">182<span></span>
</td>
<td class="num">(1,128)<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance', window );">Change in valuation allowances</a></td>
<td class="nump">16,259<span></span>
</td>
<td class="nump">15,186<span></span>
</td>
<td class="nump">14,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_PermanentDifferencesRelatingToStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_PermanentDifferencesRelatingToStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 12,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OperatingLossCarryForwardsExpirationYear', window );">Operating loss carry forwards expiration year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and Development tax credits</a></td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentTaxCreditsYear', window );">Research and development tax credits year</a></td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Decrease in valuation allowance</a></td>
<td class="nump">$ 16,300<span></span>
</td>
<td class="nump">$ 15,200<span></span>
</td>
<td class="nump">$ 14,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax asset</a></td>
<td class="nump">20,700<span></span>
</td>
<td class="nump">15,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=avxl_FederalMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 148,800<span></span>
</td>
<td class="nump">128,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OperatingLossCarryforwardsDescription', window );">Operating loss carryforwards description</a></td>
<td class="text">$37.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 19,100<span></span>
</td>
<td class="nump">16,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">17,100<span></span>
</td>
<td class="nump">16,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member] | Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 25,900<span></span>
</td>
<td class="nump">$ 23,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OperatingLossCarryForwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OperatingLossCarryForwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OperatingLossCarryforwardsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OperatingLossCarryforwardsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentTaxCreditsYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentTaxCreditsYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=avxl_FederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=avxl_FederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmented Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Research and development costs</a></td>
<td class="nump">$ 37,592<span></span>
</td>
<td class="nump">$ 41,838<span></span>
</td>
<td class="nump">$ 43,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative costs</a></td>
<td class="nump">13,816<span></span>
</td>
<td class="nump">11,039<span></span>
</td>
<td class="nump">12,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">5,031<span></span>
</td>
<td class="nump">9,875<span></span>
</td>
<td class="nump">8,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(46,377)<span></span>
</td>
<td class="num">(43,002)<span></span>
</td>
<td class="num">(47,505)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=avxl_PreclinicalStudiesMember', window );">Preclinical Studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Research and development costs</a></td>
<td class="nump">543<span></span>
</td>
<td class="nump">663<span></span>
</td>
<td class="nump">627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=avxl_ClinicalTrialsMember', window );">Clinical Trials [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Research and development costs</a></td>
<td class="nump">15,805<span></span>
</td>
<td class="nump">21,301<span></span>
</td>
<td class="nump">21,873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=avxl_PersonnelCostsMember', window );">Personnel Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Research and development costs</a></td>
<td class="nump">13,466<span></span>
</td>
<td class="nump">13,676<span></span>
</td>
<td class="nump">10,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative costs</a></td>
<td class="nump">2,288<span></span>
</td>
<td class="nump">2,177<span></span>
</td>
<td class="nump">2,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=avxl_NonCashShareBasedCompensationMember', window );">Non Cash Share Based Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Research and development costs</a></td>
<td class="nump">7,013<span></span>
</td>
<td class="nump">5,813<span></span>
</td>
<td class="nump">10,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative costs</a></td>
<td class="nump">4,536<span></span>
</td>
<td class="nump">3,625<span></span>
</td>
<td class="nump">5,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=avxl_OtherResearchAndDevelopmentCostsMember', window );">Other Research And Development Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Research and development costs</a></td>
<td class="nump">765<span></span>
</td>
<td class="nump">385<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative costs</a></td>
<td class="nump">$ 6,992<span></span>
</td>
<td class="nump">$ 5,237<span></span>
</td>
<td class="nump">$ 3,961<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=avxl_PreclinicalStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=avxl_PreclinicalStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=avxl_ClinicalTrialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=avxl_ClinicalTrialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=avxl_PersonnelCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=avxl_PersonnelCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=avxl_NonCashShareBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=avxl_NonCashShareBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=avxl_OtherResearchAndDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=avxl_OtherResearchAndDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>104</ContextCount>
  <ElementCount>272</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>35</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995440 - Disclosure - Recovery of Erroneously Awarded Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/ErrCompDisclosure</Role>
      <ShortName>Recovery of Erroneously Awarded Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999014 - Disclosure - Business Description and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation</Role>
      <ShortName>Business Description and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Equity Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferings</Role>
      <ShortName>Equity Offerings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Segmented Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SegmentedInformation</Role>
      <ShortName>Segmented Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://anavex.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/AccruedLiabilities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Segmented Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SegmentedInformationTables</Role>
      <ShortName>Segmented Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/SegmentedInformation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Other Income (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncomeDetailsNarrative</Role>
      <ShortName>Other Income (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/OtherIncome</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Equity Offerings (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingsDetailsNarrative</Role>
      <ShortName>Equity Offerings (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/EquityOfferings</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Commitments and Contingencies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails3</Role>
      <ShortName>Commitments and Contingencies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Commitments and Contingencies (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails4</Role>
      <ShortName>Commitments and Contingencies (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Commitments and Contingencies (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails5</Role>
      <ShortName>Commitments and Contingencies (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="e7052_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Segmented Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SegmentedInformationDetails</Role>
      <ShortName>Segmented Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/SegmentedInformationTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>avxl-20250930.xsd</File>
    <File>avxl-20250930_cal.xml</File>
    <File>avxl-20250930_def.xml</File>
    <File>avxl-20250930_lab.xml</File>
    <File>avxl-20250930_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="e7052_10-k.htm">e7052_10-k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="447">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="11">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="14">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>64
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "e7052_10-k.htm": {
   "nsprefix": "avxl",
   "nsuri": "http://anavex.com/20250930",
   "dts": {
    "schema": {
     "local": [
      "avxl-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "avxl-20250930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "avxl-20250930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "avxl-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avxl-20250930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "e7052_10-k.htm"
     ]
    }
   },
   "keyStandard": 217,
   "keyCustom": 55,
   "axisStandard": 14,
   "axisCustom": 0,
   "memberStandard": 12,
   "memberCustom": 23,
   "hidden": {
    "total": 52,
    "http://fasb.org/us-gaap/2025": 26,
    "http://anavex.com/20250930": 23,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 104,
   "entityCount": 1,
   "segmentCount": 35,
   "elementCount": 487,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 447,
    "http://xbrl.sec.gov/dei/2025": 39,
    "http://xbrl.sec.gov/ecd/2025": 14,
    "http://xbrl.sec.gov/cyd/2025": 11
   },
   "report": {
    "R1": {
     "role": "http://anavex.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://anavex.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://anavex.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://anavex.com/role/StatementsOfCashFlows",
     "longName": "00000005 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-012023-09-30",
      "name": "avxl:NoncashFinancingRelatedCharges",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://anavex.com/role/StatementsOfChangesInStockholdersEquity",
     "longName": "00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2022-09-30_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-09-30_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
     "longName": "995440 - Disclosure - Recovery of Erroneously Awarded Compensation",
     "shortName": "Recovery of Erroneously Awarded Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-10-012025-09-30_2023-11-30",
      "name": "ecd:RestatementDeterminationDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-012025-09-30_2023-11-30",
      "name": "ecd:RestatementDeterminationDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation",
     "longName": "999014 - Disclosure - Business Description and Basis of Presentation",
     "shortName": "Business Description and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://anavex.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999015 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://anavex.com/role/AccruedLiabilities",
     "longName": "999016 - Disclosure - Accrued Liabilities",
     "shortName": "Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "avxl:AccuredLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "avxl:AccuredLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://anavex.com/role/OtherIncome",
     "longName": "999017 - Disclosure - Other Income",
     "shortName": "Other Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://anavex.com/role/EquityOfferings",
     "longName": "999018 - Disclosure - Equity Offerings",
     "shortName": "Equity Offerings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "avxl:EquityOfferingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "avxl:EquityOfferingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://anavex.com/role/CommitmentsAndContingencies",
     "longName": "999019 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://anavex.com/role/IncomeTaxes",
     "longName": "999020 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://anavex.com/role/SegmentedInformation",
     "longName": "999021 - Disclosure - Segmented Information",
     "shortName": "Segmented Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://anavex.com/role/SubsequentEvents",
     "longName": "999022 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999023 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://anavex.com/role/AccruedLiabilitiesTables",
     "longName": "999024 - Disclosure - Accrued Liabilities (Tables)",
     "shortName": "Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "avxl:AccuredLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "avxl:AccuredLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesTables",
     "longName": "999025 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://anavex.com/role/IncomeTaxesTables",
     "longName": "999026 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://anavex.com/role/SegmentedInformationTables",
     "longName": "999027 - Disclosure - Segmented Information (Tables)",
     "shortName": "Segmented Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://anavex.com/role/AccruedLiabilitiesDetails",
     "longName": "999029 - Disclosure - Accrued Liabilities (Details)",
     "shortName": "Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "avxl:AccruedInvestigatorPayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "avxl:AccuredLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "avxl:AccruedInvestigatorPayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "avxl:AccuredLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://anavex.com/role/OtherIncomeDetailsNarrative",
     "longName": "999030 - Disclosure - Other Income (Details Narrative)",
     "shortName": "Other Income (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2022-10-012023-09-30",
      "name": "avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-012023-09-30",
      "name": "avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://anavex.com/role/EquityOfferingsDetailsNarrative",
     "longName": "999031 - Disclosure - Equity Offerings (Details Narrative)",
     "shortName": "Equity Offerings (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "avxl:EquityOfferingTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "avxl:EquityOfferingTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails",
     "longName": "999032 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
     "longName": "999033 - Disclosure - Commitments and Contingencies (Details 1)",
     "shortName": "Commitments and Contingencies (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:PensionContributions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DefinedContributionPlanDisclosuresTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:PensionContributions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DefinedContributionPlanDisclosuresTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
     "longName": "999034 - Disclosure - Commitments and Contingencies (Details 2)",
     "shortName": "Commitments and Contingencies (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30_us-gaap_StockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30_us-gaap_StockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
     "longName": "999035 - Disclosure - Commitments and Contingencies (Details 3)",
     "shortName": "Commitments and Contingencies (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-012025-09-30_us-gaap_StockOptionMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails4",
     "longName": "999036 - Disclosure - Commitments and Contingencies (Details 4)",
     "shortName": "Commitments and Contingencies (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-012025-09-30_us-gaap_GeneralAndAdministrativeExpenseMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails5",
     "longName": "999037 - Disclosure - Commitments and Contingencies (Details 5)",
     "shortName": "Commitments and Contingencies (Details 5)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Ratio",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Ratio",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999038 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://anavex.com/role/IncomeTaxesDetails",
     "longName": "999039 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://anavex.com/role/IncomeTaxesDetails1",
     "longName": "999040 - Disclosure - Income Taxes (Details 1)",
     "shortName": "Income Taxes (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://anavex.com/role/IncomeTaxesDetails2",
     "longName": "999041 - Disclosure - Income Taxes (Details 2)",
     "shortName": "Income Taxes (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://anavex.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999042 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://anavex.com/role/SegmentedInformationDetails",
     "longName": "999043 - Disclosure - Segmented Information (Details)",
     "shortName": "Segmented Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-09-30",
      "name": "us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7052_10-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "currency_AUD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2025",
     "localname": "AUD",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australia, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r538"
     ]
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation and benefits",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "avxl_AccruedInvestigatorPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "AccruedInvestigatorPayments",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued investigator payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued liabilities - Note 3",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "avxl_AccuredLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "AccuredLiabilitiesTextBlock",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued Liabilities",
        "label": "AccuredLiabilitiesTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r687",
      "r688",
      "r689",
      "r690",
      "r746",
      "r770"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operations:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r581",
      "r592",
      "r606",
      "r633"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r584",
      "r595",
      "r609",
      "r636"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r621"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2025",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r628"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r585",
      "r596",
      "r610",
      "r628",
      "r637",
      "r641",
      "r649"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "auth_ref": [
      "r647"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r267",
      "r268"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share for potentially dilutive common shares",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r69",
      "r83",
      "r102",
      "r103",
      "r104",
      "r137",
      "r149",
      "r160",
      "r163",
      "r172",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r311",
      "r313",
      "r357",
      "r384",
      "r385",
      "r388",
      "r455",
      "r521",
      "r522",
      "r528",
      "r538",
      "r539",
      "r540",
      "r551",
      "r701",
      "r702",
      "r762"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r563",
      "r565",
      "r588"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r563",
      "r565",
      "r588"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r563",
      "r565",
      "r588"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r640"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "avxl_BoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "BoardMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r82",
      "r501"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r52",
      "r99"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Decrease) Increase in cash and cash equivalents during the year",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r52"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal deposit insurance corporation",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "avxl_CashPaidForStateAndLocalFranchiseTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "CashPaidForStateAndLocalFranchiseTaxes",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for state and local franchise taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "avxl_ChiefExecutiveOffice1rMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "ChiefExecutiveOffice1rMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Office 1r [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_ChiefExecutiveOfficer1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "ChiefExecutiveOfficer1Member",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r84",
      "r85",
      "r86",
      "r102",
      "r104",
      "r128",
      "r129",
      "r131",
      "r133",
      "r139",
      "r140",
      "r172",
      "r183",
      "r185",
      "r186",
      "r187",
      "r190",
      "r191",
      "r194",
      "r195",
      "r197",
      "r198",
      "r200",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r357",
      "r413",
      "r414",
      "r415",
      "r416",
      "r419",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r442",
      "r463",
      "r483",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r669",
      "r683",
      "r684",
      "r691"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r107",
      "r210"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "avxl_ClinicalTrialsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "ClinicalTrialsMember",
     "presentation": [
      "http://anavex.com/role/SegmentedInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trials [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "avxl_CommitmentShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "CommitmentShares",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_CommitmentSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "CommitmentSharesMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_CommitmentSharesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "CommitmentSharesShares",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies - Note 6",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r64",
      "r390",
      "r441"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares of common stock reserved for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "avxl_CommonStockConsiderationExerciseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "CommonStockConsiderationExerciseShares",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock consideration exercise shares"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_CommonStockExcludingCommitmentSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "CommonStockExcludingCommitmentSharesMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Excluding Commitment Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_CommonStockIncludingCommitmentSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "CommonStockIncludingCommitmentSharesMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Including Commitment Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_CommonStockIssuedUponCashlessExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "CommonStockIssuedUponCashlessExerciseOfStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon cashless exercise of stock options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r542",
      "r543",
      "r545",
      "r546",
      "r547",
      "r548",
      "r687",
      "r688",
      "r690",
      "r746",
      "r767",
      "r770"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://anavex.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://anavex.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r442"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://anavex.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://anavex.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r41",
      "r442",
      "r461",
      "r770",
      "r771"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital stock Authorized: 200,000,000 common stock, par value $0.001 per share Issued and outstanding: 86,668,521 common shares (2024 - 84,795,517)",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r195",
      "r202",
      "r392",
      "r538"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r511"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r573",
      "r660"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r573",
      "r660"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r575",
      "r662"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r575",
      "r662"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r577",
      "r664"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r575",
      "r662"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r568",
      "r655"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r569",
      "r656"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r569",
      "r656"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r567",
      "r654"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r570",
      "r657"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r572",
      "r659"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r572",
      "r659"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r573",
      "r660"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r576",
      "r663"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r661"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r571",
      "r658"
     ]
    },
    "avxl_DeferredGrantIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "DeferredGrantIncome",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred grant income",
        "label": "DeferredGrantIncome"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_DeferredGrantIncome1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "DeferredGrantIncome1",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred grant income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax expense",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r73",
      "r682",
      "r686"
     ]
    },
    "us-gaap_DeferredRentCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredRentCredit",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred grant income - Note 4",
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r759"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible asset costs",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross deferred tax asset",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development tax credit carryforwards",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "DeferredTaxAssetsResearchAndDevelopmentCapitalization",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development capitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development tax credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "avxl_DeferredTaxAssetsUnpaidCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "DeferredTaxAssetsUnpaidCharges",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unpaid charges"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance of deferred tax assets",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232"
     ]
    },
    "us-gaap_DefinedContributionPlanDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanDisclosuresTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of contributions under the plan",
        "documentation": "Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r432",
      "r433",
      "r447",
      "r448",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r470",
      "r471",
      "r472",
      "r473",
      "r476",
      "r477",
      "r478",
      "r479",
      "r487",
      "r488",
      "r489",
      "r490",
      "r502",
      "r503",
      "r505",
      "r532",
      "r533",
      "r541",
      "r543",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r742",
      "r743",
      "r744",
      "r745",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r432",
      "r433",
      "r447",
      "r448",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r470",
      "r471",
      "r472",
      "r473",
      "r476",
      "r477",
      "r478",
      "r479",
      "r487",
      "r488",
      "r489",
      "r490",
      "r502",
      "r503",
      "r505",
      "r532",
      "r533",
      "r541",
      "r543",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r742",
      "r743",
      "r744",
      "r745",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "DirectorMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r768"
     ]
    },
    "avxl_DisclosureAccruedLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "DisclosureAccruedLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_DisclosureEquityOfferingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "DisclosureEquityOfferingsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Offerings"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_DisclosureOtherIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "DisclosureOtherIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r565",
      "r588"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r565",
      "r588",
      "r629"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "avxl_EarningPerShareBasicAndDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "EarningPerShareBasicAndDilutedAbstract",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r94",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r126",
      "r128",
      "r131",
      "r132",
      "r133",
      "r136",
      "r193",
      "r266",
      "r306",
      "r309",
      "r352",
      "r353",
      "r383",
      "r399",
      "r512"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r94",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r128",
      "r131",
      "r132",
      "r133",
      "r136",
      "r193",
      "r266",
      "r306",
      "r309",
      "r352",
      "r353",
      "r383",
      "r399",
      "r512"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and Diluted Loss per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r135"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationGiltiAmount",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences relating to GILTI inclusion",
        "documentation": "Amount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r733",
      "r735"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r529"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r529"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining stock based compensation",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r75",
      "r76",
      "r77",
      "r91",
      "r92",
      "r93",
      "r110",
      "r111",
      "r112",
      "r114",
      "r121",
      "r123",
      "r125",
      "r138",
      "r173",
      "r174",
      "r175",
      "r192",
      "r211",
      "r266",
      "r297",
      "r298",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r376",
      "r398",
      "r403",
      "r404",
      "r405",
      "r419",
      "r483"
     ]
    },
    "avxl_EquityOfferingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "EquityOfferingTextBlock",
     "presentation": [
      "http://anavex.com/role/EquityOfferings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity Offerings",
        "label": "EquityOfferingTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r581",
      "r592",
      "r606",
      "r633"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r578",
      "r589",
      "r603",
      "r630"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "avxl_FairValueOfInitialCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "FairValueOfInitialCommitment",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of the initial commitment"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_FederalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "FederalMember",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange gain (loss)",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r362",
      "r363",
      "r364",
      "r365",
      "r480"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "avxl_ForeignExchangeAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "ForeignExchangeAndOther",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign exchange and other",
        "label": "ForeignExchangeAndOther"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r596",
      "r610",
      "r637"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r596",
      "r610",
      "r637"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r596",
      "r610",
      "r637"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r596",
      "r610",
      "r637"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r596",
      "r610",
      "r637"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r466"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "avxl_GrantIncomePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "GrantIncomePolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant Income"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r563",
      "r565",
      "r588"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r105",
      "r277"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r66",
      "r68",
      "r384",
      "r386",
      "r396",
      "r507",
      "r509",
      "r510",
      "r515",
      "r521",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r105",
      "r277"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r316",
      "r322",
      "r339",
      "r340",
      "r354",
      "r355",
      "r356",
      "r358",
      "r359",
      "r360",
      "r401",
      "r402",
      "r467",
      "r499",
      "r500",
      "r530",
      "r531",
      "r533",
      "r534",
      "r535",
      "r536",
      "r739",
      "r740",
      "r766"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r316",
      "r322",
      "r339",
      "r340",
      "r354",
      "r355",
      "r356",
      "r358",
      "r359",
      "r360",
      "r401",
      "r402",
      "r467",
      "r499",
      "r500",
      "r530",
      "r531",
      "r533",
      "r534",
      "r535",
      "r536",
      "r739",
      "r740",
      "r766"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r278",
      "r279",
      "r286",
      "r294",
      "r529",
      "r737"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r278",
      "r279",
      "r286",
      "r294",
      "r529",
      "r737"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://anavex.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r106",
      "r274",
      "r278",
      "r283",
      "r284",
      "r285",
      "r287",
      "r293",
      "r299",
      "r300",
      "r301",
      "r302",
      "r387",
      "r408",
      "r418",
      "r529"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r275",
      "r276",
      "r287",
      "r288",
      "r292",
      "r296",
      "r412"
     ]
    },
    "avxl_IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign income taxed at other rates",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r282",
      "r529",
      "r733"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax benefit at statutory federal rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r529"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development tax credits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r735"
     ]
    },
    "avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credits, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other permanent differences",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r733",
      "r734"
     ]
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to true up to prior years\u2019 tax provision",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r734"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and local taxes",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r529",
      "r733"
     ]
    },
    "us-gaap_IncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive and tax receivables",
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r670"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Incentive and tax receivables",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in working capital balances related to operations:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and deposits",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "avxl_IncurredExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "IncurredExpenses",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incurred expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r596",
      "r610",
      "r628",
      "r637",
      "r641",
      "r649"
     ]
    },
    "avxl_InitialCommitmentShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "InitialCommitmentShares",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Commitment shares"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_InitialCommitmentSharesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "InitialCommitmentSharesShares",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial commitment shares, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r647"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r566",
      "r653"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r566",
      "r653"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r566",
      "r653"
     ]
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income, net",
        "documentation": "Amount of interest income (expense) classified as operating."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r509",
      "r693"
     ]
    },
    "avxl_IssuanceOfCommonSharesNetOfShareIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "IssuanceOfCommonSharesNetOfShareIssueCosts",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares, net of share issue costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of operating lease costs",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r102",
      "r103",
      "r104",
      "r172",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r312",
      "r313",
      "r314",
      "r357",
      "r440",
      "r514",
      "r528",
      "r551",
      "r701",
      "r762",
      "r763"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r65",
      "r394",
      "r538",
      "r539",
      "r540",
      "r682",
      "r685",
      "r698",
      "r756"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_LicenseFeesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "LicenseFeesPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Fees"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_LincolnParkCapitalFundLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "LincolnParkCapitalFundLLCMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lincoln Park Capital Fund L L C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r179",
      "r180",
      "r181",
      "r182",
      "r269",
      "r527",
      "r699",
      "r700"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r179",
      "r180",
      "r181",
      "r182",
      "r269",
      "r527",
      "r699",
      "r700"
     ]
    },
    "avxl_MarketPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "MarketPrice",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market price"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r599",
      "r600"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r599",
      "r601"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r599",
      "r602"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r599",
      "r602"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r599",
      "r602"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r599",
      "r602"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "avxl_MichaelJFoxFoundationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "MichaelJFoxFoundationMember",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Michael J Fox Foundation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_MilestoneBasedContractAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "MilestoneBasedContractAccruals",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone-based contract accruals"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows provided by Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r54"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows used in Operating Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://anavex.com/role/SegmentedInformationDetails",
      "http://anavex.com/role/StatementsOfCashFlows",
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity",
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss and comprehensive loss",
        "verboseLabel": "Net loss",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r54",
      "r67",
      "r77",
      "r81",
      "r88",
      "r89",
      "r93",
      "r102",
      "r103",
      "r104",
      "r109",
      "r113",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r124",
      "r125",
      "r130",
      "r172",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r193",
      "r196",
      "r199",
      "r204",
      "r266",
      "r306",
      "r309",
      "r353",
      "r357",
      "r397",
      "r462",
      "r481",
      "r482",
      "r507",
      "r509",
      "r510",
      "r549",
      "r701"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "avxl_NonCashShareBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "NonCashShareBasedCompensationMember",
     "presentation": [
      "http://anavex.com/role/SegmentedInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Cash Share Based Compensation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "avxl_NonOperatingIncomeFromGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "NonOperatingIncomeFromGrant",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non operating income from grant"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_NonOperatingIncomeFromGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "NonOperatingIncomeFromGrants",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant income"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "avxl_NoncashFinancingRelatedCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "NoncashFinancingRelatedCharges",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non cash financing related charges"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consideration shares issued",
        "documentation": "The number of shares issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r17"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OffsettingAssetsLineItems",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r503",
      "r504",
      "r505",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r742",
      "r743",
      "r744",
      "r745"
     ]
    },
    "us-gaap_OffsettingAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OffsettingAssetsTable",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Table]",
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r503",
      "r504",
      "r505",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r742",
      "r743",
      "r744",
      "r745"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r507",
      "r510",
      "r515",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease costs",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r537"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r537"
     ]
    },
    "avxl_OperatingLossCarryForwardsExpirationYear": {
     "xbrltype": "stringItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "OperatingLossCarryForwardsExpirationYear",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carry forwards expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "avxl_OperatingLossCarryforwardsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "OperatingLossCarryforwardsDescription",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards description"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "OptionIssued",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option issued"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionPrice1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "OptionPrice1Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionPrice2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "OptionPrice2Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionPrice3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "OptionPrice3Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 3 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionPrice4Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "OptionPrice4Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 4 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionPrice5Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "OptionPrice5Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 5 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r78",
      "r79",
      "r80",
      "r409",
      "r410"
     ]
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All other accrued liabilities",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OtherFinancingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "OtherFinancingExpense",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other financing expense",
        "label": "OtherFinancingExpense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/SegmentedInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r464",
      "r491",
      "r492",
      "r493",
      "r539",
      "r540"
     ]
    },
    "avxl_OtherIncomeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "OtherIncomeDisclosureTextBlock",
     "presentation": [
      "http://anavex.com/role/OtherIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Income",
        "label": "OtherIncomeDisclosureTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Incentive and tax receivables",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r450",
      "r522",
      "r539",
      "r540",
      "r765"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "avxl_OtherResearchAndDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "OtherResearchAndDevelopmentCostsMember",
     "presentation": [
      "http://anavex.com/role/SegmentedInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research And Development Costs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherSignificantNoncashTransactionValueOfConsiderationGiven1",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consideration payment",
        "documentation": "The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r17"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r583",
      "r594",
      "r608",
      "r635"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r586",
      "r597",
      "r611",
      "r638"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r586",
      "r597",
      "r611",
      "r638"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r615"
     ]
    },
    "us-gaap_PaymentsForDelayedTaxExemptExchange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForDelayedTaxExemptExchange",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment for taxes related to cashless exercise of options",
        "label": "Payments for Delayed Tax Exempt Exchange",
        "documentation": "Cash outflow related to a property which is traded for the promise to provide a replacement like-kind property in the near future also known as a tax deferred exempt exchange."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/SegmentedInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development costs",
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_PensionContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PensionContributions",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contributions to 401(k) plan",
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "avxl_PermanentDifferencesRelatingToStockBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "PermanentDifferencesRelatingToStockBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences relating to share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_PersonnelCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "PersonnelCostsMember",
     "presentation": [
      "http://anavex.com/role/SegmentedInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Personnel Costs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r703",
      "r704",
      "r705",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r703",
      "r704",
      "r705",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "avxl_PreclinicalStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "PreclinicalStudiesMember",
     "presentation": [
      "http://anavex.com/role/SegmentedInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preclinical Studies [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://anavex.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r205"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://anavex.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r442"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r195",
      "r201",
      "r391",
      "r538"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance or sale of equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r413"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r10"
     ]
    },
    "avxl_PurchaseAgreement2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "PurchaseAgreement2023Member",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "avxl_RecentAccountingPronouncementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "RecentAccountingPronouncementsPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r578",
      "r589",
      "r603",
      "r630"
     ]
    },
    "us-gaap_RedemptionPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RedemptionPremium",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock net proceeds",
        "documentation": "The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r108",
      "r109",
      "r171",
      "r212",
      "r229",
      "r377",
      "r378",
      "r389",
      "r395",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r460",
      "r486",
      "r769"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r108",
      "r109",
      "r171",
      "r212",
      "r229",
      "r377",
      "r378",
      "r389",
      "r395",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r460",
      "r486",
      "r761",
      "r769"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://anavex.com/role/SegmentedInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r732"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development incentive income",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development incentive income",
        "label": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://anavex.com/role/SegmentedInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r732"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://anavex.com/role/SegmentedInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r732"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r499",
      "r507",
      "r508",
      "r521",
      "r764"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "avxl_ResearchAndDevelopmentIncentiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "ResearchAndDevelopmentIncentiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development incentive income"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_ResearchAndDevelopmentTaxCreditsYear": {
     "xbrltype": "stringItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "ResearchAndDevelopmentTaxCreditsYear",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development tax credits year"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r579",
      "r590",
      "r604",
      "r631"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r580",
      "r591",
      "r605",
      "r632"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r587",
      "r598",
      "r612",
      "r639"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r57",
      "r393",
      "r406",
      "r407",
      "r417",
      "r443",
      "r538"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r77",
      "r110",
      "r111",
      "r112",
      "r114",
      "r121",
      "r123",
      "r125",
      "r173",
      "r174",
      "r175",
      "r192",
      "r266",
      "r297",
      "r298",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r341",
      "r343",
      "r344",
      "r346",
      "r351",
      "r372",
      "r373",
      "r403",
      "r405",
      "r419",
      "r770"
     ]
    },
    "us-gaap_RevenueRecognitionIncentives": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionIncentives",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Incentive Income",
        "documentation": "Disclosure of accounting policy for sales incentives."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of principal components of accrued liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r23",
      "r24",
      "r25",
      "r26",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of income tax expense",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r529",
      "r733"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of general and administrative expenses and research and development expenses",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of loss before income taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r686"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://anavex.com/role/SegmentedInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development, Contract to Perform for Others [Table]",
        "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r732"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://anavex.com/role/SegmentedInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of summarizes the significant expenses",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of summarizes information about stock options",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r58"
     ]
    },
    "avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of weighted average assumptions for fair value of each option award"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stock option activity",
        "documentation": "Tabular disclosure of the change in stock options."
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://anavex.com/role/SegmentedInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segmented Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r137",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r167",
      "r168",
      "r170",
      "r516",
      "r519",
      "r520",
      "r521",
      "r523",
      "r525",
      "r526"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment and Geographic Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r166",
      "r169",
      "r517",
      "r518",
      "r524"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/SegmentedInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative costs",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r506",
      "r507",
      "r508",
      "r510",
      "r681"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4",
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation",
        "verboseLabel": "Total share based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value, Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average grant date fair value, Outstanding beginning balance",
        "periodEndLabel": "Weighted average grant date fair value, Outstanding ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value of options vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annualized volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional shares of common stock available for issuance",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option available issue",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value, Exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate intrinsic value, Outstanding beginning balance",
        "periodEndLabel": "Aggregate intrinsic value, Outstanding ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options, Outstanding beginning balance",
        "periodEndLabel": "Number of options, Outstanding ending balance",
        "label": "Number of outstanding options",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Outstanding beginning balance",
        "periodEndLabel": "Weighted average exercise price, Outstanding ending balance",
        "label": "Weighted average exercise price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price options vested",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value, Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value, Forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value, Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationForfeituresPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation",
        "documentation": "Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r235",
      "r265"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise prices, Lower range limit",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise prices, Upper range limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life of options (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value, Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life",
        "verboseLabel": "Weighted average contractual life of options outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of vested options",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable",
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssued",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "SharesIssuedPursuantToCashlessExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to cashless exercise of stock options"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_SharesIssuedPursuantToCashlessExerciseOfStockOptionsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "SharesIssuedPursuantToCashlessExerciseOfStockOptionsShares",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to cashless exercise of stock options, shares"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_SharesIssuedPursuantToExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "SharesIssuedPursuantToExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to exercise of stock options"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "SharesIssuedPursuantToExerciseOfStockOptionsShares",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to exercise of stock options, shares"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_SharesIssuedUnderPurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "SharesIssuedUnderPurchaseAgreement",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under 2023 Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_SharesIssuedUnderSalesAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "SharesIssuedUnderSalesAgreement",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under 2025 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_SharesIssuedUnderSalesAgreementShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "SharesIssuedUnderSalesAgreementShares",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under Sales Agreement, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning, shares",
        "periodEndLabel": "Balance at ending, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "avxl_SharesWithheldRelatedToCashlessExerciseOfStockOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "SharesWithheldRelatedToCashlessExerciseOfStockOption",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares withheld related to cashless exercise of stock option"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_SharesWithheldRelatedToCashlessExerciseOfStockOptionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "SharesWithheldRelatedToCashlessExerciseOfStockOptionShares",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares withheld related to cashless exercise of stock option, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r84",
      "r85",
      "r86",
      "r102",
      "r104",
      "r128",
      "r129",
      "r131",
      "r133",
      "r139",
      "r140",
      "r172",
      "r183",
      "r185",
      "r186",
      "r187",
      "r190",
      "r191",
      "r194",
      "r195",
      "r197",
      "r198",
      "r200",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r357",
      "r413",
      "r414",
      "r415",
      "r416",
      "r419",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r442",
      "r463",
      "r483",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r669",
      "r683",
      "r684",
      "r691"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r41",
      "r44",
      "r45",
      "r75",
      "r76",
      "r77",
      "r91",
      "r92",
      "r93",
      "r110",
      "r111",
      "r112",
      "r114",
      "r121",
      "r123",
      "r125",
      "r138",
      "r173",
      "r174",
      "r175",
      "r192",
      "r211",
      "r266",
      "r297",
      "r298",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r376",
      "r398",
      "r403",
      "r404",
      "r405",
      "r419",
      "r483"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative",
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r138",
      "r194",
      "r195",
      "r197",
      "r200",
      "r373",
      "r381",
      "r411",
      "r420",
      "r431",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r465",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r483",
      "r509",
      "r510",
      "r544",
      "r769"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative",
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r138",
      "r171",
      "r194",
      "r195",
      "r197",
      "r200",
      "r373",
      "r381",
      "r411",
      "r420",
      "r431",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r465",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r483",
      "r509",
      "r510",
      "r544",
      "r769"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r582",
      "r593",
      "r607",
      "r634"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r41",
      "r57",
      "r413",
      "r483",
      "r495"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise option shares purchase",
        "negatedLabel": "Number of options, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r41",
      "r57",
      "r244"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued, value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r41",
      "r57",
      "r419",
      "r483",
      "r495",
      "r550"
     ]
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "StockIssuedDuringPeriodValueNewIssues1",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pro rata basic number of shares obligated to purchase"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues2": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "StockIssuedDuringPeriodValueNewIssues2",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares issued, value",
        "label": "StockIssuedDuringPeriodValueNewIssues2"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of shares remain available",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionExercisePriceIncrease",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "exercise price",
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionMember",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r741"
     ]
    },
    "avxl_StockOptionPlan2015Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "StockOptionPlan2015Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2015 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_StockOptionPlan2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "StockOptionPlan2019Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2019 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_StockOptionPlan2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "StockOptionPlan2022Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase shares, shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r41",
      "r57",
      "r416",
      "r483",
      "r497"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase shares",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r41",
      "r57",
      "r419",
      "r483",
      "r497",
      "r550"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets",
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r44",
      "r45",
      "r55",
      "r444",
      "r461",
      "r484",
      "r485",
      "r538",
      "r551",
      "r682",
      "r684",
      "r685",
      "r698",
      "r756",
      "r770"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://anavex.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r760"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "auth_ref": []
    },
    "avxl_TotalAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "TotalAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued liabilities",
        "label": "TotalAccruedLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r141",
      "r142",
      "r143",
      "r144",
      "r384",
      "r386",
      "r513"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "avxl_ValueOfSharesObligatedToPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "ValueOfSharesObligatedToPurchase",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of shares obligated to purchase"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_WarrantsOutstandingWeightedAverageExercise": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://anavex.com/20250930",
     "localname": "WarrantsOutstandingWeightedAverageExercise",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r133"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r133"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "70",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481178/840-20-25-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-7"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479341/842-30-25-11"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>65
<FILENAME>0001731122-25-001596-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-25-001596-xbrl.zip
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ML)E//;XI%@XC4PD$]_*EA\"TUDU)]A"1%O0YASY?EG\8FTI"!#OJ==]6M9!
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M$@.&XL:504R5+U:Q_9+%%K0'^GK'E8%2JAFKP'[- @ME0&X)Y H+&QF*&JM
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MM4I R=SIU6#M$5=;MEJ!>6'<[3824+75K%6@2EK6 ZTQ7AJ+6ZN E1RL!]S
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MSX .%H2:&9YR+'43R%IB50BROFDP&E'SC\82ZBAE4(6$#D#3($G[T70X2DV
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M. D<N*8"L*"A?O%FY3WZ:Q;$08(>$)D''LK6ANPVRCBCJF)G0W?-]AI2FPH
M+<[8QLHM2K(+Z$4_X;)YK"6SGLLR6E#QA:V1WP\V!*'5?%?B':PJ &=>8=%9
MN,=\Z5=IF+=PL5B'E>NL"D[=MQ=%.W ,3+622@?BY EXO"G@HK0-21?E:9!J
MB^"<:Q*=G9T=]DXVY5F4YA2*2WE*"V1>WJ)XG\H\UB6C=I8%.MT4*"^*(2\4
MYJQ*<Z#@>JJ$X87W+ -_OPD\S^8(PH*J0K@6][,,[<,FM#2]PP\4J@I3*0IH
M&=>OF[BR/ X8.E3=Y29!+- RSK-2K[C*GU]A$403505Z+5QH">31X2;(++W#
MC2^JK)USXX:6P?5*K7J1T1%$'%77&VU&$RTC+(U\JTP./P9INWVEH,\\*@UJ
M\GVF\\OB+VTWR^!XHV5)2L,9IQ-U?LGR:P,L$7NTC+PT;@G[".TR<"*4EC&7
MAJQBEZ$=HBA::1EK:0SC]B#Z03<,4UH6J#3XU6FT>07.LH866^\R6%=9IM)
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MC*B&^&;LFE4+M0YS;\/^]%=.=]+B32@1LFVS+^&6--$P'$'AMD^N*%WVWCK
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MPC=UG<,$3_N->8FO+JBPV!@N(:\C3-(]8W@XAO,,>Z=F1F45NRU58D'D*7]
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MPJKR\E!4O!EO';6<*[.GLMYM\@3J@D%9>4;6%:-KU7_ICB"/I@H\-WQ(9GZ
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M-E^5P$XKK.J[=8QZ;N\XL32C?[V)0<F[ QV+5)R<+/40^UH]_I4W@T)AH7T
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MOF-#951'P"DG!& ](C1/X=3^$)*P$>L)DS"F/0P7\E'7'TF0%FRCZ%D0$QY
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M.!ICNLWBJ$5Q,/D^R8:1BZ5UP:@\7[LJNN?*H4S2V7Z,J<D"]L6^@$8R*8W
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MWY E7&&F8>I\N61V?DDM[B6'S,+[J&2A;!:PQ D[?8P-=>A0"+.K[-AT'^^
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M&-]B\AB'6/YY5@F'P0_\KA)3_XZC:TSB+&)QGGD#X'+O\]/.%OIL\N8W\\L
MMLIE+-0UU@U.Z5 CX5D)0;2-TYAMKN6YTKA*SN?/2#>W.NKD5N.94O@5<X8R
MCW4=/+-7_XKCS4.!H]4CM6"#V=1\^7URZH%*!Z/MY18HW]F,XQ*?I9F0G+-P
M[XUL*8MTC>I+528*RD)1T!;&[VM?L[6D1[Z61,5Q0-M5'52RN!10OUBF$GS
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M&KYJ1^"A'^ L(VL<%^ST=,57J R0I5*X?+N[G8G./VF[N]'9J[VW8#_V3AT
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M)M220&K# J"PYM2J@*J5%=]K<YQD.;[+?DYW,8O_%/6BDP52,U80!;=6GO3
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M ZY72^16=<S^+@M#O=)X,C(O3U+EW9\NZ%_TY_HG^O]8,B3]Y?\#4$L#!!0
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M2NEU4:X^F:/R*0XYPDG^<*9Y[P ? :VN^^';/%N8T*VM1#!X%ZCK@U8<OJT
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M$^$H>(M/[W>2D]F,^H0E5Y%!ZP'=P'+H/FC#B'%LPPB*7.X(89]8O%IFUZ,
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M^'C$[N$W+U2;@K8#<N@"4!  GC&,0KK9AUB&J2-R2,/!_A!L&Y%2IKUFT?=
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M=O\HFCM9U %Q)(OBB<M\_SQY#$4*/0FF\=9IKI"'N1MVK2/E'6X9>"CW^![
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MLL]!M'R6O+-TTOV1^=Z-)>\L39S\F!R?T$[O2C1[2U-(%F?3TR<]GVCVELO
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MGG-@7B8>*U]8?6:6R^_?P6^SORK'P>C K%5'\5M3?-(-8I#!!V8#/[MQG7B
M#U1_VLC\O!N$,!_^\P^>97\WZZ/8C +/==Z:XDLY$O^^EG[?@PM5CMQ_V %^
MNO'^O_ZCME-]RY<F_JDMX4UF#5-6+H<891[ %\$[FO#J*^"7D7G&;LQ+8&)^
MB7]0,CMPX7MJ\;2>ZL1>P"?( <J6Y_;A?38P+M0_WG7??SD[N6H?F9VKUE6[
M\^Y-]_WC3Z'3/OQR>7)UTNZ8K;,CL_WGX:?6V<>V>7A^>GK2Z9R<G\V85_V!
MYO4'V/^NWX\#&.ZH<E@QZ]7MYOZ42507G<34U\T\_KV'V_OC\\M3\UTTLGSB
M [?.[=?]:N,K<YA;+A\%-N'+H;[VU4:Q!?>H]A55C>WJ/N@<_[#ZOW]S]S_N
M_F5_A^'@FON!3YS0M4TA=2Y9+Z^UQ$$JSC:X5@.:8A6UC-J&Z5NHBL $#O3W
M;[R'G_Y*K"1]!Q %3OW]#/KX\:.!79*GLY2W;+S?/+7"[^:YS[:6,MQ,VL'[
M<0BL&-4\&*PD_U(R3P,_@-VSV?P=(/K0QBWWK*'KC0]F3U+^,"6L=HZP6KZ?
M6-XE&P5A7$Q@G6\G<=7K?635WKT)#*T/*_YYP[V-#[I!X#$+3).$Y2BO7D1Y
M^@1QH_=WFSMOIQ A/X;6V=F7UF?CLGUQ?GEE7GRY['QIG5V95^<FL+DKX&5F
MK6&>7YJU[4UGRSP_-J\^M4V- RKNUSJ\PJ]K^XVFHO*G8#X_/CQ8?B:8>&;/
MC6S+,\=@YYF@O3+'A*N5H2WZM</L("1/ZX&9((:DY_ILDI9:.5JZ(,6WS;7B
M8F+Z];Q^\N>GVW%SQUD*,3EH7L#O!HXUQE4Q/T=3C2*:RDQT<EV2^?)2EOB8
M-NTO&'WFTOX*+[Y=;%^$A]^6<T_TI4TLJZDO:]H\-]YWV"CFMAY:+85WIC0A
M>PYSQYJ.>PR?1,6KOQX-?[EH-?_\O=%?CAC:+CJXW%0VR"B;*I&F?/P\Y-7"
M6M/#RX1Z7MD(+3]R\?K/D@N.NQW4=Z];W_?JRY0+/<N+\H)AIU ER<U2"(?F
M;.%P==DZZYR@%%@+B (!$:M--;D;P^S!\9E?,_\QX^!K[C^KNN[#8#AT(_2!
M@6STF.DGY.CLOC\P[RT6C\1U:I-KZAB&/4MX?6G1-=IVAK:[_>UJ9V@MAW'N
MZI<E/P=T)-;*C=V=ZL[SYH_UA:W=66^Y]QEN9\[PDO4)5]2/L=M[\3EZXV]?
MKCX>W8[^L)=SCGN3YYB=Q\;[UEGK]_:?YN>38^!/AR?MLT/@3H?GEQ>5YW*X
MF^U;6 \MQ QZ9J@68%J1&8V8C0YLQW!A[^/(M =6"&,LPR9;@)O$5A=NO,T\
M#VTPU^__O %G@'\?68XC_W[G*6C^+N7&L@//LT81@YF(/Y&G[UT<RO&O61AC
M$KV<<1R,A#/P7>QD*'@Y6D#6@U9%%]J/W)=&YKY@ 7HX$K\CE!I1:WX8.%.N
MCS/89</CLR_?1O?7'S5MHAPQ^X""#Z,PN$;RFU"A]R?OU\QY;[P_8]>68RUR
MM<0?8V?B" 5U;"-Q/-_CW,D<YY5U>R*"31R2<I8\JS;^[O\6)Z?[S;VE\,%Z
M=?*<IDQHX_W^7KFZ4]UK5IMW.R7X1_C\+N0FD: )JEF \5GSFP;Q!-QT%ID]
M\,1.+D$+'HZ\8(Q1X>>^CZY^K6D[P[[EN__0W[>>;ANS-&R>!96MPLU\0Y+J
M_0JJUS_"@PXS/*CE."&+(O&OS_"+6C'_N:C]\9M]_,?OOWQ:CC^\7IOD/P63
MV7B_TZB:V_' ;%TS/V$+>UMVYBRS7KS,_N7.V6_=NOOYS^9REEE?9)EU]+C
M&H^]( @77N)QT1(/X8_GX55PXQ<OL#GZI>]VHX^)MQQ]NMZ8NL!T*BCC;\R_
M@O#[PHNK%BV.&/=Y> &Z!S"?*2I/[%YV1]^_]9++QG)6V)RZPMQ\8)E_35G@
MQ/K:A8?'U:(IJMQX]]?KT[-/1Q^ZRUG7]O23X_/8>/^E,V4]+6.:MRLST$4
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M;LURIY;524<3Z32OXS;?X8B>S9P+TZ[F!@!$ %OHM%AF@RX,*XX)01]O'5Q
MA$B"*5B\O8,J,[2B"/1%_$A>2M;K,?)OHB))$X$O\-<NRAP?. 0*]1 HQPS
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MM(GT)\%PF/CJ0.7+<'0\L@R%AY:/X9>1"&2(\!8FP@OGLY^0-PZC"DCO(N:
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M\5DD:N&P< [GB@4ADHQ@;H$P7T5MG3A+-#/@X.0=E&D_ADZY=M#WT[(8Z4U
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M(-%"Q?]H<)AA<!,/,-I"+@!\6Q>4G#X<5S+$Z*T4YNBS5(4^W< 9R] 2^2&
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M>BF?/C$#O#S\82/[<-<-A&W,38A%-$;1G09GC% 6=-D5G:GN'Z32IC%4U=]
M]B6=22(P.X;54*";8+Z7R,06Y-@^_*BH$=&>81*R4E<KRYGB>(<?:S_2$/4,
M=:Z9$G+SMRO[..U[($8GK2KM\<%/3M;3"2(K:'(V:\E:95[EE?"N;._=A@&R
M$GAWF5=A878 "$L)DBN4GF]!$N+%>.>^/T/-!NB73"*DV[X(%(',<6,4H*2+
M[KR%9]L4J\K7>?IH[1*;=/M#JUPCO@.J:FA8?6S_'%/R/(<NU(PSFTK\*15!
M,_]"1 >G7 01^B'V)97E,J6E27M.F7(X7:$QET!D8P*(4&&XX\I0CBLS&B*A
M#8%EVHDWM<*)2&FS=;Q;JW[8FLPHX!:O V(_=+NRO9 *L C%L)QZ@9 9L1 Y
MH3%',PAF.:@TTY7G84<1(9?D?' ""%G-)P_+(DX#\_VX/MX?<XCZ:2]^11=)
M1Y HD7O"%[ZD.URI0TDG%T)&T9FYRAN@K A^S? L\**5M)MVH<)B90[R=9C*
M &79QEQGSHI!2M5$0=56K:LYP2%]82S[C'RS'7%7+\5=Y16RJ9\*KO1IZL"2
M3QDM<:,)B3F-%2+Y7,UQ62 QPH'9 _>?8#0 CB[A4!3=28QW07]\=[(]O-)M
M(<@XPYZV+;^F$IOE-F**X$@S-SBD!*E$5F0S7[2_C308<:DJCS(H*=)_)'7'
MC!1/434F%)3Y*H,H0 @R^51938 O-N#HPG.-@VP;9P6P@C\4]@?NYL)9X&*.
M\<2^I0;1-DZ?ZY$E=%]P?:XTN1LE%=9&3 ^>@E#A-#U#4YNS5C<RTIQ)=@L'
MYD1Z>7+:;HVT,=GLK"=-X &9P/S\YQV5++$1,7B"74><!;S]F@]!8N^_%O9*
MC$P<6L0,07N"!\RXF=@M3\]GPE+N4EK91MCTV,9!=!VX)L_];(N'("14AD+9
MP1(%WRA,@U!-IF8V6HBR;.WXZBC+VB;]>?*686=>O:F@0%71P5%FIEFEEYFC
M;ZG*(8'6JE(",AZ0S'Q?  '.3Q9HKI,%,%F@N4X6>"[\$-2\C#;T(A)@%]:T
M5:M6T+,G/,^$5WM\U *^SPCS9P;S*W?^34V!LU[C X0ZFP<%G 4<=GTCRQ8U
M-XU('>2YZ#>!2$R/296@[G0I<DQ&8R37%P99KETG4>#9F=?D0/'J>V7'&AL%
MR,$(A,9[N','7P8/&7NQJPPSS!*VPA374V'F*@<,"K'L++)]2"]$<1GYD,\H
M> Y:;$>@?DJ@THO66:<C<$]YRD?/2T0.@7 \C0;CR%7Q&BTID&9,VAA6NHE*
MS!*ES(:\JY_L=R5$.C4@$*,BI8P&EL<[5XW?D$$K8_N:Z;O9;G]\T[Z\V,JD
M(^;$GQ3W7#("H7I6-Q"A7Z728_DE*,+C,@)%PHAIXKKY&QPL^<7H%X=4@1F[
MR9!79FKA-%+79V\+16$LB7V*[8W(@< WEX)0*F(=A..2 ;HJ3-;#)&BA-J,K
MQ0Y=/*=L%J9H%TNHXA%3&939K2 7@YK<>)YNIB *:(*@RR=68=K/"] P%N)K
M6J-F(V-;43??EC0N[\S-2I(!B;8[UC1^DUJHM9U<=Y4<S!M%'])\Y,6,9*1C
MX'Z(_P4W*W>ILHGE!:Q4Q*$XFBCEW().K8%X2H 1B1'/<=]D3BS!.>9F+8,
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M.FU"%U#M<=#@[&CL=W+>&/NG<L@"DV[B\.,<%$]./GTZ+>QG&2>$F6.$9>S
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MH-!N..&Q 57$MM%M%OGB^A"3: .<N[0J(0F-DU*)^V&8H$+3-B?H2%JV/?
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MTN9R[*+@%95/^^U:H(YN9\K,RR(]G;Q,#Z P 8G;]01ESP#9$7"@5[W O@;
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MQ6""GYEMRC12]K*@32BQ*!O\1=KI;9IL,T:^KM$;:WZW)K]MY01G\DDR,!%
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M]/,P.%SQSS]QC..&XF<;ZR)8VKJ_5/A4V8%3V8J=]&;<YRC+52NAQ=,$08P
MC)#K^K)5BE'-TPNSSGYVG)$7#PT[],0OHY-@V75H&/AI#/_3_9*+[&=95_^N
M2VF][6:"+EY6 N'O- F#M)\QS'*%5:8$#ZUF$!/,(V2(&6RY$MWL9:7_85<S
M0H+@C& YNM7X"R_&T]&5^"<:WC\?I;_Q=C1B:L([:J^EJR_$6N=M%PN &O<5
MH_ZIR@9EOU/R*B-S4R]3HL.10!!AUQ14II?6&+;3=!O?SC6(?2+B8+DK4)U
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M5O46YF<&):6-9!\9'_K$7#C,Q)NXT8!D2[NXV]*NHWG_F1;V2,ZL^#==V'?
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MP&B.KFI)JI5:=03PMWEG1X;>52)N;%4C*\Z&I*U)8;B&0IP7I%!Q(_P?VH&
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M$F]VJW H<@H^>YHI6KIK'?0L+YD*HAU%?X;"8AJD4JZJ9AM,2UGSK[0QSO#
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MXRV5,C>D2>ECD$U.:%MF\XC/IA,^X2UH^1R/DB'E,HN68$'L4'R$#+ZT\DY
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M&9HW&Y)Y9C;G\K7??*_))Z_JG,K4#DFY7LHDLS89PPIF%H%CE(Z;B@ !\C6
M;@C:P@@!'N#B3;$9\!_Y1DC-F74X(7]W43$\!P.YMU>XF0#69OX??I/KYA9&
M@!TK/,$-@!OWW3_2QY5[.7NKA1":6(;"WRSH4@C+H_]ZO@D:"-%1Q$#=W\J'
MZ;1C]]VLJ+IBEKO"/O7L4SJ!IVVX7:K$PJKOO#OM5"!7ICGLT/@%%*"^IH [
M:-\O%?O.I(5^,R#?/K0H-!@\K*C_AMB_.LHPG+2O9TCL-]I1MF^V02\I#(J
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M0#J)I-+\@A3B'^!<X[J9.-:Y;8BK6VXF0\L?:X(V'!>7<[1OFU-_/+O>3"H
MOI.[$DQ:5PT)6=6DP+3+.SJ?:^UF_H"""D_N!Y'X=KE6R5Z4)Z*YK95#P-1:
MC.M7(@I\.^E&467,:%;>QQ\8).'W&@95CBTOP;S6,T4ST@<:'95DD;:$WB$/
M9\63_-)LUEU3%;^*V-P[KY.2CLTFU4S96$ +>1Z!4QTC,-?/D@LF</ 1-_2"
MDG$%&PHGC?Q>C!-EUVOC*&?F;9$A7 38H[9(##)%=\7J#K'SY")JI!F?B3;
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MJJ6'&%T 11QL4Y$R8[U:&NNEH08:P@11_F1/'?4+8%L"^C=MX5\U?7CC8;-
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M?=;93,);R[.5=Z%,QLLP'10)T5+3#O?,+>&(=U6OD_AT/+GFMJ2&$5OYH3R
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M[9HEG6=6DT8+D6)8U2N>S>ML7C-/,-2A/&7E417'R$# ==YZ$VH3!9:F34_
M[XU]G;?-DS+ PI^(&A(1N"WRUV/2O[+>,4(6.<M(YP&V^$C!Q@"O@8B(=:>5
MRP;T/DXX9QL]V^A/>8)Q/VZ?O[$MXL3SN"^OVESER+:L1LJM"4!%!$*.BJ%
M5')M_5$=""N1JSH;Y]DX?PGC)/*5YR\3MA_B/-@TK7+E<<8Y\B# 4,_V=[:_
MG_($NN-ZIYAR!I U7C>5HNL/^9$DZ/A[9V,[&]O/,3:N;VV.@<5NRAL5>[]C
M!UM,2@<,(Q]I^(PM*//,N$ZK>NNO@V9-U+[0)V4J+?XWJN=#)^[C>V/AY_/V
M^V3 0>YA-=22H^$S3$Q?<T\-1Y!#C;IG*7H.U(;(9#+U+"'3V>C.1C?S!%+D
M@(C6->F,7Z$A=$*V ;+;3JK H <PW=ZK;@!<% !/VR:[R0^&IOM\ECEO[[]
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M'SS[4$IXG4#497MRX6LOJ;KP9W.,TK]]B0PY'?*H/9>?2]L_HQ?UH5(1-2F
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MP$C.Z_HQ]5LU>?,[[G@7BYB=:V<);$8SR-5@6= Q6 .]"P>[XU]P+K /W]:
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M ]HXJ HUD!K)$8H41^),?@/D/J#M>,Z8D(%$>&.@GI@^!11!"]FG(#)+7=5
M@;7#)%]*"!+M=Y ]S(_ .Q'?3ZF#**T&=EB[#KLCH1>AQ3D=9#AJP&T!IA8M
M&L0A*SCI[=<" ,QZJT[EY55\CD9!YV0LM[,5 ;CA$I'&P,X(?'G83+E,:"W7
ME[R%<JFEY+W#T;Y*32Z&I2H<%':"UUL(UDV2?F%JS9)4:PD>(DG'#-B9=,J
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M:&GU?UL)OPY?M9,D"L0<B^=W8\+Y_?XU77DM39+__6+-Y+7L%TJV%&7GS!%
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MU:N+'&GD<N9RG9[1&;P-C;&N XI&$,0(.KB56NALY6L:?O#9,->(OS+3I1S
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MU28[&TKY_JE>JW%?#,R7D$W =,&Z8PQ#$&K8H(=C?/DCZ4TQ7J=ZO!Z3,=!
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M4KR81EA4':.<R:(V&,:[5FL!Q>6A7SY%O?36<[TTU$MO+7N]]+/>FT;O7<]
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M^U.]UK"C54BGC437XA\.D&)?^Q$U93&"DL0N6F\VUAHZ:5ORIG&>WE(OZ\<
MHYUQ-Q^^&664:.BPAY,J=T]G(AS\0"Y: R[RN'PU-@2K3G8JC)9PNH$DWKT1
M.LZ5#7QN\2]I,%#..(:,'#-RQWWE%BY#,I.@T&28UO8S3 M@6MM/ :8U;[&\
M>U.RN\0CPM>[H(0/D&.DNE'2O =A1D0>-!Y3*!*7KK7L''*@:)DQ*D^LS+>
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M)#_5-W09H3FD$_ZHFDRH](VA@%!#$!Q?[ +;E(%58&',;188YWF+3<7SWP_
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MBSNG^&@J3"H95 K,17!=B)GX=!,J>%L@%J>/$0<<NK"U^[)$ *\1NO P)Q@
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MVA1\S@IPS;I%1H#!1%B-, 9G-QZ*DZ5\3T^&FE.T [Q\Q&\.<#(9FEYS=S6
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M.]Z_# C:HEEKS(H$HVI%"P9=R+0I!&WM(&6:SQ]W2A>.]"<#/<)KM1?&)N%
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M$1ND2K:O1;"ZOO"OKH(X@Q DI"TL-D>3/9'!0YB]D"BHCFP(GVF<HB+>3H/
M@8B18O!BO&$N@&3/2&&:5 4<L8G97,JI+(P&]#O!NQ1M<EE@R=&+H%NM',8<
M546YE:6%$^)2TAW%5%ATB\U#H?I >;E<TE2HT\3T+->!F:0(T^ZO7A;E-V/7
M$7L_X5>3-@7#>)ESITVAMIN@:2$O2Q4)I61M):QN9?QM>'#Z 1!1S5^;W5TA
M(#6_J16\,@H)+DE&[@A5?GHZ:H-O([FD#9J)$TRL0Y,IN@E>6"OR4C6O.MUM
MG;S1;-^&L"@6;TSQQK(,,XD(Y*N%C8)UQ+4F!N94[JLJ7%6@7HT%,-K@U)O
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MBZ5LT!.&Y)D+EA\"K"M7-)+<)[+$>LT]IW[IZL-R.D[PU2>B$X]*JH8 =$)
M@.<&T, .%AS:$Z0*R:_ZC0%'19A!/R-^9N6TK*5$8T"MIR:#<:2G4+2"1I('
MIIQ]4I)C:>V&I$TWV'@RR_/-(/5.%!78%*W!.^;@\X2NQJ&03:U]4U3;^H;1
M!O%B7H:* II.GEC/(?K-"W@CE@]5LM3SOT-,O:E6YI)^GZUR_.:X\R>U$W$#
M]D<Q(D*9>,JZ<JP_2Z('')ALYABPGO?%5%_47[(#QHTD\ @!EY1Y@DI9]ZOU
MFWCZB\9+30U,%6! ,((.0P>:1 ;Q)1YN7:3C,7!5'*ROFAH)+V5%/*$YL'1;
MQD[I\B_<[?5+]HO[]JQU?.%>_'YR=GQQ<NP>'9TNVBAED 1!T%WI<^?-*UQI
M)-P!+2Q,[L;"+?>[(+H.A9AY^.E/X*I@L$UZ#*YT%F83&9SAR*>(]Z__T*']
M'RMU_$AA_.? _5,.W$\=5YK5VW]U>:G_[V:K4=_8GWMD?_K(V8.']MTIPW+.
M?,)R[OW"<DY96*X\N*XI0\4N8&/><>%SU=9]^CUS[KFBLPMTPB(LG,VS@ 'M
MR8&XTC0)'"\&(SN3T-3CXL)N24C8N@OD!1#&W>0&;JR5U]B"I! R9L7O8, 1
M ACS C/_P''E@I]A]/0),QT3CJ@&2ZH7+)202L2Y0\J$A0QC/Q8/,M;CR"?&
M3$$\]8,]'<5B?6.EF=^I2:EY6B7FH+SRBHG>I<O6S^2[IHJ6.Q.BY=,O63%J
MCD&H*8/FSAR#YN[407/G.6@^O&/,W,68N3/_F/G4MH"C91)*9[6E46EH&*%>
M'>2ED9$R*#:>FO[$.Z0_9"07:P@I:*8'<B,<4-0E6.D'N $F(,3*;#L4W T@
MH$QWFRX&FZ21-#TQ+C\.2?P,HRD$Z+&2CFH&C? [!J=5IV\L H&2;"BAERR&
M9A.GT@BT0VO, >AL:2/0>T$/.WCS$<?:=ZT<'MR#FJE6:+F=>]\!4))),I-!
M$2H(*JENF7(H/>=VJ@9XX0V*XZK;&7$KV/]/)4-*:;D1_B+;#0Q&PD]CFN;[
M]B*$8JM[KY##ZB5C2U&ULL(CF$N,00!^((MR$Z9%P*X</M<"$S\Y?=QS;3W:
M#<07(P\F,4JI;!ZM&L0L"1W9BR0?DU5_RQDR"552VEZ7>PV9?ETLP*\8S!^[
MN124M][ K(@I6$%"JV@] H("P?SA-#O[/7OHJ30'E4T/N,N;W638FBH.NQW
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M=47+#X+:T&EW[XY;]2#[TJ1]J8SXSB056/=JS<D)YK$K]82WH*&VH%FZ!;-
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MS%U%DX:*?".][KTJ_8&]]]K&Y'20P*Y#&Z6PDS^X?1P,E6-]GISC93D3V%$
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M^,,GQ/B $9GVC3&ALGRT_]@XN2\?'P][ZU15'HRD#-@IH-PPMIH\I?MC?SZ
MKN1N:><:I?/7O-F&!N7L;ID#8@O>/K.#)=V;J92T[7>\G[>6K906OYH"J:;X
M[^\"F!EJ>VH,>OSG<TY1T $8&B_>I0ORSY:'VI21FDH0.]E\A!EAOGK/YA+1
M,(-%7$JEW4JVLL;#FQ+>W*6UG1F[2AH*44<ZG422# J<+ZO$5SOWAUSH6%%Z
M8TR@?X16"[P&<!\KNH7M!*^@7;-%-)UKQ7Q6VPKU)5PI;:.KXRK,YVX^W)SN
M5<X.SNSR.AC:>!@!3P/Q7/<X2\\C8!RR'JR1E+>K&\7;W-FU;*)>XK62REB"
M<E:LK&\\(2'ME3<K1+]>M!>DJG(J^F,:5!5Y']6#,VH/=2*7E1/#(H;XT[YR
MO_?[]$ _7TW[W62&.$R<U<C^PF??H%$=$^ZC#S.I)*D0BE5N/R$6@EBL+_BC
M0"RF8"$@Z6;4*))4+913G=-7K&1+N=F[^$[ [5BMPH=&:PAO\PWN6R7>(DMS
M2^C:%5W7;C%9:6[CH:A=%G\^VI>]59N'LY;C7BL#&QE-$'-8D2M.]3PN95"L
MYXLO):Z]#>,D%7>[?6^TGFWU\<&29ZN]75W![8Q>UDI:!;?50C97+F=+^80N
MUY1F!:=.:VDB+%D)UXP8*Z>1EE2-3TGZQ-)4+,W@WRBGX=\HBL5L5:Q](+2E
M4_LZCQ992;?VM282T9@2YL:4R#5#6IHX"R$EG:+6?+9:6H+PB_3QU&:K9#TH
MW=FYYV+_6E36R._S6<KZN9F/M9DTBF[RG:/'\X-?.ZW"VXR?>H/ZFZ00"B=&
M+<52^SWHE,3]9[U6[*Y=_<W8?**DJG\UK7K60K98RGVT^IOYP9Y&QO_ZYCNO
M%-0SF$W55!2^?+90C7=)K'E8N+I9Q;@I$T^(+%(9U0QD$=^.:+'TZ_'ZFZO+
MW;N<)/[:$U?8K.9-BF[VDQ?=+.7^KYH/1>6^);[>*>M0=#/WW5-+J^2VE"T7
M%TVL>WLYN&#!Q-L?8&USRY(>8&TK01,>H+9@AE6Z-3=[NM%JW=1:>76>W@PK
MF%+\]N4W<\)V);=,,7=GW]K*6;FH;G[YS?QW5%J%H86*F!7+ZVN4)A4QL=E
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M?ABQM ??$9:F_4ZAF>6JQ=.)U6_W%J<2:W$K)X:)U;T[W?O%M7 1+5[%(7N
M_VR/98KO!BG/3]6 V\Q$\PUVPPTH\A5D5N,X::+$\L((*"2&)G62JOG[COHH
MVV>2^DM&?.R@!.B;CTF'5LV6ZU^,JF>&]_.D?H_I:&4]FVSF^BS=RCYFL76D
MMFMM1QIH6'OKTO 8^_A8!ZK_"6GH&*GJ *N[PBE?HCR4#3@ >,X[U(^0K4];
M*A->JL(*<Q08">P9KP-H$FC;BOP>N36LF2Q=4ZD$-)4Z)'DI\HGGIIV@E\"
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M5_8+C=M*/W>F;B*&8R(.U<0U2%.9.JJ )@%3-]X H4F8NM32"W_V'@NMWKM
M^32F3D-/*VY/3*QR[VD<U0$CX96V'><#I!, B?&@MK#1]+10N86MOYBC.Y31
MX+:S0Z\]=:S3=EXLJG7NC]!_9>M]X\V^ NV8)WOA=9J/Y?93RVB&]?;=KU::
MKQD5#LQ"PB[E#&QH2!VJX,.%O&L7%]:XF*^'"^>NO,=H?1SG;69,#:S&CGGV
MN%<]^./RJ_MR(>+EB4J%?&]-7A!12T/OS<TK3PLS0BZ!+"SM_;HS2HI8;BFK
MA^T4P55+0QO-)Q!<$PT,,3&PF7'0/[Q_5/Y<]H>/JP1EI"Y?2T.7FUN7K\T(
MN01DZM3Z9V:Q=]:]$%</VVEDFH9^)<8#^AO+[\7KSYAXLUH9%ID+)X"Z'2]#
M,X)-1>VW'-/BDRN]$%M4<C(+H='8&[DG<)84N7<'IM$UI?Z'NA1OIB@X&080
MT$DDP5*TSA9ML\DA!3F&IA*<RBKT'1C.1W\'B0%40Z(#RV!6-<.D 8U5H;&G
M3G0:]1O,><6)@G20AVJYFE7FJ^I]#8H93*EP=\J&.*DLF<!5QX"7R(/>DZJ.
M0X8!\?S90"H"CL'0E5<'V[):#MGH^#MHXU1^4H4.$U?&S\F)B@9H/=V;PTVR
M^.1N@AD-6Y-:/46A0]N" Z)QUB'K<\K:S6H*3#[,D-]*@O0LJ1JP_O9X#!O0
M!K" &><&I(<X]-](][ V/V!PDSBNT1(T S)%X6SDE7U)U:T@=/F2&%U!W3:I
M,LQ _J'XK*Y!O\YN+\ J+0(P APV+DZEHVM 2]=4IOV[$VHXUGVCK)&$(HF.
MDQEBDBS >_(BYA4Z85BHWYR[ P6Q!C.#4\&?57+V**D)(WK)&4&NLO4M3H_C
MB3WX9C[I'<9Q0T=N; *\+1QV*'M)_&TO1(A@]@^TE:754[ YF B-7"FKG0X.
MZJ9-AHD-8TLN!'B/9#\D6$=FVNL8WL>7Q+[,IL*!&WDYH.3"1]$@H"$<>D3?
M@!YI,%#(C9@%K+5AXJFO#310 Y\T1"'D&]K,61EZKL'Y87HI H;M@"*)[$,S
M%4D>N@DEVYFZVU\:IJFK@;L-4^8=G;.[K/0-F'\,T@3 +%D&?#<D,K+KX(_<
MT4NV]*C@/"?$"7VY1R#T:.2@!@-,AB!9TJB\Y5V?80(T-IX:,L2Z$/A8/-[@
MW:BS4925"4I9AF;,X(72"T ;S4^%25D$RCBGRH"F^Q"C9JS"[EJ"&B+O _2
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MJ39D]XS"P?U-"-IA-#[D;V.3X&4%!AM*?BJF/]AXRD5EX5H")W4==%JX=%=
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MJ!:SS4PM_HD#S(1,@UR!_'_W7R+O #'M_.PG,><,Z(;EW!P]V<8# Z78S*,
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MA2;IRW;S;8Z'L8>C464"&5V!^U2W3;7ET*"O]$RXR!*(Q<:;#5ZSH!,#*?.
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MN4F?"15FM5'L<&RUQ*2M-FF+1<,[QV)SNRD#(IZ*JH5@$P2G42"<P;!$1K3
M[4RY;WE@9"TX=(29TP(*$<"VA"C2T6&Y<)PA Z!L^* 2@-W 1V0EF!_86 \H
MY#$^!]+CEC::.([KRC$Y_7BZB*698DP"T1)/X3/WWDWF C"[ -T.:Q[!;,=H
M)F BU 3D-F0")CZQ"1B5!==)4T?43_!9!_4=3A6 IHPO(=.AMT49TBSV0PG:
M4G%+0!F 7UW:LL;F7[X.(@$L);$!;C_E:9WF]@F;S&ZMO@ZH.>F!,^W^%P[-
M)/$'JCD<_RR<]\,UE*T.PLEQZXSQG\2J_(=;A/_8;J! !I.@Y>M O(/X_#W+
M$GMB[^]9C-@?"/>B:F^(/ZJ68 CINO:=H "+!,"-=#!!6\4;&H\,)#GV)$!3
M]:(V\#ZX-D G+Q &^HG<8H^#+ /\= ,Z2?P -B5U$_BQ+Z:"_T1]66X!%Z$(
MH-.1](#J[/LV>XZSXQFP$UFGS1,(_L*+0%%]"I_5:13(ICY?? /PTUT)V_GA
MFYWI2GA&QD5HIP>QC0H[NFR3G(VJH!J!R*2T!I\T:16!C=::]&+;,4[CI9ZF
M$P:NW%^<_2K65,E=S\7SA!>DT0V@G"2>"1.3[<B+"PF6H^]>GTPI'QB(\T,;
MY $PM=F=^\@.H;\3 Z6-D+AKN[TMYW0?_2RAU[(9T+J:"C!F'OFY7E><'O%3
M#^M+>V69P'\IP0<TX1II^>>KZLDO]?S6Z\OFP!BCI\ZS2W6.];U[7HNM\8P'
M/JY9I?S<.5H)UGC%Z9L,)N?TH9UF5U2D@$"9:G96\9J=N6UQO<<GVL\X;3(#
MK^'X_5R7'D]>J]+<:^#>[#7=42+1NG;2CF?1M[C ;:TZQGYL I:0FGUAG-?H
MC"DP93BQP@D\I9G\#L]JM!D=BA/;9<D49J1[HAJL&^3G+UNC;Q/2?(ZCH.!8
M<]F-U.MM^JQ@!'A<G]D!_/C @@E#!11U'92T%I@'%$)7/54&%0M4=HR:H7*/
M8!H+S-/?X:=.3#YI:T&X$LMXL6V;#G(%FC)"X<X:RS,?#2H-Z"U *X9U*04^
MV:+AA0 -*NDKUL.GT1ZP%),QL3$[;(>I%;TD/?%=[ED]7^=,U+R<=JZLORO\
ME^@#!F8V?F*B)(9Z.>?-YO1WV!;[,FC7C%'>V"O7-;UNF99.L#LNV%J!73:]
M7&AX)<9#QQML^MHXXP\0:9SNFI7N\>GUB]*^+S=]W34G#S[[T%R;;HZZ"W%W
MH2K$HL>-TK9SYODFQ-BJ(XX=$99/IG/I9"XWL[>X:P[X\N?$%F(7]9C8IC@6
MH%*2%#FG#6>P'T-BD))'5$KL,%FY[+_T1[!_QPF-;!\/S9C_.+.G'U&(V.P^
M,9_=E^:Q>V,%=L^-L?M$ +M/CO%ZFG?6&LB&-N6 VV4,72C3II3^LS-MBI\S
MTZ;P-+K.J:^E3/WU_FREG(_8,FUR3Z/S@=DI7?\>"!EA6_(Q8LVTR3^-&D/]
M2'ZW?O./\K8<<>V9-H=/HY?WWYW*\[G^FMV:!*/03!MAF4R;[-/HZ.2PK^BC
MLB"MU!][&S)MUFLD"),#ZP[17^!W%Y31T].AB'<X]'YRS68LE%&J7])M7;7+
M;H\2IL.6+;.KZ7#?\V:;+6Q5E-R9[Z>#RZOGTY-JQIL*[FUAYA3L@2@KU V'
M6DQ4BV*-L%ELE,1,>(Q;(<*JLVU\5DAZKO=S;X6L-%Q22$[19#8.FK1G[QU1
M-^V)RF;S>63(NV0H+$>&@N"0H5(9D88PZKU?EGQ=VRD-4?L@XAC*V X92$^\
M2T]""#TY!YN@I]C&^J3SR>QLFS[AV%!]G0PPATL9^CB6Q]!=&\TI7^-<)QW7
M)!)F704_)@BVP4='?+39? ^B:&_?=IC6'(L?#O<G6/RL7$S(.0QDIKT/\(AD
M[]M(X99<T;1"#U=H&JRS<G/H#U?3MF.8ABFP/"!AYG #_)*&'J897GK32HB0
MS@A9F_MEA-PJW,^T&IKR>']=J"J?3@D!5IDY$++N7[E%F69L<UG3H5J(& 1S
M>SXEXPE.E6XP[">4Y20J+LZ:3@:VO;"[0"(2/TYQ9<S58.XO?P#6'K_BLOHQ
M+YJMLN.>=3IL9$R_4I%I<WU1;K%5$BS[@VZ<E6H.G=WZ'O._W-[/U![H:VG.
MDY>!#C)(8L-7-'RM;T7Z6GNIKS1=)D%35NC$*-%@:6<&,8$LG,%S-%F,/2$[
MQLLW=E#1 N02:?,4!3.S:+UUZ'6Y?&J'!=@XOW7]K$Y.&K:B1,QM]635SB!*
MV)FZE.\G.=LARZ0 _KQ%:%8D85>$%:PXQ*XI*[(Y9,G)$NU@9Q*[O^;$T%&O
MIMT_!LPG:6AJ9<*464D\\P3#;=HT9M*&UB8'",0RN6@%@RCKSMBW 8[60^%!
M]X>^CA1WTO:\RH30'": [E]CZ5%VN3M['SY&Q9]*D\TGCL!VPXK:Z> =ED[%
MXY*8=CJ]FV"39 8/G]I)BC$:5X6S;\U6@@.U,);$Z-LXU6#Q57:[4:)2Z\'@
MVL"2QZ:GN;YWVIR \0Q,M$=PXF&!%-EJF _I[&7&;8X9;_ Z1<:=TE\Z67F<
M*&&.)J4]=_C?E(#?=3K$E%J:"^+4.P<J5\CEL: =69KCM/-IUC[5JNS\;%RU
M<C^>4JVHF)E0KUCE=MI?N>TM(-M#<EN4 B;G+TXA[5A4=1XSQ<UD':GKK$;1
M%7 $LS.U=O 8V_2J86<6<<[RA:>1WKV[^6T5K]YNO(%@ETL=<6,1X^P!7YC0
M@A8:XCBM^V3#=!^<-YYP=!6&L!Y^$ .;Z\A&EU6K@?Q 1^( /J;3&UU^HZFV
MGX+>,0IC)J/G<2_: P1;']L&!Y;EZ(3F&*&$D22003JR*_S2>27Z@&S=@\T!
M-4A?M >W4B9GL%;)2<9FG/7)NT0<TYBV238QEQR]XZ K3!X:Z*D+L@X'4BHR
M8(NC%&*B^5!2V-Q*D+$&[<.\N^PJ,.5SVKXJ>+F%3&EG,Y!G.V5'[=+YJS 2
MSM2?\J1/9_[D9IH=Z'_)<EW9,@O-9)_KO@16DBP*,X=SNT%K3(G%8@3F.Y^-
M\&OQUCD&FFV6.2HO<!WJVXHC&\<S686SXI7V;EPWC,+DY7K*-H7"V@W2&>==
M*ATGV ;-Q.4(+R:SF7RR6 SJ?S:.26QXX)39\AEM%M;VG!9VT5;9\@AGNZL,
MX!2A:"6FW[!-(-0&:(6TQCWD@8UG*4?[OB$@Q=T$/3,UI-#I<0V8[Z&O<0-0
M!-1'PEBY!WK)SXX6>]O3Z*)L#4='9<%JQC'.D!,^NOEY4-/5!U;6M&2'XMG]
M5">;GI>?1K7<X_.M-BKI(RE*T_,Q]X]#)1/=SN?UI(S:X3*@ V7X#X,6W*K-
M.+\;KUZ;LT/_#Z.W!YW]U-S=+_:R+0+LLAW2HW>.7V=7Z*!=> :DS1 _>D-.
MY0QGE\YP3NT,=TW]6/\T];__Y;[^]]O6;90J:UP53;PZ>M/NJ1MM:_9;[G1T
MY@25L7>N:H!4'P1M,6IC^[4U\<Y&GA@8T*S6EU#EJ\=*3BM2V1FC,^Q="'\M
MT*(]XK4LTH#9M:F*L00$;>KV@811_I-\&R4=J>I6NY^H!NAVN.Z-;+PP,\O;
MGJ=9.?:57M7/[E7KV6QU KQ6MI60Y'P; \,3M%3:'*@I*LR]M"" T\NTEHX=
MMH&&F]T"W('9TQ3()K3FV**&N60Z4T@6<@L-B R@@(6;AV\/)=770TDSBCVI
MO%H[?65^5W_7AZ\//>R4YU2XSB]F_6S4-@_^L=#@0C[KD%K<?*H8Y+O^0R@P
M'P<%UEXML 4]0C&N,-;>Z(JJC1N7FHH.=M*:P RJH:&"AOH95<_63IY&C3_,
M6_6K^U9N-GEZ45,6AZ5JV6Y3:8QW% <)9U=UH?M).)?B%YK[\+E(N+ >(7KB
M&"4>7?;3:R1,GNAZ^Y?2+3YZ>NE,$VFW:3$,V+$06-3(0GH6>5$5M2CDDH42
MOV;J6OOHMF4MUB,67X[3S>D1+K^V3/HC73.,]<K1\J/43+]IE?1+9IX9:0/P
M2Q!X-D)D 8")6-(2E=#BRKWGD]EB,9D+S*38H.=[2>O,6.@>YEIH:\7;B\OW
MCE45:IGG.?K?I'FV?BR.#WPQ8_>J[@Z_GE9,Y8HK(_>Z(REC_-G-5UCU_NJ:
MWB8RIFC-ND0;Q]:+_6KW].>]T9)/BJV%K9^EB8!FW6P.@C$30+R^!B'<4-F2
M8%Q1X(5EHG$?$:B(0]6KO?=E?5VJ7IPA Q\AE-46W39=P:NCE"\9%VG):V,D
MPZ:4;S_4'PI=<9[Z9P-U'L_XNE[]+Q1:\;*+7%RI@7!G27XI7?!;S+A;B5,-
M#+B C],%VZ="/FL>7PY[A>BZ8 247K,NN" ,8T;P53,6Q_I@@D ,*C;>DD2?
M)43@=NUF:_TJ#H*N2=R.N401GUFV-VMZP"B&H: _\]#=TR;DYUEC^'#=^OEP
M*K7GRT][3ZM(T(4!$#/'B,]!DBEFDJ7B,C9DW$)QH;A9.$-G@-\"D6C\:CY;
M3;-\^MQ<1"1&P-*U"\4%8!@S@L?I(\FDA'!O^_;X2'(;]9%X+'J]>J%TJ)[4
M2\T+\7EA+TDT6I@K')V*C9!??:BO95VR(DYO"Y_*!)%28)+A!ITN'O&48O0*
M3/&_!M;!3@1QUQO!';6/LL5BYE='B!3!W834B %H\2)X/JI_8$Y8MI3,"-ED
M*;VJG-AI=YW-HJ8LB(6SN9?(X([38;(X)]Z$>5(_5/KM\W[NY2>99YZXE[!4
M(OS&'8#K<?GE8ZOA3"=SQ7!W2,3\BN7K&^*GB%BMI>C*R29<B,^WY\UN]75@
M*M'MI5C(9LWVU()0CIFD5G49^-7 ;"J7CXNH5JP1BY^RJANUOUS$72]1Y:Z:
M9_4+[51_D!:VO]9(6YNRK7Q'B)6HXG13I%.YW"<CJN71989O?HV)D)LO'5^N
MIB^W?=IY9KW5>[7ULD:^9$E]_5SJW!:B5N_90U 738W>TG*]19G>J@XE7Z.K
M4IZ/4T'?$K8WIDMLOAIOS?1R7](?!S^'6<.:D_ VKQIO!ZEGX?*[!6FJ$&?M
M3B$E?#9%8INKZ]8MGO2S8?=4UTY?%M?<=XKJUEU.MRA)QIF5DTME/Z_!O*%J
MN=J:8RV9;/:D?/;;ZI641:OEMIZVEBJ/6Y1@HGJ8YL1A,J5D@<\E\^GPA)0-
MFX(?'IVI>?/$5[ *A51N&<9 '^-:F@5OW[RX'@\M(@0<TW!.E\SE&<'USY-L
M=G!7:?-\A$0RW,Y\BI\-O$U&9#VPQ4+L,4YZR/) 4OSB1B"%Z_(2<M.D$&=M
MJN].Y]N":R$0[=9J2N7WZ].?+PMGM.T2N:S=ZMMX(=2.DU!A@=#,TF;&; 0(
MLO[60F!&7<I+E=L']2&S;+;<VN@L6LAF(]"/@P:+<7I>LJDE?)D[1H/%23'6
M#$>#9CBO';='>$I8KKD7'V4U:Q?O#S^+I1>37R"A;C-":RV C(5&8FA\DLDF
M"WDAF8M0:K 4@3BVW=^T?S8V]_Y[K+NW?V)PL9Q[&I&+GU?U(^/,.EOOQ."M
M&"C/_]D#Y4N?<Z!\_6F4M4:O +_[D]?GK1@H7P7K0$JKMR_#^_)A:5O&CL<Z
M4!Z@?J:;]W>C?J==+VS+$=<^4#[[-*J_UWM:[?6E>=?:EF.'#I3/+#-0/OTT
M4N3&*'-:U(A(-DI8VS.WPTB(0=.&<$Z8R.G.2.]Q,]_8U<D=I?2<R1V!QHZ_
MS+-LSVY8>9A'+GB8QY(;>!K]'M3)5?6MW/CY',=\C\P.S?=83AN99WDMM^)8
M?9HW+23S-/HE6X5FYG3P4E,B30N)3+@S8@$?!Y&YYNF6752<2^YAMX?='G9[
MV.UAMX?=XIM<>!*3.T5G&:MTVB?SY=^;22W?L-7\>"\W8/K/:OOV1>N]C)<M
MW_-4?$<G/5&F+;C1O$%G*4Y65^0VV;63.-BSY?OVL(:E&6[Y=D/ O$2CJB6F
M<*UV!+35E^>>ZYPNMMJY&MIG/)5K77Z^HWV553:2=JK$^S.<CLKLSWBP3XR1
MOCM;;]IJ]&W.G:7RWZ6JG^QQX);9U="SU;K#@=D3@[Z-L;PKJI*>:V]$9W_)
M/=E<:P'&4QQ'.!Q.'V)\?+O]8_R6=Y(5WA\O"]WCUYLL1M+L9(4IE=S6R),<
M!8KMF%<0+$OH&<X53][Q"IEW\5SQJG7;SA#Y:3!/Q &$&-.!A%0FO-MP3/2W
MJBGJSF"*R?Y>F%F$=^Y:$I/N^OT_@5D8KQ=I0U;J[X=B!&9!@?)IF,7$%6^,
M661C+1&+T)K\3V06,S,1L^MM.[".S-X/Y _=E_I5XY"DW[/9H*H67S6;K55O
M!T?8>+.#R,2?CZD")IO,\+ED84_]Z]SL3)0<"\N7TD*,V<VS^P?<.*[=BN?9
M;1"])SRUS,?/J)L<5H?G-5(=\)W9]0RS_=TNYPC/]UF5PGT4?6 0Z7O+TM$O
M-$'ZQ:EDH<VC"O:UYG-36<ZKIGY\'LX19&1\R'3T3Z9(]'[Q1H$,G@^E.<5)
MXP;'"JK$1X^1C;\&,**"44RG8^V!GPZO#OP3N43TIF8KL/=[&D]D6JF=SKG>
M6;(?Z;2\))53]=S,U%X"[ P668W!Q%B>+\1\CQMR-A33JWHF/7M#$-))(4*E
MXI_(#X*TAJF2QQ5$"T,A-C>/2/!G0\.//K2@_P.YQ</#:?%4S.9^U>9TMQI7
M)ASF8?.27=,M5D. -:L<<3HTA52I]!$L9@T-7U?)Z MB*.&>RWU@-(!K" [7
M^/7:/CLN#@KF879#@='/'@P5 MG!JB[.B?A&^'253YAV'$3_X1WS]K'.>?1O
MGIWFTHWJ[[*XJ5CG9X]O!M-_,=:NM+%&.':&_C?2&N_3AB]=DG\SI6Y9JJKW
MP]S:PI>?*&092,_\JAY%UYN8%$JE9"X3WM/V\Q-T_,7!I?14XN0^"AD#"[FJ
M9L_JQZ_G#_4YOH:/C$(*BT0AB[RP%5'(G&_>?&Q1R)UA!D':_9H$^Y_@%W1I
M]>+7?;G??E.;0[+&(..G#RP&JP'QIBWFXPPL[@SA[^.&,5-\_J?Z]O K6Y7-
MSCKBAI\U5AA,X7'E)@K)C)!+\G\FB0?)]CA'G>U#@6,,X'?YWCJL/>K93G=S
MH< _-?P7S#;B]/?E4H7-<8UM*9'<UT6ND5-D'$YQUS7YNRM!)._\/OP7BQ:1
M"6('0IP)B(5]^,^E_]H^_+<2_;=?R<_J18Z\I=O[\-\:Z3_.6NC2/OPWS@32
M^_#? B0OW%U;]XV+Q_IM9A_^6Y:>5_7[^2H6"T(RDRWL"7HMX;^I ,(^_!<#
M"VF<W?:.*S]/[HBRG>&_S$+A/R&_%>&_?"J?WX?_-C .]T_P!;JTVKPJ%I6?
MEZ9V_;P/_\6M!L3IY2NFTG$F^>\,X<]4ZP_WX;^E*#YWD<[JP]+U3?EY'_Y;
MD<(S<>7Y"4E!$)+\WG/G4/=4>Y!]^"\V"_]5+>1?AS*YB3Q4>!_^BU4QR,3I
M[RNDBKL1_MM0R5]X#?$^YA? 'K(.>U#ON\5?^9=+4GG>Q_QB41VR@3P@SMS
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M=+E'05,SEZ765462%@P[KN=R=SPL&<PZXIIFPB<S^5S,8<D]Z]@(/N^;GFZ
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M&5(?I4%50YUT1+WE<P>T?-BPPRHRH+<D@N$%Y]'02Z(Z5AJ<.NFA$EP/7/^
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M,MEEF6,S*D>AP?%WNHR:T&?D12PMD);*(GTW==0/;3)SVX. 'N5I3*ZF1US
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M[<A-&\#<Q&4E<3X&]R8:7K-$AZXJ8I^2\1&<HH]WE)'9WP $KJ-H3?@.Q/(
MW7W8XQ8$!.MVY=QSEMUSNH N5YU.XIBZ5U'2-3!N/"":HMUYJ&ISD6.;BS0N
M&LRG3GLF "Q2F"POD99CFLS9-T6K!((<-#N SH!.V'%0W_7@PV_/+3H\I.'
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M*?5=6N1,T<)XFKO;??AW-<U@3B$54*_WY=>&UOOF_21!%2J#*.T#QW=OZ_5
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M#;;)K[][J))*0L+8!AO<G*';@%2UJVK7GH>J4-E\U9POOM)];K/#K/;8](!
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M_@YLM\.YJBDK4]<,;BCR!71Z&:RB8<G7=(3OVI_W$5OLI.*Z!\(D]DS^1):
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M@"J^,+0(YC (.5H(MQM#OZ=BZ^!9WTRL5L$?_E%=FT1$>8WUD67#97 =-H
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M0N;V(8C@\+&BGP+3ZL+=.I+-M6CWGRKK\IFZ/30V11:HR$+U7U5D84EIP//
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M_AC)XWX7:VENQ>5'P$XATYRH__10/"@V;=K)NBH6?O)7)MNAVF8 J+<M] '
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M-CTX6%@FX '0(GC/=4Q?@QGL$-FP7GZM!T.3P#><B6XZ5\85?@^C&[IO]ER
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MI4\W?_0,W2QKI@YW-L.Y'",(/3-W*D2D1T\W364'Q@CP]_>[3ILILO739.3
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MO<M7C;%%7%6-KRHIW4(7YTDE]-="!QN($%8T'<*J>W J<0UT^A'VA@+:<#U
M[^$]US'768GI !_B"NP25R,<%D0K1>]<345.XKXCHV]*Q=#%6&!, D"-F'7S
M;NA;L$GKO$LB&T#EN["PO$;D2/NUJ"O42Q,&#TE0R0H [Z7VQZ']B:0NS57V
M)Q++8.*Q39X>WS3G%"^*0@I8=X22.((I!.88N0W0E9>&+[%?]:1SL=_Y0XC3
MQ^P!.<<.#*JU&[B59F0XCT;&#[(G&8!$A'K7L5N!,4ZTND"+( OIQ.<LD&5Y
M9/8P2O.6%6UY$..BS&I&R5R+A#WD$2"F^K&4J=H%+6I_P"1.^L]NW!"47 L>
MLKS(;!<?,7.?:+VJ>T0L OZQ-_0L8"]C%#&.@;.C[;:@GPWW43!%()45%'!%
M_"H,Q+TO!M+=(K:]WBC5MXS76Y77!?1S8J=/_=@KZG)LWAKRVB"G.X,CL'CL
MO:%E#N*KJ)U*[0F7#^*\1];,-2;O\YQ&1M/P@I;5U1EF373OA3-+M5?%;?L
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M1PY0]O'*0@R.8W((DXCTN@HQ=&E@H<T\Z1(0EM:"F$FXQ-"@%,47HXW'-H,
MG1-)HXTVI]$F"RA<9!BX'CLD&$3Z**%$HY5S)4)HUM\1>\8!.I@IZ9G;'8JR
M@;/N3M(1-H 7FHQ0T<^B<X4'9UH_]9=N_43[;WJKQK"5(F#)IS2(J8@ [2$&
MRZ*.PK1,PL.^\O' B*U$'"B,(#=TRIV&=HDH_$2Q1EE'@-XGI!(6$T+*K#&H
MN Q&%!@CW-<T0<VU1\/&)4W%9"GF-$X;DP:DGPGS &1*".=.BN.A?!C,*. "
M-:$CXVE$%!(1: K]0<^_$5BR([V.R:.!*)8S#404C9?PB:XQ49I#*FMLI#*2
MRJH;J6PV0C[<TR@=H?7($7K6.;_4C[XL;J+5\/0V4I[>>E$_^/;^:/?H\J*@
M'QZ==$[VCCJ?M(O+#OQ\<'*I7^R]/]C__&G%7+VQ6TQU@Z7=9/=&OD0QX5P?
M&94)GK^.\%VVEVC27V,?D<>>G'JQ6<?[*;]&U5Q^F[5S'$C_^UW+Y%VV?IJ\
M*\2W#VXI]U'GDFFBB!NS<;'Q:(.XQ[)4NTQ.S6BQ\G;IUY1EIK3PY=&R]BD:
M?\P5%9,K8QO'[&.=TSZ582Q[^N/<*K^>=7AS',Z2#X1"VVZP?A_(.1V94K&H
M8Y'&[94XBW*QO/BS,/2A9P[^]VH8!./?=W9N;FZ*OMDK7KG7.QVO-\14UAVS
M?V5X.WTC,';*U7*M5*_LE$JE<K-:+E<JE3K\6:I6=\Q&LUK_R[PM;Y>+PV"T
MR,5?&!A/%9UN0=0[_Q#:4:5S^&=W(D3KX,8492'4(,'+?5TI-KWU^:+S&B3A
M/7W+<GJN-W8]&I-*F Q ]D>12,:3<&Z53'T""?H0>(K>VOXHZK%3IC["TF)8
M7D=G9+Q0LE!]/9.H/S]=Z.#^BBB\H^B J=8UX,+NQ#9N_*DEK#^9J!;+^JH1
M"!"#*J5&9<>L5DL-(!#511.(K".YX2/)10,*\J12'G!_[R8!R>1'20'*)20!
MPH8X*UVI'!.*$_>:?Q)EK\HOFUA4BY55P\<J_-VHEW?,6KU=708^ MH)Q$):
M<VZ2 ;RO)X;/Q5A!FA;#E41%&\:T:HQIBT&X52%[,^X_\JK:ZHJPLR$_<OS
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M&3.SE!#UZ0#UQX?+/&C2=F,Z&> \M,UM&5"NAK6KHU4S0MBKB8XFU-)D.F&
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M P  O@T  !    !E-S U,E]E>#(S+3$N:'1MU5==;]HP%'U'XC_<(6W:)$*
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MPJ.M<2F&6$V+X6C>4S]FE\W.XT@,A&6GQY^.&_7+YE,1&VC9=/H*RB]8$5H
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M2!MB(('H@ %RVT *,Z(65"U&/XU\-;H.A0FD,BFV(P].*^GY9JQ5 "'>-NP
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MUK"5JJL5T),OR7*=LJ0A<H O%)S:UF<L((^;,0M"-3,YF6@QDB;1'#5Q>NB
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MK/4MQU8/=WPSZQIKODGGB=T!8SJ'_%]02P,$%     @ \X-Y6[Y.W&A#!@
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MHB;E6A E.DZ8-& 4E*(I5S9%DT52,D^A\-X.> %$SIBS-V=ZP22/ZY.[D&_
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MO"<KD643Q'Y'4 ,X<;(6%#;5OVCK^K'M+\]%_<6 H*.+TG&)%NL@ UZ%'7'
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M@(Q7G"MKMNJC4;<F-%UP1;>*SB5PI.V[]@F>-MJN,'8B<R2R9(&7& [:WM^
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M@B8V=K\;V+&%KX1KXVV=/\0$;Y7T, 6\]MUL#^BX5&37/$W;$>/-X0/R:4E
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MFS:O+^6Q(KS-6BL@\V^^:C0DY[[GFI)J40Z+*Y?5.6S\L.'IU4(4RN7#+?V
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M5+S/K43'@\HXS[E["9HY^]F66C*G&GO3M+OE6VGJG/VFC#Y8[B:&IH[T?K!
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M#8K\K8W7X%^ R-N,R#?UZ2+%@6]JP3_?U"=WWTH_]?-<'70 >L8<M'8_/+!
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M<WG3XT>QXMQ"%<$P6EV)<G6#Q4ERE7O]_<EU@)PA'@BXB:,:TSP:P /[0WB
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MML5XSO"%Y[/C <Q#LXWDTP=%)*IDWQ4CYLYYUPL@;IPK\<7>?"[Z?OH8DX3
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MZ[5HYWI!".D.RZYM'6RKVY#'OG1 +\?NYMD=C2#['&0KWA% ?$\'A2D_/N#
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M+%N7#Q6?Y,LNV9X'.]-Y7(T'],<'L K'T<_Y<8U%S_S*Z)L,C[RU8+"N'*2
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M)&73)_3'>5NQ!YI?;U"@(_# <C\ES4+I'B_Y:A+5_2=:++[WFCF^;S]0>?_
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M5UU@MMFO26I/6,SM-C4%+H==",CZXOE8!NL8X@P?U.__P'3Q%>-EI.OX:E:
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MM'V._9)_4T\RC%+%)W.Y;$D[2:U:*6;9T3+30?0J?K=3"D%=62,SK,8!JSC
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MS>BEGSXE)&M"8]B=#CF2,;KA9&T<"E3*=@Y(R-#3BPGZK!*J_76T)Z"OD\/
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M?Q[ KT/X8:5-:N@._L$Q^,QR_A'@FF"#. !\;=\SQ<@&]*3HAVE)"U= ZW@
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ME,?.8=NRO-<][XI\O_(M-Z/UEN<:YU"DPG+V#%(I9IM*$0+]UL\:AX.90>&
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M'VBTWRF8_J4)#S>.(U)[?0E;)%\*3PBUAN=&R?6+(:X _L*S6-_U:\NY[0I
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MT@>:!9/XB,?MUKH>WFO;PC0_BHC&];P"5(E=ZY4^0I"6DUFK8;FJI,RJK2O
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MHYHU!QNY^V+MII+.;>I&D6T*XZU).5EQB:+TA$;]0R$3=GTC(X?G!'=PQ^R
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M=N35L"Y.7\C?T[?EV40,5;6";'@ O?BYTU1/WQ!:=\8Z*7XSH->WU0/M?[9
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MP2F/&&ID7 [(_?61O34WS YD3-6597FC?-\?\I^2NOJ-5#-N"TJ+:[8G3[8
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M-3EH7,/LO&NY0FFYM5YGXCRH15[Y2^^6,04&W3+%=L7#W:LQ>+(G(?E@Q-8
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MRS7** *IK_R1S#D!$LM#J]LWB[(8(/8S\Z[NUIH;V2DRR=J.Y\_-5UGQ4=]
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M%CYA$XN'!:FYK,GM1[XM$TNB 6_:/(B"R^I!A@"P!4_.8M[NSL;M\CS6O:)
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MEO?*GF-!51&)],7ZAO?'$A\>0T0K[T-J-MM;*;6.QW+>8C0G=^' D)*"[V?
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M'-I(VDA" .+,T0UHPD.R"W<JGI8T0/^31NK5K[R 43I"$'V,$ $8NQZ(*D0
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M6K?M5&S?]O!JHGNZ*K:56<N6#PO2(,:9>L&SFPC 588]!00 2RX? 0!"]K&
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M(#+#'53[<T-V%/%W<73TTJ**^Z.$N('QSBR6/Q/6#Z*9T:8=J4FYZQ4^;=S
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M[E[.A(B@YPO'@B7\BLW(O]J_-_2TD)%9V>0W)S@-71 !V=5XSG1Y*M_N#I.
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M%#))(S-:GY:L[0\?:F6(Z7^M*=\ D7_/)M?"IMNP'YKK3I_(%>L!#".CN&!
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M+$7+/ELW(?>@N)F]\I*R5O;]I_B+R&,@/A@MO_EG*1?$.#]T+!5CRG=8*(B
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M;IJ;F9>/( (H4[1UE VBUB7NWJ!Z-A'&$#H:7%N!-,L>E$?5#8V8P_83>X@
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M3\UXOT9;3U3KU*3=WS6^<;__]N,@!O3']FF'HCYWJ,.]NFGR=Q@J=!&\7$!
MWOB!'PBM+#/AX=]S8R3BI-AWGL(\X!.Z]K.-2N(#6Z!!(+B%SI9-R,P] Y:5
M4;&LY6]:,FY1=5CO)]JHG=N5-Z_V:BCA*:=1Y@Y[$5Y5?:E)V9SY-:VN;58J
MM[5%YHUSAU+_$E"$05.LG._< \"[E5P:-,OLG?Y1Z*J8+1%@??\J?2@W8A(_
MB:3E(M%;T/&]@GQYP>(]1VP6=_3>ZI?>L15&6\@14]SRZF*HK4076GO%_8)<
MB0BP("5\FA@PZ+=;BTS!OI&_:]#6.:?;UO$6K#%&KWGSU0>YX!^EK0?GY6WK
MO'>^3 9AI6R/)< =L$.2,2@5_B98(0]CX&3VP8)+ZS@!VMBT78^$Z#U8 89K
M<I^Y'TIOZ4.>8EZ>)[F&;&ARN%.UH:-4^38[3/5L-PR<8(=/YD,X$,#[.@\(
MM-EO3,2];MJS-UL8ZU&9?5L@TWG+:I.2Y6<K75:H.QFF*TO8[=XP;"*5<=J;
M72J![\N_=2_+(]RG,SSACEMUUCM7I@](>JEJM=%'!&Q/?/NR(]<6:#L]J<59
M'WQ(1TT%[WH1""9A))=74#5KJ<]=1\J)T'T%?\Q7!_7C*=JSQ;*51K(-@&)F
MLK#/I:4G,HBU,6J0\@T-W]5]A9)'K1;G'_[Q:V/W*QUW_PD@[!.4,SUI"C]M
MA._J#?4;Y) M!W".\NSD-CUBD)O;K% >M<6;"\DP*]UH\@P,6:UEX:SYU>!E
MYY0L(F];NZ3[?W/<N"\^Y5460OGN[5XPF+OC"0X*0Y4A3%_S=#:&MH$M%30+
MM<3Y>I,NM=6Q]\]1DI9F]+?ES.Y=.[NY<1&U7E(;OJ=WH):96IMXVYTFIYO4
MKQC[<>M*"<5?%@,:%[)/11X5J<!Z*]N7N*UR2U3FHY'')^(YD6$,SBF6#+@0
MLD;*L-?-Z;^4];UGHI-P':J+G51%"T\7:6^&0K@0Q29;LIJCU6C*OW>J;F1]
M/^' PD9S]H&X4$LB "U!@(QI=M(6#>ON2K64U WI:QD5HYQ[0;4_!-Z\E6"6
M,AK-/*2/<JS1.V8'QH#WQZ%3T[XYQ2]^O1GO_(Z-S3WZ78JG//L;RG57E]J4
M@0NGQUK&[]A)T^5D0QO]6#B+76LQQ!N;A+V28LGJ=E8(.<,!TXW9.<&3B$+'
M,_>+N[4.T&L6<DQ5#SFR-T+TEF9@%>>Z03'?<#6^T[IB[_B0<"+@"Q2((R<"
ME&D=VVHZCUJ]9TBF[1TMVQWIK]?D#NSP'N[][2^>F1J\]$XF I8DB8 B9^C"
M$ &I/X'3Q)?8G[I7E%H_=?US-+9?0@3L?]0F H!75#-TZ'Q<*I0B%37H$E?#
M?CO7<>9G]*(CJJY87229(6.LK/-X[7UTTA?TNO<5M/*/*/O_NK[A_S4X'/=G
M)R@_ IYT0T4LFB L5VDN/FP([\7:#_:U)IQ068]D^B^<!3QT"[9=M=1Y=.HE
MV64_E(XF94FQ<J</&-:\NB)TP@\3*U ?+;4X%S+=+?AJ]9U:YFV 8W0F=ASZ
MKWI%YTND2X[.K'IT+%+K[!W)/":3OL&!_O[FI_H2GI/B>-Y\5D,1),^K0'J.
M<H\XIJVMS\8>EZ>XL//1#*=P/,3>A6:"A)I*:A"A%M2/X]8B]0K+Q]$2MTZD
M@P+* S;3UJ>:'$_@ESPX?K^+)V=?Q.L$W0<V!?8'O9,&4<?80*-L,@A#5BN3
M?4XW[G8)]A;.#)7.E13LIP$/XRX1MCVA'2J?EI<JIVCSC&PA52$\*;9(WE9Y
M1/6^*1AF8#L@:]"FMZRM)S%<7M(YXB)5/!>\ 7PO0ZO5\&6'KZN]M[9&2BMI
MA_']!G"/\ONXI.*#"+UD2PQ8GVY9KB;VD>(J$< W6& -,F8,KPB<QYJ,TF$\
M"Y*K$[=0&Y)8R%I8/PEF;OGNRLU8JA7+YI8R(L"VYSH^Q>'HFHQ@M"U+9UV6
MGXDE&/Q.!5;5^IL-V.[=0S ><YDFWQ9]UN=1$? L%BPS"&RM_SF2; .2!OMF
MU"P V3,:D_-UEFFK_68[B8!/,X2<*W^! K$3[XLQK--^.Y"UV[4 R8_9*</0
M5@IA'!' C;\$KI@RS(=C>3_Z; M_:Z"SL*4C AC6.M09MN8KS\"%FSXV:Y\,
MD8(+\-IE(N#BYA6(LL:G_L(<6X+57!UUJV,<[@>\DM3:D/]W+-$L=\L*X>:O
MANFKM17@$HJ1M:A*R5I8E_I-!!R<^!&N1,FN7_WCE5,H=G-AL'Z!W(R1V5$?
MZ4AI>Z?A76= @<XBW#Y;4W'Z8]##KE3_'NQX'[E9V</['QITP7S2448'-,G9
M,>QQ9=@KKG<I]@>%MGJ9YOR^.M-1,.KW1*,(5\IKMXPMNVL?=LAB6V+<I[<V
MC/8AR.)N=H'ON^P*C.+[XB[Z<.GIT;6QO8=""+Z?G\K]CYP=B(!65R+@Y3@1
MT +#._>AD L[GY?U*DL53;G9JC()UY'0)9(T C2)@(<=% ?"PNS&?"[<!J:[
MV3N-N,022<N;=-ZL4Q=,J.Z>3/KD?S#493R>;2F\RBUA$"+@!N%U4BLVV2^U
M/-?*)B7Y\]&LGW5;T8\VPG/^\O-'1[0]'?QM?-J,M#YL*1&VJEJ['W,Y:X5*
MZG\I1Y46=Y5+9A="EIHD=81?CN_ .*&^^BV-+9(41OLJ)!^P DN5A<<2#;G.
MGICZP-F[9*1]?%C6_3T+EK!B(L .PR]V_;5-Y3/9%?1^6=U@*HN1_:/=RP5O
M(H ]XS[<3,(HK:EPOJ5_T.?-JIU-N($2R[$ZXP"?*D.J'YL1Y2K:L<C?%VT6
MO^!4Z_F16T@6KMCH12&GNX\O^W1U@OH-T94A?T:43DZX&O?^3C>>7BKL(FP;
MMH\OA$\;('7O"Z8L)L_#.^6*K+A$/TA1MFAM(5NHH?;67Z 5I0N/73L.T(KS
M$^'UZ1/!UBX>UTS:HQ+@?W-QZ[42+12*B% AT)8MX_4=WNSTL[.R?MF,7'T;
M2_R.Y'27H!\IB(JFL&&CJ7_A7*<%PP [.R("$!9S)T,SP@YUDS3]KV>4!OGS
MKQR P?J"H'=Y"NW\B<SBK0[JJ'5ZGI]+]>NN'SL6S"(DW46.-A/6&\:T:=\I
M=)9KL1X?*MMN?2A(DB0X#-#VT&V=>[<86E?&-T]:5Q=U\_)06O^$JW[HT8O4
M0$A!&EGK(C5PRHIT'9I"1VYHT*[]!J%@8NNNW_DI%+T:6;UP=][$.6'^6W=F
M.&<GI0D+4J4SE<5X%5RD:!J.)@+\??# %*^367.J'2* E$YO0)Z_.G#7"O:5
M &GB'6TWR+JM-@1!G*A)L!N$:: RRVH"S=7 8T3 JG+]?SQ2$-%<"M&2ZP./
ME#_M[7T>L"M7OC2N;T,$/*%%X\@OHE:74Y92.&.BZN_UME7D&S1\W^QQ[2O>
M+9/6-TXQ.5D?&]]ME"KHR<<P9%6MEN_V2IVEK?\I<VF3!+JA?LR*,5DWN;<5
M;D?M'+OJ*H#US-^_?WQA;ZU"8-ZF:?M<#XYP@\@ 9A=3ACRD;QS(E/4,%\RQ
M@'>%G()KB8!W7IW5HR7]31OV1Y-59>>A&R9-IJ!U\1@:9SCI@81B?KZVYU)<
M96^?8/OM.Y5G_ 3VN,[&D[D\7U\9!QF.,XF1<\G+[G&KD;@^V37H/"O^+5J!
MR9(!F6DA.)3KUU(0?N(QX61@8-#"!3?98$_XD<*A$J%,KY=#B_9/?V0P(G!B
M$O'LQLI/X*(_SH6\_2%P"ML_PM/N%MR.924TJR^99S](E<-+;FO^6@L]C#O5
MLPBAI%JQF#11#/QJ>H)#=9Y'"IF\MAT[#(KEOJ3Y\RIDYDO+T#H1< OODCW<
MLBIG?T5"5)W\6\_UX(ABUKF9LJ? QD#"U](Y<H)*C?7)N+Z5T[*-KIQ:WP$8
MIQQM/;$FX\[?\F=F7W;'O1TV!5Y>^.LBU<WH&0P9JD7^EU@SBL*)8Y'G=>;Y
MT6_)JPL"'1?FJUK^>[ I5VLYC4"F59V[%W11L,*#)(9:+ >=L1L[:546?\G6
M15R_;]".GFO]021:FBVK/&"[;9%)PMQSNES2MB1#4IV:J,7QWI:Z&R/RA\,5
MF\F0U&%6S^0$^B0@\DJS-H?]!Y[T8LM"W$F6TB3JLO#'+A'0PYSBS-?S,K?*
MK+F[;CE(I'CK)R;5BYY:O$=_S-T[3G_A'V^+R9I%2>G/_IZQ4TG8#(EQ.P>;
M7G)V3;HQXEEL#Y-&S'$4X .A&'QZT/ISX$@!1^$E=_WX,K@FJF-L82= <27G
M$BXOH5,?4-:.9BA+**HVF.L*N5F1&58+X:,R4 OT-CYQ]5\PQR=.L<@%?]AA
M=PNXO6E"L$YY/4RB>\NK[Q%($R$QWP?=7O7IHM 55)P)>'B\([EA6'?/O$ /
M9#NB#B\K6UX?:@T,0"*?F&^1F,"L#3<5;KF8;ND4;A(!]E4^L8OE _Q"7G-#
MYZ 'V7=^I:HEZJB:3JY6L7' !IM,7FW;;,TGNTNA=13D<4.2)L7&&Y<]9N2%
M4&MV;O41.W3VNEK=_<I[)I6[ N:*A FOJ],4MK61&&D$WR_;:;82PZ*$\NVF
MW7($<^)EXEB?T@T^ Z**[;#H]"&M^QYPW4.T^8D"I5EB8B;W[E9^_:-C<[8B
M9]3I7]&P6N!E;A*!%K'"?R2!-67#S][@H-ICW:?##6@N?OYH/=L?F&>CO@S%
M3@QAQ$)R#>J_R5#QWS\>HBW!SY.9![3\H2<":![N58.7>R?@N=M);UIM[HJT
M9( YCV84868.$2$L624J\GU?Z\ KTJ0M2Y:4\*6/Q9;?=A37;S MB+EQTY_<
MO*$?GFO<-3T<>A@$J?6JH'6"!\GVS84$!E);"[9$!BMB/^2J>[HA.O^^4^<(
M6@4YI"])C?N<EW4L=W(,]:UMT'$$7H)BCE.;F?=Q&6^]R=P*;CYE#K7YH%=(
MV[&*1>L*^:P8")4&Y+L'#D[C&J.?#L-Y- U2<D/$FV'[ZZ?Y2Z<C>=7QLY'!
M/<J+7")8M$XYYA1K%R]PJNUE04UNN]:IH%1V?98(R%<AG%\1E?,-@J+ /Y/@
MUWE'2G.4$5K::4M'N Y04HJS1_%>2]JJZYOI_/""\E-S_\4ZI:RP9S@OV:@5
MG%) D84S!>WY[1$F/IZ+9R<L=2?%DN#$22MU;[*VG$$%=0^7GVC7)V@?DQ,Y
MI71;G<E=<#W,DZ"(U"T]^.KX8(=GVWX"^INZD$D0PM4TY13:O_%W3R+DVD,E
MQJZ;A6SV*LB8MW]6I+FLA0A=:PI:]]H.)212.N(^'YL<7Z8_]Q-Y1RHM<^-:
M1#FSJC$+:5K_GV8]872?#*X*?/MUSH/]RO6/QQ<E]V66UJ?;A4R%K1O=/_M\
M>3CV"#3V3F.0G&\_CT64U#9[O,^:1&$@3PR/!/>KAC1;>2; S+ZU/ZKQE15]
M@_(BN_W;B]+WG7?/"5<=$\QLH[V/ZLY0!MEFN:,=S/"MO(MN:F)-&1KLN^D;
MJ!OK8WV_@T:74_3WZKT&S^ZS,F^+6Y"^8>A&%2LJ/6\!ZN@<;\F4HG81<<G]
M$;==.!$L7S_7BF& ]'/:WPA=]NRBIV/-5S2.;/NE;P:W0F\.>P?=P4U8Q9@1
MG!+>L I_/%%3H/H6=[FH7XR;)ZG@'WXPM*HJ5"%8$[ETD*?$DQ@ 1-T?O[N:
MM+45I^46YNE:O.G^8[:7/=ZQC_O7H)K"GYTM2[#6I,OE;.K%_*G,"73GX5@&
M$<!OMB&3?WVZ*9XY^)@(& Y[>S[^L;1=X3$KEL88+]QF/24%=1\7LCE<6O/0
M%<-XXTJH]TQ-&S4D[GW[H4DRP5Y,";3>MO#*V[1IRK)DRFM>&]\RIK505U P
M,KQ<4*Y)*N[+LY#?[XSM_Z88O"]*Y9X/\1@@_7(,MTT5H^WGCA;YS>$1FLD0
M!QIA/[BA7N14*V*?S$\BSQ0BR^KLP^N^),AG*[#-^;>-#5S'+/)7-*"L_D'Q
MB!LM\Y;I=CZL,'W(+%\6KG5GPN?$JEF=4HV2X@%$1AP\E#W\STN%_TW7M1'S
M__,;:#XY]_/C"'P'P9@SZ/ZY_EJ?[P,&'@EE27$Z8S/SNMM&2M4TPRQ$P,8\
M8E+UP2,OF99P0ZE;UY@20Y&I9P<4; ++8$I=.XZ[5S]9,J*-DK:7MI<A:3#V
M']/7M)K&375O]N8FN:&'T94UDME/[OLR1N&?>NHA&XW'W4HWUNGM/<0F-[!C
MUN":H&V7<J&7W?G6[P?5W4)<^):5!,<KRY[Y"8BADYX7=V98Q&);ZK['R!B%
M8FN^[-75<N::OD&/2+'W]\+T#T>=/ 087B3*EY#KI8#=VFI/B@^WR1634:,E
MZ9]O>-P@S4:2Y$-IQSU4W,HJGHN$=YG5&>4_&F+YHKI->,X'X:BSG\#@*<SY
M-12[).(;HSP?<]QBY]]#;YG4T$B$YX6=3\\P!?E(T&;U5#?&NFD8=C-W!8;F
MRDN!8\3O8$JOL;UC0HF6/+K=*RO=\GM:?#6?I\D0-V WUGH>-AO]/'=PR/TH
MDV"L-K\X=Q[&]7?4\[B+5CQCM#EE]1:T^L'MH??1(:$IWVQE9ZPZQ#X84VHP
M.Q<;%>33DN9?(8/R)S9DOWIZ7%R$M_LGFR?8/IR:3+?2W\FVK$CJ&JUR=U]I
MB#$6?/+I8Z(A/3#?,N-2+1N4JFTZ-9/H'8?/*!F2C#^@#9_V\5+OU_40&SH(
M=(BJ]&II1N #;O$4S<SZ$1I[?.1\U8.VF+KN.BL!Y^$2W3%SC>!]&?^:Q;C=
M2R) Q1C"K"6SLX)$JL7.J;/5)VD6.+LX<(1#G 1GO7(S&6BUG!5;L7Y7;."Q
M1]%"34U38TN_MJ6:!%(2S;?FFPR.8_R0G9L]OHW0E:RY9Q[!4:26^E**EOG7
MCNE8@)7WA5QC(ZZA?CE#Y)>C]%[4^NF8=BI!73F?Y*+TS5:]:9VAI\>\9?&A
MR4'#EFY+<RS6W_7U$WZC5]]A?< PBV^@T8WWCQ/G%]NS'G@ U4HO>WQJ/SY,
M/>P24A?P[UIW"2A29OJ9>+2+JYEL%?*"B2_C&H05>O)'WXYR0R;87A=KZ,>&
MU(^;,==.2W (*&HT>Y_[X%TDJWT&E/GIW#[RIW-8L+U\2J4 %3%I]9DSJ2E-
M@Y>N2.CD[4Z1Y/NX"Z^FR5@L*7[,OR=?[],G7O-[U[!:JY$UL,C%1H)?KD1Z
M<9PMOEKES@'6Z,]13T_OD(\16L#(H%[0\B*P.8UV1N13WGM&[C5 /!G>VVAM
M]&WBU99L_G-+8\(GTG;5YG+2T;Z+J[N8B30S5(E.GU'>3G-#^FB^!#-SRNF8
M;5[4,K\[A;D\:ELVC=TE<*T.?KS]S;R(,XC1Y'6]4FMEW+H<2*#V0/.'BATM
MKCVD/5XD%MI9;#JGD#*JQVHL'Z<_"_KR(%<:,9%6OK"J/C&;*W1F_WF4<&;H
M^P(/UUWIMORU7"[\F8Z P0[*>'CX$\)SZB=L&!*MIMA+5JCYW]T(5<<M%R02
M :KUWH(=F26\:S5GN,_P+_KU83KN:(?FI1X9TUX&\X+M _)+<MX=USU7O22F
MQ)O!QX!,QQG:N_6JR9YR927DHG V-9G3;7UGLQ]SRJFH@P#)GFZK592]/2A?
MR/%-X1DB.(;7$-Y;SM6\D5.[3%,O1\KJT]&U]1PH_*E,"OH@E_4J,;TOVCGA
MEREEKQY_XGL?WZ7[W2@P-?_!Z8B9V7/;FCC8-[A$7B%Y;[DD!K4=Q/'<1DXM
MJ\:O1=MJE<#=TQS6\JE=Y"(#=--?BRW6RCHY\!#:^HVET![B^( A6E3L^=-*
M;L^7SH$9E@)/S=5>UT;L?AR'F7%+6T&,FCEK+=_>^[3#X'MNA9=-,+/HRYL5
M21S1CK]-#;\9%-52QF<Y.>/L5/<"QJ;L16H%2\A+,AR#W(PI7TS6_7@K=W,!
M830A(=%DLOA!F&]:N+X0#O?ZQ*O%A-:S1Q%LM0S@]%Y3)W_!8Z:&ADC'RQ^J
M!(A+NWZ]"[78#>2$%EXD;IU?J&8%Y>JVDTIA,)?'._I\VV34,T5*2W=ZCF'<
M($95G_^8Q^E^8SWRYS-_CRZ6CTF63&[EQ9B9H.??\;X9 PQ-89]TQ6= U#^[
MTKF)@+(2)]D\22\+Y'0/=[8,_P<]BXV$;4MQ1]TT 9ERQ,QF]9O64FZ#H[4M
MN_K=]"1+JO!9=:>B[FXFONM&Q](4'2JG,"KH4,P0_AAZ7NP&@T^:-F'$Q1@#
MNN_DTI,/D<(">S_9:OU(RMB^ +)KC:9HN?$)%VY@Y"X#9PCO'RX4GH.,=UKG
M+*KA=Y0+Z9YO\H-W%)F) !@C[/**-QP8PXHT;3D^OV5+Y+BQ3AD(ZQ\'>WFB
MG+#0MB>;17 GDB;HTI1MVW"DA&H"897/CAN'=U%<M_7T%AB8F*S=  N4_Z@>
M<V>_:!Z1OMWH\:@%&%F*Z?322G[5.(-K83=1K4],.M38#):[[*-0HR4"3'JZ
MRA]';<29(0L7M OG! X63^T5Z )!I6G3%/W9P2AO@8A4XTV]11=K+P3/E>X8
M=QWW#."\7C4P6\&WW-KB+7:LCK,R0PJ>H]4X4+2[X#I3Y\@KEJD>X+BQ@CGX
M,E#]IL@%: 0_?@+_>U*D$U\YCNC?+[_3MD=UM&V4Q:@5E1H[?5$^G%H\+V$V
M8:W'C4V7/)!'BZC3<4Z]HRNK]P,=N!;'EI -$11,*S 9:K!T@;>K3MU+>?)4
MXQ/DS(:]*%4\:F/0SY7I4*3#DM?P1W) DFO!3J5&1D*6>5\J2G=NQJ$:MH5U
M@[N@M)WFGV/=K@X_"H?1@ Y_TQCKHFSOXSE[3 1$XDJXND#:.@Y!E64VZ3 ^
MD4R:! ULI>;RK7%FZU[0DG^WQ6O$:]XI+<+)SF'3WMD;E1RY7S/:UALNYGOC
MDV/059=QX"QPP$5^8?-V>XRDP>\S>>BFT8R.\_R">7V33W(77_SW:PG=VT-(
MFZ1$'7M#ZMR;.8ZEM>#MG'Q9BIXZRS?U,SDE(47:B+F9F8Y[44__V"K-R-NA
M4.6.KJ(STT2 D]);P<[K(O2#)%3Z,Q=H8*Z5^:3UER^?$C[ I^_=Z,'"7DQH
M-X0W-*3Z;K,_["I$:K5SZO2&'N>=;/TXYAUV<Q8940T5'M_$:;K5ROH\&M%(
M_$I0]Y&Y&4B #L+_A, WGSZO[$2X\\Q&=<D'W1]#J.9C?IH[G4F"G=@[A.<F
MK_UASR[<,IC>3AUZ71.859$M_EO-ZGOH:R3$:3 4);J69!T'*Q8SVJ"[E&)Y
M4W@>$/C(M7 4>>82(/#IT4UJ>A%<UTEI@P9$4&+7#>%A6^L;JZSQY\_Q-@AM
M,EJ]YCOV=F'(YMVA#RM<0EL;E5>182TCO^D@DZ#GO:T%X:U3S[8ZK>_:/SEB
MLM'G]>J:&U,_3QMK!X$_<>47=GK_25#SQ$/-/,=>CP4;.CSF[DT2^)ZY\K'C
MN7"C;"RW.=F7C_$1!:'I'<:R2S"+<(+/$^E?MS/C9? !!9@N/2=.;HA# Z2A
MDM,PM7E0D%^!-31U?&K,5/T+Y!8P('GEB+9[B+%-/J'[-N0UHR+2:\7 ?2>M
M!2GPJ7EM5@;+,)9F/ *AYFRI3'#L$J1?)/RHR(2COD2(ZDA.G#IEM(KE<PJ9
M%Z3.%'QLY>F#>'OX1[+_X2[PAFT]IR "'KAN"[-N :)]+Q)SFM$VEV058Z[]
M]Z3N=NW=-\X9SXEKJ]I:LQY(?/;G':-GRMEIB;%3J^* UFDT\B@DT@>C<ZE6
MZSG6XR=A0D7]YENXXL);&2+ A0A XS! FF=GL@.99&=YT3PX$Y30-RC7M\ T
MLFXF62(@("AJ.JG](?6VI[6X87(4=91DF1\-NCQ'?,4LQ1E4M,,U&NH$N?RT
M991OL ^.TITOSPDRJ41FN2)("F\5S]R]^5HL\RY+;NU1\3Q7K39"<I[ 2VW+
MVL.1D/E! 0K<L)A8Z[.<U_&8LWL]>7R*$.0'U]:,E96Z4ZM'63?\O/%!C<I
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M?THB=T2%!-1%_".L^*$81<<6$O">?,Q. #'78UR NC7P%I%$S-<=[88<O^2
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MO>-6IN%]V&$<^-0F.2 T]L>V)=P/Y]S:<I'.MQH)>#(^?;IJLA"47QB:U57
MKON!M4'>*1I;F^%C*?]>UG2[0]_'CKD%#,&;P#05?W:&=I(#ASM $D.Z(I6[
M&=<?>>EPI"XP@>P%E0D>[+8F3^I.C3LI##TTE7Z]V\:F'LP>/']TJNS.WVR:
M.4F5<)ZJ2<U_Y5%@XGLO:<)*Z)I*46..&)[RIG"+NS#I,_(&#?<Q8HZUO56A
M-VNG-O3+\6M24FKJ-#@+?6ZY/5AB$7IS'P,4$.9@MJ CN"(9E;KYAUW*URW
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MQ6;X180:EKSV'S9F?[&I"3$;W7N!1VC?C/4M'B&;DQ'F/Q'ZE>AO66:.G3A
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MC@-$86 ;HCL%!1I#+9]LG.F[L]6B%?=)[Q,2C-58>ZL\X=-0Y?NP7Q)@;\4
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MY0/&U&#7[A[N%9KUNOK"Q(B%/O'\Z[.3#[L^63)VP96^K$;";*KG8'B-*W"
M0J4C%*^)V)JN]5-VFB^9'P+)R%1U6+D4C-=?2,^2K(.T10Z83/ON5'95B=/D
MU62'N-*K:RU.\7$\L]-U^B"&6<GVA\V+P59#80(ZPM-'5Z=P )0V^(ZN?9[B
MBUY,WPZ+F)>9X3M/W?R0 U2I#;6]L\RTP'9R!L&KD$ :S.A<I-A4D_-RS,./
M# P1Y?/BXFH)ABD)(9H+$4&NA2N@F54HU$3F0K@^<U+A_8Y=X=3,PXKU(O/
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MO325)H[\U?1+<:;9NEELEXD,6@T2]#6HZ*DDN8G5FPV+TJ&]Q#=&S]]&R>(
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MUB;1QP1HV!;-Q^%LJT^ZR67Z!+&MF<='9W7"0#11A5IZ.@JN-L910Q*:W\7
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MQI/I;K)]+/ICHDE^\84G<B.QO> 'G,:""R?)>]-'$YO3C;)L[QQ2[B<>#\G
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MCD-IB J(UNKL9E^NYUV$:4M#X"2_;?&8H!)8U^26->:8M$.P*NXQQ$;+RK9
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MRKV\,,42BQY).YRI^'[.3TL"U#N_QN+HYUAD"SM-,J:;CZL^TS^G@<,P$7I
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MV_W.K8+;&Z&( #=;I!WX\R#<+T]YTOC6KG72K>N1I#2-;*Q!X ,-2C,$&F0
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MELHM=!6W,/,+'%G@_(/HSN]$?8DQH( @FDDP3[F7_ZO#YVRTQR"N#SV*ON7
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M)#V#Y442 [BNGN2M+(D%K(.-HJY$8/'<#4E)9IC0&27MEQ] )G%? ^OBBK/
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M+7?7_-<V.$]<@[&%$^-&;!E9X"/&!GS9;U:K8*X$$4<61_J=O)P0.&GR&A'
MZH3C0\UZ\"&C&:JBW6!9C^.Y\!FKM/&/^<WN/.%M%Z8O,^+Q/57D'=4<%Q]C
M.J2=RLB[X1W "*/[=S]?XG_*,8WX>2U@%>%/S[8L"/Z,!HV]W4*$[0I CZN]
MH*^5)4GF$YM"?-$@FF&.HR66VTV&6U?!NXW0V-S5\\%/VE"5 =V;K]"@EQ-
M=V=!M+O=1(/L8@YB9AZW(=<@D]#8SM!JT9+!@^6WW]MX9:!%Z+;\$X4T0M2R
M+FH440<_;N=(GGFTT'N;S#_W3L.9L#L>.W3S =/"XNE4+$HT6,?"L>:AF5D(
M%DM$V(20!+^ XIQE8V3W0::XN\R7\^5/#T/U]FR;4PJDJHT-.%/V(E4-GV1-
MIC$I1^3MZ<5!O8+RWD _Q>= APV1I$PH GK'X3W<TQ>E9RP<S4W*-C(*\',T
M[G"S8'\Y-(H';#D\LP0V1$9VB_.J>$/;./I8M.O*#F(6'A!>6IJ87^T\)-S(
MCQ ?@)0]B%?H4Z:SC^W@K(:^V,NG+O.X3G[@?5WPM-'X/>@1K//CE.6Q>6-+
M\8[%<L5P0'WOGDJXAI5NRI!D=N%FT).&^;:P/K!R\01*'1P(F7F0C.Q#@[HD
MS=<(-B^S]'I!+E&9N12AI"C0H%%%Y&F-J-04WP2-UH>.Z;,O@I*UJ"YD\W;$
M3,*4,]C)+/W#-.FEN),;]O,M>QOB$DOJ/@URR<8>AM]^);T#T]%\N;93KC+F
MXK$@=HA-E8M;N,:B[F1(L)1+NO35**Q\9+$,F \8+NNVIEN5MR8:2(5WCW)L
M<051$4^K)',Y]UN:'&2L*\++O=V9;K=YOW]P=Z=9>3<OUD01[\"+DXBI.AX4
M@5RQ5WR7:^T@$7JWHBR)E,.*]IF?</9RT#YY'N%5/S1(W';RL'EZJ]LM<M2R
M1T9>UU8TB^W<,;.R<V M2A__<L%2ABW?:L]:AUT2A#VJS!WVQ8KZ*AIT+XRV
M]MXJEHR0?V8A&B3"$IZ9RU7\4#+XL^5C+:8/"*OVS$ 8"6/9Y[BOHXB.Q<GL
MTKCN_"$JY^?PF7-92$64CY[3$U$B-.C5C;1=R!&!77\I"W(L- WQ>0,-:H(M
MP:_?I;$*?#&I"*<];9C-GS^H#@^MIW0DO<58ZQ"T]J"W/S2;M\W<A,"^S5F1
MUTJU*:=>ZT62'U;HY_X'Z8L/,C7 )#UP$WG''",:!5UMN"JOAWA.;JJX)Y/H
M\QDO?98L K( A.A*=\[8[03C(JPDD=##13VV)Z(X&L,>XW6RA,USL _JB;*U
M33:;X<[P.85;"4R]>^\T[ I5/RHU'"7T\)^9#IWI?)2D>+B;<U1;DGOC+9=P
MS["O$0G9+'DGV##/3&=T1-NPI#U)7,4-W[O6?ZCR;O4#,P?R4.5WG]:+<0T_
MH4&["VDJ1&^R*K9XQFK (\S%\Y0=!0Q<%FXIE9HO\M:*EP/E+1]XWX)%TKV#
MB/>Y#=@^+]_$=Q$X!"?7E1I*=_,.FT7<<PHP1:V)X8XJVKXU<=&Y%=@ NQ(D
MB*M!_1SO:TY."=B\+VK'*CO.<92Y^F6FM>J"7/ZR6U1^B0,^GTU8&B@'-/T,
MF*QMA%FB0=M(AAE(7:6\HF8WVRY3:F6O\-?(X,Y9ID[L"E[%8^=Z^ XN&O2)
M"<4#DSR6\4*R&23M^;RE;P&/C"M>S_3-")]N2+70*@[)UPYU"/ JRUO2&.K_
M?'.T4BK85PGW*EY@G:]NPX/(![(5V%WJBI< I(^NJ .41.%>1,@Y_AK7Y!FK
M%@JCN/!CEFW>8@CQ:,G.D\$.^@ 58@$EO(C>3,NTJ41>'J02#S,ITZ"+<A?U
M!!32])ZMGK=/7'3S,>X@;]_!K'^L$;P!.V+G$%KGJZ+^SF$O9(U-^\CGN851
MVJ?<]$24-*U^1B#K*Q?V):W7L(+7ZOY*CUD"\Z?K"TZY*#A7J'3AV"\)!>$E
M%!V\'QA;IH8<6,DMA1@?0]6!R>PB7'!9F!=JE_M%_[;7Z:QR^1GCQ]=FP)F[
M.0.J!SI;DP_DQ*\4UAT&B#'TYLE-44E94_9I?]5AO?DIG;7M _4;K*[C01MJ
MKM1$B_ZY@(5\-(@[O"A8(ULBF359T\3NPJE/K1?$Z+"7]5=SLR='KR@&B&%W
M,A*9E:[)(/A)6A9((;8#]U\$-65^AKY!@Y8GO'A[#B*D^TITOWS&2[ICX3MR
M,+,+:=O*]\!GEHA<[@T>:]M%@V@]3%($P]+X3*N0^% R+<\8C6.)(.G'?- /
M_H8+4$JSY] 9"/@X& %+'> Y#NP\GU6NO%?E>.&Q0S@_Y/5<Q?A9($)>D/TK
MA^KJ:2N;7>$:*A: 'Z;D!:L/!&[L!E@A7CJ-&BN7#:RE^JVI!6N=41>^<(;]
MY12!_*ZN"UUL9H@F7NN'J]CCHJ-6JJHU&RMN"=UC.D(=9\<F[<]]V,\[34HJ
M:&4I*!_DX%%!;7@Z!)$$Q5L(I@RISH"9)P[)EUGM<3K=S\JJU"DQV1GOFT=H
MGK9S\?O:!>IA+GHVLM8$5>PI%M;--M"2LV0S,_>!D38)+.J5-"*&HG/*N,,J
M$L6P4X-V2(:7C_SB3>E.H=I6SSS[\H3%.,.M3S7!LJEZDEUM:!!UI<+!)Y-9
M.=(U3E'QP"$$\Q\-34RH(30H$H6UHR5D_UJ&A;84EHBO8_)P+14:] :"$E?<
MS"70F!M80KXM\OGT_.DI:VQ<^*EJA(0EN&EN:W!7R+QX%L%N* *1B'H2Q].C
M>\ ^I_4Z]V4U[$)3>>6*8^?A)5O1</79CGZZP2WXIR#[ZNO)V[0$'C*P[$\U
MT$8U-$AVL7CX$T(YO=/")8!!(1=WIGX<L9]/5)E\&@?554&[]N(I1&\3:;E!
M'A">F]U>1F'>VY=@2FF7/D_RL$2>8HPJ.'63M]CF9NM:NKLO+^2ENF$C:\CC
M7./31_AX^IP^!R/OD;UV3."#7<FI=XHO,D$FJ\"PI6(AC3-H$2PT%8%:A$\%
MMJW>&AH3 CTH^XB_4,/9Y:Y!'3&E.VRU@.JWWQHNPKH6D4"H/!Y0E'E0.==!
M7U9;QLT<A--QA?IP6>?2J(N5CMWE#^\^(PC:WD7L7O5R&F0.J)%4"=85$1ET
MVEJQ;Z)NBO?5<=8?@(O.0Z9D5FR<5$6"GG7WD=6%;7O1]I)T6Y4-WJ+$2=HK
MXKDW+$Y;/JPW5I.62+VIK%?-1=!=N+Q&X#2X'WW+C2UB? B90J'&O$K@4U;
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M')>!]S\ ]2!;-!KDR!&*VN@\D' </UP'JCS/ LPFW;\B9J)!=:9 Y?!D&G4
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MD1VM7^$Q"Y<K6RRQ2^+]@D$V8<,"_3!+I(O\_J[D]?E6K.;HN0K9,>)U_NZ
M4\SQ/BU58]<^.@R(7RT=1>9_?@M)<;#+:_ &SPA8 =69,B)BZ <T;T>OFU*F
M]-U4G\F;VDL5@7"GDL6;I%_J.90P&H#/;N=@ 6 N9"2C-+U'4.]2;)Q8=W1]
M#5<V,NEM5@GB*MRO[N.B]]*R71@0?:YC;%CTS^C+0#ED]K[1OSU6O@?*UR.F
MJ@\;E"DW8YQ V.Q6FLSR[JZ ZRN &,%1>]1NSYO+I@F4F/:(%14/!K@N)4][
M[6,XIJ>UW.I/C3_,:3!>K4(L(^X"&O<8&]&&.)_?NO'UB^4))E26$= 3"!PP
ME]]0[X*RU:"@\JHEY:X;I6=K)A>U!,??V&T&)[%7\ .9K59\R1:&"L+>!5*;
MT&%J<WA.5A#9>>J;F"9L _*)^7VG:^JF!<M Y!*L>&&7=0]4)8-!Q$'AU>W0
M.#T+68$KQ:1T*>]Z=W*#W;L'4"T/@03<55:*L$ - Z,%@#,.D54%>26TP@;\
M>21K<[%@!N>YBJAO;8VQ9 36[$!:@S#]1$/45^WCC&>[EW@FX) 0+@F-'@]+
M82(P=%NM;M2HT ]R9K.T$9C8BJ+)<=!A8&8KB1^W>S BG9![O!?1P'C>9_G:
MSTAV*6&P(-@64@+TPJNV3H.="5B@\Q[('\M-Y+O>VQVF K'N2'>VL"H_MSFH
MT':Z)^9U@H_BW+1>?@ULC:YXO^YJ7N<DI]+'O-H6/SLE'V7(R2])_ZUM:?6%
M-7V*8C>LNB@8'V\ )OLT94;@9%]'Q9]"-KOI)F0MVQ< ]W*E" _ RK<[_:N!
MQ)9YM[BTZ:?2L .=NS$BWZ>:]>O&FL8A$@^J 3"$5DRL*!4Z&:#>//P)XE?H
M"*^/:,6BLE?FW);'.6GJBP?;PZ*7& L.O'SN]5*VPW,#KSW0$2:BS+=AOE9B
M,NXT'@ZL+:FV'2=YC:S"@JSI7X;-WL=O2/W3T\%?GS,6HV+S!;"1'KJ^W$@&
M?\(!X[?3HL&;,&UEJ!8PBOB^VQ2&860D+NV!VNB7#Z(OF$AK ,F]H,]=)9@_
M>?JJ>+<S9ZO2Y1U-8% D)HU(A&]^VP/1C;@9CY;#J.8AJ5?B>T<D<Y]!W >)
MA5M'YP^<_0GO;,U)J!7. YBYXO-Q54X*]-UJK5.'J9"*+M*;^\RK#<&MF]/'
M2LY+A#-A.:'P&8$]4"A\-]P^]A1J'?YZ_4/.\ -("&OYG=Q'_0%YT=,VN.5Y
M55K/H%YZK0]6=A% O]N-,6%154?1EXIR\*S[6.E?%U'?Z?;)DZTLF-6Y<2+.
M? D^>BEO+0*WQ32N2QM0(6PU%F/A<+Q;>^"D!G>@5?DG-N$!<?-H5-;# M;3
MDDZ:(CF<-09K] <0:5EW!]<Z/6>I])<L<XW2F_QT9JB^-N?"B-!:,JRZQ/\(
M((C;(\-D.A@='8O;ZS0EA#3^C_L7YVZW.C')O6\B9L@4S+T^- U8=W*ZEG=K
MU!WHQ5/XH5)A9%%DI55^!JOGTAM*0:^35=?]Z//6YAEBB5?EPYA[F96'44@\
MKO?'<%UDL]!LJL#GH$'#'^V6K>>#[$I@KFOI=M6%3]O?\A$/ZLZ)Q9'"VBW)
M\;7PM&X7]H[3&.1;!=A^4_ #(07IQ)-PY'5K>H1X.A-&DP_6;@H$%C#XFNB1
M>[B)6HQ:6!02=6N/G-/F]K<J3B,2'G#G>(P*Z=%*X[I?7-H"JQ9"G\)!#0YQ
MW04552C/#]T&T^H7)KZ6[IT7_U/O-LR]!?<K/_4F[#_06_PO>J=PO-?(1)[U
MNB2:$2,3,IJS3?IU']LQD$@G'QZL@C.M]U+L5-?%ZDL5 :'ETHH$+M.%P#R#
M9(IIFY0)"Q2?"_,?45;>617<644?M_T'"$Y)Y5ILK%\$H)UT7_^L2 :9/"7W
MDAT,%8@%5(ZE'=Y/>?959%V6"Q-5P76(++-+%(5E;0[GN"3<:_]0^IB]B3LK
MSR0+7P[!"51#NVX7H9_FDVZ;DS]C*=9RY*?/]S**7F(:VN5(4B7IB9)\4,OF
M8)>Z _:"SP@1X4XTZ#MDFP&%*EI@0I\)P,E]CY->*]?E%L_?))V/[2'"<J;"
M9OAA**!TR,\:/HFQ'*ZA6S%72BVLSGSF>:*JZ]M\3'WR]6H9=</&QTF5K3 <
M18Z/P>KR3YS(C))R;+=.+8KI./8ZW[U&O)1PHE3X"Q"0P!W$K,&)P_L!.8JU
M2-"!%JL6E\MO%E'<F5PT%3()M=OTSE)-\S1OR9F?8#TM!Z#;(!]J@O.PAHWH
M.DQ77>PJ[(=3Z=6--B67Y5>?>RT4$BI=-_C%:MFD4 -_GAKY+F$P[@_8AD/Y
M*!. ;R-]!5D W^J!;SX6(YT9[$JZZT;&EC+5WG%HBT9O8ED,SL"FAW:.BJ3@
M:CKU]9@6)+1H,7/%YQ'EH/0I6[L7LAO90.%W5H?\P-<UT'Z90K1EBI5CQ/(S
M9N\F9+MEV^7I97+M%%5BUJ>(]176.V=C.DT4-@Q. ]4H@.Y3016;M726Y4YC
M_B45PO8(#>B=,X"S[_TH+R'=7=A(AZ-R+@+C8@<0ODJXUF(WEM%^J].0QC2)
M> 1);AX5S8X22[83G4_%!;T>O] Z>1F[.""1F(R18W>.TG8'YHYL57YIN0'-
M8&&L\ND_7%._6BI:$TOT#,.J%0QGA?##> F,WG2CBKM[<:ES:_'U@RU7;=*^
MB>C=T7FU.</+F4A<U=W4QZIE]V>?-XW&'6#;!A&+\5;L7:I0=B#WMD1.M2]>
M\[%BN8SU<#KF[;:1/HS*>?2GVD455T?+K4@QKT@5UJ_$&&FJGBM&*JH%E0=G
MW3?V\"_+5=%*,UTRA%7?0!/AW)=A^T7>,.I=>.K#.5H^3-'L0D<\Z<G8N6M:
MT]%/(M=X,;(+XH<Q23WNSM-5AW@7UN#.6AQR7C*+<&%B&@Q5%WDORRD(SWGS
MEN_JX!5[\!-4PR[A**!,R?P+])68S$%HI*F;D"-"(TFSZ<R0M*RH]!(!V=:B
M&E#FZ0/6W4X :NFXW1@+J&J-XQ =^CA=U)R22'UV,I]5070:@Q.3]OL*JGV'
M-SX<J $<;C1&A-W1!^K.=7SFAE5K*^PF[38_YRYSY3?UD&0K"Z 1GCY_I9((
M=S80O)./?P8*\4-7?3 9ZV^2]UE.+%IA85?_.!@=/;U,\CM0I#; IV'MMDS8
M4WXEY!2S974(WV3O&B<+!W-UMUSJB2=A!98CUY9C>Y1PU.OP(W07CBJ1:6.L
M:L^86Z6)S=.5O:^KZK1-=!AP-V=&*3MI<,C3LIK8G<)1!/LPK2ZZ[H%@" #?
M0-%#;$:[$;'Y=X<S8>3L]T!++?N/D;-YZ[<MXORMN'E8JD+[OP5\TO!PM+6+
MJP!2"1'KT_%=-U\UM"S>YX: SXDNX7V>@?=YQ@ T4DM,&&II\5#S.X6^M#Q#
MZ3-0S7 A4%J__F,8YZ%PX'((QJ!&HXH!S9"<OAW5^MFJ^7&_F6A(1/:R"][E
MB*LJ6J6<HN^'40%NM_9 <9#A'1R0""TQJM+=60*R$741O"8$DO<EW+N-["P9
MKBL]0P"SHFIU8%KD",,_2;:INIF;C[;O59%Q92WNZ^GV\G!<_+$',G4! ".8
M.0#+">&(O2J:N ?*^0#?8 *RU:'KP92SD8DXEA4W >>-#)- N9,Y1I>+R!9
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M1C9"3MWSCZOT&WU6=0-3KB9[^7,[RSO^9S2G(7UB^GZQIWL%/QJL:<Z(9[S
M$/K@J. #?K!.(N7%6^=JQC;]L[3$E[TEZ[!WST(ZW2C'6X3J':46HXRKK=$4
MKSA37+4NZV4=?Y:2RL'YU=YTM!-WLXWP[0_?KDV?E!=V+2#W8[K>P6X6M*_6
M4I<229:FC\EFY[YG+A<:5([<0M39Z+HIH]?KPTTN[7 GD\DPOQ!?ENQ)Z"V
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M[0GQT-1B%YVLG0M>?%(ZW87$#J*S/,8CQ23P0?WJ=,W3H2KF/#/S_A97-H$
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M#5NY]A4W#X3EE6('!7J9TN[DR&DUK:>/A:2-;P<1&6GI Z-]B!?YIL$>Z+8
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M;;.ILU/12N,7.D;,;<E(_#;3Q_I+M\-J%O]"FPU_3_O^N/R?@-+T__9E!$W
MW<K";2.44<LX*2!3SN?O@42^5>7Y/RBZIE!N>!&;0N0W7R&>?#MQIKV_/X*]
MIGFK5?'><43YBRS:VYWSKK$2U]]6YJ5U]@H A<V\\*M_Z([_?Z8[UOF"$ZOJ
M%?A1(+QH$7KND_%#2L?QSZ ;87YKZ:@<+_#*@[9=N\C*WBH<G90+$S78%_"H
MVKV_TK[^<_U/7K*1-VZ=<$;46E$8S%+J)"7D>8F-5=(*1,$^_9A3R8S@6V9)
M-B7P]1X3?<B:E51+J./UU2BV/BO8U['Q<OS80"VEJ+1=65$B2C^,"WV_@P%=
M-&*F\S7RSJ!XS9UWCZ3)%4T)XH+'W*Z;*4$M',-G2G=Z1-RD@YS/W7ZJ=Y9)
MH%^<\P&&4EHP?OB[A<=0MC;&X'[!0YJ;T% P=_[LK0N.N>,,,@M%B%Y4N)_N
M]52P,Z2D0\!G/4: )]SQB=N7C70-''D7=W<J66.?U@1O9[9@R,1LCHDA<[_7
M.2Y-_K$PQR>-A32=I0V8!'5W(Q6%ZPA6@D?CO>GS*OJFUV>1^G$AEYL^W&,,
M;Y]]3K)S E7V;K/5V@Z7P]1;=GZM7,=_9OER ']NP%6!F<<9=T+Y3>$.S[E6
MKITSK^J%1LL5# W=&P\.PM4V4;SX%O+BB5O/2S1=2U:S/XV.&(]+;]WTZX*F
M02G>)P'>JJ$9U7&IJ;!1X@X<TO+U_7,!%FU,X<X->8\;T%>N+X4]?/MT#Z3>
M-I39 FYPHIG"S6V"RR4;*;([K8AG5:5R/\VV!\6G!1\#AK>GIB2BA'.R4R^N
M*=721_4M>E:F:;%ZN%:YT,62,SG+^4Y\. M>#X[6V$(Y1DS4G4W@J >=X^]S
M.Y_89'>A_QP5[@P4K UJZL)=3-K(,3'G)OGJP/LV=!J349*IY2:0_&6CY<)-
MP96MW!T!"X+(_X,CH;X"F>I$E@1.3Q#-\TG-Y,$M,N(+ 8[)P_JRJ?J-#NS*
MEU^?I7IDW["6OJ:^(VMK:Z"P('/9N70Q5>-=5-; [ ,%*F)*+CBTY'(07_W)
M3"2[IZQJ!#_#>T6*R,G0,I+B%/,;LTZ/IP:R1TYR#'@Q>J4KRUVW,5=V-+7U
M"YU\UW +QPLW?LM%D]IY^D;Z-7&^V$I(7+Q?6>&<>G&!4R[5K&3<ETQY"QO6
MI&9-BC.,@J=O+&JLZSUVU[\W-'93.>$XP3D6EN'+O>Y4X;*I-]D29E13:%D%
M"Z7?Q60/SQH].>M!8S=9\GT/M XGZ9$0JNQ[:6%)CYAJF(R<8L]*&^?L"N9Z
MVGD]EB9@F#\^6[];P'50 =[YE/78-ZE1F5&ESL*,&(8DP5E*YX^$J\?$;\S(
M9)DH/^3HH=I-N3&U9#JK:CU1%.-?]CQ%,,K%\I,64O)DS2L9L"2G 8[20AX'
MU88-D^)?Z!62TA-3-X>\.VM&(2;.$;0:V%?N--:TTR]KD>CWX[)_0;A&VVIJ
MP?!9?3.-N*>O;IX7HFE*8V.;D3+J4)IWV-K:BMF@[4E=6;'-8&##7D%&8%%
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M5PH"JQ8"?-=&#4SFZYP78L^CT2%^_?J+C0W+"&!2I2QS3"-I.27-P>;M+!+
MP<./"%9 M89:\JV-RD/>%DV]T652C/?.5>E/!/XO%N,$I=@8RGO4F]*[ GNK
M7G<UJ$9GKJW3_RH)_JH"IW0:BOE69Y'C.#&^.=^%VTY->)&A D1J6<EW^T4
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M%6Q]7Q& EWH)\U8O ^T,LVP#-3,=!KE(!<B,9:<F4$"?3 F&37>NXO9 ^X<
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M.VPTM)/A.1'/>TK:]R_H-(I_>L>8.^BMI*B]5S"7I_+C,']%3;:]>B-'K/9
MB&.SCM(MI,#5F[:&@TIE'Z+C)5%PTT$_?*H+^8D"ON<C*4<+=RJV@J@D9$LY
M7]IEE=UOIL0_BO\DF.1+35H_W-ZW$<0?_,GZNXG/,'1N<CBQL7'(SD?6%04T
M<YXZ/@49?AR*M!@(:ZGK'-]M:G\)R>ASZ1>WWA<&,V\<%STQ<_.["/XP:QE"
M=GPU ?*':!V9[_)8$VM!3)Z[^:XPA*WTC5HNE<X[YOXJY3GV,['2548,NFP+
MG231'UC!GMF<9&2:$6X]DB)2ZO CM9U+CDY2=RB2UF6^8#.D^+P 1P&$9\3+
MBJ=>@^[R 7D;(VO+7OU>OE]S-]W>'&IW.M*0?<][MV*'G[98IXO69K_IK&_0
M".6;S<$K&$-+HV(JUW,QT1!Q[.;HDZ3S5SZ/:$X7EF^=I+0ZQ39)##8R2OE]
M#)(^->U0,?E=P":OO3'9&:W:42B@R]"_,09?/?GU=MLQ(<'%GU;MGF3J$TJO
MRA1E79UN5T?6MAQV6A+^7(OV_"6F:JKB?JUX<RP9]WM$BIHQ?W6>?9NSW^(6
M_SWXIYQ]#&<)1CQC9B>6O7%0KB/GM(N6Y:PJMR1=7E<;NF@J]C: N;/24L+&
M]R*[.-A"5#G@N6X81?50Y9;E&UU]S>LF2=T>>B'L"3C/ TB[T\9IO6/E6])E
M%?,3RX(OAZ&"MI*O7(C'GGLD*"FJ2]+9$$CE,'QT76LM<INOF&1+[>SS\9N!
MCZ6K)T,^2F&V1=A3&DEL\Q$,->*>%-IZ%)O;;A9;^JXJV,1*OD^'LH1O_9MK
MT"E*23/>,?TO%0[]RX>T_D_"W[V7=-5URXY" 4\L0)=G82C@-?'N,JPM)1W1
M#WIQ3KMU27JC^J7RS[]Z%<);W.*_$X\PHC"2Q(%G#YXQP170)8BXK _'G,]*
M>Z5\9/[XEHRG0N'N^\'_MP]W8Z#_3HGC1J>WAK'41J;G&[6OV[FW8^:.]DBO
M]UG:VXVM&M45I<<.A3^)O,\=5EAI#*-/;[3X7P:,5_35B*MV%."!O8ILCSU"
M8J" R4&D?-NA%LMH4[<E"A Y@,S=#2O3AO0WZ)_]S+@BT>\_QSRM@$0=",5
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MLC=-GT'.)E'  2_FOQZ4Y)\V3VENE 8%(!XBX3<J(B#S_^#1#5X'PM8Z%U
M.KB2X>;D0T#GZ"A@WW<#=C2[A[S21SX+.Q=UF+O8<T8!GB4HX)$"I*5M +R6
MU7E]R?/GS0_L%P?GD&;\6XUN-;K5Z%:C6XUN-;K5Z%:C6XUN-;K5Z%:C6XUN
M-;K5Z%:C6XUN-?I'-"KVGKU7506=P6(B1%>:L<$0*#9$DCS[<G/H;."]P8P_
M;1?E&2MG3N5(%5Q FKGRPE2)<Y36U,7M4OX=4:U/GDL>@FLZMXA@<52ZQ#W_
M-C]/&0)$V"Y^H1+2R-%!G>G?U^.?O(F4REQ$C SJY/S;ZL-+05W(^<MV]E7)
M_X 92*D-0GOE<TOLEM@ML5MBM\1NB?T?1XR=1H)K-U]8JIU[AP/2?Y.=[*5I
MQ)M\K2@AT+^.'/MM%\$33,7!SPPN^G0-G4*Z%!DH)6XT:19P:_1QJP?5[%4T
MWP3UC)L4P ]DYH-TE[Q)(K"MQXM@:]#!4Q;KB\7*.+&F84S$:1CRDL@S&_]B
M!W1]S 3[4'5SZ"R2?[,;0+LUN#6X-;@UN#6X-;@UN#6X-;@UN#6X-;@U^,<,
M5N(9^*4(PE+?FX-+M2']Q#F2UKBRM;38;D8*Z!7_ \HZ_D=P'6N7O_!% 5/6
MUY$-JXT4BSF(%LA.-;);SU[?) 92U[EV4;YVD-(1>S+ F X]EE/XJPO W>*_
M#6@5YX8H@):^\]JU&ND?O7FR L*%+!O5H("2%RA@8*A1KTF,#P6X>@6>V8";
M+WZD0UEZ7HI"&5/OWN+_'*37U4)[ABSRINDXTB+&3Q6X9&5T,-N3+*[ K4PY
M'>/QUZ>)CH=C]V"Z&0<\=ZR1)#E^D+5-R-7^R(0DC2RA# 6&I$)/:QIF6LDW
MS@YW]48$VR@*J/1@H*H(B=NFZ/YT,C&"O]*)P/C\TGRU,H5J70LO?93TJ"<J
MW__IA^<<;G8L627HYP4WE]EO%'#2 5YY13V<;C$)"?PDNYK$%_?0+B2:626T
M#=124;#6']#$)$(Q-F+BH:&[*' T*+\/6T!\+4EM1C>R8T0+"UBT]C>I"YU]
M&?<[DE\< V-3[IX3\>%N](WO>['7GI(H( UZ"?U\UX;+39T,!1 U/ _]=5H;
MBL?UY,,#K7.?(L@'%]&=P:I^&Y%^TF+M/ 3ILR;G3O*=5R 5L[/3R^24>R<9
M>]X.>"'!-N:M5/ER6#_[,+6.Y'TNYR9Y"HH>JUWL:/<&@G8YE[T>W+2DGJV
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MK%$?IGEO\RG&!^7A)-PQ:6ZW\.2Z<POSJVYRA7S+PJ5XOHD,\)C/W2'4A#2
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M8"*O7:^:[\*H5ABIVKVZE<R^(NQV;*",TR\0D7WZ02.FH[>T3]"[7Q@2'K>
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MO#VT/EL"ACT4%/+FGI3,KLRL"70W%TH[5DMB]3,;I]6QBLRY]+8J35($H<V
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MCCC<4!A\.9@WWWL\66&B/K !*3TWW&MA$K0@;T)O?X9RZN)DB+;3-(ARV<Y
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MT[]*7!3GZO9V&M52#?"4-IW.OWGK310^AQWL+K^A>N ,9\ :A^\FV6S,-$]
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MQAFQ_>H - E</X!T_@#2@T_^<1W=8'68QR]"^.L$5N\<V%TV$F2:YIWKF$Z
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M4H_;ERCD)'JF[@D1&I&ZZ60']#UT94_19U#9MK1_<O* ]F!W6U4. ]F![AY
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MW=N0B7R[>)]=D.@A9\B+4]WG<7<7%[H9;9TV,N#&/)+DJS%5BO$0*RNF RS
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MR_JJQZ%G!\F9>]/J"R;WY2VEFH5"Q6OV,#SE&NWB=<(U:)R'7;!%>\&!AWW
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M7HQ^VVAI<XJE=[Z,TB>EP%*E$> RA2468$1Q(?&EI3Q9P:-"Y_0Y_WQ.1K7
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M[@/T:/*MG-V:-F=FE2UB:H\TU@E>FNS^HZ?64+S?.N2<JSPPROW2:E0W&@O
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MGP/UQ%T<!Q*%(NF */PBCGTH^=ULF')$2(TZ"84W"G;ZS17,&[ZDBP.U..-
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M4;5]D"@2,2/'?#"<SZH4*GRIB_J$L$%N)E: @!CE2.DFI]-UT[C;@5ED!^'
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M=O_3L&&(SFLK46J !M>*+I2D)7*Q<C(5I3Y.K)C.Y\ZJ_,:XG ]Y$W6&IT-
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M;T@(;%EWY159&R(JA1%$L3A+1P3N;)A&BZJ[G'2]T90>IY).,QL=8B[GISA
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MB<!& 2'&9^UW7Y-O;H0A!*6N:EMXRV6B@*L7X<XF^WRCD-XL3%+D1W1]*._
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MD!?QB46'+@G'^ZOJ TJ_%8O9K(-$R.G*#X/K1\0,TJ#K0:3_@#,66&+]TXF
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M82LQ]QTY ]8B^S4/[:4%_U,NK!YEL(RIC)ZR[J!7VQF1>IS//<^3+9>[K*0
M@_E^$VTI.!WF]FLL7T VE,,T/@BC-JQ-V][[ \M$FV?:^--ZY1591MB^EKC5
M_=.GUFV3TW,M/T-@VH2ZQW[7Y_7K_KC=ZCS9LQW4Z+A3_E5HV;RVA)I_)N=;
MZ8[ISTE0FH ^>S%2&$!7D1A]Y)=2R=(QG:^N3]*T;T3@V(]D,&FL68JL]>PC
MT,*]2B=#RO;KQ9=7'^QU-,"::[KJP"T!5]],&ZZ>D,T!!.G"- ]4>F'\"WYL
MZ;:XQ0QQY,Z7TW _"^:KSMX;6X;5TPD*+S[WV//+?*[:_@"OKYH-V4VE25EJ
MQ&U&F:UIUEU_^0G"\V:!>X@#YS,J8)5C8K"FLWK5R' NR??P^8]8[Y,(,_L\
MK'_VZHY=^V27V @9^&UMHD&O5),\C:^_'1M24FN8P&MJ>*?[Y<V.8V.RMQ(G
MU *J4JG7<F%4V(FN2N.^BSLV)DXDW5#.*A@.<$]P01_H#CT^TDO(%HSOB*_L
MUAYB9X_#12WA[Z<JA.9JTJOSC<U0L+!]B'XFNDIC=Q!<QF%B7SXR,M@C5.0T
MHZ;Y^,&F?S;Y]9XM2)L>S,G[W0_'>7U1>@/:QH>+U>#(AFU6DHX6P([?#*<(
MT,(CQEW@;%V*CSL.*@[P$L.P<[ %<9(YFQ&!(Y%4:F$FD2(TQ7M[\-=X;XVQ
MS1.,A(>L.W:[^^$$^JWP0O6GC5,3IPY%O_5;0B*D\:K>'XHT3R+/9P]\":?*
MNZ9T<)YLT(MB44/.T(GU7+&;F\NJ1"+AH;Z6TXDFS"/_0 "=U+AW610WXM32
M0P.KX'B$8I7B5KXH*%(;%ZQ>R()?=3AW5TM_SKUM^ 9SE$P:Q[<'EZ&QHMA^
MBG)$OCHT4MP<;,?L917W7!9'J]Z-& Y0^-;1E=:5BEUL_E;<7S:I38F8,YW?
MXZ"^CY&#@U]L_8B)DM&N,N!48FXJ4!I<*L,DOK9TOS1<7U09J]9XE/?I'/8:
M9.D\V5<\:4R(BY\AU#$1 16?>?MB+,FQ<?,V'/L($\+VVO_+UM!^K7_]PG\W
M_H/U+S.Z.>@A_SG8Z#KL2,BWSDL]@C1H99,&4W.27JZ7DFWN/@\\PP>X7THL
MV5N,\Y/-*35?._4I(Z"&YC)YKS@LXEUO3EXY O5&K;^-;D2$NPL^!Z!/74)@
M*,T&W)\78>3K=69EQ2PXR @78IGUA69;"JB-+%$+,?FM? '''RZIN=3,,%3D
M8SW;I[EJ E?U1C9D+A@T]YR-%UT&D\B6V37,8S/F0<L4<<U\1YHQVA0P>]$^
M>\"C2@$P$W9[E6EXMD)20B/@H5!8K\P\1 1/K8L-IYY"9H4+Y8\^?3EVTN(#
MJIW\F4)PG4K3!AG:(_[A1,EZYP>8+T22(/\.F-T5CC!J+YH[,K[W*/;KW%-O
M8S+^2CE'0MD@=JE]!AW]R2,Q[E/%SE54PV9KW75UOYV@#3-WU ZYG_;S"8<C
MZ8:7;169D^4BV'MXC>N2L9LMEF2/SJ2\&8/FVY!KU9K/=U$^^';UHZ7EA5.W
M$[^> V4IG@9-CJ;:3%^!FZ&1[3F.P5=0,0>M=S9B<Q&M;N(==CI^JO5#?*5U
MP:/KQ9=&NY33(288O5H6U+&QTH [)KNQJ$.^W%* OUY#OV^*;UB'@C,9(]Q:
M4C/!(S)M>OM$8R[3E'POR.P*#V8IVDU(T_+;L*3:-:VSF?ICV1"$&.+,(W6,
M:4MQL&7)LZIU3ZZ^!>TE(RCS THD;U&GIAJ,@12U +M7]HYD8=0PQZJ+8XV7
MR*N^,)OG\)S=8:YUG1>"W7UIT[]QX[#VC87^V;H*43 :Z43KC4!GEFX@/!^S
M$1"$6MV"Y\H0K/I6U'SOD7[?6L6CC6-/'5 RML"H?J1,8V$8&5KWH_;BM&X3
MRX4W2Z"LZ16SHTP26[LZ1*C,(@0+M!.N1*A':[^.61R'2D*FEPKP( ??2^^)
M %>--FX.@3N=2OG/,LE_!@R_S9KHY5XC KEXFQ,W_YA*DGLQSUE6[RO$> D%
M&K]$/KQP&5\!:=45#E.@*1Q-K:__YN!WY&9QGM_PE>-J1[#,B89DGSM9LS :
M>YGG%0<XSV37JY(-B(M+ %GC0QDRHW=Z"98?#7@3DX'@*<T+Y(P+'U(T>?HI
M('@!^!E8/P=L:Q>!U_7N:-TZ_1T;8"]0=W6FL_0-\Q0Y(UD'UT*\-X@(<!0X
M?V:MC\E:*S>W'$:VHAW!I44F=/T+M+[]H'=X]A&TDYNF<0'N!A>!+)P0#)-9
M"OCW55Q]I&T*"+T(SU;WM\AZXVC9V[&S\/0QK9>@TNP[#^1L W@MJ?W@[A!^
M+4PG [_"%#04^O#R"7!XP_:%%>A>3\.N1#[?W&BHAT;]A5+XCZ>\8W?[=_7Q
M/I#F.FWMH0VWW--Y3S]N(].8;TS>H7 =7CC(FAIO\K<50G;;"YZ[H*ZVW+B7
M"G[CYG1(0PK-]G8@A.<"H_7"]N:/^U,'TY]J>AU](B=X%T!S+;?%:T MB+/&
M?>P86^/',2%I1S>R3K+'(O7=X:!EH^.YJ56/2W-62JP5R1=12GS,>N15J6 N
MK#W*UXENC0F<K;3XW5@UT;25P@.EI@1*M<3JY\":*]%)QV0_3^\B\<HVO?H8
MU+%PR\BV4L;X"Z\%_TW)$GJ7V#Q-)#^ (0*19J>'W/PY9^X-;,@]C]5*R/9X
M&G:4M<C'S U!\Z>A$XR/P!&?AGB?JO@AKOIJ5''OL(7_,.O)MMVOSG@^HE\8
MB<QD,SW#S5UP]TL>FWEX/5-13=CFQ&V1/LI(;A>7*^.-"YQ&@3(^:.%(''3?
M//K26R;:Z>QDER$75,-=1'O=?G%9 ;4MYT7:&+UN$V_I;2+@]45?JF^*NU\'
MU!? ,$A3,V=/+9=O&:]C102<G\VDBN]^ 0"@D0/(DX<TC=.$>(WZ6 4&/PNE
M/,PG E>X$+7:J<BO $J!1$:^O"8"3G=);,=,$P6CUT8YZ&YMS,9:VT0;/^:A
MHJ?QPND/L);'6.1_]X??J]C9. !]KTN*Z_^A(1Y"BE[[FB&[IXE YUL8MAI
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M >ARH*0+I0?U-S.K.AQ?4$LP#R@#\,OY.Y\%F:8]8NQ)]*7NX'9G_XT*;.'
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MP>6NT]6%C,'HU]-\Y)P1>]![ V2W1AK545<M4Z:^(G=N\BA41PJ6Y:E8L%>
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M'Q6%CG^@+W&F5YVIES8EWG"PI<)IL8@'Z&OB2YZA71FG'%Y]GSV@DH+%T2@
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M*$W-Q^,J.2[87,>=,T)/EIA%EC;)]3L+?7?;19$(*EU/H@N;QI=;])_>.D$
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M<7$!\D3IEPX@E[>J_?% G' 5&Z6?\$BE\_0>RSO9.;FC%@*4G<#J+.KH4VW
M7>K(-&VK!0P7NN<'_%.1)HNRL2+9LC+6'+0N/7/<*;=AQY&D5IBJG-G9C2/9
M+SP]U/GN8O<S/E0CF^&B6T8O:&.K#4RGIYR-K]QY<AOT'A+VB2AN1ZX+F0K,
M[L':*:%TLT%AB]/;-;5\@&O?=?FE6N71[]C'> !6S'_> TT=5_^XT7QEK%'E
M].CMBR'KJ -SZ: T&C&];\3]MW;>6.YV@C"G0]"9MR?%P%T\<%6:I;HU:_V[
M.[L PZ=$EIZ6K2I_VLY*14F4F'-JNK];_M/JX=YIGB0)[]WM3YR:BEZ*XU;(
M[S+4_&U'QM6H J(K%:]O/>6R@WNX?%/FO<T!3]@N>60 N^E^=]D]A48#R@46
M! XS=.Y7#;TX*2WEW5^(MH?99'$NCZ?UH,"F(R)64DJ4W^/!C3 AVY&7G6!S
MGXZS$T8EF5;VZ)G&<M%\9DKL%!PYSXFQ41W8*7H2AK*ZS&*JBE!86N7]N98*
M5&5A]2R*U5^<._=M/U0@N2+B':E$?&,EN''<S\^/-"*]QN<!Q4*,CD+FUT:'
MKF:>@4:ME''60,F<;=>J.:VO/^_Y<*4O+($>FEO?'%MKP-A_('M=,7N9[XD?
M5)1K#=6*%;@PVM7!H7>*6ARHM+G%E'OHQ ZS*AP^+ (S^HXVJB/1P[LW4X=P
ME#G>]S-RO+\H^9'SNEO'+W (4DM^E=%E)1+^]L3/AKW,37.9@N$[UF+HT1EI
M;E$TH[MH(@_1\6]A&L%I4'-@2Y$.#URS)G@5EM#\XM.6/4ULC+_)N3LNMV:=
MN*>9X-=V'?WZXR?<DX8FJ 64UM=P\WY+A90+,\7W$ \57-77P%]SOR.$J]/&
M=KR8OPQ=SOB.CL(#JN; Q%YN'7]T)?,A"Y>IV>S;)]4JK1T>$-1]82\EC:E=
M?2+A5Y^4+9*&Y (!WQ;FGOXJEU_QN<3K\[CZ'CSPP80<62Q#K;\8_\V'+N9:
M[*I?+.?+0G8'U+40:5Y,=JEZ]:HN#6\%I-[,T@Z*&$:7K'W-O%&-TLL\:&.)
M='QW<Z#LQY#_Y8#P_F67IYMCE-/:KFX\)I%& IN:)*S[L)?J;RU';/M!#B2P
MYVU87<![[B:J^&U$\C7'[QW;K^JX'X:0%W)^K:/%F%E?-U5?<J0[CSY8]9,@
M@AT?Q*Y=']UVP+QR_[REJKV]5!=X[?.SB.[;89KLEW;[._2IR^G%K9-Y2.\)
MQ4'G#8G*D#9,D[ZYD]\$!JSN$*60W6I1:OTI^/85U@>"?)_T@PU:92/_\T;#
MI1!T?QVZ5'$/E^< 04E<1,,EA"C?8ZOB(^>3.V66!L27U@7Q0()M\T!@<.KN
M:[[0U%O<#BRJ1BJ"0;0LV'C Y@UAE0M?MISS];*MQ!VH"=*>K:-.32!(*/TD
M)K=UK48CUC3:[(-MTDOT6JWBP8[E2EX'!_F#T.(J';/B%*,;7/8'/%Q[&IK@
MG&<8M=L#4A.\C0,EUHNW6HQ?]]6R>W>2T4H1#8\%UQ1<C\FVW!2]>O>+P)/8
MY_I<7E@7U8)-R<EIIP/=S\P='ZFZ[2Q+)&>"'(G[$<CG!!]E@!-RA@5_A6$L
M91!H\C0<'J#=*^[':&$OX@&ERGDL&1[8=L0#+V$M\(-I78+'",%UAO#NY<4C
M44:S'8W>HFZ/XVX)<ST[@-W=W+JJ-AJH!%7,_]A4>+> *HRYFMT!<:%ZG9BM
M0WX:$Z "?Y! ^C[;GHCE"XTI[9:E3J!10WU-=93N(/9<0^5>M*Q$?D^+P2TW
ML0"ODJA%&VST,7SW5XG#V.R]4NVPZ;:H!Q/4'=-?YC2YZ9>(421XX/0SL7S?
M8L1.;E9U\[4AZL]R,]U%<>$CV1Z:)ZOU>("ACQU',;(:T];%ERTAD1Y)8D=G
M!KY:62L:R"^\Q'6FGB:4'?J#DI1GXP>4R+2>=&L6RS&RE%AQ9)=Z63^7F/;\
M4H@PE@!&$X//<,V((_5B?4;?T_ZVAT$)<N:;9XZVS*X%(>B9H"!$LOT?7RMD
MS0U%-K&UM[7+5Q?T"6D]O:RG=B'@L<IL:*<\FI[HE6B[#:,:TY3=WCY?B613
M\0HQ:->!8=07W'F$NW'PR,73U>_*KN.QF['E$A?.,B VSP>EW_:ZD*)YU',[
M\1'H;#UV$<?93S]/9V[ABWW'=U5"\WST%E<PNP&YZZ(-)X@&DS*OFS3(.CG*
M:?:*O2"%:X'H!U#$!HN5;^KK$4G^2%:A%K8O5-=59TET.@9I)]B&I3X+]S'3
M)_K?WYF4FDVV/G9@R"ER81<7,#3B +)H-+^"+C]&\6U\J:MB'+?7N3XV4V[[
M^9 <@7SH.][I@7G@(K!8H0.K).=M2)Z.\Z?U7_RY\W$8)]G!44ZQ)'M?9G2!
M>ITR^--H?QP8=?@)#]2)'I@#54$HU=/%3<,!J7!W$H?W=AI/-$M&.\E'1ONI
ML/>L+ Q?Z8X\2YERLK#SX+F2<TZA"-,['/-UT0W7WCM,+J)[V7[WAZ:QAX0V
MUN5;,(^%NOW2](V= 8T#3?H2D[A:#\D3(A7.BGQGF7H]N/3A<J8E'579%IIX
M)O7 3YE_BS6B+S?J@U]9WG'BRC/_U^^ZMO0P".BUKMP)GD2VMRGJASQ$T+2'
M6(6E><IU<XZJ. -KH8_$0A0F:X&![1DS!RJ,E:"8/J_/)?!BLZ!8AT=AZC\&
MNK+L%4O'4W=%1;F^5*3\W+S-3G?#P7/") YSW.[/%'-E:DD_\D53?'5##[-5
M3\+RU71VVTT7G8[4F6,H5277$&/ 1Y(B?=&597:<'#@",*_%9.?/6RN:,[Y:
MNX:>*^9))!C<X*JHQ7[6FNA&Y=2@E3?F-JTO2GHE*TO&R$NYEA.$!AN)<V[G
M^FKT9*OPU<7I"RVE"'=C0R_4(5[YWP,]JAQ-O/"#;Y_WD?+^:ZW^8<B6"H=#
M&'A99PBQ!3N41IAR$CS-1%&"I2\!CXR=_Y=BJB>[B\I5YQ5+E*_CWPF#!Y?0
M)\$H/-!<@2&RGEPLMG-49FT>D2!)[*H6]5$4W?3$F'PGZG_?U'F0_KIKEZ"0
MAB!8CF7LM:I&@L'+U< #KL&W)C DP91?<&3ERLPNT$EEX80YC7:FMNYGZ-E1
MVK4N[*52?13D86U%TI"ND+Z8-DO\&]KX3X\2FI/74-THK7*-#BL*^\<C=',A
MRJ6E))A"/,#S#0\<=H)7K/N135;2\[1FSCKQPQJRH9-=5& QETYE@@KO/@"?
MN\-.#,@EH=DS&T?R0=OA,L>#+->>RW7S,IS&T7XS*0L40>D?-</.D[VN0V[^
M1LI[P&M%A)4/-N),1DXTZNXE?>WX4D$QN? :#Y"$IH%"UX/B_63>?K;QM6D7
MG[TFY2.3E)QT?4D.^1ON8PCW$&+Y43D>*/V,!]#B-O=-^E)OSY::PBT^]^,4
MA3:*-4Z%)77KFM,7A7RG-(X!!WJB)1LFZ=)J3"2'B,PW8^VWQ#A_F8O8R/FQ
M(E^?UGD(QB)_EOG QV,N",&^>'.!MO0'F,[:+\A/)!OJ'G#K6T7WT*UC?NGI
M#3S **TDJU==%J[[A<ZBLZR4=H *ZA]R:Y?,!3K!*5C>]'2:""((T8UO!4>1
M[Y5^VEH1BKES+/&MK$B')X4N3[WG!_F7T@_*(!?H=/#EJL1IKX[:,\7F.NLH
ME"7H1\BM^3AY\)34*UUSZ9,=F][7L)^RJL%QY.>'EO-?A6VV@_G2]+S;?<H"
ML\\K>T"YNT--X1;#/&,O=+[+WWNR>%U%WW8"1T[X:NIVB9N4KAO;ZQRWFVM4
MAJ?YRZ ^>J)-/,!<!>'1JAA*;'9Y3U5.=-ZQ3CL"QWJ7*=,2#)7CF%N5$]-R
M%:PO#KY;\T YEO;79V%>Z]C;B_D_LX*.RCYV$$R;'14<ZUL5 &K; 9VQM8[=
M+]])70CZ:%/H >:; E\"OF%J"*C+Y+Q)$QOO)QJAJ",:X>6 B)T48?D@_LQ;
M\!;7&KK4_(_OU+057VK['^U]9UA47;;F091"HHH@$@0!04% )$LH4$DBH"(Y
MB61*0'*F0 245 0! 26(DH-(CD7.25*1,Q0YARJH,.77=_K[^D[WG?M,S]SN
MV\./]^$Y9]<^[+7#.N_:9ZVUFZ0YHGJ?O?_F9Y,@D[WH\Z+C'BPKA0J&NR*W
MA27*PP-;A.5 5O8-8U U* R1X.Q_(5?^F>WV#8ZP+A(/3X0RH;"J ;HWRX\[
M"T8-EB938@3,W"D'1>Z>-XXTO6_A& AB#SWN ^GH6S1!R=/A*5*#W%^.VQ]'
MEJFT#WU(;F2?\$18&)KLZ#4GF_X*K?+I49ONJ<J/5YM4[3R0PM86$\U7B+6X
M2>4@:FG<=%Z62K-5/C&-NV5-O5T@;Y>UX"VX9J@:ZWI)I],EHDJOJ2-*$=3Q
MK<@7RFX8M%W0##>NP=571],A*!-=3(XXP(W[=LB#%*JC.;H D9I9I9<ESQ":
M/7QL&JM-IA</ZL6.FAWH$#_<UO2VA_:O*26KL6]LM\UJ&P=JWSJIFTFZYU2@
MDZ]F@'+_ HDSW[Y=JO5V4U!/9+)U,#S^B%Z(*"S'\HHA_4ZH#T?_N>I[D()C
M)Q7NIA0HG:!?[UG/X!#9!#4&KX?0"_+AE9KQ5P,G/YITO20HL='WAVCK!2.R
M8C2GPN"!@3R6YJN#DA\.'$D[/CJJ9S4<.39:%R%+W_"%@O""\,[RNN/MV(P8
M^XS=;3:[[1<K)F\0V"?.%;"RI<_29'.W5W%';227MY_<J0Q&!G_0+M5;49#*
M4U][&]JVQ87U;"4P.@^[1C4TUY@1EM#7/POT,UJRWADP7/!Y9NX WO(%Q^<7
M_'$?.%]M_KD"P^VZUY*+7#@4^W'?6?BYM#.]6G%,Q9%\/G[PEBR,52CY!IN^
MP\^VC&T>G+#K3+'OJ/6.!4%58!JA <]0 ZRB8P]U%DTB87-:!&-2;680>4*N
M_BXY5L(7M=\12O@GPO.[CRTJW9<ZKSALA:/%A==92&:X9 <7V!>C9CA]@@5_
M4?;P3L8'/$WS%*'/8?8RS,U;S; +W>(B4/,B7Y8HX7?25[YS'& $#(+\<#=$
MJCP2#/,NVQN48[M^;O^X..+?AP? MEB7F%2KTBD&_\=ZVDD_4\_(F9U55%Q(
M?N8-04*6>\+F>#YN3"SU;,2*](+9/S'A+A.M0!DLC*G" #"/4(]"^0AH3[@1
M9=%RQ9"VI$:/W"UA:3ECRZR=-*?*5TH)_,TE^>KS3KO42>Z(MX^H/$VOL[0-
MNS90WNW?TZNI*@\SC1J^(4!RE4P[.7%5X+COG!YUB"%;:06UZZ%GN>.>O FI
M_;I6QGS"H0&-3@EB_Z,PHPCG+85)N^JWSNJ;/+T^ BN:.1DCJUD,W]H3VUR>
MOEE]'IFL;X.UYG]SI&HRM''^QN56[O"ZSW5XX#I!_>?\'6%D_^%.K_15W?-1
MST_:Z@-L(3NYAX='/W=)ZZ5;([&0,Y64O &X,*EHAV5IHR6P+@!K[ /V#.#D
M##,TZ.0!]+#*X-+JJE(B:APL.U::WWOH&C17MG)[VA.1I+9/V]L'>C"G=D '
M5\<$B*K5%E<,-(>MD(<3<0'A$X="6Y>@F27'R0O<-5/1#"N%!KIV#C*W!9-(
M4\XO;"_85N7E_Y"PO<KR,7=\V2Y/XT6%JP!UQ=ZE:@\-[?38*R2WF!FQT<'+
M)23NDO<*G 1$.]SIQ7M13X@%%]S4;]6;+<!<D/OY#I52$@R!_C=2V+L>PQ!L
M%2OL;E]OL<68B;'V$<^6)TP4!LK?;SR;U0Q!V8<8]G0IO8SG2%(3IH-]XYU"
MVUY LQJ[MZAH][TU4:^\$&5"'L!Q<#4%I#*[==>=XT0WK$M5Q*G]>/"NFV?G
M^^D-:Y<LL5'$06X.'(5)QE6*[F5:$JO)X(&(;&CE=$<Q?_&M_((;G\WEJ!R(
M0/U%^]1HLHR3/$Q60G%X93'*A=ZX[X0,Z"_Y>:G#K**R7*7PDU^?Q41"][#=
ML\,C)P6!+QL@Q%3Q?D[SH,U4RQ[RE=?7 V,<VX^O QRPYWJ"T16!PP=&NL!@
M(1YX[^+/VSZGY&ZT &Z)?NA</9!1&+'?(QV$H=09+!$K/@H?T<M-N2G&ZUL3
M9**15X)2:> ?Z6=MNO5Z$OP(J(L2"=8,:[FJ=-9S& ?' ]?HDI$EFCN4!3%N
M19EH,R:L IK6PHA@NI.K[8WYBJ\2&!9'$-8+ND6--. LR= W4B*_?SG@+-,G
M+5'J8Q0>F&+I*</(.DM5?R<U=ZM7_YQQ-87LNYO+XE<C\4@:R9F%N<]S/!^B
M+%/NGX?=*!Q)&OJ(.+*]@Q"\N%(]8),"2<R<-<P?Z=U+H>QD0<59WIU(XHB+
MP3W 6 DIZ'7?\[Q*_7A^&5HW]%E9/43-;2.@LN.,_YL1\A$78=UQH[<3;-@P
M-HK[<90#^RD4Y]DMOUE.&'^(4*BQ6P7O\HYA:= :=A?&T%HA]V"Q3WL'H9&:
MSBQHN@V?]YA,H- %UOBL\M)5)=;P5K9O\>KZ_6_? >6P,KC]OC!E 29XCV!Q
MPC_F=O-A1@P"Q7<3@ZY-%1-ES*;(5IU]$5;MX]R+L#M7;#^A8G^1_M,ML97(
M)"@3XN+?G<^6&?3G_?%\:"/+[@$> ' E??]PGZY3_.N!V!0/:$X_RM)<^-/?
M/TU"-T3("%=SHLO+,^\WWG-L@SH-._7YW]<R01L4\I6SH-;8Y"X-(_[UDQV_
M\*J@W12JIE41&=,I/3\\8*"%@23N*(3OUS"JQ?/:SE7 S=ANSKV85<NY6->J
M[RS<#6WXA <RCW"/H(?.:1F8&_TVB]2>[O8NH&V 7?V@16U-YBKT_+Z.X>J:
M_F?5[G1Z92@-32PX4 "5_.C;SOU-2 &=[DI_U\OB<"%VKL5S[SMQ^CZT:Z6'
MVV-ZK79VE^0H3*S9*,[1]KH5U;L8WE)<<->=VKPQ%LV-9/\99(\Z2CD[@#DW
MFTA_(4Q:XLUEFML+M5M>U\#7#4WF&;'WUEHB* 6,]?2>,K$VI%R__I[#)#R#
M)<!IQXMOL MJEMP412Y0%T;[CAW;/T)KBP=F19*%Z-J-O6_D-%$GLK<N755J
MH9X"3)*2BHGRYOD9P &<I; 3T0V>UU_?4U3)L.X*^">E[64M;K<&5"N;Q^68
MV*[<W=1)P8Z*'XR'^Y2X:F\OYL/3%(RS!"+[SO!=L'DQ\^+[6NBQ%B6!F.<\
M*S57YK_P*@#&;G(=X[?D*]Z90XH1WJ$;'I"O<B]5N\"TZ/?R[MMP.-9C"M6(
M!UATU4ZB\(!P?G0#'J!:]P*[E WT(.)"CNCS!Q^L@B1/HC4E36;@*.4;Q= -
MZA_8S]HF[=-58@3[Q>0;X/27>3>,=L6LD@\VDX\%<H9G8>UOQ(H^!U^1+J=M
M1V7436]'K=$1[) QL/DN^_FBMNDJ"E7'<I,\P!$/7-E'7^,5??*04XC_<JB$
MQ3EHM.910"Z&OV!9\TC ZA[D<2:=TRZ-@QB]^#S\J8%\JK%-MG:GF?N%V*FG
M0>HX#\2G"0QG F-L]*/A! ZIL\$/B%8JU, 1*>1)_(.2O+/NK'Z2$NF3DXH.
M.Z0_7?BS)-0,I\/4=[KCQFM9K#P"2I-*GS8TJ+_R?<GAM5?'W'&XI55L%! ;
M&Y?CFCU5<I)C>W%]["T>*(E2]HF9ZK6C[*Z.W9/_\8#M@Y-QA.R&#!.\<=)Z
M^OEV25ZE(MRJ6):B$!D!(O-Y:W*0#YT;+K1]9>/DMJ!9OO>P/T!\!& E/IA,
M;H@ES CI\=)$A2'=44:Q<#F.@N\O'&%YY-OA=(7V(KE+!Q.BGQ?-GKLRNCJH
M98$# .>DO]C[L%A.L#@4";'*<)]R'1VPB"^SW6KDHDV5N::R$X0#%Q<<+W+M
MT0YXR>*!*%?1?A;L>6LHO1L7[E+[AAFN[X1_="CNFBIVE!V;&AZ3,<=,?.+9
M6/ 5F]$V6714)6IB!4I7R,@#3+W^8@>=?0:&YM9-'I[' P\*Y+=; O  Z=+[
M:XF'R<6OS.T$S;L6D.EJ>[EAU'73(U.W*H?AQ5Y;DFU>R>RVDQO)->5(ED?
MVEJ;SR4\T-:<!47 <3T\B)R([3@_^"S=H"UAA13[#" 5BBPBB^Q8D1+A'D]
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MXA2G.,4I3G&*4YSB%/^* .-'_P=02P,$%     @ \X-Y6YLON.G1?P  VY<
M  T   !I;6%G95\P,#(N:G!G[+IY/)O;US><CDX'536=TDJK1<VGQAY%.J&H
MIB@Q18Z:I:B:@DA.!U44G4A14A0E(L<0,2:ML:6HN6((4?.4&!.9WO0WW.]S
M#^_G'M[_GN?9R?I\KES7OO9>:Z_IN_:.X+M@ G#4TLS"#+!KUR[ '\(/0#"Y
MB^4;&GK/4$LK,$33W3/HCI>F1U" %L+]GM9YS=^T $8@Q#UW#[A7Z*D[7CY^
M@<;*JW44Y5-^GL;*$#WKWZSO7?7R];L>==_++NKF;8\HN,?OGLH@$]&#1@A#
M1,"] *]0]U.(@+N!(88(8X6_C6XHO/YY6TO!Q.B^I[>A[36S?_00_C)6^ <O
M$1$1FA$ZFD'W?;3.__[[[UJ_:6MI:VL(>VB$1 :&NB,T D/._&. :UXA'O?]
M[H7Z!06>^OG;_4Y06*BQ0EB8GZ>AM[NWWAU/3SV-.^XZGAKGSWNZ:[A[ZIS7
M\-31\330.W]!V_O\'85_3._I\2^SWPN[?_=O<WMZ:'G=]0KP"@P-$:[&^9\\
M>WH8WO?S\0T-^?OLE^^&_O]C_Z[?S_<-[[H'^A@K(#0\O;S=P^Z&"A]J_?WI
M/RZ$\PA7]<"! T9:_PL'6O]F ?YQ1[BFPJM_T<!/=?R+%KT"A:J+$.I(, E0
M,$7X>0, UM8 50  \ M@U\,W@-W"JUV ?S3!". J8,_NW3^_PK97^-WWR[Y]
M>_?N.R@BLO^7PP</'SYT\- AT2/'CHH>$3]RZ-!1Z:/B$I)24E*'Q61^E9;\
M]9BDE.3/07;M$;ZS=]^!??L.2(H>$I7\;S?!1X#X+[O>[;ZW9Y<"8+?XKCWB
MNP3- *"0UWV[_M;^R?*NW4(>]XO\<N#@(6$'XE' [EU[]NS>N^<GU\*G,<+G
M@+WB^XZ=/G]YOX2-NXA"L*3V@Q<YOYRY4O9)RK:'<5;GSOV'!PY*R_QZ7%91
M2?F<BJJNGK[!A=\-KUXS-3._;F%I=]O> >+HY.PA5)6/KY]_2&A8> 0B,NK1
MX]@G<4_C$UZ^>IV:AGF3GI&;]SZ_H/!#47%Y126QBE1=4]O8U-S2VO;Y2WMO
M7__ X-#W8>HD?>K'],SLW/P"<VU]8W-KF\7>^2G7+L">7?]L_Z%<XD*Y=N_=
MNV>OR$^Y=NV.^-E!?.^^T^?W'[ML(^(>+*&@_> 7R2LO<LH^'3BC8\N0NG._
MYZ#T6=U)1>9/T?XFV7]-L(?_(\G^1;#_5RXJX/">74+E[1$'@  \N]R$<X!_
M3U,F9Q$@>^9@G#PF'T&R9;A'/X9G7;V>(%WK:V9U)475L*U.;3U@K 40'@II
M=)YM[CXQ)P!4H%NF^XQ"</Y5M6))ZMR+DP+ \1MW^-_2AE>6<JMA.M[#SBI>
MU8F=(^MW!0#O!DNK%!E^-^PX"CA'RC8<J(^9(,BY=K__M?[:<^,M#.*Y<;-M
MB]%Y)5:6>ZBG%QOE,'8):-WC!IZRT SDFR"-^O;GQ 049"E#*&E=O<N3"73'
M_+^NUP^ -Q-PNA0U),48.4SGV371A@4 >5V0J-LX5(X'L:@VD(@IGK>;)5G,
MUGJ/]E)QR/)B=,>I^;5O(F.JBPHK=M5VN/6,(&#'!.4(\GS/)OC$ E;4Z'0Q
MHK#9XL.BVW%P!16JVNSSH$3:,2N7N.YRIV"(#THG\Z+PZWX^MWA91A:30?*L
ME-;?8(BJ&!4BWMP6PS,<QFM-(PKBI<]A/<N4!GU)R->[MA2E&-@FRE-G6!)*
M&]%MP02WI?PZ9Z)4Q1S,>>_G)M.WHF %(5F$C[144BG\.*AT'*.OQ0!827I:
MOP_4VOVT.V>.?Z*/V.SQP9E-4"?9Y>51AMG658L"0$P#(";5%)G*P%QEQ7+,
M$?+ A$=TRE,CF> 2L''K@YQY_2U"P??ADM+G^&;;YL[0%5P#/Y3#@7A3=X .
M0T?P[_UK(YZ$-4C#I#0JBP(Q8C,M)[@?_.Z8C?UE8J !".N'= $K@(GUE_/G
M*+]2)D',U^-G!(#'D!:20^^B04\;7%*_;-C9<MK&Q''*>JV*AH\4 !J!*6X&
M@R:ZK*EFOFIU]L@G&=1^X3N$RXRO\=/&60^AUB>TOP@ UCX)6K]3:F:*!0!1
M0 S6%&G-T>;^4<6*IXOM71P_QR),G66BXP.H6\ CUOG&*7'*8Q*4[\L9+M#R
M2E6AW(KC?(?5=/@ ^FZW+ QA/AD8&U: R$7_\BF&GJ5L31E<FDE6)I9GSTM'
MK$.=[ Z\JOW3Y'$NQ;C>B5G18@)D76:.(N#T)W@Z[0#+>_%*BCESX\Z!P+SH
MQ&K,+:(3/;&]>NUYT7C1&GL$/DR689F;L\K>+8HC7*9(+2<=+FC^P3$=:(Z'
MJQ^6^GQM_>ZKZ0":P3@G\1+0I@>FR6]VUHHWLF#T764]H(.>CJLS-?CY)Y?K
M,P)Q87N&-3N^W+&0DI;Z@W,'1N<K%2)P6_%QDZ"GY//^%4XL;$M2[F+4D;1:
M]9!+<X1(T5K58:6!NRN8$#7*5]K8.[$/YPAI!,I=,:EY$OE<KS)+F9!R%.'<
MJ1?CWZGGHD1Z=#/4V\(A9L0SM<J*DP]C>PH >F$P<0' 3TT .,AR:VO)!K+0
M,?04D<X\4T(W_N3-P1:3KL]>PY*V56P?<4W>&]@D^\.>\3E"!OD4__N!=VW1
MP9-B>_Q1!N6]]3HBS_2BWZR>JK!2.S 5'L<+ZCQ;\L*2(Y-4M%VQ-JB?PP$K
M/UDQLI_*Y(%@Y^=I8J'=$IV3:-)(PVL5HVTY9)6]   CHB+&*@*I@)W:!/;L
M=1XNH^/6X')]Q 34YR/L#J.E[9D&:BAX7]_H_#>/[M$R@Y5"Z/P;"I733XL5
M "J'XHVBF5?-&8%EC$:AF746SVG0KVN5ZL']!(!O$;F:/\!LOX8>)U <VAFP
MHY# A#T%RA,#9-KZ$%J?W/90A-JX>-)8S_CFKT'ORA^V'C@YJ.CG-9F/:<?X
MBZUX)0QU4Z11VO[">9233$0<63Y-V6?K&)#X@+"+[&5UY*5:O=%MAY8[:>,.
MYA S8LQ21YU'U5C=UBV1L=>0Y_S>;*-^\@DNL-^E:0W(L@QSTM@0%4$YD6EA
MJI\DA&/:H3,WXG&-F[1G;@9]:'<!X&EB&%UEF:_,DEV#'5Z0_0'G#&6K?7BI
M]HZR,3CNF"\ //@F0KT-:7- R]=[%+MPY7N(%V=[Z^&%R$NP XC>WC%[V_DA
M<%VJ*[I/+?9Z(6Q; !@NJH]A3K74!BT;!!5_IQDB%1CC!(\)?-2HDBW4;$<I
M.)C"J5KK*&RF;8[-[5G<49O&*T]5Y3/BFFB5^U*>$:8'P[0 8QTE?OA@?M7Z
MS?K$SK\2>7FSD54TQCZ"(M,@44\ V,/B?.0?9A4Q4UJSCY]G[:;=IM0R-MSN
MDIQQXU9;27QH"45!ZS-%E=?R3HPR1WB.TN Z,,%+GP2 7]H22XBB+G2#ATC3
M]RYS^H/.[S]@K/![O?M6C@_;^4.17[2^K%4-;A%4>02D%K.OB2;*!_JIT3NC
M;]>M*=4.Z"6IWWAN451129!J>YXYN,]A;0*VA0K*] *@XGM@.BSECWQ]YNS'
MU5\H":A3B":A/;ET)+9"'M(<LD<ZT>6'ODR;KV6=/N@J5D^+)#N/\3"H<VYP
M 0# /5^*&&G^S=5MW)A*]:?^F=P.O=EU,=YV</X5*,I16ODBFI(!V*Y5^X&E
M$AI1IQ@%<2&E+#B=E(Q'VM,#'$2!31FB>%[Q=XWECF4P9FFZ_L.KSE0RNDX"
M.? 5-21O6,/2\5%?99):9-')?_3A*9/'&3S\>PNOB! ^+F9*U\7)*U4NQ$I5
M53/\F\A(I?U)?;_\OF6OFC7^MQZ<U;3^]!AI9@3RX3_(VO\S(BCR<NOEF'OH
M,DUR%#'NQ:$E(QV<O\1[ PR)[/]715,D[E#+>ML9+H["NDT>U1^4)YH"D+@2
M5+< <,S(@J._( S7F@H,F2<F'9H9X_)Q34RWF 3)JKJ$R9=HG5EV?4D@>%5_
M8;%>B_&H;5R-]6IR519I/[@AEV[T&T8L=TY>IBI=XTYUZF%PF'J?/AO6[F,/
M+<8UU Z1;2[)7YZ*?E#(_X857=5T?^O<D;>H+]YYLK[<K.*+9O;GY(5JVPX)
MWNJ*7A1/\I9(*DL F$S.HPL SX 'N5"_Z"#1PL>%_5[UI'27SJS  -F]:QQD
M2<@ZY#CG"NRDW93(1_R1KFZ[>G(5TV)@]N5XZR1^>=FA<4LY4ME^#3,;"BT9
M(?OOR"< UE8?4 YMBL5N\2\DWJHG-?#'F=YY]%],NO"<#Z50J,TV^A@],Y^K
M1?Z+EV=DRMRWLHRU[N<:N.=I$#IGSSYW=;7LYHU1*,Z;AN?VS(@=Y$JP6A@I
MUM4,6%.W-,MLZ*-5A%%MP#BQP!5<Y,OH4+O.4% K@1PLZ2S#^LW.C%4U^(,>
MH^09_HN&VP_KE2>S=-H,PBOV#=S,2)NA1[#7+S;7;55F.I6Y)0K54LB8W;K/
M[,J1:2:(<>WDQ0>X,E/+5V)<[*H87!(#FM_4$B3SNG0$'59%XZUB.40/4UX<
MUSB'Z]_ M&[@?Q@_@6T2S<$G#=:A(X)GZ]K+Z]CEY?5N-^H<E$<3:/K4G9<)
M +;=)U@%J%DNAS'4Y&;$E(D+ ^U&7LSRZ3N2Z:/J+XN[&J2!)U!)59]3%5))
MJH'CM+'267K;TG >"_<I0R8.J9SOBY(O(S+-, 0WYY@DV_&%BWX]TV:W85E9
M,D&=;M.F@$BQ91$&:IM>^'',XY.\%.;F-X)B6E>T4G5\6J_^PQ6UI)(7(<3Z
M$B1E')\BS (,(FK@@S#ZMP@A!>AS(R^.+XXF!HZM!ZTC!0"6V-@VP2SW3Z.Z
MK2"6.YKA,S'^:()GNS+.W[X970#/A([;'0C,3PVNP]:=(UQ@SBZUE"(JFK%'
MB8=B7&X^T3J&R&MRWBS_^C+HB<;%I7%_$ ?\0Y^VC9M/.+>G)0S\L#8[9XJ2
MN+.V(!TODF2DXY5#O=;.>9>VM\$A$B0$GI;@.MX@090YM&1.IQSUBQ+]$_M)
M_FRRV.[OK,M"8U4KRYX.C9R([UF]*XZ"]J[ R%*44*P!8VCD]2V1Z=E6V!._
M25KB,3^RY@ ^M+_'2";73S8*;BA?5$1%Q+^+YW[_@W.B+#"QDXH/TMSR9E<-
M?:-2/H)^Y48R@/&;/#,:F.% FL+&&7K_N:/1: FJT%)(BWRC/34-WHBUID2&
M0X8J;XETT(@&C5AQ-S_R:6;KBQ,9[VO134E!37[Y\Y/96W3ZXF=/!-F!0[9"
M$SLCE9=<RQ @>E7F>\2M.;Y!GU8E)-&)N2\MMMC1U==J?W<%-9+TLIWL4D?:
M,;P[4A%.Y:PE !B@$T@55OP[KO- ?32CZ3:CUW5Q!UJ:B9O/5GT8GAB#LPQ8
M44"8!(SXA'D&-<2R<3J3M*6Z&,:Z*^MW8S+Q2%[ Q)S>S("FIL*PWN9@[A>U
MCF.$]L09-D5KVS)Y8"-&<A<=*TO>U<;L:W,[*#2!%^_J&?(/MG"<++FOJ6?K
M*9[B+B8;(X_CG<,YPZ,=;BY3X._)+M"+], 'C(5M:\9L;+U?WG=336Q4WVBD
M<Q9^4)B: P,$@#.?U@PXUU,WER5WK1>VH(>]ZOTXU[@FK,+<A:)\Z[PQ]8SI
M1WEW^P?/Y5N9L]'3)3#?U CL)'H+GDP2 !ZB62[-P%_"<$#I$D-,BVAPD!:A
MWLXOY/Y3/8OI2(?01-18V<5K,M.<,HV82*';?IKJ'H;!6.E3*;$HY4'N9:^3
MK9GN</A4M)4G6@W*T2V#NA2GK"CV7D32&C>_(:U8[DP34(HXTI05%C-IU#%)
M_*9Y%WF#!&L*76<7_4 W5#7PA8XZU$RK0.4SFUJDMRDR!;UAUL>ZF[H+77P-
M+[Q:8M)&"SHZOJUQ1U)WGX6-CG9N+_:A#K/0+:ACK*#<N6R=00WN98)?#R]U
MT]?F]5AS2I6*YY@ H.'\6R:%.@85KLH$B&C>2'D*D]F($;G,2,Y_1V7Y=$<*
MZX)%L^G]>-G7:_CA"7;:GG5V(A>FP!L;^.:+/C#%I,4N::#.(W0^&O)QA?4O
MADW="V)RVP=I/ZAE&NW2MN%)GU"P%_"A#^_$E ;)1\=8CZ;:'G-=HD.$>?D7
MTN,-W-/*) 5)K[!^'UY?%ZV)&-#?BMT<6$QC34X GZ'%%9@^CS>28!\7)V#B
MSL8I63B_;:T/?HP.L53] <A:X=TTK[&*5;3T..IA[I^_&<E,(HQD)GAB38-]
M%L$![QT_N4M65,V&)>B9^@@ \&DIBJDDP.:_3[M8+Z:Z6:JS;10QUF*SLU<6
M/_9D5EI>2-!N <!+3>I::FJDQK(CC+$-ILKQ'V:(\ _T<>'3L 3:VFTC#P'
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MV4M2X[T[3-9=R=]QG=?6.,;Z5G'4!&M?-X3W0B_H?*Z7\\Y((Z4"7^Y4N"(
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M+P"(WF:,&CQO%P#\'+[W"\L@/P/GP R'U=EJOC*^]8E#G&],04-\C(O:1P$
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MTZB^3)M8]1MY-_CQ35UV^<<_>Z&O8ADW!0"V]FHL;.LPFB>,B]F&_#C01)8
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M[68(>7TK#9&8Y=TO!8#&N@;?*EXKH0]QL^'W6?$BJ[&DZUE&H*=%CSM]+P@
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M5KV5FZ% /Z1#.)4+UB\\=^<]&MK+.MK^'P 8M%$8[PCZTT4!X$<'60K]_;P
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MNJOD7Z^+++59-^U::=[@@^,KF!]K9%@V1<5$S? +O8.'C?A*Z!4 J'+-@]E
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MMZ.VO>$^P<8-3$,RW^R0Z'%MUOJM@RZ>61': D 4^32S[2F%M!E9 *[M7!N
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M/XWLVH 5!D^1,HSUR;:D[+5!SA7FZ^O'7-"4PJZN$84L-/6:MQE?(X5'_<Y
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M)I*G;,G/30/QJM=J! "_L51[--5_CFR U*AE:3!EMQLA&?@T4HA7$/PBS8]
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MZ_+PE%WYSUKJ(N8(-E$NM?>VY8&Y-QXT:A#LS7WM>['8ZVW[Q6O+=-/N36Q
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MGZZ\R.)$@7L'K7Q7=LBV/KC=1.]^=7X1(5]A<]\!(?6](A\T>H=YRC2KHVJ
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M=ED<HH$GV23-C3/44"ID0>R":R745 V$VG3P7N[VE8'N>:5,@5LUC(-:TG9
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MM(X/U<XAXC(-W6GN>D,5I.:B"PEX9-0"0UXG\)6UG%KG<L82_ 84H@:")M7
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M<"2L1)F<Q&_T:PAZ?JO;):V+>>YFF0ML6256+3GS7EJ 9T/E- 6,[WMUQH=
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M4]O:UM[1V=7=\VUX9'1L'#7Q8W(!O;BT_'-E=6T=L[NW?W!XA#W&_?8+!%"
M_N/ZIWXQD?TZ14E)00G^[1?HU//? Y@HJ<Y?I3ZK9@!^X,;,+QE"PW(]*;NT
MA59 RG"']:'[T&DV0>F%"YC?KOWQ[/^>8R_^7WGVGX[]EU^3 #T%B!P\"B8
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M-"HFVT?G]HATM:'SQ/PITT=@.WNA8$7$R(;%'OXFQO9[TXEI^I Q1S,T?!+
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MHI,VB7=NXI!XG(H>$K.M>LDCNL?0WX9R5</^K/F$34!WIL /ZT)7S\="OKL
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MXXB#>01.\M;A.@8:"]^5-8.C7L!7>X0I(H?+Z][;WXW0*S-RCHJBX?PB1WF
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M@_LFB3ZVZ+'!NGA4.QU/8@W=83[*6:@.U *]'22ST1P.O*!1>B$,<OCL]ZG
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MWK%L[3RQJ_.JHO1JZ7'%>S)A!\%I/BN=S_F$1C.%[3R'%YZHL^MBB=>.E!O
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M4RVBG /%\B1.O;G*U7\^[J(C[>,SQ[ZPS>2FX4979'80%[Q'99@$;"&)<7Y
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MP[ZI<3M.%EG1E<1($PS'=V]2;E 6"KWJ GWQ>.$\1 (6/*=_[S)*X&E@>%W
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M%H9L(@?--%*&2LWM&12LA: ]\9/@0,,$JW!G]FB/%_L&'[1DP?#.C!=X4CF
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M>1H_ P# 1)1>\EXG3+)Z(X^SL:"B6KU._(:-1*3=N"+7^<: I##^AJ,M%K?
MMNT>QR"RWDCE=.9T"CH#B1R/S9:D]K&JT<Q(/(!?S\-,V8ZD@N<TG/NNJ-MS
M:ZIE6.VV 3XX8 _<J@N;X4T5B[WM_M3JE;*F^!.T"KKT ?K*O%0)@X.C,UT
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M3N]%K#--XP!?MR+^?_S$Q*1;? XXUM>>JA<^'4=$<#K.Z@-%%';5KPVN_OP
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M?)I0_L'@MB1NY)3/:^@L"3S%<RL5\B9JNG<#/KGRJ2O]5[%/#0T.4)L4Z=Y
MB['YPN>;].)=!OA\'KQ/2$"#4!PU#'E6XKT&E3M2VW&:4.,R,DNRRZ\'P_9
MI8VO>;MCV;L/--0W-]U9G7CN2CEQUMK$ZQ44\1=@9K/$EU/U,[=#TA=/2OHX
MEA4]?LE>&T__IGYZ4XJ-9>AUQV3KO9W]JZ"S-0]TQ+VRL)XGB9_%WY)CN2<6
MO%+H5[_X*'^P&2B-:'"_!5G$]\.]+\^DIXQL)%8I6>D'KM==@I2YMTA\U]J>
M&A-U?V @PQA1KJHI.]B%12V47YDH3PX@-@ZLN[5=_Z0F)[@0\O^P]YY1;2U=
MVJ P&+ -B&@RL@&# 9--#K+!)&,,F)Q--CGG(#"89$ FVX 1&)-SSCGGG+-$
MSAD!0@SWO3WO=/>LF?6M7MW?_;K7_?$<27N52E5UCFH_M?>N76&<^R)/P]N&
M5A(A+S^-O O[E*EP)%O8F.NDF&]CG/'R[/7=,HCKUY^AIW_C;_R/1SXMI.-*
M,5B%7,4N.?(I-!Z\HJU=UT,'=3]Z3/SBA6J1DL-L/:_\H4&(J"0WK-M91LCJ
M:[2TS^7J,'9ET9&*>KVK/.[H(!UL$5+HI<'B5F0YM5>[CH:K; ]:C94/!=9Z
MBQ@HUT6OU/V&L*)]K#(K#F6"V;%)Y/UO 3NY!VAGC).#G_R[EU"87A>?YYC!
MQ"Z!C<NC$.@UA]4F$"E]RE4'*=GEWCIWN04\S'%9+B)8*)P:+1A;9)R&O 6<
M*###4TI,U#C3(X^?;KLV;>A#5VX!U!9T3^X)FAW;.O3S+).<GN6SRZR(QX#Y
M!4BTOPE^< NX/-$5+SN\UAMYD"*('GMXLCX7_19-"V$%7(2Q@5I+%3F#7E[4
M6% 9X\Z;#.Y>KU?^KX_DCI*"J9VX=W=LS!+-^*D2]IM%4&4,$[\)^-VD\R)=
MS>OO,Z#3PCNU#V<JK@D0-WECW*#!*J.L=Z.>I%B>['WX5#SUXS .T%^NLC:G
M7LQZ@[N,N4I["-8V)?L@_'=*\S*Z(CQ[+'YSD2*L9.9[D@(W0H/"&<N32".C
MI";PVV%UUQ\18K^*W:7J]2+C(FRT'=X-^? ,OB]^?J'/FI^(7P:,6@#FK%=R
MB83QA[L(%1CKT,HL9Z-O 2="VX:._3)'+)RU2V$E0STK&P]%<R:2Q"@^JBJL
M[*Q<>&>)?2ZY&_ZMP&<A#U^#XUBJ8D'5BKY"A=D;W[<A5(H3D*B-\17OPLKR
M.6CZ#66/>&AV*G6!KEDN!=/[DNJKL#W_*&H&>X;13/(Q_XK?'(V1CF#MW:QV
MZ-[8->PRQ47_$115FW=1="SX+%IS4.V'[*E@7O'.;$9UN\98T<B *Q-\U/!K
M!/^HHLIJ-OA[]FQ?V]@)1^)1LC&W./C=E(G3[C/%2';O&-'+PTQ#>6T5Q9%R
MPQ:$GN5CG+U[[_ ,I_A\02&)89#"JB#%3/4"T*--<IHN#[&F5-.!-^A[D4J=
M8ZK^375-T,'*2+87>7/[0FO^@X<W.I=+)QR21W3\.(-CO2ESC$.G9.E :+D'
M%X6NM-?^:^CP%+N GXM[RW$_SRV@^@;"Q28,>6CE>@OP;>D>Q/@ /.:#J#6K
M(DWO=.\/V-2))YB&^@QZ29< #"O7*OFZ^L&+B[ZH+5MKWKRW)O1H"H^M(V/,
M+LV(L?R'[$XL'X8640T>[N_CQ ](YDN>]':U%=1;JR.9>ASUZWS@\.A44$?V
MXARBMS9%U'GN*9DOD,R*Z_XC'S8;].4":N>!R1EY&Z.+9"@+.!+?I_]<F*W/
M\.B\./@BB 6G%@.5)P$*.0X(S5<*=Y%>KUF+@S_N ?^8P[N^SSZGGWW*RA81
M .=(V<::K,)=.,0 #98;'A4&<R[6?KH%+$8TI19:?#PB6L3;#3(/2)D@7[+K
MW_R4CW09X'!M=QLF"3^>1KLX<#R)V5>@AM0V3XD$IM>*,*B3($U@ \3*4F1,
M_O\[;)BZ61'B3S;16)$S9Y_V%VP?/#AW;W,^ZR$+/8)T>%Y\.15A$17#R]R7
M#Z__BI.8ZT?SF<LS6>,S\@1NNA3IK$/-+J\HRVF]_L)4PGZY4 @G;0#@8YJ^
M73F['F65,VMW+=9KIX# ASIHY*UUHU\B0U]2LY.T";M]8_^EV=\*YIN;"B=D
MFZTX(+.T1SU'+Y:65>N]MS+E;G_Z+&K(L7H 8(?,:C^G(QQAG*@@_5F0_C'_
MR:N!H1+Z7X?0KZ=#5%LX*J.3+GY"X:'#;"9>]ZS6]R#P\XHB=XF3ML4G8\/S
M;TDSN@W8_?& ;&.I+X<>H+3&ZUE6L(;+%83TCW[^+*2Q;6$.Y_05^X2Y(]Q]
M)!"R6\^2-I"W_8!71S*BE0QO_IJ8S7\$90.GA@8() YT9/1,/2%^4U/U].=5
MWF[7>QG%M\<^Y@B"FGSWM[> MD7ZL8GUGUP)&**5ZE@NNA@[KT!22'"GIT'$
M:0\?/HOM8XJE/D/A^]9HK"DI T:D"+PR;07XD)9<>BQ>?L;$G+=I(/RT]0)E
MM2A.B<S3F!)]P)%6J*-X?JWQ37SSG9F2N&&%P^8KQ*B?B%=?]JYU9FTL=R0I
M1XOT>YP,QQ1\9%(J<OT8/B4GWQZ](- T2_\0=U"PC>HH!"V S'J?N#]F,.8[
M8L%M\HB1B5Q*/!D/S=>-$D=^8?:;4TZ<4]2IJ\M0A7H1YO(.O6_(QMSU9.L5
M!R(1[;YLM1/T4WMK%/<^,5Z#X_T];7!HKJ;RAO]JD_O?^)\%S&>FLC^G3=7D
M&&:KHX[D)4EPO7,ZJ>T6EET+!P_0HEFW@$(;5-ZZVRW@6^C=^Z9)/_'DB/:H
M_*\7FM@@22TG=]B;RI\K2:H5<H1[IA: )Q/78.11U5U)>53>!HP,TCV1 YEJ
M@P@#KE@ITZN_,'V9E)W'UE#Y]GJ?#:<CA17:6CEY(F\]%II<2%82_K!D!7Q)
MZ@R[.OM';JUN[X]W/ZN>= O02[I\"%@\S(I(/5(8:.>>E</X(FGZG68#O**G
MY@%L!5X^M 2?W>F&(OU4  #[GUND_@/  (031:EEC.TQ";F3B*=#U]0_I>)9
MU(M@ A=D>WTNR6 "P?OI0_%JS:=\XR.O:%Y6NCV^HX;T+A=SRJ'/WOGUU^P,
MN'V1Q",$3N;)9VD/1!\6*CIT !RM/#?N2<F ]IZ@?2Q?/PO,NO@FZ@$Z'H""
M?EHKK$R#OF<XWP*\L+,55JZSCY7R_+>46>WC-T?YS&E_ $J*OT-93YD4%V*-
MSS)\'FY@M7Y0$DG'5#,MK[X;9RUJYG&B=W(9(6LT1:,E[MK6BX*]>04=\:W;
MH"8L/\\]/@(3%=2KL-%@G?J0C[75IPZ)U;4#^=/D_"&*V?FF 6AU9QD0:H0;
M,<X!OXZI/A_0#VX7B+HYUP(O&AQV&!!M5DD"+O5J$9>CX. GL;:?5Y=/NW$N
M5;VH#I$&<(-)KA-DPC(/F#@/3]$6M^OP%G"VK=8T8NN>.$NH> ''.>M02FA+
M^/1 HE"L=D+(N:[;41L'X#9KD8L,\[H%&-AG!+6J[=UX)N%('BYLA^LT.PSU
MKBEN6I8OWAM9 S'_!%T7P38T;P'"*8ZX9SD,]=5?]]^V;5KE4E:XGT$@E\E\
MCC3LBJ6-!\>,22OM]YL<O)Y0H+F X"_F?8?;-SC[^X8Q)V0E= W>P3\P(?6\
M&D9'O.$>Q2RW &=X7<Y&G/KQ]<BZVHJWR"S(R9P$_-FE6K5J)L#_I@OG=,!<
M,76[<H/8XH*6-XJ2X81LN\3]\P :O;JQH\$P;KV&:=/N?<YT5TFTUPP:)T'C
M2TY!<L+\$+&[>2!<=E42/1HEH:M(?E5CHGBA&7;!0$H,>.=0+)Z+KYHD,;HO
MX%')5;FO2(%6FZ&!<\+]-^2#-F@MQE%4*"A#L-[$$ZQG**3H\27:)0,84=%=
M4KLIBV,6 4DMW(;<WXPQ?[P'NHZ$%)@K'AZ\]_8@%W@P)!)BMZ5VMDNF& GV
MAYVKF\LCG:Y_WP)4Z( A"9NOXF=Q: =QP8/E3Y!0;##$Z'+H4  Y88&F[N<Q
M'"<*_CB".!LP[UO&-^0M;GM"!PV0X=!3*;T>=MI0=5.XZ=_^>'0.91)M>V&@
MRGRI'DC'.F(^5XGFKLN\!22<#+T]T:IG*9# X">NA%37H-4D;,3/EVYLRG/.
M/CQ'#[8.+</@WR$VQEN0Q[#ED3UN2WX5X][ZJACPPC>J8ER&)ZL: 4%10#R9
MX?'#;8%O-!U.K,G&0?EK,;> %[< 3'<'SI,_*'?Z?'8137"'Y_Q#,KOD[$T*
M3&W".YZJ^37H\3'P_-LM0%+WN->J(-'<Y$\+3.\M(&?;60-V1X=?+345JU.@
MR;M.^=*![6)"MX#)N0'0<%"AA2GR^TU,*>7@0XCM8I6,H933,'+J3:SYWHMD
M!$%U 47% *O=F>>7.M K>,W:O]A@#+^VC2/-8 -4I"K$FJMZW=MMXU0^1L[,
M]G<K*0KE?[MY]C\"#!G-1@5>F;J&Z <<Q+A?OZ=+[")W 3L&+%NS_'E'P5WD
M)S)XZ@[YMAM](?3M@*>DRXYRS<Q%VE>;X>%4&<;I6[,F4SS3,VUVS_H.OG=6
M+RYF^HG;W1$=MJ%'[B,H-DBFQR^+?I.":IX69H693M?3H8]"15D4>Q\\ELW#
M,@B@63K;*MM*,Q()97[/DCG[IR_RQC&.8>$'!XU,WN^")4O&OOQ6[C>4XL+Z
M!O U=PH_I6S)?EDU[DN(4O!ZE$?:Z)\LK=I,,T $9F.F7#@]Z/!Y5RN>G%AF
MF6>*V_0)529H\+W0*1Q-&K-YY3*9@9TN%LNC_RK#Z$?""[\KI?O9STATI%CS
MGCCCD07A=@_B[AFPHUY/<#;2>TL'M\VZ)K)'LX1SY[TBEA:Z_#G(@RU"=?4K
M!V*\M33;IG9-"K;#-2:G]K7)RAY:>05BF^O*\:9#)IQK[3$T^G]_CH]K)\XD
M2MJ]4NM\UR@#"^'YF1;ASJ/\DKQ E]E>W$'<7<N&06B6_O;CBPM^I0$7:]P@
M#=W8(5VU;<#E$F(J;+UZ@OZP(B6I2M""V0N2\L$3B]&<#EX= 6D5GFH=D)&<
M6&"([:/J.^FD)7[G/5+,0+NS0[T >C]>R)Y57QKD49 L]ZAV-9T _C/'0MBW
MY-[K[%DI)V+!*'6I;CQA*L#@H6MU"L-A05!VO*(),Y0)1R%)4=)_:].'S35*
M35DB]XL2%X#B7OQ?'G7U-_YGX6G=+0!ZIP9WDB"LES]O :OTD)VBLZ),CEL
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M$P\%%UI5R,%C]M]&G'ZT?+L7!":LA&U[5/ DTU1E)BQ"^9)6)G\U;=O:+-W
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MI8Q[_%:I=&GG2'5O<4N&NCJE.LZFA95"_SGO+:#$&K(!W=%Z8&R[^(1_';R
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MB\"ER'#$(Z]/%&Z?JL%1A6%]G51\FYA[XBJW %<EF9W1^NUJUM,+Z$+.GM(
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MGL6P%5:E&]SV4W&OD?IQ87//IXY[5\Q*$-&)(A"M'9IP9^(0Y22>NLR**VV
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M<-ZOQFT[<5'!7 *-RJO#:\>86"^?C*R;DF*^Z+WSN4ORMC2-^)Q:ULZS#P2
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MT;VNL_O]GQY:WEM;DY#Q(F&0L3X##6&1J1IQ !5AK"C<2DNIY\_+27#/S+G
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M9O5!7 &Y7L]Q&IJ9M=5?R(_.$P)FNHU1RPJ5Z:&[WI08B)B'#]32O0=R:.6
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M-P%J[\3LN\]6U<OF*-TWG)%!CU1XSYLH+HVJU"21,I"I,/-VSK)%I$WI21"
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M\T2TQ<G>?&.H<'7\1Z##^.>2TUY!H..1:=LWFX'$XGH5'.C$[0?FU!M>V*L
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MWX,\HC3M1L^K%1>A?6-::FR633@_"5<>?ES8ALL/L@P1(>\K#E]H'W2\L!^
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MF/8[3FU;IKQ0I"XF$_&Y2';9=>6[9SVF4 $=\6$"%&RWP0&H7G7]B)$F $&
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M5EDW0SFN?S(H]K;*O0P1^D/00+-DWJB22O5Y@.2#LXNI#)W/'F8*E.AM640
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M?;\NJ84J!&3WFX9"XZ##MXI]=I%-[WR29SYP UU?FRV!+NRU+E^5RT=0! X
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M:07QD)8$V'1*/>\>.V)XS)E8O;G" [;>OC[1H41I*-[W9U%> F3=/R$\B1Z
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M&QY0(O.*+=P3S-TB39YS)5KLJFIA4B),N++ ]6Y?F]%R$8+8]I-M$3NV^S]
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MS_XP^&,#T56J+W<[JB5IF[)3$CVVUMDF6B>WDOQPR>SSP3,UUMHD)E"<]@/
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M&<V+8E1 N2>>L+CZV%#4&BE1-AHPY /G: XANM*$/ZAO<3Q\KN'S5@C3MBG
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M>+VA8C_X\U?I#!FD=(>=(,CW4![WD2'\04=L0N%RI. ;S**AY*S$E7K+1LJ
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MHQNJ?#YK\E]V5/$_.'?3SPDKXA3][HSS*_YI,%[)\XYHD$OY<7'T//Q\$6.
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MP([HI!4:$(DY2-MQ1 ,'/\"""\@JU ZU%AIP]!**K)A& X.&R/5SG2;DL<)
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M.TK'3HV@N$A2H1+=,H_%),YIL>KQE&JY(+H'3\,NUE [SH6!"]T55O<J0TY
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M(@+1/!3JOCX>>[R-<>>^-HV-KA!L\]V(NX-HTOV6F&_>P4?:T(MX+Q'E=LW
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M?_M:S-*$+O_R3K/-[Z%P,5D=5V5W6V][E#0>&F T?$(R"0*NE%X]$;ASDQ@
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M#8BJ:T%FGL'I"-& GM=@A-2=O4@'W='%_0A&575(7'SQU;X?BXQWGOQGC6B
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MF6X67X@,N"23H@+@-VY-&6O%;@<KWRA?='(/J/7I1*0ZY+L W2N,^SF79*
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MD^NRCZP\&T(!X\<-!YTH@ :Z( E#_WN A'8-QP'Y%S!+%"#8L+> Y 9-)U!
M+P?"!04$:Z9XL?[Q&O+[[6IFR;BSOU]*'7L4(O910%LH?#B.Z5+%[Y?]O]?-
M8Q+PLZF?3?ULZF=3/YOZUVK*6#?+9VTAE"65'#C'G<D3$D="TQ#0L.1K0E"D
MH"$"C,WET99' :'D* "R;-$-D"A*_(6B4X<"WO/@)5I8W6H:>36E,^EE?<]:
MXYT!8S+_(BP3_ATS*^6S0\WL]?2S\0TMCVQUI0[G%YN&6" >JYUP69W(91+%
M_UA(X_/E<[4GFB>$$OB48U4$OIV+9=H/N:M%_;_:U=#C'-KF!G'U];3*QX?%
M4@T?R=ZG0'")W"I5$_9.DTF?W(E1&>+0,U)" 1;Q+FK;ZB$"A\>D9($\@74W
MI+3C2;RW:5SF%/GI)1>"$JZ;83H%+&]!YWC.=: O4<!;<'.R+7[Q=/+X9#*)
MZZ@@P@N7-;'_:",WE,C"C2&=ZL'49#A]S6,<XD8W&IE%6UAA&7MTG6,VO/KD
M66G(C4R-9,WEV]'F\KO9/?PK@C1^7@*43"E>N+^4/)#(Q0=".);6C3>E(W<[
M8&8&6L>:Y./%RU2@O#7#ZRT\RAN3+H=S*SB-BS^!4*Z-1?Z@((7QP$"&E]-:
M85+G>="Q\"%P]EMUR8?)EP*6$)C.]JYSH]'K\YJ+YRJY]>ILKP@Q&:H# *:\
M+7O-\C[N;)Y;:5%S03E1[RY-)1"DN0WG9B:^-(D8X(GX+OE4>@4CGNJ29RF&
M$*G\D^@S*\ZK/(]<MG8H[-D4RY>483I),T=V_]8<2]W)I' +QS$8?ES74'TN
M^;H6!92%V!X6W$,!.GL%L%SS,X?L9.[1I6@&T0>*I4;;*T+GF"+42Z0QJ:"-
M5?RY_3G?0QKUL8KS%2<4T)1NH8 A81)L,5[[>.*VC.= .0HPY_ NL=XT?-@#
MX@Z@!6.-&2S8UI]G*+$X(2ZK=2KB?*SS0<DV EM4A%J"1)TP8\/S_HCOXMEK
M+7(?O-C;>/<_/)SP>$_S 6,*/3O(]_ L1RKNS@]-S&@]?5[I[_2=W TBOYL_
M\:=*&?%Z")SU7>J7( $4_X&B1O,)O8 &/"'M:DL&ZY"]"\8YA"]@OH8"]A8@
M"XANS9P)$.'2!D<!7&IF0$H TW^Y%##.]=WB68F$F LD)-D45JQKU5@L<;SF
MR=:TC-R@H:JM\+%,\,@869,)4+[8#!$]4\"6=82.YZW ;M5FC>]M>,?-O7XX
M%\A!:K:WX78:=[R_6<+,Q9G'0NY%PDR^IDL R[0<G,YOK<K2=K4(2NEI(9<<
M)^_DLG/II2F+,4YV@37UUX7X>V1T9Y*Q$\^R[KR]D7"M%J)G=BDC4*BE/'&^
M#M?RO;7A8/A;XF]VDQ2W<.7+H5K9J7#A3I5=;K+109U>U^,7(_L4FA+U&!-$
MHJW\%.T/EZNM'C419JY6)W X'B?**JJ;;^M8X2]>YZ<F,44<YFKQ1@HGSLEZ
ML)@&9X9,-6M>98U,6C2E0LO%F.)B1W@#+LDNKUU34UOK$M_A]+$PO.*V%? ]
MB5.FQYSF;$$!SDK?,A1,UTJ</K885OS=Z(3_4G4#@=D))=37ZK#&_WUF,+6L
MI(Q.A/PK0O#)"@\US8(H7,(Q8UI0GOM!8C<1_3/C7@K@Y# 9>\J%Y=M.4Z8B
M&IW'J)_S)53D<S%+XE4"R5MXD^1K,VF!RI^':C'2I^$^9R[A[01WG=0J#:(F
MQ/;'-[S7GLK=:JD0(-$RTBI[/[CLK3(E<\LC72%$/?3#7JL+XT2I(Q2GQ.Q,
MKCY20,(VK;U8.W;4[B&UL^'00;@(58XP+ T>\]B#\,EP:1%/NX^M_:TT>]KG
MALN,C'66\-!GR&'X^TQ-GJ[/XO2!IS.*30)7Z K<,5L]<KIGO.=UM14'=GAN
MU?'<_+9F?"Y4Z9$NI5SE)^O4=JFL@%L[]K6Y:5YN,_M<F8NFS*-.8GE,\K8%
M$7*:>P-L#O+X&A/FNQ^?(P=]&\E,OC(FR3#DPR<&YMWS>37SMG=*S3HOBB>&
M0^:E3S6\1)^S*K=HL?=496IK3PI*[^E*<5'(8%I$)GD=*%L4;:  ,QD']T!,
MFNG"R_/W*7IG\&M7RA^$,&%>&57L+RW$L1A%4B;.\(=]]IY^Y[T76CU5*+CP
MJ8V4)O:['(=RO]5.&6-5U=#V)TVMW2G>11.*TU>VWDF<U\S,ZV^$1VK$:\91
M6#L:7Q68R-;H%_DRF22S\I!':U1J+SK6J%HW*3.]+L&RF#4V%10B*P=.GSTR
M\7KP+-71?;=0RV_?),F2.6ZHJXV^L?@[K!?BJSGT&F*21!2I[AY?Y?@NW[.O
M(L,)/^W>*X ?;PS?5IL++MZQ*]3SQI"S]""X5W Q>%N#N(VB[<E(W:!)U6[I
MQ ON%\ZE]Z_0;4U74*PE>)( *(!PNA.<FQ;8MH\UJ9"R7W\2%->]UYKMF 9_
M89X'ZZR,&B")/(\/9=SO-E]UXER+(PT.Z@IFK\6[14*7?=LP:-#QXB;A=;/!
MM<&:N^T8ZGHY7Q8A/5X/:PK]JU4$GI8TL0^LOZ<(T[_XA&C\;LJ8X'B<)^?0
M-$_HZW2VM'GG""=,LH18% 5HD(92V8>.5&,/O#:W?^%0=:3[P$KS=7E-"!\?
M?J( )(9.M<ZT<0;TT6XZTPP1R@F\];2-ZOX+&6#?=6O&B_M0Z)9\?]YC-X_B
M+Q%S4U<8V4-JXP*;JVDWSI3&VYR/U34C5&,Z9WTRA3A9U>B8<>^TJHKPYU V
M"]2&H7WV<"E7JG'$,F?'[38Q*=K1 &#YR$JJV9,XY-;YEMBDRF!7+M7"YLS3
M\#?33A&$"RA@E/KS0R#$K_*T%EJX<:!=^*Z0C?C;U<<9$U_U;Q -VGJ*')..
M*6"3+L!-!I4&6VX^4MO^6BZ\'7IK[\V&#ZBLRM&,O ZW-BH/;RB]-ZYEZ;L4
M%$%50OB*GW0 7B%5.5K+YYBI52O#G>Y4FN8[Y[T"),U$W<O]))$'=RR-CYZ@
MY%'8Z!DA_PIYETPH7%,\.#\X8<4JNO=8:P#HG^6IK1F'+U6U$CR<K_:PMKJW
M(3V@W>RW*<\M@@),172X!T@I+M^(?'.(R?/BE@UE"^5$?#=%JF*I+K<=A?01
M<^,VPE9^Y)#ZR8+RH*,'[_KDN5@W):_V!V&=3_Z,2TOR>DFE&-UF]MKFR$?%
M90,.%[)R)34^HCQE\YRLG#[B3"_ WI&\[I26 H3T\%;!\@?-_%H.-J(B13YR
MC'<KF _;!DJ_]_&L(50S-[32IP/Q',(I\5Y]N4V+:4[+'N'*2#.<:IHR-0EO
M4AJ>GN<]N2]%R<3HPCI*2WYAAJG4V#K[M"C@6S^N=C-O2C2[=U*LX"C]_/U;
M\WR^S6/[(A\*W&S:( 436[EDS4G4@<V\MHQ)QZ-J^U>MMJ\;M2Y,5B9?RUFT
M 1>SUV#'A)$H0(S[J&2O=N\B>D%YX'G@+;DAHD=//8X3F!@/,S>$J8;HZ@?+
MY&B.>8;84O;E)SD[. WA[U:$/*N2<7AF3YEFR%" W0H*$,E;XW8Y*GQ/65?6
M=<#^L=PWW8>1B6$!>$#UW2C!0XA5$D)@&4/#,'"4_PPYHEY^@!4FEI=-6?P=
MJYT^1)XN?*(T[U ['B2WT*JIE9Q9QEF0P-JY[+9H",D'[*(]J4,X*/5<G&YU
M5CK(E^0/:J9U^S$&UU1[=_00"JKYO3&&^"-OZYF-7+MK/J 1&([Y\'EH)0=%
M?J6#]D>$E6T^6>#F@&8>ANBCDRL]MD&&>VFZ-Y=>VYV-N]1WC4!-KD8V."%6
MR%NAE$#OKC/"#Z&, @PP$=GUMU! ^$9+P\XD"EB]DLC@7;@6MW2T_<;9X-C]
MF%B.=+UJ?[9*MPZD+)EK()@U.ZO/=W5UBS$Y_V;#1?[B&\%FP?TK\L"-+\GX
M.U@?_;UW!,_]ROU[*F<%ZIO(>]D(7PA9QH_<: I?NS%K5FU2=IRFSTFM2FR5
M[@UYX"3$?UC0\'0WH=]%X$2\+NG^"0?SP9W.RU-VA+=-::*>+#0AV6MW#\PB
M9M8>:+,)*W40"Y\"Y KCY JO.$6X,>3;U,K/8IK.=5\L7Q_M)*$WZKCE'#7=
M]LQ>]\:J@(G_7+>">7F@-4.9/0-YXIAX2-I9' _'M?K,[Q_Z9HQ#C'VXB?&C
M9CXB;,/E2TM&M[EE)^5>Z/)WTS$PR14@[-*, ]T7DI,)]"ROWO.\L183C= U
M;Z^PA9Q<93SL0+"*-T\$P/W%^TLW>)LL[>X\)V2]?IJ ).UW 64C97>GD^(=
M#)T#.-B/B56.UL)8,1O1/J7?,?M>H75*TL0T#2N6DDPP12#5(H'KD9 <8 (/
M6&=&:-+XVYMGZYCS1@>T#LI+&M)283288YN1(\S/ $L.,FVIE#7*ENA(0>M[
M*37>(]ROKJHI-7\_+GBCV<>1-O)IE%O[X^TA8EJ\],8;)!T)7F.+ST]HABWE
M0INMG.B&,P>5+F/AO.SO,%S7K#8<4[C2;5O/^&/0&\&C 9L++'5C#<H>?_LL
ME\C'0R]<U&Y="4]7IWLP!=QR:;->5+@BF8_G$M/&*%8=IS*P9?5X_^NMJ(.Q
M\":BGH<YHQ,Z-'A[!('"08/BYNYV[-;L^'GMD]5\7?*TT)6$+4L]FOH8[4#=
M_GOS%4-*'/0+E4HO8KD2J.R@A!8!DTUG]:EY6NMZM-6E8%'$R''YD\;[*&"6
MOHIQ$A&&S[!;'FB[QSO_39O4TNGSN:Q4W6<C#I]I\&RX9MY%$'JYS#<IZX2!
M5)GJYLV>4Y@7P%);_J"-?V4F,<],JPU!5V19374LMK") DRB6;^<XZX\O.S:
M"U?:H"3(M<\RCVOQ[4X>VEQX4/TL>+&=W#[([M'"A@C5LC]/.6RAAE6747ZH
M=/)1)=T-;3W:NR5,=)Q^C(@+2WM9%!"16 ".ID$'WG%?<P-)S<]&LIU?-$[3
M2?I,W<?!^3(AW6F4)--69C:^6L&+O#]4YNP27-=%U!IP=0;WJ+T5J@5,%][?
M1=2S^,N-T/7-#QI[VV0^8IA=N=G>,R-VYE@HG\>!9U8A0)^^J<YQH_0DXED&
MIS3NV)>'F$E,F$G]'.R'#?[5(36&CZ9FNNM=%Z/$8/Q[/G4 U@ID02/ZN%IW
M)BR&3(#C_;:C^0O"B^3/TMJN%)>E7SXW#1%0-S"8TV2W/IK4U&/L/^(TTGA#
MO5=#&!]D" DU4-182^(88*<=S.?@#HR75J%3UDD+O*W8=[V6BD"@#_OAO*6F
M(Z&?6G52B?E=B]W+H0Z?HKYP6G50.9(+AAR-UK_),/.D&KX2;U8^;ZG.:?!^
M^BW_NGQV-D_^E06=W;0XU>[YLL&<2/Y0BQALVJ5>S""5.-V,$MY$6\MY["+;
MNZZRQT*(;"SBEAJ8@0CI:UH4</<*# 7H99Z-LEJB +H'*& *O*"R-)7?W0EX
MR086&0Z_5)?5R=%A>VDM=J,/<S\D,\E6J67NT2J2JL'_]218%O4<8O]R66[:
M-BEI",.RJ9ZLN$165TL];D7%1=0]F\Y:G&-Z,C&9P,NPS%Z/<#<]I"Y%EC?G
M8*JY@CB-%VEY5^+ [@LSQ0MYY2V]]Z9XVF-?,<.T^*.N4G->865L=&/O\4WE
M21QLWJ=8C'Q +$F^Z'C)BPN!R=-V[)1J(-C+.:8O8W.C?=SJ#3G6J+:&'F6_
MM8/SL%Q3\ZQEO?L[1/$STB(O.VR>FK_=2OC/RF\1FO7O<9O"E:3?-\[S,U%
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M=M?.5.N<.U' 6W7I<]ZIBY3>S7/HC![,#\0%UO_-*5;9!@=DCMH;GE&:K*&
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MEC14;Q2Z^E[<2JKQESQ# <&F&ANC;CKSG>I27[X_<;T-;C;-Y*M%,79J6Z.
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ML"8*F,_FC:BY1*VO$OJDA+.<4FV>^P@ZIS%#/;!8E;!^,FY.M1W$!QXW-*&
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M:+V$$'F(ESOAP4R*(5] 67!N%=NGG55H\Z@AB>)77 EBW\?DJM2^KPJ/WQ]
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M?F.=4K7%+]T>,\T+9V)DJM&0-DQ2MPKKDO 'C&YX!K_@W>B8,YY2IV+.3OQ
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MIQ(A[:@]55I,W>]W@N38+4CR LBI<%F?J$3Q[W]*?XY&7XJ^?R5_YL^*<NU
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M._\&->5_A6B9OP/+L5]._P=02P$"% ,4    " #S@WE;RGQ%PZ$-   -DP
M$0              @ $     879X;"TR,#(U,#DS,"YX<V102P$"% ,4
M" #S@WE;P[J2H> *  !6=@  %0              @ '0#0  879X;"TR,#(U
M,#DS,%]C86PN>&UL4$L! A0#%     @ \X-Y6XTW#0F;&P  7JD! !4
M         ( !XQ@  &%V>&PM,C R-3 Y,S!?9&5F+GAM;%!+ 0(4 Q0    (
M /.#>5LZINF& E<  , (!0 5              "  ;$T  !A=GAL+3(P,C4P
M.3,P7VQA8BYX;6Q02P$"% ,4    " #S@WE;=X8R^CH\  #2U , %0
M        @ 'FBP  879X;"TR,#(U,#DS,%]P<F4N>&UL4$L! A0#%     @
M\X-Y6^PMQ0<C%P, -D<6  X              ( !4\@  &4W,#4R7S$P+6LN
M:'1M4$L! A0#%     @ \X-Y6T;,I?^O @  D1   !               ( !
MHM\# &4W,#4R7V5X,C$M,2YH=&U02P$"% ,4    " #S@WE;:I<FO T#  "^
M#0  $               @ %_X@, 93<P-3)?97@R,RTQ+FAT;5!+ 0(4 Q0
M   ( /.#>5O^UJQWW@<  /-"   0              "  ;KE P!E-S U,E]E
M>#,Q+3$N:'1M4$L! A0#%     @ \X-Y6X=NL#<X"   CCP  !
M     ( !QNT# &4W,#4R7V5X,S$M,BYH=&U02P$"% ,4    " #S@WE;OD[<
M:$,&  #]&P  $               @ $L]@, 93<P-3)?97@S,BTQ+FAT;5!+
M 0(4 Q0    ( /.#>5L>JXD'-.4$ %H:"  -              "  9W\ P!I
M;6%G95\P,#$N:G!G4$L! A0#%     @ \X-Y6YLON.G1?P  VY<   T
M         ( !_.$( &EM86=E7S P,BYJ<&=02P$"% ,4    " #S@WE;M*54
MMKL: @#ZC@, #0              @ 'X80D :6UA9V5?,# S+FIP9U!+ 0(4
M Q0    ( /.#>5L1,8)%^5@  ".;   -              "  =Y\"P!I;6%G
?95\P,#0N:G!G4$L%!@     /  \ J0,   +6"P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>e7052_10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avxl="http://anavex.com/20250930"
  xmlns:currency="http://xbrl.sec.gov/currency/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="avxl-20250930.xsd" xlink:type="simple"/>
    <context id="From2024-10-01to2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-11-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2025-11-24</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-012024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_MichaelJFoxFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:MichaelJFoxFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-03</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockIncludingCommitmentSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommonStockIncludingCommitmentSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockExcludingCommitmentSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommonStockExcludingCommitmentSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommitmentSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommitmentSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockIncludingCommitmentSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommonStockIncludingCommitmentSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockExcludingCommitmentSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommonStockExcludingCommitmentSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommitmentSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommitmentSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_BoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avxl:BoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ChiefExecutiveOfficer1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avxl:ChiefExecutiveOfficer1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_ChiefExecutiveOfficer1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avxl:ChiefExecutiveOfficer1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_ChiefExecutiveOffice1rMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avxl:ChiefExecutiveOffice1rMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-03-242022-03-25_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-24</startDate>
            <endDate>2022-03-25</endDate>
        </period>
    </context>
    <context id="AsOf2025-04-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2025-04-17</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_FederalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_FederalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_FederalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_ForeignCountryMember_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_ForeignCountryMember_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_PreclinicalStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:PreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_custom_PreclinicalStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:PreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_custom_PreclinicalStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:PreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_ClinicalTrialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:ClinicalTrialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_custom_ClinicalTrialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:ClinicalTrialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_custom_ClinicalTrialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:ClinicalTrialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_PersonnelCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:PersonnelCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_custom_PersonnelCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:PersonnelCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_custom_PersonnelCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:PersonnelCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_NonCashShareBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:NonCashShareBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_custom_NonCashShareBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:NonCashShareBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_custom_NonCashShareBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:NonCashShareBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_custom_OtherResearchAndDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:OtherResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_custom_OtherResearchAndDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:OtherResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_custom_OtherResearchAndDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">avxl:OtherResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-09-30_2023-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:typedMember dimension="ecd:RestatementDateAxis">
                    <ecd:RestatementDateAxis.domain>2023-11-30</ecd:RestatementDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Ratio">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-10-01to2025-09-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-10-01to2025-09-30" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-10-01to2025-09-30" id="Fact000005">0001314052</dei:EntityCentralIndexKey>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl0106"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0108"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:OtherFinancingExpense
      contextRef="From2024-10-01to2025-09-30"
      id="xdx2ixbrl0178"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:OtherFinancingExpense
      contextRef="From2023-10-012024-09-30"
      id="xdx2ixbrl0179"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:NoncashFinancingRelatedCharges
      contextRef="From2024-10-01to2025-09-30"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:NoncashFinancingRelatedCharges
      contextRef="From2023-10-012024-09-30"
      id="xdx2ixbrl0239"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForDelayedTaxExemptExchange
      contextRef="From2023-10-012024-09-30"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForDelayedTaxExemptExchange
      contextRef="From2022-10-012023-09-30"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommonStockIssuedUponCashlessExerciseOfStockOptions
      contextRef="From2023-10-012024-09-30"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommonStockIssuedUponCashlessExerciseOfStockOptions
      contextRef="From2022-10-012023-09-30"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2022-10-012023-09-30"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2023-10-012024-09-30"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedUnderSalesAgreement
      contextRef="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfStockOptions
      contextRef="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesWithheldRelatedToCashlessExerciseOfStockOption
      contextRef="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0441"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl0991"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0992"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2024-10-01to2025-09-30"
      id="xdx2ixbrl1000"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2022-10-012023-09-30"
      id="xdx2ixbrl1002"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount
      contextRef="From2024-10-01to2025-09-30"
      id="xdx2ixbrl1008"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount
      contextRef="From2023-10-012024-09-30"
      id="xdx2ixbrl1009"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2024-10-01to2025-09-30"
      id="xdx2ixbrl1032"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2023-10-012024-09-30"
      id="xdx2ixbrl1033"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-10-01to2025-09-30" id="Fact000011">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-10-01to2025-09-30" id="Fact000012">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-10-01to2025-09-30" id="Fact000013">2025-09-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-10-01to2025-09-30" id="Fact000014">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-10-01to2025-09-30" id="Fact000015">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-10-01to2025-09-30" id="Fact000016">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-10-01to2025-09-30" id="Fact000017">001-37606</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-10-01to2025-09-30" id="Fact000018">ANAVEX LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-10-01to2025-09-30" id="Fact000019">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-10-01to2025-09-30" id="Fact000020">98-0608404</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-10-01to2025-09-30" id="Fact000021">630 5th Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-10-01to2025-09-30" id="Fact000022">20th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-10-01to2025-09-30" id="Fact000023">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-10-01to2025-09-30" id="Fact000024">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="From2024-10-01to2025-09-30" id="Fact000025">US</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2024-10-01to2025-09-30" id="Fact000026">10111</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-10-01to2025-09-30" id="Fact000027">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-10-01to2025-09-30" id="Fact000028">689-3939</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-10-01to2025-09-30" id="Fact000029">Common Stock Par Value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-10-01to2025-09-30" id="Fact000030">AVXL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-10-01to2025-09-30" id="Fact000031">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-10-01to2025-09-30" id="Fact000032">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-10-01to2025-09-30" id="Fact000033">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-10-01to2025-09-30" id="Fact000034">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-10-01to2025-09-30" id="Fact000035">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-10-01to2025-09-30" id="Fact000036">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-10-01to2025-09-30" id="Fact000037">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-10-01to2025-09-30" id="Fact000038">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-10-01to2025-09-30" id="Fact000039">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-10-01to2025-09-30" id="Fact000040">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-10-01to2025-09-30" id="Fact000041">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000042"
      unitRef="USD">708000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-11-24"
      decimals="INF"
      id="Fact000043"
      unitRef="Shares">89348107</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000044">

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Risk management and strategy &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We have implemented and maintain various information
security processes designed to identify, assess and manage &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20241001__20250930_zdv53dXGo97l"&gt;material &lt;/span&gt;risks from cybersecurity threats to our cloud networks, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20241001__20250930_zRxyuWweayrh"&gt;third party&lt;/span&gt;
hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information
that is proprietary, strategic or competitive in nature, and data related to our clinical trials and products.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We have processes designed to protect our information
systems, data, assets, infrastructure, and computing environments from cybersecurity threats and risks. Our cybersecurity strategy includes
the use of third-party IT professionals to assess the effectiveness of our cybersecurity practices for possible cybersecurity threats
and to manage our IT systems to mitigate these threats. We also use multi-factor authentication, maintain logical, physical and technical
controls designed to deter, prevent, mitigate and respond to cybersecurity threats. Further, we provide periodical cybersecurity reminders
to our employees and subscribe to a third-party cybersecurity training program required for all employees, to emphasize the importance
of adherence to our security policies and awareness of evolving cybersecurity threats. We also carry a separate cybersecurity commercial
insurance policy covering the potential financial losses that may occur in the event we experience a cybersecurity incident.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20241001__20250930_zlJZVmtouZA1"&gt;Our assessment and management of material risks from
cybersecurity threats are &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20241001__20250930_zTtCiHPGKa8l"&gt;integrated &lt;/span&gt;into the Company&#x2019;s overall risk management processes.&lt;/span&gt; We conduct organizational risk assessments
commensurate with our size and complexity of our operations. We are in a continuous process of reviewing and implementing incremental
information technology strategies to mitigate cybersecurity risks as new risks arise and as our operations evolve. This has led us to
engage third party professionals to assist in the implementation of processes to manage these risks. We also use third-party service providers
across a variety of functions throughout our business, such as application providers, hosting companies, contract research organizations,
contract manufacturing organizations, distributors, and supply chain resources. We have a vendor management process to help manage cybersecurity
risks associated with our use of certain of these providers. For certain vendors, these processes include a comprehensive vendor audit
process.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of the date of this Annual Report, we do not believe
that any past cybersecurity incidents that have been detected have materially affected, or are reasonably likely to materially affect,
our business strategy, results of operations, or financial condition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;See &#x201c;&lt;i&gt;Risk Factors - Risks Related to Our
Business and Operations&lt;/i&gt;&#x201d; for additional information about the risks to our business associated with cybersecurity or a breach
or compromise to our information security systems.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Governance &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;div class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_980_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20241001__20250930_zu38dIlHJAS2"&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20241001__20250930_zqfCSDYTZXkh"&gt;Our Board of Directors addresses the Company&#x2019;s
cybersecurity risk management as part of its general oversight function. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20241001__20250930_zOSArugJT6Vg"&gt;The audit committee of the Board of Directors is responsible
for overseeing the Company&#x2019;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity
&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20241001__20250930_zdM05lQaYVC9"&gt;threats&lt;/span&gt;.&lt;/span&gt;&lt;/span&gt; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20241001__20250930_z6KSwD07O2Ba"&gt;The audit committee receives periodic updates as required from senior management concerning updates to the Company&#x2019;s significant
cybersecurity threats and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20241001__20250930_zzhFYYiJaqYj"&gt;risk&lt;/span&gt; and the processes the Company has implemented to address them.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Currently we have two cybersecurity experts on our
Audit Committee.&lt;/p&gt;

&lt;/div&gt;

</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2024-10-01to2025-09-30" id="Fact000045">true</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="From2024-10-01to2025-09-30" id="Fact000046">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000047">Our assessment and management of material risks from
cybersecurity threats are &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20241001__20250930_zTtCiHPGKa8l"&gt;integrated &lt;/span&gt;into the Company&#x2019;s overall risk management processes.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2024-10-01to2025-09-30" id="Fact000048">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000049">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20241001__20250930_zqfCSDYTZXkh"&gt;Our Board of Directors addresses the Company&#x2019;s
cybersecurity risk management as part of its general oversight function. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20241001__20250930_zOSArugJT6Vg"&gt;The audit committee of the Board of Directors is responsible
for overseeing the Company&#x2019;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity
&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20241001__20250930_zdM05lQaYVC9"&gt;threats&lt;/span&gt;.&lt;/span&gt;&lt;/span&gt; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20241001__20250930_z6KSwD07O2Ba"&gt;The audit committee receives periodic updates as required from senior management concerning updates to the Company&#x2019;s significant
cybersecurity threats and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20241001__20250930_zzhFYYiJaqYj"&gt;risk&lt;/span&gt; and the processes the Company has implemented to address them.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Currently we have two cybersecurity experts on our
Audit Committee.&lt;/p&gt;

</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000050">Our Board of Directors addresses the Company&#x2019;s
cybersecurity risk management as part of its general oversight function. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20241001__20250930_zOSArugJT6Vg"&gt;The audit committee of the Board of Directors is responsible
for overseeing the Company&#x2019;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity
&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20241001__20250930_zdM05lQaYVC9"&gt;threats&lt;/span&gt;.&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000051">The audit committee of the Board of Directors is responsible
for overseeing the Company&#x2019;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity
&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20241001__20250930_zdM05lQaYVC9"&gt;threats&lt;/span&gt;.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="From2024-10-01to2025-09-30" id="Fact000052">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000053">The audit committee receives periodic updates as required from senior management concerning updates to the Company&#x2019;s significant
cybersecurity threats and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20241001__20250930_zzhFYYiJaqYj"&gt;risk&lt;/span&gt; and the processes the Company has implemented to address them.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="From2024-10-01to2025-09-30" id="Fact000054">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <dei:AuditorName contextRef="From2024-10-01to2025-09-30" id="Fact000055">GRANT THORNTON LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-10-01to2025-09-30" id="Fact000056">Melville, New York</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="From2024-10-01to2025-09-30" id="Fact000057">248</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000065"
      unitRef="USD">102577000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000066"
      unitRef="USD">132187000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxesReceivable
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000068"
      unitRef="USD">809000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000069"
      unitRef="USD">2449000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000071"
      unitRef="USD">429000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000072"
      unitRef="USD">931000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000074"
      unitRef="USD">103815000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000075"
      unitRef="USD">135567000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000083"
      unitRef="USD">4249000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000084"
      unitRef="USD">9627000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000086"
      unitRef="USD">3892000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000087"
      unitRef="USD">4835000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRentCredit
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000089"
      unitRef="USD">805000</us-gaap:DeferredRentCredit>
    <us-gaap:DeferredRentCredit
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000090"
      unitRef="USD">842000</us-gaap:DeferredRentCredit>
    <us-gaap:Liabilities
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000092"
      unitRef="USD">8946000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000093"
      unitRef="USD">15304000</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000098"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000100"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000102"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000104"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000110"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000112"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000114"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000116"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000118"
      unitRef="Shares">86668521</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000120"
      unitRef="Shares">86668521</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000122"
      unitRef="Shares">84795517</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000124"
      unitRef="Shares">84795517</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000126"
      unitRef="USD">87000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000128"
      unitRef="USD">85000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000130"
      unitRef="USD">477230000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000131"
      unitRef="USD">456249000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000133"
      unitRef="USD">-382448000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000134"
      unitRef="USD">-336071000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000136"
      unitRef="USD">94869000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000137"
      unitRef="USD">120263000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000139"
      unitRef="USD">103815000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000140"
      unitRef="USD">135567000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000146"
      unitRef="USD">13816000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000147"
      unitRef="USD">11039000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000148"
      unitRef="USD">12046000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000150"
      unitRef="USD">37592000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000151"
      unitRef="USD">41838000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000152"
      unitRef="USD">43717000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000154"
      unitRef="USD">51408000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000155"
      unitRef="USD">52877000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000156"
      unitRef="USD">55763000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000158"
      unitRef="USD">-51408000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000159"
      unitRef="USD">-52877000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000160"
      unitRef="USD">-55763000</us-gaap:OperatingIncomeLoss>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000166"
      unitRef="USD">37000</avxl:NonOperatingIncomeFromGrants>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000167"
      unitRef="USD">75000</avxl:NonOperatingIncomeFromGrants>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000168"
      unitRef="USD">25000</avxl:NonOperatingIncomeFromGrants>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000170"
      unitRef="USD">648000</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000171"
      unitRef="USD">2291000</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000172"
      unitRef="USD">2718000</avxl:ResearchAndDevelopmentIncentiveIncome>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000174"
      unitRef="USD">4678000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000175"
      unitRef="USD">7320000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000176"
      unitRef="USD">6519000</us-gaap:InterestIncomeExpenseNet>
    <avxl:OtherFinancingExpense
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000180"
      unitRef="USD">964000</avxl:OtherFinancingExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000182"
      unitRef="USD">-332000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000183"
      unitRef="USD">189000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000184"
      unitRef="USD">-40000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000186"
      unitRef="USD">5031000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000187"
      unitRef="USD">9875000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000188"
      unitRef="USD">8258000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000190"
      unitRef="USD">-46377000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000191"
      unitRef="USD">-43002000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000192"
      unitRef="USD">-47505000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-10-01to2025-09-30"
      decimals="INF"
      id="Fact000198"
      unitRef="USDPShares">-0.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-10-01to2025-09-30"
      decimals="INF"
      id="Fact000200"
      unitRef="USDPShares">-0.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-10-012024-09-30"
      decimals="INF"
      id="Fact000202"
      unitRef="USDPShares">-0.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-10-012024-09-30"
      decimals="INF"
      id="Fact000204"
      unitRef="USDPShares">-0.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-10-012023-09-30"
      decimals="INF"
      id="Fact000206"
      unitRef="USDPShares">-0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-10-012023-09-30"
      decimals="INF"
      id="Fact000208"
      unitRef="USDPShares">-0.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-10-01to2025-09-30"
      decimals="INF"
      id="Fact000214"
      unitRef="Shares">85289447</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-10-01to2025-09-30"
      decimals="INF"
      id="Fact000216"
      unitRef="Shares">85289447</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-10-012024-09-30"
      decimals="INF"
      id="Fact000218"
      unitRef="Shares">83468049</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-10-012024-09-30"
      decimals="INF"
      id="Fact000220"
      unitRef="Shares">83468049</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-10-012023-09-30"
      decimals="INF"
      id="Fact000222"
      unitRef="Shares">79787596</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-10-012023-09-30"
      decimals="INF"
      id="Fact000224"
      unitRef="Shares">79787596</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000230"
      unitRef="USD">-46377000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000231"
      unitRef="USD">-43002000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000232"
      unitRef="USD">-47505000</us-gaap:NetIncomeLoss>
    <avxl:NoncashFinancingRelatedCharges
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000240"
      unitRef="USD">845000</avxl:NoncashFinancingRelatedCharges>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000242"
      unitRef="USD">11549000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000243"
      unitRef="USD">9438000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000244"
      unitRef="USD">16370000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000250"
      unitRef="USD">-1640000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000251"
      unitRef="USD">-260000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000252"
      unitRef="USD">-484000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000254"
      unitRef="USD">-502000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000255"
      unitRef="USD">278000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000256"
      unitRef="USD">299000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000258"
      unitRef="USD">-5378000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000259"
      unitRef="USD">5305000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000260"
      unitRef="USD">497000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000262"
      unitRef="USD">-943000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000263"
      unitRef="USD">-2460000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000264"
      unitRef="USD">1350000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <avxl:DeferredGrantIncome
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000266"
      unitRef="USD">37000</avxl:DeferredGrantIncome>
    <avxl:DeferredGrantIncome
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000267"
      unitRef="USD">75000</avxl:DeferredGrantIncome>
    <avxl:DeferredGrantIncome
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000268"
      unitRef="USD">-473000</avxl:DeferredGrantIncome>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000270"
      unitRef="USD">-39044000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000271"
      unitRef="USD">-30812000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000272"
      unitRef="USD">-27785000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <avxl:IssuanceOfCommonSharesNetOfShareIssueCosts
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000278"
      unitRef="USD">9198000</avxl:IssuanceOfCommonSharesNetOfShareIssueCosts>
    <avxl:IssuanceOfCommonSharesNetOfShareIssueCosts
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000279"
      unitRef="USD">11284000</avxl:IssuanceOfCommonSharesNetOfShareIssueCosts>
    <avxl:IssuanceOfCommonSharesNetOfShareIssueCosts
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000280"
      unitRef="USD">27875000</avxl:IssuanceOfCommonSharesNetOfShareIssueCosts>
    <us-gaap:PaymentsForDelayedTaxExemptExchange
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000282"
      unitRef="USD">2707000</us-gaap:PaymentsForDelayedTaxExemptExchange>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000286"
      unitRef="USD">2943000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000287"
      unitRef="USD">691000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000288"
      unitRef="USD">1776000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000290"
      unitRef="USD">9434000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000291"
      unitRef="USD">11975000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000292"
      unitRef="USD">29651000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000294"
      unitRef="USD">-29610000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000295"
      unitRef="USD">-18837000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000296"
      unitRef="USD">1866000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000298"
      unitRef="USD">132187000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000299"
      unitRef="USD">151024000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-09-30"
      decimals="-3"
      id="Fact000300"
      unitRef="USD">149158000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000302"
      unitRef="USD">102577000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000303"
      unitRef="USD">132187000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000304"
      unitRef="USD">151024000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <avxl:CashPaidForStateAndLocalFranchiseTaxes
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000310"
      unitRef="USD">125000</avxl:CashPaidForStateAndLocalFranchiseTaxes>
    <avxl:CashPaidForStateAndLocalFranchiseTaxes
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000311"
      unitRef="USD">300000</avxl:CashPaidForStateAndLocalFranchiseTaxes>
    <avxl:CashPaidForStateAndLocalFranchiseTaxes
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000312"
      unitRef="USD">136000</avxl:CashPaidForStateAndLocalFranchiseTaxes>
    <avxl:CommonStockIssuedUponCashlessExerciseOfStockOptions
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000314"
      unitRef="USD">1493000</avxl:CommonStockIssuedUponCashlessExerciseOfStockOptions>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000323"
      unitRef="Shares">77942815</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000318"
      unitRef="USD">78000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000319"
      unitRef="USD">387977000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000320"
      unitRef="USD">-245564000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30"
      decimals="-3"
      id="Fact000321"
      unitRef="USD">142491000</us-gaap:StockholdersEquity>
    <avxl:InitialCommitmentSharesShares
      contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000335"
      unitRef="Shares">75000</avxl:InitialCommitmentSharesShares>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000331"
      unitRef="USD">845000</avxl:InitialCommitmentShares>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000333"
      unitRef="USD">845000</avxl:InitialCommitmentShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000342"
      unitRef="Shares">3275000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000337"
      unitRef="USD">3000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000338"
      unitRef="USD">27872000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000340"
      unitRef="USD">27875000</us-gaap:StockRepurchasedDuringPeriodValue>
    <avxl:CommitmentSharesShares
      contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000349"
      unitRef="Shares">13943</avxl:CommitmentSharesShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares
      contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000356"
      unitRef="Shares">759753</avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000351"
      unitRef="USD">1000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000352"
      unitRef="USD">1775000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000354"
      unitRef="USD">1776000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000359"
      unitRef="USD">16370000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000361"
      unitRef="USD">16370000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000365"
      unitRef="USD">-47505000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000366"
      unitRef="USD">-47505000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000373"
      unitRef="Shares">82066511</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000368"
      unitRef="USD">82000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000369"
      unitRef="USD">434839000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000370"
      unitRef="USD">-293069000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000371"
      unitRef="USD">141852000</us-gaap:StockholdersEquity>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000385"
      unitRef="Shares">2450000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000380"
      unitRef="USD">3000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000381"
      unitRef="USD">11281000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000383"
      unitRef="USD">11284000</us-gaap:StockRepurchasedDuringPeriodValue>
    <avxl:CommitmentSharesShares
      contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000392"
      unitRef="Shares">5646</avxl:CommitmentSharesShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares
      contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000399"
      unitRef="Shares">273360</avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000395"
      unitRef="USD">691000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000397"
      unitRef="USD">691000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000402"
      unitRef="USD">9438000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000404"
      unitRef="USD">9438000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000408"
      unitRef="USD">-43002000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000409"
      unitRef="USD">-43002000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000416"
      unitRef="Shares">84795517</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000411"
      unitRef="USD">85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000412"
      unitRef="USD">456249000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000413"
      unitRef="USD">-336071000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000414"
      unitRef="USD">120263000</us-gaap:StockholdersEquity>
    <avxl:SharesIssuedUnderSalesAgreementShares
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000423"
      unitRef="Shares">927910000</avxl:SharesIssuedUnderSalesAgreementShares>
    <avxl:SharesIssuedUnderSalesAgreement
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000418"
      unitRef="USD">1000</avxl:SharesIssuedUnderSalesAgreement>
    <avxl:SharesIssuedUnderSalesAgreement
      contextRef="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000419"
      unitRef="USD">9197000</avxl:SharesIssuedUnderSalesAgreement>
    <avxl:SharesIssuedUnderSalesAgreement
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000421"
      unitRef="USD">9198000</avxl:SharesIssuedUnderSalesAgreement>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000430"
      unitRef="Shares">646488</avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000425"
      unitRef="USD">1000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000426"
      unitRef="USD">2942000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000428"
      unitRef="USD">2943000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfStockOptionsShares
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000437"
      unitRef="Shares">737500</avxl:SharesIssuedPursuantToCashlessExerciseOfStockOptionsShares>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfStockOptions
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000432"
      unitRef="USD">1000</avxl:SharesIssuedPursuantToCashlessExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfStockOptions
      contextRef="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000433"
      unitRef="USD">1492000</avxl:SharesIssuedPursuantToCashlessExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfStockOptions
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000435"
      unitRef="USD">1493000</avxl:SharesIssuedPursuantToCashlessExerciseOfStockOptions>
    <avxl:SharesWithheldRelatedToCashlessExerciseOfStockOptionShares
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000444"
      unitRef="Shares">-438894</avxl:SharesWithheldRelatedToCashlessExerciseOfStockOptionShares>
    <avxl:SharesWithheldRelatedToCashlessExerciseOfStockOption
      contextRef="From2024-10-012025-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000439"
      unitRef="USD">-1000</avxl:SharesWithheldRelatedToCashlessExerciseOfStockOption>
    <avxl:SharesWithheldRelatedToCashlessExerciseOfStockOption
      contextRef="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000440"
      unitRef="USD">-4199000</avxl:SharesWithheldRelatedToCashlessExerciseOfStockOption>
    <avxl:SharesWithheldRelatedToCashlessExerciseOfStockOption
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000442"
      unitRef="USD">-4200000</avxl:SharesWithheldRelatedToCashlessExerciseOfStockOption>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-10-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000447"
      unitRef="USD">11549000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000449"
      unitRef="USD">11549000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000453"
      unitRef="USD">-46377000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000454"
      unitRef="USD">-46377000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000461"
      unitRef="Shares">86668521</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000456"
      unitRef="USD">87000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000457"
      unitRef="USD">477230000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000458"
      unitRef="USD">-382448000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000459"
      unitRef="USD">94869000</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000463">&lt;p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zGqPc0XbeUT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Note 1 	&lt;span id="xdx_823_zLqv9QImUj4f"&gt;Business Description and Basis of Presentation
&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Business&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Anavex Life Sciences Corp. (&#x201c;Anavex&#x201d; or
the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#x201c;CNS&#x201d;) diseases with high unmet need. Anavex analyzes genomic data
from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative
and neurodevelopmental diseases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s focus is on developing innovative
treatments for Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases,
including Rett syndrome, and other central nervous system (CNS) disorders.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These consolidated financial statements have been
prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and the instructions to Form
10-K and have been prepared under the accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain immaterial amounts from prior periods have
been reclassified to conform to the current year&#x2019;s presentation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All of the Company&#x2019;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, the Company has not generated any revenue from our operations. The Company expects the business to continue to experience negative
cash flows from operations for the foreseeable future and cannot predict when, if ever, its business might become profitable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management believes that the current working capital
position will be sufficient to meet the Company&#x2019;s working capital requirements beyond the next 12 months after the date that these
consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials
are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change.&#160;The
actual amount of the Company&#x2019;s expenditures will vary depending upon a number of factors including but not limited to the design,
timing and duration of future clinical trials, the progress of the Company&#x2019;s research and development programs and the level of
financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future
clinical trials.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other than our rights related to the 2025 Sales Agreement
and the 2023 Purchase Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available when
needed or, if available, that it can be obtained on commercially reasonable terms. The Company will need to file a prospectus supplement
in order to access funds under the 2023 Purchase Agreement. If the Company is not able to obtain the additional financing on a timely
basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;














</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000470">&lt;p id="xdx_803_eus-gaap--SignificantAccountingPoliciesTextBlock_z5taQo9J6NA" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 2	&lt;span id="xdx_826_zDMJqvHfGSmi"&gt;Summary of Significant Accounting Policies&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zxon4wP4Wia2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zde3wXM9zkBb"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive and tax receivables, valuation and recoverability
of deferred tax assets, share based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zVD4XzL1tzEb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zpCBy5brpQk2"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#x201c;Anavex Australia&#x201d;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zD8NNHkBuK9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zLtybN7cq6Qd"&gt;Cash and equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span&gt;The Company considers only
those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to
be cash equivalents&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Highly
liquid investments that are considered cash equivalents include money market&#160;accounts, money market&#160;funds&#160;and&#160;certificates
of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities. The Company&#x2019;s
investment policy allows for investments in domestic money market certificates, certificates of deposit, money market funds, bonds or
commercial papers, and establishes diversification and credit quality requirements and limits investments by maturity and issuer. The
Company currently maintains the majority of its investments at one large well known financial institution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the
Federal Deposit Insurance Corporation (FDIC) up to $&lt;span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_pp0p0_c20250930_zE1i1FXPrd3j" title="Federal deposit insurance corporation"&gt;250,000&lt;/span&gt;, under current regulations. At September 30, 2025 and 2024, substantially
all of the Company&#x2019;s cash balances were in excess of these federally insured limits. The Company mitigates this risk by maintaining
the majority of its cash balances in a large well-known financial institution. The Company has not experienced any losses in such accounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ResearchAndDevelopmentExpensePolicy_zApC1CPXlzx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zfNu11ZjOfR9"&gt;Research and Development Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development costs are expensed as incurred.
These expenses are comprised of the costs of the Company&#x2019;s proprietary research and development efforts, including preclinical studies,
clinical trials, manufacturing costs, employee salaries and benefits and share-based compensation expense, contract services including
external research and development expenses incurred under arrangements with third parties such as contract research organizations (&#x201c;CROs&#x201d;),
facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when
the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification
(&#x201c;ASC&#x201d;) 730, &lt;i&gt;Research and Development&lt;/i&gt;, as these materials have no alternative future use outside of their intended
use.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Nonrefundable advance payments for goods or services
that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods
are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs
incurred in relation to external CROs, and clinical site costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes
progress of the trials and studies including the phase or completion of events, invoices received and contracted costs. Judgments and
estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s
estimates. The Company&#x2019;s historical accrual estimates have not been materially different from actual costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition, the Company incurs expenses in respect
of intellectual property costs relating to patents and trademarks. The probability of success and length of time to develop commercial
applications of the drugs subject to the underlying patent and trademark costs is difficult to determine and numerous risks and uncertainties
exist with respect to the timely completion of the development projects. There is no assurance the drugs subject to the underlying patents
and trademarks will ever be successfully commercialized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Due to these risks and uncertainties, the patent and
trademark costs do not meet the definition of an asset and thus are expensed as incurred within general and administrative expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--RevenueRecognitionIncentives_zqniuP8zbxt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zaSKSRZ4JeZ8"&gt;Research and Development Incentive Income&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is eligible to obtain certain research
and development tax credits, including, through its wholly owned subsidiary Anavex Australia, the Australian research and development
tax incentive credit (the &#x201c;Australia R&amp;amp;D credit&#x201d;) through a program administered through the Australian Tax Office (the
&#x201c;ATO&#x201d;) and AusIndustry, a division of the Australian Government&#x2019;s Department of Industry, Innovation and Science (&#x201c;AusIndustry&#x201d;).
The Australia R&amp;amp;D credit program provides for a cash refund based on a percentage of eligible research and development activities
undertaken in Australia by Anavex Australia. Anavex Australia is also eligible under the Australia R&amp;amp;D credit program to receive the
cash refund for certain research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses
are pre-approved by AusIndustry pursuant to an advanced overseas finding application.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Australia R&amp;amp;D credit program is available
to eligible companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period at a rate
of 18.5% above the claimant&#x2019;s company tax rate in Australia.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The tax incentives are available on the basis of specific
criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company
has accounted for the incentives outside of the scope of ASC Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt; (&#x201c;ASC 740&#x201d;), since the incentives
are not linked to the Company&#x2019;s taxable income and can be realized regardless of whether the Company has generated taxable income
in the respective jurisdictions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;With respect to the Australia R&amp;amp;D credit, as there
is no authoritative guidance under GAAP for accounting for grants to for-profit business entities, the Company accounts for the grant
by analogy to IAS20 &lt;i&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/i&gt; (&#x201c;IAS 20&#x201d;). The Company
recognizes the research and development incentive income as it incurs costs eligible for reimbursement under the Australia R&amp;amp;D credit
program when it is reasonably assured that the cash incentive will be received, as evidenced through enrollment in the program and when
the applicable conditions under the program have been met. The Company accrues for the amount of cash refund it expects to receive in
relation to research and development expenses outside of Australia only to the extent it has received advanced approval from AusIndustry,
pursuant to an approved advanced overseas finding application.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition, Anavex Australia and Anavex Canada incur
Goods and Services Tax (GST) on certain services provided by local vendors. As a domestic entity in those jurisdictions, Anavex Australia
and Anavex Canada are entitled to a refund of the GST paid. Similarly, Anavex Germany incurs Value Added Tax (VAT) on certain services
provided by local vendors, to which it is entitled to a refund of such VAT paid. The Company&#x2019;s estimate of the amount of cash refund
it expects to receive related to GST and VAT incurred is included in Incentive and tax receivables in the accompanying consolidated balance
sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;














&lt;p id="xdx_844_ecustom--LicenseFeesPolicyTextBlock_zd34ancWC3ii" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zrfDP49gLz2k"&gt;License Fees&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
Company expenses amounts paid to acquire licenses associated with products under development when the ultimate recovery of the amounts
paid is uncertain and the technology has no alternative future use when acquired. Acquisitions of technology licenses are charged to expense
or capitalized based on management&#x2019;s assessment regarding the ultimate recoverability of the amounts paid and the potential for
alternative future use. The Company has determined that the technological feasibility for its product candidates is reached when the requisite
regulatory approvals are obtained to make the product available for sale.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zEDn9LOkfxBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zkqk8L0aChs9"&gt;Basic and Diluted Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2025, diluted loss per share excludes
&lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241001__20250930_zki1oXWZpULk" title="Loss per share for potentially dilutive common shares"&gt;14,971,583&lt;/span&gt; potentially dilutive common shares (2024 - &lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20231001__20240930_zM4mHEQ3JuJ5" title="Loss per share for potentially dilutive common shares"&gt;15,047,754&lt;/span&gt;; 2023 &#x2013; &lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230930_pdd" title="Loss per share for potentially dilutive common shares"&gt;14,271,780&lt;/span&gt;) related to outstanding options and warrants,
as their effect was anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zceoKf43s8ij" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zClX3phJ8r49"&gt;Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The book value of the Company&#x2019;s financial instruments,
consisting of cash and equivalents, incentive and tax receivables, accounts payable and accrued liabilities approximate their fair value
due to the short-term maturity of such instruments. Unless otherwise noted, it is management&#x2019;s opinion that the Company is not exposed
to significant interest, currency or credit risks arising from these financial instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zQ4n5Kxzx4L9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zOW8TWby7Rkj"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The functional currency of the Company is the US dollar.
Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date
and non-monetary items are translated at exchange rates prevailing when the assets were acquired, or obligations incurred. Foreign currency
denominated expense items are translated at exchange rates prevailing on the transaction date. Unrealized gains or losses arising from
the translations are credited or charged to income in the period in which they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has determined that the functional currency
of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd. is also the US dollar.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ze2L1H2uNjul" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zRKtUWWLX863"&gt;Segment and Geographic Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company determines and presents operating segments
based on the information that is internally provided to the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), its Chief
Executive Officer, in accordance with ASC 280, Segment Reporting. The Company has determined that it operates in a single business segment,
which is a clinical-stage biopharmaceutical company developing differentiated therapeutics by applying precision medicine to central nervous
system (&#x201c;CNS&#x201d;) diseases with high unmet need. Refer to Note 8 &#x2013; Segmented Information for further information related
to the Company&#x2019;s segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;














&lt;p id="xdx_84F_ecustom--GrantIncomePolicyTextBlock_zEftaHZ3lpN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z8TzpgSXhhE9"&gt;Grant Income&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Grant income is recognized at the fair value of the
grant when it is received, and all substantive conditions have been satisfied. Grants received from government and other agencies in advance
of the specific research and development costs to which they relate are deferred and recognized in the consolidated statements of operations
and comprehensive loss in the period they are earned, typically when the related research and development costs are incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zDoEUYITEGC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zVQe3W1QkAn4"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows the provisions of ASC 740, which
requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and
liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying
amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows the provisions of ASC 740 regarding
accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more
likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently
measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax
authority assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information.
The Company considers many factors when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions
and tax benefits may not accurately anticipate actual outcomes. As additional information is obtained, there may be a need to periodically
adjust the recognized tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements
of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes interest and penalties related
to current income tax expense on the interest income, net line, in the accompanying consolidated statements of operations and comprehensive
loss. Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zzoJR4HR6L54" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zbECW6HHmcb4"&gt;Share-based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for all share-based payments
and awards under the fair value method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of all share-based payments are expensed
over their contractual vesting period, or over the expected performance period for only the portion of awards expected to vest, in the
case of milestone-based vesting, with a corresponding increase to additional paid-in capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Compensation costs for share-based payments with graded
vesting are recognized on a straight-line basis. Stock based compensation expense is adjusted for actual forfeitures of unvested awards
as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has granted share purchase option awards
that vest upon achievement of certain performance criteria, or milestone-based awards. The Company estimates an implicit service period
for achieving performance criteria for each award and recognizes the resulting fair value as expense over the implicit service period
when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its
estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest upon achievement
of the performance criteria.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company uses the Black-Scholes option valuation
model to calculate the fair value of share-based awards at the date of the grant. This model requires the input of subjective assumptions,
including the expected price volatility and expected life of each&#160;award. The Company uses the U.S. Treasury daily treasury yield
curve rates for the expected term of the option as the risk-free rate. The expected term represents the period that options granted are
expected to be outstanding using the simplified method. Historically, the Company&#x2019;s historical share option exercise experience
did not provide sufficient basis for estimating the expected term. Expected volatility is based on the average of the daily share price
changes over the expected term. The Company does not estimate forfeitures and elects to record actual forfeitures as they occur. The Company
has not paid any dividends on its common stock historically, therefore no assumption of dividend payments is made in the model. These
assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#x2019;s
judgment. Changes in these assumptions can materially affect the fair value estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The purchase price of share-based compensation awards
may be paid in cash or, if approved by the Company&#x2019;s compensation committee (or in the case of warrants by the Board of Directors)
in advance, &#x201c;net settled&#x201d; in shares of the Company&#x2019;s common stock. In a net settlement of an share-based award, the
Company does not receive payment of the exercise price from the holder but reduces the number of shares of common stock issued upon the
exercise of the award by the smallest number of whole shares that have an aggregate fair market value equal to or over the aggregate exercise
price for the option shares covered by the instrument exercised. Shares issued pursuant to the exercise of options and warrants are issued
from the Company&#x2019;s treasury.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z92M6wRNMox" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zxkKj0wYCM0h"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fair value is defined as the exchange price that would
be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair
value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes
the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities that the Company has the ability to access at the measurement date;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2025 and 2024, the Company did not
have any Level 2 or Level 3 assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zyxIcg1Lt1u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_z5CZrOPiGmE6"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2023, the Financial Accounting Standards
Board (FASB) issued ASU No. 2023-07, &#x201c;Segment Reporting: Improvements to Reportable Segment Disclosures.&#x201d; This guidance requires
disclosure of incremental segment information on an annual and interim basis, including disclosure of the title and position of the Chief
Operating Decision Maker and requires that a public entity that has a single reportable segment to provide all the disclosures required
by the amendments in ASU No. 2023-07. The Company adopted the new standard effective September 30, 2025, and for subsequent interim periods.
Since ASU No. 2023-07 addresses only disclosures, the adoption of ASU No. 2023-07 did not have a significant impact on the Company&#x2019;s
consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;














&lt;p id="xdx_845_ecustom--RecentAccountingPronouncementsPolicyTextBlock_zpvzsd0U9Chf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zVt6QSRQlqpi"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In December 2023, the FASB
issued ASU No. 2023-09, &#x201c;Income Taxes:&#160;Improvements to Income Tax Disclosures.&#x201d; This guidance requires consistent categories
and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment
is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In November 2024, the FASB
issued ASU No. 2024-03, &#x201c;Income Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures. The
amendments in ASU No. 2024-03 address investor requests for more detailed expense information and require additional disaggregated disclosures
in the notes to the financial statements for certain categories of expenses that are included on the face of the financial statements.
The guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after
December 15, 2027, with early adoption permitted. The Company is currently assessing the impact of this guidance on its disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-10-01to2025-09-30" id="Fact000472">&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zxon4wP4Wia2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zde3wXM9zkBb"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive and tax receivables, valuation and recoverability
of deferred tax assets, share based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000474">&lt;p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zVD4XzL1tzEb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zpCBy5brpQk2"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#x201c;Anavex Australia&#x201d;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000476">&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zD8NNHkBuK9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zLtybN7cq6Qd"&gt;Cash and equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span&gt;The Company considers only
those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to
be cash equivalents&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Highly
liquid investments that are considered cash equivalents include money market&#160;accounts, money market&#160;funds&#160;and&#160;certificates
of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities. The Company&#x2019;s
investment policy allows for investments in domestic money market certificates, certificates of deposit, money market funds, bonds or
commercial papers, and establishes diversification and credit quality requirements and limits investments by maturity and issuer. The
Company currently maintains the majority of its investments at one large well known financial institution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the
Federal Deposit Insurance Corporation (FDIC) up to $&lt;span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_pp0p0_c20250930_zE1i1FXPrd3j" title="Federal deposit insurance corporation"&gt;250,000&lt;/span&gt;, under current regulations. At September 30, 2025 and 2024, substantially
all of the Company&#x2019;s cash balances were in excess of these federally insured limits. The Company mitigates this risk by maintaining
the majority of its cash balances in a large well-known financial institution. The Company has not experienced any losses in such accounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000478"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-10-01to2025-09-30" id="Fact000480">&lt;p id="xdx_844_eus-gaap--ResearchAndDevelopmentExpensePolicy_zApC1CPXlzx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zfNu11ZjOfR9"&gt;Research and Development Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development costs are expensed as incurred.
These expenses are comprised of the costs of the Company&#x2019;s proprietary research and development efforts, including preclinical studies,
clinical trials, manufacturing costs, employee salaries and benefits and share-based compensation expense, contract services including
external research and development expenses incurred under arrangements with third parties such as contract research organizations (&#x201c;CROs&#x201d;),
facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when
the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification
(&#x201c;ASC&#x201d;) 730, &lt;i&gt;Research and Development&lt;/i&gt;, as these materials have no alternative future use outside of their intended
use.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Nonrefundable advance payments for goods or services
that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods
are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs
incurred in relation to external CROs, and clinical site costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes
progress of the trials and studies including the phase or completion of events, invoices received and contracted costs. Judgments and
estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s
estimates. The Company&#x2019;s historical accrual estimates have not been materially different from actual costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition, the Company incurs expenses in respect
of intellectual property costs relating to patents and trademarks. The probability of success and length of time to develop commercial
applications of the drugs subject to the underlying patent and trademark costs is difficult to determine and numerous risks and uncertainties
exist with respect to the timely completion of the development projects. There is no assurance the drugs subject to the underlying patents
and trademarks will ever be successfully commercialized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Due to these risks and uncertainties, the patent and
trademark costs do not meet the definition of an asset and thus are expensed as incurred within general and administrative expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RevenueRecognitionIncentives contextRef="From2024-10-01to2025-09-30" id="Fact000487">&lt;p id="xdx_84B_eus-gaap--RevenueRecognitionIncentives_zqniuP8zbxt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zaSKSRZ4JeZ8"&gt;Research and Development Incentive Income&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is eligible to obtain certain research
and development tax credits, including, through its wholly owned subsidiary Anavex Australia, the Australian research and development
tax incentive credit (the &#x201c;Australia R&amp;amp;D credit&#x201d;) through a program administered through the Australian Tax Office (the
&#x201c;ATO&#x201d;) and AusIndustry, a division of the Australian Government&#x2019;s Department of Industry, Innovation and Science (&#x201c;AusIndustry&#x201d;).
The Australia R&amp;amp;D credit program provides for a cash refund based on a percentage of eligible research and development activities
undertaken in Australia by Anavex Australia. Anavex Australia is also eligible under the Australia R&amp;amp;D credit program to receive the
cash refund for certain research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses
are pre-approved by AusIndustry pursuant to an advanced overseas finding application.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Australia R&amp;amp;D credit program is available
to eligible companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period at a rate
of 18.5% above the claimant&#x2019;s company tax rate in Australia.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The tax incentives are available on the basis of specific
criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company
has accounted for the incentives outside of the scope of ASC Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt; (&#x201c;ASC 740&#x201d;), since the incentives
are not linked to the Company&#x2019;s taxable income and can be realized regardless of whether the Company has generated taxable income
in the respective jurisdictions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;With respect to the Australia R&amp;amp;D credit, as there
is no authoritative guidance under GAAP for accounting for grants to for-profit business entities, the Company accounts for the grant
by analogy to IAS20 &lt;i&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/i&gt; (&#x201c;IAS 20&#x201d;). The Company
recognizes the research and development incentive income as it incurs costs eligible for reimbursement under the Australia R&amp;amp;D credit
program when it is reasonably assured that the cash incentive will be received, as evidenced through enrollment in the program and when
the applicable conditions under the program have been met. The Company accrues for the amount of cash refund it expects to receive in
relation to research and development expenses outside of Australia only to the extent it has received advanced approval from AusIndustry,
pursuant to an approved advanced overseas finding application.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition, Anavex Australia and Anavex Canada incur
Goods and Services Tax (GST) on certain services provided by local vendors. As a domestic entity in those jurisdictions, Anavex Australia
and Anavex Canada are entitled to a refund of the GST paid. Similarly, Anavex Germany incurs Value Added Tax (VAT) on certain services
provided by local vendors, to which it is entitled to a refund of such VAT paid. The Company&#x2019;s estimate of the amount of cash refund
it expects to receive related to GST and VAT incurred is included in Incentive and tax receivables in the accompanying consolidated balance
sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;














</us-gaap:RevenueRecognitionIncentives>
    <avxl:LicenseFeesPolicyTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000494">&lt;p id="xdx_844_ecustom--LicenseFeesPolicyTextBlock_zd34ancWC3ii" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zrfDP49gLz2k"&gt;License Fees&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
Company expenses amounts paid to acquire licenses associated with products under development when the ultimate recovery of the amounts
paid is uncertain and the technology has no alternative future use when acquired. Acquisitions of technology licenses are charged to expense
or capitalized based on management&#x2019;s assessment regarding the ultimate recoverability of the amounts paid and the potential for
alternative future use. The Company has determined that the technological feasibility for its product candidates is reached when the requisite
regulatory approvals are obtained to make the product available for sale.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</avxl:LicenseFeesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000496">&lt;p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zEDn9LOkfxBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zkqk8L0aChs9"&gt;Basic and Diluted Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2025, diluted loss per share excludes
&lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241001__20250930_zki1oXWZpULk" title="Loss per share for potentially dilutive common shares"&gt;14,971,583&lt;/span&gt; potentially dilutive common shares (2024 - &lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20231001__20240930_zM4mHEQ3JuJ5" title="Loss per share for potentially dilutive common shares"&gt;15,047,754&lt;/span&gt;; 2023 &#x2013; &lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230930_pdd" title="Loss per share for potentially dilutive common shares"&gt;14,271,780&lt;/span&gt;) related to outstanding options and warrants,
as their effect was anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-10-01to2025-09-30"
      decimals="INF"
      id="Fact000498"
      unitRef="Shares">14971583</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-012024-09-30"
      decimals="INF"
      id="Fact000500"
      unitRef="Shares">15047754</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-012023-09-30"
      decimals="INF"
      id="Fact000502"
      unitRef="Shares">14271780</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-10-01to2025-09-30" id="Fact000504">&lt;p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zceoKf43s8ij" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zClX3phJ8r49"&gt;Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The book value of the Company&#x2019;s financial instruments,
consisting of cash and equivalents, incentive and tax receivables, accounts payable and accrued liabilities approximate their fair value
due to the short-term maturity of such instruments. Unless otherwise noted, it is management&#x2019;s opinion that the Company is not exposed
to significant interest, currency or credit risks arising from these financial instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000506">&lt;p id="xdx_847_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zQ4n5Kxzx4L9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zOW8TWby7Rkj"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The functional currency of the Company is the US dollar.
Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date
and non-monetary items are translated at exchange rates prevailing when the assets were acquired, or obligations incurred. Foreign currency
denominated expense items are translated at exchange rates prevailing on the transaction date. Unrealized gains or losses arising from
the translations are credited or charged to income in the period in which they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has determined that the functional currency
of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd. is also the US dollar.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000508">&lt;p id="xdx_84E_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ze2L1H2uNjul" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zRKtUWWLX863"&gt;Segment and Geographic Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company determines and presents operating segments
based on the information that is internally provided to the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), its Chief
Executive Officer, in accordance with ASC 280, Segment Reporting. The Company has determined that it operates in a single business segment,
which is a clinical-stage biopharmaceutical company developing differentiated therapeutics by applying precision medicine to central nervous
system (&#x201c;CNS&#x201d;) diseases with high unmet need. Refer to Note 8 &#x2013; Segmented Information for further information related
to the Company&#x2019;s segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;














</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <avxl:GrantIncomePolicyTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000515">&lt;p id="xdx_84F_ecustom--GrantIncomePolicyTextBlock_zEftaHZ3lpN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z8TzpgSXhhE9"&gt;Grant Income&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Grant income is recognized at the fair value of the
grant when it is received, and all substantive conditions have been satisfied. Grants received from government and other agencies in advance
of the specific research and development costs to which they relate are deferred and recognized in the consolidated statements of operations
and comprehensive loss in the period they are earned, typically when the related research and development costs are incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</avxl:GrantIncomePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000517">&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zDoEUYITEGC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zVQe3W1QkAn4"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows the provisions of ASC 740, which
requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and
liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying
amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows the provisions of ASC 740 regarding
accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more
likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently
measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax
authority assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information.
The Company considers many factors when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions
and tax benefits may not accurately anticipate actual outcomes. As additional information is obtained, there may be a need to periodically
adjust the recognized tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements
of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes interest and penalties related
to current income tax expense on the interest income, net line, in the accompanying consolidated statements of operations and comprehensive
loss. Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000519">&lt;p id="xdx_841_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zzoJR4HR6L54" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zbECW6HHmcb4"&gt;Share-based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for all share-based payments
and awards under the fair value method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of all share-based payments are expensed
over their contractual vesting period, or over the expected performance period for only the portion of awards expected to vest, in the
case of milestone-based vesting, with a corresponding increase to additional paid-in capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Compensation costs for share-based payments with graded
vesting are recognized on a straight-line basis. Stock based compensation expense is adjusted for actual forfeitures of unvested awards
as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has granted share purchase option awards
that vest upon achievement of certain performance criteria, or milestone-based awards. The Company estimates an implicit service period
for achieving performance criteria for each award and recognizes the resulting fair value as expense over the implicit service period
when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its
estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest upon achievement
of the performance criteria.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company uses the Black-Scholes option valuation
model to calculate the fair value of share-based awards at the date of the grant. This model requires the input of subjective assumptions,
including the expected price volatility and expected life of each&#160;award. The Company uses the U.S. Treasury daily treasury yield
curve rates for the expected term of the option as the risk-free rate. The expected term represents the period that options granted are
expected to be outstanding using the simplified method. Historically, the Company&#x2019;s historical share option exercise experience
did not provide sufficient basis for estimating the expected term. Expected volatility is based on the average of the daily share price
changes over the expected term. The Company does not estimate forfeitures and elects to record actual forfeitures as they occur. The Company
has not paid any dividends on its common stock historically, therefore no assumption of dividend payments is made in the model. These
assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#x2019;s
judgment. Changes in these assumptions can materially affect the fair value estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The purchase price of share-based compensation awards
may be paid in cash or, if approved by the Company&#x2019;s compensation committee (or in the case of warrants by the Board of Directors)
in advance, &#x201c;net settled&#x201d; in shares of the Company&#x2019;s common stock. In a net settlement of an share-based award, the
Company does not receive payment of the exercise price from the holder but reduces the number of shares of common stock issued upon the
exercise of the award by the smallest number of whole shares that have an aggregate fair market value equal to or over the aggregate exercise
price for the option shares covered by the instrument exercised. Shares issued pursuant to the exercise of options and warrants are issued
from the Company&#x2019;s treasury.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000526">&lt;p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z92M6wRNMox" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zxkKj0wYCM0h"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fair value is defined as the exchange price that would
be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair
value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes
the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities that the Company has the ability to access at the measurement date;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2025 and 2024, the Company did not
have any Level 2 or Level 3 assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000528">&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zyxIcg1Lt1u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_z5CZrOPiGmE6"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2023, the Financial Accounting Standards
Board (FASB) issued ASU No. 2023-07, &#x201c;Segment Reporting: Improvements to Reportable Segment Disclosures.&#x201d; This guidance requires
disclosure of incremental segment information on an annual and interim basis, including disclosure of the title and position of the Chief
Operating Decision Maker and requires that a public entity that has a single reportable segment to provide all the disclosures required
by the amendments in ASU No. 2023-07. The Company adopted the new standard effective September 30, 2025, and for subsequent interim periods.
Since ASU No. 2023-07 addresses only disclosures, the adoption of ASU No. 2023-07 did not have a significant impact on the Company&#x2019;s
consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;














</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <avxl:RecentAccountingPronouncementsPolicyTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000535">&lt;p id="xdx_845_ecustom--RecentAccountingPronouncementsPolicyTextBlock_zpvzsd0U9Chf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zVt6QSRQlqpi"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In December 2023, the FASB
issued ASU No. 2023-09, &#x201c;Income Taxes:&#160;Improvements to Income Tax Disclosures.&#x201d; This guidance requires consistent categories
and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment
is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In November 2024, the FASB
issued ASU No. 2024-03, &#x201c;Income Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures. The
amendments in ASU No. 2024-03 address investor requests for more detailed expense information and require additional disaggregated disclosures
in the notes to the financial statements for certain categories of expenses that are included on the face of the financial statements.
The guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after
December 15, 2027, with early adoption permitted. The Company is currently assessing the impact of this guidance on its disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</avxl:RecentAccountingPronouncementsPolicyTextBlock>
    <avxl:AccuredLiabilitiesTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000537">&lt;p id="xdx_80D_ecustom--AccuredLiabilitiesTextBlock_zVboWXwlA6Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 3	&lt;span id="xdx_82F_zQru5WRVent6"&gt;Accrued Liabilities&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The principal components of accrued liabilities consist of (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zEFXjdmOG7z5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Liabilities (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BA_zI3it03iRoGk" style="display: none"&gt;Schedule of principal components of accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20250930_zyqxLuwprtle" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20240930_znZa56PfFcAk" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AccruedInvestigatorPayments_iI_pn3n3_z91BpzDoygW5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Accrued investigator payments&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;860&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccruedBonusesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued compensation and benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,562&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--MilestoneBasedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Milestone-based contract accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;523&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;557&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherAccountsPayableAndAccruedLiabilities_iI_pn3n3_z7ckRxVrVmq4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;All other accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,711&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,891&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--TotalAccruedLiabilities_iTI_pn3n3_zK1vlMEb0Dl3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total accrued liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;3,892&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;4,835&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"&gt;&#160;&lt;/p&gt;

</avxl:AccuredLiabilitiesTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000539">&lt;table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zEFXjdmOG7z5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Liabilities (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BA_zI3it03iRoGk" style="display: none"&gt;Schedule of principal components of accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20250930_zyqxLuwprtle" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20240930_znZa56PfFcAk" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AccruedInvestigatorPayments_iI_pn3n3_z91BpzDoygW5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Accrued investigator payments&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;860&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccruedBonusesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued compensation and benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,562&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--MilestoneBasedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Milestone-based contract accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;523&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;557&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherAccountsPayableAndAccruedLiabilities_iI_pn3n3_z7ckRxVrVmq4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;All other accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,711&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,891&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--TotalAccruedLiabilities_iTI_pn3n3_zK1vlMEb0Dl3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total accrued liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;3,892&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;4,835&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <avxl:AccruedInvestigatorPayments
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000541"
      unitRef="USD">96000</avxl:AccruedInvestigatorPayments>
    <avxl:AccruedInvestigatorPayments
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000542"
      unitRef="USD">860000</avxl:AccruedInvestigatorPayments>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000544"
      unitRef="USD">1562000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000545"
      unitRef="USD">1527000</us-gaap:AccruedBonusesCurrent>
    <avxl:MilestoneBasedContractAccruals
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000547"
      unitRef="USD">523000</avxl:MilestoneBasedContractAccruals>
    <avxl:MilestoneBasedContractAccruals
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000548"
      unitRef="USD">557000</avxl:MilestoneBasedContractAccruals>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000550"
      unitRef="USD">1711000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000551"
      unitRef="USD">1891000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <avxl:TotalAccruedLiabilities
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000553"
      unitRef="USD">3892000</avxl:TotalAccruedLiabilities>
    <avxl:TotalAccruedLiabilities
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000554"
      unitRef="USD">4835000</avxl:TotalAccruedLiabilities>
    <avxl:OtherIncomeDisclosureTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000556">&lt;p id="xdx_805_ecustom--OtherIncomeDisclosureTextBlock_z0okJWlDII35" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 4	&lt;span id="xdx_82F_zfaCasMrBFNe"&gt;Other Income&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Grant income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;As of September 30, 2025,
the Company had received a $&lt;span id="xdx_907_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20241001__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxFoundationMember_zFb5BginfwW5" title="Research and development incentive income"&gt;1&lt;/span&gt;.0 million research grant awarded by the Michael J. Fox Foundation for Parkinson&#x2019;s Research. The grant
will be used to fund a clinical trial of the Company&#x2019;s lead compound, ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73 (blarcamesine) related to Parkinson&#x2019;s
disease. Of the total, $&lt;span id="xdx_906_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20221001__20230930_zKQ4v4iMvXh4" title="Research and development incentive income"&gt;0.5&lt;/span&gt; million was received during the year ended September 30, 2023 and $&lt;span id="xdx_90B_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20201001__20210930_zbwgyCM3Qd8b" title="Research and development incentive income"&gt;0.5&lt;/span&gt; million was received during the year
ended September 30, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The grant income has been
deferred when received and is being amortized to other income as the related research and development expenditures are incurred. During
the year ended September 30, 2025, the Company recognized $&lt;span id="xdx_90E_ecustom--NonOperatingIncomeFromGrant_pn5n6_c20241001__20250930_z2wVNObUC3r4" title="Non operating income from grant"&gt;37,000&lt;/span&gt; (2024: $&lt;span id="xdx_902_ecustom--NonOperatingIncomeFromGrant_pn5n6_c20231001__20240930_zo7Pgibr0eDg" title="Non operating income from grant"&gt;75,000&lt;/span&gt;; 2023: $&lt;span id="xdx_909_ecustom--NonOperatingIncomeFromGrant_c20221001__20230930_pn5n6" title="Non operating income from grant"&gt;25,000&lt;/span&gt;) of this grant on its statements of operations
within grant income. At September 30, 2025 an amount of $&lt;span id="xdx_90D_ecustom--DeferredGrantIncome1_pn5n6_c20241001__20250930_zfjzuMk2QZs2" title="Deferred grant income"&gt;0.8&lt;/span&gt; million (2024: $&lt;span id="xdx_909_ecustom--DeferredGrantIncome1_pn5n6_c20231001__20240930_zsed7MY5Qs05" title="Deferred grant income"&gt;0.8&lt;/span&gt; million) of this grant is recorded as deferred grant
income, representing the amount of this grant which has not yet been amortized to other income. The Company will recognize this income
on its statements of operations as the related expenditures are incurred to offset the income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Research and development
incentive income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Research and development
incentive income represents the income earned by Anavex Australia of the Australia R&amp;amp;D credit. This cash incentive is received by
Anavex Australia, upon filing of a claim in connection with Anavex Australia&#x2019;s annual income tax return.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;During the year ended September
30, 2025, the Company recorded research and development incentive income of $&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20241001__20250930_zyhXZ2WjcWVd" title="Research and development incentive income"&gt;0.6&lt;/span&gt; million (AUD &lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20241001__20250930__srt--CurrencyAxis__currency--AUD_z0G6WBCwBb82" title="Research and development incentive income"&gt;1.0&lt;/span&gt; million) (2024: $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240930_zboRkqIm1B" title="Research and development incentive income"&gt;2.3&lt;/span&gt; million (AUD &lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240930__srt--CurrencyAxis__currency--AUD_zTiZVTCD76Ek" title="Research and development incentive income"&gt;3.5&lt;/span&gt;
million); 2023: $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230930_zA7F2CU7m0Ni" title="Research and development incentive income"&gt;2.7&lt;/span&gt; million (AUD &lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230930__srt--CurrencyAxis__currency--AUD_zT5bn2jEk2bh" title="Research and development incentive income"&gt;4.1&lt;/span&gt; million)) in respect of the Australia R&amp;amp;D credit for eligible research and development expenses
incurred during the year. This amount is included within Other income (expense) on the consolidated statements of operations and comprehensive
loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;At September 30, 2025, Incentive
and tax receivables includes $&lt;span id="xdx_90A_eus-gaap--OtherReceivables_iI_pn5n6_c20250930_zpsCBrNkE8Hj" title="Incentive and tax receivables"&gt;0.7&lt;/span&gt; million (AUD &lt;span id="xdx_902_eus-gaap--OtherReceivables_iI_pn5n6_c20250930__srt--CurrencyAxis__currency--AUD_z5EWVo5e36be" title="Incentive and tax receivables"&gt;1.1&lt;/span&gt; million) (2024: $&lt;span id="xdx_903_eus-gaap--OtherReceivables_iI_pn5n6_c20240930_zmIXkejQmyke" title="Incentive and tax receivables"&gt;2.3&lt;/span&gt; million (AUD &lt;span id="xdx_909_eus-gaap--OtherReceivables_iI_pn5n6_c20240930__srt--CurrencyAxis__currency--AUD_zu9mNr4hNgP3" title="Incentive and tax receivables"&gt;3.3&lt;/span&gt; million)) relating to Australia R&amp;amp;D credits
earned during the year that are expected to be reimbursed upon filing of the Company&#x2019;s annual claim under this program.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Australia R&amp;amp;D credit
program is a self-assess program whereby the Company must assess its eligibility each year to determine (i) if the entity is eligible
(ii) if the specific R&amp;amp;D activities are eligible and (iii) if the individual R&amp;amp;D expenditures have nexus to such R&amp;amp;D activities.
The Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Anavex Australia is able to continue to claim the R&amp;amp;D tax incentive for as long as it remains eligible and continues
to incur eligible research and development expenditures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Although the Company believes
that it has complied with all the relevant conditions of eligibility under the program for all periods claimed, the ATO has the right
to review the Company&#x2019;s qualifying programs and related expenditures for a period of four years. If such a review were to occur,
the ATO may have different interpretations of certain eligibility requirements. If the ATO disagreed with the Company&#x2019;s assessments
and any related subsequent appeals, it could require adjustment to and repayment of current or previous years&#x2019; claims already received.
Additionally, if the Company was unable to demonstrate a reasonably arguable position taken on such claims, the ATO could also assess
penalties and interest on any such adjustments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Currently, the Company&#x2019;s
tax incentive claims from 2020 to 2025 are open to potential review by the ATO. Additionally, the period open for review is indefinite
if the ATO suspects fraud. The Company has not provided any allowance for any such potential adjustments, should they occur in the future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</avxl:OtherIncomeDisclosureTextBlock>
    <avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1
      contextRef="From2024-10-012025-09-30_custom_MichaelJFoxFoundationMember"
      decimals="-5"
      id="Fact000558"
      unitRef="USD">1000000</avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1>
    <avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1
      contextRef="From2022-10-012023-09-30"
      decimals="-5"
      id="Fact000560"
      unitRef="USD">500000</avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1>
    <avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1
      contextRef="From2020-10-012021-09-30"
      decimals="-5"
      id="Fact000562"
      unitRef="USD">500000</avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2024-10-01to2025-09-30"
      decimals="-5"
      id="Fact000564"
      unitRef="USD">37000000000</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2023-10-012024-09-30"
      decimals="-5"
      id="Fact000566"
      unitRef="USD">75000000000</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2022-10-012023-09-30"
      decimals="-5"
      id="Fact000568"
      unitRef="USD">25000000000</avxl:NonOperatingIncomeFromGrant>
    <avxl:DeferredGrantIncome1
      contextRef="From2024-10-01to2025-09-30"
      decimals="-5"
      id="Fact000570"
      unitRef="USD">800000</avxl:DeferredGrantIncome1>
    <avxl:DeferredGrantIncome1
      contextRef="From2023-10-012024-09-30"
      decimals="-5"
      id="Fact000572"
      unitRef="USD">800000</avxl:DeferredGrantIncome1>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2024-10-01to2025-09-30"
      decimals="-5"
      id="Fact000579"
      unitRef="USD">600000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2024-10-012025-09-30_currency_AUD"
      decimals="-5"
      id="Fact000581"
      unitRef="USD">1000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2023-10-012024-09-30"
      decimals="-5"
      id="Fact000583"
      unitRef="USD">2300000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2023-10-012024-09-30_currency_AUD"
      decimals="-5"
      id="Fact000585"
      unitRef="USD">3500000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-10-012023-09-30"
      decimals="-5"
      id="Fact000587"
      unitRef="USD">2700000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-10-012023-09-30_currency_AUD"
      decimals="-5"
      id="Fact000589"
      unitRef="USD">4100000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:OtherReceivables
      contextRef="AsOf2025-09-30"
      decimals="-5"
      id="Fact000591"
      unitRef="USD">700000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2025-09-30_currency_AUD"
      decimals="-5"
      id="Fact000593"
      unitRef="USD">1100000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2024-09-30"
      decimals="-5"
      id="Fact000595"
      unitRef="USD">2300000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2024-09-30_currency_AUD"
      decimals="-5"
      id="Fact000597"
      unitRef="USD">3300000</us-gaap:OtherReceivables>
    <avxl:EquityOfferingTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000599">&lt;p id="xdx_80F_ecustom--EquityOfferingTextBlock_zRYeKkgxLVs9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 5	&lt;span id="xdx_821_zQTXlbtIMU17"&gt;Equity Offerings&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s Board of Directors&#160;(the &#x201c;Board&#x201d;)&#160;has
the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number
of shares constituting any series or the designation of the series.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2025 Sales Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 25, 2025, the Company entered into a Sales
Agreement (the &#x201c;2025 Sales Agreement&#x201d;) with TD Securities (USA) LLC (the &#x201c;Sales Agent&#x201d;). Pursuant to the 2025
Sales Agreement, the Company may offer and sell up to an aggregate offering price of $&lt;span id="xdx_90B_ecustom--ValueOfSharesObligatedToPurchase_pn3n3_dm_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zj8GB2AoXg8a" title="Value of shares obligated to purchase"&gt;150&lt;/span&gt; million (the &#x201c;Offering&#x201d;) in shares
of common stock from time to time through the Sales Agent.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Upon delivery of a placement notice based on the Company&#x2019;s
instructions and subject to the terms and conditions of the 2025 Sales Agreement, the Sales Agent may sell shares of common stock by methods
deemed to be an &#x201c;at the market offering&#x201d;, in negotiated transactions at market prices prevailing at the time of sale or at
prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to
the Company&#x2019;s prior written consent. The Company is not obligated to make any sales of shares under the 2025 Sales Agreement. The
Company or the Sales Agent may suspend or terminate the Offering upon notice to the other party, subject to certain conditions. The Sales
Agent will act as sales agent on a commercially reasonable efforts basis consistent its normal trading and sales practices, applicable
state and federal law, rules and regulations and the rules of Nasdaq.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has agreed to pay the Sales Agent commissions
for its services of up to&#160;3.0% of the gross proceeds from the sale of shares of common stock pursuant to the Sales Agreement. The
Company has also agreed to provide the Sales Agent with customary indemnification and contribution rights.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended September 30, 2025, the Company
issued &lt;span id="xdx_903_eus-gaap--SharesIssued_iI_c20250930_zyjvy8YZOYv4" title="Common stock issued shares"&gt;927,910&lt;/span&gt; shares of common stock for net proceeds of $&lt;span id="xdx_908_eus-gaap--RedemptionPremium_pn3n3_dm_c20241001__20250930_zBHwAG4gwVa2" title="Common stock net proceeds"&gt;9.2&lt;/span&gt; million pursuant to the 2025 Sales Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2023 Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 3, 2023, the Company entered into a $150.0
million purchase agreement (the &#x201c;2023 Purchase Agreement&#x201d;) with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;),
pursuant to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $&lt;span id="xdx_90F_ecustom--ValueOfSharesObligatedToPurchase_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z7EqpYMKIk1j" title="Value of shares obligated to purchase"&gt;150.0&lt;/span&gt;
million in value of its shares of common stock from time to time over a three-year period until February 3, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In consideration for entering into the 2023 Purchase
Agreement, the Company issued to Lincoln Park &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zQcYwUOS2Lod" title="Share issued for offering, shares"&gt;75,000&lt;/span&gt; shares of common stock as a commitment fee (the &#x201c;initial commitment shares&#x201d;)
and agreed to issue up to an additional &lt;span id="xdx_907_ecustom--StockIssuedDuringPeriodValueNewIssues1_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zU6fyfMArFzi" title="Pro rata basic number of shares obligated to purchase"&gt;75,000&lt;/span&gt; shares pro rata, when and if, Lincoln Park purchased, at the Company&#x2019;s discretion,
the $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn3n3_dm_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zz4L6KMbsd98" title="Proceeds from issuance or sale of equity"&gt;150.0&lt;/span&gt; million aggregate commitment. The Company determined the fair value of the initial commitment shares was $&lt;span id="xdx_909_ecustom--FairValueOfInitialCommitment_iI_pn5n6_c20230930_zJBqs5uOEhtk" title="Fair value of the initial commitment"&gt;0.8&lt;/span&gt; million with
reference to the closing price of the Company&#x2019;s shares on the Purchase Agreement date. In addition, the Company incurred third party
expenses of $&lt;span id="xdx_90B_ecustom--IncurredExpenses_iI_pn5n6_c20230930_zlAL1dQJV4F1" title="Incurred expenses"&gt;0.1&lt;/span&gt; million in connection with entering into the Purchase Agreement. These amounts were expensed to other financing expense
on the statements of operations during the year ended September 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended September 30, 2025, the Company
did not issue any shares of common stock under the 2023 Purchase Agreement. During the year ended September 30, 2024, the Company issued
to Lincoln Park an aggregate of &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20231001__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockIncludingCommitmentSharesMember_zG4l7ZvjtNE3" title="Number of shares issued, shares"&gt;2,455,646&lt;/span&gt; shares of common stock under the 2023 Purchase Agreement, including &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockExcludingCommitmentSharesMember_zDEJXtBLySoe" title="Number of shares issued, shares"&gt;2,450,000&lt;/span&gt; shares of common
stock for an aggregate purchase price of $&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_dm_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zuy4NyY9D1N3" title="Number of shares issued, value"&gt;11.3&lt;/span&gt; million and &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommitmentSharesMember_zO3MTIC3nZj8" title="Number of shares issued, shares"&gt;5,646&lt;/span&gt; commitment shares. During the year ended September 30, 2023, the Company
issued to Lincoln Park an aggregate of &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockIncludingCommitmentSharesMember_zefqrGFq41vd" title="Number of shares issued, shares"&gt;3,288,943&lt;/span&gt; shares of common stock under the 2023 Purchase Agreement, including &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockExcludingCommitmentSharesMember_zRKoC3QKcy4b" title="Number of shares issued, shares"&gt;3,275,000&lt;/span&gt; shares
of common stock for aggregate proceeds of $&lt;span id="xdx_901_ecustom--StockIssuedDuringPeriodValueNewIssues2_pn5n6_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zEchpl1UyS6c" title="Number of shares issued, value"&gt;27.9&lt;/span&gt; million and&#160;&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommitmentSharesMember_zirlILwWijVk" title="Number of shares issued, shares"&gt;13,943&lt;/span&gt;&#160;commitment shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2025, there was an unused amount
of $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueOther_pn5n6_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zsvFtqHHMK29" title="Amount of shares remain available"&gt;110.8&lt;/span&gt; million under the 2023 Purchase Agreement. The Company will need to file a prospectus supplement in order to access funds under
the 2023 Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Exercise of Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended September 30, 2025, the Company
issued&#160;&lt;span id="xdx_90F_eus-gaap--SharesIssued_iI_pip0_c20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zKA4X7e03q83" title="Shares issued"&gt;217,503&lt;/span&gt;&#160;shares of common stock to the Company&#x2019;s Chief Executive Officer upon a net exercise of an option to purchase&#160;&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zHCh2lYflJAh" title="Exercise option shares purchase"&gt;500,000&lt;/span&gt;&#160;shares
of common stock at an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z0K8goYCYl5l" title="Common stock exercise price"&gt;0.92&lt;/span&gt;&#160;per share. In connection with the exercise, the Company withheld&#160;&lt;span id="xdx_901_ecustom--CommonStockConsiderationExerciseShares_c20241001__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zptS1rPbLdAg" title="Common stock consideration exercise shares"&gt;47,745&lt;/span&gt;&#160;shares
of common stock as consideration of the exercise price of $&lt;span id="xdx_908_eus-gaap--StockOptionExercisePriceIncrease_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zXN8FJ0MntRl" title=" exercise price"&gt;0.46&lt;/span&gt;&#160;million and&#160;&lt;span id="xdx_904_eus-gaap--NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zZ4qo5NmjuGa" title="Consideration shares issued"&gt;234,752&lt;/span&gt;&#160;shares of common stock as consideration
for the payment of $&lt;span id="xdx_90E_eus-gaap--OtherSignificantNoncashTransactionValueOfConsiderationGiven1_pn3n3_dm_c20241001__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zfJ8OqevFlq2" title="Consideration payment"&gt;2.3&lt;/span&gt;&#160;million in connection with tax withholding obligations associated with the exercise. The number of shares
withheld were based upon a market price of $&lt;span id="xdx_90E_ecustom--MarketPrice_iI_pip0_c20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zy2fbb4B83Ed" title="Market price"&gt;9.63&lt;/span&gt;&#160;per share as determined by reference to the average high and low sales price reported
on the Nasdaq stock exchange on the date of exercise.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended September 30, 2025, the Company
issued&#160;&lt;span id="xdx_900_eus-gaap--SharesIssued_iI_pip0_c20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zlqHCxA1saph" title="Shares issued"&gt;38,651&lt;/span&gt;&#160;shares of common stock to a director of the Company upon a net exercise of an option to purchase&#160;&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_z2iMyzfF8dw8" title="Exercise option shares purchase"&gt;50,000&lt;/span&gt;&#160;shares
of common stock at an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20250930__srt--TitleOfIndividualAxis__custom--BoardMember_z5K9Xu1l2zXh" title="Common stock exercise price"&gt;1.76&lt;/span&gt;&#160;per share. The Company withheld &lt;span id="xdx_90E_ecustom--CommonStockConsiderationExerciseShares_pn3n3_c20241001__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zKBP2n6qVJfi" title="Common stock consideration exercise shares"&gt;11,349&lt;/span&gt; shares of common stock as consideration of the
exercise price of $&lt;span id="xdx_902_eus-gaap--OtherSignificantNoncashTransactionValueOfConsiderationGiven1_pn3n3_c20241001__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zi3z3HaXphyc" title="Consideration payment"&gt;88,000&lt;/span&gt;. The number of shares withheld were based upon a market price of $&lt;span id="xdx_90D_ecustom--MarketPrice_iI_pip0_c20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zT6drhsIPPg3" title="Market price"&gt;7.75&lt;/span&gt;&#160;per share as determined by reference
to the average high and low sales price reported on the Nasdaq stock exchange on the date of exercise&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended September 30, 2025, the Company
issued&#160;&lt;span id="xdx_90F_eus-gaap--SharesIssued_iI_pip0_c20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zeFZaTZ6dGf2" title="Shares issued"&gt;42,452&lt;/span&gt;&#160;shares of common stock to the Company&#x2019;s Chief Executive Officer upon a net exercise of an option to purchase&#160;&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_z86Ta8DByNQ6" title="Exercise option shares purchase"&gt;187,500&lt;/span&gt;&#160;shares
of common stock at an exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zprUIgjB3PRl" title="Common stock exercise price"&gt;5.04&lt;/span&gt;&#160;per share. In connection with the exercise, the Company withheld&#160;&lt;span id="xdx_904_ecustom--CommonStockConsiderationExerciseShares_c20241001__20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOffice1rMember_zUPfuIALfIug" title="Common stock consideration exercise shares"&gt;98,643&lt;/span&gt;&#160;shares
of common stock as consideration of the exercise price of $&lt;span id="xdx_90D_eus-gaap--StockOptionExercisePriceIncrease_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zempGZr7JFYd" title=" exercise price"&gt;0.9&lt;/span&gt;&#160;million and&#160;&lt;span id="xdx_904_eus-gaap--NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zTHUd0TFfjdk" title="Consideration shares issued"&gt;46,405&lt;/span&gt;&#160;shares of common stock as consideration
for the payment of $&lt;span id="xdx_907_eus-gaap--OtherSignificantNoncashTransactionValueOfConsiderationGiven1_pn3n3_dm_c20241001__20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zXKWeicBVcI9" title="Consideration payment"&gt;0.4&lt;/span&gt;&#160;million in connection with tax withholding obligations associated with the exercise. The number of shares
withheld were based upon a market price of $&lt;span id="xdx_906_ecustom--MarketPrice_iI_pip0_c20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zv3nATBsxgqc" title="Market price"&gt;9.58&lt;/span&gt;&#160;per share as determined by reference to the closing price reported
on the Nasdaq stock exchange on the date of exercise.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</avxl:EquityOfferingTextBlock>
    <avxl:ValueOfSharesObligatedToPurchase
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="-3"
      id="Fact000601"
      unitRef="USD">150000000</avxl:ValueOfSharesObligatedToPurchase>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000608"
      unitRef="Shares">927910</us-gaap:SharesIssued>
    <us-gaap:RedemptionPremium
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000610"
      unitRef="USD">9200000</us-gaap:RedemptionPremium>
    <avxl:ValueOfSharesObligatedToPurchase
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="-6"
      id="Fact000612"
      unitRef="USD">150000000.0</avxl:ValueOfSharesObligatedToPurchase>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      id="Fact000614"
      unitRef="Shares">75000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      id="Fact000616"
      unitRef="Shares">75000</avxl:StockIssuedDuringPeriodValueNewIssues1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="-3"
      id="Fact000618"
      unitRef="USD">150000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <avxl:FairValueOfInitialCommitment
      contextRef="AsOf2023-09-30"
      decimals="-5"
      id="Fact000620"
      unitRef="USD">800000</avxl:FairValueOfInitialCommitment>
    <avxl:IncurredExpenses
      contextRef="AsOf2023-09-30"
      decimals="-5"
      id="Fact000622"
      unitRef="USD">100000</avxl:IncurredExpenses>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockIncludingCommitmentSharesMember"
      decimals="INF"
      id="Fact000624"
      unitRef="Shares">2455646</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-10-012025-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockExcludingCommitmentSharesMember"
      decimals="INF"
      id="Fact000626"
      unitRef="Shares">2450000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-10-012025-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="-3"
      id="Fact000628"
      unitRef="USD">11300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-10-012025-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommitmentSharesMember"
      decimals="INF"
      id="Fact000630"
      unitRef="Shares">5646</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockIncludingCommitmentSharesMember"
      decimals="INF"
      id="Fact000632"
      unitRef="Shares">3288943</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockExcludingCommitmentSharesMember"
      decimals="INF"
      id="Fact000634"
      unitRef="Shares">3275000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:StockIssuedDuringPeriodValueNewIssues2
      contextRef="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="-5"
      id="Fact000636"
      unitRef="USD">27900000</avxl:StockIssuedDuringPeriodValueNewIssues2>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommitmentSharesMember"
      decimals="INF"
      id="Fact000638"
      unitRef="Shares">13943</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-10-012025-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="-5"
      id="Fact000640"
      unitRef="USD">110800000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-09-30_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000642"
      unitRef="Shares">217503</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-10-012025-09-30_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000644"
      unitRef="Shares">500000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000646"
      unitRef="USDPShares">0.92</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <avxl:CommonStockConsiderationExerciseShares
      contextRef="From2024-10-012025-09-30_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000648"
      unitRef="Shares">47745</avxl:CommonStockConsiderationExerciseShares>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="From2024-10-012025-09-30_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000650"
      unitRef="USDPShares">0.46</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
      contextRef="From2024-10-012025-09-30_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000652"
      unitRef="Shares">234752</us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1
      contextRef="From2024-10-012025-09-30_srt_ChiefExecutiveOfficerMember"
      decimals="-3"
      id="Fact000654"
      unitRef="USD">2300000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <avxl:MarketPrice
      contextRef="AsOf2025-09-30_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000656"
      unitRef="USDPShares">9.63</avxl:MarketPrice>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-09-30_srt_DirectorMember"
      decimals="INF"
      id="Fact000658"
      unitRef="Shares">38651</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-10-012025-09-30_srt_DirectorMember"
      decimals="INF"
      id="Fact000660"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_custom_BoardMember"
      decimals="INF"
      id="Fact000662"
      unitRef="USDPShares">1.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <avxl:CommonStockConsiderationExerciseShares
      contextRef="From2024-10-012025-09-30_srt_DirectorMember"
      decimals="-3"
      id="Fact000664"
      unitRef="Shares">11349000</avxl:CommonStockConsiderationExerciseShares>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1
      contextRef="From2024-10-012025-09-30_srt_DirectorMember"
      decimals="-3"
      id="Fact000666"
      unitRef="USD">88000000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <avxl:MarketPrice
      contextRef="AsOf2025-09-30_srt_DirectorMember"
      decimals="INF"
      id="Fact000668"
      unitRef="USDPShares">7.75</avxl:MarketPrice>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-09-30_custom_ChiefExecutiveOfficer1Member"
      decimals="INF"
      id="Fact000675"
      unitRef="Shares">42452</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-10-012025-09-30_custom_ChiefExecutiveOfficer1Member"
      decimals="INF"
      id="Fact000677"
      unitRef="Shares">187500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_custom_ChiefExecutiveOfficer1Member"
      decimals="INF"
      id="Fact000679"
      unitRef="USDPShares">5.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <avxl:CommonStockConsiderationExerciseShares
      contextRef="From2024-10-012025-09-30_custom_ChiefExecutiveOffice1rMember"
      decimals="INF"
      id="Fact000681"
      unitRef="Shares">98643</avxl:CommonStockConsiderationExerciseShares>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="From2024-10-012025-09-30_custom_ChiefExecutiveOfficer1Member"
      decimals="INF"
      id="Fact000683"
      unitRef="USDPShares">0.9</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
      contextRef="From2024-10-012025-09-30_custom_ChiefExecutiveOfficer1Member"
      decimals="INF"
      id="Fact000685"
      unitRef="Shares">46405</us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1
      contextRef="From2024-10-012025-09-30_custom_ChiefExecutiveOfficer1Member"
      decimals="-3"
      id="Fact000687"
      unitRef="USD">400000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <avxl:MarketPrice
      contextRef="AsOf2025-09-30_custom_ChiefExecutiveOfficer1Member"
      decimals="INF"
      id="Fact000689"
      unitRef="USDPShares">9.58</avxl:MarketPrice>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000691">&lt;p id="xdx_804_eus-gaap--CommitmentsDisclosureTextBlock_zalZYt2KeFV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 6	&lt;span id="xdx_82E_z9NKLvS885p2"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Lease&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
Company leases office space under an operating lease with an initial term of &lt;span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20250930_zG4Pg7b23bOh" title="Operating lease term"&gt;12&lt;/span&gt; months or less. Under the terms of the office lease, the
Company is required to pay its proportionate share of operating costs. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
operating lease costs were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--LeaseCostTableTextBlock_pn3n3_zLGK3MGNJdu8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8B4_zO1LJNj6anr4" style="display: none"&gt;Schedule of operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49A_20241001__20250930_zIJOpFzaZD61" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49E_20231001__20240930_zZipdRTLjkMb" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_491_20221001__20230930_z67COQZbK2se" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="font-weight: bold; text-align: center"&gt;Years ended September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseCost_zWMuXvMMUw3a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Operating lease costs&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;134&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;125&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;118&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zMgEw3HONocf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Employee 401(k) Benefit Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based
employees. United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the
Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing
employees. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
Company made matching contributions under the 401(k) plan as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_ze32GXQdn995" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8B9_zV9yNdYZC4wk" style="display: none"&gt;Schedule of contributions under the plan&lt;/span&gt;&lt;/td&gt;&lt;td style="color: black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_495_20241001__20250930_zOHLuBnpjGgk" style="color: black; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49C_20231001__20240930_zHvshI3hnLy" style="color: black; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49D_20221001__20230930_zjLfn9CR0Wtk" style="color: black; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="color: black; font-weight: bold; text-align: center"&gt;Years ended September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="color: black; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="color: black; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PensionContributions_z8DWIeNHh9s6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; color: black; text-align: left; text-indent: -10pt"&gt;Contributions to 401(k) plan&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;255&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;279&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;232&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zQ6RHsNUWttd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Litigation &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there
can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter
will not have a material adverse effect upon the Company&#x2019;s consolidated financial statements. The Company does not believe that
any of such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;On March 13,
2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York and it
named the Company and an officer of the Company as Defendants. The complaint was amended on July 12, 2024 (the &#x201c;Initial Action&#x201d;).
The complaint alleged violations of the Securities and Exchange Act of 1934 associated with disclosures and statements made with respect
to certain clinical trials for ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73 related to Rett syndrome. This lawsuit was dismissed by the United States District
Court for the Southern District of New York on June 18, 2025. The plaintiff filed a notice of appeal on July 17, 2025. Briefing on the
appeal concluded October 30, 2025. No decision has been entered. No amount has been recorded in these consolidated financial statements
for any loss contingencies associated with this lawsuit as the Company believes that it is not probable that any loss will occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;On May 8, 2024,
a similar complaint was filed in the same court by Kenneth Downing, a purported shareholder of the Company, against the same defendants.
The Company believed that this lawsuit was also without merit and filed a motion to dismiss the complaint. Plaintiff Downing voluntarily
dismissed this complaint subsequent to the filing of the motion to dismiss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;On or about
May 13, 2024, a derivative lawsuit was filed against the Company (as nominal defendant), an officer of the Company, and members of the
Company&#x2019;s Board of Directors in the U.S. District Court for the District of Nevada by another purported shareholder. The complaint
asserts various common law claims (including breach of fiduciary duty) and violation of Section 14(a)of the Securities Exchange Act regarding
the same or similar allegations at issue in the purported class action lawsuit related to disclosures and statements made about certain
clinical trials related to Rett &lt;span style="background-color: white"&gt;syndrome&lt;/span&gt;. On January 22, 2025, pursuant to a stipulation of the parties, the Court entered an order staying
this purported derivative lawsuit until the motion to dismiss filed by defendants in the Initial Action is decided by the U.S. District
Court for the Southern District of New York.&#160;The stay has been extended through the appeal. No amount has been recorded in these
consolidated financial statements for any loss contingencies associated with this lawsuit as the Company believes that it is not probable
that any loss will occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;On February
14, 2025, another derivative lawsuit asserting state law breach of fiduciary duty and unjust enrichment claims based upon similar allegations
was filed against the Company (as nominal defendant), an officer of the Company, and members of the Company&#x2019;s Board of Directors
in the Supreme Court for the State of New York, County of New York, by another purported shareholder. On August 18, 2025, pursuant to
a stipulation of the parties, the Court entered an order staying this purported derivative lawsuit until the appeal in the Initial Action
is resolved. No amount has been recorded in these consolidated financial statements for any loss contingencies associated with this lawsuit
as the Company believes that it is not probable that any loss will occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;We know of no
other material pending legal or governmental proceedings, other than ordinary routine litigation incidental to our business, to which
our Company or our subsidiaries are a party or of which any of their property is subject. There are no other proceedings in which any
of our directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, or any associate
of such persons, is an adverse party or has a material interest adverse to our or our subsidiaries&#x2019; interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Share Purchase Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2025 and 2024, the Company had &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pip0_c20250930_zo6jODIXnLS9" title="Warrants outstanding"&gt;10,000&lt;/span&gt;
share purchase warrants outstanding exercisable at $&lt;span id="xdx_90C_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_pip0_c20250930_zoHxLrcYIqDc" title="Warrants outstanding weighted average exercise price"&gt;12.00&lt;/span&gt; per share until April 21, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock&#x2013;based Compensation
Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2015 Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 18, 2015, the Company&#x2019;s Board approved
a 2015 Omnibus Incentive Plan (the &#x201c;2015 Plan&#x201d;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The maximum number of our common shares reserved for
issue under the plan was &lt;span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pip0_c20250930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zChHJPklfVAb" title="Maximum number of common shares reserved for future issuance"&gt;6,050,553&lt;/span&gt; shares, subject to adjustment in the event of a change of the Company&#x2019;s capitalization.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2019 Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#x201c;2019 Plan&#x201d;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The maximum number of our common shares reserved for
issue under the plan was &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20241001__20250930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_z5JvNOjJID3i" title="Additional shares of common stock available for issuance"&gt;6,000,000&lt;/span&gt; shares, subject to adjustment in the event of a change of the Company&#x2019;s capitalization.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended September 30, 2022, &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pip0_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zlCzeT2zmxN9" title="Option granted"&gt;406,453&lt;/span&gt;
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2022 Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#x201c;2022 Plan&#x201d;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20220324__20220325__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_ztuTolYVP7Dl" title="Additional shares of common stock available for issuance"&gt;10,000,000&lt;/span&gt; additional shares of Common Stock will be available for issuance under the plan, in addition to the shares available
under the 2019 Plan and the 2015 Plan. Any awards outstanding under a previous stock option plan will remain subject to and be paid under
such plan, and any shares subject to outstanding awards under a previous plan that subsequently cease to be subject to such awards (other
than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2022 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then
the exercise price shall not be less than 110% of fair market value of the Company&#x2019;s shares of common stock on the grant date. Stock
options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser
periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 17, 2025, the Board approved an amendment
to the 2022 Plan (the &#x201c;Amendment&#x201d;). The Amendment was approved by the stockholders on June 10, 2025. The Amendment increased
the number of shares of common stock reserved for issuance under the 2022 Plan by 4,000,000 shares for a total of&#160;&lt;span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20250417_zrhURZu8OwRh" title="Number of shares of common stock reserved for issuance"&gt;14,000,000&lt;/span&gt;. In
addition, the Amendment established a minimum vesting period of one year for all awards granted under the 2022 Plan and limited the discretion
to accelerate the vesting of awards upon a separation from service, with limited exceptions permitted. Finally, the Amendment prohibited
liberal share recycling provisions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2025, &lt;span id="xdx_907_ecustom--OptionIssued_pip0_c20241001__20250930_zf9Lq2z2KnQi" title="Option issued"&gt;6,504,829&lt;/span&gt; options had been
issued under the 2022 Plan and &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pip0_c20250930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_z2K8OoxsPTs7" title="Option available issue"&gt;8,436,882&lt;/span&gt; options were available for issue under the 2022 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following summarizes information about stock option
activity during the years ended September 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zMAuyzGA2ub8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BA_zE5YjSoz9rzc" style="display: none"&gt;Schedule of stock option activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: white; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: white; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: white; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted Average Exercise Price &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted Average Grant Date Fair Value &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate intrinsic value &lt;br/&gt; ($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 44%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrDrKVnujtdg" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Number of options, Outstanding beginning balance"&gt;15,037,754&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3ZDZFyqWmI6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average exercise price, Outstanding beginning balance"&gt;6.80&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsE1B6uFOVd5" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average grant date fair value, Outstanding beginning balance"&gt;5.12&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1errfXlh8Yg" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Aggregate intrinsic value, Outstanding beginning balance"&gt;15,825,791&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAYcb0woC0k3" style="text-align: right" title="Number of options, Granted"&gt;1,488,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMNxguD2E3j5" style="text-align: right" title="Weighted average exercise price, Granted"&gt;8.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: white; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znhJQVsdiI8d" style="text-align: right" title="Weighted average grant date fair value, Granted"&gt;6.22&lt;/td&gt;&lt;td style="color: white; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zybc6fWFW7ha" style="text-align: right" title="Number of options, Expired"&gt;(100,100&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfJ264tHNym7" style="text-align: right" title="Weighted average exercise price, Expired"&gt;16.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKTyWPdQWJcf" style="text-align: right" title="Number of options, Exercised"&gt;(1,383,988&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsXbjubtAJjb" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;3.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: white; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfcBnIF9bMaj" style="text-align: right" title="Weighted average grant date fair value, Exercised"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt; &lt;span style="font-size: 10pt"&gt;1.31&lt;/span&gt;&lt;/td&gt;&lt;td style="color: white; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzfG4883Xg2g" style="text-align: right" title="Aggregate intrinsic value, Exercised"&gt;9,324,901&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFBlpfLp5kQe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Forfeited"&gt;(80,583&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfjSLbhDqvtl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited"&gt;4.56&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5ObKFMoJrWc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Forfeited"&gt;0.55&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z19ucprLcgS7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Outstanding ending balance"&gt;14,961,583&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zV9rYvQy4sud" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Outstanding ending balance"&gt;7.25&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1rKyhJroJkc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Outstanding ending balance"&gt;5.46&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z344IAKZum9l" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, Outstanding ending balance"&gt;39,715,608&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercisable, September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zPQI44vUCf11" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Exercisable"&gt;10,418,213&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoSubcAxPJQk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable"&gt;6.22&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsFc6cCSWnW3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Exercisable"&gt;4.83&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbEMxWQ89kt1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Exercisable"&gt;34,762,588&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zeMQOFGsKuK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following summarizes information about stock options
at September 30, 2025 by a range of exercise prices:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zZvFeODwATQj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_8B3_zXiu7b3JvkEl" style="display: none"&gt;Schedule of summarizes information about stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Range of exercises prices&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of outstanding&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted average remaining contractual life&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted average exercise&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of vested&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted average exercise&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;From&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;To&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;options&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;(in years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;options&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zxYN7hHqR4B9" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Range of exercise prices, Lower range limit"&gt;2.30&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zsqM0silFxBa" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Range of exercise prices, Upper range limit"&gt;5.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zhkFOTBe0x44" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of outstanding options"&gt;4,315,700&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zsBDyLEeDv1g" title="Weighted average remaining contractual life"&gt;3.15&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zmX1s7evjBc3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price"&gt;3.02&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zxNeCJnLt3Ek" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of vested options"&gt;4,220,283&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zWWJ8Ja45XEc" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price options vested"&gt;2.99&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zXqfKH8v7tB4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit"&gt;5.01&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_ztKJ50TDZAaa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit"&gt;7.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zwtchAcDnVy5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options"&gt;3,299,536&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zOD4KFHqLWFc" title="Weighted average remaining contractual life"&gt;5.23&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zMXVApfwnbye" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"&gt;5.62&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z6QnwWX4Ditg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options"&gt;2,325,162&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zZAVuBEYr4gh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested"&gt;5.72&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zUht1UO2aex1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit"&gt;7.01&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zfqeQDM5ew0f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit"&gt;9.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z2UPuVTMYFS3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options"&gt;4,372,347&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zTKSmHCQIUel" title="Weighted average remaining contractual life"&gt;6.66&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zbO88lQNtoPj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"&gt;8.09&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z5M04ry9PRAj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options"&gt;2,222,101&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z2qn76qyieRk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested"&gt;7.82&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_znVh8X6kNeCj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit"&gt;9.01&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z3RjfNfj6a07" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit"&gt;13.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_ziNfLlIh6zNi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options"&gt;1,609,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zZiMFdT9M54l" title="Weighted average remaining contractual life"&gt;6.31&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zMJwqgNnrXte" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"&gt;10.29&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zlxWmYRpuc35" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options"&gt;1,120,667&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zzv1vXIqLBue" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested"&gt;10.37&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z1WTTJpPSKbb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit"&gt;13.01&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zH4K4ZLjlZC8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit"&gt;25.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z7on3N9dOCcc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options"&gt;1,365,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zT4jk8nQvG57" title="Weighted average remaining contractual life"&gt;5.91&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zktkXtOXgkH9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"&gt;18.33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zY3g27ILay83" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options"&gt;530,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zBp15L52zgqg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested"&gt;18.67&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z88YIicqOvj6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options"&gt;14,961,583&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBaB9MhtDPrb" title="Weighted average remaining contractual life"&gt;5.22&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBXUBkfD88Fb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"&gt;7.25&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNZ6TnWEEXM8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options"&gt;10,418,213&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6okIJiIgxGk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested"&gt;6.22&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AB_zwUrGWiovHth" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The weighted average per share fair value of options
vested at September 30, 2025 was $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20241001__20250930_zXe09v8Nrp0g" title="Weighted average grant date fair value of options vested"&gt;4.83&lt;/span&gt; (2024: $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20231001__20240930_zDmfeLFZWZXg" title="Weighted average grant date fair value of options vested"&gt;4.34&lt;/span&gt;; 2023: $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20221001__20230930_zimoxsiShoF5" title="Weighted average grant date fair value of options vested"&gt;3.94&lt;/span&gt;). At September 30, 2025, the weighted average contractual life of options
outstanding was &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930_zEqoepsiaxR1" title="Weighted average contractual life of options outstanding"&gt;5.22&lt;/span&gt; years (2024: &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930_zE1fHsCVaO78" title="Weighted average contractual life of options outstanding"&gt;5.48&lt;/span&gt; years; 2023: &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230930_zOkLtOJoSRe2" title="Weighted average contractual life of options outstanding"&gt;6.0&lt;/span&gt; years) and for options exercisable was &lt;span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930_zpMC8suFkDw" title="Options exercisable"&gt;4.11&lt;/span&gt; years (2024: &lt;span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930_zyZwf0KNFeDh" title="Options exercisable"&gt;4.03&lt;/span&gt; years; 2023: &lt;span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230930_zLZyD2LSSVWd" title="Options exercisable"&gt;4.75&lt;/span&gt;
years).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#x2019;s stock for the options
that were in-the-money at September 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;	The Company recognized share-based compensation
expense of $&lt;span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20241001__20250930_zZUO3WW2hmof" title="Share based compensation"&gt;11.5&lt;/span&gt; million during the year ended September 30, 2025 (2024: $&lt;span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20231001__20240930_zSG8NjUafQmc" title="Share based compensation"&gt;9.4&lt;/span&gt; million; 2023: $&lt;span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20221001__20230930_zItd0E1Ahml4" title="Share based compensation"&gt;16.4&lt;/span&gt; million) in connection with the issuance
and vesting 	of stock options in exchange for services. These amounts have been included in general and 	administrative expenses
and research and development expenses on the Company&#x2019;s consolidated statements of 	operations as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zy1ul9YLEJZ4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B6_znpz9vQT6TPl" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="font-weight: bold; text-align: center"&gt;Years ended September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zMMfe5cVuu5c" style="width: 11%; text-align: right" title="Total share based compensation"&gt;4,536&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHWirUELtqqe" style="width: 11%; text-align: right" title="Total share based compensation"&gt;3,625&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zFn7iKSnTNkg" style="width: 11%; text-align: right" title="Total share based compensation"&gt;5,558&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zaiJwxtkDUMe" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;7,013&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zqLuPraCrmB6" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;5,813&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zr4kWOUUKPc6" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;10,812&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total share-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930_zI3bl7GkOB54" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;11,549&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930_zjWKBnIfnP51" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;9,438&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930_zViBeqdRp5qj" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;16,370&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A9_zjfcyIweY4yh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;An amount of approximately $&lt;span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20250930_z6RQETTxpAQ2" title="Remaining stock based compensation"&gt;6.3&lt;/span&gt; million in share-based
compensation is expected to be recorded over the remaining term 	of such options and warrants through fiscal 2029.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;The fair value of each option and
warrant award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_zkFvazW9RlF" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BB_zs6JLQseyw75" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20241001__20250930_zvlq3707ODsh" title="Risk-free interest rate"&gt;3.98&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20231001__20240930_znVjDE6iMPAf" title="Risk-free interest rate"&gt;4.28&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20221001__20230930_zRhCY04Mi2y2" title="Risk-free interest rate"&gt;3.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20241001__20250930_zaWkTo9C2cj2" title="Expected life of options (years)"&gt;5.57&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240930_zBB0jUO5Ejr" title="Expected life of options (years)"&gt;5.78&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230930_zspTKYDKT6Ee" title="Expected life of options (years)"&gt;5.64&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20241001__20250930_zRD3GocNYn87" title="Annualized volatility"&gt;86.49&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20231001__20240930_zJlr6T9OaP24" title="Annualized volatility"&gt;84.81&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20221001__20230930_zoZva1sCuFIk" title="Annualized volatility"&gt;85.13&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20241001__20250930_z6KTW8JNaUX9" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20231001__20240930_zaiICJexi8Ml" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20221001__20230930_z3tTbZw1FGa8" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zyyYVoRU9ir3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of stock compensation charges recognized
during the years ended September 30, 2025, 2024 and 2023 was determined with reference to the quoted market price of the Company&#x2019;s
shares on the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;














</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2025-09-30" id="Fact000693">P12M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000695">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--LeaseCostTableTextBlock_pn3n3_zLGK3MGNJdu8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8B4_zO1LJNj6anr4" style="display: none"&gt;Schedule of operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49A_20241001__20250930_zIJOpFzaZD61" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49E_20231001__20240930_zZipdRTLjkMb" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_491_20221001__20230930_z67COQZbK2se" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="font-weight: bold; text-align: center"&gt;Years ended September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseCost_zWMuXvMMUw3a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Operating lease costs&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;134&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;125&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;118&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000697"
      unitRef="USD">134000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000698"
      unitRef="USD">125000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000699"
      unitRef="USD">118000</us-gaap:OperatingLeaseCost>
    <us-gaap:DefinedContributionPlanDisclosuresTableTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000701">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_ze32GXQdn995" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8B9_zV9yNdYZC4wk" style="display: none"&gt;Schedule of contributions under the plan&lt;/span&gt;&lt;/td&gt;&lt;td style="color: black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_495_20241001__20250930_zOHLuBnpjGgk" style="color: black; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49C_20231001__20240930_zHvshI3hnLy" style="color: black; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49D_20221001__20230930_zjLfn9CR0Wtk" style="color: black; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="color: black; font-weight: bold; text-align: center"&gt;Years ended September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="color: black; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="color: black; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PensionContributions_z8DWIeNHh9s6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; color: black; text-align: left; text-indent: -10pt"&gt;Contributions to 401(k) plan&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;255&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;279&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;232&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DefinedContributionPlanDisclosuresTableTextBlock>
    <us-gaap:PensionContributions
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000703"
      unitRef="USD">255000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000704"
      unitRef="USD">279000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000705"
      unitRef="USD">232000</us-gaap:PensionContributions>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000712"
      unitRef="Shares">10000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <avxl:WarrantsOutstandingWeightedAverageExercise
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000714"
      unitRef="USDPShares">12.00</avxl:WarrantsOutstandingWeightedAverageExercise>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2025-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      id="Fact000716"
      unitRef="Shares">6050553</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2024-10-012025-09-30_custom_StockOptionPlan2019Member"
      decimals="INF"
      id="Fact000723"
      unitRef="Shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-10-012022-09-30_custom_StockOptionPlan2022Member"
      decimals="INF"
      id="Fact000725"
      unitRef="Shares">406453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2022-03-242022-03-25_custom_StockOptionPlan2022Member"
      decimals="INF"
      id="Fact000727"
      unitRef="Shares">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2025-04-17"
      decimals="INF"
      id="Fact000729"
      unitRef="Shares">14000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <avxl:OptionIssued
      contextRef="From2024-10-01to2025-09-30"
      decimals="INF"
      id="Fact000731"
      unitRef="Shares">6504829</avxl:OptionIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-09-30_custom_StockOptionPlan2022Member"
      decimals="INF"
      id="Fact000733"
      unitRef="Shares">8436882</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000735">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zMAuyzGA2ub8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BA_zE5YjSoz9rzc" style="display: none"&gt;Schedule of stock option activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: white; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: white; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: white; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted Average Exercise Price &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted Average Grant Date Fair Value &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate intrinsic value &lt;br/&gt; ($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 44%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrDrKVnujtdg" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Number of options, Outstanding beginning balance"&gt;15,037,754&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3ZDZFyqWmI6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average exercise price, Outstanding beginning balance"&gt;6.80&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsE1B6uFOVd5" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average grant date fair value, Outstanding beginning balance"&gt;5.12&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1errfXlh8Yg" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Aggregate intrinsic value, Outstanding beginning balance"&gt;15,825,791&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAYcb0woC0k3" style="text-align: right" title="Number of options, Granted"&gt;1,488,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMNxguD2E3j5" style="text-align: right" title="Weighted average exercise price, Granted"&gt;8.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: white; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znhJQVsdiI8d" style="text-align: right" title="Weighted average grant date fair value, Granted"&gt;6.22&lt;/td&gt;&lt;td style="color: white; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zybc6fWFW7ha" style="text-align: right" title="Number of options, Expired"&gt;(100,100&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfJ264tHNym7" style="text-align: right" title="Weighted average exercise price, Expired"&gt;16.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKTyWPdQWJcf" style="text-align: right" title="Number of options, Exercised"&gt;(1,383,988&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsXbjubtAJjb" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;3.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: white; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfcBnIF9bMaj" style="text-align: right" title="Weighted average grant date fair value, Exercised"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt; &lt;span style="font-size: 10pt"&gt;1.31&lt;/span&gt;&lt;/td&gt;&lt;td style="color: white; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzfG4883Xg2g" style="text-align: right" title="Aggregate intrinsic value, Exercised"&gt;9,324,901&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFBlpfLp5kQe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Forfeited"&gt;(80,583&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfjSLbhDqvtl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited"&gt;4.56&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5ObKFMoJrWc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Forfeited"&gt;0.55&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z19ucprLcgS7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Outstanding ending balance"&gt;14,961,583&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zV9rYvQy4sud" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Outstanding ending balance"&gt;7.25&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1rKyhJroJkc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Outstanding ending balance"&gt;5.46&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z344IAKZum9l" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, Outstanding ending balance"&gt;39,715,608&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercisable, September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zPQI44vUCf11" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Exercisable"&gt;10,418,213&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoSubcAxPJQk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable"&gt;6.22&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsFc6cCSWnW3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Exercisable"&gt;4.83&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbEMxWQ89kt1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Exercisable"&gt;34,762,588&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000737"
      unitRef="Shares">15037754</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000739"
      unitRef="USDPShares">6.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000741"
      unitRef="USDPShares">5.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000743"
      unitRef="USD">15825791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000745"
      unitRef="Shares">1488500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000747"
      unitRef="USDPShares">8.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000749"
      unitRef="USDPShares">6.22</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000751"
      unitRef="Shares">100100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000753"
      unitRef="USDPShares">16.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000755"
      unitRef="Shares">1383988</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000757"
      unitRef="USDPShares">3.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000759"
      unitRef="USDPShares">1.31</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000761"
      unitRef="USD">9324901</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000763"
      unitRef="Shares">80583</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000765"
      unitRef="USDPShares">4.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000767"
      unitRef="USDPShares">0.55</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000769"
      unitRef="Shares">14961583</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000771"
      unitRef="USDPShares">7.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000773"
      unitRef="USDPShares">5.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000775"
      unitRef="USD">39715608</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000777"
      unitRef="Shares">10418213</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000779"
      unitRef="USDPShares">6.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000781"
      unitRef="USDPShares">4.83</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000783"
      unitRef="USD">34762588</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000790">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zZvFeODwATQj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_8B3_zXiu7b3JvkEl" style="display: none"&gt;Schedule of summarizes information about stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Range of exercises prices&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of outstanding&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted average remaining contractual life&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted average exercise&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of vested&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted average exercise&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;From&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;To&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;options&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;(in years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;options&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zxYN7hHqR4B9" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Range of exercise prices, Lower range limit"&gt;2.30&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zsqM0silFxBa" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Range of exercise prices, Upper range limit"&gt;5.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zhkFOTBe0x44" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of outstanding options"&gt;4,315,700&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zsBDyLEeDv1g" title="Weighted average remaining contractual life"&gt;3.15&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zmX1s7evjBc3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price"&gt;3.02&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zxNeCJnLt3Ek" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of vested options"&gt;4,220,283&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zWWJ8Ja45XEc" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price options vested"&gt;2.99&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zXqfKH8v7tB4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit"&gt;5.01&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_ztKJ50TDZAaa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit"&gt;7.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zwtchAcDnVy5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options"&gt;3,299,536&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zOD4KFHqLWFc" title="Weighted average remaining contractual life"&gt;5.23&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zMXVApfwnbye" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"&gt;5.62&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z6QnwWX4Ditg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options"&gt;2,325,162&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zZAVuBEYr4gh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested"&gt;5.72&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zUht1UO2aex1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit"&gt;7.01&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zfqeQDM5ew0f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit"&gt;9.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z2UPuVTMYFS3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options"&gt;4,372,347&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zTKSmHCQIUel" title="Weighted average remaining contractual life"&gt;6.66&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zbO88lQNtoPj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"&gt;8.09&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z5M04ry9PRAj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options"&gt;2,222,101&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z2qn76qyieRk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested"&gt;7.82&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_znVh8X6kNeCj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit"&gt;9.01&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z3RjfNfj6a07" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit"&gt;13.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_ziNfLlIh6zNi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options"&gt;1,609,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zZiMFdT9M54l" title="Weighted average remaining contractual life"&gt;6.31&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zMJwqgNnrXte" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"&gt;10.29&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zlxWmYRpuc35" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options"&gt;1,120,667&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zzv1vXIqLBue" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested"&gt;10.37&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z1WTTJpPSKbb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit"&gt;13.01&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zH4K4ZLjlZC8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit"&gt;25.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z7on3N9dOCcc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options"&gt;1,365,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zT4jk8nQvG57" title="Weighted average remaining contractual life"&gt;5.91&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zktkXtOXgkH9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"&gt;18.33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zY3g27ILay83" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options"&gt;530,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zBp15L52zgqg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested"&gt;18.67&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z88YIicqOvj6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options"&gt;14,961,583&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBaB9MhtDPrb" title="Weighted average remaining contractual life"&gt;5.22&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBXUBkfD88Fb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"&gt;7.25&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNZ6TnWEEXM8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options"&gt;10,418,213&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6okIJiIgxGk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested"&gt;6.22&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000792"
      unitRef="USDPShares">2.30</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000794"
      unitRef="USDPShares">5.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000796"
      unitRef="Shares">4315700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      id="Fact000798">P3Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000800"
      unitRef="USDPShares">3.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000802"
      unitRef="Shares">4220283</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000804"
      unitRef="USDPShares">2.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000806"
      unitRef="USDPShares">5.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000808"
      unitRef="USDPShares">7.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000810"
      unitRef="Shares">3299536</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      id="Fact000812">P5Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000814"
      unitRef="USDPShares">5.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000816"
      unitRef="Shares">2325162</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000818"
      unitRef="USDPShares">5.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000820"
      unitRef="USDPShares">7.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000822"
      unitRef="USDPShares">9.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000824"
      unitRef="Shares">4372347</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      id="Fact000826">P6Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000828"
      unitRef="USDPShares">8.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000830"
      unitRef="Shares">2222101</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000832"
      unitRef="USDPShares">7.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000834"
      unitRef="USDPShares">9.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000836"
      unitRef="USDPShares">13.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000838"
      unitRef="Shares">1609000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      id="Fact000840">P6Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000842"
      unitRef="USDPShares">10.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000844"
      unitRef="Shares">1120667</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000846"
      unitRef="USDPShares">10.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000848"
      unitRef="USDPShares">13.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000850"
      unitRef="USDPShares">25.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000852"
      unitRef="Shares">1365000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      id="Fact000854">P5Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000856"
      unitRef="USDPShares">18.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000858"
      unitRef="Shares">530000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000860"
      unitRef="USDPShares">18.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000862"
      unitRef="Shares">14961583</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember"
      id="Fact000864">P5Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000866"
      unitRef="USDPShares">7.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-10-012025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000868"
      unitRef="Shares">10418213</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000870"
      unitRef="USDPShares">6.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-10-01to2025-09-30"
      decimals="INF"
      id="Fact000872"
      unitRef="USDPShares">4.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-10-012024-09-30"
      decimals="INF"
      id="Fact000874"
      unitRef="USDPShares">4.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-10-012023-09-30"
      decimals="INF"
      id="Fact000876"
      unitRef="USDPShares">3.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2024-10-01to2025-09-30" id="Fact000878">P5Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-10-012024-09-30" id="Fact000880">P5Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012023-09-30" id="Fact000882">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2024-10-01to2025-09-30" id="Fact000884">P4Y1M9D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2023-10-012024-09-30" id="Fact000886">P4Y10D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012023-09-30" id="Fact000888">P4Y9M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-10-01to2025-09-30"
      decimals="-5"
      id="Fact000890"
      unitRef="USD">11500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-10-012024-09-30"
      decimals="-5"
      id="Fact000892"
      unitRef="USD">9400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-10-012023-09-30"
      decimals="-5"
      id="Fact000894"
      unitRef="USD">16400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000896">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zy1ul9YLEJZ4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B6_znpz9vQT6TPl" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="font-weight: bold; text-align: center"&gt;Years ended September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zMMfe5cVuu5c" style="width: 11%; text-align: right" title="Total share based compensation"&gt;4,536&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHWirUELtqqe" style="width: 11%; text-align: right" title="Total share based compensation"&gt;3,625&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zFn7iKSnTNkg" style="width: 11%; text-align: right" title="Total share based compensation"&gt;5,558&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zaiJwxtkDUMe" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;7,013&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zqLuPraCrmB6" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;5,813&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zr4kWOUUKPc6" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;10,812&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total share-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930_zI3bl7GkOB54" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;11,549&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930_zjWKBnIfnP51" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;9,438&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930_zViBeqdRp5qj" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;16,370&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-10-012025-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact000898"
      unitRef="USD">4536000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact000900"
      unitRef="USD">3625000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact000902"
      unitRef="USD">5558000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-10-012025-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000904"
      unitRef="USD">7013000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000906"
      unitRef="USD">5813000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000908"
      unitRef="USD">10812000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000910"
      unitRef="USD">11549000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000912"
      unitRef="USD">9438000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000914"
      unitRef="USD">16370000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2025-09-30"
      decimals="-5"
      id="Fact000916"
      unitRef="USD">6300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <avxl:ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000918">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_zkFvazW9RlF" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BB_zs6JLQseyw75" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20241001__20250930_zvlq3707ODsh" title="Risk-free interest rate"&gt;3.98&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20231001__20240930_znVjDE6iMPAf" title="Risk-free interest rate"&gt;4.28&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20221001__20230930_zRhCY04Mi2y2" title="Risk-free interest rate"&gt;3.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20241001__20250930_zaWkTo9C2cj2" title="Expected life of options (years)"&gt;5.57&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240930_zBB0jUO5Ejr" title="Expected life of options (years)"&gt;5.78&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230930_zspTKYDKT6Ee" title="Expected life of options (years)"&gt;5.64&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20241001__20250930_zRD3GocNYn87" title="Annualized volatility"&gt;86.49&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20231001__20240930_zJlr6T9OaP24" title="Annualized volatility"&gt;84.81&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20221001__20230930_zoZva1sCuFIk" title="Annualized volatility"&gt;85.13&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20241001__20250930_z6KTW8JNaUX9" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20231001__20240930_zaiICJexi8Ml" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20221001__20230930_z3tTbZw1FGa8" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</avxl:ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-10-01to2025-09-30"
      decimals="INF"
      id="Fact000920"
      unitRef="Ratio">0.0398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-10-012024-09-30"
      decimals="INF"
      id="Fact000922"
      unitRef="Ratio">0.0428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-10-012023-09-30"
      decimals="INF"
      id="Fact000924"
      unitRef="Ratio">0.0370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2024-10-01to2025-09-30" id="Fact000926">P5Y6M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-10-012024-09-30" id="Fact000928">P5Y9M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-10-012023-09-30" id="Fact000930">P5Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-10-01to2025-09-30"
      decimals="INF"
      id="Fact000932"
      unitRef="Ratio">0.8649</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-10-012024-09-30"
      decimals="INF"
      id="Fact000934"
      unitRef="Ratio">0.8481</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-10-012023-09-30"
      decimals="INF"
      id="Fact000936"
      unitRef="Ratio">0.8513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-10-01to2025-09-30"
      decimals="INF"
      id="Fact000938"
      unitRef="Ratio">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-10-012024-09-30"
      decimals="INF"
      id="Fact000940"
      unitRef="Ratio">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-10-012023-09-30"
      decimals="INF"
      id="Fact000942"
      unitRef="Ratio">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000949">&lt;p id="xdx_80C_eus-gaap--IncomeTaxDisclosureTextBlock_ziHkRR5Bh728" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 7	 	&lt;span id="xdx_82F_zCiWeAJSiPml"&gt;Income Taxes &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s U.S. and foreign losses before income
taxes are set forth below (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_pn3n3_zgKs5dfVY5l5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_zzFnLgkQPPoi" style="display: none"&gt;Schedule of loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20241001__20250930_z5MJb7OW8u69" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20231001__20240930_zFTtjaLIsDAh" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20221001_20230930" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;United States&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(44,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(39,195&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(41,198&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,877&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,807&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(6,300&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(46,377&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(43,002&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(47,498&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zV0AvDCRTxC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the years ended September 30, 2025, 2024 and 2023, there were no
current or deferred income tax provisions (benefits) for any U.S. federal, state &amp;amp; local, and foreign jurisdictions. The components
of net deferred income tax assets as of September 30, 2025 and 2024 are as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_z6GPFZ33krw8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt"&gt;Schedule of components of net deferred income tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20250930_zOY5k9iTWpFk" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20240930_zjQgJ3N6VP5j" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;54,752&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;48,134&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development tax credit carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,288&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,185&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,091&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsResearchAndDevelopmentCapitalization_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development capitalization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,737&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Unpaid charges&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,843&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,197&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Intangible asset costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;946&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;758&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ForeignExchangeAndOther_iNI_pn3n3_di_zOVd3Vxooh6e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Foreign exchange and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(259&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(254&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_zYf0Q9J5VkZ4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Valuation allowance of deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(108,492&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(92,233&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0991"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0992"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zN93NJrimqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A reconciliation of income tax expense at the statutory
federal income tax rate and income taxes as reflected in the consolidated financial statements for the years ended September 30, 2025,
2024 and 2023 is as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_pn3n3_z4dOHPfPkGL9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B0_zKPJn14YVjM9" style="display: none"&gt;Schedule of reconciliation of income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20241001__20250930_zHrqqR1Sedf8" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20231001__20240930_z8d0FFMP0se1" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20221001__20230930_znWxur4eJxqc" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Income tax benefit at statutory federal rate&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(9,739&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(9,030&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(9,975&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Foreign income taxed at other rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1000"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(61&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1002"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--PermanentDifferencesRelatingToStockBasedCompensation_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Permanent differences relating to share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,219&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(601&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationGiltiAmount_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Permanent differences relating to GILTI inclusion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1008"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1009"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;130&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(276&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development credits, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(941&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(860&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(37&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;State and local taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,672&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,821&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,122&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Adjustment to true up to prior years&#x2019; tax provision&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;182&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,128&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance_zahCpujyiQi2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Change in valuation allowances&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;16,259&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,186&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;14,098&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1032"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1033"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zs7Ty23yYUHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2025, the Company had U.S. federal
net operating loss carryforwards of approximately $&lt;span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_pn5n6_c20250930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zIT809G1wVXi" title="Operating loss carryforwards"&gt;148.8&lt;/span&gt; million (2024: $&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_pn5n6_c20240930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zDDBNxm6IMIh" title="Operating loss carryforwards"&gt;128.5&lt;/span&gt; million) of which &lt;span id="xdx_903_ecustom--OperatingLossCarryforwardsDescription_c20241001__20250930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_z6ZDzmnCuXh1" title="Operating loss carryforwards description"&gt;$37.7&lt;/span&gt; million will begin to expire in
2026 and $111.2 million can be carried forward indefinitely, state and local net operating loss carryforwards of approximately $ &lt;span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_pn5n6_c20250930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z3WXKe40ojNj" title="Operating loss carryforwards"&gt;19.1&lt;/span&gt;
million (2024: $&lt;span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_pn5n6_c20240930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zj8nZX6iACK" title="Operating loss carryforwards"&gt;16.9&lt;/span&gt; million) which will begin to expire in &lt;span id="xdx_901_ecustom--OperatingLossCarryForwardsExpirationYear_c20241001__20250930_zxVIrL1KmEI" title="Operating loss carry forwards expiration year"&gt;2036&lt;/span&gt;, and Research and Development tax credits of approximately $&lt;span id="xdx_90B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_pn5n6_c20241001__20250930_zq9QfxYlsJu5" title="Research and Development tax credits"&gt;5.3&lt;/span&gt; million
(2024: $&lt;span id="xdx_90A_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20221001__20230930_pn5n6" title="Research and Development tax credits"&gt;4.3&lt;/span&gt; million) which will begin to expire in &lt;span id="xdx_906_ecustom--ResearchAndDevelopmentTaxCreditsYear_c20241001__20250930_zvGoZpeSY8g1" title="Research and development tax credits year"&gt;2029&lt;/span&gt;. The calculation of the Research and Development tax credits, by their nature,
involve estimates and subjectivity. If examined by the U.S. federal and state tax authorities, it is possible that some portion of these
credit carryforwards would be disputed by the tax authorities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company had approximately $&lt;span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_pn5n6_c20250930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zsNPX58GEVUg" title="Operating loss carryforwards"&gt;17.1&lt;/span&gt; million (approximately
AU$&lt;span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_pn5n6_c20250930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_z4k1lkTZXCJh" title="Operating loss carryforwards"&gt;25.9&lt;/span&gt; million) (2024: $&lt;span id="xdx_900_eus-gaap--OperatingLossCarryforwards_pn5n6_c20240930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zx7knFevFoXe" title="Operating loss carryforwards"&gt;16.6&lt;/span&gt; million (approximately AU$&lt;span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_pn5n6_c20240930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_znwFH72WmEX9" title="Operating loss carryforwards"&gt;23.9&lt;/span&gt; million)) of net operating loss carryforwards in Australia, which have an
indefinite life, available to offset future taxable income in those jurisdictions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates its valuation allowance
requirements based on available evidence. When circumstances change, and this causes a change in management&#x2019;s judgment about
the recoverability of deferred tax assets, the impact of the change on the valuation allowance is reflected in current income.
Because management of the Company does not currently believe that it is more likely than not that the Company will receive the
benefit of these assets, a full valuation allowance has been established at September 30, 2025 and 2024. During the year ended
September 30, 2025, the valuation allowance increased by $&lt;span id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20241001__20250930_z9rGW6yiJXwa" title="Decrease in valuation allowance"&gt;16.3&lt;/span&gt;
million (2024: $&lt;span id="xdx_907_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20231001__20240930_zYd0Viq4W3rd" title="Decrease in valuation allowance"&gt;15.2&lt;/span&gt;
million; 2023: $&lt;span id="xdx_90B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20221001__20230930_zQg4RSi4E1N2" title="Decrease in valuation allowance"&gt;14.1&lt;/span&gt;
million).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Tax Cuts and Jobs Act of 2017 (TCJA) has
modified the treatment of IRC 174 expenses related to research and development for tax years beginning after December 31, 2021.
Under the TCJA, the Company must capitalize the expenditures related to research and development activities and amortize them over
 5 years for U.S. activities and over 15 years for non-U.S. activities using a mid-year convention. Therefore, the capitalization of
research and development costs in accordance with IRC 174 has resulted in a net deferred tax assets at September 30, 2025 of $&lt;span id="xdx_901_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_dm_c20250930_z5eSnKSjyeR3" title="Gross deferred tax asset"&gt;20.7&lt;/span&gt;
million (2024: $&lt;span id="xdx_900_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_dm_c20240930_zPXHgII3Xyia" title="Gross deferred tax asset"&gt;15.1&lt;/span&gt;
million). On July 4, 2025, the United States President signed into law the One Big Beautiful Bill Act (&#x201c;OBBBA&#x201d;), a
budget reconciliation package that changes many key provisions of the U.S. federal income tax code, including extensions of various
expiring provisions from the TCJA. The new legislation, which will be effective for the Company beginning in fiscal 2026, will now
allow for more tax-payer favorable treatment of domestic research and development expenditures for US income tax purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Uncertain Tax Positions&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company files income tax returns in the U.S. federal
jurisdiction and various state and local and foreign jurisdictions. The Company&#x2019;s tax returns are subject to tax examinations by
U.S. federal and state tax authorities, or examinations by foreign tax authorities until the respective statutes of limitation expire.
The Company is subject to tax examinations by tax authorities for all taxation years commencing on or after 2005.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under the provisions of the Internal Revenue Code,
the net operating loss (&#x201c;NOL&#x201d;) carryforwards are subject to review and possible adjustment by the Internal Revenue Service
and state tax authorities. Under Section 382 of the Internal Revenue Code, NOL and tax credit carryforwards may become subject to an annual
limitation in the event of an over 50% cumulative change in the ownership interest of significant stockholders over a three-year period,
as well as similar state tax provisions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company conducts a Section 382 study annually
and has reduced its federal NOLs by $&lt;span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20250930_zHiwV7YXLFM7" title="Operating loss carryforwards"&gt;12.1&lt;/span&gt; million and its Research and Development tax credit carryforwards by $&lt;span id="xdx_902_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_dm_c20250930_zz1wK7r4ljPf" title="Research and development tax credit carryforwards"&gt;0.8&lt;/span&gt; million, which are
the amount of tax assets that will expire unutilized pursuant to Section 382. Subsequent ownership changes in future years could trigger
additional limitations of the Company&#x2019;s NOLs&lt;span style="background-color: white"&gt;. During the year ended September 30, 2025, the
Company determined that there were no changes in ownership pursuant to Section 382.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2025, the Company did not provide
any foreign withholding taxes related to its foreign subsidiaries&#x2019; undistributed earnings, as such earnings have been retained and
are intended to be indefinitely reinvested to fund ongoing operations of the foreign subsidiaries. It is not practicable to estimate the
amount of taxes that would be payable upon remittance of these earnings, because such tax, if any, is dependent upon circumstances existing
if and when remittance occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2025 and 2024, the Company had determined that no liabilities
for uncertain tax positions, interest or penalties were required to be recorded.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000951">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_pn3n3_zgKs5dfVY5l5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_zzFnLgkQPPoi" style="display: none"&gt;Schedule of loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20241001__20250930_z5MJb7OW8u69" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20231001__20240930_zFTtjaLIsDAh" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20221001_20230930" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;United States&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(44,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(39,195&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(41,198&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,877&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,807&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(6,300&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(46,377&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(43,002&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(47,498&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000953"
      unitRef="USD">-44500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000954"
      unitRef="USD">-39195000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000955"
      unitRef="USD">-41198000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000957"
      unitRef="USD">-1877000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000958"
      unitRef="USD">-3807000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000959"
      unitRef="USD">-6300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000961"
      unitRef="USD">-46377000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000962"
      unitRef="USD">-43002000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000963"
      unitRef="USD">-47498000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000965">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_z6GPFZ33krw8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt"&gt;Schedule of components of net deferred income tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20250930_zOY5k9iTWpFk" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20240930_zjQgJ3N6VP5j" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;54,752&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;48,134&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development tax credit carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,288&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,185&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,091&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsResearchAndDevelopmentCapitalization_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development capitalization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,737&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Unpaid charges&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,843&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,197&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Intangible asset costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;946&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;758&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ForeignExchangeAndOther_iNI_pn3n3_di_zOVd3Vxooh6e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Foreign exchange and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(259&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(254&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_zYf0Q9J5VkZ4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Valuation allowance of deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(108,492&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(92,233&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0991"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0992"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000967"
      unitRef="USD">54752000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000968"
      unitRef="USD">48134000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000970"
      unitRef="USD">5288000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000971"
      unitRef="USD">4203000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000973"
      unitRef="USD">23185000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000974"
      unitRef="USD">21091000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <avxl:DeferredTaxAssetsResearchAndDevelopmentCapitalization
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000976"
      unitRef="USD">20737000</avxl:DeferredTaxAssetsResearchAndDevelopmentCapitalization>
    <avxl:DeferredTaxAssetsResearchAndDevelopmentCapitalization
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000977"
      unitRef="USD">15104000</avxl:DeferredTaxAssetsResearchAndDevelopmentCapitalization>
    <avxl:DeferredTaxAssetsUnpaidCharges
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000979"
      unitRef="USD">3843000</avxl:DeferredTaxAssetsUnpaidCharges>
    <avxl:DeferredTaxAssetsUnpaidCharges
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000980"
      unitRef="USD">3197000</avxl:DeferredTaxAssetsUnpaidCharges>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000982"
      unitRef="USD">946000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000983"
      unitRef="USD">758000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <avxl:ForeignExchangeAndOther
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000985"
      unitRef="USD">259000</avxl:ForeignExchangeAndOther>
    <avxl:ForeignExchangeAndOther
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000986"
      unitRef="USD">254000</avxl:ForeignExchangeAndOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000988"
      unitRef="USD">108492000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000989"
      unitRef="USD">92233000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact000994">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_pn3n3_z4dOHPfPkGL9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B0_zKPJn14YVjM9" style="display: none"&gt;Schedule of reconciliation of income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20241001__20250930_zHrqqR1Sedf8" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20231001__20240930_z8d0FFMP0se1" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20221001__20230930_znWxur4eJxqc" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Income tax benefit at statutory federal rate&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(9,739&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(9,030&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(9,975&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Foreign income taxed at other rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1000"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(61&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1002"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--PermanentDifferencesRelatingToStockBasedCompensation_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Permanent differences relating to share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,219&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(601&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationGiltiAmount_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Permanent differences relating to GILTI inclusion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1008"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1009"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;130&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(276&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development credits, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(941&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(860&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(37&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;State and local taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,672&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,821&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,122&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Adjustment to true up to prior years&#x2019; tax provision&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;182&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,128&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance_zahCpujyiQi2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Change in valuation allowances&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;16,259&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,186&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;14,098&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1032"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1033"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact000996"
      unitRef="USD">-9739000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact000997"
      unitRef="USD">-9030000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000998"
      unitRef="USD">-9975000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact001001"
      unitRef="USD">-61000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <avxl:PermanentDifferencesRelatingToStockBasedCompensation
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact001004"
      unitRef="USD">-1219000</avxl:PermanentDifferencesRelatingToStockBasedCompensation>
    <avxl:PermanentDifferencesRelatingToStockBasedCompensation
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact001005"
      unitRef="USD">-10000</avxl:PermanentDifferencesRelatingToStockBasedCompensation>
    <avxl:PermanentDifferencesRelatingToStockBasedCompensation
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact001006"
      unitRef="USD">-601000</avxl:PermanentDifferencesRelatingToStockBasedCompensation>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact001010"
      unitRef="USD">165000</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact001012"
      unitRef="USD">130000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact001013"
      unitRef="USD">-276000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact001014"
      unitRef="USD">273000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact001016"
      unitRef="USD">-941000</avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet>
    <avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact001017"
      unitRef="USD">-860000</avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet>
    <avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact001018"
      unitRef="USD">-37000</avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact001020"
      unitRef="USD">-4672000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact001021"
      unitRef="USD">-3821000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact001022"
      unitRef="USD">-4122000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact001024"
      unitRef="USD">182000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact001025"
      unitRef="USD">-1128000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact001026"
      unitRef="USD">206000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <avxl:IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact001028"
      unitRef="USD">16259000</avxl:IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance>
    <avxl:IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact001029"
      unitRef="USD">15186000</avxl:IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance>
    <avxl:IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact001030"
      unitRef="USD">14098000</avxl:IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact001034"
      unitRef="USD">7000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-09-30_custom_FederalMember"
      decimals="-5"
      id="Fact001036"
      unitRef="USD">148800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-09-30_custom_FederalMember"
      decimals="-5"
      id="Fact001038"
      unitRef="USD">128500000</us-gaap:OperatingLossCarryforwards>
    <avxl:OperatingLossCarryforwardsDescription
      contextRef="From2024-10-012025-09-30_custom_FederalMember"
      id="Fact001040">$37.7</avxl:OperatingLossCarryforwardsDescription>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-09-30_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="Fact001042"
      unitRef="USD">19100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-09-30_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="Fact001044"
      unitRef="USD">16900000</us-gaap:OperatingLossCarryforwards>
    <avxl:OperatingLossCarryForwardsExpirationYear contextRef="From2024-10-01to2025-09-30" id="Fact001046">2036</avxl:OperatingLossCarryForwardsExpirationYear>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="From2024-10-01to2025-09-30"
      decimals="-5"
      id="Fact001048"
      unitRef="USD">5300000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="From2022-10-012023-09-30"
      decimals="-5"
      id="Fact001050"
      unitRef="USD">4300000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <avxl:ResearchAndDevelopmentTaxCreditsYear contextRef="From2024-10-01to2025-09-30" id="Fact001052">2029</avxl:ResearchAndDevelopmentTaxCreditsYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-09-30_us-gaap_ForeignCountryMember"
      decimals="-5"
      id="Fact001059"
      unitRef="USD">17100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-09-30_us-gaap_ForeignCountryMember_currency_AUD"
      decimals="-5"
      id="Fact001061"
      unitRef="USD">25900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-09-30_us-gaap_ForeignCountryMember"
      decimals="-5"
      id="Fact001063"
      unitRef="USD">16600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-09-30_us-gaap_ForeignCountryMember_currency_AUD"
      decimals="-5"
      id="Fact001065"
      unitRef="USD">23900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2024-10-01to2025-09-30"
      decimals="-5"
      id="Fact001067"
      unitRef="USD">16300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2023-10-012024-09-30"
      decimals="-5"
      id="Fact001069"
      unitRef="USD">15200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2022-10-012023-09-30"
      decimals="-5"
      id="Fact001071"
      unitRef="USD">14100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact001073"
      unitRef="USD">20700000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact001075"
      unitRef="USD">15100000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact001077"
      unitRef="USD">12100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact001079"
      unitRef="USD">800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact001081">&lt;p id="xdx_80C_eus-gaap--SegmentReportingDisclosureTextBlock_zzQV2YJU41o2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 8	&lt;span id="xdx_821_zn5pQPMSkFpj"&gt;Segmented Information&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Operating segments are defined as components of an
entity for which separate financial information is available and regularly reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;)
in deciding how to allocate resources and assess performance. The Company&#x2019;s CODM is the Chief Executive Officer. The Company has
determined that it operates in a single operating segment, which consists of the development of clinical and preclinical product candidates
focused on advancing novel therapeutics for CNS diseases and disorders, and related administrative activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accounting policies of the segment are the same
as those described in the summary of significant accounting policies. The CODM evaluates performance and allocates resources based on
consolidated net loss, as presented in the Company&#x2019;s consolidated statement of operations, and monitors forecast-to-actual variances
for significant expense categories given their direct relationship to cash burn. The CODM also reviews the consolidated balance sheet
to assess liquidity, funding capacity, and segment assets, which are reported as total consolidated assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The CODM receives and reviews financial information
on a consolidated basis and does not assess performance or allocate resources based on geographic regions. In addition, management does
not internally organize or evaluate operating results by geography. Accordingly, management has determined that it is not required to
present financial information disaggregated by geographic region under ASC 280.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below summarizes the significant expense categories regularly
reviewed by the CODM for the years ended September 30, 2025, 2024 and 2023 (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_pn3n3_zjxBEOPR4tqc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segmented Information (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BF_zYgw4UzcBeSd" style="display: none"&gt;Schedule of summarizes the significant expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20241001__20250930_zLHHUDIGsfxd" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20231001__20240930_zKk7pL1wdZwe" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20221001__20230930_zMYAJn06VFw8" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Preclinical studies&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zFrZBm3FoeY9" style="width: 11%; text-align: right" title="Research and development costs"&gt;543&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zxp07xxy7yY7" style="width: 11%; text-align: right" title="Research and development costs"&gt;663&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zH9KDDhEzkph" style="width: 11%; text-align: right" title="Research and development costs"&gt;627&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Clinical trials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_z1WONuLox7we" style="text-align: right" title="Research and development costs"&gt;15,805&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_zuj3PHG4gT9a" style="text-align: right" title="Research and development costs"&gt;21,301&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_zcUamCUFHlx8" style="text-align: right" title="Research and development costs"&gt;21,873&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Personnel costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_z2yP8sByQ5me" style="text-align: right" title="Research and development costs"&gt;13,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zpO21lKV8dJ5" style="text-align: right" title="Research and development costs"&gt;13,676&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zQXUpJcSUJy2" style="text-align: right" title="Research and development costs"&gt;10,264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Non-cash share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z60xdm80O0He" style="text-align: right" title="Research and development costs"&gt;7,013&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z2I3TxlZGWl2" style="text-align: right" title="Research and development costs"&gt;5,813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_zFJDZrcFbA51" style="text-align: right" title="Research and development costs"&gt;10,812&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Other research and development costs&lt;sup&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zZTM1o5KWTAl" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development costs"&gt;765&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zY2z0BJ6cNu" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development costs"&gt;385&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zPV5eE24LOyd" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development costs"&gt;141&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total research and development costs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930_znLAEUCsjnY4" style="font-weight: bold; text-align: right" title="Research and development costs"&gt;37,592&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930_zgxBsosS3X9f" style="font-weight: bold; text-align: right" title="Research and development costs"&gt;41,838&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930_zuC4GxaJ0iW2" style="font-weight: bold; text-align: right" title="Research and development costs"&gt;43,717&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;General and administrative costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Personnel costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zh6aOjZq8sT4" style="text-align: right" title="General and administrative costs"&gt;2,288&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zpYJz6yuFcz" style="text-align: right" title="General and administrative costs"&gt;2,177&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zRa7H2ZF3xv9" style="text-align: right" title="General and administrative costs"&gt;2,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Non-cash share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_zuYd8YPkHrFd" style="text-align: right" title="General and administrative costs"&gt;4,536&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z97W6Cm3eqO" style="text-align: right" title="General and administrative costs"&gt;3,625&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z05ZWu0DGffg" style="text-align: right" title="General and administrative costs"&gt;5,558&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Other general and administrative costs&lt;sup&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zmqi0fztDEVc" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative costs"&gt;6,992&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_z1zIttFFD8tg" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative costs"&gt;5,237&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zWYlj8jzeV3k" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative costs"&gt;3,961&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total general and administrative costs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930_z84cBtzE4JTa" style="font-weight: bold; text-align: right" title="General and administrative costs"&gt;13,816&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930_zRTSScKRdqce" style="font-weight: bold; text-align: right" title="General and administrative costs"&gt;11,039&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930_zMzJBfRDgPl9" style="font-weight: bold; text-align: right" title="General and administrative costs"&gt;12,046&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other income&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OtherIncome_c20241001__20250930_zSQrsMX0gtDl" style="border-bottom: Black 1pt solid; text-align: right" title="Other income"&gt;5,031&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OtherIncome_c20231001__20240930_zBzEhImJe7Bb" style="border-bottom: Black 1pt solid; text-align: right" title="Other income"&gt;9,875&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OtherIncome_c20221001__20230930_z7gQovPJrPY7" style="border-bottom: Black 1pt solid; text-align: right" title="Other income"&gt;8,258&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Net loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--NetIncomeLoss_c20241001__20250930_zHoQRnoi8oKd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net Loss"&gt;(46,377&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--NetIncomeLoss_c20231001__20240930_zBcrRhrJpkXd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net Loss"&gt;(43,002&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--NetIncomeLoss_c20221001__20230930_zUh6s7Tme0V" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net Loss"&gt;(47,505&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;(a)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Other research and development costs include, but are not limited to, publications, sponsorships, membership fees, scientific conferences,
and medical affairs strategy and branding.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;(b)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Other general and administrative expenses include, but are not limited to, office rent, public company reporting requirements including
professional fees, insurance, and other general operating expenses not otherwise included in research and development expenses.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AA_zaEsEC3Uej16" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact001088">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_pn3n3_zjxBEOPR4tqc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segmented Information (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BF_zYgw4UzcBeSd" style="display: none"&gt;Schedule of summarizes the significant expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20241001__20250930_zLHHUDIGsfxd" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20231001__20240930_zKk7pL1wdZwe" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20221001__20230930_zMYAJn06VFw8" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Preclinical studies&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zFrZBm3FoeY9" style="width: 11%; text-align: right" title="Research and development costs"&gt;543&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zxp07xxy7yY7" style="width: 11%; text-align: right" title="Research and development costs"&gt;663&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zH9KDDhEzkph" style="width: 11%; text-align: right" title="Research and development costs"&gt;627&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Clinical trials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_z1WONuLox7we" style="text-align: right" title="Research and development costs"&gt;15,805&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_zuj3PHG4gT9a" style="text-align: right" title="Research and development costs"&gt;21,301&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_zcUamCUFHlx8" style="text-align: right" title="Research and development costs"&gt;21,873&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Personnel costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_z2yP8sByQ5me" style="text-align: right" title="Research and development costs"&gt;13,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zpO21lKV8dJ5" style="text-align: right" title="Research and development costs"&gt;13,676&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zQXUpJcSUJy2" style="text-align: right" title="Research and development costs"&gt;10,264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Non-cash share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z60xdm80O0He" style="text-align: right" title="Research and development costs"&gt;7,013&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z2I3TxlZGWl2" style="text-align: right" title="Research and development costs"&gt;5,813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_zFJDZrcFbA51" style="text-align: right" title="Research and development costs"&gt;10,812&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Other research and development costs&lt;sup&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zZTM1o5KWTAl" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development costs"&gt;765&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zY2z0BJ6cNu" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development costs"&gt;385&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zPV5eE24LOyd" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development costs"&gt;141&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total research and development costs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930_znLAEUCsjnY4" style="font-weight: bold; text-align: right" title="Research and development costs"&gt;37,592&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930_zgxBsosS3X9f" style="font-weight: bold; text-align: right" title="Research and development costs"&gt;41,838&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930_zuC4GxaJ0iW2" style="font-weight: bold; text-align: right" title="Research and development costs"&gt;43,717&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;General and administrative costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Personnel costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zh6aOjZq8sT4" style="text-align: right" title="General and administrative costs"&gt;2,288&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zpYJz6yuFcz" style="text-align: right" title="General and administrative costs"&gt;2,177&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zRa7H2ZF3xv9" style="text-align: right" title="General and administrative costs"&gt;2,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Non-cash share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_zuYd8YPkHrFd" style="text-align: right" title="General and administrative costs"&gt;4,536&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z97W6Cm3eqO" style="text-align: right" title="General and administrative costs"&gt;3,625&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z05ZWu0DGffg" style="text-align: right" title="General and administrative costs"&gt;5,558&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Other general and administrative costs&lt;sup&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zmqi0fztDEVc" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative costs"&gt;6,992&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_z1zIttFFD8tg" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative costs"&gt;5,237&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zWYlj8jzeV3k" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative costs"&gt;3,961&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total general and administrative costs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930_z84cBtzE4JTa" style="font-weight: bold; text-align: right" title="General and administrative costs"&gt;13,816&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930_zRTSScKRdqce" style="font-weight: bold; text-align: right" title="General and administrative costs"&gt;11,039&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930_zMzJBfRDgPl9" style="font-weight: bold; text-align: right" title="General and administrative costs"&gt;12,046&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other income&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OtherIncome_c20241001__20250930_zSQrsMX0gtDl" style="border-bottom: Black 1pt solid; text-align: right" title="Other income"&gt;5,031&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OtherIncome_c20231001__20240930_zBzEhImJe7Bb" style="border-bottom: Black 1pt solid; text-align: right" title="Other income"&gt;9,875&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OtherIncome_c20221001__20230930_z7gQovPJrPY7" style="border-bottom: Black 1pt solid; text-align: right" title="Other income"&gt;8,258&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Net loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--NetIncomeLoss_c20241001__20250930_zHoQRnoi8oKd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net Loss"&gt;(46,377&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--NetIncomeLoss_c20231001__20240930_zBcrRhrJpkXd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net Loss"&gt;(43,002&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--NetIncomeLoss_c20221001__20230930_zUh6s7Tme0V" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net Loss"&gt;(47,505&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;(a)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Other research and development costs include, but are not limited to, publications, sponsorships, membership fees, scientific conferences,
and medical affairs strategy and branding.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;(b)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Other general and administrative expenses include, but are not limited to, office rent, public company reporting requirements including
professional fees, insurance, and other general operating expenses not otherwise included in research and development expenses.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2024-10-012025-09-30_custom_PreclinicalStudiesMember"
      decimals="-3"
      id="Fact001090"
      unitRef="USD">543000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2023-10-012024-09-30_custom_PreclinicalStudiesMember"
      decimals="-3"
      id="Fact001092"
      unitRef="USD">663000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2022-10-012023-09-30_custom_PreclinicalStudiesMember"
      decimals="-3"
      id="Fact001094"
      unitRef="USD">627000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2024-10-012025-09-30_custom_ClinicalTrialsMember"
      decimals="-3"
      id="Fact001096"
      unitRef="USD">15805000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2023-10-012024-09-30_custom_ClinicalTrialsMember"
      decimals="-3"
      id="Fact001098"
      unitRef="USD">21301000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2022-10-012023-09-30_custom_ClinicalTrialsMember"
      decimals="-3"
      id="Fact001100"
      unitRef="USD">21873000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2024-10-012025-09-30_custom_PersonnelCostsMember"
      decimals="-3"
      id="Fact001102"
      unitRef="USD">13466000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2023-10-012024-09-30_custom_PersonnelCostsMember"
      decimals="-3"
      id="Fact001104"
      unitRef="USD">13676000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2022-10-012023-09-30_custom_PersonnelCostsMember"
      decimals="-3"
      id="Fact001106"
      unitRef="USD">10264000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2024-10-012025-09-30_custom_NonCashShareBasedCompensationMember"
      decimals="-3"
      id="Fact001108"
      unitRef="USD">7013000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2023-10-012024-09-30_custom_NonCashShareBasedCompensationMember"
      decimals="-3"
      id="Fact001110"
      unitRef="USD">5813000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2022-10-012023-09-30_custom_NonCashShareBasedCompensationMember"
      decimals="-3"
      id="Fact001112"
      unitRef="USD">10812000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2024-10-012025-09-30_custom_OtherResearchAndDevelopmentCostsMember"
      decimals="-3"
      id="Fact001114"
      unitRef="USD">765000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2023-10-012024-09-30_custom_OtherResearchAndDevelopmentCostsMember"
      decimals="-3"
      id="Fact001116"
      unitRef="USD">385000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2022-10-012023-09-30_custom_OtherResearchAndDevelopmentCostsMember"
      decimals="-3"
      id="Fact001118"
      unitRef="USD">141000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact001120"
      unitRef="USD">37592000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact001122"
      unitRef="USD">41838000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact001124"
      unitRef="USD">43717000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-10-012025-09-30_custom_PersonnelCostsMember"
      decimals="-3"
      id="Fact001126"
      unitRef="USD">2288000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-10-012024-09-30_custom_PersonnelCostsMember"
      decimals="-3"
      id="Fact001128"
      unitRef="USD">2177000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-10-012023-09-30_custom_PersonnelCostsMember"
      decimals="-3"
      id="Fact001130"
      unitRef="USD">2527000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-10-012025-09-30_custom_NonCashShareBasedCompensationMember"
      decimals="-3"
      id="Fact001132"
      unitRef="USD">4536000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-10-012024-09-30_custom_NonCashShareBasedCompensationMember"
      decimals="-3"
      id="Fact001134"
      unitRef="USD">3625000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-10-012023-09-30_custom_NonCashShareBasedCompensationMember"
      decimals="-3"
      id="Fact001136"
      unitRef="USD">5558000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-10-012025-09-30_custom_OtherResearchAndDevelopmentCostsMember"
      decimals="-3"
      id="Fact001138"
      unitRef="USD">6992000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-10-012024-09-30_custom_OtherResearchAndDevelopmentCostsMember"
      decimals="-3"
      id="Fact001140"
      unitRef="USD">5237000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-10-012023-09-30_custom_OtherResearchAndDevelopmentCostsMember"
      decimals="-3"
      id="Fact001142"
      unitRef="USD">3961000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact001144"
      unitRef="USD">13816000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact001146"
      unitRef="USD">11039000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact001148"
      unitRef="USD">12046000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherIncome
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact001150"
      unitRef="USD">5031000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact001152"
      unitRef="USD">9875000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact001154"
      unitRef="USD">8258000</us-gaap:OtherIncome>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2025-09-30"
      decimals="-3"
      id="Fact001156"
      unitRef="USD">-46377000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-09-30"
      decimals="-3"
      id="Fact001158"
      unitRef="USD">-43002000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact001160"
      unitRef="USD">-47505000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact001162">&lt;p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_z809reeRPkY6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 9	&lt;span id="xdx_82C_zREFbpQGHIe3"&gt;Subsequent Events&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates subsequent events occurring
between the most recent balance sheet date and the date the financial statements are available to be issued in order to determine whether
the subsequent events are to be recorded and/or disclosed in the Company&#x2019;s financial statements and footnotes. The financial statements
are considered to be available to be issued at the time they are filed with the Securities and Exchange Commission (SEC).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;There were no subsequent events or transactions that
required recognition or disclosure in the consolidated financial statements.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact001163">None of our directors or Section 16 officers &lt;span id="xdx_904_eecd--Rule10b51ArrAdoptedFlag_dbT_c20241001__20250930_zNeVxKmrq1Bg"&gt;&lt;span id="xdx_904_eecd--NonRule10b51ArrAdoptedFlag_dbT_c20241001__20250930_zUVbq55qNoQj"&gt;adopted&lt;/span&gt;&lt;/span&gt;,
modified or &lt;span id="xdx_909_eecd--Rule10b51ArrTrmntdFlag_dbT_c20241001__20250930_zbQWKfxMgypc"&gt;&lt;span id="xdx_908_eecd--NonRule10b51ArrTrmntdFlag_dbT_c20241001__20250930_zRPFC994X9V1"&gt;terminated&lt;/span&gt;&lt;/span&gt; a &#x201c;Rule 10b5-1 trading arrangement&#x201d; or &#x201c;non-Rule 10b5-1 trading arrangement&#x201d; (in each case,
as defined in Item 408(a) of Regulation S-K) during the three-month period ended September 30, 2025.&#160;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-10-01to2025-09-30" id="Fact001164">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2024-10-01to2025-09-30" id="Fact001165">true</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-10-01to2025-09-30" id="Fact001166">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-10-01to2025-09-30" id="Fact001167">true</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="From2024-10-01to2025-09-30" id="Fact001168">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:ErrCompAnalysisTextBlock
      contextRef="From2024-10-012025-09-30_2023-11-30"
      id="Fact001169">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Clawback Policy&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2023, the Board adopted an executive officer
compensation clawback policy that may be applied in the event of a material financial restatement. The clawback policy covers all of the
named executive officers and includes all incentive-based compensation. Specifically, in the event of an accounting restatement, the Company
must recover, reasonably promptly, erroneously awarded compensation in amounts determined pursuant to the policy. Compensation that may
be recoverable under the policy includes cash or equity-based compensation for which the grant, payment or vesting (or any portion thereof)
is or was predicated upon the achievement of specified financial results that are impacted by the material financial restatement, and
the amount of compensation that may be impacted by the clawback policy is the difference between the amount paid or granted, and the amount
that should have been paid or granted, if calculated on the updated financials. Recovery under the policy with respect to an executive
officer will not require the finding of any misconduct by such executive officer or such executive officer being found responsible for
the accounting error leading to an accounting restatement. Our equity awards provide that the Company may annul an award if the grantee
incurs a separation from service for &#x201c;cause&#x201d; (as defined in the agreements). In such case, all awards and any amounts or benefits
received or outstanding shall be subject to cancellation, recoupment, rescission, payback and other action in accordance with the terms
of the Company Clawback Policy or any applicable law. &lt;span style="background-color: white"&gt;In addition, in the event
of a restatement of the Company&#x2019;s financial statements due to material noncompliance with any financial reporting requirement under
the law, whether such noncompliance is the result of misconduct or other circumstances, an employee shall be required to reimburse the
Company for any amounts earned or payable with respect to an award granted under the Company&#x2019;s equity plan to the extent required
by law and the Company&#x2019;s clawback policy.&lt;/span&gt;&lt;/p&gt;

</ecd:ErrCompAnalysisTextBlock>
    <ecd:RestatementDeterminationDate
      contextRef="From2024-10-012025-09-30_2023-11-30"
      id="Fact001170">2023-11-30</ecd:RestatementDeterminationDate>
    <ecd:AwardTmgMnpiDiscTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact001171">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Policies and Practices for &lt;span id="xdx_903_eecd--AwardTmgPredtrmndFlag_dbT_c20241001__20250930_zE9N9TVCaIM7"&gt;Granting Certain Equity
Awards&lt;/span&gt;&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our policies and practices regarding the granting
of equity awards are carefully designed to ensure compliance with applicable securities laws and to maintain the integrity of our executive
compensation program. The Compensation Committee is responsible for the timing and terms of equity awards to executives and other eligible
employees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The timing of equity award grants is determined with
consideration to a variety of factors, including but not limited to, the achievement of pre-established performance targets, market conditions
and internal milestones. The Company does not follow a predetermined schedule for the granting of equity awards&#x37e; although the Company
generally grants equity-based awards annually after the completion of annual calendar year performance review process. Each grant is considered
on a case-by-case basis to align with the Company&#x2019;s strategic objectives and to ensure the competitiveness of our compensation packages.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In determining the timing and terms of an equity award, the Board or the Compensation
Committee may consider material nonpublic information to ensure that such grants are made in compliance with applicable laws and regulations,
but does not take material nonpublic information into account when determining the terms of awards. The Board&#x2019;s or the Compensation
Committee&#x2019;s procedures to prevent the improper use of material nonpublic information in connection with the granting of equity awards
include oversight by legal counsel and, where appropriate, delaying the grant of equity awards until the public disclosure of such material
nonpublic information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_907_eecd--AwardTmgMethodTextBlock_c20241001__20250930_z3FZVQqnEI88"&gt;For all stock option awards, the exercise price is
the closing price of the Company&#x2019;s common stock on the Nasdaq on the date of the grant. If the grant date falls on a non-trading
day, the exercise price is the closing price of the Company&#x2019;s common stock on the Nasdaq on the last trading day preceding the date
of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During fiscal 2025, the Company did not grant equity
awards to its named executive officers during the four business days prior to or the one business day following the filing of its periodic
reports or the filing or furnishing of a Form 8-K that discloses material nonpublic information. &lt;span id="xdx_90A_eecd--AwardTmgHowMnpiCnsdrdTextBlock_c20241001__20250930_zkSJb6166DMf"&gt;The Company has not timed the disclosure
of &lt;span id="xdx_902_eecd--AwardTmgMnpiCnsdrdFlag_dbF_c20241001__20250930_zJn2n2F4G4r8"&gt;material nonpublic information&lt;/span&gt; for the purpose of affecting the &lt;span id="xdx_901_eecd--MnpiDiscTimedForCompValFlag_dbF_c20241001__20250930_zDuh5Qy8B9c6"&gt;value of executive compensation&lt;/span&gt; for named executive officer grants
in fiscal 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is committed to maintaining transparency
in its executive compensation practices and to making equity awards in a manner that is not influenced by the timing of the disclosure
of material nonpublic information for the purpose of affecting the value of executive compensation. The Company regularly reviews its
policies and practices related to equity awards to ensure they meet the evolving standards of corporate governance and continue to serve
the best interests of the Company and its stockholders.&lt;/p&gt;

</ecd:AwardTmgMnpiDiscTextBlock>
    <ecd:AwardTmgPredtrmndFlag contextRef="From2024-10-01to2025-09-30" id="Fact001172">true</ecd:AwardTmgPredtrmndFlag>
    <ecd:AwardTmgMethodTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact001173">For all stock option awards, the exercise price is
the closing price of the Company&#x2019;s common stock on the Nasdaq on the date of the grant. If the grant date falls on a non-trading
day, the exercise price is the closing price of the Company&#x2019;s common stock on the Nasdaq on the last trading day preceding the date
of grant.</ecd:AwardTmgMethodTextBlock>
    <ecd:AwardTmgHowMnpiCnsdrdTextBlock contextRef="From2024-10-01to2025-09-30" id="Fact001174">The Company has not timed the disclosure
of &lt;span id="xdx_902_eecd--AwardTmgMnpiCnsdrdFlag_dbF_c20241001__20250930_zJn2n2F4G4r8"&gt;material nonpublic information&lt;/span&gt; for the purpose of affecting the &lt;span id="xdx_901_eecd--MnpiDiscTimedForCompValFlag_dbF_c20241001__20250930_zDuh5Qy8B9c6"&gt;value of executive compensation&lt;/span&gt; for named executive officer grants
in fiscal 2025.</ecd:AwardTmgHowMnpiCnsdrdTextBlock>
    <ecd:AwardTmgMnpiCnsdrdFlag contextRef="From2024-10-01to2025-09-30" id="Fact001175">false</ecd:AwardTmgMnpiCnsdrdFlag>
    <ecd:MnpiDiscTimedForCompValFlag contextRef="From2024-10-01to2025-09-30" id="Fact001176">false</ecd:MnpiDiscTimedForCompValFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
